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Outcome of vitamin C supplementation on lead-induced
apoptosis in adult rat hippocampus
M. Mehdizade1, F. Kermanian2, I. Nourmohamadi3
1Department of Anatomical Sciences, Iran University of Medical
Sciences, Molecular and Research Center, Tehran, Iran;
2Department of Anatomical Sciences, Mashhad University of Medical
Sciences, Mashhad, Iran;
3Department of Biochemistry, Iran University of Medical Sciences,
Tehran, Iran
Background Lead (Pb), due to its numerous industrial applications
has caused widespread pollution of the environment. One principle
target for lead in the human body is the central nervous system (CNS).
Research has shown however that the toxic effects of lead can be
moderated by antioxidant agents such as vitamin C.
Objective To investigate the protective effects of vitamin C supple-
mentation against lead induced apoptosis in the adult male rat
hippocampus.
Design, time and setting Animal experiment, including light and
electron microscopic staining and western blot analysis, was per-
formed in the College of Medicine, Iran University between
December 2007 and April 2009.
Materials Lead (Pb) was used for toxication and Vit C was use as an
antioxidant drug and Bax and Bcl-2 were used as primary antibodies.
Methods Animals were divided into three groups; control, Lead
treated, Lead + Vit C-treated group) rats. They treated for 7 days.
Main outcome measure At the end of treatment, blood Lead level
was measured. Neuronal death was determined using light and elec-
tron microscopic staining and western blot analysis
Results Lead + Vit C treatment reduced neuronal apoptosis com-
pared to Lead treated rats. There were decrease of Bax expression in
the hippocampus of Lead + Vit C group compared to Lead group in
western blotting. Changes in blood Lead level was not significant in
three groups.
Conclusion The results suggest that supplementing essential nutrient
vitamin C may prevent lead-induced apoptosis.
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Suboccipital neurostimulation in chronic headache:
a prospective, randomized with cross over study
F. Marchioretto1, G. Serra2
1Headache Center, Negrar, Italy;
2Anthalgic Therapy Service, Ospedale Sacro Cuore, Negrar, Italy
Patients affected by chronic headache experience a significant reduc-
tion in quality of life. No effective treatments are today available for this
condition We performed a prospective, randomized study to evaluate
safety and efficacy of bilateral suboccipital neurostimulation in patients
with chronic migraine (CM) and medication overuse headache (MOH).
Patients with CM and MOH were enrolled in a single Hospital headache
Center by a neurologist with experience in headache. In a preliminary
phase, after signed informed consent, stimulators (Medtronic Synergy
Versitrel) were provisionally implanted as an external device. After
30 days, if attack frequency was reduced C50%, neurostimulator was
subcutaneously implanted. Patients were randomized into treatment
(ON stimulator) or control (OFF stimulator) groups. At week 4 cross-
over between groups was realized. The frequency and the intensity of
headache as well as the amount of drug intake were registered on a
standardized diary from three months before the implant until the end of
follow-up. Quality of life was measured using a dedicated scale (SF_36
e MIDAS) at -3 0-1-3-6-12 months follow-up.34 patients have been
enrolled in this study.After 1 year follow-up our results demonstrate a
significant reduction in headache frequency (56%) and intensity (from
7.8 to 5.8 in Visual analogic scale): drugs intake reduced (): media from
45 to 11 intakes for month) till then MOH changed in original primary
headache (100% migraine without aura (1.1 ICHD-II).; chronic
migraine (1.5.1 ICHD-II) became too migraine without aura (1.1 ICHD-
II). Adverse events were light and completely reversible.
17
Wolff’s extracranial vascular theory of migraine:
a great story confirmed by the facts
E. Shevel
The Headache Clinic, Johannesburg, South Africa
Objectives To clarify the role of extracranial vasodilatation in
migraine, and to expose the distortions and misrepresentations in the
literature concerning this subject.
Background There has over the years been a considerable amount of
controversy over whether the vascular component of migraine pain
arises from the intracranial or the extracranial vessels, or both. Some
have even questioned whether vasodilatation actually plays a signif-
icant role in migraine pain, and have described it as an unimportant
epiphenomenon. The controversy is an artificial one though, which
has been generated as a consequence of misrepresentation of the facts
in the headache literature.
Methods The literature on the subject is extensively researched for
verifiable hard scientific data on the subject.
Results There have been blatant distortions in the literature with
regard to the role of extracranial vasodilatation in migraine. There is a
plethora of hard scientific evidence to show that extracranial vaso-
dilatation is important in migraine.
Conclusions There have been significant distortions and misrepre-
sentations in the literature, which have led many headache specialist
to believe, erroneously, that extracranial vasodilatation is not
important in migraine. The hard scientific evidence shows that
(i) vasodilatation is indeed a source of pain in migraine,
(ii) that this dilatation does not involve the intracranial vasculature,
(iii) that the extracranial terminal branches of the external carotid
artery are a source of pain in migraine.
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Endothelium dependent vasodilatation in migraine
patients
D. Perko, M. Zaletel, B. Zvan, J. Pretnar-Oblak
Vascular Neurology, University Clinical Centre Ljubljana,
Ljubljana, Slovenia
Although endothelial dysfunction might be an important feature
involved in the pathophysiology of migraine, it has been
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investigated only in a few studies. The obtained conflicting results
did not provide definitive answer on the presence of endothelial
dysfunction in migraine patients. We sought to explore flow-medi-
ated dilatation (FMD) in migraine patients. By employing strict
inclusion criteria we avoided the possible changes of FMD by
confounding factors, that could produce previously obtained con-
flicting results. Forty-two patients with migraine (female 34, male 8)
and twenty-one healthy subjects matched by gender and age were
included. All patients had normal values of intima-media thickness
of carotid arteries and did not have diseases known to affect
endothelial function. FMD of brachial arteries were measured by
using standard procedure. We did not find any difference in FMD
between patients with migraine and healthy subjects (p = 0.78).
Also no differences were found between group of healthy subjects,
migraine with aura and migraine without aura (p = 0.92) nor
between group of migraine with and without aura (p = 0.76). We
found that FMD is not impaired in migraine patients, neither in
those with nor without aura (p [ 0.05). Thus, it could be convinc-
ingly concluded systemic endothelial function are not altered during
the interictal period, but migraine could be associated with cerebral
endothelial dysfunction.
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Orthostatic headache revealing multiple periradicular
cysts
J.A. Elosegi, C. Cuvelier, M. Rinkowski, Y. Khayat, C. Neugroschl,
J.M. Gerard
Neurology, Hopital Ambroise Pare, Mons, Belgium
Spontaneous postural headache was observed in a 49 years old
woman. MRI of the brain showed a Chairi I like aspect of the pos-
terior fossa but with a meningeal enhacement. the lumbar puncture
pression was lower than 5 cm of H20 without cellularity. MRI of the
spine cord revealed multiple epidural ectasia without proved CSF
leak. The patient had no cutaneous or morphological aspect of Marfan
disease or connective tissue disorder. She was succesfuly traited by an
epidural blod pach.
Conclusion Our patient had orthostatic headache secondary to
intracranial hypotension. MRI of the spine cord revealed multiple
epidural ectasia without CSF leak.
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Prophylactic treatment of chronic tension-type
headache with trigger points: comparison
of Gabapentin and local injection of Depomedrol
F. Khorvash1, B. Asadi2, F. Mehrabi2, A. Najjaran2, M. Ghasemi3
1Neurology, University of Medical Sciences, Isfahan, Iran;
2Medical University of AJA, Tehran, Iran;
3University of Medical Sciences, Isfahan, Iran
Introduction Chronic tension- type headache (CTTH) is one of the
most common disorders affecting quality of life. Trigger points(TrPs)
play an important role as a causative factor. Gabapentin and Local
injection of trigger points with corticosteroids are noted to be effec-
tive in prophylactic treatment of (CTTH).
Materials and methods We selected CTTH patients who had active
trigger point in the head and divided them in two groups of De-
pomedrol and Gabapentin. Depomedrol was injected 10 mg per each
TrPt up to total dose of 40 mg in each patient. Gabapentin was
initiated with 200 mg/day and gradually increased to 300-600 mg
daily.
Results Headache Intensity 9 Duration index showed marked
decrease in both groups. It was significantly lower in Depomedrol
receiving patients at the end of first (368.13 ± 195.75 Vs
467.73 ± 203.09, P \ 0.05) and second months (165.44 ± 62.75Vs
238.68 ± 81.39 P \ 0.05). similar superiority was detectable for
Intensity, Duration and Frequency of headaches.
Conclusion We found trigger point injection more potent in com-
parison to daily Gabapentin. This superiority was statistically
significant after 4 weeks and continued up to 8th week. It should be
noted that trigger point injection was more effective to decrease all
aspects of headache including intensity, duration and frequency.
Keywords Chronic tension-type headache, Depomedrol, Trigger
point, Gabapentin, Prophylactic
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Blood-patch: immediate effective remedy for headaches
secondary to dura mater injury
M.A. Hachimi
Mohammed V, Mekne`s, Morocco
Objective The aim of this study was to evaluate if bed rest during 2 h
in a supine posture is required to improve the efficacy of the blood-
patch procedure.
Patients and methods Patients whose postdural puncture headache
remained distressing 48to 72 h after dural tap despite the use of
stage II WHO painkillers were included in this prospective single
center study lasted for a 2-year period. The patient’s own blood
injection in the epidural space was performed until discomfort or
pain in the lumbar area occurred or was limited to 20 ml if no
such sensation was observed. After blood had been injected, the
patient was allowed to stand up as soon as desired, under close
observation. The patient was thendischarged to the ward for a 48 h
follow-up.
Results Nine female and 12 male patients (age: 16-35 years) were
included. Headache occurred after spinal anaesthesia in 16 cases,
epidural analgesia for delivery in two cases and lumbar puncture by
during neurological workup in three cases. Autologous blood volume
injected was 20 ml in 19 patients and was reduced to 18 and 16 ml,
respectively, in two patients due to lumbar pain. All blood-patches
were technically uneventful and led to immediate headache relief,
associated with a feeling of wellbeing and desire to stand up. The 48
following hours were without any incident and pain killers were no
more needed.
Conclusion In this prospective study, blood-patch was mainly per-
formed after spinal anaesthesia and was associated with a high rate
success. This encouraging result suggests that recumbent position
maintained for 2 h after the blood-patch is performed might not
be necessary to obtain full efficacy.
J Headache Pain (2010) 11 (Suppl 1):S1–S150 S3
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Complementary and alternative medicine (CAM)
therapies for treatment of cervicogenic headache:
a systematic review
A. Tsertsvadze1, F. Yazdi1, A.D. Furlan2, A. Gross3, L. Santaguida3,
C. Ammendolia4, S. Tsouros1, S. Doucette1, R. Daniel1,
B. Skidmore5, M. Ansari1
1Evidence-Based Practice, Clinical Epidemiology Methods Centre,
Ottawa Hospital Research Institute, University of Ottawa,
Ottawa, Canada;
2Institute for Work & Health, Toronto, Canada;
3The Department of Clinical Epidemiology and Biostatistics,
McMaster University, Hamilton, Canada;
4Joseph and Wolf Lebovic Health Complex, Mount Sinai Hospital,
Toronto, Canada;
5The Society of Obstetricians and Gynaecologists of Canada,
Ottawa, ON, Canada
Objectives This systematic review is part of a large evidence-based
comparative effectiveness report conducted under contract to the
Agency for Healthcare Research and Quality (Contract No.
997392062), Rockville, MD, and funded by the National Center for
Complementary and Alternative Medicine, National Institutes of
Health, Bethesda, MD. The review compared effects of CAM thera-
pies (acupuncture, manipulation, mobilization, and massage) in adults
with neck or back pain.
Data sources MEDLINE, Cochrane Central, CINAHL, and EM-
BASE were searched up to 2009; unpublished literature was also
searched.
Study selection For this review, randomized controlled trials (RCTs)
reporting benefits/harms of CAM therapies for treatment of cervico-
genic headache in adults (age C 18 years) were selected. Trials
reporting effects of CAM therapies on other types of headache (ten-
sion-type, migraine) were excluded. The selection of studies was not
limited to English language.
Results and conclusions Since the final report of the review is
expected to be published in July 2010, Results and Discussion sec-
tions for this abstract will be available for presentation at the 2nd
European Headache and Migraine Trust International Congress in
Nice (October 28-31, 2010).
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Alleviation of migraine, taurine and analogues
in nutrition: a hope to cope
R.C. Gupta
Chemistry, Nagaland University, Medziphema, India
Migraine headache is not a sudden happening. It is accumulative
effect of deficiency symptom, toxin and its complex nature. Patho-
genesis of migraine is not well understood, yet it is believed that
neuronal hyper-excitation, cortical spreading depression, platelet
activation and sympathetic hyperactivity are part of complexity.
Besides neuro-chemical changes, bad life styles, also partial respon-
sible for such happening. Hence migraine headaches are caused by a
constellation of causes. It is recorded that chromo-pathological forms
of magnesium depletion is involved in physiopathology of migraine.
There is increasing evidence that magnesium and taurine are
complement to each over. Taurine, a sulfur amino acid has neuro-
transmission/ neuromodulatory role. For record in CSF, taurine has
been noted to be high in migraine patients. Plasma taurine levels in
patients with classic migraine are correlated negatively with severity
of headache. The higher taurine level in CSF may be due to accu-
mulation of taurine via transport to site of action and to participate in
preventive measure .In mechanistic view such central taurine libera-
tion during migraine crises may be due to spontaneous depolarization
or defensive action of cerebral homeostatic processes. Metabolic
platelet defect in migraine patient has been observed, with higher
taurine platelet concentration during headache. It seems that taurine
has a role in prevention of migraine. Another cause of migraine
headaches is neurotoxin monosodium glutamates (MSG). It is
believed that taurine neutralizes its effect. Dietary supplementation of
magnesium and taurine has alleviating effect on migraine. To provide
synergetic effect of both together, magnesium taurate has been found
to be effective . Through no one can deny the role of pharmaceutical
in therapy of migraine, yet nutritional intervention is a right choice for
safe and effective solution to cope with bad life style. Hence sup-
plementation of taurine alone or in combination of its derivatives may
provide a hope.
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BI 44370 TA, An oral cgrp antagonist for the acute
treatment of migraine attacks: results from a phase II
study
J. Podhorna1, H.-C. Diener2, C. Dahlo¨f3, J. Habeck4
1Clinical Research, Boehringer Ingelheim Pharma GmbH & Co. KG,
Biberach/Riss, Germany;
2Department of Neurology, University Hospital Essen,
Essen, Germany;
3Gothenburg Migraine Clinic AB, Go¨teborg, Sweden;
4Medical Data Services, Boehringer Ingelheim Pharma GmbH & Co.
KG, Biberach/Riss, Germany
Objectives To assess efficacy and tolerability of BI 44370 in adult
female and male patients during a migraine attack.
Background BI 44370 is a novel, orally available, calcitonin gene-
related peptide (CGRP) antagonist being developed for acute treat-
ment of migraine attacks.
Methods This was a randomized, double-blind, parallel-group, pla-
cebo and active-comparator controlled clinical trial. 416 patients aged
18 to 65 years with migraine with or without aura according to IHS
criteria were randomised to BI 44370 TA 50 mg, 200 mg, 400 mg,
eletriptan 40 mg or placebo, taken orally during a migraine attack
with headache of moderate or severe intensity. The primary endpoint
was the proportion of patients reporting pain-free at 2 h after dosing.
Results BI 44370 TA was effective and its effect was dose-depen-
dent. The primary endpoint, pain free after 2 hours was reached by
significantly more patients for the 400 mg dose of BI 44370 TA (20/
73 = 27.4%) compared to placebo (6/70 = 8.6%, p = 0.0016). The
200 mg was numerically better than placebo (14/65 = 21.5%,
p \ 0.035) while the effect of 50 mg BI 44370 TA was similar to
placebo (5/64 = 7.8%). Eletriptan 40 mg was superior to placebo
(pain free rate 34.8%, p = 0.0001). Analysis of secondary endpoints
supported the conclusion from the primary analysis.
During the treatment period 23 patients (11.4%) in the BI 44370 TA
groups, 7 patients in the placebo group (10.0%) and 12 patients in the
eletriptan group (17.4%) reported at least one adverse event (AE).
Frequency of AEs was independent of the dose of BI 44370 TA.
S4 J Headache Pain (2010) 11 (Suppl 1):S1–S150
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Conclusion Proof of concept was shown in a dose dependent manner
for BI 44370 TA in the acute treatment of migraine attacks. The
incidence of AEs was low in all groups (\5%).
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Smell scores of patients with tension type headache
H. Tekeli1, M.G. S¸enol2, H. Yas¸ar2, M.F. O¨zdag˘2, M. Sarac¸og˘lu2
1Neurology, C¸anakkale Military Hospital, C¸anakkale, Turkey;
2Neurology, Haydarpas¸a Hospital of Gu¨lhane Military Medical
Academy, Istanbul, Turkey
Objective Smell scores of patients with migraine are different from
normal individuals. Our aim was to investigate smell scores of
patients with tension type headache (TTH) by applying short smell
test battery of GATA Haydarpas¸a (SSTB-GH).
Materials and methods In 2008, during a thesis study Neurology
Department of Haydarpas¸a Hospital of Gu¨lhane Military Medical
Academy established SSTB-GH which was composed of five smell
samples (bananas, lemon, rose, mint, chocolate). Within the test the
patient was ordered to smell each sample randomly with one minute
break and to say the name of it. For each correct answer 1 point was given.
Mean value of SSTB-GH for the normal individuals was determined as
3.35 (p\ 0.01).
240 patients with TTH were admitted to the study.148 female and 92
male patients’ mean age was 27.4.
Results In patients with TTH mean SSTB-GH score was determined
as 3.42 (p \ 0.01) revealing that it was similar with the scores of
normal individuals.
Conclusion Patients with TTH did not have different smell scores
compared to normal individuals.This may help to explain why smell
is not a usual triggering factor for TTH patients compared to the ones
with migraine.
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Headache presentation and 1-year development
in patients with transient ischaemic attacks:
results from ‘The Aarhus TIA Study’
H. Kasch1, P.V. Weitzel-Mudersbach1, A. Hansen2, G. Andersen3
1The Headache Clinic, Department of Neurology, Aarhus, Denmark;
2Danish Pain Research Center, Aarhus, Denmark;
3Department of Neurology, Aarhus University Hospital,
Aarhus, Denmark
Introduction 262 consecutive patients with recent (B31 days) tran-
sient ischaemic attack (TIA) were included in a 1-year prospective
study, examining pre-existing headache and development of head-
ache-related disability after TIA.
Methods 262 consecutive patients (M:144; F:118; Age; mean ± SD:
64.1 ± 14.0, range 19.8-94.0 yrs). Initial examination took place
after median 2.5 days (25th, 75th percentiles: 0; 11) with clinical
follow-up and questionnaires after 1 week, and telephone interviews
after 3, 12 months. Based on questionnaires patients reported previ-
ous headache and present VAS headache at first visit (N = 262) and
the HIT-6 scale was applied after 1 week (N = 248) and after 1 year
(N = 220). Previous medical history was obtained and changes in
medication and stroke/disability scales were assessed at each exam-
ination point. Patients underwent initial neurological examination,
and assessment of BP, height/weight and paraclinical bloodtests,
MRC/CTC, ultrasonography of precerebral arteries/transcranial
Doppler were performed (see Weitzel-Mudersbach et al).
Results 80.5% reported less than one week of headache in previous
year, 8.6% less than 1 month and 10.9% had more than one month of
headache during last year. HIT-6 score (from 36-78) was low after
1 week (38.6 ± 6.7) and 1 year (38.9 ± 5.8). After 1 week 92.3% had
no or minor impact of headache and 7.7% moderate to severe disability,
with similar figures after 1-yr (92.2% and 7.8%). No raised risk of
headache disability was encountered during initial treatment with
dipyridamol (prescribed to 4.8% or warfarin (3.6%), and no significant
change in HIT-6 disability during ASA treatment (prescribed to 29.8%).
Conclusion After TIA there was no development of significant head-
ache. Only 5% of men and 15% of women complained of initial and
1 year significant headache, which is less than expected in an age and
gender matched population. It may be speculated whether TIA exposure
moderates descending inhibitory/facilitatory nociceptive pathways.
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Psychopathologies in migraine and tension headaches
S. Tanvir1, N. Najam2
1Punjab University, Lahore, Pakistan
2Karakoram International University, Gilgit/Baltistan, Gilgit,
Pakistan
Headaches present a persistent and significant clinical challenge,
research shows that psychotherapeutic results are not always main-
tained over time and pain is unrelieved. The aim of the research was
to find the underlying psychopathologies which are causing, main-
taining and exacerbating headaches. After an initial pilot study on 19
patients this was carried out in two phases, in phase a 100 headache
sufferers, age range 15-55 diagnosed with Migraine/ Tension Headaches
were recruited. All under-went diagnostic clinical examination by the
Psychiatrist, and only those who fulfilled the criteria of the (Ad hoc
Committee for the Classification of the headaches (1962) were referred to
the Clinical Psychologist for psychological assessment. Crown and Crisp
Experiential Index, adapted version, Afaq & Najam (1992) clinically
used in hospitals was utilized to assess psychological status, it has six sub
scales: Depression, Free floating anxiety, phobia, somatic, obsession and
Hysteria. Significantly higher levels of depressive psychopathology were
found in headache patients. These subjects also scored higher on free
floating anxiety, Hysteria and very high on somatic scales, keeping in
view the above findings phase b a longitudinal study of 37 patients with
chronic (reported) headaches was carried out using CCEI, the findings in
both studies shed light to help headache patients and the clinicians to
achieve effective management of headaches.
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Efficacy of effective management techniques
S. Tanvir1, N. Najam2
1Punjab University, Lahore, Pakistan
2Karakoram International University, Gilgit/Baltistan, Gilgit, Pakistan
Objectives To compare the efficacy of various modalities of head-
ache treatment.
Method Headaches sufferers (N = 37) ages range 15-55 diagnosed
with Migraine/Tension and Combined headaches recruited from hos-
pitals, underwent diagnostic clinical examination. Those who met
J Headache Pain (2010) 11 (Suppl 1):S1–S150 S5
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criteria (Ad hoc Committee for the Classification of Headaches 1962)
were referred to the clinical psychologist for assessment and treatment.
Pre and post assessments using Interview, MPQ, Faces test, Rating
scales, medication index and subjective report of pain were carried out.
All participants underwent six weeks of intervention in their respective
groups a Drugs, Drugs plus Psychotherapy, Acupuncture Relaxation,
Training and Placebo. Significant differences were found among treat-
ment groups, findings of the study showed that Drug plus Psychotherapy
is superior to other interventions, but other modalities like Acupuncture,
Relaxation and Placebo have beneficial results on outcome.
Conclusion These findings have important implications for future
interventions. It is highly recommended that different modalities need
to be integrated under one umbrella.
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A CK1 delta mutation in familial migraine with aura
alters behavior related to migraine and brain
physiology
E. Bates1, K.C. Brennan2, A. Charles2, R. Shapiro3, L. Ptacek4
1Chemistry and Biochemistry, Brigham Young University,
Provo, UT, USA;
2Headache Research and Treatment Program, University
of California, Los Angeles, CA, USA;
3Department of Neurology, University of Vermont,
Burlington, VT, USA;
4Neurogenetics, University of California & Howard Hughes Medical
Institute, San Francisco, CA, USA
A mutant allele of the gene that encodes casein kinase 1d (CK1d T44A)
was found to segregate with dominantly inherited migraine with aura
and familial advanced sleep phase syndrome. Mice expressing CK1d
T44A showed alterations in cortical spreading depression (CSD),
cerebrovascular response, nociceptive behavior, and astrocyte signal-
ing. CK1d T44A mice had a reduced threshold for CSD induction,
increased frequency of CSD, and greater arterial dilation associated
with CSD as compared with wildtype controls. CK1d T44A mice also
showed significantly reduced thermal and mechanical nociceptive
thresholds following administration of nitroglycerin, a compound
known to induce a migraine-like headache and other migraine symp-
toms. Astrocytes from CK1d T44A mice showed increased
spontaneous and evoked intra- and intercellular calcium signaling.
These data show that a mutation in CK1d causes changes in multiple
physiological mechanisms involved in migraine. Alterations in the
function of CK1d may be a novel genetic basis for migraine with aura.
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A valve disorder which is seen more frequently
among refractory migraine patients than normal
individuals; mitral valve prolapsus
H. Tekeli1, M.G. S¸enol2, H. Yas¸ar2, B. Deveci3
1Neurology, C¸anakkale Military Hospital, C¸anakkale, Turkey;
2Neurology, Haydarpas¸a Hospital of Gu¨lhane Military Medical
Academy, Istanbul, Turkey;
3Cardiology, C¸anakkale Military Hospital, C¸anakkale, Turkey
Objective Our aim was to investigate cardiac disorders among
refractory migraine patients and interpret the results.
Materials and methods 30 migraine patients were included to the study
who had appealed for neurology polyclinic at C¸anakkale Military Hos-
pital. Age range was 26-32 and 17 were female. Within the study
refractory migraine patients who had the disease at least for 10 years and
were without cardiological symptoms were examined by cardiologist
with pulmonary X ray graphy, ECG and transthoracic echocardiography.
Results Mitral valve prolapsus (MVP) was found within 12 patients .
Conclusion MVP which has the prevalence of %4-5 has been
detected among %40 of our study group. This suggests refractory
migraine patients also should be evaluated cardiologically.
47
The peculiar diagnostic approach of migraine
in patients with histrionic personality disorders
V.-I. Cristina1, M. Ion2,3
1State Medical and Pharmaceutical, Chisinau, Moldova;
2State Medical and Pharmaceutical University, Chisinau, Moldova;
3Institute of Neurology and Neurosurgery, Headache Center,
Chisinau, Moldova
Introduction Migraine (M) in patients with hysteria was reported by
different authors, but their pathogenetic interaction remains unclear. M
diagnosis, due to exclusively subjective criteria, is sometimes difficult
to establish in histrionic personality disorders (HPD) associated with
conversion disorders (CD) and somatoform disorders (SD).
Objectives Analysis of clinical features of M in HPD patients and the
settlement of specific additional diagnostic support to increase the
diagnostic certainty of M.
Methods The study included 31 female patients, average age
- 41.8 years, referred to the Headache Center (HC) with a diagnosis of
M. The M clinical diagnosis in the HC was based on the International
Classification of Headache Disorders criteria (ICHD-2004). The HPD,
CD, SD diagnoses were confirmed according to DSM-IV criteria.
Additionally, we have practiced discussions with relatives concerning
the patients’ verbal and non-verbal behaviour, repeated discussions
with patients about M history in different psychological context, and a
detailed analysis of medical documentation.
Results All the patients met the criteria of HPD: 12 associated with
CD, 19 - with SD. M was present in 25 patients (80.6%), 6 (19.4%)
had tension-type headache. Four patients had episodic probable M, 7 -
episodic M (3 with aura) and 14 - chronic M (4 with medication
overuse). In 6 patients M attacks coincided with CD and SD exac-
erbation, usually within a psychogenic context.
Conclusions Headache, including migraine, in patients with HPD and
other hysterical phenomena, raise diagnostic problems. The use of a
larger diagnostic approach, parallel to ICHD-2004, considerably
enhances the M diagnostic certainty.
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Ethno medicinal flora of North Western TARAI forests
of Uttar Pradesh, India for headache and migraine
T.P. Mall
Post Graduate Department of Botany, Kisan P. G. College,
Bahraich, India
India represents one of the mega biodiversity centers of the world. In
India the North Tarai belt is next only to Eastern and Western ghats
S6 J Headache Pain (2010) 11 (Suppl 1):S1–S150
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due to its prosperous and distinctive flora including many species of
medicinal plants, which may be a source for gainful exploitation of
natural resources and ethnic culture. Geographically it covers the area
from district Bahraich to Pilibhit. During the survey of study area
fourteen plant species viz., Abrus precatorious L. (Ghoomachi, Fab-
aceae); Acacia catechu (L.) Willd (Khair, Leguminosae); Allium
sativum L. (Lehsun, Liliaceae); Amaranthus spinosus L., A. viridis L.
(Chauli, Amaranthaceae); Citrus medica L. (Nimbu, Rutacae); Cli-
toria ternatea L. (Aparajita, Fabaceae); Ipomea carnera ssp fistulosa
Mart ex choisy (Behaya, Convolvulaceae); Leucas aspera L. (Guma,
Lamiaceae); Mucuma pruriens (L.) DC (Kewanch, Fabaceae); Nyc-
tanthes arbor- tristis L. (Harshingar, Oleaceae); Swerrta chirayita
(Roxb ex Flem) Karsten (Chirayita, Gentianaceae); Vanda tasselera
(Roxb.) Hook ex G. Don (Harjodi & Tarwari, Orchidaceae) and
Withania somniferra L. Dural (Ashgandh, Solanaceae) were recorded
by interviewing traditional herbalist, local healers, elderly men and
women of the tribal society which were used as herbal medicines for
the treatment of headache, sciatica, rheumatism, joint pain, disloca-
tion and body pain .
Use of Citrus medica L., Clitoria ternatea L. and Leucas aspera L.
were recorded to be the common plants used in severe headache. Leaf
juice of Citrus medica is used as nasal drop in migraine and perma-
nent headache. The root paste of Clitoria ternatea is applied on
forehead to relieve headache. The root juice of Leucas aspera is put in
to the nostril for relief in headache. The magical effect of these plants
has been personally observed by the author. The phytochemical and
clinical investigations of these plants are desirable for more uses and
interesting results.
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Comorbidity of migraine with somatic diseases
in a large population based study
H. Le1, P. Tfelt-Hansen1, M.B. Russell2, A. Skytthe3, K.O. Kyvik3,4,
J. Olesen1
1Danish Headache Centre, Neurology, Glostrup Hospital,
University of Copenhagen, Glostrup, Denmark;
2Head and Neck Research Group, Research Centre, Akerhus
University Hospital, Løvenskrog, Norway;
3The Danish Twin Registry, Epidemiology, Institute of Public Health,
University of Southern Denmark;
4Institute of Regional Health Services Research, University
of Southern Denmark, Odense, Denmark
Context Migraine affects 11% of the adult population in the world
and is a common complaint in all specialties and general practice. It is
known to be comorbid with depression, anxiety and a small number of
somatic diseases. Comorbidity with a variety of other somatic dis-
orders is unknown. Comorbidity in migraine with aura (MA) and
migraine without aura (MO) separately and its relation to sex are also
largely unknown.
Objective To determine sex specific comorbidity of migraine and its
subtypes MA and MO with a number of common somatic diseases.
Design Questionnaire sent to all Danish twins containing previously
validated questions to diagnose migraine and its subtypes as well as
questions regarding a number of somatic diseases. The twins are
representative of the whole Danish population and were used as such
in the present study.
Setting and participants Twins residing in Denmark and born
between 1931 and 1982. Of 46,418 possible participants, 34,944
(75%) responded but only 31,865 were eligible due to missing data.
Main outcome measure Odds ratio for somatic disease in migraine
and its subtypes.
Results A total of 21, 23 and 12 conditions were comorbid with
migraine, MA and MO, respectively at p \ 0.001. Comorbid diseases
included previously documented diseases: asthma, epilepsy and
stroke as well as new conditions: kidney stone, psoriasis, rheumatoid
arthritis, osteoarthritis and fibromyalgia. Twelve conditions were
significantly more comorbid with MA than MO. The difference
between MA and MO was primarily seen in females. Significantly
more women than men had comorbidities with regard to 11 of the
diseases.
Conclusion A number of medical diseases were comorbid with self-
reported migraine. MA had more comorbidities than MO and females
more than males. Migraine occurs in 20-30% of several medical
conditions. It should be diagnosed and treated along with the primary
disease.
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Association between migraine, lifestyle
and socioeconomic factors: population-based cross
sectional study
H. Le1, P. Tfelt-Hansen1, A. Skytthe2, K.O. Kyvik2,3, J. Olesen1
1Danish Headache Centre, Neurology, Glostrup Hospital,
University of Copenhagen, Glostrup, Denmark;
2The Danish Twin Registry, Epidemiology, Institute of Public Health,
University of Southern Denmark, Odense, Denmark;
3Institute of Regional Health Services Research,
University of Southern Denmark, Odense, Denmark
Objective To investigate whether sex-specific associations exist
between migraine and lifestyle or socio-economic factors. We dis-
tinguished between the subtypes migraine with aura (MA) and
migraine without aura (MO).
Setting and participants In 2002 a questionnaire containing vali-
dated questions to diagnose migraine and questions on lifestyle and
socio-economic factors was sent to 46,418 twin individuals residing
in Denmark. The twins are representative of the Danish population
with regard to migraine and other somatic diseases and were used as
such in the present study. 31,865 twin individuals aged 20 to 71 were
included.
Results An increased risk of migraine was associated with lower level
of schooling and education, retirement, unemployment, and smoking.
A decreased risk of migraine was associated with hard physical
exertion and regular intake of alcohol. Direct comparison between the
subtypes showed that the risk of MA was lower than MO in subjects
with lower education and weekly intake of alcohol whereas the risk of
MA was higher than MO in unemployed or retired subjects. Direct
comparison between sexes showed that the risk of migraine was lower
for men than women in subjects who were lower educated, unem-
ployed, or retired. However, the risk was higher for men than women
in subjects with hard physical exertion, regular intake of alcohol, and
body mass index greater than 25. Migraine subjects had lower self-
rated health.
Conclusion Migraine was associated with several factors. Most
associations such as lower education and job status were probably
due to migraine while others such as smoking were risk factors
for migraine. More targeted research is needed to evaluate these
relations.
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Magnetic resonance imaging of craniovertebral
structures: clinical significance in cervicogenic
headaches
H. Knackstedt1,2, J. Krakenes3, D. Bansevicius1,2, M.B. Russell2,4
1Department of Neurology, Innlandet Hospital Trust, Elverum,
Norway;
2Head and Neck Research Group, University Hospital Akershus,
Oslo, Norway;
3Section for Neuroradiology, Department of Radiology, Haukeland
University Hospital, University of Bergen Medical School,
Bergen, Norway;
4Faculty Division Akershus University Hospital,
University of Oslo, Nordbyhagen, Norway
Objective To investigate the relevance of morphological changes in
the main stabilizing structures of the craniocervical junction in per-
sons with cervicogenic headache (CEH).
Material and methods A case control study of 46 consecutive persons
with CEH, 22 consecutive with headache attributed to whiplash asso-
ciated headache (WLaH) and 19 consecutive persons with migraine.
The criteria of the Cervicogenic Headache International Study Group
(CHISG) were used for diagnosing CEH; otherwise the criteria of the
International Classification of Headache Disorders (ICHD II) were
applied. All participants had a clinical interview, and a physical and
neurological examination. Proton weighted magnetic resonance
imaging (MRI) of the craniovertebral junction, and the alar and trans-
verse ligaments were evaluated blinded to clinical information.
Results The MRI of the craniovertebral and the cervical junctions, the
alar and transverse ligaments disclosed no significant differences
between those with CEH, WLaH or migraine. The site of CEH pain
was not correlated with the site of signal intensity changes of the alar
and transverse ligaments. In fact very few had moderate or severe
signal intensity changes in their ligaments.
Conclusion MRI shows no specific changes of cervical discs orcra-
niovertebral ligaments in CEH.
Keywords Cervicogenic headache, Alar ligaments, Transverse liga-
ments, Craniovertebral junction, Cervical junction, MRI
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Cases intractable headache: pathogenic research
and new therapy
P. Gao1, Y. Jin2
1Hanze University Applied Science, Groningen, Netherlands Antilles;
2Physiotherapy di San Marino, San Marino, San Marino
Patients suffered from 20-49 years history of intractable headache
with sleeping or depression disturbances. They have not any
improvement after many years’ pharmaceutical therapy. After
8-10 times’ Modern Acupuncture (MAC) cure, their headache dis-
appeared. The result of this study suggests that headache usually
occurs in patients with Cervicobasilar Part (CBP) injury combining
with social, mental and hormone disturbances. The essential problems
of headache are possibly formed by CBP biological structure injury to
block cervical nerves roots in C1-C3 level which innervate on the
head cutis. Because there are no algesireceptors in the brain tissues
like in other organs, so that the headache is only the pain on the derma
and subcutaneous tissues of the head. The clinical therapy will be
focused on the CBP to achieve satisfied result. MAC is a new acu-
puncture set upon human anatomy and Neuroanatomy that taking on
the column vertebrae near the radix nerve where respondent to all of
organs, body or extremities. The new headache pathogen and therapy
have been proposed in this paper.
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Recurrent neck pain and headaches in preadolescence
associated with mechanical dysfunction of the cervical
spine
S.A. Weber
Ta¨by Kiropraktor Klinik, Vallentuna, Sweden
Background Recurrent neck pain and/or headaches in adults can be
initiated and exacerbated by aberrant cervical spinal mechanics
including forward head posture, reduced cervical range of motion,
trigger points in cervical musculature and cervical joint dysfunction.
The contribution of dysfunctional mechanics in the cervical spine to
recurrent neck pain and/or headaches in children is unknown.
Objectives To establish if there were differences in the cervical
biomechanics in preadolescents who had recurrent neck pain and/or
headaches as compared to those who were symptom-free.
Methods In a cross-sectional observational study, Swedish preadoles-
cents (n = 131) completed a questionnaire and 110 students were
examined to establish head posture, active cervical range of motion,
trigger points in cervical paraspinal musculature, and passive cervical
joint functioning. Parents completed an informed consent form which
had additional questions. Data were analyzed using descriptive statistics.
Results Recurrent neck pain/ headaches was reported by 40%
(n = 52). There was an even gender distribution of preadolescents with
neck pain/headaches and an increase in prevalence as students transi-
tioned into adolescence as well as a gender shift with female
preponderance. Joint dysfunction in the lower cervical spine was a
significant finding associated with neck pain and/or headache in those
pre-adolescents with symptoms. More than half of all the students
examined had forward head posture, upper cervical joint dysfunction
and trigger points the suboccipital muscles. There was significant dis-
crepancy between parental report and self-report of both trauma and
frequency of symptoms.
Conclusions Neck pain/headaches in preadolescents were signifi-
cantly associated with cervical joint dysfunction. Children and parents
may present different historical information. There were altered
biomechanics in the upper cervical spine in the majority of the
preadolescents examined. Future studies should follow a cohort of
preadolescents through adolescence to investigate if this is a factor in
the increasing prevalence of neck pain/headaches seen in the ado-
lescent population.
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Precipitating and releaving factor of migraine in 200
Iraqi Kurdish patients
I.K. Abdulzahra
Dept. of Neurology, Hawler College of Medicine, Erbil, Iraq
Objectives To study precipitating and relieving factors of migraine
headache in a group of Iraqi Kurdish patients including the effect of
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fasting in Ramadan, and to estimate the percentage of family history
of migraine.
Patients and methods A review of a series of 200 migraine case from
different parts in Kurdistan region in the North of Iraq attending the
out-patient Neurology clinic at Rizgary Teaching Hospital and a
private Neurology clinic at Erbil City was carried out during the
period between October 2007 to May 2008. The precipitating factors
and relieving factors for migraine headache were registered and
tabulated to be compared with others. Case definition of migraine was
according to the International Headache Society (IHS) criteria.
Results 33% of patients were at the age range 30-39 years. 40.5% of
patients had first attack at the age between 20-29 years. Stress or
psychological upset is the commonest triggering factor (80%), fol-
lowed by increasing physical activity (68%), change in whether
(65.5%), relation to fasting (65%). Fasting in Ramadan was a trig-
gering factor for headaches in 65% of patients. No significant
association have been found with any of the triggering factors in
regarding to sex difference. Relieving factors of migraine in our
studied sample were NSAID in 50% of patients, and sleep (45.5%).
61% of the studied sample had positive family history of migraine,
32.5% of them mentioned maternal history of migraine.
Conclusions Psychological upset and stress was and excessive
physical activity were the commonest triggering factors of migraine
headache, while NSAID was the commonest relieving factor of
migraine in this population, family history is present in 61% of
migraine patients which is mostly of maternal root.
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Effects of microiontophoresed calcitonin gene-related
peptide (CGRP) and CGRP-antagonists
on trigeminothalamic transmission
O. Summ1,2, A.P. Andreou1, A.R. Charbit1, P.J. Goadsby1
1Headache Group, Department of Neurology,
University of California, San Francisco, CA, USA;
2Department of Neurology, University of Mu¨nster, Mu¨nster, Germany
Objectives Calcitonin gene-related peptide (CGRP) receptor antag-
onists are effective in treating acute migraine. The main site of anti-
nociceptive action of CGRP receptor antagonists is likely to be within
the central nervous system. However, this was only demonstrated at
the level of second order neurons within the trigeminocervical com-
plex. To test the effect of CGRP receptor antagonists at further sites
within the trigeminovascular nociceptive pathway we have performed
electrophysiological recordings from neurons in the venteropostero-
medial (VPM) nucleus of the thalamus of rats. We investigated the
effect of microiontophoresed CGRP and CGRP receptor antagonists
on cell firing evoked by electrical stimulation of the superior sagittal
sinus (SSS) or by microiontophoresis of L-glutamate.
Methods Male Sprague Dawley rats (N = 7) were anesthetized with
pentobarbitone(60 mgkg-1) and cannulated for anesthesia, physio-
logical monitoring and drug administration. Thalamic cells (N = 13)
with facial receptive fields and trigeminocervical input, identified by
electrical stimulation of the SSS, were recorded using electrophysi-
ological techniques. We tested the effect of microiontophoresed
CGRP and the CGRP receptor antagonists olcegepant and CGRP8-37
on neuronal firing in the VPM, evoked by electrical stimulation of the
SSS or microiontophoresed L-glutamate.
Results Microiontophoresis of control, CGRP and olcegepant had no
effect on neuronal firing, evoked by SSS-stimulation or L-glutamate
evoked. In comparison to control, a 14% reduction of cell firing was
seen when CGRP8-37 ejection was tested on SSS-stimulation induced
firing (t21 = -2.397, P \ 0.05) or L-glutamate evoked cell firing in
the VPM (t16 = -2.173, P \ 0.05). Although microiontophoresis of
CGRP had no effect on L-glutamate evoked firing, CGRP did increase
the background-activity (t13.1 = -2.904, P \ 0.05) by 25%.
Conclusion This is the first report showing local CGRP-mediated
effects on thalamic nociceptive trigeminovascular neurons, which
further extends the potential site of action of this novel class of anti-
migraine treatments.
Conflict of interest Oliver Summ received a fellowship by the Eur-
opean Federation of Neurological Societies and fellowship by MSD.
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Immunological profile of herpes associated migraine:
pathogenesis and treatment
U. Ashonov, V. Garib
Tashkent Institute for Postgraduate Medical Education,
Tashkent, Uzbekistan
Cytokines may be a cause of the migraine pain: in fact an high levels
of chemokines could stimulate the activation of trigeminal nerves, the
release of vasoactive peptides or other biochemical mediators, such as
nitric oxide, and then to cause inflammation. Herpes virus switch
from latency to re-activation within trigeminal ganglia could be also
trigger of trigeminal activation, inflammation and pain release. In
fact, it appears that HSV replicates in sensory neurons after primary
and/or secondary infection, inducing cell-cell spread in neuronal
ganglia without causing lyses. If the replication process ensues, a
particular gene expressed by the virus becomes active vs. or inactive
(which balances with perpetuating LAT). At the earliest stage of
recurrence, there is already an intense inflammatory response with
inflammatory cytokines release. Herpes virus re-activation themselves
or together with cytokines release may be a cause of the migraine
pain: could stimulate the activation of trigeminal nerves, the release
of vasoactive peptides or other biochemical mediators, such as nitric
oxide, and then to cause inflammation. In parallel, pain syndrome
cause to release of ‘‘pain hormone’’ - substance P, which influence on
immune cells. 20 patients with migraine had been investigated by
PCR-analysis. HSV-1 had been fond in 100% cases. In our study,
Substance P, is added in 3-dimensional collagen matrix, reduces
migration activity of CD16 + cells. The stimulatory effect on natural
killer cells cytotoxicity had been noted. It is necessary to underline,
that all mechanisms of migraine pathogenesis, had been previously
discovered and discussed, can be combined via HSV-associated
theory.
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Protective effects of flunarizine on cerebral
mitochondria injury induced by cortical spreading
depression under hypoxic conditions
S. Yu, F. Li, E. Qiu, Z. Dong, R. Liu, S. Wu, L. Jiang
Chinese PLA General Hospital, Beijing, China
Cortical spreading depression (CSD) may induce potentially harmful
mitochondrial lesions under hypoxic conditions. Flunarizine may
have a protective effect on cerebral mitochondria. We established a
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rat CSD model and explored whether cerebral mitochondria injury is
induced by CSD under normal and hypoxic conditions and whether
flunarizine has a protective effect on cerebral mitochondria.
Seven randomly selected Groups of SD rats received as follows: no
intervention (control Group I); 1 M NaCl injections to the left parietal
cortex (Group II); 1 M KCl injections to the left parietal cortex
(Group III); intraperitoneal flunarizine (3 mg/kg) 30 min before KCl
injections (Group IV); 14% O2 inhalation for 30 min before NaCl
injections (Group V); 14% O2 inhalation followed by KCl injections
(Group VI); 14% O2 inhalation and intraperitoneal flunarizine fol-
lowed by KCl injections (Group VII). Following treatment, the rats
were sacrificed by decapitation and brains removed for the analysis of
number, amplitude, and duration of CSD, mitochondria transmem-
brane potential (MMP) and oxidative respiratory function.
The duration of CSD was significantly longer in the Group that
received additional oxygen than KCl alone . However, the number
and duration of CSD in the Group that received flunarizine in
addition to oxygen was significantly lower than the Group that
received oxygen and KCl. Similarly, MMP in Group VI was sig-
nificantly lower than in Group III, and MMP in Group VII was
significantly higher than in Group VI. State 4 respiration in Group
VI was significantly higher than in Group III and State 3 respiration
in Group VII was significantly higher than in Group VI. Respiration
control of rate in Group VII was also significantly higher than in
Group VI.
Aggravated cerebral mitochondria injury might be attributed to CSD
under hypoxic conditions. Flunarizine can alleviate such cerebral
mitochondria injury under both normal and hypoxic conditions.
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Modulation of cortical spreading depression
and trigeminal nociception by nociceptin/orphanin FQ
S. Bongsebandhu-phubhakdi1, T. Phisolkulkasem2,
A. Srikiatkhachorn1
1Department of Physiology, Faculty of Medicine, Chulalongkorn
University, Bangkok, Thailand;
2Department of Physiology, Faculty of Medical Science, Naresuan
University, Pissanulok, Thailand
Migraine is a primary vascular headache which is characterized by
recurrent moderate to severe throbbing headache. Activations of
cerebral cortex and trigeminal nociceptive system are essential steps
in pathogenesis of migraine. The control of these systems is extremely
complex and involves several chemical messengers, both small
molecule transmitters and peptides. Nociceptin/orphanin FQ (N/OFQ)
is known as a neuropeptide with close similarity to the opioid pep-
tides, while its effect in migraine is not fully understood. In this study,
we will investigate whether there is a modulation of N/OFQ in the
trigeminal nociception induced by cortical spreading depression
(CSD). The CSD is an electrocorticographic phenomenon which is
believed to underlie the transient neurological deficit observed during
the aura phase of migraine. Intrathecal administration of N/OFQ
significantly increased amplitude, number of peaks and area under the
curve (AUC) of CSD. Additionally, expression of TRPV1 in the tri-
geminal ganglia (TG) and number of Fos-immunoreactive neurons in
the trigeminal nucleus caudalis (TNC) evoked by the CSD were
facilitated. N/OFQ modulation is likely to intensify the trigeminal
nociception by increasing cortical excitability. Orphan opioid recep-
tor-like 1 (ORL-1), the receptor of N/OFQ, may be a future target for
pharmaceutical treatment of migraine.
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Are CGRP antagonists inherently slowly acting drugs
in migraine?
P.C. Tfelt-Hansen
Danish Headache Centre, University of Copenhagen,
Glostrup, Denmark
Migraine patients want to be pain free and a quick onset of action .
Two new CGRPantagonists, olcegepant and tecagepant, have been
studied in migraine .After i.v. olcegepant the maximum effect was
observed after 60 min (2.5 mg) and 120 (5 mg). This is rather slow
for an intravenously administered anti-migraine drug. For oral tel-
cagepant 300 mg the maximum effect (as judged from the difference
to placebo) was about 4 hours.
Compared to rizatriptan 10 mg the effect of telcagepant 300 mg up to
2 hours was slower in onset of action, with sumatriptan 100 mg in
between . At 1 to 2 hours rizatriptan 10 mg (40%) was superior to
telcagepant (26%). (p \ 0.01).
There are thus some indications from both studies of the CGRP
antagonists, olcegepant and telcagepant, that there is compared to
other drug a somewhat slow onset of action of CGRP antagonists in
migraine. If correct, this could indicate that for this treatment prin-
ciple, CGRP antagonism, the action takes place in a so-called
hypothetical ‘‘deep compartment’’.
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Headache, migraine and cardiovascular risk factors:
the hunt population-based study
B. Winsvold1,2, K. Hagen3, A.H. Aamodt3, L.J. Stovner3, J. Holmen4,
J.-A. Zwart1,2
1Department of Neurology, Oslo University Hospital, Oslo, Norway;
2Institute of Clinical Medicine, University of Oslo, Oslo, Norway;
3Department of Neuroscience, Norwegian University of Science
and Technology, Trondheim, Norway;
4HUNT Research Centre, Department of Public Health and General
Practice, Norwegian University of Science and Technology,
Trondheim, Norway
Background Migraine with aura (MA) has been found to be a risk
factor for cardiovascular disease including ischaemic stroke and
myocardial infarction. Studies have also reported a higher prevalence
of unfavourable cardiovascular risk factors among migraineurs, but
results have been conflicting as to whether this is restricted to MA or
also holds true for migraine without aura (MO). The aim of the
current study is to examine the relation between headache and car-
diovascular risk factors in a large scale cross-sectional population-
based study.
Methods A total of 51,383 subjects (age C 20 years) completed a
headache questionnaire in the population-based Nord-Trøndelag
Health Study in Norway 1995-1997 (HUNT 2). Framingham 10-year
risk for myocardial infarction and coronary death could be calculated
for 46,482 (90.5%) of these. Parameters measured were blood pres-
sure, body mass index, serum total and high-density lipoprotein
cholesterol.
Results Compared to controls Framingham risk score was elevated in
non-migraine headache sufferers (OR 1.17, 95% CI 1.09-1.25),
migraineurs without aura (OR 1.16, 95% CI 1.06-1.27) and most
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pronounced among migraineurs with aura (OR 1.53, 95% CI 1.21-
1.94). Framingham risk score increased with headache frequency for
all headache types. For non-migrainous headache and MO the
increased risk was accounted for by unhealthy lifestyle factors, while
such factors did not explain the elevated risk associated with MA.
Conclusions Both MA, MO and non-migrainous headache are asso-
ciated with an unfavourable cardiovascular risk profile, but different
mechanisms seem to underlie the elevated risk in MA than in the
other headache types.
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Onabotulinumtoxin-A treatment reduces adverse
impact of chronic migraine (CM):
PREEMPT clinical program HIT-6 results
R.B. Lipton1, S.F. Varon2, S.K. Aurora3, R.E. DeGryse4,
C.C. Turkel4
1Albert Einstein College of Medicine, Bronx, NY, USA;
2Allergan, Irvine, CA, USA;
3Swedish Neuroscience Institute, Seattle, WA, USA;
4Allergan Inc., Irvine, CA, USA
Objective Assess effect of treatment with onabotulinumtoxinA
(BOTOX) on headache impact in patients with chronic migraine
(CM) (ICHD-II migraine and C 15 headache days/month).
Background CM is a burdensome neurological disorder character-
ized by pain, disability, and activity limitations. Reducing CM impact
is an important treatment goal.
Methods PREEMPT program included 2 phase III multicenter,
double-blind, placebo-controlled studies evaluating efficacy and
safety of onabotulinumtoxinA in CM. HIT-6, a validated headache-
impact measure, was administered at baseline and every 4 weeks.
Each of the 6 individual questions score from 6-13, resulting in a total
HIT-6 score ranging from 36-78, with higher scores reflecting greater
adverse impact. We computed change in HIT-6 relative to baseline at
each timepoint and present pooled data through end of the 24-week,
double-blind phase of these studies. Negative change scores reflect
reductions in headache impact.
Results 1384 subjects included in pooled analyses (n = 688 onabo-
tulinumtoxinA; n = 696 placebo). Mean baseline scores were
comparable between treatment groups (all P = NS). Statistically
significant (all P \ 0.001 by Wilcoxon rank-sum test) between-group
differences favoring onabotulinumtoxinA over placebo were observed
for change from baseline in total HIT-6 score and all 6 individual question
scores at all visits throughout the double-blind phase, except question 3 at
Week4. Baseline and mean change from baseline scores (SD) at Week24
for onabotulinumtoxinA and placebo, respectively: Q1-Pain severity
when having headaches: BL = 10.7(0.80)/10.7(0.89), Week24 =
-0.6(1.30)/-0.2(1.12); Q2-Limit in ability to do usual daily activities:
BL = 10.6(0.90)/10.6(0.94), Week24 = -0.6(1.33)/-0.2(1.11); Q3-
Wish to lie down when having headaches: BL = 11.5(1.18)/11.5(1.16),
Week 24 = -0.7(1.54)/ -0.4(1.35); Q4-Too tired for work/daily activities
due to headache past 4 weeks: BL = 10.6(0.95)/10.6(1.02),
Week24 = -0.9(1.53)/-0.4(1.39); Q5-Irritation because of headache past
4 weeks: BL = 11.3(1.29)/11.2(1.24),Week24 = -1.2(1.92)/-0.6(1.64);
Q6-Limit in ability to concentrate past 4 weeks: BL = 10.8(0.85)/
10.8(0.94), Week24 = -1.0(1.54)/-0.4(1.33); Total HIT-6 score:
BL = 65.5(4.05)/65.4(4.32); Week24 = -4.8(7.04)/-2.4(6.09).
Conclusions Treatment of CM with onabotulinumtoxinA is associ-
ated with reductions in headache impact as measured by HIT-6.
Study support Allergan, Inc.
Conflict of interest Dr. Lipton receives research support from the
NIH [PO1 AG03949 (Program Director), PO1AG027734 (Project
Leader), RO1AG025119 (Investigator), K23AG030857 (Mentor),
K23NS05140901A1 (Mentor), and K23NS47256 (Mentor)], the
National Headache Foundation, and the Migraine Research Fund;
serves on the editorial boards of Neurology and Cephalalgia and as
senior advisor to Headache, has reviewed for the NIA and NINDS,
holds stock options in Neuralieve Inc. and Minster Inc; serves as
consultant or has received honoraria from: Allergan, Autonomic
Technologies, Boston Scientific, Bristol Myers Squibb, Eli Lilly,
Endo, GlaxoSmithKline, Minster, Merck, Nautilus Neuroscience,
Neuralieve, Novartis, and Pfizer.
Catherine Turkel, PharmD, PhD is full time employee of Allergan
Inc., Irvine, California, USA.
Sepideh Varon, PhD is full time employee of Allergan Inc., Irvine,
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Onabotulinumtoxin-A treatment improves quality
of life in patients with chronic migraine (CM):
MSQ results from PREEMPT
S.D. Silberstein1, S.F. Varon2, H.-C. Diener3, R.E. DeGryse2,
C.C. Turkel2
1Thomas Jefferson Headache Center, Philadelphia, PA, USA;
2Allergan, Inc., Irvine, CA, USA;
3University of Essen, Essen, Germany
Objective Determine effect of onabotulinumtoxinA (BOTOX)
treatment on health-related quality of life (HRQoL) in adults with CM
(ICHD-II migraine and C 15 headache days/month).
Background CM is a primary neurological disorder with significant
physical/emotional disability, reduced HRQoL, and interrupted work-
place productivity/social activities. The Migraine-Specific Quality of
Life Questionnaire (MSQ) measures how migraines adversely affect
patients’ HRQoL and daily performance over the preceding 4 weeks.
Methods The PREEMPT clinical program included 2 phase 3,
24-week double-blind, placebo-controlled, multicenter studies eval-
uating efficacy and safety of onabotulinumtoxinA in CM with
injections of onabotulinumtoxinA or placebo at baseline and week 12,
followed by 32-week, open-label phase of 3 injection cycles. HRQoL,
measured by 14-item MSQ v2.1, across 3 domains (Role-Restrictive,
Role-Preventive, Emotional-Functioning) was obtained at baseline
and every 12 weeks. Item scores range from 1 to 6, with lower scores
reflecting worse impact of CM on HRQoL. A positive change from
baseline reflects HRQoL improvement. Pooled results of all 14
questions from the double-blind phase are presented.
Results 1384 subjects were included in the predefined pooled analyses
(n = 688 onabotulinumtoxinA; n = 696 placebo). Baseline mean of
each MSQ question score was comparable between treatment groups.
Significantly more improvements in HRQoL were observed in the
onabotulinumtoxinA group than placebo group for all individual
question scores from baseline to week 12 (P B 0.002), week 24
(P \ 0.001), and for each domain (week 24, P \ 0.001). Mean change
from baseline scores (SD) at week 24 for onabotulinumtoxinA and pla-
cebo, respectively: Q1-Family: 0.9(1.24)/0.4(1.18); Q2-Leisure:
0.9(1.29)/0.5(1.17); Q3-Activity: 0.8(1.21)/0.4(1.16); Q4-Work:
0.9(1.29)/0.4(1.21); Q5-Concentrate: 0.8(1.26)/0.4(1.22); Q6-Tired:
0.7(1.36)/0.3(1.27); Q7-Energy: 0.9(1.37)/0.5(1.25); Q8-Cancel:
0.6(1.24)/0.4(1.15); Q9-Help: 0.6(1.31)/0.2(1.20); Q10-Stop: 0.7(1.32)/
0.3(1.17); Q11-Social: 0.7(1.35)/0.4(1.27); Q12-Frustrated: 1.1(1.63)/
0.6(1.45); Q13-Burden: 0.8(1.50)/0.4(1.41); Q14-Afraid: 0.8(1.56)/
0.4(1.49).
Conclusions Treatment of CM with onabotulinumtoxinA produced
statistically significant and clinically meaningful improvements in
J Headache Pain (2010) 11 (Suppl 1):S1–S150 S11
123
HRQoL. HRQoL improvement was maintained with repeated injec-
tions of onabotulinumtoxinA.
Study support Allergan, Inc., Irvine, CA.
Conflict of interest Dr. Silberstein has acted as a consultant, speaker
or received research support from Allergan Pharmaceuticals.
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Onabotulinumtoxin-A treatment reduces pain intensity
in adults with chronic migraine: pooled results
from the double-blind, placebo-controlled phase
of PREEMPT
S.D. Silberstein1, S.K. Aurora2, R.E. DeGryse3, C.C. Turkel3
1Thomas Jefferson Headache Center, Philadelphia, PA, USA;
2Swedish Neuroscience Institute, Seattle, WA, USA;
3Allergan Inc., Irvine, CA, USA
Objective Assess the efficacy of onabotulinumtoxinA (BOTOX) for
the prophylaxis of headache (HA) in adults with chronic migraine
(CM).
Background CM is a prevalent, disabling, and undertreated neuro-
logical disorder. Few preventive treatments have been investigated,
and none is specifically indicated for CM.
Methods Two phase 3, 24-week, double-blind, parallel-group, placebo-
controlled studies (PREEMPT 1 and 2), followed by 32-week, open-label
phases evaluated the efficacy, safety, and tolerability of onabotulinum-
toxinA in CM (ICHD-II migraine and C 15 HA days/month). Qualified
subjects were randomized (1:1) to injections of onabotulinumtoxinA
(155U-195U) or placebo every 12 weeks for 2 cycles, and then received 3
open-label cycles. The primary efficacy variable was mean change from
baseline in frequency of HA days per 28 days (primary endpoint, Week
24). Additional variables included mean change from baseline in fre-
quency of severe HA days and in the daily HA severity score, an
assessment of patient0s extent of daily suffering from HA, per 28-day
period. Data from the double-blind phase are presented.
Results 1384 adults were randomized to onabotulinumtoxinA
(n = 688) or placebo (n = 696). Pooled analyses demonstrated a
large mean decrease from baseline in frequency of HA days, with
statistically significant between-group differences favoring onabo-
tulinumtoxinA over placebo at week 24 (-8.4 vs -6.6; P \ 0.001).
Additional statistically significant between-group differences favoring
onabotulinumtoxinA over placebo at Week 24 were found in reduc-
tions from baseline in the mean frequency of severe HA days (-4.5 vs
-3.0; P \ 0.001). Fewer onabotulinumtoxinA-treated patients had a
daily average HA score of severe compared to placebo at Week 24
(3.5% vs 7.6%; P = 0.004).
Conclusions OnabotulinumtoxinA treatment reduced HA severity
compared to placebo. The comprehensive results from the PREEMPT
clinical program demonstrate that onabotulinumtoxinA is effective in
the preventive treatment for CM.
Study supported by Allergan Inc., Irvine, CA.
Conflict of interest Dr. Silberstein has acted as a consultant, speaker
or received research support from Allergan Pharmaceuticals.
Catherine Turkel, PharmD, PhD is full time employee of Allergan
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Onabotulinumtoxin-A for chronic migraine:
PREEMPT trials establish a safe and effective dose
and injection paradigm
A.M. Blumenfeld1, S.D. Silberstein2, D.W. Dodick3, S.K. Aurora4,
C.C. Turkel5, W.J. Binder6
1Neurology Center, Encinitas, CA, USA;
2Jefferson Headache Center, Philadelphia, PA, USA;
3Mayo Clinic Arizona, Phoenix, AZ, USA;
4Swedish Neuroscience Institute, Seattle, WA, USA;
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Objective To establish a safe and effective onabotulinumtoxinA
dose and injection paradigm for patients with chronic migraine
(CM).
Background CM is a prevalent, disabling, undertreated neurologic
disorder for which few preventive treatments have been investi-
gated and none is specifically indicated. Various onabotulinum-
toxinA dose and injection paradigms have been evaluated in
studies for prevention of headache including migraine, but until
recently, none is uniformly safe and effective for the treatment of
CM.
Design/methods The PREEMPT clinical program (two phase 3,
24-week, double-blind, parallel-group, placebo-controlled studies,
followed by a 32-week, open-label phase) evaluated the efficacy and
safety of onabotulinumtoxinA in CM (ICHD II migraine and C 15
headache days/month). Randomized patients received a minimum
dose of 155 U onabotulinumtoxinA or placebo administered as 31
fixed-site, fixed-dose injections across 7 specific head/neck muscle
areas (corrugator, procerus, frontalis, temporalis, occipitalis, cervical
paraspinal, and trapezius). Patients with predominant pain location(s)
could receive up to 40 U additional onabotulinumtoxinA (maximum
dose 195 U) or placebo injections to 1 or both sides in up to 3 muscle
groups (occipitalis, temporalis, and trapezius). Using a sterile 30-
gauge, 0.5 inch needle (with a Luer Lock) intramuscular injections of
0.1 mL/site (5 U) of onabotulinumtoxinA or placebo were adminis-
tered every 12 weeks (double-blind: 2 cycles), followed by
onabotulinumtoxinA (open-label: 3 cycles).
Results The PREEMPT dose (onabotulinumtoxinA 155 U to 195 U)
and injection paradigm demonstrated that onabotulinumtoxinA yiel-
ded significant improvements over placebo across multiple headache
symptom measures including reduction in headache days: -8.4
onabotulinumtoxinA/- 6.6 placebo; p \ 0.001 (pooled data). Onab-
otulinumtoxinA using this injection paradigm was safe and well
tolerated. No new safety findings emerged throughout the 56-week
studies.
Conclusions/relevance OnabotulinumtoxinA injections using the
‘‘modified’’ follow-the-pain model were safe and effective in the
PREEMPT clinical program and provides an evidence-based injection
strategy to optimize clinical outcomes for patients with CM.
Study supported by Allergan, Inc.
Conflict of interest Dr. Blumenfeld has acted as a consultant, speaker
or received research support from Allergan Pharmaceuticals.
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support from Allergan Pharmaceuticals.
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Inc., Irvine, California, USA.
S12 J Headache Pain (2010) 11 (Suppl 1):S1–S150
123
79
Onabotulinumtoxin-A treatment improves HRQOL
and reduces the impact of chronic migraine: 56 week
results from the PREEMPT clinical program
R.B. Lipton1, S.F. Varon2, P.J. Goadsby3, R.E. DeGryse2,
C.C. Turkel2
1Albert Einstein College of Medicine, Bronx, NY, USA;
2Allergan, Inc., Irvine, USA;
3University of California, San Francisco, CA, USA
Objective Determine the impact of onabotulinumtoxinA treatment on
health-related quality of life (HRQoL) in adults with chronic migraine
(CM).
Background CM is disabling and associated with low HRQoL,
diminished workplace productivity, and high healthcare resource
utilization.
Design/methods PREEMPT included two phase 3 studies. Each had a
24-week, double-blind phase (2 injection cycles of onabotulinum-
toxinA or placebo) followed by a 32-week, open-label phase (3
onabotulinumtoxinA injection cycles). The Headache Impact Test
(HIT)-6, used to measure the disabling impact of headaches on
patients0 lives, was administered at baseline and every 4 weeks during
the double-blind phase, and at Weeks 28, 36, 48, and 56. The
Migraine Specific Quality of Life Questionnaire v.2.1 (MSQ), which
captures information about long-term migraine impact on HRQoL in
3 domains: Role Restrictive, Role Preventive, and Emotional Func-
tioning, was administered at baseline and Weeks 12, 24, and 56.
Pooled 56-week data are presented.
Results Baseline mean total HIT-6 scores were comparable between
groups (p = 0.638); 93.1% were severely impacted (C60). At all
time points in the double-blind phase, onabotulinumtoxinA treat-
ment was associated with significant reductions in HIT-6 scores
compared to placebo treatment (p \ 0.001). At all open-label visits
there were significant within-group improvements from baseline in
mean HIT-6 scores: 48.8% of patients achieved a mean HIT-6 score
of less-than-severe impact (\60). In the open-label phase, signifi-
cant differences favoring onabotulinumtoxinA treatment in the
double-blind phase were observed at all visits, except Week 56.
OnabotulinumtoxinA significantly improved overall HRQoL at all
visits in the double-blind phase for all MSQ domains (p \ 0.001).
Significant HRQoL improvements were also observed at the Week
56 exit visit.
Conclusions/relevance Treatment of CM with onabotulinumtoxinA
is associated with improved functioning and HRQoL. Effects are
maintained with repeated injections. The magnitude of HRQoL
improvement is statistically significant and clinically meaningful.
Study supported by Allergan, Inc.
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Onabotulinumtoxin-A for treatment of chronic
migraine: 56-week analysis of the PREEMPT chronic
migraine subgroup with baseline acute headache
medication overuse
S.D. Silberstein1, J.R. Saper2, M.R. Stein3, R.E. DeGryse4,
C.C. Turkel4
1Jefferson Headache Center, Philadelphia, PA, USA;
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Objective Evaluate efficacy and safety of onabotulinumtoxinA
(BOTOX) as headache prophylaxis for PREEMPT chronic
migraine (CM) subgroup overusing acute headache pain medications
(AHPM).
Background CM is a prevalent, disabling, and undertreated neuro-
logic disorder. Up to 73% of CM patients overuse AHPM.
Design/methods PREEMPT included two phase 3 multicenter stud-
ies. Each had a 24-week double-blind phase with 2 injection cycles of
onabotulinumtoxinA (O) or placebo (P) and a 32-week, open-label
phase with 3 injection cycles of onabotulinumtoxinA. Criteria for
medication overuse (MO-yes) subgroup included subjects who during
the 28-day baseline had taken AHPM C 2 days/week, and had taken
simple analgesics C 15 days/month and/or other AHPM type-
s C 10 days/month (eg, triptans). Investigators were trained not to
enroll patients who used frequent opioids. 56-week pooled results for
patients in the PREEMPT MO-yes subgroup strata are reported.
Results Of 1384 PREEMPT subjects, 65.3%(n = 904) met MO-yes
criteria (O/O: n = 445, P/O:n = 459). Most (69.9%) had multiple
analgesic MO; few (n = 2.7%) had opioid MO. For the MO-yes
subgroup at Week24, statistically significant between-group decreases
from baseline favoring O vs P were observed for primary (headache
days, p \ 0.001) and all secondary efficacy endpoints: migraine days
(p \ 0.001), moderate/severe headache days (p \ 0.001), cumulative
headache hours (p \ 0.001), headache episodes (p = 0.028), and
percentage with severe Headache Impact Test (HIT)-6 category
(p \ 0.001). During the open-label phase, further large mean
decreases were observed through Week56 compared to Week24.
Overall, few MO-yes patients (4.1%) discontinued due to adverse
events (AEs). The overall AE incidence was 72.6%. Treatment-rela-
ted AEs were 32.5%.
Conclusions/relevance Most PREEMPT patients had baseline MO;
very few had opioid overuse. PREEMPT subpopulation analyses
demonstrated that repeated treatment with onabotulinumtoxinA is an
effective, safe, and well-tolerated headache prophylactic treatment for
CM patients with non-opioid 28-day baseline MO, resulting in clin-
ically meaningful improvements for multiple headache symptom
measures.
Study supported by Allergan, Inc.
Conflict of interest Dr. Silberstein has acted as a consultant, speaker
or received research support from Allergan Pharmaceuticals.
Catherine Turkel, PharmD, PhD is full time employee of Allergan
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Onabotulinumtoxin-A for treatment of chronic
migraine: pooled results from the double-blind,
randomized, placebo-controlled phase
of the PREEMPT clinical program
D.W. Dodick1, S.K. Aurora2, R.E. DeGryse3, C.C. Turkel3,
S.D. Silberstein4, R.B. Lipton5, H.-C. Diener6, M.F. Brin3
1Mayo Clinic Arizona, Phoenix, AZ, USA;
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3Allergan, Inc., Irvine, CA, USA;
4Jefferson Headache Center, Philadelphia, PA, USA;
5Albert Einstein College of Medicine, Bronx, NY, USA;
6Department of Neurology, University Hospital Essen
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Objective The PREEMPT clinical program assessed the efficacy and
safety of onabotulinumtoxinA (BOTOX) for the prophylaxis of
headaches in adults with chronic migraine (CM).
Background CM is a prevalent, disabling, and undertreated neuro-
logic disorder. Few preventive treatments have been investigated;
none is specifically indicated for CM.
Design/methods Two phase 3, 24-week, double-blind, parallel-group,
placebo-controlled studies (PREEMPT 1 and 2) followed by a 32-week,
open-label phase, evaluated the efficacy and safety of onabotulinum-
toxinA in CM (ICHD II migraine and C15 headache days/month).
Qualified subjects were randomized (1:1) to injections of onabotuli-
numtoxinA (155 U-195 U) or placebo every 12 weeks for 5 (2 double-
blind, 3 open-label) cycles. Key endpoints were mean change from
baseline in frequency of headache days (primary PREEMPT 2) and
headache episodes (primary PREEMPT 1) at Week 24.
Results Pooled analyses of 1384 randomized adults (onabotulinumtoxinA
n = 688, placebo n = 696) demonstrated a large mean decrease from
baseline for key endpoints (headache days and headache episodes), and for
almost all secondary variables favoring onabotulinumtoxinA at Week24
(headache days: -8.4 onabotulinumtoxinA, -6.6 placebo; p\0.001;
headache episodes -5.2 onabotulinumtoxinA, -4.9 placebo; p = 0.009)
and all other time points. The percent of patients that had C 50% reduction
from baseline in headache days at Week 24 was significantly greater for
onabotulinumtoxinA (47.1% onabotulinumtoxinA, 35.1% placebo;
p\0.001). The only efficacy variable that did not show a significant dif-
ference at Week 24 was overall acute headache medication use (all
categories; p = 0.247). However, a significant between-group difference in
triptan use reduction was observed (p\0.001). Most AEs (62.4% onabo-
tulinumtoxinA, 51.7% placebo) were mild to moderate in severity, with few
discontinuations (2.8% onabotulinumtoxinA, 0.7% placebo) due to AEs.
Conclusions/relevance This pooled analysis of the PREEMPT trials
supports the efficacy, safety, and tolerability of onabotulinumtoxinA
for the prophylaxis of headache in adults with CM.
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Effectiveness of flunarizine treatment in patients
with medication overuse headache:
a case-series study
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1Neurology, Hospital Universitario Miguel Servet, Zaragoza, Spain;
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Introduction Medication overuse headache (MOH) implies second-
ary headache on a daily or near daily basis, for 15 days or more a
month for 3 month and chronic migraine CM is the most common
subtypes of MOH in speciality care.
There are no patients’ studies with MOH’s criteria according to the
appendix of ICHD-2 treated with flunarizine.
Aim of the study We report our experience of flunarizine in patients
with MOH y CM.
Patients and methods Of a database of 800 outpatients with migraine
we selected those with MOH. They had several moderate-severe
migraine attacks per month and frequent headache (C 15 days per
month) and overused medication. They had never received prophy-
lactic treatment before. All patients received the same treatment from
the first day: Suppression of the medicine of abuse and establishment
of treatment with flunarizine 5 mg/day.
The patients were evaluated initially and to the fourth month of
treatment. Effectiveness was assessed by:
– Change in mean number of days with headache and severe migraine
attacks in the previous month and at the fourth month of treatment.
– Responder rate.
Results Of 164 ITT outpatients with MOH and treatment with flu-
narizine, 148 (90.2 %) patients continued the treatment and 123
(75%) responded to the treatment and left the abuse.
Responder rate 68%.
There was significant decrease (p = 0.0001) in mean number of days with
headaches: 14.9 to 6.7 days and severe attacks at the fourth month: 9.1 to
3.9 (p = 0.0001). The mean percentual reduction in number of days with
headaches was: 65.4% and severe migraines at the fourth month: 56.0%.
Side effects: 40% patients, none of them was serious.
Conclusions Flunarizine showed effectiveness when used as the
initial drug in the prophylactic treatment of MOH and CM, together
with the suppression of the medicament of abuse.
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Objective The aim of this research was to assess the prevalence of
primary headache (PH) in the emergency department (ED) in Lazio
region in a four year longitudinal study.
Methods We assessed the trend in the number of patients discharged
with an ICD 9CM diagnosis of PH between 2005 and 2008 and the
direct costs (DC) related to this phenomenon.
Results Our results show that although the overall number of patients
going to the ED in Lazio decreased in this period (mean of 2.171
million patients/year), the number of patients who visited the ED for
PH gradually increased. Indeed, the prevalence of 0.67% in 2005
(14825 patients) rose to 0.77 in 2008 (16556 patients), which repre-
sents an increase of 15% in the number of patients and of over 20% in
the DC, from 2,445,525 euros to 2,937,187 euros.
Conclusion This study, longitudinal, first in the Italian and in the
international literature, show, for the first time in our population, an
important rise in the number of visits to the ED for PH, which results in a
significant increase in the DC. Probably a closer collaboration between
headache centres and the ED may help reduce the burden of PH.
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Sustained efficacy of occipital nerve stimulation
in drug-resistant chronic cluster headache after
up to 5 years treatment
D. Magis1, P.-Y. Gerardy1, J.-M. Remacle2, J. Schoenen3
1Neurology—Headache Research Unit, University of Liege,
Leige, Belgium;
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University of Liege, Liege, Belgium
Background Drug-resistant chronic cluster headache (drCCH) is a
devastating condition for which various invasive procedures have
been tempted without any satisfactory effect. Our prospective pilot
study of great occipital nerve stimulation (ONS) in 8 drCCH patients
showed encouraging results at 15 months (Magis 2007).
Methods We recruited 15 patients with drCCH according to the previ-
ously published criteria of intractability (Goadsby 2006). They were
implanted with suboccipital stimulators on the side of their headache.
Long-term follow-up was achieved by questionnaires administered
during a headache consultation and/or by telephone interviews.
Results One patient had an immediate post operative infection of the
material. Mean time with ONS was 28.8 months (range 3-60 months).
Nine of the 14 remaining patients were totally pain-free (64%), 2 patients
had an improvement in frequency exceeding 90% and one patient a 89%
amelioration. Two patients did not respond or described mild improve-
ment. Intensity of residual attacks was not improved by ONS. Four patients
(29%) were able to reduce their prophylaxis. Common technical problems
were battery depletion (N = 8/14, 57%) and material infection (N = 3/
15, 20%). Recurrent battery replacement (until 2/ year in one patient) is
now avoided by the availability of rechargeable batteries. Clinical pecu-
liarities associated with ONS were occurrence of infrequent contralateral
attacks (N = 5/14, 36%), and/or isolated ispilateral autonomic attacks
(N = 5/14, 36%). Rapid attack recurrence after stimulator switch off was
reported by 7/12 improved patients (58%). Two patients found ONS-
related paresthesias unbearable; one had his stimulator removed, the other
switched it off though he was objectively ameliorated. Subjectively, nine
patients are very satisfied by ONS and one patient moderately satisfied.
Conclusions Our long-term follow-up confirms the efficacy of ONS
in drCCH, which remains a safe and well-tolerated technique. The
occurrence of contralateral attacks and isolated autonomic attacks in
nearly 50% of ONS responders may have therapeutic and patho-
physiological implications.
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Spontaneous CSF leak presenting as headaches
and movement disorder
B. Mokri
Neurology, Mayo Clinic, Rochester, MN, USA
Headache, often but not always orthostatic, is the most common clinical
manifestation of spontaneous CSF leak. Many patients may report
additional symptoms. We present three patients, a 59-year-old man and
two women 49 and 60 years old, with spontaneous CSF leak, headache,
and movement disorder. The headache was orthostatic in one patient,
exertional in another patient who also had orthostatic nausea, while the
third patient had lingering bifrontal headache and pronounced head
pressure sensation plus gait unsteadiness. All had substantial movement
disorder that had appeared along with the development of the other
symptoms and consisted of choreiform movements in two patients and
cervical dystonia in one. Diffuse pachymeningeal gadolinium enhance-
ment and imaging evidence of sinking of the brain was noted in head MRI
of all three patients. CSF opening pressure was low in two patients (5 mm
and 60 mm H2O) and 120 mm H2O in the third patient. Active CSF leak
was confirmed by CT-myelography in all three. CSF leak ceased spon-
taneously in one patient with time, one patient was treated successfully
with epidural blood patches. One patient required surgery to stop the CSF
leak. On follow-up, two patients were entirely asymptomatic with
complete resolution of headaches and the abnormal movements (chorea
in one, cervical dystonia in the other). The third patient, who was only
8 weeks postoperative, had noted marked and steady improvement
beginning approximately 4 weeks following the surgery. Chorea and
cervical dystonia may sometimes occur as manifestations of CSF leak
and can be expected to resolve with cessation of the leak.
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Neck pain is highly prevalent in migraine and tension-
type headache: a cross-sectional population study
S. Ashina1,2, L. Bendtsen2, A.C. Lyngberg3, R.B. Lipton4, R. Jensen2
1Pain and Palliative Medicine, Neurology, Beth Israel Medical
Center, Albert Einstein College of Medicine, New York, NY, USA;
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Background Neck pain is a common complaint from patients with
primary headaches. It may contribute to head pain, disability and
should be considered when treating headaches. However, the preva-
lence of neck pain in primary headaches is largely unknown.
Objective To assess the prevalence of neck pain in subjects with
migraine and tension-type headaches (TTH).
Methods We recontacted a sample of 1000 subjects, who were
invited to participate in a population study 12 years earlier. In addi-
tion, 300 new subjects were invited. A total of 834 subjects completed
a diagnostic headache interview and provided self-reported data on
neck pain, and 518 completed a Quantitative Sensory Testing study.
Subjects were assigned to the following groups: migraine, TTH or
coexistent headache if both disorders were present. Pericranial ten-
derness was recorded from 8 right- and left-sided locations using
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pressure-controlled palpation method. A local tenderness score for
each of the 8 locations was calculated by summations of both sides
with maximum possible score = 6.
Results The 1-year prevalence of neck pain was 68.9%. Multiple
regression analysis adjusted for gender, primary headache and age
demonstrated that subjects with neck pain had higher local tenderness
score in neck muscle insertions (3.4 ± 0.1 vs. 1.9 ± 0.2, p = 0.003)
and trapezius muscle (4.3 ± 0.1 vs. 2.9 ± 0.2, p \ 0.001) compared
to subjects with no neck pain. A higher proportion of subjects with
than without primary headaches had neck pain (86.4% vs. 57.1%;
OR = 3.45, 95% CI = 2.37-5.02, p \ 0.001). Using a model
adjusting for age and gender, the prevalence of neck-shoulder pain
was highest in coexistent headache (90.1%), followed by pure TTH
(88.7%) and migraine (77.6%), in comparison to subjects with no
headache (57.1%) (p \ 0.05 for all 3 group comparisons).
Conclusion Neck-shoulder pain is highly prevalent in primary
headaches from the general population. Prevalence is highest in
coexistent headache, followed by pure TTH and migraine.
Conflict of interest Dr. Lipton receives research support from the
NIH [PO1 AG03949 (Program Director), PO1AG027734 (Project
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Headache Foundation, and the Migraine Research Fund; serves on the
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Headache, has reviewed for the NIA and NINDS, holds stock options in
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honoraria from: Allergan, Autonomic Technologies, Boston Scientific,
Bristol Myers Squibb, Eli Lilly, Endo, GlaxoSmithKline, Minster, Merck,
Nautilus Neuroscience, Neuralieve, Novartis, and Pfizer.
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Effect of kynurenic acid on sensitivity to cortical
spreading depression in rats
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Background Migraine is sexually dimorphic and associated in 20%
of patients with an aura. Cortical spreading depression (CSD) is most
likely the neurophysiological correlate of the migraine aura (Laurit-
zen, 1994) and there is some evidence in rat that it can activate the
trigeminovascular system thought to be responsible for the headache
(Bolay et al., 2002). CSD is associated with glutamate release and can
be blocked by NMDA receptor antagonists (Nellgard & Wieloch,
1992). Kynurenic acid (KYNA) is the only endogenous NMDA
receptor antagonist in the brain.
Objective To determine if exogenous administration of KYNA is able
to modify KCl-induced CSD in rat and if the effect differs between
males and females.
Methods Male and female adult Sprague-Dawley rats were divided
into 4 groups (n = 8/group) receiving intraperitoneal injections of
L-kynurenine sulphate (L-KYN, a KYNA precursor; 300 mg/kg) com-
bined with probenecid (PROB, an organic acid transporter inhibitor;
200 mg/kg), L-KYN alone (300 mg/kg), probenecid alone (200 mg/kg)
or saline (NaCl 0.9%). Half an hour after the injections, CSD were
elicited under chloral hydrate anesthesia by applying over the occipital
cortex a cotton ball soaked with 1 M KCl. The electrocorticogram was
recorded (DC-100 Hz) with ipsilateral parietal and frontal electrodes for
1 hr. We studied treatment-induced changes of cortical KYNA concen-
trations with HPLC in 7 additional animals per group.
Results CSD occurrence L-KYN + PROB, L-KYN and PROB sig-
nificantly decreased the CSD number per hour in female rats, while in
males only L-KYN + PROB significantly decreased CSD frequency.
HPLC dosages in both sexes L-KYN + PROB and L-KYN signifi-
cantly increased the cortical KYNA level.
Conclusion These results show that interventions increasing the
levels of cortical kynurenic acid are able to decrease the sensitivity of
the cerebral cortex to cortical spreading depression. KYNA could thus
be a possible candidate for the treatment of migraine with aura.
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Lost productive time and cost due to headache
in chronic (CM) and episodic migraine (EM):
results from the AMPP study
A. Manack1, D.C. Buse2,3, D. Serrano4, C.C. Turkel1, W. Stewart5,
R.B. Lipton2,3
1Allergan Inc., Irvine, CA, USA;
2Montefiore Headache Center, Bronx, USA;
3Neurology, Albert Einstein College of Medicine of Yeshiva
University, Bronx, NY, USA;
4Vedanta Research, Chapel Hill, NC, USA;
5Center for Health Research, Geisinger Health System,
Danville, PA, USA
Background CM is associated with work-related consequences.
Objective To estimate and compare lost productive time (LPT) over
the lifespan between CM and EM sufferers and quantify the per
person cost of reduced productivity.
Methods In 2005, questionnaires were mailed to 24,000 severe head-
ache sufferers identified from a 2004 US population survey. Valid
returns were obtained from 18,500 severe headache sufferers aged
18 + . The analysis sample included respondents who had ICHD-2
defined migraine, were employed either full or part-time and completed
the Work and Health Questionnaire. Respondents were divided into EM
(\14 headache days/month and CM (C15 headache days/month). LPT
was based on self-report and calculated as the sum of missed hours plus
reduced productivity hour equivalents. Rate ratios (RR) for LPT scores
were calculated adjusting for age and gender. The interaction between
EM/CM and age was analyzed to characterize the effects of EM and CM
on LPT across the lifespan. Per-person cost analyses are underway and
will be presented estimating the annual cost of LPT.
Results The analysis sample included 6,319 respondents with EM and
298 with CM. Rates of LPT were higher in females than males
(RR = 1.06; 95%CI = [1.02, 1.09]) and in those with CM than EM
(RR = 1.36; 95%CI = [1.16, 1.60]). Additionally, the interaction effect
indicated that rates of LPT differed between CM and EM and the differ-
ence increased between the two populations over the lifespan
(RR = 1.01; 95%CI = [1.01, 1.02]). The main effect of age approached
but did not significantly impact LPT (RR = 1.01; 95%CI = [0.99, 1.00]).
Conclusions Rates of LPT were significantly higher in CM than in
EM and in females than males. Though the RR for the interaction of
LPT with age in CM and EM is modest on a yearly basis, the effect
becomes substantial over many years. LPT associated with CM
reflects a substantial individual and societal burden.
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Rates and predictors of remission from chronic
migraine (CM) to episodic migraine (EM):
results from the AMPP study
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R.B. Lipton2,3
1Allergan Inc., Irvine, CA, USA;
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3Neurology, Albert Einstein College of Medicine of Yeshiva
University, Bronx, NY, USA;
4Vedanta Research, Chapel Hill, NC, USA
Objective To estimate remission rates for CM and assess potential
predictors of remission from CM to EM.
Background Each year, approximately 2.5% of episodic migraineurs
develop CM (i.e., progression). Though rates and predictors of progres-
sion have been studied, data are limited on CM remission and persistence.
Methods In 2005, questionnaires were sent to 24,000 severe headache
sufferers identified in a previous US population survey who were
followed annually between 2005–2009. Participants studied had CM
(ICHD-2 migraine criteria and C15 headache days/month) in 2005
and 3 consecutive years of follow-up data. To assess predictors of
remission, two groups were compared: persistent CM (i.e., CM in
2005 and CM or high-frequency EM [HFEM:10-14 headache days/
month] in 2006 and 2007) and remitted CM (i.e., CM in 2005 but low-
frequency EM [LFEM:0-9 headache days/month], probable migraine,
tension-type headache, other episodic headache, or no headache in
2006 and 2007). Demographic variables, body mass index (BMI),
depression, age-of-migraine onset, allodynia, acute and preventive
medication utilization, and headache-related-disability (MIDAS) were
examined as predictors by assessing between and within group effects.
Results Subjects included 383 individuals with CM in 2005 who
contributed 3 years of data; 64%(n = 292) were classified as persistent
CM while 26%(n = 100) were classified as remitted CM. With regard
to predictors of remission, all models were adjusted for age, sex, race,
population density, geographic region and income. Exploratory anal-
yses suggested that depression, MIDAS, BMI, age of migraine onset,
allodynia, acute medication utilization by class and overuse did not
significantly predict remission. Current use of preventive medication
predicted remission in that participants utilizing preventives were half
as likely to remit [OR(95%CI) = 0.48(0.28,0.84)].
Conclusions Over 2 years, the majority of CM sufferers were per-
sistent. Preventive treatment was associated with a lower rate of
remission, perhaps because CM sufferers on prevention are a more
severe subgroup with a worse prognosis.
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Association of a notch 3 gene polymorphism
with migraine susceptibility
S. Menon1, H. Cox1, M. Kuwahata1, S. Quinlan1, J. Macmillan2,
L. Haupt1, R. Lea3, L. Griffiths1
1Genomics Research Centre, Griffith University, Gold Coast,
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2Department of Medicine, University of Queensland Graduate School
of Medicine/Queensland Institute of Medical Research, Brisbane,
QLD, Australia;
3Institute of Environmental Science and Research, Porirua,
New Zealand
Cerebral Autosomal Dominant Arteriopathy with Subcortical infarcts
and leucoencephalopathy, an autosomal dominant disease, shares com-
mon symptoms with migraine. More than 65% of all CADASIL
mutations occur in exons 3 and 4 of the Notch 3 gene. A number of
synonymous polymorphisms have also been identified in these exons.
This study investigated the role of C381T (rs 3815188) and G684A (rs
1043994) single nucleotide polymorphisms (SNP) in exons 3 and 4
respectively of the Notch 3 gene in migraine. The first study found a
significant association between the C381T variant and migraine
(P = 0.005), specifically in migraine without aura (MO) (P = 0.002)
sufferers, in a population of 275 migraineurs and 275 control individuals
matched for age, gender and ethnicity. The G684A variant was also found
to be significantly associated with migraine (P = 0.015), specifically in
migraine with aura (MA) sufferers (P = 0.001). The follow-up study in
300 migraineurs and 300 control individuals did not show replicated
association of the C381T variant with migraineurs (P = 0.245). However
the G684A variant was again shown to be significantly associated with
migraine (P = 0.004), specifically with MA (P = 0.003). Our findings
support the hypothesis that synonymous polymorphisms in the Notch 3
gene, particularly the G684A, may play a role in migraine.
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Assessing educational needs of American Headache
Society (AHS) members in the field of chronic migraine
(CM)
B.M. Grosberg1,2, D.W. Dodick3, F. Sheftell2, D.C. Buse1,2,
R. Nicholson4, S. Pearlman5, R.B. Lipton1,2
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2Neurology, Albert Einstein College of Medicine, Bronx, NY, USA;
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4Family Medicine, St. Louis University School of Medicine,
St. Louis, MO, USA;
5Department of Biology, Armstrong Atlantic State University,
Sanannah, GA, USA
Objectives To assess the attitudes and educational needs of AHS
members in the area of chronic migraine.
Background Little is known about the educational needs and pref-
erences of AHS members who treat CM.
Design Invitations to complete a 14-item web-based questionnaire
were sent to 3,206 recipients via e-mail. A total of 194 responses (6%)
form the basis of this report.
Results AHS members identified the following disorders as their ‘‘most
challenging’’ clinical problems: chronic migraine with or without med-
ication overuse (80.9%); tension-type headache (12.2%); cluster
headache (5.9%); hemicrania continua (3.7%); and migraine with or
without aura (1.1%). Chronic daily headache (CDH) including CM
accounted for more than one quarter of all headache patients for 62% of
survey participants, and for more than half of all headache patients in one
third of participants. More than half of respondents (56.5%) stated that
more than a quarter of their CM patients had unmet treatment needs.
Though the vast majority of respondents were ‘‘familiar’’ with the ICHD-
2 definition of CM (92.6%) and its revision (ICHD-2R, 85.4%), only half
correctly identified the features required for diagnosis (51.9%). Similarly,
only half of the responders expressed a moderate understanding of the
mechanism underlying chronic migraine (53.2%). Most respondents
were interested in learning more about chronic migraine with or without
medication overuse. Preferred educational platforms included continuing
medical education (CME) accredited educational meetings (52.4%),
peer-reviewed journal articles (40.1%), web-based educational materials
(32.1%), and mail-based educational materials (17.6%).
Conclusions Through a survey, AHS members identified CM as their
greatest headache challenge. The majority reported that they manage
CM patients with unmet treatment needs. Respondents over-estimated
their knowledge of diagnostic criteria for CM, and wanted to learn
more about mechanisms and treatment. CME meetings remain the
educational venue of choice for most AHS members.
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Posttraumatic and postsurgical nummular headache
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Objective To describe 6 new cases of posttraumatic NH and 2 new
cases of postsurgical NH.
Background NH is a rare primary headache disorder characterized by
focal and well-circumscribed head pain. Though most cases arise
without precipitants, herein we describe eight patients with NH onset
temporally linked to head trauma or surgery.
Methods Case series.
Results Of 35 consecutive patients with NH seen since 2004, 6 had
posttraumatic (5 women, 1 man) and 2 had postsurgical (2 women) NH. All
patients had a history of either mild (n = 5) or major (n = 1) head trauma,
sinus surgery (n = 1), or craniotomy surgery (n = 1) immediately pre-
ceding the onset of the NH. Age at onset ranged from 13 to 63 years (mean,
47 years). The temporal pattern was chronic and continuous in 7 and epi-
sodic in 1. Head pain occurred in a round (n = 3), oval (n = 4), or bean-
shaped (n = 1) area, ranging in size from 1.5 cm-6.5 cm. The pain was
parietal (n = 4), frontal (n = 3), or parieto-occipital (n = 1) in location.
Three patients reported mild or moderate pain, but 5 reported severe pain.
Five patients reported superimposed exacerbations lasting minutes to days.
Five patients reported sensory disturbances (i.e., allodynia, hyperalgesia)
within the region of spontaneous pain. Prophylactic treatments were gen-
erally ineffective in 5 of 7 treated patients. Nonsteroidal anti-inflammatory
drugs and opiates provided incomplete relief. Prior or coexistent headache
history included chronic migraine (n = 4), posttraumatic hemicrania
continua (n = 1), or episodic tension-type headache (n = 1). Comorbid
depression or anxiety was documented in 50%.
Conclusions NH may arise as an immediate sequela of head trauma
or surgery. In the cases with allodynia or hyperalgesia, posttraumatic
NH may represent a focal form of complex regional pain syndrome.
In our series of patients, prophylactic and abortive medications typ-
ically employed in the treatment of other headache disorders
produced varying, generally unsatisfactory, results.
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Introduction Red ear syndrome (RES), is a rare disorder character-
ized by burning pain and cutaneous erythema in the ear. For first we
described a link between RES and pediatric migraine.
The aim of this study has been to establish frequency, sensibility and
specificity of RES in a pediatric migrainous population and possible
association with other clinical migrainous features.
Methods Medical records of the children admitted for headache
between 1st December 2004 and 30st November 2005, were consec-
utively studied. A semi-structured interview about their headache and
the presence of the RES was administered.
Results We visited 226 children(4–17 years) with headache in the study
period. According to IHS criteria we classified the migraine in 172 chil-
dren (76.5%), the other primary headaches in 54 children (23.5 %) The
prevalence of RES was in 42 cases (18.5%). It occurred in 40 (23.25%)
migrainous children and only two case (3.6%) respectively in the other
headache group. RES resulted statistically more prevalent in migraine
(p\ 0.0001), and got a high specificity (96.3%) and PPV values (95.3%)
versus low sensibility (25.3%) and PNV values (28.3%) . The univariate
statistical analysis showed a statistically significant association of RES
with male gender, throbbing pain, vomiting and phonophobia. It was
confirmed by multivariate stepwise logistic regression model for throb-
bing pain [OR 2.7 (CI 1.1-.7); p = 0.04], male gender [OR 2.1 (CI 1-4.7);
p = 0.05] and vomiting [OR 2.5 (CI 1-4.5); p = 0.05].
Discussion Our study shows that red ear syndrome is not infrequent in
migraine. It may be an useful clinical marker in the diagnosis of pediatric
migraine. The evidence of an association of the RES with some migraine
features partially provoked by the parasympathetic systems supports the
hypothesis of a shared pathophysiological background (for example, via
the activation of the trigeminal -autonomic reflex).
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Distribution of occlusal forces in the maximum
intercuspal position (MIP) among adolescents
with tension-type headache (TTH)
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Introduction The psychosocial stress and related emotional problems
almost always induce motoric reactions of facial mimic and masti-
catory muscles and are among the most probable causes of TTH.
The aim of the study was to investigate the prevalence of occlusal
dysfunctions due to an increased activity of masticatory muscles in
adolescents with TTH.
Material and methods The study comprised 56 students of a secondary
school: 36 of them had TTH, 6 showed chronic TTH for 252.5 days per
year and 30 had frequent episodic TTH for 98.1 days per year on average.
The remaining 20 students constituted the control group. TTH was ana-
lysed in accordance with the IHS criteria. The influence of the perceived
stress was evaluated using the PSS-10 Cohen’s scale. Four value ranges
were distinguished: 0-25 scores - probable; 26-50 - slight; 51-75 - mod-
erate; and above 75 - strong reaction to stress. The occlusal conditions were
assessed using the T-Scan II computer system. A contact of the opposing
teeth in the maximum intercuspal position (MIP) and the centre of occlusal
forces (COF) were recorded. The results were statistically analysed.
Results An asymmetric distribution of occlusal forces in the front area of
the dental arch was identified in 75% of the diagnosed students with TTH,
while a symmetric distribution of occlusal forces was observed on the
whole dental arch in 80% of the controls and on incisors and molars in
20% of them. The prevalence of moderate or strong reaction to stress was
recognised in 50% of the students with TTH, while a slight reaction was
identified in 70% of cases in the controls.
Conclusions TTH correlated with the degree of the perceived stress,
resulting in changes in occlusion conditions and leading to a signif-
icant dislocation of MIP and COF in the direction of the front arch.
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The efficacy of wet-cupping in the treatment of tension
and migraine headache
A. Ahmadi1, D.C. Schwebel2
1Department of Anesthesiology, Kermanshah University of Medical
Sciences, Kermanshah, Iran;
2Department of Psychology, University of Alabama at Birmingham,
Birmingham, AL, USA
Wet-cupping is an ancient medical technique still used in several con-
temporary societies, but little empirical study has been devoted to test its
efficacy to treat tension and migraine headache. Using a pre-post
research design, 70 patients with chronic tension or migraine headache
were treated with wet-cupping. Three primary outcome measures were
considered at the baseline and 3 months following treatment: headache
severity, days of headache per month, and use of medication. Results
suggest that, compared to the baseline,mean headache severity decreased
by 66% following wet-cupping treatment. Treated patients also experi-
enced the equivalent of 12.6 fewer days of headache per month. We
conclude that wet-cupping leads to clinical relevant benefits for primary
care patients with headache.Possible mechanisms of wet-cupping’s
efficacy, as well as directions for future research are discussed.
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Objective To explore novel therapies for medically intractable
SUNCT, SUNA and primary stabbing headache.
Background SUNCT/SUNA and primary stabbing headaches are
clinically different entities. However, they share the feature of very
brief attacks, which constitutes a major limitation for acute therapy
approaches. SUNCT/SUNA and primary stabbing headaches respond
selectively to a limited number of preventive medications; in certain
cases these do not offer satisfactory relief, are not tolerated or both.
ONS is a relatively novel therapy showing promising efficacy results,
good tolerability, with a low risk profile in a number of medically
intractable primary headaches.
Methods The response was recorded in four patients with SUNCT
following bilateral ONS therapy in three cases and unilateral ONS
stimulation in one patient respectively and two patients with SUNA
following unilateral and bilateral ONS treatment respectively. Of the
four ONS treated patients with primary stabbing headache, two
received unilateral stimulation.
Results All primary stabbing headache patients responded well to
ONS therapy. Both SUNA patients had almost complete cessation of
the attacks. Two SUNCT patients had excellent response to bilateral
ONS, one SUNCT patient showed a 50% response to bilaterally
administered ONS and one patient had no benefit from ONS applied
on the pain side only.
Conclusions Our observations indicate that ONS is a promising
therapeutic approach for patients with primary stabbing headache and
SUNCT/SUNA. This therapeutic approach appears particularly
attractive for headache conditions not suitable for acute treatment and
for which the preventive alternatives are limited.
Keywords ONS, medically intractable primary headache conditions,
SUNCT, SUNA, primary stabbing headache.
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Altered response of trigeminocervical complex neurons
after lesioning the dopaminergic A11 nucleus,
and the effect of dopamine and serotonin receptors
A.R. Charbit, S. Akerman, P.J. Goadsby
University California San Francisco, San Francisco, CA, USA
Introduction Both 5HT1B/1D and dopamine receptors are are known
to play a role in treatment of migraine headache, as activation of those
receptor groups in the trigeminocervical complex inhibits transmission of
nociceptive signalling from this nucleus. The A11 nucleus of the pos-
terior hypothalamus, provides the only known source of descending
dopaminergic innervation to the dorsal horn and was identified as the
possible source of inhibitory dopamine to the trigeminocervical complex.
Lesioning of the A11 nucleus was shown to facilitate transmission of
nociceptive signaling from the trigeminocervical complex.
Methods Extracellular recordings were made in the rat trigeminoc-
ervical complex in response to electrical stimulation of the dura mater
and mechanical noxious and innocuous stimulation of the periorbital
skin. The A11 nucleus was lesioned and, following a period of




D2-like receptor agonist with a 5-HT1B/1D receptor agonist,
D2-like receptor agonist with a 5-HT1B/1D receptor antagonist
Results Both the 5HT1B/1D receptor agonist and the D2-like receptor
agonist with 5-HT1B/1D receptor antagonist inhibited firing in the tri-
geminocervical complex evoked by noxious stimuli, returning it to pre-
lesion baseline. However the response to innocuous stimuli remained in a
facilitated state. The D2-like receptor agonist and the D2-like receptor
agonist with 5HT1B/1D receptor agonist both had a greater inhibitory
response to noxious stimuli so that cell firing dropped to below the pre-
lesion baseline, while the response to innocuous stimuli was inhibited
enough so that cell firing returned to baseline.
Conclusions It seems likely that trigeminovascular traffic is affected by
at least two antinociceptive pathways, one serotonergic and one dopa-
minergic, that act simultaneously on neurons in the trigeminocervical
complex, and that both systems need to be functioning for effective
inhibition of nociceptive transmission to take place.
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Recurrent migraine and transient stroke-like episode
in child with Sturge-Weber syndrome: a case report
Y.I. Rho
Pediatrics, School of Medicine, Chosun University, Gwangju,
Republic of Korea
The clinical features of the Sturge-Weber syndrome(SWS) Type I
include headaches (30 * 45%), epilepsy (75-90%), hemiplegia (30%),
glaucoma (30%), and mental retardation (50% of patients and 75% of
those with seizures). The relationship between headaches, seizure
clusters, and stroke-like episodes is related to the pathogenesis of SWS.
The risk of stroke in patients with SWS increased because preexisting
perfusion and metabolic defects subject them to prolonged phases of
oligemia, a characteristic of migraine-induced stroke. We present case
of a 9 year-old female with SWS type I, glaucoma, hemiparesis, and
normal psychomotor development, who presented recurrent severe
migraine and transient stroke-like episodes, separated by complete
recovery. She was managed with oxcarbazepine for seizure, amy-
triptyline for migraine, and aspirin for stroke like episodes without
surgical treatment. After one year, she didn’t have seizure and stroke like
event but does have mild headache (1/month). Her quality of life and
hemiparesis was improved. We recommend that it is need aggressively
prompt treatment for recurrent seizure, migraine, and strokelike episode.
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The effects of tianshu capsule on blood flow dynamics,
and vaso-active substances in migraine models
T. Yang, Q. Zhang, D. Zhou
Sichuan University, Chengdu, China
Purpose To investigate the effects of TianShu Capsule (TSC) on
blood flow dynamics, and vaso-active substances in blood plasma or
brain in migraine models.
Methods After subcutaneously administration of nitroglycerin (NTG) and
tube-feeding TSC, we used radioimmunoassay and spectrophotometry to
measure the contents of calcitonin gene-related peptide (CGRP), nitric
oxide (NO) and nitric oxide synthase (NOS) in rat plasma; we evaluated the
distribution of NOS1, CGRP in rat trigeminal nucleus caudalis using
immunohistochemistry, and monitored the systolic maximal blood flow
velocity with Transcranial Doppler in rabbit internal carotid artery.
Results TSC could inhibit the NTG-induced increasing of NO, NOS
and CGRP in plasma, attenuates NOS1 and CGRP expression in the
brainstem, and reversed the vasodilation effect of NTG.
Conclusion TSC could modulate the unbalance of vaso-active sub-
stances and neurotransmitters during the migraine attacks and resulted
in relief of the headache.
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Treatment of cluster headache using peripheral nerve
stimulation; a case report
A.E. Yakovlev, S.A. Karasev
Comprehensive Pain Management of the Fox Valley, SC,
Appleton, WI, USA
Introduction Cluster headaches are one of the most severe and dis-
abling types of headache. Control of cluster headaches can be difficult
to achieve despite multiple pharmacological modalities available in
the field of pain management. Peripheral nerve stimulation (PNS) has
been used to treat patients with injuries to a specific nerve; including
application to occipital, ilioinguinal, supraorbital, and trigeminal
neuralgia. Recently this type of treatment is utilized to control dif-
ferent headaches including chronic cluster headaches.
Materials and methods The patient is a 39 year old female with
intractable cluster headaches for the past 12 years who failed con-
servative therapy and had short lasting pain relief after supraorbital
and auriculotemporal nerve blocks. She underwent a successful trial
of percutaneous placement of an 8-electrode lead in the left supra-
orbital region. During the 2 day PNS trial, the patient reported
complete resolution of headaches. Two weeks later the patient
underwent subdermal implantation of a permanent lead and
RestoreULTRA (Medtronic Inc.) rechargeable generator.
Results After final implantation, the patient reported excellent con-
trol of headaches. The frequency of her cluster headaches
significantly decreased from 5-7 per day to 1 episode every one to
two months. The patient was able to terminate the cluster headache in
2-3 minutes after turning the PNS on. She discontinued use of all
medications including opioids. The patient also reported other
positive outcomes including the ability to return to social and
occupational activities. At 12 months post-implant, the patient con-
tinued to report good control of the cluster headaches and improved
functional status.
Conclusion PNS appears to be a therapeutic alternative for patients
with chronic intractable cluster headaches who in the past exhausted
all available treatments. This technique is a relatively easy to perform,
effective, and safe procedure. The therapy is reversible should
patients lose its pain-alleviating effect or headaches resolve.
117
Aspirin vs propranolol: comparative study of their
interactions with other drugs in the prevention
of migraine
M.K. Kechagioglou
University of Naples, Research Center, Naples, Italy
Aim The aim of the present study is to be shown the interactions of
aspirin or propranolol in the prevention of migraine.
Material and methods There were studied the interactions of aspirin
or propranolol with other drugs.
Results As regards its interactions with anticoagulants, such as
coumadin, aspirin may cause severe lifethreatening bleeding. Con-
comitant use of aspirin with antihypertensives, such as beta-blockers,
has been shown to decrease their antihypertensive effect, while
aspirin combined with antineoplasmatics, such as methotrexate, tends
to increase its toxicity through bone marrow suppression and liver
toxicity. Aspirin combined with probenicid may lead to reduced
urinary excretory action. Co- administration of aspirin with antihis-
tamines, such as phenylpropanolamine, may cause severe
hypertensive crises. Combination of aspirin with corticosteroids
increases the risk of ulceration of the gastrointestinal tract. Regarding
the interactions of propranolol with hypolycaemics, they may lead
diabetic patients to hypoglycaemic coma with increased blood pres-
sure. The administration of propranolol is contraindicated in
asthmatic patients who receive broncodilators due to high risk of
severe bronchospasm. Antihypertensives, such as nifedipine with
propranolol may cause heart failure and severe hypotension. Co-
administration of propranolol with glycosides may cause severe
bradycardia and lead to death. Antiarrythmics, such as verapimil, with
propranolol may cause severe sinoventricular obstruction with severe
myocardial depression due to negative cumulative inotropic action.
Conclusions Aspirin or propranolol may function as a preventive
shield against migraine only when used properly.
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An analysis of patients with primary headache
at a tertiary care hospital
A. Malik1, A. Zafar2, S. Ali1
1Jinnah Postgraduate Medical Centre, Karachi, Pakistan;
2Liaquat National Hospital, Karachi, Pakistan
Background Headache is one of the most common reasons for
neurological consultation. The estimated life time prevalence of any
headache approaches 90% in men and 95% in women. Headache has
been classified into primary and secondary headache disorders. The
four categories of primary headache include migraine, tension type
headache, cluster headache and trigeminal autonomic cephalgias, and
other primary headaches. As primary headache is a common health
care problem and there is not enough data on types of primary
headache in our population, therefore, we have designed this study
with the aim to identify different types of primary headache and their
characteristics.
Objective To identify different types of primary headache and to
describe demographic characteristics as age and sex.
Methods This is a prospective, observational study, carried out at a
tertiary care hospital over the period of 1 year. Data was analyzed by
spss version 15.0.
Result Total of 1071 patients with diagnosis of primary headache
were included in the study. 720(67.2%) were female and 351(32.8%)
were male. Migraine was the commonest type of headache, seen in
744(69.5%) patients followed by tension type headache, seen in
318(29.7%).other types of headache as cluster headache and parox-
ysmal hemicrania continua were very uncommon. Among patients
with migraine, migraine without aura was the commonest subtype.
Conclusion Primary headaches are more frequent in females as
compared to males. Migraine is the commonest type of primary
headache followed by tension type headache. Further epidemiological
studies are needed to identify the characteristics of headaches in our
population.
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Evaluation of knowledge of specific migraine attacks
treatments according current French recommendations
by first-time consulters in a tertiary headache centre
C. Lucas
Neurology, Lille University Hospital, Lille Cedex, France
The prevalence of migraine in France is between 12 to 21%. Around a
quarter of patients have a significant impact in their daily life.
However, there is an inadequate therapeutic management of migraine
attacks by migraine sufferers in French general population, charac-
terised by exceedingly high level of analgesic use and few use of
specific treatments such as triptans.
The aim of our study was to evaluate the knowledge and the satisfaction
of specific migraine attacks treatments according current French rec-
ommendations by first-time consulters in a tertiary headache centre.
We evaluated these items by a self-administered survey in each new
consultant for migraine (IHS codes 1.1, 1.2 and 1.7). All patients were
referred by their GP. Patients who had already consulted a neurolo-
gist, those who had consulted for chronic migraine, and those who
had consulted again in our centre were not included. We have pro-
spectively interviewed during 2 months 57 episodic migraine
sufferers (44 females, 13 males; mean-age: 39.2 years). The duration
of migraine disease was 10 years or more in 52.6% patients. Almost
 of patients were informed that NSAIDs and triptans are effective
treatments and  had already used at least one NSAIDs and/or one
triptan for migraine attacks. Around 2/3 of patients were not satisfied
with triptans despite an early intake. Only half of patients did change
the triptan in case of failure for the next migraine attacks.
The knowledge and the use of recommended acute treatments for
migraine attacks is much more higher in patients who consult for the
first time in a tertiary headache centre in comparison with the French
general migraine population. However, we have to improve the
education of such patients because the majority are not aware about
the absence of class effect with the triptans.
Conflict of interest C. Lucas has perceived personal fees for activities
(consulting, clinical research) with Allergan, Almirall SAS, Astra Zeneca
Pharmaceuticals, Boehringer Ingelheim, Bouchara Recordati, Glaxo-
Smith Kline Inc, Menarini, Merck, Pfizer Inc, Sanofi-Aventis, Servier.
120
Greater occipital nerve blockade with lidocaine
in pregnant migraine patients
M.S. Robbins1,2, R.B. Lipton1,2, D.C. Buse1,2, U. Napchan1,2,
S.C. Crystal3, B.M. Grosberg1,2
1Montefiore Headache Center, Bronx, USA;
2Neurology, Albert Einstein College of Medicine, Bronx, USA;
3Neurology, New York University School of Medicine,
New York, NY, USA
Objective To present a case series of pregnant patients treated with
greater occipital nerve blockade (GONB) for acute migraine attacks.
Background Acute treatment options for migraine are limited in
pregnancy because of safety and teratogenicity concerns. Based on
reports of safe use of lidocaine in pregnancy, GONB may provide a
safe and effective treatment option.
Methods GONB was offered to pregnant patients presenting to a
hospital’s labor and delivery service for acute migraine. All nerve
blocks were performed in the greater occipital nerve regions bilater-
ally with 4 mL of 1% (10 mg/mL) lidocaine HCl at each site. Pain
scores were captured immediately before the procedure and 1 and
24 hours after the blockade.
Results Three patients were treated with GONB, including one who was
treated for two separate acute attacks. Two patients were in the third
trimester and one was in the second trimester. All patients had a history of
episodic migraine without aura, and one patient had evolved to chronic
migraine (CM) 2 years previously. Acute headache duration ranged from
2 to 10 days, and the CM patient reported severe daily headache that
predated her gestation. All patients had normal examinations (except for
GON tenderness), MRI and MRV. All patients were tried on intravenous
metoclopramide, diphenhydramine, and a narcotic (codeine, oxycodone,
morphine). Pre-treatment pain ranged from 5 to 8/10. After GONB all
patients experienced complete relief within an hour. At 24 hours, only the
CM patient had recurrent pain. GONB were well tolerated, and all
patients experienced cephalic numbness. Two patients delivered healthy
babies and the third patient was having an uneventful pregnancy when
last seen at 33 weeks gestational age.
Conclusions In a small series, GONB with lidocaine appears to be a
safe and often effective acute migraine treatment for pregnant
women. Larger and randomized studies are warranted.
Conflict of interest Dr. Buse has acted as a consultant or received
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ticals, Merck Inc., and Iroko Pharmaceuticals.
Dr. Grosberg serves on a scientific advisory board for Kowa Phar-
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Merck and Nautilus Pharmaceuticals; and received institutional
research support from Allergan Inc., Merck, GlaxoSmithKline, Endo
Pharmaceuticals, Boston Scientific, Neuralieve Inc., Advanced Bio-
nics, ProEthics, Minster Pharmaceuticals, and Capnia.
Dr. Lipton receives research support from the NIH [PO1 AG03949
(Program Director), PO1AG027734 (Project Leader), RO1AG025119
(Investigator), K23AG030857 (Mentor), K23NS05140901A1 (Men-
tor), and K23NS47256 (Mentor)], the National Headache Foundation,
and the Migraine Research Fund; serves on the editorial boards of
Neurology and Cephalalgia and as senior advisor to Headache, has
reviewed for the NIA and NINDS, holds stock options in Neuralieve
Inc. and Minster Inc; serves as consultant or has received honoraria
from: Allergan, Autonomic Technologies, Boston Scientific, Bristol
Myers Squibb, Eli Lilly, Endo, GlaxoSmithKline, Minster, Merck,
Nautilus Neuroscience, Neuralieve, Novartis, and Pfizer.
Dr. Napchan serves in the Advisory Board Iroko Pharmaceuticals,
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Study of the prevalence of patent foramen ovale
in patients with migraine headaches
M.A. Arami1, M. Karimi2, S. Shahbeighy3
1Social Security Organization, Tehran, Iran;
2Shahid Beheshti University of Medical Siences, Tehran, Iran;
3Iranian Neurology Association, Tehran, Iran
Subjectives Migraine is a common primary headache disorder whose
etiology remains unknown. Coexistence of migraine and patent foramen
ovale (PFO) has been reported in many studies. The aim of this study was to
evaluate the prevalence of PFO in patients with migraine with aura (MA)
and those without aura (M) and in a healthy age-matched control group.
Material and methods We evaluated 50 patients (38 females) suffering
from migraine with aura, 75 without aura (58 females) and 50 normal
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controls (25 females). PFO was detected by the contrast transcranial
Doppler study using standard agitated saline test and Valsalva manure
and confirmed by transesophageal echocardiography.
Results The presence of PFO was found in 19/50 (38 %) patients with
MA compared to 15/75 (20%) without aura, and in 9/50 (18%) control
subjects. The observed differences of PFO prevalence between MA
and M groups and also the difference between MA patients and the
control group was statistically significant (p \ 0.05).
Conclusions According to our study results it suggests that at least
some attacks of migraine with aura may be associated with patent
foramen ovale and probably due to paradoxical embolism.
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Laughing headache: a new case report and literature
review
P. Giraud, S. Chauvet
Consultation Cephale´es et Migraine, Centre Hospitalier d’Annecy,
Pringy, France
Laughing is an uncommon provoking factor for headache and only few
cases have been reported to date. Simonds in his 1956’s study points out
laughing as a trigger of sudden and transient headache as well as
coughing, snoring, straining, sneezing or stooping. Laughing headache is
considered as a particular form of exertional headache (EH). In the
absence of intracranial abnormalities, the pain mechanism remains
uncertain but the main hypothesis is that laughing headache is secondary
to transient and reversible intracranial hypertension such as during a
sudden valsalva maneuver. Recently Donnet and coll explored an alter-
native hypothesis: in a preliminary study they had demonstrated that in
some cases EH can be due to increase in venous pressure, secondary to an
undiagnosed venous stenosis revealed by specific MRI sequences. We
report a new case of EH where headache was provoked almost exclu-
sively by outburts of laughing. General and neurological examination
was normal despite of an abdominal obesity with a BMI at 35. Blood and
CSF tests were normal. Brain MRI excluded parenchymal lesion, venous
stenosis or thrombosis. There was no Chiari malformation but intrave-
nous hypertrophic Paccioni granulations were detected. This original
case leads us to discuss other possible mechanisms for pain associated
with laughing. In this case several factors such as obesity and intravenous
hypertrophic Paccioni granulations may have played a role, in
the absence of others classical factors. A review of published laugh-
ing headache case reports is suggested and different etiologies discussed.
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Cerebellar distribution of CGRP and its receptor
components, CLR and RAMP1, in rat
S. Eftekhari1, L. Edvinsson1, C.A. Salvatore2, K. Warfvinge3
1Department of Clinical Sciences, Division of Experimental Vascular
Research, Lund University, Lund, Sweden;
2Department of Pain and Migraine Research, Merck Research
Laboratories, West Point, PA, USA;
3Warfvinge Science Support, Lund, Sweden
Clinical and experimental results have revealed a fundamental role of
CGRP in primary headaches. Moreover, in acute attacks of migraine
there is evidence of cerebellar activation.
Immunofluorescence method with specific antibodies against CGRP,
CLR and RAMP1 (Eftekhari 2010) were used to study the distribution
of CGRP and its receptor components (CLR and RAMP1) in rat
cerebellum.
CGRP immunoreactivity was only found intracellularly in the cere-
bellar Purkinje cell bodies, whereas CLR and RAMP1 were detected
on the surface of the Purkinje cell bodies and in their processes. The
elaborate dendritic tree of Purkinje cell fibers was distinctly visual-
ized with the RAMP1 antibody. In addition, profoundly stained fibers
spanning from the molecular layer into the medulla was observed
with the RAMP1 antibody. Judged from the high density of immu-
noreactive cells expressing CGRP, RAMP1 or CLR, and from the
double staining of CGRP and RAMP1 it is likely that most, if not all,
Purkinje cells express both the peptide and the receptor components,
but with different localizations. Double staining with RAMP1 and the
glial cell markers GFAP and S-100 revealed an almost identical
staining pattern of the antibodies in the area of the cell body surfaces.
However, as judged by confocal microscopy, no double staining was
present. Instead, it was discovered that the glial cells tightly sur-
rounded the Purkinje cells which easily could be interpreted as co-
localization in the epifluorescence microscope.
Our observations demonstrate that there is a rich expression of CGRP and
CGRP receptor elements in the cerebellum which points towards a
functional role of CGRP in cerebellar Purkinje cells. Recent advances in
the biology of the cerebellum indicate that there may be a role in noci-
ception. The recently discovered CGRP receptor antagonists, that have
demonstrated improvement in migraine pain and associated symptoms,
could have an effect on cerebellar CGRP receptors.
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Clinical and encephalografical effects of amitriptyline
for patients with a chronic migraine without aura
T. Maykova
Headache Center Kyiv, Kyiv, Ukraine
Purpose of study To reveal the electroencephalographical features of
application of amitriptyline in prophylactic treatment of chronic
migraine without aura.
Groups and methods 31 patients with a chronic migraine without
aura accepted amitriptyline in doses 0,05 - 0, 075 g/per day;
29 patients accepted amitriptyline in the same doses in combination
with cinnarizin (0,075 g/per day);
30 patients accepted cinnarizin in doses (0,075 g/per day).
All patients were clinical examined and EEG studied by the device
Neurofax (Germany) on traditional methodology before and after two-
month treatment. A clinical criterion was frequency of migraine attacks.
Inclusion criteria Age 19-45 years of both sex; accordance to the
diagnostic criteria of ICDH II for a chronic migraine without aura.
Exclusion criteria Reception of neurotropic drugs for the last
3 months prior to the study.
Results 3 groups of patients with the different dynamics of disease flow
on a background treatment were defined: with the reliable diminishing of
amount of attacks; without the reliable change of amount of attacks; with
the reliable increase of amount of attacks.
In the group of patients accepted cinnarizin, neither clinical nor EEG
dynamics were registered.
Discussion Known pharmacological effect of amitriptyline is strength-
ening of catecholamines influences on the postsynaptic membrane of
neurons due to the increase of their amount or decreasing the rate of
turnover. Study results allow to define EEG markers of patients with
successful and not successful treatment by amitriptyline. Drawn a con-
clusion about different pathogenesis of increase of brain excitability
for patients with a migraine and role of different concentration of
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catecholamines in the mechanism of migraine development. Possibility
of the differentiated prescribing of amitriptyline from EEG data was
shown.
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Risk factors for the chronification of migraine
G. Haag
Michael-Balint-Klinik, Koenigsfeld, Germany
According to the concept suggested by Bigal & Lipton, the transition from
episodic migraine to frequent episodic migraine and chronic migraine
manifests itself in clinical, physiological, and possibly anatomical changes
in pain-processing structures of the brain and central nervous system.
Various risk factors have been mentioned for these relatively frequent, and
notably bidirectional, processes. Based on a systematic literature search
(search terms: migraine or migraine illness, chronification) in MEDLINE
for 1950 - February 2010, the parameters discussed as risk factors for
progression or chronification were analysed regarding frequency of
mention from 15 overview works proving this information.
Twenty-six risk factors emerge (in order of number of mentions):
overweight (12), medication overuse (11), headache frequency (10),
age (9), depression (7), low education (7), female gender (7), caffeine
consumption (food and drink, medications) (7), anxiety disorders (6),
head injuries (6), other pain syndromes (5), genetic factors (4), sleep
disorders (4), sleep apnoea (4), allodynia (3), Caucasian (3), arthrosis
/ musculoskeletal pain (2), diabetes (2), psychiatric illnesses (2),
physical or sexual abuse (2), proinflammatory states (2), prothrom-
botic states (2), opioid / barbiturate overuse (1).
In the overview works, differences are apparent in type and number of
mentioned risk factors, possibly due to the subjective selection and
evaluation of studies underlying these reviews. The largest limitation
of explanatory power is that almost none of the studies considered all
possible factors as confounders, and this limitation was neither suf-
ficiently accounted for in the results, nor appropriately discussed.
Moreover, the examined case numbers are often problematically
small in relation to the number of parameters considered in the
multifactorial analyses. The mentioned risk factors thus continue to be
fraught with uncertainty regarding their clinical relevance. It is first
necessary to reach a consensus regarding which parameters should be
vitally examined in studies on the chronification of migraine.
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Epileptic seizures in children with SLE: case series
M.H. Moradinejad, G. Zamani
Rheumatology, Tehran University of Medical Sciences, Tehran, Iran
Objective Systemic lupus erythematosus is a multisystem autoim-
mune disease characterized by circulating autoantibodies and immune
complexes. The disorder most commonly affects young female.
Involvement of the nervous system is one of the most profound
manifestations of disease.
To evaluate the frequency and risk factors of epileptic seizures in
children with SLE.
Methods 65 patients with JSLE were studied, with follow-up ranging
from 4 to 10 years. Risk factors associated with acute and recurrent
epileptic seizures in JSLE were determined.
Results Eight (12.4%) patients with epileptic seizures were identi-
fied. Seizures occurred at the onset of JSLE in 3 (37.5%), and
after the onset of JSLE in 5(62.5%) patients. Six (75%) patients had
acute symptomatic seizures, and 1 (12.5%) had recurrent epileptic
seizures. One patient who presented epileptic seizures had anti-
phospholipid syndrome and interictal epileptic abnormalities on
EEG.
Conclusion Despite the relatively common involvement of CNS in
SLE, presentation of this disorder with neurologic symptoms appears
to be uncommon. True incidence of seizures in SLE is difficult to
determine, owing to multiple potential etiologies. Epileptic seizures
were observed in 12.4% (JSLE) patients. The case who had recurrent
seizure was associated with antiphospholipid antibody syndrome.
Keywords SLE, Seizure, Antiphospholipid syndrome.
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Necrosis lingual caused by ergotamine in a patient
affected by arteritis of gigantic cells
E.D. Doctorovich, C. Stefani, S. Pigretti, A. Bisonni
Neurology, Hospital Italiano, Buenos Aires, Argentina
Ergotaminic derivates are substances widely used for the relief of pain
during migraine attacks.
Since the 1918 isolation by Stoll the ergotamine were the reason of
numerous tests that demostrated its efficiency and helped to formulate
the neurovascular theory through its vasoconstrictor and modulator
effect of the trigeminal process of pain (1).
Such vasoconstrictor effect could work as isquemic trigger over a
vascular territory previously compromised because of an arterial
vasculitic process (2).
Up to 40% of the patients with arteritis of gigantic cells presents
infrequent symptoms such as, dry cough, sore throat, and tongue
symptoms such as pain, and glositis (3).
The lingual necrosis is an unusual manifestation of the arthritis of
gigantic cells, however, at the same time it constitutes the first cause
of ischaemic of tongue.
We present a patient who suffered from necrosis of the tongue caused
by ergotamine. For this reason we diagnosed the arteritis of gigantic
cells.
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Neurovascular dishabituation in patients with migraine
without aura
B. Descamps1,2, P. Vandemaele1,2, H. Reyngoudt1,2, K. Deblaere1,2,
L. Leybaert3, K. Paemeleire3,4, E. Achten1,2
1Radiology, Ghent University Hospital, Ghent, Belgium;
2Ghent Institute for Functional and Metabolic Imaging,
Ghent, Belgium;
3Basic Medical Sciences, Ghent University, Ghent, Belgium;
4Neurology, Ghent University Hospital, Ghent, Belgium
Background Absence of habituation during VEP measurements has
extensively been studied in patients with migraine [1,2]. It is unclear
whether this electrical phenomenon is accompanied by hemodynamic
anomalies. In healthy controls, VEP-habituation is well-known and
hemodynamic refractory effects are observed in the net BOLD-
responses to repetitive visual stimuli [3], i.e. a decreased amplitude and
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increased latency in time-to-peak for interstimulus intervals less than
6 seconds. Interictal hemodynamic differences between patients with
migraine without aura and healthy controls have not been investigated.
Methods In this study, we measure interictal hemodynamic responses
with functional magnetic resonance imaging in patients with migraine
without aura and compare them with responses from healthy controls.
Net responses to paired visual stimuli with varying interstimulus
intervals are calculated. Several characterizing parameters of the
responses are quantified. ANOVA and post-hoc Bonferroni tests are
used for statistical analysis (significance level = 0.05).
Results and discussion Refractory effects are not observed in
patients. There is no amplitude decrease, nor increased latency in
time-to-peak in patients, not even for the shortest interstimulus
interval, whereas in controls, refractory effects are found for all
parameters of the net responses for an interstimulus interval of
1 second (amplitude and time-to-peak: p \ 0.001; width: p \ 0.01).
The nonlinearities (i.e. differences in measured vs. expected respon-
ses) fade away with longer interstimulus intervals and have
disappeared at the interstimulus interval of 6 seconds.
The absence of refractory effects in patients with migraine without
aura reflects the neurovascular correlate of the absence of habituation
in this patient group. Multi-modal data acquisition (VEP/fMRI) or
follow-up of patients taking prophylactic drugs may be subject to
further research.
References
[1] Schoenen J. et al. (1995). Eur J Neurol 2(2): 115–22;
[2] A´fra J. et al. (1998). Brain 121(2): 233–41;
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A case of cardiac cephalalgia without angina
K. Kalamafkianaki, I. Gkogkolakis, D. Tsiakiris, M. Futuli,
R. Chirmbaki, G. Vagionis, N. Kouroumalos, G. Georgakakis,
E. Nikolakaki
2nd Neurology Department, General Hospital Chania, Chania, Greece
Background Cardiac cephalalgia is a rare condition, first proposed in
1997, and since 1966 there have been 34 cases described in literature.
Cardiac cephalalgia was classified in International Classification of
Headache Disorders (ICHD-I) under the group ‘headache attributed to
disorder of homoeostasis’ and was renamed to ‘cardiac cephalalgia’
in the second edition of ICHD-II in 2004.During an episode of
myocardial infarction or angina, 6% of patients will demonstrate
cephalalgia from the onset of the episode, concomitantly with the
major symptom of chest or arm pain.
Case report The unique feature of the female patient with cardiac
cephalalgia we present was that, she didn’t have retrosternal pain,
although she fulfilled all the criteria of ICHD-II. Instead, she came to
medical attention in Emergency Department of our hospital due to
symptoms of first-time in life, intense, vasomotor type cephalalgia,
combined with vomiting. The duration of the headache was 50 minutes
the time that it was necessary for effective medical therapy of myocardial
ischemia. Electrocardiography (ECG) in the Emergency Department
revealed changes consistent with acute myocardial infarction which was
also confirmed by laboratory tests. Neurological examination and CNS
imaging including CT, MRI and MRA were negative.
Discussion Cardiac Cephalalgia is a rare syndrome that many car-
diologists are skeptical regarding its existence. The mortality rate of
patients due to cardiac disorders causing cephalalgia is close to 12%.
Therefore every neurologist should consider evaluation for cardiac
causes in patients with acute cephalalgia which does not seem to have
a neurological etiology.
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The epidemiology of migraine in armenia: preliminary
results of simultaneous multicenter study
H.R. Vekilyan1, A.H. Karapetyan1, E.M. Gevorgyan2,
H.M. Manvelyan1
1Neurology, YSMU, Yerevan, Armenia;
2Neurology, NIH, Yerevan, Armenia
Objectives Headaches are highly common complaints addressed to
physicians, and take 3rd place among pain syndromes. High abun-
dance and economical burden of headaches are prioritizing medical
assessment and treatment. Currently there are many studies of head-
aches epidemiology in the world, meanwhile there is a lack of
attention toward this problem in Armenia.
Aim Aim of our study was investigation of prevalence of migraine in
Armenia.
Study design Special questionnaires were created (correspondingly to
diagnostic criteria and recommendations of International Headache
Society) and distributed among matching population in the capital
city, other cities and villages. From 2000 questionnaires we had
completed about 500. In study were included 489.
Results From included 489 (356 women/ 133 men) patients we had
following distribution Yerevan, Vanadzor and Ararat valley (207, 94,
188 correspondingly). Age of participants was 18-60 yrs. Data anal-
ysis revealed that: 92 (19%) (79 f/ 13 m) of respondents suffer from
migraine without aura, 33 (6%) (31 f/2 m) from migraine with aura, -
356 (72%) (257 f/ 99 m)
Conclusion All together our data is matching with similar interna-
tional studies, but we had some prevalence of Tension type headaches
in women in villages. Another issue is that despite of wide distribution,
many doctors are mistaking cluster type headaches with trigeminal
neuralgic types or migraine. More educational work toward under-
standing and correct assessment of headaches must be done.
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Age at onset and gender ratio in cluster headache:
clinical observations over 15 years
C. Lisotto, F. Mainardi, F. Maggioni, G. Zanchin
University of Padua, Padua, Italy
Objectives Cluster headache (CH) is considered as a disorder of
young men which predominantly begins at age 20 to 40 years. In
recent studies M:F ratio ranges 4.4:1 to 2.5:1.
Materials and methods We reviewed the clinical charts of 10560
consecutive outpatients referred to our Headache Centre from 1995 to
2009. All data were collected prospectively and assembled in a
database since 1995.
Results A total of 221 patients (165 males and 56 females), consti-
tuting 2.1% of the whole population of headache sufferers, fulfilled
the ICHD-II diagnostic criteria for CH. The overall M:F ratio was
2.9:1 and interestingly it was 5.1:1 within the age of 55, and over this
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cut-off age it completely reversed, resulting 0.8:1. The mean age at
onset was 36.9 ± 15.6 (range 13 to 84). We diagnosed 30 cases with
CH (3.1 according to ICHD-II), 155 episodic CH, 30 chronic CH and
6 probable CH. In females the mean age at onset, being 46.7 ± 18.9,
was significantly higher than in males, resulting 33.6 ± 12.7. Out of
the 43 patients aged over 65 years, 24 were females and in this elderly
subpopulation the prevalence of chronic CH was remarkably higher
than in previous ages, accounting for 25.6.6%. In patients below 65,
chronic CH was found in 9.5% of cases.
Discussion The onset of CH seems to be independent of the life
period of the patients, even if the average age of onset peaks towards
the third decade. Apparently peculiar to the female distribution, an
increased frequency appears to occur in middle-age and elderly
patients.
Conclusions In the elderly group females represented the majority
of cases, in contrast with the evident male preponderance in the
previous decades. To our knowledge we report the largest case
series of CH elderly patients published in the literature to date.
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Kinematics of headaches related to occipital-
cervicothoracolumbar mal-posture: significance
of axial muscles in headaches
M. Sinaki
Mayo Clinic, Rochester, MN, USA
Axial posture is not static but rather a dynamic process represented by
alignment of the body’s anatomical units in relationship to one
another at any given time. Posture affects body locomotion, energy
expenditure, and risk of falls. Posture can be influenced by multiple
factors; i.e. aging, gender, bone loss, muscle strength, and occupation.
The most disfiguring effect of axial loss of muscle strength and bone
is the anterior wedging of the thoracic spine due to the effects of
gravity on the natural thoracic kyphosis, forward position of the
cervical spine and head. We regularly treat patients with neck pain
and/or headache in our outpatient clinic. Here, we report cases with
headache and neck pain of hyperkyphosis (thoracic kyphosis [ 508),
who had tried other measures for pain relief without success. All had
neurological and musculoskeletal evaluations and full assessment of
gait and physical activity.
Intervention All subjects, after their preliminary evaluations, were
provided with instructions to improve their occipital -cervicothora-
columbar kinesiology through specific muscle strengthening
exercises. Our mechanical intervention included use of orthotics when
necessary and posture training through reeducation of axial muscles
with or without use of orthotics. The kinesiology and efficacy of these
techniques will be discussed.
Conclusion Headaches are complicated and their etiology needs
elaborate work ups. In this presentation we discuss the headaches
related to overuse of posterior cervical muscles in the setting of mal-
posture of the spine.
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Quadriplegic migraine in identical twins
S.A. Sparr
Neurology, Montefiore Medical Center, New York, NY, USA
A 38 year old Hispanic woman presented to Montefiore Medical
Center with a history of recurrent headaches since age 30. Head-
aches began as bifrontal pressure-like pain and vertigo. The
episodes progressed to quadriplegia lasting 5-10 minutes during
which time she was unable to speak but remained fully aware of
her environment and was able to open and close her eyelids. As
the quadriplegia abated she experienced severe, diffuse headache
with photophobia and sonophobia lasting hours to days. The only
trigger identified was lack of sleep. Episodes came on 4-5 times
per month. One year previous an MRI of the brain revealed a
Chiari malformation. Surgical correction of the Chiari malforma-
tion did not improve her headaches. She obtained some reduction
in intensity of headache while on topiramate but the frequency was
unchanged. The patient had an identical twin with similar head-
aches beginning at age 20, except that her prodrome consisted of
photopsia, restriction of visual field and unilateral sensory symp-
toms prior to the onset of quadriplegia. A third sister suffered from
migraine without motor manifestations. The patient was observed
for 6 days with EEG monitoring but failed to have any episodes
during the hospitalization. Genetic screening for hemiplegic
migraine revealed a mutation in the CACNA1A gene with a G to
A transition at nucleotide position 2826, codon 942, which was
reported to be ‘‘of unknown significance’’. In summary, we
describe monozygotic twin sisters whose migaine headaches are
preceded by quadriplegia/locked-in-syndrome and have an identi-
fied mutation in a gene associated with familial hemiplegic
migraine.
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Headaches in patients with systemic lupus
erythematosus: a prospective case-control study
M. Vikelis1, C. Katsiari2, E. Paraskevopoulou1, P.P. Sfikakis2,
D.D. Mitsikostas1
1Department of Neurology, Athens Naval Hospital, Athens, Greece;
2First Department of Propedeutic and Internal Medicine,
Athens University Medical School, Athı´nai, Greece
Background-objective Whether headache, and in particular
migraine, belongs to the spectrum of neurological manifestations of
systemic lupus erythematosus (SLE) remains uncertain. We con-
ducted a retrospective, followed by a longitudinal, one-year
assessment of patients with SLE versus healthy controls, and patients
with multiple sclerosis (MS), an organ-specific autoimmune disease
affecting the nervous system.
Methods At baseline, patients with SLE, MS and 1:1 matched
healthy controls for age, gender and level of education were
examined for the presence of headache during the prior year
(classification criteria of the International Headache Society); anx-
iety, depression and quality of life were also assessed. Prospective
follow-up using specific headache diaries was then performed at 3,
6, 9, and 12 months.
Results Seventy two patients with SLE, 72 paired controls and 48
patients with MS participated in the study. Migraine was pro-
spectively diagnosed in 21%, 23 % and 22 % of lupus, multiple
sclerosis patients and controls, respectively, which was almost
identical with data derived from the retrospective evaluation. Aura,
migraine frequency and consumption of analgesics were compa-
rable between lupus patients and controls. Frequent Tension Type
Headache was equally observed in SLE and controls (both 17%)
and MS (19%). In contrast, Chronic Tension Type Headache was
significantly increased in patients with SLE (12.5%) and MS
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(8.3%), compared to controls (1.4%). SLE patients had signifi-
cantly more anxiety and depression, and worse quality of life than
controls, but headache was not associated with these differences.
Any type of headache could not be related to a particular clinical
manifestation, type of auto-antibody or overall disease activity in
SLE.
Conclusions Migraine should be no longer regarded as a neurologic
manifestation of systemic or organ-specific clinical autoimmunity.
A higher risk of chronic tension type headache in SLE and MS is
probably due to the increased psychological burden associated with
these diseases.
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Computer-animated relaxation therapy in children
between 7 to 13 years of age with tension-type
headache: a pilot study
B. Tornoe1, L. Skov2
1Children’s Headache Centre, Department of Paediatrics,
Copenhagen, Denmark;
2Department of Paediatrics, Glostrup University Hospital,
Copenhagen, Denmark
Objectives To examine the effects of modified progressive relaxation
therapy assisted by computer-animated SEMG at the trapezius mus-
cles. To collect the children’s experiences with therapy.
Background Tension-type headache are the most common type of
headache illnesses in childhood (Anttila, 2006; Zwart et al. 2004).
Interventions with children younger than the age of twelve are
challenged by the child’s limited ability to participate in cognitive
approaches. This study aimed at evaluating the effect of a com-
puter-animated progressive relaxation therapy with children seven
to thirteen years of age with frequent or chronic tension-type
headache.
Methods Nine children, mean age 10.9 (+/-1,7) years attended a 9
session-modified relaxation therapy and biofeedback. The therapy
(Bernstein and Borkovec, 1973) was modified for younger children
with pictograms of relaxation exercises for every day use. In sessions
the child exercised the technique followed by SEMG-biofeedback at
the trapezius muscles (Nexus-10). The feedback provided was music
and animations visualizing tension-level. Root mean squares and
mean median frequencies were extracted. Pain was measured with
Visual-Analogue-Score. Outcome measures were
(a) headache frequency and intensity
(b) pericranial tenderness
(c) tension patterns
(d) logbook notes, at baseline, postintervention and at 3-month
follow-up
.
Results The results showed a mean improvement of 45% (+/-51) of
headache frequency at 3 month follow-up versus baseline (reduction
P B 0.03). Total tenderness score was reduced from mean value
24.6 (6.6) to 18.8 (8.5) from baseline to three month follow up
(P B 0.08). The children expressed a growing understanding of
body reactions, and an acquired ability to regulate these. This study
suggests that children below the age of 13 need both the dialog and
guidance from a participant observer in order to achieve body-
awareness.
Conclusion This study, though an uncontrolled pre-post design,
suggests that computer-animated relaxation therapy is an applica-
ble learning strategy with younger children with tension-type
headache.
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A proactive approach towards migraine patients
in general practice: a pragmatic randomized
controlled trial
A. Smelt1, J. Blom1, F. Dekker1, E. van den Akker2, F. Zitman3,
M. Ferrari4, W. Assendelft1
1Public Health and Primary Care, Leiden, The Netherlands;
2Medical Decision Making, Leiden, The Netherlands;
3Psychiatry, Leiden, The Netherlands;
4Neurology, Leiden University Medical Center, Leiden, The Netherlands
Objective Optimizing treatment of patients with frequent migraine
attacks in general practice by implementing a proactive intervention by
general practitioners (GPs). Main goal: a pro-active approach of headache
complaints by ensuring adequate management of attacks, stimulating use
of prophylaxis and treatment of medication overuse headache.
Design Cluster randomized trial with randomization by GP.
Setting 64 general practices in the Netherlands.
Participants Patients using C 2 triptans per month.
Outcome measures Primary outcome measure: Headache Impact Test
(HIT-6) at 6 months. We defined 2.3 points as clinically relevant. Sec-
ondary outcome measures: health-related quality of life (EQ-5D), migraine
characteristics, medication use and a cost-effectiveness evaluation.
Intervention GPs in the intervention group received training and
supporting materials on treatment of migraine according to the
guideline for headache treatment from the Dutch College for General
Practice. Subsequently, they invited participants for a consultation to
evaluate their current migraine therapy. GPs in the control group were
asked to continue usual care.
Results We included 490 patients (233 intervention group, 257
control group). The evaluation consultation was attended by 193
(83%) of the intervention patients. After the consultation, 41 patients
(18%) started prophylaxis, 27 (12%) continued current prophylaxis,
and in 22 (9%) patients the prophylactic treatment was changed.At
6 months the HIT-6 scores in the intervention group were improved
3.1 points, however the difference was only 0.5 points compared to
the control group (p = 0.083). In patients who did not use prophy-
laxis at baseline the HIT-6 score improved 0.7 points more in the
intervention group compared to the control group (p = 0.010).
Conclusions An educational intervention for GPs and a proactive
approach of migraine patients resulted in the initiation or change of
prophylaxis in 27% of participants. However, the difference in
reduction of headache complaints between the intervention group and
the control group was not clinically relevant.
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Predictors of headache impact (HIT-6) by migraine
status: results from the american migraine prevalence
and prevention (AMPP) study
R.B. Lipton1,2, A. Manack3, D. Serrano4, S. Varon3, C.C. Turkel3,
D.C. Buse1,2
1Neurology, Albert Einstein College of Medicine, Bronx, USA;
2Montefiore Headache Center, Bronx, NY, USA;
3Allergan Inc., Irvine, CA, USA;
4Vedanta Research, Chapel Hill, NC, USA
Background Migraine is a common, disabling neurologic disorder which
can impact all aspects of sufferers’ lives. Chronic migraine (CM) has been
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demonstrated to have even greater impact than episodic migraine (EM) on
headache-related-disability, health-related quality of life, direct and indi-
rect costs, and comorbid medical and psychiatric conditions.
Objective To identify predictors of headache impact in EM and CM
sufferers in the population.
Methods The AMPP study is a longitudinal, US population-based,
mailed survey. Participants eligible for this analysis were respondents
to the 2009 survey who met criteria for either CM (ICHD-2 criteria
for migraine and C 15 headache days/month) or EM (ICHD-2 criteria
for migraine and \ 15 headache days/month). The Headache Impact
Test (HIT-6) is a validated six-item questionnaire that measures the
impact of headache over a 4 week recall period. A series of four
hierarchical regression models were fit. Analyses were stratified by
CM and EM. Order of predictor-block entry constituting the model
hierarchy included demographics (gender, age, population density,
household income, US geographic region), headache characteristics
[(migraine symptoms, pain intensity, headache-related disability
(MIDAS Grade)], depressive and anxious symptomology, and current
preventive headache medication use, respectively.
Results 27,253 questionnaires were fielded and 20,107 were returned
yielding a sample of 373 participants with CM and 6,796 with EM. For
CM, predictors of HIT-6 score included pain intensity (b(SE) =
0.86(0.16), p \ 0.001), headache-related disability (b(SE) =
1.35(.26), p \ 0.001), depression (b(SE) = 2.52(1.0), p = 0.01), and
anxiety (b(SE) = 0.2(0.07), p = 0.003). Demographic variables and
preventive medication use were not predictive. For EM, predictors of
HIT-6 score were similar to those for CM but also included age
(b(SE) = -0.03(0.01), p = 0.04) and preventive medication use
(b(SE) = 1.26(0.32), p \ 0.001).
Discussion The impact of CM and EM, as measured by HIT-6, is
associated with pain intensity, disability, depression, and anxiety. Age
and use of preventive medications are unique predictors of HIT-6
scores for EM.
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Bifocal nummular headache: a series of three new cases
A.L. Guerrero1, M.E. Garcı´a-Garcı´a2, M.L. Cuadrado2, E. Cortijo1,
S. Herrero1, O. Rodrı´guez-Go´mez2, P. Mulero1, J. Porta-Etessam2
1Neurology Department, Hospital Clı´nico Universitario,
Valladolid, Spain;
2Neurology Department, Hospital Clı´nico San Carlos, Madrid, Spain
Objective Nummular headache (NH) is a new entity described in
2002 and defined as a chronic head pain felt in a small, well-cir-
cumscribed, coin-shaped area, according to the appendix of the
International Classification of Headache Disorders II (ICHD-II). The
temporal pattern is variable and in situ exacerbations have been
described. More than 150 cases of NH have been reported from dif-
ferent countries, and, among them, four patients localized their pain in
two separate areas. We present a new series of bifocal NH.
Methods We reviewed all patients diagnosed with NH at the head-
ache units of two tertiary hospitals searching for cases with head pain
in two different areas.
Results Three patients (2 female and 1 male; age at onset: 30, 61 and
69 years) had bifocal NH. Neuroimaging studies were performed in all
cases with no abnormalities. The shape and size of both painful areas were
identical in each patient. The painful areas were located at symmetrical
points of either side in two patients (two parietal and two occipital areas,
respectively), while the third patient had both symptomatic areas on the
same side of the head (temporal and parietal). The chronological pattern
was synchronous in one patient, whilst the other two showed an additive
pattern with unifocal pain evolving to bifocal pain after 6 months and
30 years, correspondingly. Pain intensity was slightly lower at the latter
point in these two cases. In two patients a preventive was prescribed
(carbamazepine and gabapentin). In the only synchronous case, the
painful areas showed an unequal response to therapy.
Conclusion This series reinforces the proposal of bifocal NH as a variant
of NH, thus enlarging its clinical spectrum. Pathogenic mechanisms of
NH might be active in different areas in certain patients.
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Epicrania fugax with backward radiation. clinical
characteristics of 5 new cases
P. Mulero, A.L. Guerrero, S. Herrero, E. Cortijo, M.L. Pen˜as,
E. Rojo, S. Miranda, R. Ferna´ndez
Neurology Department, Hospital Clı´nico Universitario,
Valladolid, Spain
Objectives Epicrania fugax (EF) is a novel syndrome described as a
paroxysmal and brief head pain, starting in posterior cranial regions
and rapidly spreading forward through a linear or zigzag trajectory to
ipsilateral eye. Two patients with comparable clinical features stem-
ming from frontal scalp to posterior regions have been recently
described and proposed as backward radiation epicrania fugax
(BREF). We report a new series of 5 BREF and compare their clinical
characteristics with 12 forward radiation EF (FREF).
Methods Since first description of BREF in February 2010, 5 patients
(3 males, 2 females) with this clinical picture have been attended at
our neurology outpatient office. Comparison is established with 12 EF
patients (4 males, 8 females).
Results Magnetic Resonance Imaging and blood tests were performed
in all cases with no abnormalities. Pain was strictly unilateral in all
patients and was described mainly as electric or stabbing. We found
no significant differences between BREF and FREF respectively in
age at onset (50 ± 10.6 vs 38.2 ± 15.6 years), attacks intensity
(6.4 ± 2.3 vs 7.1 ± 1.8 in a 0-10 visual analogical scale) and dura-
tion (16.6 ± 24.4 vs 10.2 ± 16.1 seconds). Number of episodes per
day was lower in BREF, not reaching statistical significance (2 ± 3.4
vs 13.2 ± 18, p = 0.05). 7 (58.3%) in FREF but none in BREF group
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presented an interictal pain in stemming area. 5 (41.6%) cases in
FREF and 1 (20%) in BREF group associated autonomic symptoms.
Conclusion This series reinforces the proposal of EF as a new
headache variant or a new headache syndrome. Clinical picture of
brief pain paroxysms starting in anterior scalp and radiating back-
wards does not fit known headaches or neuralgias and might
correspond to a reverse variant of EF, which clinical characteristics
are comparable to FREF.
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Prevalence of migraine and headache in Moroccan
schoolchildren
Z. Laaouina
Neurology, Private, Agadir, Morocco
Objective To determine the prevalence rate of migraine in school
children aged 6 to 13 years in the city of Agadir.
Background This study is the first survey of migraine in children in
Morocco.
Methods 1999 subjects were randomly selected using a multistage
clustered sampling procedure. A combination of a questionnaire and
clinical interview with examination was used between January and
June 2004. 586 children who had reported having moderate or severe
headache were invited with their parents to the School’s medical
room for an interview and clinical examination by a neurologist. 97%
attended. Diagnosis of migraine headache was made according to the
International Classification of Headache 2004.
Results Participation rate was 93.7% (1874 of 1999). According to
the interview and clinical examination, 9.7% fulfilled the criteria for
migraine headache. The prevalence of migraine increased with age.
Among girls, the prevalence was 10.2% but for boys it was 9.2%. The
highest prevalence for girls (25%) occurred at age 12, but for boys the
highest prevalence (20%) occurred at age 13. The mean age of onset
of migraine was 7.9 years. 52.6% had a frequency of occurrence of
one to two attacks per month. In 58%, the headache lasted one to four
hours. 64.3% had bilateral location.78.8% had pulsating quality.
Symptoms that were constantly experienced with the headaches were
phonophobia 86.2%, photophobia 72% and nausea 61%.
84% had a family history of headache.30% of subjects had missed
school because of migraine attack in the previous 3 months. Doctor
attendance rate was very low. 86.7% of migraine sufferers had never
consulted a doctor for headache. Of the remaining 13.3% who had
seen a doctor, a diagnosis of migraine was not made.
Conclusions Migraine is a common health problem among school
children in Agadir. It is still mostly under- estimated and under-
diagnosed.
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Chronic and episodic migraine - functional and organic
distinctions
M. Koreshkina1, A. Khalikov2
1Neurological, St-Petersburg, Russia;
2MRI, International Clinic MEDEM, St-Petersburg, Russia
Chronic migraine is complication of episodic migraine. It is consid-
ered to be headache during 15 days or more each month within at
least three months period. Chronic migraine should response to
treatment with triptans or ergot after eight days at most.
Methods We studied 78 patients with migraine, all female 22 to
52 years old (35,7 years old in average). 46 patients had episodic
migraine and 32 patients had chronic migraine. The protocol included
neurological examination, questionnaire form filling, doppler ultra-
sound study, EEG, 3T contrast brain MRI. The MRI protocol included
T1WI, T2WI, Diffusion-tensor imaging (DTI), Diffusion-weighted
imaging, T2* GRE pulse sequence and MR-angiography.
Results Patients with chronic daily headache had additional com-
plaints concerning disability, memory impairment, reduced attention.
MIDAS scale showed 8,3 total in patients with episodic migraine and
25,8 total in patients with chronic migraine.In patients with chronic
migraine EEG study showed diffuse functional cortex disorganiza-
tion. Doppler US results showed increased perfusion in MCA of
relevant brain hemisphere with headache location. MRI study
detected lesions in brain white matter in 78% of total patients and in
100% of chronic migraine patients. White matter lesions varying in
size between 2 and 8 mm were visualized mostly in frontal and
temporal lobes in subcortical area. Multiple lesions were found in
patients with chronic migraine. Single lesions were found typically in
patients with episodic migraine. FLAIR imaging proved to be the
optimal MRI pulse sequence for detection of migraine lesions. The
number of lesions does not depend on presence of migraine aura but
depends only on migraine attacks frequency and duration of disorder.
Conclusion There is an organic difference between chronic and
episodic migraine which requires special attention from medical
society. White matter lesions in brain MRI reflect the intensity of the
disease.
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Living knowledge of the healing plants: results
from a cross-sectional study in Kishoreganj
district of Bangladesh
A.H. Mollik1,2
1Epidemiology, Biostatistics, Community Nutrition
and Noncommunicable Diseases, Peoples Integrated Alliance,
Dhaka, Bangladesh;
2Biotechnology and Genetic Engineering, University of Development
Alternative, Dhaka, Bangladesh
Various types of body pains are common afflictions affecting
people throughout the world. A more debilitating type of pain
arises from migraines and headaches, which is believed to affect
at least 13% of the world’s population, mostly the elderly. Since
regular use or over-use of various pain-killer drugs may have
side-effects, an alternative route to treat pain is through use of
plants provided by the traditional medicinal practitioners and
which are generally believed to be without any side-effects. The
present study was carried out in Kishoreganj district of Bangla-
desh; to gather information on plants used to treat various types
of pain. Extensive interviews were conducted of the traditional
medicinal practitioners and information collected as to plants or
plant parts used and the ailments treated. All plants were iden-
tified and vouchers were stored at the Bangladesh National
Herbarium; under the author0s collector series. Plants used to treat
migraines and headaches included Santalum album (L.), Periploca
indica (L.), Coccinia cordifolia (L.) Cogn., Datura metel (L.),
Achyranthes aspera (L.), Bacopa monnieri (L.) Pennell, Aloe vera
(L.) Burm.f., cocos nucifera (L.), Ipomoea aquatica Forssk.,
Ocimum gratissimum (L.), Iawsonia inermis (L.), Cinnamomum
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camphora (L.) Sieb., and Nigella sativa (L.). Plants used to treat
general body pains included Olea europaea (L.), Curcuma longa
(L.), Chenopodium ambrosioides (L.), Musa sapientum (L.),
Nicotiana tabacum (L.), Brassica napus (L.), Alternanthera
glabra Moq., Allium cepa (L.), and Linum usitatissimum (L.).
Paederia foetida (L.), Amaranthus viridis (L.), and Wedelia
chinensis (osbeck) Merr. was used to treat stomach pains, while
Cissus quadrangularis (L.), Randia dumetorum (retz.) Poir., and
Allium sativum (L.) was used to treat rheumatic pains. Informa-
tion on indigenous use of plants has led to discovery of many
medicines in use today. Scientific studies conducted on the above-
plants may lead to discovery of more effective drugs than in use
at present.
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Local administration of herbal medicine in treating
insomnia disorder: an ethnographic case study
from Habiganj district of Bangladesh
A.H. Mollik1,2
1Epidemiology, Biostatistics, Community Nutrition
and Noncommunicable Diseases, Peoples Integrated Alliance,
Dhaka, Bangladesh;
2Biotechnology and Genetic Engineering,
University of Development Alternative, Dhaka, Bangladesh
Insomnia disorder is the most common sleep disorder which
affected more than 18300000 people in Bangladesh. 7600000
people develop chronic insomnia disorder with symptoms of dif-
ficulty falling asleep for more than 30 minutes and last for more
than 01 month. Patients with insomnia disorder in Bangladesh took
2900000 sleeping pills each year for insomnia disorder. However,
there were still some side effects about sleeping pills such as
allergy, amnesia, hallucination etc. Because of the side-effects of
modern medicines and because of the inability of modern medi-
cines to cure insomnia disorder, international scientific interest has
re-focused on the traditional uses of medicinal plants to find
effective cure for insomnia disorder as well as hundred of other
disorders. A study of traditional health practitioners in Habiganj
district of Bangladesh suggested that some of the herbal medicines
prepared from medicinal plants might be quite effective for
insomnia disorder. Interviews were conducted with the help of a
semi-structured questionnaire and medicinal plant samples as
pointed out by the traditional health practitioners were collected
and identified at the Bangladesh National Herbarium. In the current
study 24 medicinal plants belonging to 23 genera and 21 families
were found to be used to treat insomnia disorder. These medicinal
plant family names included Fabaceae Lindl., Rutaceae Juss.,
Convolvulaceae Juss., Piperaceae Bercht. & J.Presl, Papaveraceae
Juss., Apocynaceae Juss., Cucurbitaceae Juss., Solanaceae Juss.,
Amaranthaceae Juss., Plumbaginaceae Juss., Lamiaceae Lindl.,
Meliaceae Juss., Linaceae S.F. Gray, Ranunculaceae Juss., San-
talaceae R.Br., Scrophulariaceae Juss., Asparagaceae Juss.,
Asphodelaceae Juss., Arecaceae Schultz-Schultzenstein, Lythraceae
J.St-Hil., and Lauraceae Juss.. It was noted in this study that the
patients were quite satisfied with treatment by the traditional health
practitioners. It is important that modern scientific studies be
conducted on these medicinal plants towards isolation and identi-
fication of compounds through which insomnia disorder can be
effectively treated.
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Headache frequency in Germany remains constant
from 1995–2009: results from yearly population-
representative cross-sectional studies
A. Straube1, S. Foerderreuther1, B. Aicher2, J. Ko¨ppl2, S. Mo¨ller3,
R. Schneider2, G. Haag4
1Dept. Neurology, Ludwig-Maximilians-Universita¨t Mu¨nchen,
Klinikum Großhadern, Munich, Germany;
2Boehringer Ingelheim Pharma GmbH & Co. KG,
Ingelheim am Rhein, Germany;
3Ipsos Operations GmbH, Mo¨lln, Germany;
4Michael-Balint-Klinik, Ko¨nigsfeld im Schwarzwald, Germany
Population-based cross-sectional studies on the prevalence of
headache disorders are available for several countries, but there are
only few studies on the development of this prevalence over longer
time periods. Now, for the first time, data are presented for the
German Federal Republic for the period 1995-2009. Due to rele-
vant methodological differences, the data for 2006-2008 are not
considered.
The cross-sectional studies were implemented as surveys once yearly
by Ipsos GmbH, from 1995 as PAPI, and from 2005 in the form of
CAPI. Randomly selected German-speakers aged 14 and over living
in private households throughout Germany were surveyed
(N = 10898 - 12538). The following sociodemographic data were
measured: gender, age, school education, occupation, current job, net
household income, and in random order, up to 31 illnesses, including
self-diagnoses of headache and migraine, which as self-diagnoses by
the sufferers are not in accordance with ICHD-2.
Headache prevalence has remained stable over the years, at 58.8 -
62.5% (women: 67.3 - 70.7%; men: 48.4 - 54.3%). There is no dif-
ference between West Germany and East Germany (former GDR).
Urban populations (city size [ 50,000 inhabitants) show, in the
sliding 4-year average prevalences, a trend towards a 3-4% peak
higher headache prevalence than the population in small towns or
cities or in rural areas. No differing headache prevalences can be
discerned either for different occupations or for different net house-
hold incomes. Only the highest net income group ([ €3,500) shows a
trend towards higher 4-year average prevalences. On the one hand,
the results correlate well with the results from a large American study,
which also found a trend towards higher headache frequency in large
cities. However, in contrast to the American findings, in Germany, no
trend towards a higher prevalence in the shares of the population with
a low income is apparent.
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Characteristics and self-medication of headache
in germany 2007/2008 - results of a representative
population survey
S. Foerderreuther1, A. Straube1, B. Aicher2, J. Ko¨ppl2, S. Mo¨ller3,
R. Schneider2, G. Haag4
1Dept. Neurology, Ludwig-Maximilians-Universita¨t Mu¨nchen,
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So far, very few population-based cross-sectional studies are available
on characteristics of headaches, and particularly over-the-counter
treatments. New data for the German Federal Republic are presented
here.
This representative cross-sectional study was conducted as an
omnibus survey in 2007/2008 through ‘‘Computer-Aided Personal
Interviews’’. 15,802 persons were surveyed, selected through ran-
dom-route procedures. Participants were aged 14 years and over,
German-speakers, and living in private households throughout
Germany.
Besides sociodemographic data, in random order, 31 illnesses were
assessed, including self-diagnosis of headache and migraine (non-
ICHD-2-compliant), headache characteristics and data on the use of
headache preparations.
48% of participants suffered from headache within the last year
and 41.3% within the last 4 weeks (proportion of women 61.4%
and 63.1%, respectively). Headaches had occurred for 2 - 10 years
in 43.6% (women 42.9%, men 44.5%) and for [ 10 years in
39.8% (women 42.5 %, men 35.5%). For 63.3% of sufferers,
headache severity had remained the same compared to previous
years; for 18.6% it was stronger, and for 14.1% weaker. Headache
frequency was constant for 58.1% of sufferers, increasing for
18.5% and decreasing for 19.7%. The stronger the headache, the
more frequent complaints of further illnesses and the more fre-
quent the doctors’ consultations. Nevertheless, the proportion of
sufferers with strong headache who consulted doctors lay at only
24%.
Independently of the time window (4 weeks vs. 12 months),
approximately 81% of sufferers (approx. 64% women) took headache
preparations. Highly predominantly, 1 - 2 different preparations were
used (85%); only 0.3% mentioned C 5. Over 97% of participants
took headache medication on a maximum 10 days per month. \ 1%
of sufferers took over six tablets daily. Medication doses correlated
with pain severity.
In summary, headaches occur frequently; improvements and deteri-
orations over time are approximately equally frequent. Acute
medication is used frequently and predominantly responsibly.
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Differences in the use of analgesics for self-medication
of headache - results from a German representative
population survey 2007/2008
G. Haag1, S. Foerderreuther2, B. Aicher3, J. Ko¨ppl3, S. Mo¨ller4,
R. Schneider3, A. Straube2
1Michael-Balint-Klinik, Ko¨nigsfeld im Schwarzwald, Germany;
2Dept. Neurology, Ludwig-Maximilians-Universita¨t Mu¨nchen,
Klinikum Großhadern, Munich, Germany;
3Boehringer Ingelheim Pharma GmbH & Co. KG,
Ingelheim am Rhein, Germany;
4Ipsos Operations GmbH, Mo¨lln, Germany
The majority of headache sufferers successfully treat their headaches
with over-the-counter migraine and headache remedies. So far, dif-
ferences in the use of these treatments have barely been examined.
First data are available from a German population-based cross-sec-
tional study conducted in 2007/2008.
This representative study was conducted as an omnibus survey in 2007/
2008 through ‘‘Computer-Aided Personal Interviews’’. 15,802 Ger-
man-speakers aged 14 and over from private households in Germany
were selected through the random-route procedure and surveyed.
Besides sociodemographic data, 31 illnesses were assessed in random
order, including self-diagnoses of headache and migraine (non-ICHD-
2-compliant), headache characteristics and detailed data on prepara-
tions used (including brand name) and manner of use.
4,665 headache sufferers provided information regarding utilisation
duration and dosage of the examined 7 proprietary medicinal product
brands, and 3 medications predominantly containing the generic
active ingredients (acetylsalicylic acid [ASA], ibuprofen, paraceta-
mol). Five of these 10 user groups indicated taking these preparations
for longer than 3 consecutive days within the last year: a proprietary
drug with 1000 mg ASA (4.24 days), ibuprofen-containing prepara-
tions (3.69 days), proprietary drugs with 400 mg or 200-400 mg
ibuprofen-lysinate (3.29 or 3.14 days, respectively) and ASA-con-
taining products (3.04 days). By contrast, combination analgesic with
250 mg ASA, 200-250 mg paracetamol, and 50 mg caffeine were
taken for max 2.88 days, and effervescent tablets with 300 mg ASA
and 200 mg paracetamol for max 2.12 days. Permitted daily doses
were exceeded for the ibuprofen-lysinate- or ASA-containing pro-
prietary drugs marked with the brand name addition ‘‘migraine’’, and
for the ibuprofen-containing medicines. Of these, up to one fifth of
headache sufferers took more than the highest daily dosage recom-
mended in the patient instruction leaflet. For paracetamol or the fixed
combination analgesics, by contrast, this was only observable in
approx. 1%. Besides other factors, the medication description appears
to influence utilisation behaviour.
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Prevalence and clinical characteristics of primary
headache in Korea: a nationwide population-based
survey
B.K. Kim1, M.K. Chu2, K.S. Lee3, J.M. Kim4, C.S. Chung5
1Neurology, Eulji Hospital, Seoul, Republic of Korea;
2Hallym University, Chuncheon, Korea;
3Catholic University, Gyeongsan, Korea
4Chungnam University, 5Samsung Medical Center, Seoul,
Republic of Korea
Background and purpose Since International Classification of
Headache Disorders was announced in 1988, many epidemiological
studies on migraine have been performed. However, the epidemiology
of headache disorders in Asian countries is only partly documented.
We investigated the prevalence and clinical characteristics of primary
headache in Korea in 2009.
Methods Among Koreans of 19 years old or above, we randomly selected
1,507 target population by stratified random sampling with clustering,
regarding area, age and gender. Face to face survey was conducted by
structured interview using 29-item questionnaire in 2009. The question-
naire includes basic demography, headache characteristics, associated
symptoms, occupation, income, headache related disability, and use of
medical care. Headache characteristics and associated symptoms were
constructed to sort out migraine and tension-type headache based on ICHD-
II and to investigate clinical characteristics of both headache disorders.
Results One year prevalence of all types of headache was 61.4%. The
overall prevalence rates were 6.0% (9.2% in females and 2.9% in
males) for migraine and 30.7% (29.3% in females and 32.2% in
males) for tension type headache. The prevalence of migraine peaked
at the ages of 40-49 years in overall and female cases, respectively,
but of 19-29 years in males. Almost one-third of migraineurs reported
as being substantially or severely impacted by migraine (HIT-6
scores C 56). Only 28.9% of migraineur visited doctors for their
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headache and 4.4% of migraineurs knew their correct diagnosis.
Migraine patients most commonly treated their headache (51.6%)
with OTC drugs and only 18.7% of migraineur treat their headaches
with prescription drugs in last one year.
Conclusions While the prevalences of migraine and tension type
headache in Korea are lower than those in Western countries, they are
similar to those of other Asian countries. Although headache related
disability is substantial, headache patients still remain inadequately
diagnosed and treated.
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Effects of cortical spreading depression (CSD)
on C-FOS expression in rat periaqueductal grey matter
A. Lombard1, V.B. Bogdanov2, V. Chauvel2, S. Multon2,
J. Schoenen2
1Headache Research Unit (Dept of Neurology &
GIGA-Neurosciences), Lie`ge, Belgium;
2Universite´ de Lie`ge, Lie`ge, Belgium
Background The migraine aura is likely due to Cortical Spreading
Depression (CSD), a neuro-glial event associated with propagating
depolarisation followed by prolonged neuronal inhibition. It is not
clear if CSD is also responsible for the activation of the neuronal
systems causing the migraine headache and the associated autonomic
symptoms. The periaqueductal grey matter (PAG) is involved in pain
and autonomic control and possibly in migraine pathophysiology.
Objective Our objective was to search for neuronal activation
induced by experimental KCl-induced CSD in the PAG.
Method We induced CSD during 2 hours by cortical application of KCl
in anesthetized rats (n = 6 per group) treated daily for 1 month with
NaCl or lamotrigine (LTG) (15 mg/kg) and used non-stimulated ani-
mals as controls. Fos immunocytochemistry was performed on serial
transverse sections of the brain stem and immunoreactive nuclei were
counted in rostral (Bregma -6.5 mm) and caudal (Bregma -8 mm) PAG
using an image analyzing system. We used the Mann-Whitney U test to
compare controls to CSD + NaCl and the latter to CSD + LTG.
Results The number of Fos-immunoreactive nuclei was significantly
reduced in both rostral and caudal PAG after CSD, more so in LTG-
treated rats. The median number of Fos-positive neurons in rostral
PAG was 126 [75% CI: 64-294] in controls, 42 [29-50] in the
CSD + NaCl group (p = 0.03) and 16 [14-27] in the CSD + LTG
group (p = 0.02). The respective numbers in caudal PAG were 75
[54-134], 38 [37-41] (p = 0.03) and 31.5 [21-35] (p = 0.2).
Conclusion CSD significantly decreases neuronal activity in the
periaqueductal grey matter which might promote the occurrence of
central sensitization and headache during attacks of migraine with
aura, as well as associated autonomic disturbances.
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Involvement of latent Herpes Zoster Virus
in the development of forehead allodynia
and aggravation of cluster headache (2nd report)
T. Shimizu1, I. Arakawa2
1Headache Clinic, Department of Neurosurgery, Tokyo, Japan;
2Department of Medical Service and Hospital Administration,
Tokyo Women’s Medical University, Tokyo, Japan
Background and aim Joseph R and Rose FC reported the possibility of
an association between cluster headache and herpes simplex in 1985
(Joseph R et al. BMJ 1985; 209: 1625-6.). We, however, lately experi-
enced several cases developed forehead allodynia and aggravated cluster
headache after onset of herpes zoster. Accordingly, we deemed latent
herpes zoster virus (varicella-zoster virus, VZV) infection in the trigem-
inal and occipital innervations areas may be involved in the development
of forehead allodynia and aggravation of cluster headache. The aim of the
present study is to confirm an association between cluster headache and
herpes zoster. We still reported an interim result of the present study at the
14th International Headache Congress 2009 in Philadelphia.
Methods We conducted a retrospective review of 27 patients (female
vs male = 1:2, mean age 38.0 ± 8.6 yrs) diagnosed with migraine
(based on the ICHD-II) who had measured values of antibody titer to
VZV. Ethic aspect was considered based on the ethic guideline of
clinical research published in Japan.
Results VZV antibody titer in 70% of 27 patients was increased with
reactivation. In 4 patients, VZV antibody titer in episodic duration
was trended to be high, Thus, VZV antibody titer was expected to
detect initiation of episodes of cluster headache. It was deemed that
central sensitization in the trigeminal and occipital innervations areas
is developed due to reactivation of VZV. We further investigated
DNA test in serum, but not detected antigen of VZV in pre- and post-
episodic points so far.
Discussion We’re further investigating DNA test in tears to detect
antigen of VZV in pre- and post-episodic points on the basis of a
method by Furuta et al (J Clin Microbiol 2001).
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PDE8A expression in the rat brain. implications
for migaine?
L.S. Kruse1, M. Moeller2, C. Kruuse3
1Danish Headache Center, Dept. Neurology, Glostrup Hospital,
University of Copenhagen, Glostrup, Denmark;
2Dept. of Neuroscience and Pharmacology, Faculty of Health
Science, University of Copenhagen, Copenhagen, Denmark;
3Neurology, Glostrup Hospital, University of Copenhagen,
Glostrup, Denmark
Phosphodiesterase 8A (PDE8A) is an enzyme responsible for the
hydrolysation and inactivation of cAMP. It modulates the levels of
intracellular cAMP available for signal transduction. The only
available inhibitor, although unspecific, is dipyridamole which is
known to cause headache. Only few reports had addressed the pres-
ence of PDE8A in the brain and none in the pain pathway. We
investigated the distribution of PDE8A in male Sprague-Dawley rats
with emphasis on migraine related structures such as dura, cerebral
arteries, trigeminal ganglion, trigeminal nucleus and thalamus by
immunohistochemistry. This was supplemented by protein extraction
from selected regions followed by Western blotting. We show that in
both the brain and the trigeminal ganglion, PDE8A was confined to
neuronal perikaryal cytoplasm as well as to processes extending from
these perikaya. The neurons exhibiting PDE8A-immunoreactivity
were widely distributed in the forebrain, brain stem, and cerebellum
as well as in the trigeminal ganglion. Immunoreactive neurons were
located in the olfactory bulb, the septal area, zona incerta, and
reticular nucleus of the thalamus. In the brain stem, strong immu-
noreactive neurons were present in substantia nigra and the sensory
trigeminal nucleus. Outside the brain parenchyma, PDE8A immu-
noreactivity was present in the dura mater, and in the neurons of the
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trigeminal ganglion. The localization of PDE8A involves brain areas
of pain transmission, motor function, cognition, vegetative functions,
and olfaction. Development of selective PDE8A inhibitors or acti-
vators is needed for a further understanding of the functional role of
PDE8A in the brain and in migraine in particular.
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Experience with onabotulinumtoxina (BOTOX)
in chronic refractory migraine: focus on severe
attacks
J. Pascual1, A. Oterino2
1Neurology, University Hospital Central de Asturias, Oviedo, Spain;
2Neurology, University Hospital Marques de Valdecilla,
Santander, Spain
Objectives To analyse our experience in the treatment of chronic
migraine (CM) with onabotulinumtoxinA (BTA) and specifically in
its effects over disabling attacks.
Patients and methods Patients with CM and inadequate response or
intolerance to oral preventatives were treated with pericranial injec-
tions of 100-150 Units of TBA every three months. Patients filled in a
headache diary. In addition, we specifically asked on the effect of
BTA on the frequency of disabling attacks, consumption of triptans
and visits to emergency for the treatment of severe attacks.
Results This series comprises a total of 34 patients (3 males), aged
24-68 years old. All except 3 met IHS criteria for analgesic overuse.
The number of sessions with BTA ranged from 1 to 15 (median 3).
Nine (26%) responded (reduction of [ 50% in headache days).
However, the frequency of severe attacks was reduced an average of
53.1% (range 30-90%) in 82% of the patients. Twenty-two (76%), out
of the 29 patients who were taking oral triptans, reduced triptan
consumption an average of 50% (from 22 to 11 tablets per month).
Those 6 patients who used subcutaneous sumatriptan reduced its
consumption a mean of 69.1% (from 4.5 to 1.5 injections per month).
For the whole series, visits to emergency decreased from an average
of 24 to 4 per month (-83%). Six patients complained of mild adverse
events, transient local cervical pain being the most common.
Conclusions In clinical practice, treatment with BTA reduces the
frequency of disabling attacks, the consumption of triptans and
the need of visits to emergency at least by at least half. This
makes this treatment option profitable both clinical and
pharmacoeconomically.
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Prevalence of right-left shunts on CTCD in chronic
migraine and medication overuse headache:
a cross-sectional study
S. Shalchian1, M. Ashina2, S. Guo2, M. Ku¨per3, Z. Katsarava3,
J. Schoenen1
1Neurology & GIGA-Neurosciences, Liege University, Liege,
Belgium, 2Danish Headache Centre, Copenhagen University,
Copenhagen, Denmark, 3Neurology-Headache Center,
Essen University, Essen, Germany
Background Various epidemiological studies show that a patent
foramen ovale (PFO) is more prevalent in episodic migraine with
aura. There is also circumstantial evidence from observational studies
that endovascular closure of a PFO ameliorates migraine with and
without aura. Recently, it was suggested that PFO may be related to
attack frequency and highly prevalent in chronic migraine.
Objective Assess the prevalence of a right-left (R-L) shunt on con-
trast enhanced transcranial Doppler (cTCD) in patients suffering from
chronic migraine (CM: ICHD-II A1.5.1) or medication overuse
headache (MOH: ICHD-II A8.2).
Methods This was a multicentre study involving 3 European Head-
ache Centers. For logistical reasons, recruitment was asymmetrical:
102 patients in Lie`ge, 48 in Copenhagen, 9 in Essen. cTCD was
performed according to international recommendations (Angeli et al
2001, Droste et al 2002) at rest and during Valsalva manoeuvres. R-L
shunts were graded according to the 3 grade International Classifi-
cation System.
Results Fifty-seven CM and 102 MOH patients were included. In the
CM group a R-L shunt was detected at rest in 12.3%, during Valsalva
in 36.8 %; 10.5% had grade 3 shunts. In the MOH group, 30.4% of
patients had a R-L shunt among whom 14.7% at rest and 12.8% grade
3. Migraine with aura attacks occurred in 53 % of CM and 28% of
MOH; a R-L shunt was found in 44% of the former (28% grade 3), in
37% of the latter (31.6% grade 3).There was no significant difference
between the two patients groups.
Conclusion Prevalence of R-L shunts in CM (36.8%) and MOH
(30.4%) is at the higher range of that reported in normal controls
(35%). This is at odds with Nahas et al (2009) who found a 66%
prevalence. The difference could be due to a lower proportion of
migraine with aura patients in our study.
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Illness perception: a discourse analysis of migraineurs
from the general population
F. Radat1, M. Koleck2, J. Faucaud3, C. Lucas4, H. Massiou5,
A. Pradalier6, F. Nachit-Ouinekh7, A. El Hasnaoui7, M. Lanteri-
Minet8
1Clinical Neurosciences, CHU Pellegrin, Bordeaux, France;
2Health Psychology, Universite´ Bordeaux 2, Bordeaux, France;
3Inpes, Saint Denis, France;
4Neurology, CHU Salengro, Lilles, France;
5Neurology, CHU Lariboisiere, Paris, France;
6Medecine, CHU Lariboisiere Louis Mourier, Colombes, France;
7Laboratoire Glaxo Smith Kline, Marly le Roi, France;
8Pain, CHU Pasteur, Nice, France
This study aimed at describing the cognitive representations of
migraine through the migraineurs’ discourse on a representative
sample of subjects taken by random from the GRIM 3 study which
was an epidemiological cross-sectional study led on a representa-
tive sample of the French general population. We perform a
quantitative analysis of discourse using the ALCESTE software. It
enables us to automatically quantify a text in order to extract the
most significant structures from it. A statistical analysis is per-
formed so as to check that the over-representation of structures
isn’t due to chance. The automatic analysis of discourse is a way
used in this work to enable filtration of the researchers’ projections
that can often be noticed in procedures of content analysis. An
interview grid was worked out in order to gather the representa-
tions of migraine through nine open-ended questions. The
population was composed of 51 subjects (11 men and 40 women)
aged 19 to 74 (m = 41,25 years). The analysis shows that
throughout the corpus, the word ‘‘migraine’’ doesn’t appear spon-
taneously and to the subjects, headaches only are successive crises,
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not a global disease that may require long-run treatment. In fact, it
seems that migraine as a chronic disease is not well understood;
the people rather have this successive crises type of representation.
. In the reactions to the crises, it may be intriguing not to find any
clue evoking the field of catastrophizing. However, the cognitive
coping strategy of resignation is to be found. The favourite inter-
locutor to start a therapeutic education of the patient is the general
practitioner since subjects say they do not expect anything of the
kind from the media. The results allows us to propose interventions
that include patient education and cognitive and behavioral therapy
centred on the feeling of loss of control and resignation.
Conflict of interest C. Lucas has perceived personal fees for activ-
ities (consulting, clinical research) with Allergan, Almirall SAS,
Astra Zeneca Pharmaceuticals, Boehringer Ingelheim, Bouchara
Recordati, Glaxo-Smith Kline Inc, Menarini, Merck, Pfizer Inc,
Sanofi-Aventis, Servier.
Radat F. Research grants :UPSA. Consulting fees or other remu-
neration received for presentations : Lilly France- Menarini- Pfizer-
MSD- Allergan. Board member : Lilly France – Allergan.
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Exercise as migraine prophylaxis - a randomized
controlled study using relaxation and topiramate
as controls
E. Varkey1, A˚. Cider1,2, J. Carlsson1, M. Linde1,3,4
1Institute of Neuroscience and Physiology, The Sahlgrenska Academy
at University of Gothenburg, Gothenburg, Sweden;
2Sahlgrenska University Hospital, Gothenburg, Sweden,
3Department of Neuroscience, Norwegian University of Science
and Technology, Trondheim, Norway;
4Norwegian National Headache Centre, St. Olavs University Hospital,
Trondheim, Norway
Objectives The aim of the study was to evaluate exercise in migraine
prophylaxis and to compare it with well documented pharmacological
and non pharmacological alternatives.
Patients and methods This was a three armed randomized, con-
trolled trial. After a baseline period, 103 patients with 2 - 8 migraine
attacks /month were randomized to one of three treatments (exercise,
topiramate or relaxation) during a period of 12 weeks. Exercise
consisted of indoor cycling for 40 minutes, three times/week.
Relaxation was done with a physiotherapist once a week at a clinic
and daily with a CD at home. The topiramate group was followed by a
neurologist. Migraine attack frequency, migraine days/month, pain
intensity, acute medication use, quality of life and oxygen uptake
were evaluated throughout the study. Long-term follow up was done 3
and 6 months post treatment.
Results Out of the randomized patients, 91 patients were included in
the intention to treat analysis. There was no significant difference
between the groups regarding migraine attack frequency during the
last month of treatment compared to baseline (p = 0.95). There was a
significantly higher decrease in pain intensity in the topiramate group
compared to exercise and relaxation (p = 0.04). In the exercise
group, oxygen uptake increased significantly compared to the other
groups (p \ 0.01). No differences between the groups were found
concerning any of the other secondary variables. No adverse events
were reported by patients in the relaxation or the exercise groups, but
by eight patients (33%) in the topiramate group.
Conclusion Exercise may be an option for the prophylactic treatment
of migraine in patients who do not benefit from, or want, daily
medication.
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Reproducibility of salivary CGRP level measurements
after capsaicin stimulation in human volunteers
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2Division of Vascular Medicine and Pharmacology, Department
of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
Objective To assess capsaicin-induced i) secretion of salivary calci-
tonin gene-related peptide (CGRP); and ii) day-to-day reproducibility
and reliability of salivary CGRP measurements in humans.
Background CGRP is assumed to play a key role in migraine path-
ophysiology and can also be found in mandibular trigeminal nerve
endings. Irritants such as capsaicin activate these nociceptive fibres,
resulting in CGRP secretion. This model can be used to study tri-
geminal sensitization, but few data are available on optimum
capsaicin concentration and day-to-day reproducibility.
Methods Thirteen healthy volunteers were exposed on two consec-
utive days to 8 increasing concentrations of Madame Jeannet pepper
extracts containing capsaicin. Extracts were intermittently applied on
the tongue during 5 minutes and secreted saliva was collected. Saliva
volume (ml), protein content (mg/ml) and CGRP (pg/ml;pg/5 min)
were measured. Optimum capsaicin concentration was defined as the
concentration with highest CGRP secretion (linear-regression model)
whilst heat-sensation was still tolerable. Day-to-day reproducibility
was assessed using repeated-measures ANOVA with day number and
capsaicin concentrations as factors.
Results On both days, maximum salivary CGRP content (pg/ml;
mean[SD]) using highest extract concentration was significantly
higher than at baseline (Day 1:13.2[6.7] vs. 10.3[2.0], p = 0.011; Day
2:13.3[3.3] vs. 9.1[3.6], p = 0.004). CGRP secretion correlates pos-
itively with extract concentration on day 1 (p = 0.028) and day 2
(p \ 0.001). This was reproduced in a second study (not-diluted
extract: 161.6[80.9] vs. baseline: 99.4[7.2] (pg/5 min.), p = 0.037),
showing CGRP increase even after adjusting for possible capsaicin/
CGRP cross-reactivity. Not-diluted extract was tolerated by all par-
ticipants. Assessing day-to-day reproducibility showed a significant
(p = 0.001) effect for extract concentration (pg/ml); not for day
number (p = 0.136) or day/concentration interaction (p = 0.600).
Conclusion Salivary CGRP concentrations are positively correlated
to orally applied capsaicin concentrations. Highest concentrations
are measured after stimulation with non-diluted pepper extracts.
Measurements of salivary CGRP are reproducible on a day-to-day
basis without evidence for day-to-day depletion or sensitisation
effects.
178
Chronic headache in paediatric age
M. Nicolodi1,2
1Interuniversity Centre of Neurochemistry and Clinical
Pharmacology, Trieste, Italy;
2Foundation Prevention and Therapy Primary Pain and Headache,
Florence, Italy
Introduction In 2004 we underlined that chronic headache was an
emerging phenomenon not present during the preceding decades.
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Aim To update the casuistry of chronic headache in children and
indicate possible impact of psychological factors. We can establish
now that in the period 2004-2010 we can see the following propor-
tions when comparing the number of cases of affected adults with the
number of affected children. Psychometric measures were compared
to the ones given in 2004 to observe their relevance.
Results The proportion of cases of children affected by a given
chronic headache is expressed as the ratio x children : 1000 adults,
both affected by a specific headache. Chronic migraine 120:1000
(male: female = 4 : 6) total number 84, chronic cluster headache 100:
1000 (male : female = 4 : 6, age 15-18) total number 80, chronic
tension-type headache 300:1000 (male : female = 12 : 3) total
number 16, chronic paroxysmal hemicrania 1000: 1000 (male: female
2 : 6) total number 32, new daily persistent headache 1000:1, (male
female1:10) total number 22. Results of psychometric tests regarded
chronic headache sufferers compared with those ones of a sex-age
matched control group of exempts (n = 170) and indicate no sig-
nificant difference as stated by Parental Bonding Instrument, CBLC,
Conners’ Scale, Wang, Zung tests. Our casuistry stresses that:
(a) new daily persistent headache occurs particularly in children,
(b) chronic cluster headache is more frequent in young females than
in males,
(c) new daily persistent headache seems peculiar to males.
Conclusions Total number of children with chronic headache was 42
versus 1000 adults in 2004, after 6 years children are 234 :1000 with
an increase over 5 times versus 2004 and augmentation over
450 times versus 1998 when only 5 child suffered from chronic
headache versus 1000 adult chronic sufferers.
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Leuprorelin as therapy of chronic cluster headache
refractory to conventional prophylactic therapies
and deep brain stimulation: open label observation
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Florence, Italy
Aim To treat intractable chronic cluster.
Subjects and procedure Cluster headache (CH), an extremely
painful syndrome may be refractory to therapies as carbolithium,
verapamil, corticosteroids, topiramate and gabapentin. In com-
pletely refractory sufferers Deep Brain Stimulation (DBS) was
used. The present observation included Group A: 67 (66 males, 1
females, mean age 42.4 ± 3.2SD) chronic CH sufferers (attacks
n = 3-6/day, duration 35-67 min) previously unsuccessfully treated
with mentioned prophylactic medication and Group B: 4 (2
females, age 29-58) chronic cluster headache sufferers (attacks
n = 7-11/ day, duration 47-110 min) previously unsuccessfully
treated with prophylactic medications and DBS. All the enrolled
subjects showed an acute abortive drug abuse: Sumatriptan in
Group A (60-80 mg/s.c/day) or Tramadol (1500 ± 5.50 SD)
sometimes (38% of the days) associated with Sumatriptan (24-
42 mg/s.c/day/) in Group B. Leuprorelin 11,75 mg was given once
a month in Group A, five times/month in Group B. The treatment
duration in Group A was 2-3 months (mean 2.1 ± 1.0 SD). Fifty%
relief was achieved during the first 14 days.
Results and conclusion The benefit consisted in a complete relief
for a period of 10-15 months (mean 12.1 months ± 3.2SD), fol-
lowing, 18 suffers had a relapse with 2-4 attacks/ day which
disappeared in a week following 1 injection of leuprorelin. The
other patients had no relapse during the following 4 years. Dif-
ferently Group B need more frequent administration: 5 vials/month.
Nevertheless, following 6 months they have no more than 0-4
attacks/month (mean 2.8 ± 1.9 SD) versus 7-11/ month . They also
use no more tramadol nor abuse sumatriptan. Patients did not
reported serious adverse effects; there is no drop-out. In males,
deficit of sexual desire was abolished by concomitant use of tes-
tosterone 50 mg/day/orally.
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Migraine susceptibility and post-dural puncture
headache; report from lumina
W.P.J. van Oosterhout, M.D. Ferrari, G.M. Terwindt,
LUMINA Study Group
Department of Neurology, LUMC, Leiden, The Netherlands
Objectives To assess
(i) whether migraine susceptibility increases the risk of developing
post-dural puncture headache (PDPH);
(ii) which factors increase this risk, and
(iii) which factors predict longer PDPH duration.
Background Hypotheses on PDPH aetiology include loss of cere-
brospinal fluid (CSF), and cerebral venous vasodilatation. Headache/
migraine susceptibility may increase the risk of developing PDPH but
no systematic studies have been performed. To our knowledge, this is
the first study systematically comparing this risk in migraineurs to
controls.
Methods Migraineurs and controls underwent lumbar puncture (LP)
for CSF collection between 8.00-12.00a.m, using traumatic needles.
Participants were contacted three days afterwards and when relevant,
PDPH was diagnosed. PDPH prevalence was compared between
groups using v2-test. Factors significantly increasing PDPH risk or
contributing to PDPH duration were identified using logistic/linear
models, corrected for age, gender and BMI.
Results In total, 156 participants (107 migraineurs; 49 controls)
underwent a successful LP. Forty-five (28.8%) developed PDPH, all
within 3 days. This is comparable with data from earlier studies.
Migraineurs suffered significantly less often from PDPH than non-
migraineurs (21.7% vs. 42.8%; v2(1,n = 155) = 7.38, p = 0.007).
Using logistic models, the following factors were found to signifi-
cantly increase the risk of developing PDPH: lower BMI (p = 0.048);
being non-migraineur (p = 0.046), increased duration of fastening
(p = 0.030), and higher reported headache-score directly after LP
(p = 0.001). PDPH prevalence also depended on age (maximum at
age 20-30yrs), albeit not significant. PDPH duration (spontaneous
recovery; n = 36) was significantly longer when subjects had suf-
fered from affective disorders (p = 0.005); when LP was performed
in one effort (p = 0.003); and in subjects reporting higher stress
during LP (p = 0.009).
Conclusion Our study shows that migraine susceptibility does not
increase the PDPH risk. Factors that increase this risk are lower BMI;
longer fastening prior to LP; and higher reported headache severity
directly after LP. Possible explanations for this difference will be
discussed.
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Propofol narcosis in refractory chronic cluster
headache
M. Nicolodi1,2
1Interuniversity Centre of Neurochemistry and Clinical
Pharmacology, Florence, Siena, Italy;
2Foundation Prevention and Therapy Primary Pain and Headache,
Florence, Italy
Aim To define usefulness of propofol in refractory cluster.
Procedure In five chronic cluster headache who reported none or
very transitory (less than 30 days) benefit following deep brain
stimulation, eptadone was overused (40 mg e.v/ 3 times/day) during
3-months treatment-period/yearly; patients were interviewed follow-
ing 3-4 eptadone treatment-periods carried out in different medical
structures. They stated they received no benefit and suffered drows-
iness, disorientation and dizziness. Largely better result was achieved
by using tramadol the use of which was continued in the years in
extremely large doses (1500 mg/day + 5.5 SD). In spite of opiates
abuse, the continuous onset of attacks led to 4/5-days lasting propofol
narcosis. The communicated protocol was: injection in rapid suc-
cession of propofol, succinylcholine, fentanyl. First bolus of propofol
was 200 mg, after propofol was given 7 mg/Kg/h. Narcotic treatment
lasted 4-6 days varying with appearance of abnormalities regarding
aminotrasferase levels, hepatic cytolysis, infections, thrombosis.
Patients who underwent the treatment stated the approach was useful
in giving a period of vacancy from pain.
Results Unfortunately the vacancy-period was shorter and shorter in
the time starting with 2 months and reaching 2-4 days following the
4th narcotic treatment. When the benefit decreased patients started
with tramadol till the next narcosis. As the vacancy period stopped the
restarting of cluster headache attacks was excruciating with high daily
number of attacks (7-11/day). Patients suppose there is no way to live
otherwise.
Conclusion Propofol
(a) acting on GABA-A for immobilizing action is not proved to
have activity on NMDA negative modulation,
(b) researches show propofol degenerative action on neural
structures,
(c) GABA-A can transitorily modulate pain perception in spinal-
cord, therefore, as regards 4-6 days propofol narcotic treatment,
basic science data and clinical evidences suggest only transitory
effects and not prophylactic properties in refractory chronic
cluster headache associate to opioids abuse.
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Features of cluster headache refractory to conventional
therapies and deep brain stimulation
M. Nicolodi1,2
1Interuniversity Centre of Neurochemistry and Clinical Pharmacology
of Idiopathic Headache, Siena University, Florence, Italy;
2Foundation Prevention and Therapy Primary Pain and Headache,
Florence, Italy
Subjects’ history Five subjects (3 males age range 29-58 years) suf-
fering from chronic cluster headache (CH) had been evidenced to be
absolutely refractory to conventional therapies: carbolithium,
verapamil, corticosteroids and open label therapies as topiramate and
gabapentin as add on medications. CH was chronic since at least 2 years
(mean 5.6 ± 1.38 SD). Pain was fixed unilateral for at least 12 months
and associated with the autonomic symptoms peculiar to CH. Fre-
quency of the attacks/ day was from 7 till to 11, duration of attacks
ranged from 47 to 110 min. Deep Brain Stimulation was performed
following the same scheme in all the 5 subjects. Briefly, electrode
implantation in the posterior hypothalamus -position as indicated by
May et al-. Position checked by postoperative MRI. Only one out of the
patients reported a benefit lasting 28 days after electrode implantation,
after, a sharp relapse followed. The other patients never reported ben-
efit. In 2 (1 male, 1 female) of them there was a switch of pain to the
other side of the cranium. A second implantation produced no result.
Features and conclusion The chief characteristics of the refractory
patients were: They have first and second degree consanguineous
suffering from migraine. One of them also listed a first degree con-
sanguineous suffering from episodic CH. Another one a third degree
with CH. All these patients were prescribed opiates and started a large
overuse/abuse of the opiate spurious compound tramadol (1500 mg/
e.v./day ± 5.50 SD) as well eptadone (40 mg e.v. three times a day).
Tramadol and eptadone were not associated; the index of preference
was favourable to tramadol periodically associated with sporadic
over-use of sumatriptan (32 ± 18 mg/s.c./day). The overuse/abuse of
opiates is seemingly responsible for an ‘‘medication overuse/abuse
cluster headache’’ crucial for ‘‘chronification’’ with ‘‘a pavement of
hereditary pain proneness’’.
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Posttraumatic stress syndrome in relation to chronic
posttraumatic headache
D. Kjeldgaard1, H. Forchhammer2, R. Jensen1
1Danish Headache Centre, Department of Neurology,
Glostrup, Denmark;
2Department of Neurology, Glostrup Hospital, University
of Copenhagen, Glostrup, Denmark
Introduction Minor traffic accidents, falls from a stair or other situa-
tions that can cause mild head traumas are not potentially life threatening
events. Patients with chronic posttraumatic headache (CPTH) after such
mild traumatic brain injuries (mTBI) may develop cognitive, somatic and
affective symptoms that could imply, that the physical trauma have had a
greater psychological impact than first expected.The objective of this
study is to examine the occurrence of posttraumatic stress disorders
(PTSD) in patients with CPTH after mTBI.
Methods The Harvard Trauma Questionnaire (HTQ) is a self-report
scale including 17 items focusing on the trauma, and measures the
intensity of the three core symptom groups; re-experiencing, avoid-
ance, and hyper-arousal. The total score estimates whether or not a
person suffers from PTSD. In a large research project regarding
psychological profile and treatment of CPTH, 30 patients were con-
secutively included. Before entering psychological treatment in The
Danish Headache Centre the patients completed the HTQ.
Results 20 women and 10 men were included (mean age 35 years,
range 19-63). On average the trauma had occurred 38 months (range
10-119) prior to enrolment. The causes of injury were: 12 traffic
accidents (40%), 2 sports injuries (7%), 11 falls (37%), 1 assault (3%)
and 4 other causes (13%). Nine patients (30%) met all tree core
symptoms of PTSD, and additional 10 patients (33%) reached the
sub-clinical level of PTSD. Only 11 patients (37%) had no PTSD
symptoms. Of the three core symptom groups, hyper-arousal had the
highest relatively score over-all.
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Discussion These results suggest that 2/3 of the patients with CPTH
have PTSD or the sub-clinical level of PTSD. This information could
be important in relation to the planning of treatments; psychological
as well as pharmacological treatments. Likewise, this overlap may
also indicate shared pathophysiological mechanisms although the
cause-effect relations are unknown.
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Assessment of the safety and tolerabilty of NXN-188
dihydrochloride in healthy volunteers and migraineurs
R.A. Medve, T.W. Lategan
NeurAxon, Inc., Toronto, ON, Canada
NXN-188 Dihydrochloride (NXN-188) is being developed a first-in-
class, immediate release, fast acting, oral acute migraine therapy with
high oral bioavailability and dual action via inhibition of both the neu-
ronal nitric oxide synthase (nNOS) enzyme and affinity for 5-HT1B/1D
receptors. Oral NXN-188 has been evaluated for safety and tolerability in
four, single-dose, safety and pharmacokinetic Phase 1 studies in healthy
male and female volunteers, one multi-dose safety and pharmacokinetic
Phase 1 study in healthy male and female volunteers, and three single-
dose Phase 2 safety and efficacy studies in male and female subjects with
migraine headaches. These studies evaluated NXN-188 over 400-fold
dose increments from\ 2 mg to 800 mg with a total exposure to NXN-
188 of 359 individuals. 191 subjects had a history of migraine headache.
Across all studies, the number of subjects reporting at least one adverse
event (AE) in the NXN-188 groups ranged from 20% to 75% compared to
19% to 100% in the placebo groups. The most commonly reported AEs in
NXN-188 treated subjects were headache (4.8%), catheter site pain
(3.9%), dizziness (5.8%), somnolence (3.6%), orthostatic hypotension
(3.1%), and nausea (5.0%). The incidence of these AEs was similar in the
placebo group. There was no apparent dose-related increase in AEs with
increasing NXN-188 doses.
No serious adverse events related to NXN-188 have been reported,
and no subject has prematurely discontinued a study because of an
AE. The majority of AEs were mild in intensity. No medically rele-
vant changes were observed with respect to vital signs, ECGs
(including QTc interval), and laboratory evaluations and no difference
was observed between treatment groups.
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Comparison of headache impact (measured
by the HIT-6) by migraine status: results
from the AMPP study
D.C. Buse1,2, A. Manack3, D. Serrano4, S. Varon3, C.C. Turkel3,
R.B. Lipton1,2
1Neurology, Albert Einstein College of Medicine, Bronx, USA;
2Montefiore Headache Center, Bronx, NY, USA;
3Allergan Inc., Irvine, CA, USA;
4Vedanta Research, Chapel Hill, NC, USA
Background Though developed in episodic migraine (EM), HIT-6 is
being used in studies of chronic migraine (CM).
Objectives
1. To establish that HIT-6 is a useful measure of headache impact in CM.
2. To demonstrate that those with CM have greater headache impact
compared to those with EM in a population sample.
Methods The American Migraine Prevalence and Prevention (AMPP)
study is a longitudinal, population-based study. Subjects in these anal-
yses were respondents to the 2009 survey who met criteria for either CM
(ICHD-2 criteria for migraine and C15 headache days/month) or EM
(ICHD-2 criteria for migraine and \15 headache days/month). The
HIT-6 is a self-administered, six-item questionnaire that measures
headache impact in the domains of lost time in work, school or social
activities, pain severity, fatigue, frustration, and difficulty with con-
centration. Total scores range from 36-78 with response categories of
‘‘no impact’’ (\50), ‘‘some impact’’ (50-55), ‘‘substantial impact’’ (56-
59), and ‘‘very severe impact’’ (60 +). Descriptive statistics and a
cumulative logistic imputation model were utilized to compare groups.
Results 27,253 questionnaires were fielded in 2009 and 20,107 were
returned yielding a sample of 373 participants with CM and 6,796
with EM. Compared to EM respondents, a higher proportion of per-
sons with CM had ‘‘very severe impact’’ (73% vs. 42%). Those with
EM had less headache impact with total scores in the ranges of ‘‘no
impact’’ and ‘‘some impact’’ occurring approximately 10% and 14%
more often in EM respectively. An ordinal logistic regression multiple
imputation model revealed that CM respondents had significantly
higher odds of greater impact as measured by HIT-6 categories
compared to EM (OR = 3.50, 95%CI = (2.77,4.41), p \ 0.0001).
Discussion These results demonstrate that the HIT-6 is useful in
measuring headache impact in those with CM, and that those with CM
experience greater headache impact compared to EM.
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Increased automatic attention orienting to auditory
stimulation in migraine patients
G. Demarquay1,2,3, A. Caclin2,3, C. Fischer1,2,3, F. Brudon1,4,
D. Morlet2,3
1Hospices Civils de Lyon, Lyon, France;
2Univ. Lyon 1, Lyon, France;
3Inserm U 821, Lyon, France;
4Clinique du Tonkin, Lyon, France
Purpose Neurophysiological studies converge in showing that
migraineurs exhibit abnormal information processing of environmental
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stimuli between attacks. In the auditory modality, deficient intensity
dependence of auditory potentials (IDAP) was demonstrated. Within
IDAP paradigms, which randomly present stimuli at various intensity
levels, a deficiency in the habituation of auditory event-related potentials
(ERPs) in migraineurs compared with healthy subjects was reported. The
aim of this study was to investigate short-term habituation (STH) and
long-term habituation (LTH) of auditory ERPs in migraineurs, using a
classic auditory habituation paradigm. We particularly focused on two
components of the N1 wave:
(1) the obligatory component resulting from sensory processing
in the auditory cortex,
(2) the orienting component resulting from non-specific frontal
activation which is recorded when the stimulus appears after a
long silent gap.
This last component is thought to reflect a mechanism capable of
triggering a transient arousal response.
Methods 22 patients suffering from menstrually-related migraine and
20 age-matched female control subjects were enrolled in this study.
Auditory ERPs were recorded in 3 sessions: in the middle of the
menstrual cycle, before menses, and during menses. In each session,
200 trains of stimuli were presented, with an average of 10 stimuli per
train (inter-train interval: 5.5-8 s).
Results Migraineurs exhibited a larger orienting response to the first
stimuli of the trains than controls. They also showed a residual ori-
enting component in response to the subsequent stimuli inside the
trains. In contrast, the sensory component of N1 showed no difference
between the two groups, with similar STH and LTH. An augmented
orienting component was observed in the session before menses in
both populations.
Conclusion Our results provide arguments for an increased orienting
reaction to auditory stimuli in migraine and emphasize the role of the
frontal cortex in the abnormal auditory information processing
observed in migraineurs.
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Pregabaline in trigeminal neuralgia
M. Togha1, S. Razeghi Jahromi2, S.M.H. Paknejad2
1Neurology, Tehran University of Medical Sciences, Iranian Center
for Neurological Research, Sina Hospital, Tehran, Iran;
2Shefa Neuroscience Research Center, Tehran, Iran
Trigeminal neuralgia is a common disorder of older adults. Most
cases are idiopathic, although it might be secondary to tumor in the
cerebellopontin angle, aneurysm of basilar artery or multiple sclero-
sis. Usually, the paroxysms of intense stabbing pain last for several
weeks or months and is followed by periods of remission. Recurrence
is very common. The most effective drug is carbamazepine and in up
to 80% of the patients leads to improvement. However, half become
resistant over a period of several years. The other recommended
drugs, such as baclofen, phenytoin and gabapantin are less effective.
Here, we present 10 cases of refractory trigeminal neuralgia that had
good response to pregabaline. All of them have developed secondary
depression and 4 have psychiatric features. One has not spoken for
one year and had 20 kilogram weight loss. Gasserian ganglion block
and ablation by radiofrequency were performed for nine patients, and
vascular decompression was done for three of them.
Pregabaline in increasing dose, up to 400 milligram daily was asso-
ciated with significant pain relief that led to the improvement of
depression and abnormal behavior. In a two year follow up period, the
drug lost its good efficacy in 2 patients but is working for the others.
We did not see any significant adverse complication in the patients.
Conclusion It seems that pregabaline could be proposed as an
effective and safe drug for trigeminal neuralgia.
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A phase 2 multicenter, randomized, double-blind,
parallel-group, placebo-controlled study of NXN-188
dihydrochloride in acute migraine without aura
R.A. Medve, T.W. Lategan
NeurAxon, Inc., Toronto, ON, Canada
NXN-188 Dihydrochloride (NXN-188) is being developed as an oral
migraine therapy with dual action via inhibition of both the neuronal
nitric oxide synthase (nNOS) enzyme and affinity for 5-HT1B/1D
receptors.
In this study subjects were randomized to receive either a single
600 mg dose of NXN-188 or placebo. Eighty-eight placebo and 86
NXN-188 subjects completed the study. Subjects were predominantly
Caucasian (79.3%) and female (80.5%) with a median age of 39 years
(18 to 63 years). The median number of previous migraines per
month was one (range of one to three) for both groups.
The proportion of patients responding (measured as pain relief and
need for rescue medication) at 2 hours and 4 hours post-treatment
was of primary and secondary interest, respectively. Treatment
comparisons were stratified by baseline headache severity. For the
whole study population across time points from 2 to 24 hours, there is
remarkable consistency across the comparisons. The numerical dif-
ference in response rates favors NXN-188 in all of the 58 pre-
specified comparisons with 36 of these comparisons yielding p-values
that are ‘‘statistically significant’’ at the nominal alpha level of 0.05.
The magnitude of the difference between NXN-188 and placebo
ranges from 5.3 to 27.2 percentage points, with a median of 20.6
percentage points, a clinically meaningful treatment difference.
NXN-188 was well tolerated with 19.3% of the placebo vs. 29.1% of
the NXN-188 group experiencing an adverse event (AE), and this
difference was not statistically significant. The most common events
in the NXN-188 treatment group were nausea, abdominal pain, diz-
ziness, chills, sensation of heaviness, and proteinuria. Most events
were mild-to-moderate in severity, none of the subjects discontinued
because of an AE; there were no Series Adverse Events.
The results of this phase 2 study support larger studies to continue the
development of NXN-188 as treatment for acute migraine.
192
Multiple cortical spreading depressions impair
hippocampal long-term potentiation
M. Maneepak1, S. Bongsebandhu-Phubhakdi1, S.M. Legrand2,
A. Srikiatkhachorn1
1Physiology, Bangkok, Thailand;
2Pathology, Chulalongkorn University, Bangkok, Thailand
It is widely recognized that cortical spreading depression (CSD) is
implicated in migraine aura. Moreover, CSD may be related to
symptoms occurring during migraine attack such as amnesia. How-
ever, the direct evidence indicating that a series of CSDs might affect
hippocampal function is scarce. Thus, the present study is designed to
investigate the role of CSDs on hippocampal plasticity, long-term
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potentiation (LTP). In the experiment, male Wistar rats weighing 150-
300 g were divided into two groups (6 rats each), namely CSD and
control groups. Multiple waves of CSD were elicited in vivo by
topical application of KCl crystal on exposed cortex. In control group,
solid NaCl was used instead. Forty minutes after, the rat was sacri-
ficed and ipsilateral hippocampus was quickly removed. Transverse
slices (400 lm) of hippocampus were prepared for electrophysio-
logical recording. Field excitatory postsynaptic potentials were
recorded in the hippocampal CA1 and LTP was induced by tetanic
stimulation. The results showed that KCl application induced a series
of negative depolarization shifts. The total number of CSD waves was
7.4 ± 1.5 waves. The amplitude and area under the curve of each
wave were 33.1 ± 4.5 mV and 901.6 ± 148.2 mVs, respectively.
These multiple CSDs significantly diminished the magnitude of hip-
pocampal LTP. The levels of LTP in CSD-induced and control groups
were 119.8 ± 16.2 and 138.2 ± 9.8 percent, respectively (p = 0.04).
This study showed that the multiple waves of CSD led to the
impairment of hippocampus function as indicated by a reduction of
LTP magnitude. However, the exact mechanism how CSDs reduce
hippocampal LTP needs to be further clarified.
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A 4-year follow-up of patients with medication-overuse
headache included in a randomized multicentre study
K. Hagen1, C. Albretsen2, S. Vilming3, R. Salvsen4, M. Grønning5,
G. Helde1, G. Gravdahl6, J.-A. Zwart3, L. Stovner1
1Department of Neuroscience, Faculty of Medicine, Norwegian
University of Science and Technology, Trondheim, Norway;
2Department of Neurology, Tromsø University Hospital,
Tromsø, Norway;
3Department of Neurology, Oslo University Hospital,
Ullevaal and University of Oslo, Oslo, Norway;
4Department of Neurology, Nordland Hospital, Bodø, Norway;
5Department of Neurology, Haukeland University Hospital,
Bergen, Norway;
6Norwegian National Headache Centre, Section of Neurology,
St. Olavs Hospital, Trondheim, Norway
Objective The aim of this study was to evaluate the outcome in 61
patients with medication-overuse headache (MOH) who 4 years
previously had been included in a randomized open-label prospective
multicentre study.
Methods Sixty patients still alive after four years were invited to a
follow-up investigation. Fifty patients (83%) participated, and of
these, sixteen visited a neurologist, 22 were interviewed by telephone,
two gave response by a letter, and ten were evaluated through hospital
records. The mean observation time was 4.0 years.
Results At follow-up, the group of 50 persons had a mean reduction of
6.5 headache days/month, and a mean reduction of 9.5 days with use of
acute headache medication/month compared to baseline. Headache index
(HI)/month was reduced from 449 to 321. Sixteen persons were con-
sidered as responders (32%) due to a C 50% reduction in headache
frequency from baseline, whereas 17 (34%) persons had head-
ache C 15 days per month combined with medication overuse. A
significant inverse correlation (p\ 0.007) was found between total
Hospital Anxiety and Depression Scale score at baseline and being a
responder, and between physical health component score (PCS-12)
and medication days/month after 4 years.
Conclusions 4 year after inclusion in the randomized MOH study
one-third of the patients had C 50% reduction in headache frequency
from baseline, whereas one-third still met the criteria for MOH.
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Reduction of high-energy phosphates in the occipital
lobe of migraine without aura patients: a 31P- and
1H-MRS study
H. Reyngoudt1,2, K. Paemeleire3,4, B. Descamps1,2, Y. De Deene5,6,
E. Achten1,2
1Radiology and Nuclear Medicine, Ghent University,
Ghent, Belgium;
2Ghent Institute for Functional and Metabolic Imaging,
Ghent University, Ghent, Belgium;
3Basic Medical Sciences, Ghent University, Ghent, Belgium;
4Neurology, Ghent University Hospital, Ghent, Belgium;
5Radiation Oncology and Experimental Cancer Research,
Ghent, Belgium;
6Laboratory for Quantitative Nuclear Magnetic Resonance
in Medicine and Biology, Ghent University, Ghent, Belgium
Introduction Magnetic resonance spectroscopy (MRS), a technique to
obtain biochemical information non-invasively, has been used in sev-
eral migraine studies. Both proton MRS (1H-MRS) and phosphorus
MRS (31P-MRS) studies were mainly performed in migraine with aura.
Aim The aim of this study was to perform absolute quantification of
metabolites with 31P-MRS and 1H-MRS in a homogeneous group of
migraine without aura (MO) patients, who were not on prophylaxis.
We were especially interested in the resting state brain energy
metabolism of these MO patients.
Methods and subjects We compared 22 MO patients with 25 age-
but not gender-matched controls. Patients experienced 2-8 attacks per
month, were not using any prophylactic medication and were head-
ache-free for at least 48 hours. MRS Spectra were acquired in the
medial occipital lobe on a 3 T Siemens TrioTim system. Spectra were
analyzed using jMRUI and Siemens software. Absolute quantification
was performed using an external reference.
Results A significantly decreased phosphocreatine (PCr) was found in
MO versus controls (4.09 ± 0.58 mM versus 4.85 ± 0.60 mM resp.;
P = 0.001) and has been previously reported. Whereas adenosine tri-
phosphate (ATP) was considered to be constant in previously published
work, we found a significant decrease in ATP in MO patients versus
controls (2.33 ± 0.63 mM versus 2.76 ± 0.59 mM resp.; P = 0.023).
No significant changes in inorganic phosphate, adenosine diphosphate,
pH and magnesium were found between MO patients and controls. Also
no significant differences in proton metabolites (N-acetyl aspartate,
creatine, choline, myo-inositol) were observed between MO patients and
controls. 1H-MRS did not show any quantifiable lactate in all subjects.
Discussion 31P-MRS demonstrated a significant decrease in the high-
energy phosphates ATP and PCr in (a subgroup of) MO patients,
implying impaired resting state brain energy metabolism and further
pointing at a mitochondrial component in the pathophysiology.
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Prevalence of medication overuse headache in Sweden
P. Jonsson1, T. Hedenrud1, M. Linde2,3
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Introduction The general view is that medication overuse headache
(MOH) is the third most common headache disorder in Sweden.
There are, however, no previous studies based on Swedish epidemi-
ological data and the prevalence of MOH in Sweden is thus unknown.
Objective The aim was to estimate the prevalence of MOH in the
general Swedish population and to analyze the extent of the disorder
in different population groups.
Methods A randomly selected sample of 45 000 individuals (55%
women) aged 15 years and above (mean age 52,7 years) was inter-
viewed by telephone using a standardized questionnaire including the
IHS 2006 diagnostic appendix criteria for MOH. The survey was
performed between March 2009 and March 2010 by SIFO, a Swedish
public opinion poll agency. The interviews also covered sociodemo-
graphic parameters, headache history and medication use.
Results A total of 867 subjects met the diagnostic criteria for MOH and
the prevalence in Sweden is thus 1,93% (95% confidence inter-
val ± 0,13). The prevalence was higher among women (2,7 ± 0,20%)
than men (1,0 ± 0,14%, p \ 0,001). The mean age among those with
MOH was 50,5 years and the mean duration of chronic headache was
14,6 years. MOH was less common among those who had attended
university (1,3 ± 0,18%, n = 15 954) than among those who had not
(2,3 ± 0.18%, p \ 0,001). The primary headache was migraine in 50%
and tension-type headache in 23%. A majority (66%) primarily over-
used simple analgesics, 20% overused combination analgesics, 7,5%
overused triptans, 3,7% overused opioids and 0,8% overused ergota-
mine. The most commonly overused substance was paracetamol (44%).
Conclusion The prevalence of MOH in Sweden is 1,93 ± 0,13%,
which corresponds with what has been seen in other western coun-
tries. MOH is thus a considerable public health problem which
warrants greater consideration within Swedish health care.
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Has the prevalence of primary recurrent headaches
changed over a four year period? The Nord-Trøndelag
health study
B.A. Jacobsen1, J.-A. Zwart2
1Department of Neurology, Vestfold Hospital, Tønsberg, Norway;
2Department of Neurology, Oslo University Hospital,
Ullevaal and University of Oslo, Oslo, Norway
Objective The aim of this study was to compare the prevalence of
primary headaches among adolescents aged 16 to 20 years in Norway
in two periods. Very few replicate studies have re-evaluated the
prevalence of primary headaches in this age range.
Methods Two cross-sectional, population-based studies were con-
ducted in Norway from 1995 to 1997 (Young-HUNT 1) and from
1999 to 2001 (Young-HUNT 2). In Young-HUNT 1, 2594 adoles-
cents in 2nd and 3rd grade in upper secondary school (aged 16 to
20 years) completed a comprehensive questionnaire including one
question regarding headache during the last 12 months. In addition,
1730 of the students were interviewed about their headache com-
plaints. In Young-HUNT 2, 2373 adolescents aged 16-20 years
completed the same questionnaire and 1655 were interviewed in the
same way as the earlier survey. In the interviews, respondents were
asked if they had experienced recurrent headache during the last year
and, if so, the headache was classified as migraine, tension-type
headache or non-classifiable headache.
Results The participation rate was 88% in Young-HUNT 1 and 81% in
Young-HUNT 2. The overall prevalence of having had headaches
during the last 12 months did not change significantly, 79.4% versus
77.5%; OR 0.89, 95%CI: 0.79-1.02, p = 0.09, whereas the prevalence
of recurrent headaches increased from 30.3% in Young-HUNT 1 to
35.4% in Young-HUNT 2 (OR 1.26, 95%CI: 1.09-1.46, p = 0.002).
The prevalence of tension-type headache changed significantly from
19.0% to 21.9% (OR 1.20, 95%CI: 1.02-1.42, p = 0.03). Also the
prevalence of migraine tended to increase (7.5% versus 8.7%, OR
1.18, 95%CI: 0.92-1.52, p = 0.18). The overall frequency of recurrent
headache changed towards more monthly and less weekly headache.
Conclusions The overall prevalence of recurrent headaches increased
significantly from Young-HUNT 1 to Young-HUNT 2. An increase
was seen in all types of recurrent headaches and was significant for
tension-type headache.
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The role of 17B-estradiol withdrawal
in the neurovascular pathophysiology of migraine
K.Y. Chan, R. de Vries, I.M. Garrelds, A.H.J. Danser, C.M. Villalo´n,
A. Maassen van den Brink
Dept. of Internal Medicine, Div. of Pharmacology,
Erasmus Medical Center, Rotterdam, The Netherlands
The prevalence of migraine is 2-3 fold higher in females than in
males; this seems to be related to (changes in) levels of female sex
hormones. These changing hormone levels may regulate the synthesis
and receptor expression of CGRP, mediating neurogenic dural vaso-
dilatation. Moreover, 17b-estradiol increases dural vasodilatation to
endogenous CGRP (caused by electrical stimulation), but not to
exogenous aCGRP, suggesting that 17b-estradiol may increase CGRP
release from sensory nerves. Apart from stable hormone levels, their
fluctuations may also influence the synthesis and receptor expression
of CGRP. This study investigated dural vasodilatation to exogenous
aCGRP after 17b-estradiol withdrawal.
Rats were ovariectomized and, 7 days later, subcutaneously implanted
with 21-day release pellets of 17b-estradiol or placebo. On day 21,
pellets were withdrawn and, on day 22, rats were prepared for intravital
microscopy on a closed cranial window. Then, the vasodilatation to
exogenous aCGRP (10 ng/kg-3000 ng/kg, iv) was investigated. An
extra group without pellet removal was used as control.
Exogenous aCGRP induced a dose-dependent dural vasodilatation.
There were no differences in vasodilatation between incubation with
17b-estradiol or placebo pellet without removing the pellet, which is in
line with previous findings. Furthermore, the vasodilatation to exogenous
aCGRP in the group where the 17b-estradiol pellet was removed was
similar to that in the placebo group or where the 17b-estradiol pellet was
not removed. Our results suggest that one day withdrawal of 17b-estra-
diol does not affect the vasodilatation to exogenous aCGRP. The effects
of 17b-estradiol withdrawal on the vasodilatation to endogenous CGRP
(released by dural electrical stimulation) are currently being investigated.
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Efficacy of telcagepant in subgroups: pooled analysis
of data from phase 3 studies
T.W. Ho1, K.M. Connor1, A.P. Ho1, J.T. Kost1, X. Fan1,
D.W. Dodick2, S.D. Silberstein3, C.R. Lines1, C. Assaid1
1Merck & Co., Inc., North Wales, PA, USA;
2Mayo Clinic, Phoenix, AZ, USA;
3Thomas Jefferson University Hospital, Philadelphia, PA, USA
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Objective To evaluate the acute antimigraine efficacy of telcagepant
in subgroups of patients.
Background Telcagepant is an oral CGRP receptor antagonist being
evaluated for the acute treatment of migraine. It has been suggested
that the efficacy of acute migraine treatments may vary in some
subgroups, such as those with aura, menstrually-associated migraine,
or a prior response to triptans.
Methods Post-hoc subgroup analyses of data from three randomized,
double-blind, placebo-controlled trials in which patients treated a
moderate/severe migraine headache with telcagepant 140-mg tablet/
150-mg capsule (T140/150) or 280-mg tablet/300-mg capsule (T280/
300). Based on information provided in a patient diary or a self-
reported migraine-history questionnaire, subgroups analyzed included
the following: baseline aura (with/without); menstrually-associated
migraine attack in women (with/without); prior response to triptans
(C 75% or \ 75% response to prior triptan-treated attacks, no-use);
prior response to NSAIDs (C 75% or \ 75% response to prior
NSAID-treated attacks, no-use).
Results The percentages of patients with 2-hour pain freedom in the
overall population were 266/1253 (21.2%) for T140/150 and 311/
1241 (25.1%) for T280/300. Generally similar percentages of patients
with 2-hour pain freedom were seen across subgroups for T280/300,
allowing for relatively small sample sizes in some cases. Baseline
aura: with = 61/222 (27.5%), without = 250/1019 (24.5%).
Menstrual migraine: with = 53/209 (25.4%), without = 145/ 557
(26.0%). Prior triptan response: C 75% = 153/606 (25.2%),
\ 75% = 63/279 (22.6%), no-use = 91/339 (26.8%). Prior NSAID
response: C 75% = 39/134 (29.1%), \ 75% = 158/648 (24.4%),
no-use = 102/418 (24.4%). The pattern of results was similar for
T140/150 although there was some variability across the prior NSAID
response subgroups.
Conclusions These post-hoc findings suggest that the acute antimi-
graine efficacy of telcagepant is generally consistent across subgroups
including menstrually-associated migraine attacks and those with/
without aura, prior response to triptans, or prior response to NSAIDs.
Conflict of interest Dr. Dodick has acted as a consultant, speaker or
received research support from Allergan Pharmaceuticals.
Dr. Silberstein has acted as a consultant, speaker or received research
support from Allergan Pharmaceuticals.
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The effect of DHT on vascular reactivity
S. Labruijere1, K.Y. Chan1, E.L.A.F. van Houten2, R. de Vries1,
P. Kramer2, A.H.J. Danser1, C.M. Villalo´n1, J.A. Visser2,
A. Maassen van den Brink1
1Internal Medicine, Div. of Pharmacology, Rotterdam,
The Netherlands;
2Internal Medicine, Div. of Endocrinology, Erasmus Medical Center,
Rotterdam, The Netherlands
Migraine attacks are two to three times more common in women than
in men. In women, these attacks often take place before and during
the menstrual period when female hormone levels fluctuate. The
female hormone 17b-estradiol potentiates vasodilator responses to,
e.g. acetylcholine and calcitonin gene-related peptide (CGRP), which
may be relevant in view of the neurovascular nature of migraine.
However, little is known about the effects of male hormones in
migraine.
In this study we investigated whether treatment of female mice with
the nonaromatizable androgen dihydrotestosterone (DHT) changes
vascular reactivity.
All of our studies were performed on thoracic aortic vessels of female
mice treated for 60 days with DHT (25 lg/day) or placebo using
continuous-release pellets. Treatment was initiated at prepubertal age
P19.
Vasorelaxations to acetylcholine, CGRP and sodium nitroprusside
(SNP) (measured after precontraction with the thromboxane analogue
U46619), as well as contractions to 5-hydroxytriptamine (5-HT) were
induced in thoracic aortas (Ø2-3 mm).
Acetylcholine-induced relaxations were significantly smaller in aortas
from DHT-treated mice than in those from placebo-treated mice (Emax
DHT = 40 ± 21% and Emax placebo = 85 ± 15% respectively).
Relaxations to CGRP (Emax DHT = 99 ± 3% and Emax placebo
= 89 ± 13%) and SNP (Emax DHT = 91 ± 8% and Emax placebo
= 96 ± 7%), as well as contractions to 5-HT (Emax DHT = 91 ± 8%
and Emax placebo = 96 ± 7%), did not show any difference in vascular
reactivity between the treated and placebo groups.
The above data show that DHT specifically decreases the effect of
acetylcholine on mice thoracic aortas. Because the relaxation to
acetylcholine is of endothelial origin, our results suggest a decreased
endothelial function after treatment with DHT, without deterioration
of vascular smooth muscle function.
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Cranioselectivity of sumatriptan revisited
K.Y. Chan, S. Labruijere, R. de Vries, A.H.J. Danser, C. Villalo´n,
A. Maasen van den Brink
Dept. of Internal Medicine, Div. of Pharmacology,
Erasmus Medical Center, Rotterdam, The Netherlands
Almost two decades ago sumatriptan was introduced, providing a
great step forward in the treatment of migraine. Since concerns
existed about the coronary side-effect potential of the triptans, we
have formerly performed detailed studies on the cranioselectivity of
the triptans.
We concluded that, based on the modest contraction that these drugs
cause in the human coronary artery (HCA), triptans are generally safe,
but should be contraindicated in patients with coronary artery disease.
All of our studies (and those of others) were performed on proximal
segments of the HCA, although myocardial ischemia may originate
from both large and small HCA. Thus, we have now investigated
whether the contractions to sumatriptan are different in proximal or
distal parts of the HCA.
Concentration response curves to 5-hydroxytriptamine (5-HT) and
sumatriptan were constructed in proximal (Ø 2-3 mm), distal (Ø
1000-1500 lm) and small (Ø 500-1000 lm) HCAs (2 M, 2 F; 37-
62 yrs). Whereas sumatriptan induced significantly smaller contrac-
tions than 5-HT in proximal HCA (Emax = 12 ± 8% and
Emax = 83 ± 9% respectively), contractions to sumatriptan in distal
(Emax = 53 ± 31%) and small (Emax = 54 ± 17%) HCA were sig-
nificantly higher, and equaled those to 5-HT (Emax = 67 ± 29% in
distal and Emax = 53 ± 18% in small HCA).
Surprisingly, contractions to sumatriptan in distal HCA are in the
same order of magnitude as those in the human meningeal artery
(Emax = 103 ± 13%, Neurology 2000;55:1524). Thus, the above
data in distal HCA suggest that triptans have a limited craniose-
lectivity. However, in the last years triptans have been used
extensively, and myocardial ischemia is an extremely rare event.
Therefore, our findings reconfirm that the triptans should remain
contraindicated in patients with coronary artery disease, although
the risk profile definitely favors their use in the absence of
contraindications.
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Estrogen-dependent effect of 5-hydroxytryptophan
on sensitivity to cortical spreading depression in rat
V. Chauvel, J. Schoenen, S. Multon
Cephalic Pain Unit of GIGA-Neurosciences, Universite´ de Lie`ge,
Lie`ge, Belgium
Background Migraine is sexually dimorphic (male/female ratio 1:3)
and thought to be a ‘‘low 5-HT’’ condition. Reduced serotonin trans-
mission might be responsible for deficient pain control and for changes in
cortical excitability. Dietary depletion of tryptophan, the 5-HT precursor,
worsens migraine symptoms (Drummond et al., 2005).
Objective To determine if exogenous administration of 5-hydroxy-
tryptophan (5-HTP) is able to modify KCl-induced CSD in rat and if
the effect differs between males and females.
Methods Adult male and female Sprague-Dawley rats (n = 8/group)
received intraperitoneal injections of 5-HTP (100 mg/kg) or saline
(NaCl 0.9%). One hour after the injections, CSDs were elicited under
chloral hydrate anesthesia by applying over the occipital cortex a
cotton ball soaked with 1 M KCl. The electrocorticogram was
recorded for 1 hr (DC-100 Hz) with ipsilateral parietal and frontal
electrodes. For each female, the phase of the estrous cycle was
determined by vaginal smear analyses which were done just before
the electrophysiological recording.
Results 5-HTP administration has no effect on CSD frequency in
males. In females, we observed an estrous cycle-dependent effect of 5-
HTP: CSD frequency was increased during proestrus (high estrogen)
phase (+27% vs control) and decreased during estrus and diestrus
(respectively -67% and -74% vs control). There was no significant influ-
ence of the estrous cycle on CSD frequency in NaCl-treated female rats.
Conclusion These preliminary results suggest that an increase of
serotonin levels does not alter the sensitivity to CSD in males while in
females the change in sensitivity seems to depend on gonadal hor-
mone levels. Hormone-dependent changes in central serotonin effects
might thus contribute to the sexual dimorphism of migraine.
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Progression and consequences of brain lesions
in migraine: the population-based camera-2 nine year
follow-up MRI study
I.H. Palm-Meinders1, H. Koppen1,2, G.M. Terwindt1, L.J. Launer3,
J. Konishi1, J.T.N. Bakkers4, P.A.M. Hofman5, H.A.M. Middelkoop1,
M.A. van Buchem1, M.D. Ferrari1, M.C. Kruit1
1Leiden University Medical Center, Leiden, The Netherlands;
2Haga Hospital, The Hague, The Netherlands;
3Laboratory of Epidemiology, Demography and Biometry,
NIH, Bethesda, MD, USA;
4Slingeland Ziekenhuis, Doetinchem, The Netherlands;
5Academic Hospital Maastricht, Maastricht, The Netherlands
Background We previously reported that migraine is an independent
risk factor for subclinical cerebellar infarcts and, among women, high
deep white matter lesion (DWML) load (Kruit MC, et al. JAMA
2004). We re-investigated the same population-based cohort (295
migraineurs; 140 controls) nine years later, to test for migraine-related
progression of brain lesions and to evaluate cognitive consequences.
Methods Baseline and 9 yr follow-up brain MR images were
acquired in 203/295 (response 69%) migraineurs with and without
aura (mean age 57 y, SD 8) and 83/140 (60%) controls (mean age 55
y, SD 7) with the same protocols/scanners. Blinded for diagnosis,
images were semi-automatically analyzed for progression of preva-
lence and volume of DWMLs and cerebellar infarcts. DWML
analyses were adjusted for age, hypertension, diabetes and level of
education. Migraine diagnosis and presence of brain lesions were
correlated with cognitive test results from both time points.
Results Cardiovascular risk factors were comparable between groups,
although migraineurs were slightly older. None of the infarct-like
lesions found at baseline vanished. We found C 1 new cerebellar
infarct in n = 10 (5%) migraineurs vs. none in controls (p = 0.039).
These new lesions occurred in 6% of migraineurs without aura and
4% of migraineurs with aura, with no differences with respect to
gender. There was no difference in incidence of infarcts in other
locations between migraineurs and controls. Female migraineurs had
a greater progression of DWML load (OR 2.1 [1.1-4.2]), which was
stronger in those with a higher attack frequency. After adjustment for
age and level of education we found no association between cognitive
functioning and migraine diagnosis and/or DWML lesion load.
Conclusion During nine year follow-up, only migraineurs developed
new cerebellar infarcts. In women, migraine is an independent risk
factor for progression of high-DWML-load. However, DWMLs were
not associated with cognitive functioning or decline.
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Nummular headache with and without exacerbations.
comparative characteristics in a new series
E. Cortijo, A. Guerrero, S. Herrero, P. Mulero, S. Miranda,
E. Rojo, M.L. Pen˜as, R. Ferna´ndez
Neurology Department, Hospital Clı´nico Universitario,
Valladolid, Spain
Objective Apart from the characteristic chronic pain in a well-cir-
cumscribed area, superimposed exacerbations have been described
from first reports of Nummular Headache (NH). We present a new
series of NH, comparing characteristics between exacerbations (ENH)
and non exacerbations (NENH) cases.
Methods In a monographic headache outpatient office in a tertiary
hospital, 43 (26 female, 17 male) out of 903 patients (4.7%) were
diagnosed of NH (January 2008-May 2010). In each patient we
considered baseline pain intensity, temporal pattern, relief provided
with symptomatic treatment, and requirement and efficacy of pre-
ventive therapies. When exacerbations were present, we reviewed
their quality, intensity and duration.
Results Neuroimaging studies were performed in all patients with no
abnormalities. 25 cases (58.1%) presented in situ exacerbations. Mean
intensity of exacerbations was 7.5 ± 1.4 (range 7-10 in a 0-10 visual
analogical scale (VAS)) and they lasted 4 ± 10 minutes. Regarding
exacerbations quality, most of them were stabbing. There were no
differences between ENH and NEHN group respectively, in age at
onset (49.3 ± 17.6 vs 45.7 ± 20 years), sex (61 vs 60 % of females),
baseline pain intensity (5.5 ± 2.6 vs 5.4 ± 1.8 in a 0-10 VAS), size
of painful area (4.8 ± 1.5 vs 4.6 ± 1.1 centimetres), allodynia or
other sensory symptoms (68 vs 61 %), baseline pain quality (38.8 vs
31.2 % pressing), or temporal pattern (48 vs 50% with no spontaneous
remissions). There were no differences between both groups regard-
ing relief with symptomatic therapy (82.6 vs 83.3 %), requirement of
preventive therapy (64 vs 66.6%) and response to preventatives (77 vs
60%)
Conclusion In situ exacerbations superimposed on baseline pain are
frequent in NH. ENH and NENH cases do not differ in demographic
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and nosological characteristics. Presence of exacerbations does not
predict needing or response to therapy.
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Lasmiditan (COL-144), a selective 5HT1F agonist, is
a rapid and effective oral treatment for acute migraine
M. Fa¨rkkila¨1, H.-C. Diener2, G. Ge´raud3, J.M. La´inez4, J. Schoenen5,
A.J. Pilgrim6
1University of Helsinki, Helsinki, Finland;
2University of Duisburg-Essen, Essen, Germany;
3University of Toulouse, Toulouse, France;
4University of Valencia, Valencia, Spain;
5University of Lie`ge, Lie`ge, Belgium;
6Colucid Pharmaceuticals Inc, Durham, NC, USA
The efficacy and safety of a range of oral doses of lasmiditan, a novel
selective 5HT1F agonist, was explored in a prospective, randomized,
double-blind, placebo-controlled, parallel-group dose-ranging study.
534 patients were screened at 43 sites in Europe. Eligible patients
with migraine (IHS criteria 1.1 and 1.2.1 and not on prophylaxis)
were randomly assigned (1:1:1:1:1) to receive oral lasmiditan (50,
100, 200 or 400 mg) or matching placebo to use as the first treatment
of a new migraine attack provided the headache severity was at least
moderate and not improving. 391 patients treated a single migraine
attack with study medication at home and recorded their response
over the following 48 hours using a diary card. Follow up in the clinic
took place within 14 days of treatment.
The study met its primary objective, showing a significant dose
response for headache relief at 2 h (p \ 0.0001, Cochran-Armitage test
for trend). All individual doses were significantly superior to placebo
with placebo-subtracted 2 h response rates of 17 - 39%. Separation from
placebo started as early as 30 min. The dose response for headache-free
at 2 h was also significant (p \ 0.0005). The 100 and 400 mg dose
groups showed significant benefits in sustained headache response
compared to placebo. Nausea, photophobia and phonophobia were
significantly lower in the lasmiditan treated groups by 2-3 h though the
study was not powered for these secondary endpoints.
There were no clinically significant changes in laboratory parameters or
ECGs. The most common treatment emergent adverse events were
related to the central nervous system. Chest symptoms were rare,
occurring with a similar frequency across all groups including placebo.
Lasmiditan, a novel molecule with a central site of action and without
vasoconstrictive properties, is a rapid and effective acute treatment
for migraine when given orally and warrants further investigation.
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Rates and risk factors for persistence of chronic
migraine(CM) and chronic tension-type headache
(CTTH) in the german headache consortium(GHC)
study
M.-S. Yoon1, A.N. Manack2, M. Obermann3, C. Gaul3, C. Lampl3,
H.-C. Diener3, Z. Katsarava3
1Department of Neurology, University of Duisburg-Essen, Essen,
Germany;
2Allergan, Inc., Irvine, CA, USA;
3Department of Neurology and Headache Center, University
of Duisburg-Essen, Essen, Germany
Background A recent population-based study suggested that head-
ache frequency within CM varies from year to year.
Objectives To estimate rates and assess risk factors for persistency of
CM and CTTH.
Methods The GHC study is a longitudinal population-based study of
headache sufferers in which 18,000 people (aged 18-65 years in three
regions of Germany) completed questionnaires at baseline
(n = 9665), one year (n = 6694) and two years (n = 6975). CM
respondents had migraine/probable migraine and C 15 headache
days/month; CTTH respondents had TTH/probable TTH and C 15
headache days/month. Persistence was defined as headache chronicity
over two years (ie, C 15 headache days/month at baseline and during
2 follow-up years). To assess risk factors, two groups for each
headache type were compared: those who met persistence criteria and
those who did not.
Results At baseline, 177 respondents had CM and 71 had CTTH.
Demographically, CM and CTTH were different: CM were predom-
inantly females (73% vs. 47%), more likely to smoke (47% vs. 32%),
less likely to drink alcohol (5.5% vs. 19%), and more likely to use
(83% vs. 63%) and overuse (73% vs. 54%) acute headache medica-
tions. After two years, 14% had persistency of CM and 20% had
persistency of CTTH. Medication overuse (MO) (OR 10.3;
95%CI[3.9-26.8]) and obesity (OR 2.3; 95%CI[1.1-4.8]) were asso-
ciated with persistency of CM; stressful events such as
unemployment/divorce (OR 1.9; 95%CI[0.7-4.9] approached signifi-
cance. Male gender (OR 7.7; 95%CI[1.6-37.5]) and MO (OR 25.1;
95%CI[2.4-258.9]) were significant predictors for persistency of
CTTH. Full results will be presented but risk factors of age, smoking,
disease duration, and low back/facial pain were not associated with
persistency of CM or CTTH.
Conclusions The minority of CM and CTTH were persistent sug-
gesting the ICHD-2 criteria are insufficient because they don’t
incorporate disease duration. CM and CTTH have differing risk
factors for persistence; however, MO is an important factor for both.
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Pituitary headache without a tumour
R. Peatfield
Neurology, Charing Cross Hospital, London, UK
Headache is often seen in patients with pituitary tumours. It is
unrelated to the size of the tumour, and will respond to the somato-
statin analogue Octreotide, which suggests that it may be mediated by
a humoral factor. I present a patient who seems to have a lymphocytic
hypophysitis, and yet whose headaches have responded to Octreotide.
This Press Photographer (b 1958) has had a continuous bifrontal
headache since 2004. He had had several syncopal episodes, always
associated with severe pain, and after one of these he was found to be
hypopituitary, with a radiologically enlarged gland. This was biopsied
in November 2007, showing only fibrous tissue containing mature
lymphocytes. He has needed full replacement therapy since then, but
the headache has persisted, and has not responded to valproate,
citalopram or amitriptyline. Regular scans have continued to show
some structural changes in the gland. In January 2009 he responded
‘amazingly’ to a trial of Octreotide. The gland was reexplored in
September 2009, but a biopsy yielded only pituitary tissue with
extensive fibrosis, infiltrated by lymphocytes and plasma cells. The
headache persists, and still responds to Octreotide. The neurosurgeon
considers it too hazardous to reexplore the gland.
This case is unusual - there is no convincing radiological or endocrine
evidence of an adenoma. It is possible, of course, that the headache is
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due to a very small persistent tumour within the fibrous pituitary
gland, or even to the (inflammatory) process of fibrosis itself. His
response to Octreotide could be non-specific, as the drug has some
opioid properties, and the Octreotide could be working at another
level within the central nervous system. Nevertheless identification of
the humoral factor suppressed by the Octreotide might give a clue to
the mechanism of headache in these cases.
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Neck and occipital pain location of migraine differed
from that of tension type headache with new meridian
system
K.-H. Park1, T.-W. Yoo2
1Neurology, Pusan National University, School of Medicine,
Busan, Korea;
2Korean Hand Therapy Institute, Seoul, Republic of Korea
Background Primary headache has been underdiagnosed and
undertreated even there are advanced technologies and new devel-
oped medications. How do we improve efficacy of diagnosis and
treatment? One of criteria of headache is location. The literature
documenting the location of neck and occipital pain of primary
headache is sparse. There is no definite method to decide side and
sites. We propose to use New Meridian and Acupuncture Points of
Korean Hand Therapy (KHT) to determine the location.
Subjects and methods This study was performed to document the
location of neck and occipital pain in 400 persons of primary head-
ache from March 2007 to Feb. 2009 at Dept of Neurology, Busan
National University Hospital, Korea. We evaluated tender or pain
points of at CM 3 - CM 10 along gallbladder meridian of 200 mi-
grainerus, and CI 1-1 - CI-8 along urinary bladder meridian of 200
tension type headache patients on physical examination using New
Meridian System and Acupuncture Point of KHT.
Result Migraine patients showed neck and occipital pain along
Gallbladder New Meridian and Acupuncture points on the right side
(92/200), on the left side (75/200) and both side (33/200). Tension
type headache paints showed neck pain along urinary bladder New
Meridian Points on the right side (67/200), on the left side (105/200)
and both side (28/200).
Conclusion Neck and occipital pain of primary headache is closely
related with meridian systems esp. New Meridian System. Neck and
occipital pain of migraine is closely related with Gall bladder
meridian and that of tension type of headache is Urinary bladder
meridian. Cervical neck pain should be considered one clinical fea-
ture of migraine headache and tension type headache. New method is
of use and is ease to practice without difficulty.
216
Two cases of cluster headache relieved by pregabalin
S. Hong, J.-H. Oh
Neurology, Cheju Halla Hospital, Jeju, Republic of Korea
Purpose Cluster headache is the most unique and painful of the pri-
mary headache disorders. It is characterized unilateral recurrent severe
headache with cranial autonomic symptoms. Oxygen and triptan agent
have been demonstrated to be effective in the acute treatment of cluster
headaches. Verapamil and topiramate has been shown to be effective
for prophylaxis usually. I have two cases that were not controlled by
verapamil and topiramate but relieved by pregabalin.
Case 1 A 42-year-old man who had been suffering from severe
recurrent headache (10 [ times) visited our department. Headache
was mainly localized at left parieto-tempotal area, accompanied
always by ipsilateral lacrimination and conjunctival injection and
ipsilateral rhinorrhea. The headache repeated daily 2-3 times and its
duration was 20-30 minutes. Headache severity was 9 in visual ana-
logue scale (VAS). On brain MRI and EEG, there were no abnormal
findings. I gave him verapamil but it did not work. So I gave pre-
gabalin to him. The headache was improved and VAS was 4.
Case 2 A 31-year-old woman who had been suffering from severe
recurrent headache (6 [ times) for 2 years visited our department.
Her headache was mainly localized at left parieto-tempotal area,
accompanied always by ipsilateral lacrimination and conjunctival
injection and ipsilateral ptosis and sweating. The headache repeated
daily 1-2 times and its duration was 30-60 minutes. VAS was 9. On
brain MRI and EEG, there were no abnormal findings. I gave her
topiramate but her headache was not improved. So I gave her pre-
gabalin. Her headache was improve and VAS was 2.
Conclusion I present two cases of cluster headache relieved by pre-
gabalin. In case of headache refractory to verapamil and topiramate,
Pregabalin may be triable.
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The investigation of common clinical and genetic
indicators of migraine, episodic tension type headache
and irritable bowel syndrome
S.E. Cakmak1, A. Ozge1, E. Ucbilek2, O. Sezgin2, F. Soylemez3,
E. Erdal3, G.O¨. Temel4, E.A. Kanik4
1Neurology, Mersin University School of Medicine, Mersin, Turkey;
2Gastroenterology, Mersin University School of Medicine,
Mersin, Turkey;
3Medical Genetics, Mersin University School of Medicine,
Mersin, Turkey;
4Biostatistics, Mersin University School of Medicine, Mersin, Turkey
Migraine is a chronic disorder characterized by disabling, unilateral
and throbbing headache, accompanied by autonomic dysfunction,
gastrointestinal and neurological symptoms. Episodic Tension type
headache (ETTH) is sharing some common mechanism with
migraine. Irritable Bowel Syndrome (IBS) is a common functional
disorder possibly related to altered brain structure. The aim of this
study is to evaluate the phenotypic and genotypic relation of these
diseases (via clinical associates and serotonin transporter gene poly-
morphism). In this study 107 subjects with migraine, 107 subjects
with IBS, 53 subjects with ETTH patients and 53 healthy controls
were included to determine clinical variables and 5-HTT-VNTR,
5-HTT-LPR, 5-HT2A-T102C, 5-HT2A-1438 G/A polymorphisms.
In our study IBS prevalence in migraine and ETTH groups were
54.2% and 28.3% respectively. There was no statistically signifi-
cant difference between headache characteristics of migraine
patients and migraine plus IBS patients. Similarly there was no
difference between ETTH patients and ETTH plus IBS patients. In
IBS patient’s, migraine and ETTH prevalence were 35.5% and
22.2% respectively.
The frequency of HTT VNTR 10/12 allele was significantly
increased in our patients with migraine as compared with the
S44 J Headache Pain (2010) 11 (Suppl 1):S1–S150
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control group (p = 0.0247). The frequency of HTT VNTR 10/12
allele was significantly increased in our patients with ETTH as
compared with the control group (p = 0.0103). And finally the
frequency of 5-HT2a-1438 AA allele 10/12 allele was significantly
increased in our patients with IBS as compared with the control
group (p = 0.0005).
Our study suggested a highly possible phenotypic and genotypic
association between IBS and primary headache disorders (migraine
and ETTH) supporting some shared pathophysiological basis.
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Low prevalence of chronic cluster headache and aura,
and uncoupling of sense and behavior of restlessness
in Japanese
N. Imai, N. Yagi, R. Kuroda, T. Konishi, M. Serizawa, M. Kobari
Department of Neurology, Shizuoka Red Cross Hospital,
Shizuoka, Japan
This study examined the clinical profile of cluster headaches in Japan
and the presence of any features peculiar to Japan. A total of 86
consecutive new cluster headache patients (68 M/18F; mean age
38.4 ± 12.2 years) were enrolled in this study. The mean age of onset
was 31.0 years and the gender ratio (males to females) was 3.8.
Chronic cluster headache was observed in 3.5% patients and 2.3% of
patients had aura. More than half of patients (68.9%) reported feelings
of restlessness during the headache episodes and 42.9% reported
restless behavior. Patients with uncoupling of feelings of restless-
ness and restless behavior forced themselves to keep still. Similar
findings were reported in a Taiwanese study. Low prevalence of
chronic cluster headaches and aura, and uncoupling of sense and
behavior of restlessness may be common features in Japanese and
Taiwanese.
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Blood flow distinctions in acute migraine attack
and in intermission detected by MRI perfusion
M. Koreshkina1, A.D. Khalikov2
1Neurology, International Clinic MEDEM, St-Petersburg, Russia;
2MRI, International Clinic MEDEM, St-Petersburg, Russia
Brain blood flow in migraine attack MRI perfusion MRI perfu-
sion study of brain blood flow during migraine attack was aim of
research.
Methods MRI research was performed on GE MR tomograph 3.0
Tesla with Magnevist contrasting.MRI included T1 WI, T2 WI,
T2FSE, T2 Flair, T2*GRE, Diffusion-tensor imaging (DTI), Diffu-
sion-weighted imaging, Perfusion.(flow rate 5 ml/s), T1 post contrast,
3DTOF angiography.Patient was 43 year old female suffering MO
without aura during 25 years with migraine attack frequency 1-2 per
month. During last 2 months before the research attack frequency
increased up to 4-5 per month due to stress and high intensive
work.MRI study was performed during severe attack of MO being in
progress for 24 hours. Headache attack was evaluated as 8-9 points of
VAS and was attended by vomiting, photophobia and phonophobia.
Results MRI study visualized five white matter lesions. Three lesions
were visualized in frontal lobes in subcortical area, two lesions were
in subinsular area of left hemisphere. The largest lesions (4-4,5 mm in
diameter) were located in left frontal lobe and in subinsular areas of
left hemisphere. The lesions were isointensive in DWI and didn’t
show enhancement in postcontrast imaging. There were no arterial
stenosis and malformations observed in MRI angiography. Results of
perfusion measuring in left hemisphere showed lowering of blood
flow volume and regional perfusion rate at unchanged time of contrast
bolus transmission.
Conclusions
1. Lowering of blood flow volume in frontal lobe at the side of
headache location proves vascular component in pathogenesis of
migraine attack.
2. High intensity MRI makes quality and quantity estimation of
blood flow lowering in migraine attack feasible.
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Markers of endothelial activation in primary headache
disorders
M. Fischer1, G. Wille1, S. Klien1, D. Holle2, H. Shanib2, C. Gaul2,
G. Broessner1
1Department of Neurology, Innsbruck Medical University,
Innsbruck, Austria;
2Westdeutsches Kopfschmerzzentrum, Department of Neurology,
University of Duisburg-Essen, Essen, Germany
Epidemiological studies show an association of migraine, especially
with aura, with cardio- and cerebrovascular events. A dysfunction of
the vascular endothelium is suggested to be the underlying pathology
connecting these different disease entities. Ang-1 and Ang-2 are
markers of endothelial activation, changes in their serum concentra-
tions reflecting the state of the vascular endothelium. Our study aimed
to analyze angiopoietin serum levels in patients with migraine and
other primary headache disorders further investigating the role of the
endothelium in headache patients.
Bi-center prospective trial enrolling 4 groups of patients : episodic
migraine with and without aura, episodic cluster headache (CH), episodic
tension-type headache and healthy individuals (HC). In migraineurs,
venipuncture was performed twice: outside attack and during typical
migraine attacks prior to pain medication. In CH patients serum samples
were collected in- and outside bout. Analysis of Ang-1 and Ang-2 was
performed using enzyme-linked immunosorbent assay technique.
Ang-1 was significantly elevated in patients with migraine and CH
during migraine attacks / cluster bouts (p \ 0.05). In migraine
patients Ang-2 levels were increased during attacks compared to
the interval (p \ 0.05). Further, Ang-2 serum concentrations were
significantly higher in migraine patients outside attack compared to
HC and TTH (p \ 0.05). CH patients revealed higher levels of
Ang-2 during cluster episodes but showed normal Ang-2 levels
when comparing outside-bout concentrations with HC and TTH.
Our results indicate that there is an imbalance of the Ang-1/Ang-2
ratio in favour of Ang-2 in migraine and CH patients inside attack/
bout compared to pain-free intervals. Moreover, we found higher
Ang-2 concentrations in migraine patients outside attacks compared
to TTH and HC. Our findings of elevated Ang-2 serum levels
might reflect endothelial activation in this patient population and
further corroborate the hypothesis of an important affection of the
vascular endothelium in migraine and CH pathogenesis.
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Levels of nitric oxide metabolites in cerebrospinal fluid
in active cluster headache
A. Steinberg1, N.P. Wiklund2, L. Brundin3, A.I.M. Nilsson-Remahl4
1Department of Clinical Neuroscience, Karolinska Institute,
Karolinska University Hospital Huddinge, Stockholm, Sweden;
2Department of Urology, Karolinska Institute, Karolinska University
Hospital Solna, Stockholm, Sweden;
3Department of Clinical Neuroscience, Division of Neurology,
Karolinska Institute, Karolinska University Hospital Solna,
Stockholm, Sweden;
4Department of Clinical Neuroscience, Division of Neurology,
Karolinska Institute, Karolinska University Hospital Huddinge,
Stockholm, Sweden
The pathophysiology of cluster headache (CH) is only partly
understood. Nitric oxide (NO), a potent vasodilator, has been sug-
gested to be involved and increased plasma levels of nitrite, a stable
product on NO degradation, have been identified in both active
period and remission. We studied the role of NO in CH by mea-
suring its oxidation products, nitrite and nitrate, in the cerebrospinal
fluid (CSF), a biological compartment closer to the supposed focus
of the disorder. We collected CSF from 18 episodic CH patients in
active period and from 4 patients with chronic CH as an extension
of a previously published series of cases (1). The samples were
collected between attacks, except in 2 cases when an attack started
during the lumbar puncture. Eleven healthy headache free volun-
teers served as controls. We determined the levels of NO-oxidation
end products (NOx), i.e. the sum of nitrite and nitrate, by using
capillary electrophoresis. CH patients in active period had signifi-
cantly increased NOx-levels (mean 8.1, 95% CI 7.1-8.9) compared
to control subjects (mean 6.2, 95% CI 4.9-7.5; p \ 0.01). Both
nitrite and nitrate levels were significantly increased in episodic CH
patients. A trend towards relatively lower NOx values was observed
among the few chronic CH patients.
We interpret the results as an indication of a generally raised NO
tonus during active CH, possibly as an expression of inflammatory
activity, and causing sensitization of pain pathways. A trend towards
a difference in NOx levels between episodic and chronic patients
was observed. The results support NO involvement in the pathogen-
esis of CH.
Reference
1. Steinberg A, Wiklund PN, Brundin L, Nilsson Remahl AIM.
Levels of nitric oxide metabolites in cerebrospinal fluid in cluster
headache. Cephalalgia 2010; 30(6)696-702.
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Efficacy and safety of telmisaltan in migraine-
preventive therapy
H. Akiyama, M. Shiraishi, Y. Hasegawa
Department of Neurology, St. Marianna University School
of Medicine, Kawasaki, Japan
Objectives Preventive therapy for migraine is generally indicated in
patients with failures of triptan therapy. Efficacy of angiotensinIIre-
ceptor blocker (ARB) for the prevention of migraine attacks has been
reported, however Japanese guideline has not yet recommended the
use of ARBs as first-line drugs for migraine prevention. The aim of
this study was to elucidate efficacy and safety of telmisartan in
migraine attacks.
Methods We prospectively enrolled 10 patients (average
44.7 ± 15.2 years) with frequent migraine attacks (C4 times/month)
under a prophylactic use of lomerizine over the last three months.
Telmisartan (20 mg daily) was administered for three months in all
patients. Rescue treatment by triptan was allowed. The frequency of
headache and drugs used were recorded using self recording sheets at
monthly visits. The Headache Impact Test (HIT)-6 was also used for
the evaluation of effectiveness of telmisaltan treatment and changes in
HIT-6 score more than one point from the baseline after the obser-
vation period was considered significant.
Results There was no significant difference in blood pressure and
pulse rate recorded at baseline and at the end of the observation
period; 110.3 ± 11.6 / 75.6 ± 11.5 mmHg and 75.4 ± 7.2 /min at
baseline, and 106.0 ± 10.0 / 69.1 ± 9.3 mmHg and 80.4 ± 6.9 /min
at the end of the observation period. There were no adverse effects
and drop-outs during the observation period. Overall the telmisaltan
treatment was effective in 9 patients (90%). Significant decline in
HIT-6 score was demonstrated before and after the telmisaltan
treatment, 62.7 ± 2.1 and 52.0 ± 5.8 points, respectively
(p = 0.0002). The frequency of attacks per month was also decreased
from 9.8 ± 3.0 to 3.7 ± 2.7 times (p = 0.0006). The frequency of
triptan use per month decreased from 8.8 ± 2.3 to 3.1 ± 3.0 times
(p = 0.0007).
Conclusion Our study suggests further randomized controlled study
should be warranted to explore the significance of telmisaltan as a
migraine-preventive drug.
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Patterns of triptan use: results of a 2-year retrospective
cohort study in 4 countries
W.M. Golden1, T.W.-H. Ho2, B.J. Katic1, B. Stanford3,
S. Rajagopalan4, Y.-T. Chen1, D.S. Ng-Mak2
1Global Health Outcomes, Merck Sharp & Dohme Corp,
Whitehouse Station, NJ, USA;
2Merck Research Labs, Merck Sharp & Dohme Corp,
North Wales, PA, USA;
3Health Economics and Outcomes Research, IMS Health,
London, UK;
4Med Data Analytics, Inc., Williamsville, NY, USA
Aim We sought to describe patterns of triptan use in the UK, France,
Germany, and the U.S.
Methods Using electronic medical records (UK, France, Germany:
IMS Disease Analyzer) and pharmacy claims data (U.S: proprietary
administrative claims database), we retrospectively identified
migraineurs newly prescribed triptans. Included patients could not
have received any prescription therapy for acute migraine for 1 year
prior to the index triptan. Each patient was followed for 2 years from
the index date to evaluate patterns of treatment (i.e. persistency,
switches, and discontinuations). Persistency, evaluated at the time of
each refill, was defined as sustained prescription of the index triptan.
Results A total of 3618 patients in the UK, 2051 in France, 954 in
Germany, and 40,892 in the U.S. were included in the analysis.
During the follow-up period, 53.9 - 65.8% of migraineurs did not
persist with their initial triptan prescription (U.S: 53.9%; UK: 55.7%;
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Germany: 63.3%; France: 65.8%). In the EU countries, the majority
of those who did not receive further triptan prescriptions did not
receive any other prescription for migraine (85.7%), while in the U.S.
most filled prescriptions for non-triptans (67.0%), predominantly
opioids (33.8%). In the EU, a smaller percentage switched to a dif-
ferent triptan (9.5%) and even fewer switched to a non-triptan (4.7%),
whereas in the U.S. a smaller percentage discontinued prescription
migraine treatment (26.5%) and the fewest switched to a different
triptan (7.4%).
Conclusions We observed poor persistency in triptan prescrip-
tion both in the U.S. and Europe. Our findings suggest potential
unmet needs in the acute treatment of migraine. The reasons for the
lack of continuing prescription of triptans warrants further
investigation.
Conflict of interest Daisy S. Ng-Mak is a full time Merck & Co., Inc.
employee, received stock options of the company. The study was
sponsored by Merck & Co., Inc.
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Cardiovascular risk factors in migraine without aura
M. Togha1, F. Alami2, S. Razeghi Jahromi3, S.M.H. Paknejad3
1Neurology, Tehran University of Medical Sciences, Sina Hospital,
Tehran, Iran;
2Neurology, Tehran University of Medical Sciences, Iranian Center
for Neurological Research, Sina Hospital, Tehran, Iran;
3Shefa Neuroscience Research Center, Tehran, Iran
Introduction Several studies have revealed that cardiovascular risk
factors are more commonly seen in migraineurs with aura. However,
limited studies on this issue in migraineurs without aura have been
conducted. We performed a study to evaluate cardiovascular risk
factors in patients suffering from migraine without aura.
Methods One hundred and thirty migraineurs and 80 matched con-
trols from the similar age, sex and social group were selected. The
evaluated cardiac risk factors were hypertension, lipid profile, dia-
betes mellitus, obesity, cigarette smoking, past medical and family
history of ischemic cardiac and cerebral events. Chi square test was
used to compare the frequency of these factors between the cases and
the controls.
Results Comparing cardiac risk factors, no significant difference was
noted between the cases and the controls in the presence of diabetes
mellitus, hypertension, obesity, cigarette smoking, past medical and
family history of ischemic cardiac and cerebral events. Low HDL
cholesterol (lower than 40 mg/dl) was significantly more frequent in
migraineurs without aura (P = 0.023).
Conclusion The result may suggest that migraine without aura is not
accompanied by ischemic cardiac and cerebral events risk.
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The TRPV-1 agonist olvanil inhibits nociceptive
trigeminovascular activation in vivo in rat
J. Hoffmann, A.P. Andreou, O. Summ, P.J. Goadsby
Department of Neurology, University of California,
San Francisco, CA, USA
Transient receptor potential vanilloid receptor subtype 1 (TRPV-1) are
located in trigeminal fibers innervating the dura mater. While they co-
localize with calcitonin gene-related peptide (CGRP) the relevance of the
TRPV-1 receptor in migraine is unclear. Olvanil is a weak TRPV-1
agonist that desensitizes neuronal fibers. In comparison to capsaicin it
induces almost no CGRP release, lacks pungency and has anti-emetic
effects. We hypothesized, that olvanil leads to an inhibition of stimulus-
evoked neuronal transmission in the trigeminal ganglion.
In male Sprague-Dawley rats, anesthetized with propofol (20 mgkg-
1), the middle meningeal artery (MMA) was stimulated and electro-
physiological recordings of second order neurons were collected in
the trigeminocervical complex (TCC). Experimental groups received
either olvanil in a dosage of 0.1, 1 or 5 mgkg-1 dissolved in intralipid
or intralipid alone as the respective control group. The effects of
olvanil on trigeminovascular activity in response to MMA stimulation
were recorded following the drug infusion.
Olvanil significantly reduced cell firing in response to trigeminovas-
cular activation within the TCC (P \ 0.05). This effect was dose-
dependent and immediate, reaching maximum inhibition at 25 min-
utes post infusion of olvanil at 5 mgkg-1 (61.66 ± 6.29%; P \ 0.05).
Cell firing was not fully recovered at 60 minutes post-application
(49.07 ± 12.22%; P \ 0.05). Infusion of intralipid alone had no
significant effect on MMA stimulation-evoked firing.
The results show that the TRPV-1 agonist olvanil inhibits stimulus-evoked
trigeminal activity, thereby functionally acting like an inverse agonist. The
high efficacyofolvanil combined with the lackofpungencydue to its slower
depolarization deserve further investigation as these results might provide
the basis for a novel antinociceptive mechanism relevant to migraine.
Conflict of interest Oliver Summ received a fellowship by the Eur-
opean Federation of Neurological Societies and fellowship by MSD.
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Regulatory systems impairment as factors contributing
to primary headache chronicity
M.I. Karpova, A.V. Zueva, J.S. Shamurov
Neurology, Chelyabinsk State Medical Academy,
Chelyabinsk, Russia
Comparison of episodic and chronic forms of primary headache to
reveal the possible factors and mechanisms contributing to the disease
chronicity has been performed.
Clinical and laboratory examination of 237 patients with primary
headache was performed, 158 of them suffered from migraine and 79
patients from tension type headache. The control group consisted of
89 healthy subjects. The total number of leucocytes, leukocytic for-
mula, content of subpopulations, indices of neutrophils and
monocytes functional activity, content of immunoglobulins of A, M
and G class, complement components, circulating immune com-
plexes, concentration of cytokines, serotonin, b-endorphin, P
substance and cortisol were examined in the peripheral blood.
High incidence of somatic diseases has been found in patients with
primary headache, clinical manifestations of immune disorders was
quite prevalent among them. Significant differences in the rates of
chronic inflammatory and allergic diseases in patients with episodic
and chronic primary headache allow consider these conditions as a
factor unfavorably affecting the cephalalgia course.
Leucopenia, lymphopenia, lymphocyte subpopulation imbalance,
disorders of neutrophil functional activity, and alteration of cytokine
status and decrease of cortisol level were found in patients with
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episodic and chronic course of migraine and those with chronic ten-
sion type headache. The content of serotonin and b-endorphin was
found to be decreased in the peripheral blood of patients with chronic
forms of migraine and tension type headache. The results of labora-
tory tests in patients with episodic tension type headache do not
virtually differ from those in the group of healthy subjects. In patients
with chronic cephalalgia the revealed changes were similar to their
direction and intensity of alterations, what was the evidence of
existence of universal pathogenetic mechanisms of primary headache
transforming into chronic ones.
These results suggested that some factors of immune, neural and
endocrine regulation might contribute to primary headache chronicity.
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Real-world usage patterns in self-medication of pain.
Pooled analysis of five pharmacy-based
non-interventional studies with aspirin
U. Gessner, M. Petersen-Braun
Scientific Affairs, Bayer Vital GmbH, Leverkusen, Germany
Objective Analysis of usage patterns of a very commonly used
analgesic (Aspirin) under daily life conditions and compliance with
leaflet instructions.
Methods The individual data of 9444 patients fom five pharmacy-
based non-interventional studies performed in Germany, Switzerland
and Spain respectively were analyzed.In all studies Aspirin was used
for the treatment of different pain states, mainly headache, pain
associated with common cold and migraine. Patients who purchased
the drug in a pharmacy were provided with a questionnaire to be filled
in at home during/after the treatment.
Results About 90% of the patients rated their pain as moderate to
severe before treatment. Severe pain at baseline led to a higher percentage
of intake of 2 tablets (1000 mg, 50.1%) at the first dose than mild to
moderatere pain (27.7%). Mean daily dose was 2.2 ± 1.8 tablets and
mean treatment duration was 2.2 ± 4.4 days. The total amount of tablets
taken during the treatment course was 4.6 ± 5.7 tablets, thus far below
leaflet recommendations. Severe pain at baseline caused an increase in
daily dose and total amount of tablets taken. In total, 38.9% of the patients
only used one tablet, the remaining multiple doses.
Conclusions While the indication for OTC-analgesics is mild to mod-
erate pain the perceived pain severity of many patients is moderate to
severe and they adapt their self-treatment accordingly, taking higher
dosages for stronger pain and lower dosages for milder symptoms.
Overall treatment duration is short (approx. 2 days) and the total amount
of tablets taken (approx. 5) below the recommendation given in the
package insert. Thus patients show a high degree of compliance when
treating themselves. It might though be worth considering to rephrase the
indication for OTC-analgesics from ‘‘mild to moderate pain’’ to ‘‘pain’’ to
better reflect perceived efficacy and usage.
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Neurophysiological evaluation of trigemino-cervical
system in patients with chronic daily headaches:
age peculiarities
E.A. Kuznetsova, E.Z. Yakupov
Neurology, Neurosurgery and Medical Genetics,
Kazan State Medical University, Kazan, Russia
Objective To elucidate neurophysiological mechanisms of chronic
headaches in consideration with age and to evaluate functional
activity of trigemino-cervical system in patients of different age with
chronic daily headaches (CDH).
Methods 222 patients were divided into 5 groups: 1st - children and
adolescents - 61 patients, 2nd - 55 patients aged 18-44 years old, 3rd -
44 patients aged 45-59 years old, 4th - 47 patients aged 60-74 years old
and 5th - 15 patients aged 75-82 years old. 44 healthy subjects aged 14-
76 years old presented the control group. Neurophysiological investi-
gations were performed with the use of standard techniques and included
somatosensory evoked potentials (SEP), trigeminal evoked potentials
(TEP), blink reflex (BR) and EMG of masticatory muscles. Statistical
methods included Fisher’s exact test and correlation analysis.
Results The statistical analysis revealed increase of SEP interpeak
intervals N9-N11 (p \ 0,01), N9-N13 (p \ 0,01), N9-N20 (p \ 0,05)
in the 1st group of patients. In the 2nd group of patients we observed
TEP latencies decrease (p \ 0,05). In patients aged 45-59 years old
statistical analysis showed increase of N13-N20 (p \ 0,05) and P23
latency (p \ 0,05) and the tendency to TEP latencies increase. In the
4th and the 5th groups we revealed increase of N11 and P23 latencies
(p \ 0,05 and p \ 0,01, correspondingly), increase of N9-N11
(p \ 0,001), N9-N20 (p \ 0,01) and N20-P23 (p \ 0,05) and TEP
latencies decrease (p \ 0,05).
Conclusion The present study demonstrated age peculiarities of
functional activity of trigemino-cervical system in patients with CDH
which should be taken into account in treatment: conduction delay in
somatosensory pathway on spinal and brainstem level in children and
adolescents, increase of reflex irritability of trigeminal system in
young age, dysfunction of supraspinal level in middle age, conduction
delay in somatosensory pathways and increased irritability of tri-
geminal system in elderly patients.
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Genome-wide association study for migraine in a dutch
genetically isolated population
B. de Vries1, A.H. Stam2, N. Amin3, P. Henneman1, B.A. Oostra3,
Y.S. Aulchenko3, R.R. Frants1, G.M. Terwindt2, C.M. van Duijn3,
M.D. Ferrari2, A.M.J.M. van den Maagdenberg1,2
1Department of Human Genetics, Leiden, The Netherlands;
2Department of Neurology, Leiden University Medical Centre
(LUMC), Leiden, The Netherlands;
3Departments of Epidemiology and Clinical Genetics, Erasmus
University Medical Centre, Rotterdam, The Netherlands
Aim Migraine is a neurovascular disorder with a genetically complex
and heterogeneous background. Many linkage and association studies
have been performed, but so far with limited success. The aim of this
study was to identify novel genetic factors for common migraine by
performing a genome-wide association study (GWAS) in the genet-
ically isolated Dutch Erasmus Rucphen Family (ERF) population.
Methods For each of approximately 2.5 million SNPs, logistic
regression was performed using an additive genetic model, while
adjusting for age and gender. Uncertainty in the inferred genotype from
the imputation was accounted for by utilizing the estimated genotype
probabilities (implemented in ProbABEL). Data were filtered for rare
variants and low LD (MAF \ 0.05 were excluded; SNPs with r2 below
0.3 were excluded). We accounted for relatedness between study par-
ticipants of the isolate by correcting for genomic control inflation factor.
Results We performed a GWA with 330 migraine cases and 1216
non-migraine controls from the ERF population. Although none of the
SNPs reached the threshold for genome-wide significance (5.0 9 10-8),
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22 SNPs showed highly suggestive associations with P-values below 10-
5. No less than 221 SNPs had a P-value below 10-4. The most significant
SNP in this study showed association with a P-value of 1.34 9 10-7, and
is an intergenic SNP. In a sub-analysis, we investigated the SNPs that
were located in the FHM genes; SNPs in the FHM2 gene ATP1A2 showed
best signal for association.
Conclusions This is the first genome-wide association study for
migraine in a population-based cohort. Replication efforts are needed
to evaluate how relevant the present association findings are.
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Interaction between prolactine, estrogen and dopamine.
chronic hemicranial migraine in association
with hyperprolactinemia in
subsequent pregnancies: a case report
H. Ter Berg1, A. Maassen van den Brink2
1Neurology, Orbis Medical Center, Sittard-Geleen, The Netherlands;
2Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
A 24-year old female is suffering a daily pressing and stabbing strictly
unilateral headache, most prominent above the right eye in associa-
tion with mild autonomic features, i.e. partial ipsilateral ptosis and
eyelid oedema during 5 subsequent pregnancies.
The headache forced her to stay in bed. Physical activity was provocative.
After the 3rd pregnancy analysis of irregular menstruation and galac-
torrhea revealed a hyperproloactinemia (HPL) (1.2 u/l: normal \ 0.5/l).
MRI showed a pituitary microadenoma. Endocrinological analysis did
not reveal other abnormalities. On a dopamine receptoragonist, caberg-
oline, these complaints disappeared and treatment was stopped. During
the next two pregnancies (one with HPL of 1.22 u/l) the headache dis-
appeared on cabergoline after initial increase.
Between the pregnancies she was headache free. Cabergoline treat-
ment was continued by the patient (0.25 mgr/week) and later on
stopped with recurrence of the same headaches now without preg-
nancy. Her mother was known with migraine.
We examined the patient during her last pregnancy. A diagnosis of
hemicranial chronic migraine (CCM) with mild autonomic features
was made. Hemicrania continua could not be excluded totally because
of non-performance of the indotest. The association of HPL with CM
during pregnancies has not been reported before. A dopamine rece-
ptoragonist stopped the migraine totally. HPL may lead to the
occurrence of migraine and TACs which may disappear on dopamine
agonists as in our patient. The initial headache increase on cabergo-
line has been reported before. The mode of action of dopamine and
prolactine has not fully been clarified. Dopamine agonists may induce
both antinociception as well as hyperalgesia. We have no explanation
for the homolaterality of the headache.
The occurrence in pregnancies suggests a causal interaction between
prolactine and estrogen. Estrogen may stimulate prolactine with sub-
sequent inhibition of dopamine leading to headaches as in our patient.
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Orbital myositis posing as cluster headache
N. Bouzidi, M.I. Miladi, R. Kallel, M. Dammak, A. Boukhris,
I. Feki, C. Mhiri
Department of Neurology, Habib Bourguiba Hospital, Sfax, Tunisia
Introduction The headache is a reason for daily consultations in
neurology. Cluster headache, a disorder of unknown cause and
pathogenesis, can be mimicked by other disorders. Clinical exam and
investigations allowed rectifying diagnosis.
Objective To describe the case of a patient with recurrent orbital
myositis who was thought to have cluster headache for 2 years
Case report A 20-year-old woman, without family history developed
paroxysmal headache in the left orbital and supraorbital region with
lacrimation, conjunctival hyperemia, moderate proptosis, and painful
eye movements. The headache was severe and not preceded by an
aura. It fluctuated in intensity over the course of the day and lasted
approximately ten days. This patient had previously another attack
two years ago in the same period of the year, which was treated
successfully by prednisone as a cluster headache. Neurological
examination revealed paralysis of extrinsic pathway in the third left
cranial nerve. MRI of the brain and orbits demonstrated enlargement
of the left medial rectus muscle. The clinical improvement was
obtained after 3 days IV corticosteroid. After few weeks oral treat-
ment we note remission of all signs.
Conclusion This case behooves neurologists to consider obtaining
computed scan tomography or magnetic resonance images of the
orbits in cases of cluster headache especially in which eyelid edema,
ptosis, and conjunctival hyperemia are prominent features.
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Botulinum toxin treatment of cervicogenic headache:
a randomized, double-blind, placebo-controlled
cross-over study
L.J. Stovner1,2, M. Linde1,2, K. Hagen1,2
1Department of Neuroscience, Norwegian University of Science
and Technology, Trondheim, Norway;
2Norwegian National Headache Centre, St. Olavs University Hospital,
Trondheim, Norway
Objective Cervicogenic headache (CeH) is pain referred to the head
from a source in the cervical spine. Good and reliable treatment is
lacking.
Methods In the present randomized, placebo-controlled, patient-,
injector- and evaluator-blinded cross-over study, 29 adult patients
(mean age 46.2 years, 59% women) with a disabling, long-standing
and treatment-resistant strictly unilateral cervicogenic headache were
included. The diagnosis was based on clinical criteria and anesthetic
blockades. After a 4 week baseline period, injections of either botu-
linum toxin or placebo were given in m. trapezius, m. splenius capitis
and m. semispinalis. The second injections were given after a mini-
mum of 8 weeks, or when the patient had reached C 50% of days
with moderate to severe headache compared to baseline. Patients were
thereafter followed for another 8 weeks. Throughout the study, a
detailed headache calendar was filled in, and patients were followed
with algometry and neck mobility measurements.
Results With regard to the reduction of days with moderate to severe
headache during 3-8 weeks after injection, there was no significant
difference between verum and placebo in a mixed linear model
analysis (p = 0.084). The mean frequency of moderate to severe
headache was 4.48 days/week during baseline, and the mean changes
were -0.72 ± 0.20 days/week after botulinum toxin and -
0.40 ± 0.20 days/week after placebo. More patients experienced
a C 30% improvement with botulinum toxin (n = 11) than placebo
(n = 7) (p = 0.25). Four patients withdrew from the study before the
second injections, and an intention-to-treat analysis using the last
observations carried forward revealed no significant effect
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(p = 0.27). Side-effects of botulinum toxin were minor and short-
lasting.
Conclusions Botulinum toxin is probably not beneficial in CeH, but
the study may be underpowered. We are presently analysing the
secondary endpoints of the study.
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Medication use in patients with migraine
and medication-overuse headache: on the role
of problem solving and attitudes about pain medication
E. Lauwerier1, K. Paemeleire2, S. Van Damme1, L. Goubert1,
G. Crombez1
1Experimental-Clinical and Health Psychology, Ghent University,
Ghent, Belgium;
2Department of Neurology, Ghent University Hospital,
Ghent, Belgium
Introduction and aims Excessive medication intake is believed to be
a major risk factor of developing Medication-Overuse Headache
(MOH), a condition characterized by an increase of headache attacks
to a daily or near-daily pattern. Research focusing on the underlying
psychological mechanisms of the disorder is still in its infancy and it
is hardly known why some patients overuse their medication. In this
study, we examined the value of attitudes about pain medication,
especially perceived need and concerns, and problem solving style in
accounting for MOH. We also sought to examine the relation of
problem solving style with need for and concerns about medication.
Methods Patients with migraine (N = 133) and MOH (N = 42) were
recruited from a tertiary headache referral center and completed a
range of questionnaires measuring problem solving style and attitudes
about pain medication.
Results A problem solving style aimed at controlling pain was
associated with a higher need for and concerns about medication
intake. Interestingly, in a model accounting for demographic factors
and pain intensity, controlling pain (OR = 1.28, 95% CI 1.1 to 1.5),
need for medication (OR = 1.24, 95% CI 1.1 to 1.4) and concerns
about scrutiny by others (OR = 1.12, 95% CI 1 to 1.2) all had unique
value in accounting for MOH.
Discussion Results are discussed in terms of how a persistence in
attempts at controlling pain may trigger overuse of medication, even
in the presence of clear negative consequences.
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Progression of infratentorial hyperintense lesions
in migraine: the population-based camera-2 nine year
follow-up MRI study
I.H. Palm-Meinders1, H. Koppen1,2, J.M.E. Moonen1,
G.M. Terwindt1, L.J. Launer3, M.A. van Buchem1, M.D. Ferrari1,
M.C. Kruit1
1Leiden University Medical Center, Leiden, The Netherlands;
2Haga Hospital, The Hague, The Netherlands;
3Laboratory of Epidemiology, Demography and Biometry,
NIH, Bethesda, MD, USA
Background We previously demonstrated an increased prevalence of
brainstem (mainly pons) and cerebellar T2 hyperintense lesions on
brain MRI in migraineurs from the general population. These infra-
tentorial hyperintense lesions (IHLs) are reported to be strongly
associated with cardiovascular risk factors, and their development has
been suggested to reflect small vessel disease. Based on the follow-up
CAMERA MRI study we evaluated prevalence and progression of
IHLs in population-based migraineurs and controls.
Methods IHLs were hyperintense on T2 and proton density weighted
images, and not hypointense on FLAIR images (infarcts and Vir-
chow-Robin spaces were excluded). Progression was defined as an
increase in number or size of the IHL. Baseline and 9 yr follow-up
brain MR images were acquired in 203/295 (69%) migraineurs with
and without aura (mean age 57 y, SD 8) and 83/140 (60%) controls
(mean age 55 y, SD 7) with same MRI protocols/scanners as baseline.
Blinded for diagnosis, IHLs were scored if present and progression
was assessed. Analyses were adjusted for age, gender, diabetes and
hypertension.
Results After 9 years follow-up, there was no decrease in IHL
number or size. In the follow-up scans, IHLs were found in 39/203
(19%) of migraineurs vs. 5/83 (6%) of controls (adjusted OR 3.4 [1.3-
9.2]). Progression of IHL was found in 26/203 (13%) of migraineurs
vs. 2/83 (2%) of controls (adjusted OR 5.0 [1.1-21.9]). Prevalence and
progression of IHL were even more pronounced among women with
migraine, especially those without aura. In addition, an association
between the presence of IHL and attack frequency was found, with
the highest odds in female migraineurs without aura with C 1 attack
per month (adjusted OR 11.4 [2.2-58.3]).
Conclusion Migraine is, notably in women, associated with presence
and progression of infratentorial hyperintensities.
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Open-label, multicenter study of the efficacy
and outcome of onabotulinumtoxin-a treatment
in patients with chronic migraine and comorbid
depressive disorders
G.P. Boudreau1, B.M. Grosberg2, P.J. McAllister3, F.D. Sheftell4,
R.B. Lipton5, D.C. Buse5
1Centre de Neurologie Ambulatoire, Hopital Notre-Dame, Montreal,
QC, Canada;
2Montefiore Headache Center, Albert Einstein College of Medicine,
Bronx, NY, USA;
3The Headache Center at ANSC, Yale University School of Medicine,
New Haven, USA;
4New England Center for Headache, Stamford, CT, USA;
5Albert Einstein College of Medicine, Bronx, NY, USA
Objectives To prospectively assess the efficacy of onabotulinum-
toxinA as a prophylactic treatment in patients with chronic migraine
(CM) and comorbid depressive disorders and to evaluate the potential
of onabotulinumtoxinA in reducing the severity of depressive
symptoms as a consequence of reduced headache episode frequency.
Background Depression and anxiety are common migraine comor-
bidities and occur at even greater rates in CM. Some studies suggest
that migraine may provoke depression.
Design and methods Thirty-two outpatients (age [ 18 years) at 3
centers with CM (defined by ICHD-2R: C 15 mean headache days/
month) and comorbid depressive disorders (classified by DSM-IV)
participated. No changes were made from patients’ baseline medi-
cation regimens. Participants met criteria, gave consent, kept diaries,
and were seen by a physician and psychologist at 4 visits (weeks -4, 0,
12, and 24). Participants were treated with onabotulinumtoxinA at
baseline and week 12 according to the PREEMPT protocol.
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Questionnaires assessed headache-related disability (MIDAS),
depression (PHQ-9 and BDI-II), anxiety (GAD-7), headache impact
(HIT-6), and health-related quality of life (SF-36). A Wilcoxon
signed-rank test and Paired t-test were used for data analysis.
Results At 24 weeks headache diaries demonstrated C 50% reduc-
tion in headache/migraine days (-8.2, P \ 0.0001), more headache/
migraine-free days (+8.20, P \ 0.0001), and reduced days with
migraine (-6.71, P \ 0.0001). Positive change was observed on the
following measures: PHQ-9 (-4.3, P \ 0.0001), GAD-7 (-3.5,
P = 0.0002), SF-36 (+15.1, P \ 0.0001), BDI-II (-7.89, P \ 0.0001),
HIT-6 (-6.32, P \ 0.0001), Pain VAS (-2.51, P \ 0.0001), and
MIDAS score (-44.18, P = 0.0058).
Conclusion Open-label treatment of CM with onabotulinumtoxinA
was associated with reductions in headache and migraine frequency,
depression, anxiety and disability and improvement in quality of life.
As onabotulinumtoxinA has no known direct effect on mood, we
suggest that the reduction in depression and anxiety may be attrib-
utable to improvement in headache. Additional blinded studies with
larger samples are required.
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Migraine in emergency department: a study on indirect
costs
A. Granato, G. Relja, S. Musho, G. Pizzolato
Department of Medical, Technological and Translational Sciences,
Headache Centre, University of Trieste, Trieste, Italy
Background Migraine is a frequent chief complaint in the Emer-
gency Department (ED). Migraine entails an average annual indirect
costs of € 554 per patient in Western European Countries. No data on
indirect costs of migraineurs referring the ED are available.
Objective To determine indirect costs in employees with migraine
referring to ED.
Methods We performed a six-months prospective analysis of all
consecutive patients referring to ED for headache and afterwards
evaluated in the Acute Headache Centre (AHC) of the University of
Trieste. Employees with an AHC diagnosis of migraine (ICHD-II
criteria) were enrolled. Patients were properly treated in the AHC and
were re-evaluated in a three-month follow-up visit. Absenteeism
(missed workdays [MW]) and pre-absenteeism (workdays with
reduction in work effectiveness [RWEW]) over the preceding three
months (MIDAS scale), the daily costs of migraine-related absen-
teeism and pre-absenteeism of each professional employee (quantified
by mean daily wage, National Statistical Institute wage data) were
analyzed with SPSS 14.0.
Results We enrolled 69 patients, 58 F (84,1%) and 11 M (15.9%),
mean age 38 ± 8 years. Most frequent AHC diagnosis was migraine
without aura (42 patients, 60.9%). MW and RWEW over the pre-
ceding three months were 404 (median 5 days per person) and 658
(median 9 days per person), respectively. The indirect costs estimated
per year due to migraine-related absenteeism and pre-absenteeism
were €346.211 (€2.508 per patient). At three-month follow-up visit a
reduction of 70.4% of MW and 45.1% of RPCW was found. The
estimated annual wage costs saved due to the proper AHC therapy
was €235.740.
Conclusions Indirect costs in migraineurs referring to ED are about
five-time higher than in migraineurs in general population. An Acute
Headache Centre dedicated to Emergency Department is effective in
reducing about 2/3 of indirect costs due to the productivity loss
caused by migraine.
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Trigeminal nociceptive system and quality of life
in migraine in dependence on thyrotropin-stimulating
hormone levels
N. Starikova
Faculty of Postgraduate Education, Department of Neurology, Perm
State Medical Academy, Perm, Russia
Purpose To study hormonal axis hypophysis - thyroid in migraine
and its influence on trigeminal system and patients’ quality of life.
Patients and methods 123 migraine patients of tertiary care headache
center aged 16-57 years (mean age 38,08 years) and 10 healthy
subjects were investigated. Thyroid-stimulating hormone (TSH), tri-
geminal somatosensory evoked potentials (TSEPs) and quality of life
(QoL) by means of general Goetheborg questionnaire and migraine-
specific QVM questionnaire were studied.
Results Latencies of TSEPs were significantly enlarged in migraine
patients compared with control group. Asymmetries of P1 latency and
N1P1 amplitude were enlarged in migraine as well (p = 0,005–
0,016). TSEPs didn’t correlate with age of patients. TSH values didn’t
differ in migraneurs and healthy controls. TSH in migraine patients
correlated with attacks’ duration (R = -0,344; p = 0,014). Patients
with TSH values \ 2,0 mkME/ml showed significantly enlarged
duration of attacks compared with those who had TSH [ 2,0 mkME/
ml (53,14 ± 27,52 hours vs 37,34 ± 27,29 hours, p = 0,047). Sta-
tistically significant direct correlation between TSH on one hand and
Goetheborg QoL score (R = 0,355; p = 0,033), functional QVM
index (p = 0,046), social QVM index (p = 0,017) on the other hand
was found. Asymmetries of latencies P1 and N2 were significantly
higher in patients with TSH values \ 2,0 mkME/ml (p = 0,031;
p = 0,048).
Discussion Up to now there is no evidence concerning TSH influence
on trigeminal system. But changes of heart conducting system in
patients with low TSH values have been described: spontaneous atrial
fibrillation (Wilson GR et al. 2005), shortened interventricular con-
duction time, premature heart beats, atrial arrythmias (Boelaert K,
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Franklyn JA, 2005; Biondi B et al. 2008). We suppose that the
influence of thyroid system on conducting structures is universal, not
restricted to the heart conducting circuits. It could explain correlations
between the state of hypophysis - thyroid axis and electrophysio-
logical changes in trigeminal system in migraine patients.
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More antisaccade errors in migraine patients
M. Cambron1, S. Anseeuw1, K. Paemeleire1,2, L. Crevits1,2
1Ghent University, Ghent, Belgium;
2Ghent University Hospital, Ghent, Belgium
Aim Recent voxel-based morphometry studies in migraine patients
have shown subtle but significant reductions in grey matter in cortical
areas involved in pain processing (including the prefrontal and cin-
gulate cortices), which are related to migraine frequency. (1-5) We
hypothesized these changes would be reflected in the control of
saccadic eye movements.
Methods Saccades were recorded by infrared-oculography. Three
tasks were performed: a prosaccade gap and overlap task during
which the subject was instructed to look at the stimulus, and an
antisaccade gap task during which the subject had to look in the
opposite direction of the stimulus. Latency and direction were ana-
lyzed. These parameters were compared between patients with
migraine (n = 80) and controls (n = 87).
Results Our results suggested a greater latency variability in
migraine patients (pro-gap P = 0.002 and pro-overlap P = 0.004).
The latency of the prosaccades with gap was borderline increased
in migraine (P = 0.042). Migraine patients on prophylactic therapy
made significantly more directional errors than controls in the
antisaccade gap task (P = 0.001). The group on prophylaxis had on
average 10.66 days migraine per month, those who did not take
prophylactic medication had on average 3.85 migraine days a
month. No significant differences were found between migraine
patients with and without aura for all parameters studied.
Conclusion We found abnormal saccade behaviour in migraine
patients, especially more antisaccade errors in patients on prophy-
lactic drugs, suggesting it is related to migraine frequency. We
hypothesize that grey matter changes in the prefrontal and cingu-
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The pupils of migraine patients: preliminary results
M. Cambron1, H. Maertens1, K. Paemeleire1,2, L. Crevits1,2
1Ghent University, Ghent, Belgium;
2Ghent University Hospital, Ghent, Belgium
Aim To date there is no consensus whether there is a sympathetic or a
parasympathetic disturbance in migraine; most pupillometric studies
point towards a sympathic hypofunction. (1-4) By testing migraine
patients both during an attack and in the headache free interval, we
wanted to compare whether a potential sympathetic dysfunction
increases during an attack by using apraclonidine 1%, an alpha
adrenergic agonist.
Methods We used infrared pupillometry to measure the dark adapted
and light adapted pupil diameter. The minimal diameter, latency,
amplitude, constriction and redilatation velocity of the light reflex
were measured as well. We studied 31 controls and 42 migraine
patients interictally, after a migraine-free period of at least 15 days.
None of the migraine patients took prophylactic medication. Fourteen
migraine patients were also studied ictally; they were not allowed to
take any attack-aborting medication before or during the test.
Results We found no differences between migraine patients with and
without aura. None of the parameters correlated with the headache
side in patients with unilateral migraine. We found no significant
difference between migraine patients and controls, neither interictally,
nor ictally. The pupil parameters of migraine patients did not differ
significantly between and during the attack. However after adminis-
tration of apraclonidine 1%, migraine patients had a longer latency
compared to controls. This increase in latency was more pronounced
ictally (right: P = 0.046, left: P = 0.023) than interictally (right:
P = 0.075, left: P = 0.021).
Conclusion We assume there is a subtle pupillary sympathetic
hypofunction in migraine patients which is unmasked after adminis-
tration of apraclonidine 1%. The sympathetic hypofunction creates a
sympathetic hypersensitivity that causes the prolonged latency.
References
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Intracerebral aneurysm revealed by chronic daily
headache
N. Bouzidi, M.I. Miladi, R. Kallel, M. Dammak, A. Boukhris,
M. Meziou, I. Feki, C. Mhiri
Department of Neurology, Habib Bourguiba Hospital, Sfax, Tunisia
Introduction Headache is a common complaint among patients
seeking care at neurology. Fortunately, chronic headache associated
with significant morbidity and mortality, occurs infrequently.
Objective We describe the case of a woman with a chronic headaches
found to be a result of an intracranial aneurysm.
Case report A 39-year-old woman was received frequently in the
psychiatric department, for a chronic daily headaches diagnosed as a
tension-type headaches. It was generally reported to occur in relation
with emotional conflict and psychosocial stress. She was treated
during 5 years with Amytriptyline. When severe acute and sudden
headaches appear, she was hospitalized in neurologic department. The
neurologic examination was normal. The MRI showed a right
bleeding intracranial aneurysm. The patient was transferred to the
neurovascular hospital for intracranial medial carotid embolization.
After intervention, headaches disappeared and the control examina-
tion revealed complete third right nerve palsy and painful
hypoesthesia in the right fifth nerve. The evolution was favorable and
the patient hasn’t any neurological abnormality since 8 years.
Conclusion Physicians need to be aware of the signs and symptoms
that indicate whether a headache may be a result of serious problems
such as an aneurysm.
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Healthcare resource use and costs among chronic
and episodic migraine in five European countries
M. Stokes1, S.F. Varon2, A.M. Blumenfeld3, D.C. Buse4,
R.B. Lipton4, T.K. Wilcox1, P.J. Goadsby5
1United BioSource Corporation, Bethesda, MD, USA;
2Allergan Inc., Irvine, USA;
3Neurology Center, Encinitas, CA, USA;
4Albert Einstein College of Medicine and the Montefiore Headache
Center, Bronx, NY, USA;
5UCSF Headache Center, University of California, San Francisco,
CA, USA
Background Migraine is a common, disabling neurological disorder
imposing a significant burden on patients and healthcare systems.
Objective Evaluate resource use (RU) and associated costs in chronic
migraine (CM) and episodic migraine (EM) patients in France,
Germany, Italy, Spain, UK.
Methods Cross-sectional data collected via web-based survey, Feb-
ruary to April 2009. Respondents classified as CM or EM (ICHD-2
diagnosis of migraine and C15 headache days/month or B14 head-
ache days/month, respectively). Data collection included baseline
demographics, headache frequency and symptomology, and medical
RU for headache treatment (clinician and emergency department
[ED] visits, medical procedures, and hospitalizations over the pre-
ceding 3 months and medications used over the preceding 4 weeks).
Unit cost data collected for each country using public sources and
applied to RU profiles. Cost estimates were annualized and presented
in 2010 €. Cost calculations included imputation of missing RU data
using mean values of the non-missing participants. Group compari-
sons of medical RU made using Fisher’s Exact test.
Results 5,657 participants with migraine evaluated. CM were more
likely to have a primary care provider or neurologist/headache spe-
cialist visit compared to EM (p \ 0.0001). 11.9% of CM and 5.8% of
EM were treated either in an ED or hospital for headache (p \ 0.001).
75.1% of CM and 64.2% of EM reported headache-related medication
use over the last 4 weeks (p \ 0.001). Mean incremental difference in
total costs between CM and EM patients was €1,129 in France (CM
€1,650 vs. EM €521, p \ 0.0001), €392 in Germany (CM €965 vs.
EM €573, p = 0.08), €1,800 in Italy (CM €2,631 vs. EM €831,
p \ 0.0001), €6,310 in Spain (CM €8,162 vs. EM €1,852,
p \ 0.0001), and €2,329 in the UK (CM €3,204 vs. EM €875,
p \ 0.0001).
Conclusions CM was associated with higher medical RU and total
costs compared to EM.
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Dilatation by CGRP of middle meningeal artery
and reversal by sumatriptan in normal volunteers
M.S. Asghar1, A.E. Hansen2,3, T.R. Kapijimpanga1,
R.J. van der Geest4, P.J.H. de Koning4, H.B.W. Larsson2,
J. Olesen1, M. Ashina1
1Danish Headache Center, Department of Neurology,
Glostrup, Denmark;
2Functional Imaging Unit, Glostrup, Denmark;
3Department of Radiology, University of Copenhagen,
Glostrup, Denmark;
4Department of Radiology, Div. Image Processing, Leiden University
Medical Centre (LUMC), Leiden, The Netherlands
Background The neurotransmitter Calcitonin gene related peptide
(CGRP) is a strong vasodilator present in the perivascular nerve
fibers. CGRP plays a fundamental role in the pathophysiology of
neurovascular headaches. CGRP infusion causes headache and dila-
tation of cranial vessels. However, it is unknown to what extent
CGRP induced dilatation of extra- and intracrainal arteries contributes
to immediate head pain and whether the migraine specific abortive
drug sumatriptan (a 5-HT1B/D agonist) inhibits CGRP induced
immediate vasodilatation and headache.
Method To address these issues we performed a double-blind, ran-
domized, placebo-controlled crossover study in 18 healthy volunteers.
We directly recorded circumference changes of the extra cerebral
artery; the middle meningeal artery (MMA) and the intra-cerebral
artery; the middle cerebral artery (MCA) using 3 Tesla MR-angiog-
raphy before and after 1.5 lg/min human aCGRP or placebo (isotonic
saline) as well as after 6 mg sumatriptan subcutaneous injection.
Results CGRP caused significant headache (P = 0.003) and dilata-
tion of MMA (P = 0.006) but no dilatation of MCA (P = 0.69).
Sumatriptan administration resulted in a marked contraction of MMA
(15% to 25.2%) and only a marginal contraction of MCA (3.9% to
5.3%). Explorative analysis revealed that sumatriptan had a more
selective action on MMA compared to MCA on both study days; the
CGRP day (P \ 0.0001) and on the placebo day (P = 0.007).
Conclusion These data suggest that in exogenous CGRP only dilates
extra cerebral arteries. Furthermore, the present data suggests
that sumatriptan exerts part of its anti-nociceptive action by con-
stricting MMA (extracerebral artery) and not MCA (intra cerebral
artery). We suggest that sensory afferent input from extra cerebral
arteries may play a crucial role in the pathophysiology of neurovas-
cular headaches.
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Impact of chronic and episodic migraine on work
patterns in five European countries
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Background Migraine is a prevalent and disabling condition,
impacting the ability of migraineurs to work and perform daily
activities.
Objectives This study compared the impact of chronic (CM) and
episodic migraine (EM) on work patterns and productivity across five
European countries.
Methods Web-based survey data were collected from migraineurs in
France, Germany, Italy, Spain and the United Kingdom (UK).
Respondents were classified as CM or EM (ICHD-2 diagnosis of
migraine and C 15 headache days/month or B 14 headache days/
month, respectively). Questions on attendance (absenteeism) and
reduced productivity (presenteeism) in the preceding four weeks
assessed headache impact on work or school. Analysis of covariance
(ANCOVA) models predicted absenteeism by migraine group and
examined impact of adjusting for sociodemographic characteristics
(age, gender, race, education), and comorbidities (pain, vascular
disease [VD] risk factors, VD events, psychiatric disorders, and other
conditions).
Results Of 42,187 panelists contacted, 12,264 (29.1%) responded and
5,657 (13.4%) completers met migraine criteria (n = 1,461 France,
1,449 Germany, 976 Italy, 701 Spain, 1,070 UK). Participants were
4.9% (n = 277) CM and 95.1% (n = 5,380) EM. Respondents were
largely female (83.9%), with an average age of 39 (SD = 10.8 years).
CM reported more absenteeism due to headache symptoms than EM
(adjusted mean ± SE = 8.6 ± 0.9 vs. 3.9 ± 0.7, P \ 0.0001) and
working more days with headache symptoms (15.9 ± 0.7 vs.
5.3 ± 0.6, P \ 0.0001). Nearly three-quarters of CM and EM par-
ticipants reported that work was negatively affected by headache
symptoms (73.3% vs. 71.5%, P [ 0.05), with a similar number of
hours affected (5.0 ± 0.7 vs. 5.0 ± 0.6, P [ 0.05). Furthermore, CM
and EM both reported working at approximately half of their full
effectiveness with headache symptoms (51.7 ± 2.4 vs. 55.3 ± 1.7,
P [ 0.05).
Conclusions Migraine adversely affected attendance and increased
absenteeism among migraine sufferers, particularly those with CM,
who missed more days and had more days with reduced productivity
due to headache than EM.
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Zonisamide in the preventive treatment of frequent
refractory migraine: focus on patients with intolerance
to topiramate
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13Hospital Marcide, Ferrol, Spain;
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Background Chronic migraine refractory to preventive treatment is a
common clinical situation in general neurology clinics.
Objective To analyse our experience with zonisamide in the pre-
ventive treatment of patients with frequent refractory migraine.
Patients and methods Those patients with no response or intolerance
to topiramate and at least two more preventatives received zonisa-
mide. All but 5 patients met chronic migraine criteria with or without
analgesic overuse.This drug was increased 25 mg per week up to
200 mg/day. The efficacy of zonisamide was evaluated in terms of
‘‘response’’ (reduction in attack frequency below 50%) at the third
month of treatment. The use of zonisamide in this indication was
allowed by our ethics committee.
Results Our series comprises a total of 172 patients, with ages
ranging from 22 to 69 years. 85% were women. The final dosage of
zonisamide was 50-200 mg/day, with the 100-150 mg/day being the
most frequently administered dose. Zonisamide was efficacious
(response) in 76 (44%) patients; response being excellent in only 22
(13%). MIDAS score was reduced by 43.2% in responders. Zonisa-
mide was not tolerated by 27% of the patients, mainly due to
subjective mental slowness and/or digestive symptoms. Two cases
stopped the drug due to nephrolithiasis, one due to cutaneous allergy
and one because of diffuse joint pain.
Conclusions These results, obtained in a big sample of patients
refractory or intolerant to topiramate and other preventatives, indicate
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that, at least in conditions of daily clinical practice, zonisamide, at
relatively low dosages, is an option to be considered for the pre-
ventive treatment of desperate patients with frequent migraine.
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Occipital nerve stimulation for treatment of migraine
headache
V. Yakovleva, A. Yakovlev
Comprehensive Pain Management of the Fox Valley,
SC, Appleton, WI, USA
Introduction Migraine is a primary headache disorder affecting 18%
of women and 6% of men in US. Control of migraine headache can be
difficult to achieve in the group of patients who do not respond to
accepted medical treatment or cannot tolerate side effects of medi-
cations used to treat migraine. Occipital nerve stimulation (ONS) has
been used to treat patients with occipital neuralgia but recently this
type of treatment is utilized to control different headaches including
migraine and cluster headaches.
Methods The patient is a 42 year old female with 15 years history of
migraine who failed conservative medical treatment and had short
lasting pain relief after right occipital nerves block. She underwent a
successful trial of percutaneous placement of an 8-electrode subcu-
taneous lead in right occipital region. During the 3 day ONS trial,
the patient had good control of headaches. Two weeks later the
patient underwent subdermal implantation of a permanent lead and
RestoreULTRA (Medtronic Inc.) rechargeable generator.
Results After ONS implantation, the headaches were well controlled.
The patient reported over 50% decrease in headache days per month
and 4 to 5 point drop on VAS score during migraine attacks. The
patient was able to suppress the migraine in 30-40 minutes after
initiating of ONS. She discontinued the all medications for preventive
and acute therapy of migraine . The patient also reported other
positive outcomes including the opportunity to start school and
improved relations with friends and family. At 18 months post-
implant, the patient continued to report good control of the migraine
headache.
Conclusion ONS can be a new therapeutic option for patients with
intractable migraine headache who did not responded to currently
established treatments. This neuromodulation technique decreases the
intensity of pain during migraine attacks and can lead to reduction in
the number of headache days per month.
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An analysis of out-patient characteristics of headache
in a general neurology department of China
J. Zhou, Y. Wang, G. Tan, X. Li, L. Ran, K. Wang, L. Chen, H. Hu
Neurology, The First Affiliated Hospital of Chongqing Medical
University, Chongqing, China
Objective Categorize neurological headache outpatient visits in a
general neurology department, and analyze the demographic charac-
teristics and clinical features.
Background Headache is a common neurological disorder, limited
data, based on out-patient visits to general neurology department, are
available, and more studies in this area are warranted.
Methods From March to May 2010, we conducted face-to-face
consultations and investigations with patients claiming suffering
headache as the chief reason for visiting our general neurology out-
patient department. A self-administered headache questionnaire was
used, and headache diagnoses were made according to ICHD-II of the
International Headache diagnosis and treatment standards.
Results Patients with chief complaint of headache accounted for
19.5% of the total general neurology clinic out-patients. A total of
1683 cases of headache patients were investigated, the average age
was 46.14 ± 14.61, female-dominated, accounting for 68.1%.
56.1% patients were diagnosed with primary headache, the largest
population; 21.0% with secondary headache, and 22.9% with undi-
agnosed headache. Among the primary headache group, 40% were
diagnosed with migraine, the average age was 41.80 ± 13.28, women
account for 80.9%; 26.0% with tension-type headache; 19.0% with
chronic headache; and 15.0% with other types of primary headache.
In the primary headache group, 67.1% patients had received medical
diagnosis and consultation previously; however, 48.2% of them cited
the purpose of visits to be seeking definitive diagnosis.
Conclusion One fifth of out-patient visits to a general neurology
department are headache patients. The majority is patients suffering
primary headache, and among them, the No1 diagnosis is migraine.
Improve the diagnosis and treatment of primary headache, will
effectively reduce the headache patient clinic visits, and reduce the
economic and social burden.
254
Alice in wonderland syndrome among juvenile
headache patients
M. Kudo, C. Otuka, S. Obara, T. Konnno, Y. Terayama
Department of Neurology and Gerontology, Iwate Medical
University, Morioka, Japan
Background and purpose The Alice in Wonderland syndrome
(AWS) is characterized by 4 specific symptoms including
(1) bizarre disturbances of body images,
(2) illusions concerning size, position, and distance of objects,
(3) feeling of levitation, and
(4) alteration in the sense of passage of time, is considered as one of
the specific symptoms seen in migraineurs although the
mechanism and prevalence of AWS still remain unknown.
The purpose of the present study is to investigate the correlation
between AWS in childhood and prevalence of migraine headache in
adulthood.
Subjects and method We conducted a surveillance using
headache questionnaire sheet to 2289 students (599 elementary,
1123 junior high and 567 high school). The questionnaire includes
the feature, frequency and concomitant symptoms of headache, and
the experience of AWS. The prevalence of AWS among students are
compared with those of 267 adults migraineurs (15 to 70 years old)
who are visiting our outpatient clinic regularly from 2006 to 2009.
Results The questionnaire revealed that 59% of elementary and junior
high and 52% of high school students experienced headache, and
8.7% of elementary, 8.3% of junior high and 8.8% of high school
students experienced migraine headache. Among those who have
headache, 16 out of 159 (10.1%) elementary school students and 13
out of 293 (4.4%) high school students had experienced AWS com-
pared to 3 (1.1%) in 267 adult migraineurs. Among students with
AWS, 8 elementary (50%) and 8 high school students (61.5%) had
familial history of migraine headache.
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Conclusions The above data suggests higher prevalence of AWS
among school children although their experience fade out as they
grow up. It is important to ask about the experience of AWS for
early diagnosis and treatment for juvenile patients with migraine
headache.
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Multi-pulses transcranial magnetic stimulation (TMS)
and recurrent limb pain (RLP) in children
with migraine
D. Parain1, N. Chastan1, E. Guegan-Massardier2
1Neurophysiology, Rouen, France;
2Neurology, Hopital Charles Nicolle, Rouen, France
Rationale RLP have been reported in children with migraine and are
sometimes associated with motor weakness. The symptoms may
mimick functional (i.e. psychogenic or conversion) limb weakness
(FMW) which are commonly associated with pain and headache. We
have demonstrated the immediate efficiency of multi-pulses TMS in
functional limb weakness (in presss, movement disorders). Because of
the similarities between RLP and FMW, we have studied the effect of
multi-pulse TMS on RLP
Patients and methods Nine children (8F/1H, mean age: 11.7 ± 2.2
ys), with migraine presented one (n = 4) or several (n = 5) pain limb
episodes with weakness or disturbance of motor control. The symp-
toms were localized in both lower limbs (n = 5), in one limb (n = 2)
or variable localisation (n = 2). A precipitating event was observed in
4 patients, a head minor injury (n = 2) and a unusual physical effort
(n = 2). An average of 30 stimuli over the sensitivo-motor cortex,
contralateral to the corresponding affected limb, was delivered with a
circular coil.
Results TMS was delivered once for 5 patients, and was effective in
all cases, with a total recovery immediately after TMS (n = 2) or
quasi-immediately (within a few minutes, n = 3). TMS was delivered
several times for 4 patients during recurrent episodes, with, each time,
an immediate recovery after TMS. Video of patients before and after
TMS will be presented.
Conclusion Multi-pulses TMS are effective in RLP as in FMW.
These two entities are probably linked by a partially commun
physiopathology.
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Rapid initial absorption rate cannot alone explain
the high efficacy in migraine of sumatriptan nasal
powder delivered with novel device
P.G. Djupesland
R&D, OptiNose AS, Oslo, Norway
Objectives Sumatriptan is marketed as SC injection (6 mg), con-
ventional and RADIS tablets (25–100 mg), rectal suppositories
(25 mg) and nasal liquid spray (10–20 mg). Onset of pain relief is
thought to be a function of the initial rate of absorption to the blood,
rather than the extent. However, recent studies of sumatriptan
oral spray (20 mg), transdermal patch (6 mg) and nasal powder
(7.5/15 mg) offer new insights into the mechanism of action of
sumatriptan.
Methods Published data on the pharmacokinetics and efficacy of
sumatriptan administered by the various routes were compared with
published data on intranasal sumatriptan powder. Doses of 7.5 mg
(ON7.5 mg) to the side of the migraine or 15 mg (ON15 mg) spilt
between nostrils were delivered using the novel breath actuated
device, offering optimized drug deposition.
Results The Cmax and AUC0-? for ON7.5 mg/ON15 mg are similar
to 20 mg nasal spray and 20 mg oral spray, but substantially lower
than 100 mg tablets, 6 mg SC, 20 mg oral spray and 6 mg trans-
dermal patch. The initial rate of absorption (first 15 minutes) is
faster for ON 15 mg than all other treatments except for 6 mg SC.
Interestingly, the oral spray displays a similar bi-phasic absorption
pattern as the nasal formulations, with fast initial absorption across
the oral/nasal mucosa and a delayed GI absorption phase. However,
despite an initial absorption rate similar to ON15/ON7.5 mg
sumatriptan powder, the onset of pain relief of 20 mg oral spray is
substantially slower than ON15/ON7.5 mg and other delivery
routes/formulations.
Conclusions Comparison of PK and efficacy data for the various
delivery routes and formulations suggest that rapid initial absorption
alone cannot explain the high efficacy of sumatriptan nasal powder
delivered with the novel device. We speculate that improved nasal
deposition of sumatriptan powder offers a unique combination of
rapid absorption and blocking of pain signalling in the 1st & 2nd
trigeminal nerve branches directly involved in the pathophysiology of
migraine.
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Repetitive transcranial magnetic stimulation
over the visual cortex modulates trigeminal nociceptive
pathways
S.L. Sava1,2, G. Coppola2, V. De Pasqua1, F. Pierelli2, J. Schoenen1
1Headache Research Unit. University Dept. of Neurology & GIGA-
Neurosciences, Lie`ge University, Lie`ge, Belgium;
2Polo Pontino - I.C.O.T., ‘Sapienza’ University of Rome,
Latina, Italy
Background Bright light can cause visual discomfort, referred as
photophobia; however, the mechanisms linking luminance to the
trigeminal nociceptive system probably mediating this discomfort, are
unknown. Neural connections between the visual cortex and the
spinal trigeminal nucleus (STN) were observed in animal experi-
ments. We address this issue in healthy subjects (HS) by studying the
modulatory effects of repetitive transcranial magnetic stimulation
(rTMS) applied over visual cortex on the nociceptive-specific blink
reflex (nBR), reflecting STN activity.
Subjects and methods Fifteen bilateral consecutive nBR responses
were recorded by stimulating the right supraorbital nerve (1.5x pain
threshold) in 16 HS before and after rTMS over the visual cortex
(phosphene or 110% motor threshold). Nine hundred pulses were
delivered at 1 Hz (15 minutes train) or 10 Hz (20 trains of 4 seconds,
inter-train interval of 15 seconds) frequency. We measured sensory
and pain thresholds, and R2 area under the curve (AUC) on 3 blocks
of 5 responses. Habituation was defined as the slope of the linear
regression line for 3 successive blocks.
Results 1 Hz rTMS which has an inhibitory effect on the underlying
cortex, significantly increased sensory (p = 0.03), but decreased pain
threshold (p = 0.02). 10 Hz rTMS, supposed to have activating
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effect, had no effect on these thresholds. Low frequency rTMS
increased nBR R2 AUC and potentiated habituation, whereas high
frequency rTMS decreased R2 AUC and left habituation unchanged
(p = 0.03 for AUC; p = 0.05 for the slope). These effects were
significant contralaterally to the stimulated side only, while effects
were negligible in the ipsilateral recordings.
Conclusions Our data show for the first time in humans that there are
functional connections between visual cortex and second order
nociceptors in the STN. Interestingly, inhibitory rTMS modifies pain
threshold (decrease), nBR area and habituation (increase) in the same




profiling in migraine patients: electrodermal responses
to pain and emotional descriptors among migraine
patients and healthy controls
C. Pires, J. Miro´, G. Noguero´n
Department of Psychology, Unit for the Study and Treatment of Pain,
and ALGOS, Universitat Rovira i Virgili, Tarragona, Spain
Background and aims Individuals with migraine may present a
syndrome-specific descriptor profiling and demonstrate greater skin
conductance responsivity to descriptors that describe migraine due
to the additional significance that these terms have acquired from
their repeated association with the migraineurs‘ internal pain
experience (Jamner and Tursky, 1987). Enhanced autonomic reac-
tivity in chronic pain patients to words descriptive of their pain
problem has been substantiated (Flor et al., 1997). Chronic pain may
be linked to an increased reactivity to a wide range of stimuli, such
as pain-related words (Flor et al., 1997) or emotional words (Bonnet
and Naveteur, 2006). The objective of this study is to gather specific
information about the reactions of migraineurs to emotional and
pain-related words, and compare them with those from healthy
persons.
Methods 15 migraineurs and 15 nonmigraineurs observed a series
of 20 pain descriptors and 20 emotional descriptors, each pre-
sented twice, 12 sec each time. 80 trials were conducted and the
skin conductance responses were recorded during each presenta-
tion. After the experiment, participants selected pain descriptors
from the McGill Pain Questionnaire that described migraine
headaches.
Results Our hypothesis is that migraineurs will demonstrate greater
skin conductance responsivity to the visual presentation of pain
descriptors, confirming a syndrome-specific use of pain language.
Migraineurs may be conditioned or sensitized to particular sets of
verbal pain descriptors, but also to emotional descriptors.
Conclusions If confirmed, this would imply that migraineurs have
a syndrome-specific descriptor profile, which differentiates them
from pain-free individuals regarding the electrodermal responses
to pain and emotional words. There are important clinical and
empirical implications to this study. The psychophysiological
syndrome-specific profiling could be used as an adjunct in diag-
nostic procedures. Similarly, interventions could be tailored at
interfering with the learning process underlying the acquired
additional meaning and significance of specific stimuli for the
migraine patient.
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Cortical silent period duration in medication overuse
headache changes according to the drug overused
G. Coppola1,2, A. Curra` 3, M. Gorini3, C. Davassi1, M. de Micco1,
S.L. Sava1, F. Pierelli1
1Polo Pontino - I.C.O.T., ‘Sapienza’ University of Rome,
Latina, Italy;
2Dept of Neurophysiology of Vision and Neurophthalmology,
G.B. Bietti Eye Foundation-IRCCS, Rome, Italy;
3Ospedale A. Fiorini-Polo Pontino, ‘Sapienza’’ University of Rome,
Latina, Italy
Background Episodic migraineurs recorded interictally have short-
ened cortical silent period (SP), as a result of reduced activation of
GABAB-ergic circuits in the motor cortex. In episodic migraine
cortical activation fluctuates depending on the migraine cycle,
whereas in chronic daily headache due to medication overuse (MOH)
it seems locked in a pre-ictal state, it is of interest thus to study the
cortical SP in patients with MOH.
Material and methods We recorded the transcranial magnetic
stimulation (TMS) induced SP in perioral muscle in 36 MOH patients,
12 migraine without aura patients studied interictally (MO), and 13
controls. MOH patients were sub-grouped in patients who overused
triptans (n = 9), nonsteroidal anti-inflammatory drugs (NSAIDs)
(n = 12), and combination of both (n = 15) drugs. We delivered high
intensity magnetic stimuli through a figure-of-eight coil over the hot-
spot for the perioral muscles, while subjects maximally activated
target muscles, and recorded the electromyographic responses with
surface electrodes placed bilaterally.
Results MO patients had shorter SP than controls (p = 0.021).
Despite as a whole group patients with MOH had normal SP duration
(p = 0.314), the subgroup of triptan overusers had significantly
shorter SP than controls (p = 0.005) and NSAIDs overusers
(p = 0.119) or both medications combined (p = 0.847). Monthly
tablets intake, but not disease history, correlated positively with SP
duration (r = 0.476, p = 0.003) in the whole group of MOH.
Discussion In patients with MOH the activation of motor cortical
inhibitory interneurons is greater than in episodic migraneurs studied
interictally, and it is similar to that observed in controls. SP normalisation
takes place in the MOH subgroup who overuse NSAIDs, whereas SP
duration remains short in patients who overuse triptans alone. This
finding confirms that in chronic migraineurs the overuse of NSAIDs or
triptans changes the cortical physiology distinctly, and it shows that such
distinctive effect is also exerted on cortical inhibitory circuits.
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Impairment of temporal development of the visual
system short-range lateral inhibition in migraine
without aura patients
G. Coppola1,2, S.L. Sava1, C. Di Lorenzo1, M. Gorini3,
M. de Micco1, C. Davassi1, V. Parisi2, F. Pierelli1
1Polo Pontino - I.C.O.T., ‘Sapienza’ University of Rome,
Latina, Italy;
2Dept of Neurophysiology of Vision and Neurophthalmology,
G.B. Bietti Eye Foundation-IRCCS, Rome, Italy;
3Ospedale A. Fiorini-Polo Pontino, ‘Sapienza’’ University of Rome,
Latina, Italy
J Headache Pain (2010) 11 (Suppl 1):S1–S150 S57
123
Background Migraineurs lack of habituation to repetitive visual
stimulation during the pain free period, which was currently explained
as due to cortical hyper-excitability, or to low cortical pre-activation
levels. The latter should be affect both excitatory and inhibitory
cortical neurons. Which of the former or the latter contributes more to
the habituation deficit cannot be determined with the methods com-
monly used to evoke transient visual responses. Here we have used
differential temporal modulation of adjacent regions of radial wind-
mill-dartboard (W-D) or partial-windmill (P-W) visual patterns,
since they accentuate the relative contributions that arise from short-
and long- range lateral inhibition between neurons of the visual
cortex.
Methods Steady-state visual-evoked potentials (4 Hz) were recorded
in 42 migraine without aura (MO) patients (22 interictally [MOii] and
20 ictally [MOi]) and in 21 healthy volunteers (HV). Two visual
stimuli were used: W-D and P-W. For each stimulus session, 600
sweeps were acquired and 6 blocks partitioned. Fourier analysis was
performed to extract the amplitude of the fundamental (F1) and the
second harmonic (2H) components reflecting respectively short- (W-
D, F1) and long- range (P-W, 2H) lateral interaction.
Results Repeated ANOVA testing W-D F1 amplitude disclosed a
group by block interaction (p = 0.01). In MOii patients the F1 har-
monic block amplitude starts higher than HV (p = 0.01) and MOi
(p \ 0.001), and decreases with time, instead of increase like in HV
and MOi. There were no significant between groups difference in the
temporal development of the P-W 2H amplitude.
Discussion From our data emerges that interictally migraineurs visual
cortex seems basically overinhibited since early F1 W-D amplitude is
higher than HV and MOi. We hypothesize that hypofunctioning
serotonergic pathways in migraine may cause a functional discon-
nection of thalamus leading to a decreased intracortical short-range
lateral inhibition, which could contribute to induce interictal lack of
habituation.
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Trends over time in the prevalence of headache
disorders. The Nord-Trøndelag health studies
(HUNT 2 AND 3)
M. Linde1,2, L.J. Stovner1,2, J.-A. Zwart1,3, K. Hagen1,2
1Department of Neuroscience, Norwegian University of Science
and Technology, Trondheim, Norway;
2Norwegian National Headache Centre, St. Olavs University Hospital,
Trondheim, Norway;
3Department of Neurology, Oslo University Hospital and University
of Oslo, Oslo, Norway
Objective Earlier reports regarding secular trends of migraine are
conflicting, and there is a lack of long-term follow-up studies of other
headache syndromes among adults. The aim of the present study was
to assess any changes in the prevalence of the major headache types
according to the diagnostic criteria of the International Headache
Society (IHS) in a large adult population during an 11-year period.
Methods This study involved two cross-sectional surveys of
all inhabitants aged C 20 years in the Norwegian county of
Nord-Trøndelag, from 1995 to 1997 (n = 92 566) and from 2006 to
2008 (n = 94 194). Attendance rates were 56% and 42%, respec-
tively. Main outcome measures were the age-adjusted 1-year
prevalences of all headaches combined, migraine, probable migraine,
tension-type headache (TTH), chronic daily headache (CDH) and
medication overuse headache (MOH). Attack frequencies and sex-
ratios were assessed.
Results In the second cross-sectional study, the 1-year prevalence of
‘headache suffering’ was 37.4%, for CDH 2.5% and MOH (1%).
Compared to the first survey, this remained stable. The prevalence of
migraine overall increased (12.1% versus 13.6%, p \ 0.001), but the
sex ratio did not change over time. The prevalence of definite
migraine in the second survey according to the IHS criteria was
12.0% (women 14.9% and men 7.4%). The prevalence of non-
migrainous headache overall decreased (26.0% versus 23.8%,
p \ 0.001), and the prevalence of TTH in the second survey was
16.5% and for chronic TTH 0.6%.
Conclusions The main finding was a significant increase in migraine
prevalence, but no change over time in the prevalence of all head-
aches combined, nor in CDH. Together with earlier findings from
Denmark, this may suggest a recent increase of migraine among
adults in the Nordic countries.
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Is subcutaneous stimulation of the greater occipital
nerve the invasive treatment of choice in patients
with chronic headache syndromes?
D. Rasche, V. Tronnier
Department of Neurosurgery, University of Lu¨beck,
Lu¨beck, Germany
Objective In patients with chronic headache syndromes (CHS) which
are refractory to any pharmacological treatment invasive techniques
can be offered. In specific headache syndromes a dysfunction of the
trigeminovascular system and hyperactivity in the hypothalamic area
are supposed. Different invasive procedures are performed despite
there is no evidence for each of these methods.
Methods The greater occipital nerve is stimulated (ONS) using
subcutaneously placed leads at the level of C1/C2. ONS is supra-
threshold with pleasant paraesthesias in the distribution of the greater
occipital nerve. In ten patients (7 female, 3 male, mean age: 45 years;
4 pat. with chronic cluster headache (CCH), 2 pat. with chronic
migraine (CM), 1 pat. with CCH and CM, 3 patients with occipital
neuralgia (ON)) ipsi- or bilateral ONS was initiated and a test trial
performed.
Results After implantation a testing phase of 7–14 days was per-
formed. In all patients a positive effect with pain reduction was
correlated with active and suprathreshold stimulation. Patients
reported a decrease in attack frequency, intensity and duration with
active ONS. In all patients a reduction of the pain medication was
possible and a neurostimulation device was implanted. No peri-
procedural complications were observed. During the mean follow
up of 22 months (range: 6–54 months) two technical problems
needed to be revised operatively (one lead dislocation, one wound
infection).
Conclusion ONS of the greater occipital nerve offers an effective,
simple and low-risk treatment option for patients with specific CHS
like CCH, CM or ON. Despite no pain-free status can be achieved a
significant pain reduction and therefore an improved quality of life
can be observed. Therefore ONS should be offered to those patients as
the first invasive treatment option. There is an urgent need for better
evidence and a prospective randomized trial comparing ONS with
best medical and conservative treatment.
S58 J Headache Pain (2010) 11 (Suppl 1):S1–S150
123
263
Cessation of migraine after thalamic infarction
L.-C. A´lvaro, J.-M. Uterga
Neurology, Basurto Hospital, Bilbao, Spain
The thalamus, a key centre in migraine, is activated during the attack,
in the contralateral side to pain. Some drugs (triptans, propanolol)
elicit pain-relief by acting on locally activated thalamic neurons. In
similar terms, structural lesions in the thalamus could potentially
modify the course of this disorder. We support this possibility, by
providing a case with sustained cessation of chronic migraine after a
thalamic infarction. The patient is a 65 year-old hypertensive woman,
under candesartan. Since her twenties, she suffered from headache, as
many other members of her family. The pain was preceded by aura
symptoms in about a half of the episodes: they consisted of bilateral
positive and negative visual manifestations, followed by ascending
paresthesias from her left fingers to the shoulder, and later on to her
left facial side; shortly afterwards, dysartria and some difficulties
finding words ensued. All of them receded about 15 minutes later.
Aura never appeared without cephalalgia. Under different symptom-
atic (acetaminophen, nonsteroidal anti-inflammatory drugs, and four
triptans) and preventive drugs (amytriptilin, flunarizin, propanolol,
valproic acid and topiramate) she had got poor relief. She had
abandoned medical follow-up, although she never abused drugs.
During the last year she developed chronic migraine. Five days after
her last cephalalgia, she suffered from an acute episode of right
hemiparesis and paresthesias. In hospital, CT and MRI disclosed an
acute left thalamic infarction, in its anteromedial area. Paresis and
paresthesias vanished in a week. She remains headache and aura free
15 months after the stroke. As a unique cessation of chronic migraine
followed the thalamic infarction, a causal link seems plausible. The
involved nuclei, anterior and anteromedial, connect with the cingular,
medial temporal and prefrontal cortex. Therefore, their deafferenta-
tion might render unperceived the emotional and rational aspects of
headache, accounting for the final cessation of pain in this patient.
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The prevalence and characteristics of headaches
in schoolchildren in the Czech Republic
M. Muchova1, E. Janousova2, L. Danis3, H. Andrlova3, D. Schwarz2,
H. Oslejskova1
1Department of Paediatric Neurology, Masaryk University
and University Hospital Brno, Brno, Czech Republic;
2Institute of Biostatistics and Analyses, Masaryk University, Brno,
Czech Republic;
3School of Medicine Masaryk University Brno, Brno, Czech Republic
Objectives The goal of this study was to estimate the prevalence of
headache and primary headache like migraine and tension-type
headache among children and adolescents and examine the possible
differences in headache prevalence and type by gender and age. The
characteristics of headache in children was also explored. This is the
first study about epidemiological parameters of paediatric headaches
in the Czech Republic.
Methods A population school-based study was conducted between
November 2009 and April 2010 in the primary and high schools of
Moravian region in the Czech Republic. The method use in this
research was a questionnaire, which was based on the modified 2004
International Headache Society criteria for paediatric headaches. The
questionnaire was completed by 1086 pupils (635 girls and 450 boys)
aged 8-18 years and consequently processed statistically.
Results According to the questionnaires 95.5% students reported
having had headache during their life. The prevalence rates of ten-
sion-type headache were 36.3% and migraine 27% (21.6% migraine
without aura, 5.4% migraine with aura). Tension-type headache was
found to be more common than migraine in both genders and in all
age groups. 40.7% boys suffered from tension-type headache, 17.5%
migraine without aura and 4.1% migraine with aura. 36.5% girls had
tension-type headache, 25.9% migraine without aura and 6.8%
migraine with aura. The onset of headache and especially migraine
headache begins at an earlier age among males than among females.
There was a high occurrence of headache in family history predom-
inantly in mothers.
Conclusions The prevalence of headache in schoolchildren is high.
Tension-type headache and migraine were found to be the most fre-
quent types of headaches. It is very important and necessary to use
modified IHS criteria in the diagnosis of childhood migraine.
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Epidemiology of headaches in Tehran—Iran in 2010,
‘‘Face-to- Face, in-door’’ study
S. Shahbeigi1, M. Fereshtenejad2, N. Mohammadi3, S. Tadayon4,
G. Jalilzadeh5, M. Golmakani6, M. Heydari4, H. Pakdamn4
1Neurology, Shahid Beheshti Medical University, Tehran, Iran;
2Iran University of Medical Sciences, Department of Neurology,
Tehran, Iran;
3Iran University of Medical Sciences, Department of Epidemiology,
Tehran, Iran;
4Shahid Beheshti Medical University, Tehran, Iran;
5Jondishapur Neurology Clinic, Tehran, Iran;
6Tehran Municipality, Tehran, Iran
Headaches are one of the most common symptoms during life with
high impacts on individuals and societies. A few studies were per-
formed to evaluate different types of headache as face to face in door
study . Therefore, this study was performed to evaluate the prevalence
rates of different types of headache among people of Tehran urban
area.
In this cross-sectional survey performed in collaboration with Tehran
Municipality, a ‘‘face-to-face, in-door’’ structured interview was
developed and studied a population of 378725 people (census 2006)
as a pilot study of ‘‘Tehran Headache Study’’ in the year 2010. Using
the random residential block numbers, the forms were applied to the
family members with more than 10 years old age and finally 3655
individuals were enrolled. Subjects were diagnosed in accordance to
the most frequent type of headache experienced in the last 1 year,
using ICDH-2 criteria (revision 2004).
Of 3655 recruited individuals of the 8th district of Tehran urban area,
67% were female and 33% were male with the mean age of 35.87
(SD = 14.90) yr ranged between 10 to 95 years old. Overall number
of 2778 (76%) people have experienced headache within last year.
Tension and migraine headaches were the most common types with
the prevalence of 48.6% (n = 1777) and 18.2% (n = 665), while,
drug-induced, chronic daily (CDH) and cluster headaches were pre-
sented in 4.9% (n = 180), 3.3% (n = 122) and 0.1% (n = 3),
respectively.This is the first population-based epidemiological studies
of headache in Tehran general population which was performed in 8th
district as the pilot survey. Our results show that the prevalence of
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primary headaches in Tehran population is significant, particularly in
females.We showed that impact of headaches in Tehran were very
high and this emphasised that we should perform the better programs
for headache prophylaxis and control in Iran.
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Prevalence of diabetes, hypercholesterolemia
and clinical stroke in migraine patients after 9 years
follow-up: results of the population-based camera-2
study
H. Koppen1,2, I. Palm-Meinders3, M. Verschuren4, L. Launer5,
M. van Buchem3, M. Ferrari1, G. Terwindt1, M. Kruit3
1Neurology, Leiden University Medical Center, Leiden,
The Netherlands;
2Neurology, Haga Hospital, The Hague, The Netherlands;
3Radiology, Leiden University Medical Center, Leiden,
The Netherlands;
4Center for Prevention and Health Services Research,
RIVM, Bilthoven, The Netherlands;
5Laboratory of Epidemiology, Demography and Biometry,
NIH, Bethesda, MD, USA
Migraine is associated with subclinical ischaemic lesions as well as
with ischaemic stroke, coronary disease and venous thrombo-embo-
lism. Previous studies also suggested a higher prevalence of risk
factors associated with cardiovascular disease (CVD) like hyperten-
sion, diabetes, hyperlipidemia and livedo reticularis among
migraineurs. Here we investigate the presence of cardiovascular risk
factors and events after 9 years follow-up in our population based
cohort.
Methods Data are from the CAMERA-1 study (1999-2000), we
re-examined 75% of the original cohort including 229 migraineurs
(102 migraine with aura; 72% female; mean age 57 y.) and 95 con-
trols (70% female; mean age 55 y). Participants underwent a
structured computer guided telephone interview and a general phys-
ical and neurological examination, blinded for diagnosis. Presence of
(cardiovascular) co-morbidities was self-reported, but had to be
doctor diagnosed. Multivariate models adjusted for age were used to
test differences in CVD related factors.
Results Alcohol use and smoking habits did not differ between
groups. Physical examination revealed no differences for neurological
deficits, systolic or diastolic blood pressure and body mass index, nor
for presence of livedo reticularis. However, diabetes was reported by
9% of migraineurs vs. 2% of controls (OR 4.0 [0.9–17.7], hyper-
cholesterolemia was reported by 29% of migraineurs vs. 18% of
controls (OR 1.8 [1.0- 3.3]). Prevalence of reported cardiac arrhyth-
mia, coagulation disorder, deep vein thrombosis, pulmonary
embolism, myocardial infarction, angina pectoris, and TIA was sim-
ilar in both groups. However, strokes of any type were reported more
frequently by migraineurs (5%) vs. none of the controls (p = 0.04).
We found no differences between migraineurs with or without aura.
Conclusion Migraineurs from the general population have more often
diabetes (trend), hypercholesterolemia and clinical stroke, these dif-
ferences were not present at baseline nine years earlier. Obesity,
livedo reticularis, hypertension, or venous thrombo-embolism were
not more prevalent in migraineurs.
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Clinical profile of children below 5 years of age
with early onset recurrent headaches
S. Ramdas1, M. Prasad1,2, V. Jain1,3, M. Awadh3, I. Abu-Arafeh2,3
1Tayside Childrens Hospital, Dundee, Scotland;
2Department of Paediatrics, Stirling Royal Infirmary, Stirling,
Scotland;
3Fraser of Allander Neuroscience Unit, Royal Hospital for Sick
Children, Glasgow, UK
Objective Recurrent headache in children under 5 years of age is less
common than in older children and adolescents. The clinical profile of
headache is understudied in this group.It can be different from those
with onset of symptoms at a later age.
Methods A retrospective study was undertaken into children who
presented to a tertiary paediatric headache clinic over a 9-year period
(1997-2005). All children with recurrent headache who had onset of
headache symptoms before five years of age were included.
Results During the study period 815 children were seen in the
headache clinic. 123(15%) children had headache symptom onset
before five years of age. 74(60%) were boys and 49(40%) were girls.
The diagnoses made according to IHS classification were migraine
without aura in 64(52%), migraine with aura in 7(6%), migraine
variants in 4(3%), non-specific headache in 15(12%), mixed in
12(10%) and other types in 21(17%).
Children with migraine (71/123) were the predominant group. They
were studied in more detail. The site of maximal pain was frontal
(66%), with other sites being holocranial (10%) and vertex (4%).
Only 7 (10%) children had unilateral headache.The common associ-
ated symptoms were Anorexia (87%), Nausea (78%), Vomiting
(67%), Photophobia (60%) and Phonophobia (72%). Imaging was
done in 20 (16%) children and was normal in all but one. For acute
treatment all were advised lifestyle changes and 109 (87%) were
given routine analgesics (paracetamol and or Ibruofen). In children
with migraine, for acute migraine attacks 10 (14%) needed suma-
triptan and only 11 (15%) were advised prophylaxis.
Conclusions Migraine without aura is the most common headache in
children with symptom onset before 5 years of age. In this age group,
migraine without aura rarely lateralizes. Most of the children had
benefited with advice on lifestyle changes and simple analgesics for
severe headaches and were rarely prescribed prophylaxis.
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Headache as the sole presentation of cerebral venous
thrombosis: a prospective study
A. Timoteo, N. Ina´cio, A.A. Nogueira Pinto, E. Parreira
Hospital Prof. Dr. Fernando Fonseca, EPE, Amadora, Portugal
Introduction Headache is the most frequent presenting symptom of
cerebral venous thrombosis (CVT), most commonly associated with
other manifestations. It has been described as its only clinical pre-
sentation in 15% of patients. There is no typical pattern of headache
in CVT.
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Objectives To study the characteristics of headache as the sole
symptom of CVT at presentation.
Methods From a prospective study of 26 consecutive patients diag-
nosed with CVT over 16 months, we selected those who presented
with headache only: they had a normal neurological examination, no
papilloedema and no blood or any parenchymal lesion on CT scan.
All were submitted to a systematic aetiological work-up and a
structured questionnaire about the characteristics of headache was
applied.
Results Headache was the sole manifestation of CVT in 12
patients. Onset was progressive in 10 patients and thunderclap in
2. Headache was diffuse in 4, bilateral (frontal or posterior) in 7
and unilateral in 1. It was constrictive in 10 patients and pulsating
in 2. Seven patients referred worsening with sleep, Valsalva
manoeuvres or straining. There was no association between the
characteristics of headache and extension of CVT. The mean
delay between onset of symptoms and diagnosis in this group was
9 days; in those patients presenting with other symptoms/ signs
was 4 days. Five patients had previously been evaluated because
of the headache and were discharged from hospital diagnosed
with ‘‘primary headache’’.
Conclusions In our series, 46.2% of patients presented only with
headache. There was no uniform pattern of headache apart from being
bilateral. There was a significant delay of diagnosis in these patients.
Some characteristics of headache should raise the suspicion of CVT:
recent persistent headache, thunderclap headache or symptoms sug-
gesting intracranial hypertension even in the absence of papilloedema
or focal signs.
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The impact of a migraine attack and its after-effects
on perceptual organization, attention, and working
memory
H. Koppen1,2, I. Palm-Meinders3, M. Kruit3, G. Terwindt1,
M. van Buchem3, M. Ferrari1, B. Hommel4
1Neurology, Leiden University Medical Center, Leiden,
The Netherlands;
2Neurology, Haga Hospital, The Hague, The Netherlands;
3Radiology, Leiden University Medical Center, Leiden,
The Netherlands;
4Department of Psychology and Leiden Institute for Brain
and Cognition, Leiden University, Leiden, The Netherlands
Introduction Many migraine patients report mild to moderate cog-
nitive complaints during the first hours to days following a migraine
attack, like slowing of reaction and memory problems.
Goal The aim of this study was to assess whether cognitive (per-
ceptual, attentional, or memory) processes are impaired during the
first 48 hours after a migraine attack.
Methods Three different cognitive tasks (Global-Local task, the
Attentional Network Task and N-back task) were applied to 16
migraine patients (81% migraine without aura; mean age 58 yrs, 94%
female) and 18 healthy controls (59 yrs, 83% F), matched to age,
gender, and educational level. Cognitive test data were obtained at
three time points; during the first headache free day following a
migraine attack (1st session), after 24 hours (2nd session) and 12 days
after the attack (3rd session).
Results The attentional network (ANT) and N-back tasks showed no
significant differences between migraineurs and controls. For the
Global-Local task subjects were presented visual figures, in which a
larger (global) letter was composed of smaller (local) letters, and
subjects were asked to respond which letter was either the local or the
global one. Controls showed faster reaction times, when responding to
global than to local stimuli, which is the standard global precedence
effect. This effect was absent in the migraineurs. [F(1,28) = 4.99,
p = 0.034]. The found (migraine vs control with global vs local)
interaction was strongest when comparing prophylaxis using
migraineurs with controls (p = 0.06). The impact of migraine how-
ever was roughly comparable across sessions.
Conclusion No evidence for temporary changes in cognitive per-
formance was found during the post-attack phase in migraineurs on
attentional function, working memory, or perceptual organization
capabilities. Surprisingly, we found that the normal global prece-
dence effect (making responses to global stimuli fastest), was
absent in migraineurs, especially in those on prophylactic
medication.
270
The ‘trigger avoidance model of headaches’
and ‘learning to cope with triggers’
P. Martin1,2
1Psychology and Psychiatry, Monash University, Clayton, USA;
2Psychology, Southern Health, Melbourne, VIC, Australia
We have argued in three recent publications that the standard
clinical advice that headache management should involve avoidance
of triggers is open to criticism as it has minimal empirical support
and problems with implementation. In addition, the literatures on
anxiety, stress and chronic pain would suggest that avoidance is
generally a maladaptive strategy. We have proposed the ‘Trigger
Avoidance Model of Headaches’, which suggests that fear of the
experience of headache drives susceptible individuals to try to avoid
headache triggers, and this natural tendency is encouraged by cli-
nicians and advice on the internet. Attempts to avoid triggers will
result either in no exposure, or short exposure, to the triggers. This
may lead to the capacity of the trigger to precipitate headaches
being maintained or increased, through a process of sensitisation,
failed habituation/adaptation, or lack of opportunity for learning to
cope with the trigger. Hence, whilst attempts to avoid triggers may
lead to fewer headaches in the short-term, it may result in more
headaches in the long-term as tolerance for triggers decreases. We
have argued that counselling avoidance should be replaced with a
philosophy of ‘Learning to Cope with Triggers’. The stress litera-
ture demonstrates that no one coping strategy can be selected as the
best way of coping with stress for all situations and across time, but
approach strategies generally are more adaptive than avoidance
strategies. We have argued that in parallel with the stress literature,
no one strategy can be singled out as the best way of managing all
headache triggers. Sometimes avoidance will be the strategy of
choice but more often, approach/engagement/exposure strategies
will be the strategies of choice. This presentation will focus on the
practicalities of our approach to management of triggers - that is,
how it works for the diverse range of factors that can precipitate
headaches.
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Body mass index (BMI) and headache days in Japanese
migraineurs
T. Takeshima1,2, H. Yoneda3, Y. Tominaga3, M. Nagashima3,
H. Hasegawa3, S. Tominaga3
1Neurology, Osaka, Japan;
2Headache Center, Osaka, Japan;
3Neurosurgery, Tominaga Hospital, Osaka, Japan
Chronification of migraine headache is one of the most urgent issues
in headache management. Obesity is regarded as a risk factor for
chronification of migraine. To clarify possible association of migraine
chronification and obesity, we analyzed headache days and BMI in
Japanese migraineurs.
Subjects and method Four hundred and sixty five headache suf-
ferers have visited our headache center from February 2010 to
April 2010. We interviewed all patients with structured questioners.
Full neurological examination was performed to all subjects. Brain
imaging was carried out if necessary. Type of headache was
determined in accordance with ICHD-II. Two hundred thirty one
subjects had migraine headache, the other 234 s had tension-type
headache, cluster headache or other primary headache. Height and
body weight were measured in the clinic. According to BMI,
subjects were categorized to five ranks, i.e., underweight
(BMI \ 18.5), normal (18.5-24.9), overweight (25–29.9), obese
(30-34.9), and morbid obese ([35). Average headache days and
migraine days of recent three months were recorded. Frequency of
acute medication use was also recorded. The data were analyzed
with chi-square test and one way ANOVA.
Results Thirteen out of 38 underweight migraineurs (34.2%), 70 of
160 normal-weight ones (43.8%), 11 of 26 overweight ones (42.3%)
and 6 of 7 obese ones (85.7%) had more than 15 headache days
(p = 0.91, Pearson’s chi-square test). There was no morbid obese
migraineur in this series. Mean headache days were 10.9 ± 1.5 (SE),
13.4 ± 0.9, 14.0 ± 2.2, and 22.4 ± 2.4 days/month in underweight,
normal, overweight, and obese migraineurs, respectively (p = 0.013,
ANOVA). Mean migraine days were 5.3 ± 0.7, 5.5 ± 0.4, 6.9 ± 0.9
and 10.8 ± 1.9, respectively (p = 0.002, ANOVA).
Conclusion Obese migraineurs tended to have more headache and
migraine days than normal or underweight migraineurs in a Japanese
series.
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Multimodal visual functions (visual field, contrast
sensitivity, visual evoked potential) and cerebrovascular
reactivity in migraine patients between attacks
A.S. Shalash1, H.M. Elkhawas1, A.M. Said2, R.G. Zaki2
1Neurology, Ain Shams University, Cairo, Egypt;
2Ophthalmology, Ain Shams University, Cairo, Egypt
Background Migraineurs have significantly interictal altered visual
field and contrast sensitivity (CS), and it has long been thought that
these changes are related to vascular origin.
Objectives To investigate the relationship between visual functions
(visual field, spatial-contrast function, visual evoked potential) and
cerebral flow velocities and vasoreactivity in migraineurs between
attacks.
Methods The study included 27 migraineurs (23 females and 4
males) are matched to 18 healthy volunteers. They were subjected to
severity grading by migraine disability assessment score (MIDAS);
transcranial doppler sonography (TCD) with vasoreactivity testing for
MCA and PCA; pattern reversal visual evoked potential (PRVEP); CS
assessment and visual field study using standard and short wave-
length automated perimetry (SAP and SWAP).
Results Compared to controls, patients had significantly impaired
response of MCA to hyperventilation (HV) (P = 0.018) and a
highly significant lower vasoreactivity index (P = 0.0014); signif-
icantly lower mean P100 amplitude of both eyes in all (P = 0.03);
significantly prolonged mean P100 latency of both eyes (P \ 0.05);
and significantly lower CS (P B 0.01). None of visual fields in the
migraine group had homonymous defects. SAP and SWAP detec-
ted total field deficits in patients (63% and 74% respectively);
bilateral minimal criteria of glaucomatous damage (37%, 40.7%
respectively) and unilateral changes (26% and 33.3% respectively).
There was statistically significant negative correlation between
VEP P100 latency, and mean MCA flow velocity, mean MCA flow
velocity after HV and percentage of vasoreactivity. There was
positive correlation between cerebral blood flow velocity and
reactivity index and CS; however this was not statistically
significant.
Conclusions Migraneurs had significant interictal changes of visual
functions, VEP and cerebrovascular reactivity, suggesting the
underlying vascular etiology of visual function deficits and that
glaucoma and migraine may share a common vascular etiology.
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Prevalence and burden of headache disorders:
comparative study in same latitude region of China
Y.N. Fang, N. Luo
Departments of Neurology, The First Affiliated Hospital of Sun
Yat-Sen University, Guangzhou, China
Background Over the past 20 years, no investigation on the preva-
lence and burden of headache disorders on the suffered population
was carried out in China.
Objective We aimed to conduct a one-year survey on the prevalence
and burden of primary headache in Chinese in Guangdong and
Guangxi provinces. Also evaluated are the factors of similarity
and dissimilarity affecting the sufferers0 burden between the two
regions.
Methods Random samples of local residents in Guangdong and
Guangxi aged 18-65 years were invited to a face-to-face interview.
Results The 1-year prevalence of primary headache was consistent
with the previous studies in that Asian. The total cost of headache
treatment in one year would be close to 1.44% of national GDP in
2008. Migraine had more impact on patients than tension-type
headaches (TTH), while TTH had higher prevalence than migraine
among population. There was significant difference of life quality
score between headache and non-headache populations in the two
regions.
Conclusion Headache had higher prevalence in low income regions
and ethic minority areas and the financial burden on headache pop-
ulation in the low income region also relatively increased. Although
the impact caused by migraine was much more serious than that of
TTH among the population, taking the high prevalence of TTH into
account, both migraine and TTH caused similar burden on the suf-
fered population. The impact of headache is potential high and may
cause the psychological burden on patients.
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Memantine for prevention of cluster headache:
a possible new treatment?
E. Venturelli1, R. Rao1, A. Charles2
1Neurology, Spedali Civili University of Brescia, Brescia, Italy,
2Neurology, UCLA School of Medicine, Los Angeles, CA, USA
Introduction Cluster headache (CH) is the most common type of
TAC and although effective therapies exist, there remain a significant
number of patients for whom current treatments are either ineffective
or poorly tolerated. Memantine (MEM), is an activity dependent
blocker of NMDA receptors. Since glutamatergic signalling has been
implicated in primary headache disorders, we investigated the pos-
sibility that MEM may be an effective therapy for patients with CH
who had failed current standard therapies.
Methods Patients were evaluated in the outpatient headache clinic of
an academic medical center. Patients were diagnosed according to the
ICHD-2 classification for episodic CH and chronic CH. All patients
had failed first-line preventive therapy. MEM was added to other
preventive treatments in 5 CH patients, and MEM alone was used as
preventive treatment in 5 patients. A retrospective descriptive analysis
of the data was performed.
Results Patient ages ranged from 26 to 78 years (mean age 53.3);
9 M and 1 F, 5 episodic CH and 5 chronic CH. Patients used MEM
for a duration of between 1 month and 12 months (20 mg/day). The
headache frequency prior to MEM was daily with a daily frequency of
attacks ranged from 1 to 5 (mean 2.1). Out of 10 patients, 6 (60% of
all patients) reported remission, 4 episodic CH and 1 chronic CH
patients, 2 patients reported remission after only one month of
treatment. Four chronic CH patients (40% of total patients) reported a
greater than 50% reduction in estimated monthly headache frequency.
No patients discontinued MEM for side effects.
Conclusions This study, although clearly limited by its retrospective
approach, lack of blinding, and lack of a controls, suggests that MEM
may be treatment option for CH patients who do not respond to or do
not tolerate conventional therapies. Prospective placebo controlled
studies are warranted.
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Chronic pain, use of mixed analgesics/opioids
and medication overuse are associated with chronic
daily headache: results of german headache study
M.-S. Yoon1,2, M. Obermann1, P. Dommes1, I. Santowski1,
M. O¨zyurt1, H.C. Diener1, Z. Katsarava1
1University of Duisburg-Essen, Essen, Germany;
2Ruhr University of Bochum, Bochum, Germany
Objective To estimate the 1-year prevalence of headache C15 days/
month (chronic daily headache, CDH) and identify its principal risk
factors in the general population in Germany.
Methods A random sample of 18.000 participants (6.000 each in
Essen and Mu¨nster, a large and mid-sized city in North Rhine-
Westphalia, and Sigmaringen, a rural aria in the southern part of
Germany) were screened by using a previously validated
questionnaire.
Results The response rate was 54% (9.665/18000), 5.088 (52.6%)
were female; mean age was 43 ± 13.1. CDH was reported by 248
respondents hence resulting in the prevalence of 2.6% [95% CI
2.3-2.9%]. Of those, 136 individuals had medication overuse.
Risk factors for CDH were smoking (OR 1.1 95% CI 1.0-1.9), chronic
low back pain (OR 4.4 95% CI 3.3-6.0), chronic facial pain (OR 26.4
95% CI 13.0-53.4) and medication overuse (OR 13.4 95% CI 9.8-
18.4).
We furthermore analyzed a subgroup of people who reported head-
ache in the previous year (N = 5779). People using mixed analgesics
(OR 2.3 95% CI 1.5-3.5) and opioids (OR 4.1 95% CI 1.4-12.3) were
at higher risk for CDH compared to those with headache, who
reported not to take any acute headache drug. In contrast, the risk for
CDH was not increased in respondents who reported to use single
analgesics (OR 1.1 95% CI 0.8-1.5) or triptans (OR 1.4 95% CI 0.7-
2.6).
Conclusions
(1) The prevalence of CDH is in line with previous studies in
Europe and US.
(2) In addition to the well known risk factors such as medication
overuse we were able to show that concomitant chronic pain is
strongly associated with CDH
(3) The association of use (not overuse) of combination analgesics
and opioids with CDH is of clinical importance and should be
further studied prospectively.
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Prevalence of episodic primary headaches
and associated risk factors in Germany: results
of the German headache study
M. Obermann1, M.-S. Yoon2, P. Dommes1, I. Santowski1,
M. O¨zyurt1, H.C. Diener1, Z. Katsarava1
1University of Duisburg-Essen, Essen, Germany;
2Ruhr University of Bochum, Bochum, Germany
Objective To estimate the 1-year prevalence of migraine (MIG) and
tension-type headache (TTH) and identify their principal risk factors
in the general population in Germany.
Methods A random sample of 18.000 participants (6.000 each in
Essen and Mu¨nster, a large and mid-sized city in North Rhine-
Westphalia, and Sigmaringen, a rural aria in the southern part of
Germany) were screened by using a previously validated
questionnaire.
Results The response rate was 54% (9.665/18000), 5.088 (52.6%)
were female; mean age was 43 ± 13.1. Headache on \ 15 days/
month was reported by 5531 subjects. The 1-year prevalences
among these participants were as follows: definite MIG 12.7%
[95% CI 12.1-13.4%], Prob-MIG 4.2% [95% CI 3.82-4.62%],
definite TTH 3.6% [95% CI 3.1-3.9%], Prob-TTH 9.4% [95% CI
8.8-9.7%], MIG + TTH 4.6% [95% CI 4.2-5.0%], and Prob-
MIG + Prob-TTH 7.5% [95% CI 7.0-8.1%] and 15.3% of cases
were unclassifiable.
People with definite MIG were predominantly female (OR 3.1, 95%
CI 2.7-3.6), were more likely to smoke (OR 1.2, 95% CI 1.1-1.4) and
less likely to drink alcohol (OR 0.64, 95%CI 0.5-0.8).
People with definite TTH were less educated (OR 1.3, 95% CI 1.1-
1.6) and were less likely to drink alcohol (OR 0.52, 95% CI 03-0.8).
Conclusions
(1) Prevalences of migraine and tension-type headache are compa-
rable with those in Europe and the USA.
(2) The study reveals different risk factors for the two biologically
different disorders.
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From the migraine to the brain, and back.
Neuropsychology of medication overuse headache
B. Biagianti1, R. Muffatti1, S. Usai2, L. Grazzi2, G. Bussone2,
O. Gambini1, S. Scarone1
1Psychiatry, Ospedale San Paolo Universita` Degli Studi Di Milano,
Italy;
2Neurology, Headache Center, National Neurological Institute
C. Besta, Milan, Italy
Objective 30% to 50% of chronic migraineurs fall into a self-per-
petuating cycle of daily headache and overuse of analgesics,
experiencing pharmacological tolerance and dependence and devel-
oping Medication Overuse Headache (MOH). We investigate causal
relations among disability, addiction, anxious and depressive symp-
toms, neurocognitive performance.
Methods This cross-sectional study shows datasets of 50 patients
suffering from MOH, diagnosed by International Headache Classifi-
cation Criteria, before withdrawal. Patients completed self-
administered scales (MIDAS, SDS, Subs-SR, Scl90-R) to determine
disability, dependence, substance use, psychopathological dimen-
sions. Anxiety and depression were evaluated by Hamilton Scales.
Neuropsychological assessment of prefrontal cortex and frontal-stri-
atal circuits has been investigated by Probabilistic Reversal Learning
Task and Iowa Gambling Task.
Results Statistical analyses identified that disability correlates with fre-
quency of attacks, dependence-like behaviours, anxiety and depressive
symptoms. Moreover, psychopathological variables are associated with
deficits in reversal learning. A separate model involves decision making
functions, duration of migraine and overuse.
Conclusions Medication overuse is a complex phenomenon, where
prefrontal cortex dysfunction may play a key role, as seen in addicts
of other substances. Decision making deficit is linked with duration of
overuse and migraine, while deficits in relearning of stimulus-reward
associations and perceiving negative feedback could be in relation
with dependency behaviours and psychopathological symptoms.
Dependence seems pervasive in determining disability and should be
the first target of treatment. Anxiety and depressive symptoms are
more likely a consequence of disability than a predisposition. More
research is required focusing on underlying neuronal substrates of
dependence and decision-making.
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Related research in the polymorphism of CACNA1A
of migraine in the southerners of China
Y.N. Fang, N. Luo
Departments of Neurology, the First Affiliated Hospital of Sun
Yat-Sen University, Guangzhou, China
Background During the 1990 s, owing to the development of molecular
biology and hereditary statistical analysis, there was a breakthrough
about the study of Familial hemiplegic migraine (FHM) which had the
most evident hereditary tendency in all kinds of migraine. The researches
indicated that many genes like a gene ofa1A subunit of brain-specific P/Q
calcium channel might participate the pathogenesis of FHM.
Objective To determine the connection between mutations in CAC-
NA1A gene and the patients with familial hemiplegic migraine
(FHM) in the southerners (Han people) of China, through the method
that detected the three most frequent mutable points in CACN1A gene
from the peripheral blood of patients with FHM.
Design Adopted single-strand conformation polymorphism
(SSCP) method to detect the peripheral blood samples of 10
patients and their 12 normal relatives in tow families with FHM
and 53 migraineur with aura but without FHM and 10 people for
control.
Results Sequence variants in chromosomes were detected from nei-
ther the 2 families with FHM nor the sample with aura but without
FHM and we also didn’t detect the sequence variants of chromosomes
in the control group.
Conclusions None of the three most frequent mutations (T666 M,
R583Q and D715E) was detected in chromosomes from the patients
with FHM or the patients without FHM among the southerners (HAN
people) of China. The connections between FHM and CACNA1A
gene or migraine with aura and CACNA1A gene still need to be
further investigated in more cases.
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Post-radiosurgery headache: does it exist?
A. Donnet1, C. Daniel1, M. Leveque2, J. Re´gis2
1Neurology, Timone Hospital, Marseille, France;
2Neurosurgery, Timone Hospital, Marseille, France
Post gamma knife headache was first described by Rozen in 1997.
This diagnosis is included in the International headache Classification
in the Appendix (A7.9.1) and is defined as a headache developing
within 7 days after radiosurgery.
We conduct a retrospective study in Marseille Timone Hospital
(France) to determine if de novo headache can occur after radiosur-
gery and if post-radiosurgery headache is related to the location of the
lesion and the dosage and radiation field employed.
During five months, patients coming back to the follow-up consul-
tation after radiosurgery were included in a study and ask to answer to
a specific questionnaire. The goal of this questionnaire was to
determine if the patient had headaches before surgery and if he
developed a de novo headache or a modification of a previous
headache after radiosurgery.
Between February 2009 and July 2009, 82 patients were included in
this study. Twenty -one patients had no headache before and after
radiosurgery. Twenty-three patients had a headache before the radi-
osurgery and no headache after. Twenty-eight patients complain of
headache before and after radiosurgery with no modification of the
presentation of the headache for 21 patients. Finally, headache
appears after radiosurgery for 10 patients and a diagnosis of post
radiosurgery headache was proposed for one patient. A 65-year-old
male patient, without previous personal and familial history of
headache, was treated with radiosurgery in 2006 and in 2008 for a
geniculate ganglion schwannoma.
He developed six months after the second radiosurgical treatment a
permanent, retro-auricular headache ipsilateral to the tumour. Two
years after, and despite a reduction of the tumour volume, the head-
ache persists. We suggest that post-radiosurgery headache does exist
and that the pathophysiology of this headache is related to dura mater
inflammation.
Conflict of interest Dr. Donnet has perceived personal compensation
for activities (consulting, clinical research) with Almirall SAS,
Merck, Pfizer Inc.
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Current progress of a study to explore putative links
between migraine, appetite behaviours and obesity
in children
S. Singh1, S. Ray1, A. Curran2, J. Halford3, J. Harold3, R. Kumar2
1Department of Child Health, Liverpool University, Liverpool, UK;
2Paediatric Neurology, Alder Hey Childrens Hospital, Liverpool, UK;
3Psychology, Liverpool University, Liverpool, UK
Aim To discuss the progress of an ongoing pilot study of migraine
and appetite behaviours in children.
Background Recent research has highlighted an association between
migraine and obesity, including in children. A causal relationship, and
its direction, is not established. There are overlapping neurobiological
mechanisms in migraine, appetite behaviour and obesity. Migraine
has been noted to affect appetite behaviours, but this has not been
formally studied previously. We wish to explore the biologically
plausible hypothesis that migraine may lead to obesity, via alterations
of appetite and food intake.
Method A single-centre, cross-sectional, questionnaire-based, clinical
migraine population pilot study was designed. The primary outcome
measures are migraine severity and eating behaviour using validated
tools. Secondary outcomes are to classify, describe and quantify
appetite behaviour in paediatric migraineurs including food cravings.
Specific tools used are the PedMIDAS, Dutch Eating Behaviour
Questionnaire, Child Eating Behaviour Questionnaire, Child Behav-
iour Checklist, Food Cravings Inventory and the food intake
questionnaire. Body mass index z scores will be used as a measure of
adiposity. The sample size appropriate for a pilot study is 60 children
with migraine, and 30 non-migraine headache controls. The main
exclusion criterion is current treatment with migraine prophylaxis
medications due to their adverse weight altering effects. Local
Research Ethics and Trust R&D approvals were granted in June 2009.
Results The total of 60 migraine cases have been recruited as pre-
viously intended from general paediatric and neurology outpatient
clinics. Participants enrolled in the study are aged between 5 to
16 years. The primary focus will be to examine the relationship
between migraine severity, appetite behaviours and BMI z-scores.
Pending collaboration with the longitudinal ALSPAC study for data
on migraine and obesity may provide findings that can establish
causality. The analysis and discussion of results should be complete
by early August 2010.
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Serial polysomnography in hypnic headache shows
no association with REM sleep
M. Obermann1, D. Holle1, T. Wessendorf2, S. Zaremba1,
M.-S. Yoon1, C. Gaul1, H.-C. Diener1, Z. Katsarava1
1Department of Neurology, University of Duisburg-Essen, Essen,
Germany;
2Department of Sleep Medicine, University
of Duisburg-Essen, Essen, Germany
Objective To identify associations of REM sleep with the occurrence
of headache in patients with hypnic headache.
Background Hypnic headache is a rare primary headache disorder
exclusively related to sleep. Patients wake up every night with typical
headache lasting between 15 min and several hours. Early case
reports and small case series suspected a strong association with REM
sleep, as it was observed, that patients always woke up in REM sleep.
However, recent polysomnographic investigations reported patients
with headache onset in Non-REM sleep.
Design/ methods We performed polysomnography in 6 patients with
hypnic headache according to the diagnostic criteria of the Interna-
tional Headache Society (ICHD-II) in four consecutive nights. An
independent, experienced sleep medicine specialist blinded to the
diagnosis evaluated a total of 22 nights where typical headache
occurred.
Results We found no association of the occurrence of headache in
patients with hypnic headache with a particular sleep phase. Headache
onset was arbitrarily distributed to REM and Non-REM sleep. Two
patients had two headache attacks in one night and had one attack in
REM and the other one in Non-REM sleep. Headache occurred most
often in sleep phase 2, which also is the most likely finding as this is
the most common sleep phase. One patient had obstructive sleep
apnoea syndrome where headache resolved after CPAP mask therapy.
Conclusion/ relevance The occurrence of hypnic headache attacks is
not associated with a particular sleep phase, neither REM nor Non-
REM sleep. The underlying pathophysiology remains uncertain, but is
obviously not dependent on REM sleep.
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The role of eletriptan in migraine-acute attack therapy
in patients with somatic pathology
A. Vertkin, M. Feldman
Clinical Pharmacology, Pharmacotherapy and Ambulance, Moscow
State Medical Stomatological University, Moscow, Russia
Headache is one of the most frequent complaints, imposed patients for
therapists. There are several types of headache, but migraine studied
more than others. The aim of our study was to determine the fre-
quency of migraine in the practice of therapist and efficiency of pain
therapy. 284 patients were included in our prospective study. Of
these, 225 (79%) patients complained of headache. These were 133
(59%) women and 92 (41%) men. The average age of patients was
69 ± 14 years. We found that headache occurs most frequently in
patients with essential hypertension (97; 43%) and coronary artery
disease (CAD) (70; 31%). Also, the headache was observed in 34
(15%) patients with chronic obstructive pulmonary disease and 18
(8%) patients with malignant neoplasms. These types of headache
were regarded as migraine in 17% of cases (38 patients). The average
age of these patients was 43 ± 7 years. Therapists and neurologists
have identified migraine in 29% and 71% of cases (11 and 27
patients), respectively. Migraine is testimony to the appointment of
selective 5-hydroxytryptamine 1B/1D receptor agonists (selective 5-
hydroxytryptamine 1B/1D receptor agonist (eletriptan). But 20
patients had contraindications (for example, CAD) to eletriptan
(Relpax). So, non-steroidal anti-inflammatory drugs (NSAIDs) were
assigned for these 20 patients (group A). Relpax was assigned for 18
patients who did not have these contraindications (group B). We used
the scale of MIDAS (Migraine Disability Assessment) to evaluate the
characteristics of headache. Average score of the scale in these groups
was 17 and 19, respectively. The intensity of headache decreased in
both groups after drug treatment. After 2 hours the average score of
the scale in groups was 10 and 13 and after 4 hours - 4 and 9,
respectively. Thus, the intensity of headache decreased by 76,5% in
group A and 52,6% in group B.
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Osteopathic management of an adult patient suffering
from trigeminal neuralgia after an arnold chiari type I
decompression surgery
R. Zegarra-Parodi1,2, P. Allamand2, L. Fabre1,2
1CEESO, Lyon, France;
2Private Practice, Paris, France
Introduction Herniation of the cerebellar tonsils through the foramen
magnum into the cervical spinal canal with obliteration of the cere-
bellomedullary cistern is the primary feature of Arnold-Chiari type I
(AC1) malformation. Posterior cranio-cervical decompression by
opening foramen magnum and atlas lamina usually with corre-
sponding dural and arachnoid opening is the surgical procedure most
frequently used. Posteoperative pain impairing functional activity and
quality of life is common and it is possible that manual treatments
such as osteopathy may bring relief.
Objectives To describe the examination, intervention, and outcomes
for a patient suffering from trigeminal neuralgia after an AC1
decompression surgery with osteopathic treatment.
Methods A case report of a 29 year old man who presented with tri-
geminal neuralgia 5 years after decompression surgery. Encephalon and
cervico-thoracic medulla MRIs were normal, describing only scar tissue
following surgery. The trigeminocervical nucleus receives nociceptive
inputs from both the trigeminal nerve and the first three cervical nerve
roots which innervate the anatomical structures most affected during the
surgery. Musculoskeletal scar tissue was targeted for osteopathic
manipulative treatment based on its hypothesized influence on a sen-
sitization state of the central nervous system. Manual desensitization
techniques devised to reduce patient pain perception were proposed.
Results A clinically significant decrease in overall pain as measured with
a VAS occurred after the second treatment. Throughout the treatment
period, an increase in cervical function was also described by the patient.
Conclusions Pain perception in some patients suffering from tri-
geminal neuralgia following cranio-cervical decompression could be
triggered by scar tissue and reduced by appropriate manual treatment.
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An open study on the polymorphism gene
apolipoprotein e in migraine and cardiovascular disease
V. Pizza1, F. Infante2, G. Schiavo3, A. Agresta1, A. Capasso4,
A. Bisogno4, C. Colucci d’Amato5
1Neurophysiopathology Unit, S. Luca Hospital,
Vallo della Lucania, Italy;
2Molecular Biology Unit, S. Luca Hospital,
Vallo della Lucania, Italy;
3Biochemistry Unit, S. Luca Hospital, Vallo della Lucania, Italy;
4Faculty of Pharmacology, Salerno University, Salerno, Italy;
5Neuroscience Department, Second University of Naples, Napoli, Italy
Introduction Nitric oxide plays an important role in the pathogenesis of
migraine. Studies suggest that the expression of molecules involved in the
pathogenesis of headache (i.e., nitric oxide-interleukin) is influenced by
apolipoprotein E (APOE) and is gene specific. Hence, we hypothesized
that APOE polymorphism may be associated with migraine.
Aim Our study analysed the incidence of genetic polymorphism A-
poliporotein E in a sample of migraineurs and a control group of the
patients with ischemic cardiopathy.
Materials and methods In this study 103 consecutive patients aged
18-64 years (mean age 33.4 years), suffering from migraine
(1) (81 migraine without aura, 22 migraine with aura, ICHD-II
criteria) and 90 patients aged 36-74 years (mean age
46.5 years), with ischemic cardiopathy
(2) were studied with Polymerase Chain Reaction (PCR) for genetic
polymorphism Apoliporotein E.
Results ApoE: 72 patients (70%) [1] and 63 (70%) [2] had an E3/E3
genotype; 16 (15.5%) [1] and 14 (15,5%) [2] had a E3/E4 genotype; 7
(6.8%) [1] and 9 (10%) [2] had a E2/E3 genotype; 2 (2%) [1] and 4
(4.4%) [2] had a E4/E4 genotype; 3 (3%) [1] and 0 [2] had a E2/E4
genotype; 0 [1] and 0 [2] had a E2/E2 genotype.
Conclusions Our results highlighted a more or less equivalent prev-
alence of apoliprotein E gene polymorphisms in migraineurs and in
subjects suffering from ischemic cardiopathy. Further research is
required to confirm the findings of the present study in a larger sample
and to elucidate the role of APOE polymorphism in headache.
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Interventional pain management procedures
for refractory trigeminal neuralgia
A.R. Cooper1, Z. Elchami2
1Pain Relief Clinic, Causeway Hospital, Coleraine, UK,
2Pain & Headache Management Center, International Medical Center,
Jeddah, Saudi Arabia
The authors report their experience in managing refractory trigeminal
neuralgia (TN) referred for interventional pain relief therapy. The
population etiology was mixed (idiopathic n = 66, Demyelinating
Disease n = 38, post traumatic n = 7 and vascular anomalies n = 3)
and duration of symptoms ranged from 6 months to 20 years. All had
undergone extensive medical therapy and were receiving polyphar-
macy at referral. Mean age was 59 yrs (range 24-94 yr) and
M:F = 32:82 A single procedure often sufficed but in 26 cases
additional procedures were required. Techniques included Radiofre-
quency thermocoagulation (n = 105), balloon compression (n = 5)
and glycerol injection (n = 4). Mean radiation exposure times were
2.25 min ranging from 0.25 - 9.6 minutes. Most treatments were for
V2 & V3 pain (n = 98) with V1 & V2 being least commonly targeted
(n = 16). Good to excellent pain relief was achieved in 109 proce-
dures, with [ 40 - 100% relief being obtained, while in only 5
procedures was this inadequate with \ 40% relief being attained.
Demyelinating Disease was more refractory to intervention than with
idiopathic aetiology. Facial numbness was the most commonly
experienced side effect but was well tolerated. Interventional pain
relief procedures offer a safe and effective option in refractory TN
when other methods have failed or produce intolerable side effects.
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Lifestyle redesign for chronic headaches: prevention
of chronic migraines through lifestyle modification
S. McNulty1, S. Sahai2
1Occupational Therapy and Occupational Science, University
of Southern California, Los Angeles, CA, USA;
2Neurology, University of Southern California,
Los Angeles, CA, USA
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Lifestyle Redesign for Chronic Headaches is a program imple-
mented at the University of Southern California through a
collaboration between Occupational Therapy and Neurology. People
with chronic headaches have an underlying genetic vulnerability to
headaches and lifestyle factors, called triggers, which can cause
headaches. Traditional treatment includes medication management;
more recently some multidisciplinary teams have developed to
address the numerous needs of patients, which have been successful
in decreasing headache frequency. Occupational Therapy (OT) is a
health care profession aimed at improving performance, preventing
illness and disability, and promoting adaptation to life changes
through participation in meaningful occupations. OT would address
the application of headache prevention into the person’s actual routine
and activity choices with a particular focus on lifestyle balance.
Lifestyle Redesign is an approach within OT that is uniquely suited
for the headache population due to its focus on occupational self-
analysis and the health promoting effects of occupation. Constructs
applied to the headache population from occupational science include
lifestyle balance, habits, and perceived control. This program applies
occupational science research and address lifestyle factors such as
stress, physical activity, sleep routine, and diet in order to decrease
headache occurrence.
The three goals of the program are:
(1) To increase patient’s knowledge of lifestyle habits and factors
related to headaches.
(2) To improve the patient’s ability to adapt behaviors through tools
and strategies from a Lifestyle Redesign perspective, and
(3) To decrease the overall number of headaches that patients
experience.
Outcome measures used include: Migraine Disability Assessment
Scale (MIDAS), Migraine Specific Quality of Life Questionnaire
(MSQ v.2.1), The Headache Management Self-Efficacy Question-
naire(HMSE), Headache Impact Test (HIT-6), and the Canadian
Occupational Performance Measure (COPM). Initial outcomes from 4
patients result in a significant positive improvement in their quality of
life as measured by the MSQ v 2.1.
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An open study on factor XIII VAL 34 LEU
polymorphism gene in migraine and cardiovascular
disease
V. Pizza1, F. Infante2, G. Schiavo3, A. Agresta1, A. Capasso4,
A. Bisogno4, C. Colucci d’Amato5
1Neurophysiopathology Unit, S. Luca Hospital, Vallo della Lucania,
Italy;
2Molecular Biology Unit, S. Luca Hospital, Vallo della Lucania,
Italy;
3Biochemistry Unit, S. Luca Hospital, Vallo della Lucania, Italy;
4Faculty of Pharmacology, Salerno University, Salerno, Italy;
5Neuroscience Department, Second University of Naples, Napoli,
Italy
Introduction At present, it is contradictory to determine if the
combination of certain prothrombotic polymorphisms and migraine
and also the risk to develop ischaemic vascular disease. Recently, the
common Val34Leu polymorphism of the A-chain factor XIII gene,
associated with variations in factor XIII activity, has been suggested
to play a significant role in the development of arterial and venous
thrombotic disorders.
Aim Our study analysed the incidence of genetic polymorphism
Factor XIII (V34L) in a sample of migraineurs and a control group of
the patients with ischemic cardiopathy.
Materials and methods In this study 103 consecutive patients aged
18-64 years (mean age 33.4 years), suffering from migraine [1] (81
migraine without aura, 22 migraine with aura, ICHD-II criteria) and
90 patients aged 36-74 years (mean age 46.5 years), with ischemic
cardiopathy [2] were studied with Polymerase Chain Reaction (PCR)
for genetic polymorphism Factor XIII (V34L).
Results Factor XIII (V34L): 63 subjects (61.2%) [1] and 40 (44.4%)
[2] were heterozygous; 7 subjects (6.8 %) [1] and 5 (5.5%) [2] were
mutated.
Conclusion These data evidenced that the incidence the factor XIII
Leu 34 allele in two population studied not evidenced meaningful
differences. Therefore a role in the pathogenesis of such disturbances
is hypothetical and deserves ulterior deepenings in more important
casuistries.
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Investigating the molecular basis underlying
the increased CSD susceptibility in transgenic
familial hemiplegic migraine type 1 mice
R. Shyti1, B. de Vries1, O.I. Klychnikov2, L.A.M. Broos1,
R.R. Frants1, M.D. Ferrari3, C.F. Barrett1,
A.M. van den Maagdenberg1
1Human Genetics, Leiden University Medical Center, Leiden,
The Netherlands;
2Biomolecular Mass Spectrometry Unit, Department of Parasitology,
Leiden, The Netherlands;
3Neurology, Leiden University Medical Centre (LUMC), Leiden,
The Netherlands
Aim We generated transgenic knock-in mice bearing pathogenic
FHM1 mutations in the orthologous Cacna1a gene to study mecha-
nisms and pathways involved in migraine pathophysiology. Previous
investigations had shown that FHM1 mutant mice had an increased
susceptibility to cortical spreading depression (CSD), a wave of glial
and neuronal depolarization that spreads slowly across the cerebral
cortex and that is generally believed to underlie the migraine aura.
Here we investigated whether the visual (occipital) cortex is more
susceptible to CSD and whether basal molecular profiles in this brain
region differ between mutant and wild type mice.
Methods CSD induction thresholds were measured by topical KCl
application to occipital and frontal cortices of mutant mice bearing
the FHM1 R192Q mutation as well as wild type mice. Basal
molecular profiles were determined in occipital cortices (the more
susceptible brain region) of mutant and wild type mice. RNA
expression profiles were studied using Illumina mouse-6 Bead Chips
microarrays. Synaptosome proteome profiles of occipital cortices
were obtained by an iTRAQ-based LC-LC MS/MS approach.
Results The CSD induction threshold was lowest in the occipital
cortex, but only in mutant mice. This increased susceptibility to
CSD was not accompanied by profound differences in molecular
profiles of RNA and protein in this brain region between mice of
both genotypes. The proteomic profile did reveal a subtle up-reg-
ulation of certain proteins involved in neurotransmitter-relevant
mechanisms.
Conclusion Our results indicated that the increased susceptibility to
CSD in the occipital cortex of FHM1 mice apparently is not due to
major differences in molecular profiles between mutant and wild type
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mice. Studies are ongoing to investigate whether molecular profiles
are different after CSD.
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Magnesium, L-tryptophan and niacine:
a new therapeutic options in prophylaxis
of pediatric migraine?
V. Pizza1, V. Busillo2, E. Lamaida1, A. Agresta1, P. Lepore1,
D. Cassano1, Neurological Officine Salernitana
1Neurophysiopathology Unit, S. Luca Hospital,
Vallo della Lucania, Italy;
2Neurology Unit, SS Maria Addolorata Hospital, Eboli, Italy
Aim To evaluate the efficacy and tolerability of magnesium, l-tryp-
tophan and niacin in prophylaxis therapy of pediatric migraine.
Methods 35 outpatients, (19 F, 16 M) mean age 8.5 years (SD 2.1),
range 5-14 years, suffering from migraine without aura (ICDH ‘04
criteria) were enrolled. The mean duration of disease was 2.0 (SD 1.1)
years, range 1-6 years. At baseline the mean frequency of attacks was
6.3/month (SD 2.2), range 4-12; the mean number of drugs intaking
for acute attacks was 5.1 tablets/month (SD 2). During the six month
evaluation period magnesium, l-tryptophan and niacine was admin-
istered (starting dose mg/die, target dose 1000 mg/die). All patients
filled a headache-diary card during the evaluation.
Results The basal frequency of attack was 6,3 (SD 2.2) and 3,6 (SD
1.9), 2,6 (SD 1.7), 1,8 (SD 1.9), after 1, 3 and 6 months respectively
[P = 0.003; P \ 0.0001; P \ 0.0001].The basal value of intaking
drugs for acute attacks was 5,1 (SD 2) and 2,9 (SD 1.6), 2 (SD 1.5),
1,2 (SD1.4) after 1, 3 and six months respectively [P = 0.0001;
P \ 0.0001; P \ 0.0001](T-test analysis). magnesium, l-tryptophan
and niacin was well tolerated (8 patients complained somnolence,
asthenia, lack of concentration and gastralgia but none patient with-
drew the study).
Conclusions These data showed a good efficacy in reduction of fre-
quency and intensity of headache attack, a good tolerability and a
very good reduction of drugs intaking for acute attacks. Our study
suggests that magnesium, l-tryptophan and niacin could be an alter-
native therapy for pediatric migraine prophylaxis.
Essential bibliography
1. Bille B et al: Prophylaxis of migraine in children. Headache
1977, 17: 61-3
2. Adelman JU et al: Migraine prevention medication: a rappresail.
Cephalalgia 1998, 18: 605-11
3. Wasiewski WW: Preventive therapy in pediatric migraine.
J Child Neurol 2001, 16, 71-8
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Two cases of cluster-like headache secondary
to surgical intervention
F. Traverso, F. Alberti
Neurologia - Dipartimento Testa-Collo, ASL 1 imperiese,
Sanremo, Italy
We report two cases of cluster-like headache (CLH) related to sur-
gical interventions. Both patients were previously well. They had not
familiar history of headache. The first one, a 31 years old woman, had
a plastic intervention for nose septum deviation followed by left
maxillary sinusitis at 29 years. Fever and face oedema remitted after
antibiotic therapy. Severe left maxillary pain attacks persisted with
increasing frequency. It was accompanied by ipsilateral tearing,
conjunctival injection, and rhinorrea. Physical examination showed
anaesthesia in the left maxillary nerve area. Brain MRI was normal.
All pharmacological therapies were ineffective, but parenteral
sumatriptan. She completely recovered after percutaneous glycerol
trigeminal gangliorhizolysis. The second one was a 44 years old
woman. She had a right maxillary sinusitis after teeth implant at
superior right dental arch, one year before. While fever and purulent
secretions remitted with antibiotics, right maxillary pain did not. It
recurred daily, with conjunctival injection and, many hours length. It
was relieved by triptans. Physical examination showed right maxillary
nerve anesthesia. MRI was unremarkable. To our knowledge, these
are the firsts described CLH secondary to nasal septum surgery as
well as to dental implants. Both surgical interventions were followed
by infections. In a recent literature review (1) of pathologies associ-
ated with CLH, inflammatory infections were 13.5% (n = 20).
Maxillary nerve involvement emphasizes the trigeminal nerve role.
Tearing, conjunctival injection and, rhinorrea show parasympathetic
hyperactivity. Although a CNS (posterior hypothalamus) locus for the
dysfunction is largely accepted, extracerebral activation of the tri-
geminal-autonomic reflex (2) is also possible.
References
1. Mainardi F, Trucco M, Maggioni F,et al. Cluster-like headache.
A comprehensive reappraisal. Cephalalgia. 2009 Sep 7
2. May A, Goadsby PJ, The trigeminovascular system in humans:
pathophysiologic implications for primary headache syndromes
of the neural influences on the cerebral circulation. J Cereb Blood
Flow Metab 1999; 19:115-27
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Prophylaxis therapy of the episodic and chronic cluster
headache with zonisamide: an open study
V. Pizza1, V. Busillo2
1Neurophysiopathology Unit, S. Luca Hospital,
Vallo della Lucania, Italy;
2Neurology Unit, SS Maria Addolorata Hospital, Eboli, Italy
Introduction The prophylactic therapy of the episodic (ECH) and
chronic cluster headache (CCH) is based on verapamil and carboli-
thium. Besides several patients are not responders at this drugs. In
these cases the use of antiepileptic drug has been proposed. Recent
clinical experience indicates a place for zonisamide in the manage-
ment of headache disorders.
Aim To evaluate the efficacy and tolerability of zonisamide in pro-
phylaxis therapy of ECH and CCH.
Methods 17 patients (pz), (3 F,8 M) mean age 43.7 years (SD 5.9),
range 34-56 years, suffering from ECH (11pz) and CCH (6 pz)
(ICDH ‘04 criteria) were studied. In all patients with ECH prophy-
laxis therapy with verapamil, carbolithium and valproic acid was
failed in the past and patients with CCH continued therapy with
carbolithium (2 pz) and verapamil (2 pz). During the three months
evaluation period zonisamide was administered (starting dose 25 mg/
die, target dose 100 mg/die). All patients filled a headache-diary card
during the evaluation.
Results In patients with ECH the basal frequency of attack/days and
1, 2, 3 months respectively was 4.5 (SD 1.8): 2.5 (SD 0.8), 1.5 (SD
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0.8), 0.6 (SD 1) [P \ 0.0001]. In patients with chronic CH the basal
frequency of attack/days and 1, 3, 6 months respectively was 2.6 (SD
1.2), 0.5 (SD 0.3), 0.2 (SD 0.2), 0.1 (SD 0.1) [P \ 0.005] (T-test
analysis). In all patients zonisamide was well tolerated (5 patients
complained somnolence, lack of concentration, vertigo and nausea
but not withdrew the study).
Conclusions These data showed a good efficacy in reduction of
frequency of attacks. Still, the drug is tolerable, in fact none
patients withdrew the study. Our study suggests that zonisamide
could be an alternative or complementary prophylaxis therapy
for ECH and CCH. Controlled studies are warranted to determine
the efficacy of zonisamide in prophylaxis therapy for ECH and
CCH.
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Variants in the human potassium channel gene
(KCNN3) are associated with migraine
in a high risk genetic isolate
L.R. Griffiths1, H. Cox1, R.A. Lea1, C. Bellis2, M. Carless2, T. Dyer2,
J. Blangero2
1Genomics Research Centre, Griffith Health Institute,
Griffith University, Southport, QLD, Australia;
2Department of Genetics, Southwest Foundation for Biomedical
Research, San Antonio, TX, USA
Ion channel genes have been implicated in familial hemiplegic
migraine and may also play a role in the more common types of
migraine. The calcium-activated potassium ion channel gene, KCNN3
is located on chromosome 1q21.3, expressed in the central nervous
system and plays a role in neural excitability. Previous association
studies have provided some evidence for involvement of this gene in
migraine susceptibility. To elucidate KCNN3 involvement in
migraine we performed gene-wide SNP genotyping in a genetic iso-
late from Norfolk Island, a population descended from a small
number of 18th Century Isle of Man ‘Bounty Mutineers’ and Tahitian
founders.
Phenotype information was available for 377 individuals who are
related through the single, well-defined 11-generational Norfolk
pedigree, with 96 (25.5%) affected by International Headache Society
criteria. A total of 85 SNPs spanning the KCNN3 gene were geno-
typed in a sub-sample of 285 related individuals (76 affected), all core
members of the extensive Norfolk Island ‘Bounty Mutineer’ geneal-
ogy. Genotyping was performed using the Illumina BeadArray
platform and analysis performed using the statistical program SOLAR
v4.0.6 assuming an additive model of allelic effect adjusted for the
effects of age and sex. Haplotype analysis was undertaken using the
program HAPLOVIEW v4.0.
A total of 4 intronic SNPs in the KCNN3 gene displayed nominal-
level significant association (P \ 0.05) with migraine. Two SNPs,
rs73532286 and rs6426929, separated by approximately 0.1 kb, dis-
played complete LD (r2 = 1.00, D’ = 1.00, D’ 95% CI = 0.96-1.00).
In all cases the minor allele led to a decrease in migraine risk (Beta
Coefficient = 0.286-0.315), suggesting that common gene variants
confer an increased risk of migraine, possibly related to founder
effect, in the Norfolk pedigree. This study provides evidence for
association of variants in the KCNN3 ion channel gene with migraine
in the Norfolk genetic isolate with the rarer haplotypes conferring a
possible protective role.
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Evidence for a vascular factor in migraine
M.S. Asghar1, A.E. Hansen2,3, F.M. Amin1, P.J.H. de Koning4,
R.J. van der Geest4, H.B.W. Larsson2, J. Olesen1, M. Ashina1
1Danish Headache Center, Department of Neurology,
Glostrup, Denmark;
2Functional Imaging Unit, Glostrup, Denmark;
3Department of Radiology, University of Copenhagen,
Glostrup, Denmark;
4Department of Radiology, Div. Image Processing, Leiden University
Medical Centre (LUMC), Leiden, The Netherlands
Background A vascular hypothesis of vasodilatation and a neuronal
hypothesis have alternately been followed to explain migraine path-
ogenesis. Lately the prevailing theory has been that migraine is
caused by neural dysfunction without involvement of vasodilatation.
Because dismissal of vascular mechanisms seemed premature we
examined diameter of extra- and intracranial vessels in migraine
without aura patients before, during and after treatment of a migraine
attack.
Method A novel high-resolution direct magnetic resonance angiog-
raphy imaging technique was used to measure arterial circumference
of the extra cranial middle meningeal artery (MMA) and the intra-
cranial artery middle cerebral artery (MCA). Data was obtained at
baseline, during migraine attack and after treatment with the migraine
abortive drug sumatriptan (a 5-HT1B/D agonist).
Results We found dilatation of both MMA and MCA during
migraine attack (P = 0.001). Sumatriptan administration caused
amelioration of headache (P \ 0.001) and contraction of MMA
(P \ 0.001) but MCA remained unchanged (P = 0.16). Explorative
analysis revealed that in migraine attacks with half sided headache
there was only dilatation on the headache side of MMA of 12.49%
(CI: 4.16% to 20.83%). and MCA of 12.88% (CI: 3.49% to
22.27%) and no dilatation on the non-headache side of MMA (CI:
-4.27 %to 11.53%) and MCA (CI: -6.7% to 14.28%). While in
double-sided headache we found bilateral vasodilatation of both
MMA and MCA (P \ 0.001).
Conclusion These data show that migraine without aura attacks are
associated with dilatation of extra- and intra cerebral arteries and that
the headache location is associated with the location of the vasodi-
latation. Furthermore, contraction of extra cerebral and not
intracerebral arteries is associated with amelioration of headache.
Collectively these data suggests that vasodilatation and perivascular
release of vasoactive substances is an integral mechanism migraine
pathophysiology.
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Abnormal cortical venous enhancement in RCVS:
a precursor to radiographically significant arterial
vasoconstriction?
B. Vargas1, L. Ruiz-Alvarez2, D.W. Dodick1
1Neurology, Mayo Clinic Arizona, Phoenix, AZ, USA;
2Neurology, Sanitorio de Nuestra Senora del Rosario, Madrid, Spain
Objectives To hypothesize the implications of the novel finding of
abnormal venous enhancement in the contrast-enhanced brain MRI of
a man with reversible cerebral vasoconstriction syndrome (RCVS).
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Background Vasoconstriction in RCVS is postulated to initially
involve distal intracranial arteries with delayed involvement of
proximal vessels which may account for the false negative MRAs
seen early in this syndrome. This case illustrates the first description
of abnormal venous dilation in RCVS preceding marked proximal
arterial vasoconstriction by several days.
Methods A 25-year-old right-handed man with no significant past
medical history presented to the emergency department after a severe
thunderclap headache. Head CT and lumbar puncture were both
normal and he was discharged home. A constant headache persisted
with severe exacerbations upon Valsalva. Two days later, hyperten-
sive and tachycardic, he was admitted for further evaluation. Repeat
head CT was negative and he was eventually discharged with a
diagnosis of muscle tension. He later presented to another emergency
department after a severe exacerbation while having a bowel
movement.
Results Except for a blood pressure of 145/112, the patient’s
physical examination was normal. Post-contrast MRI (now one
week after headache onset) demonstrated prominent venous
enhancement and intracranial MRA showed segmental narrowing
within several arterial distributions. He was treated with verapamil
and discharged the following day with reduced headache. Repeat
imaging nine days later demonstrated unchanged venous enhance-
ment but worsened vasoconstriction on intracranial MRA. Despite
symptomatic improvement, the MRA findings warranted treatment
with parenteral nicardipine.
Conclusions Cortical venous dilation in RCVS has never been
described, may represent compensatory dilation of veins in response
to distal arterial vasoconstriction. It may be an early imaging feature
in RCVS and may precede proximal arterial vasoconstriction. Con-
trast-enhanced MRI should be obtained in patients suspected of
having RCVS. This case also illustrates dissociation between
improving symptoms and worsening MRA findings.
Conflict of interest Dr. Dodick has acted as a consultant, speaker or
received research support from Allergan Pharmaceuticals.
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GC/MS analysis of cerebrospinal fluid of familial
hemiplegic migraine patients and a transgenic FHM
mouse model; report from lumina
R. Zielman1, F. Bakels1, W.P.J. van Oosterhout1, T.H. Reijmers2,
M.M. Koek3, L. Coulier3, A.M.J.M. van den Maagdenberg1,4,
G.M. Terwindt1, M.D. Ferrari1
1Department of Neurology, Leiden University Medical Centre,
Leiden, The Netherlands;
2Netherlands Metabolomics Centre, Leiden University, Leiden,
The Netherlands;
3TNO Quality of Life, Zeist, The Netherlands;
4Department of Human Genetics, Leiden University Medical Centre,
Leiden, The Netherlands
Introduction Familial hemiplegic migraine (FHM) is a rare,
monogenetic, subtype of migraine, characterized by hemiparesis
during the aura phase. It is hypothesized that FHM in humans and
a transgenic migraine mouse model with pathogenic FHM muta-
tions (R192Q CACNA1A) can function as a good monogenetic
model for the common forms of migraine. Using a non-hypothesis
driven, translational approach, the aim of our study was to identify
biochemical markers in cerebral spinal fluid (CSF) and decipher
the neurobiological pathways for triggering and onset of migraine
attacks.
Methods After obtaining informed consent, 4,8 mL CSF was
obtained from 17 FHM patients (M:F, 8:9) and 15 healthy controls
(M:F, 8:7) by lumbar punction. A small amount of CSF (*2 lL) was
sampled via the cisterna magna of 10 wildtype and 10 mutant mice
(R192Q). CSF was sampled and stored at -80 C. Metabolites were
oximated and silylated and subsequently analysed by gas chroma-
tography coupled to mass spectrometry (GC/MS). For statistical
analysis of the metabolite profiles principal component analysis
(PCA) and partial least squares discriminant analysis (PLSDA) was
used.
Results In human CSF 104 and in mice 106 different metabolites
were detected. Separation between FHM patients and controls and
mutant and wildtype mice could be made with PCA and PLSDA.
Corresponding loadings show several, not yet identified, metabo-
lites being important for separation. Approximately 95% of all
metabolites measured in human CSF, were also found in the mouse
CSF profiles.
Conclusions Results indicate that a translational approach in
migraine comparing CSF from migraine patients and mice is feasible.
Distinction could be made between metabolite profiles of FHM
patients and controls, mutant and wildtype mice. Further analysis will
clarify which biomarkers and pathways are implicated in this
difference.
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Plasma levels of nociceptin in medication overuse
headache
T. O¨zbenli, A. Yılmaz
Neurology, Ondokuz Mayıs, Samsun, Turkey
Objective The purpose of the study is to determine the plasma
levels of nociceptin and the cerebral dural vasodilatation in the
paracetamol or paracetamol combined caffeine related medication
overuse headache (MOH) patients in headache and headache-free
periods.
The mechanisms of the MOH is unclear. The transformation of
episodic to chronic headache probably is a result of sensitization in
the trigeminal neurons. Activation of the trigeminovascular system
allows the release of vasoactive peptides such as calcitonine gene-
related peptide (CGRP) and substance P. The major cerebral
arteries and pial arterioles of the cortical surface are invested with
nerve fibers that contain CGRP, substance P and nociceptin.
Nociceptin is a marker of trigeminovascular system with CGRP
and substance P. Behavior of nociceptin variates according to the
pain model.
Methods In the study, we enrolled 30 MOH patients diagnosed
according to the International Headache Society II (IHS-II) revised
criteria and 20 healthy, volunteers. In patients, the level of the
plasma nociceptin is measured in the daily headache period while
analgesic overusing and after two months in headache free period
and the cerebral blood volume is measured in the proximal por-
tion of the middle meningeal artery using perfusion magnetic
resonance imaging. These measurements are made once in the
control group.
Results The patients have significantıy lower plasma nociceptin
levels according to the control group, in both headache and headache-
free periods. Although the cerebral blood volume was higher than
healthy volunteers, it was not statistically significant.
Conclusion These results may be interpreted as the disinhibition
of the trigeminovascular system is related with low nociceptin
levels.
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Outcome of psychological group treatment for chronic
headache patients
B. Vinther, T. Zimmer
Danish Headache Center, Glostrup University Hospital, Glostrup,
Denmark
Background Psychological factors may contribute to the sustaining
or worsening for some patients suffering from chronic headache,
making psychological treatment relevant.
Aim Evaluation of outcome of psychological group-treatment
focusing on stress- and pain management in a specialized headache
center.
Material and methods Weekly psychoeducational group sessions
within a cognitive framework including intensive relaxation training
over a 9-weeks period, with 6-9 patients, Psychological treatment was
given in addition to other multidisciplinary interventions.
A self reporting questionnaire was distributed at the last session, with
evaluation of the effect on headache, general well-being, work
capability and overall importance of the treatment.
Results 150 patients completed the treatment with an average atten-
dance of 7,3 out of 9 sessions, and 125 completed the questionnaire.
Hereof, 61% of the patients reported a positive effect on the headache.
13% reported great effect on intensity, frequency or length of attack,
whereas 53% reported some effect on either of the same variables. On
average, patients ascribed 58% of the change to the effect of the
psychological treatment.
Regarding change of general wellbeing (n = 122) 9% reported great
effect, 62% good effect, 27% some effect and 2 % no change.
Regarding change in work capability (n = 118) 3% reported great
effect, 36% good effect, 50% some effect, 10 % no change and 1
patient a negative effect.
Considering the overall importance of the treatment (n = 117) the
average evaluation on a scale from 0-10 (0 = least important,
10 = most important), the average evaluation was scored at 8,1
(range 3-10).
Conclusion Overall our findings indicate that psychological treatment
has a positive effect on headache, general wellbeing as well as work
capability. The effect on headache is present, but the effect on general
wellbeing and work capability is notably larger. Controlled studies are
needed to confirm our findings and monitor the long-term effect.
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Natriuretic propeptides in idiopathic intracranial
hypertension
R. Jensen1, M. Skau1, J.P. Goetsche2, J. Rehfeld2
1Danish Headache Centre, Department of Neurology, University
of Copenhagen, Glostrup Hospital, Glostrup, Denmark;
2Department of Clinical Biochemistry, University of Copenhagen,
Rigshospitalet, Copenhagen, Denmark
Idiopathic intracranial hypertension (IIH) is characterized by severe
headache and pulsatile tinnitus as a consequence of increased intra-
cranial pressure (ICP) in the absence of an identifiable neurological
pathology and associated to increased risk of permanent visual
defects. IIH is linked to obesity and may be more rapidly reversed if
weight-loss is achieved. A disturbed ICP autoregulation in IIH is
likely, but pathophysiological mechanisms of IIH are still
unknown. Natriuretic peptides may be involved in intracranial
pressure regulation, but cerebrospinal fluid (CNS) and plasma
concentrations in this disorder are unknown. We evaluated venous
and intrathecal concentrations of ANP, BNP and CNP precursor
peptides in 40 patients with idiopathic intracranial hypertension and in
20 controls. Natriuretic propeptides were quantitated using processing-
independent assays. In CSF, no differences in peptide concentrations
between patients and controls were found (proANP: 239 ± 23 vs
231 ± 22 pmol/L, proBNP: \ 2 pmol/L in all, proCNP: 1079 ± 318
vs 1138 ± 323 pmol/L). In plasma, proCNP was lower in IIH com-
pared with controls (35.3 ± 4.8 pmol/L vs 43.8 ± 5.9 pmol/L,
p \ 0.0001). Moreover, plasma proBNP was significantly lower in
patients compared with controls (47.1 ± 21.4 pmol/L vs
59.2 ± 22.0 pmol/L, p = 0.045). There were no associations between
peptide concentrations and ICP and BMI, respectively. Plasma proANP
and proCNP increased during 3 months follow-up (p = 0.01 and
p = 0.006), n = 12. We suggest that decreased plasma proCNP con-
centration in idiopathic intracranial hypertension may reflect
endothelial dysregulation of vascular tone and may be a marker in this
disease. Further studies of proCNP and endothelial function are needed
to establish such role.
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Disease activity in idiopathic intracranial hypertension:
a 3-month follow-up study
R. Jensen, M. Skau
Danish Headache Centre, Department of Neurology,
University of Copenhagen, Glostrup Hospital, Glostrup, Denmark
Background Idiopathic intracranial hypertension (IIH) is a disorder
of raised intracranial pressure (ICP) characterized by severe head-
ache, visual disturbances and pulsatile tinnitus.
Aim To evaluate the initial 3-month course of conservatively
treated IIH using frequent optical coherence tomography (OCT)
evaluations, visual field testings and lumbar opening pressure
measurements.
Methods A longitudinal study of 17 patients with newly diag-
nosed IIH. Peripapillary retinal nerve fiber layer thickness
(RNFLT) and retinal thickness (RT) measurements (Stratus OCT-
3, fast RNFL 3.4 protocol), and Humphrey visual field testing
were evaluated at regular intervals in a 3-month period starting
from diagnosis. Repeat lumbar puncture was performed at final
visit (n = 13).
Results Total average RNFLT and RT decreased significantly during
the follow-up period (p \ 0.0001 and p \ 0.0001, respectively).
Changes in RNFLT and RT correlated with improvements in visual
field mean deviation (MD) (RNFLT: r = -0.77, p = 0.006; RT:
r = -0.63, p = 0.03) and pattern standard deviation (PSD) (RNFLT:
r = 0.83 p = 0.002; RT: r = 0.77, p = 0.003). In patients with weight-
loss [ 3.5% of BMI, ICP decreased significantly (p = 0.0003). In
patients with weight-loss \ 3.5% of BMI, changes in ICP were insig-
nificant (p = 0.6).
Conclusions OCT combined with visual field testing may be a
valuable atraumatic tool to monitor IIH in patients with papilledema.
Weight-loss may be the main predictor of a favorable outcome with
respect to CSF pressure.
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Is a multidisciplinary treatment programme
cost-effective in medication overuse headache?
A register based follow-up study
A. Shah, L. Bendtsen, R. Jensen
Danish Headache Centre, Department of Neurology,
University of Copenhagen, Glostrup Hospital, Glostrup, Denmark
Medication Overuse Headache (MOH) is a chronic secondary head-
ache disorder caused by overuse of acute headache medication,
defined as intake of weak analgesics C 15 days/month or of specific
anti-migraine drugs (triptans) or combined analgesics C 10 days/
month. Discontinuation of medication overuse is very rewarding and
lead to more than 50% decrease in headache frequency, but the
relapse rate may exceed 30%. The cost-effectiveness of treatment has
never been documented.
Aim To analyse the direct cost of medication in patients with MOH
before and after treatment from the Danish Headache Centre (DHC).
A register based follow-up study on 336 MOH patients treated and
discharged from DHC over a 2 year period. By means of the com-
prehensive Danish Register of Medicinal Product Statistics the total
use and costs of prescription-only medication one year before and one
year after the treatment was calculated.
Results Mean age was 46.7 years and male/female ratio 1:2.5.
Overall, the total annual costs decreased with 24% (P = 0.003) and
the medication use with 15%, (P = 0.14) after the treatment. For
patients overusing triptans, the annual costs decreased with 43%
(P \ 0.001) and the use with 38% (P \ 0.001). For patients overusing
opioids the annual medication costs and use decreased with 4% and
16% resp.(NS). The annual use of prophylactics increased with 40%
(P = 0.002) and the costs with 51% (P = 0.028).
Discussion Overall our findings indicate for the first time that the
treatment of MOH is very cost-effective and that detoxification in a
tertiary headache centre as DHC has a lasting effect on the medi-
cation use and costs, and thus indirectly on the burden of MOH. In
particular a marked effect on the use and costs among triptan
overuse was identified. As expected the use of prophylactics
increased, which further supplemented the positive effects of
detoxification.
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Fibromyalgia -headache and heat-disorders associated
cephalalgias : neurologic clinics and medical issues
S.G. Echebarria Mendieta
Neurology Area, Basque Health Service, Osakidetza, H. San Eloy
(Barakaldo-Bizkaia) District Clinics, Las Arenas, Getxo, Spain
Introduction Considerations should be pinpointed around diagnostic
clusters considering headache and general pain-myofascial disorders
.Thus, it has been described an overlap between fibromyalgia, chronic
fatigue syndromes, temporo-mandibular dysfunction and tension-type
headache.Moreover, descriptive series describe the TMD pain in
adolescence such as predisposing condition to general myalgic
conditions.
Post Heat-Stroke (HS) pictures have been described (in classic and
exertional types) resembling new daily persistent headache, added to
water-deprivation headache and bath-related headache.
Methods Descriptive superposition-area boundaries in TTH and
myalgic TMD .Linear correlation between area and distributive
position in pain-drawings and active trigger-points.
Case-comparatives with heat-disorders associated cephalalgias, con-
sidering previous hypertonic saline injection model (masseter or
splenius distribution).
Results ORs of prevalence between TTH and TTD and splenious
pattern and scalp pattern, show a coefficient of 0.74.
Linear rank correlation between frontal pattern in Heat-headache and
frontal distribution in TMD is r = 0.70.
Conclusions Significant correlations may be obtained between scalp
distribution in TTH and TTD with, on the other hand, hypertonic saline
injection in splenius distribution, with OR of prevalence = 0.74.
Moreover, distributional areas of heat-related disorders cephalalgia
may be related to frontal appearances of TMD (r = 0.74) (p \ 0.05).
Such explanation may be obtained by release of substances in trigger-
points (tumor necrosis factor alpha), such as new daily persistent
headache (NDPH) and, acting as ethiological mechanism, heat stroke
(HS).
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Cognitive factors of illness perception and affective
factors of anger expression in migraine and tension type
headache
A. Giazkoulidou1, E.V. Dermitzakis2, A.C. Malegiannaki1,
A. Meimaridou1, I. Tsiptsios2
11st Psychiatric Clinic of Aristotle University Thessaloniki,
Thessaloniki, Greece;
2Department of Neurology, Papageorgiou General Hospital,
Thessalonı´ki, Greece
The role of emotional factors such as anger and anxiety has been
widely investigated in individuals suffering from headaches. How-
ever, it is not clear to what extent these variables are associated with
cognitive factors concerning the perception of illness. Therefore, the
objective of the present study was to explore the relationship between
affective parameters such as anger, and cognitive parameters such as
illness representation and their manifestations in migraine and tension
type headache. Our sample consisted of 60 outpatients (migraine
n = 38, tension type n = 22) from Papageorgiou General Hospital of
Thessaloniki with mean age 44 years. To assess anger expression
(externalization, internalization, control) we used the 24-item State-
Trait Anger Expression Inventory. The Brief Illness Perception
Questionnaire a nine-item scale designed to rapidly assess the cog-
nitive and emotional representations of illness, and the McGill Pain
Questionnaire designed to describe pain symptoms, served as mea-
sures of cognitive illness representations. Results concerning the
cognitive parameter showed that patients with migraine differed from
patients with tension type headache in (a) making more emotional
representations regarding both concern and emotions about their
headache, and (b) using significantly more often words like ‘‘con-
tracting’’, ‘‘vomit inducing’’, ‘‘of increasing intensity’’ to describe
their headache. No significant difference was found concerning the
affective parameter between the two diagnoses of headache. Women
and men of our sample differed in that the later reported better control
of anger. Finally, the only significant correlation observed was
between anger externalization and emotional representation of illness.
Those findings suggest that cognitive parameters of illness perception
and pain description would be useful in discriminating patients with
migraine from tension type patients and in ‘‘cognitively’’ treating
their perception of pain.
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Influence of etiological factors on clinical
transformation of migraine in Aral sea region
of the Republic of Uzbekistan
G. Izyumova1, D. Izyumov2
1Neurology, Republican Scientific Center of the Emergency
Medical Aid, Urganch, Uzbekistan;
2Tashkent State Medical Academy, Tashkent, Uzbekistan
Total combination of adverse factors promote development of
migraine which is marked not only by considerable clinical poly-
morphism, but also propensity to transformation.
Aim To study influence of etiological factors on clinical transfor-
mation of migraine in Aral Sea region.
Methods 639 women and 101 men out of 740 patients are observed.
All participants of the research were representatives of a local
nationality (Uzbek).
Results Out of the total number of patients addressed for medical aid
170 (23 %) patients had common migraine, 203 (27,4 %) had oph-
thalmic and 367 (49,6 %) patients had associated one. In 96 (12,8 %)
cases were observed loss of consciousness, in 76 (79,2 %) patients -
faints, in 20 (20,8 %)-epileptic attacks. 48 (6,5 %) patients experi-
enced transition of common migraine to ophthalmic; 78 (9,8 %)
- transition of common migraine to associated; 27 (3,6 %) - transition
of ophthalmic migraine to associated. 143 (19,3%) patients are
manifested with sharp increase of attacks with joining of thrilling and
tachycardia. Terms of occurrence of these changes from the beginning
of the disease were various from 3-4 to 10-15 years. The major fac-
tors defining transformation of migraine with joining of other
vegetodistonic and astenoneurotic manifestations consists of chronic
mental trauma, intellectual overstraining, the meteorological factors
which have changed sharply continental climate in Aral Sea region in
connection with drying of Aral Sea. On this account migraines attacks
became extremely intense, proceeding in the form of typical simpa-
tico adrenalic crises.
Conclusions Migraine is a disease prone to rather considerable
transformations depending on various factors, including meteorolog-
ical. Developed critical ecologically adverse conditions in Aral Sea
region and worsening indicators of health of the population, high
death rate from cerebrovascular diseases demand urgent modern
complex preventive action.
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General practitioners with migraine: perceptions,
treatment and impact of migraine headaches
A. Ducros1, S. Romatet2, T. Saint Marc3, B. Allaf4
1Hoˆpital Lariboisie`re, Paris, France;
2Hoˆpital de Poissy-St Germain, St Germain En-Laye, France;
3General Practice, St Germain-En-Laye, France;
4Almirall SAS (at the Time of the Study), Paris, France
Personal experience of migraine may influence prescribing practices
of physicians treating patients with migraine. Little data is available
on perceptions of migraine by GPs.
An observational, cross-sectional, pharmacoepidemiological survey
was conducted in primary care in France to assess headache treat-
ments and impact of migraine on daily activities in two groups: GPs
who suffered from migraine themselves (GP-M; N = 277) and GPs
having a close family member with migraine (GP-CFM; N = 641).
Most GPs completed one of two questionnaires, and GPs belonging to
both groups (N = 85) could complete both. Data were collected on
headache treatments used (GP-M) or prescribed (GP-CFM), and on
self reported (GP-M) or described (GP-CFM) migraine features and
impact on daily activities.
The most frequently reported acute headache treatments in both
groups were triptans and non-steroidal anti-inflammatory drugs
([ 75% of GPs); [ 81% of GPs in both groups were satisfied with
acute headache treatments. Only 6.9% of the GP-M group used and
17.2% of the GP-CFM group prescribed a prophylactic treatment,
which was considered satisfactory by 46.2% and 56.1% respec-
tively. In the preceding 3 months, 79.4% of the GP-M group
reported handicap in daily activities due to migraine, 23.6%
interruption of extraprofessional activities and 7.6% interruption of
work. In the GP-CFM group, 32.6% described interruption of ex-
traprofessional activities and 57.3% interference with daily
activities or work.
In conclusion, acute headache treatment prescribed by French GPs for
their own migraines or those of their relatives respect practice
guidelines and is considered as effective and satisfactory. Use of
prophylactic medication is low and its effectiveness perceived as
limited. Better use of prophylactic treatments may attenuate the
impact of migraine on daily activities.
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Acetylsalicylic acid inhibits purinergic facilitation
of neck muscle nociception in mice - implications
for acute treatment of tension-type headache
D. Ristic, J. Ellrich
Medical Physiology and Experimental Pharmacology Group,
Department of Health Science and Technology, Medical Faculty,
Aalborg University, Aalborg, Denmark
Infusion of a,b-meATP (ATP) into semispinal neck muscles
induces facilitation of brainstem nociception in anesthetized mice.
This animal experimental model is suggested to be appropriate for
investigating pathophysiological mechanisms in tension-type head-
ache (TTH). Reversal of ATP-induced facilitation of neck muscle
nociception by acetylsalicylic acid (ASA) was hypothesized.
Experiments were conducted in anesthetized C57BL/6 mice (n = 42,
male, 23 to 33 g). Noxious input from semispinal neck muscles was
evoked by intramuscular administration of 100 nM ATP (20 ll).
Brainstem nociception was monitored by the jaw-opening reflex
(JOR) elicited via electrical tongue stimulation. Two different
experiments were performed. One hour after ATP infusion and
established reflex facilitation, different dosages of ASA (15, 30,
60 mg/kg) or saline were intraperitoneally (i.p.) administered in 7
mice each. JOR monitoring continued for 90 min. In the second
experiment, either 60 mg/kg ASA or saline was injected one hour
prior to ATP infusion. JOR monitoring continued for 90 min.
With subsequent ASA, ATP-induced reflex facilitation decreased
dose-dependently (2-way ANOVA, interaction of drug 9 time
p \ 0.001). With 60 mg/kg ASA, facilitation completely reversed
back to baseline within 30 min. Within 90 min after i.p. injection,
saline group significantly differed from all ASA dosages. Preceding
administration of 60 mg/kg ASA prevented ATP-induced facilitation
as compared to control experiments (2-way ANOVA, interaction of
drug 9 time p \ 0.05).
Subsequent and preceding i.p. administration of ASA reverses
and prevents increased neuronal excitability in the brainstem.
J Headache Pain (2010) 11 (Suppl 1):S1–S150 S73
123
Cyclooxygenases are involved in nociceptive transmission. These
enzymes are inhibited by ASA. Unspecific inhibition of cyclooxy-
genases by indometacin fails to prevent purinergic facilitation in this
model suggesting a specific mode of action of ASA.
Due to known involvement of neck muscle nociception in TTH
pathophysiology the objective proof of ASA effects in the experi-
mental model may emphasize its major role in pharmacological
treatment of TTH attacks.
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The effect of riboflavin and vitamin-E on brain total
calcium and calcium-atpase levels in rats with glyceryl
trinitrate-induced headache
A. Butun1, S. Demirci1, M. Naziroglu2, C. Uguz2
1Neurology, Su¨leyman Demirel University, Isparta, Turkey;
2Biophysics, Su¨leyman Demirel University, Isparta, Turkey
Objective The prophylactic treatment of migraine remains chal-
lenging. Riboflavine is shown to be effective in migraine treatment. In
this study we aimed to investigate the effect of riboflavine and vita-
minE on total brain calcium and calcium-ATPase levels.
Methods Sixty rats were administered into 4 groups: Grup I: sham
control (saline), Group II: glyceryl trinitrate (GTN) administered,
Group III:GTN and riboflavine (RBF); and Group IV: GTN, ribofla-
vin and vitamin-E group (RBF + E). Group I and II were given no
drugs. Group III was given riboflavin 100 mg/kg/d p.o and Group IV
riboflavin 100 mg/kg/d p.o. and 100 mg/kg i.p on alternate days for a
ten day course. Twenty-four hours after the last drug treatment, group
I infused with saline and the remaining groups with GTN 10 mg/kg
i.p. for 3 hours. After slowing of movements and reaction to tail test
was observed, rats were decapitated under ketamin HCl (50 mg/kg)
and xylacine (5 mg/kg) i.p. anesthesia. Calcium and Ca2+-ATP-
ase(PMCA) activity was measured spectrophotometrically in isolated
microsomes.
Results Total brain calcium level was significantly lower in GTN
administered group (3.73 ± 0.14 mg/kg) compared to the control group
(5.99 ± 0.24 mg/kg) (p = 0,002). Total brain calcium levels were sig-
nificantly higher in RBF (4.09 ± 0.14 mg/kg) and RBF + E
(6.66 ± 0.19 mg/kg) groups compared to GTN group (for both
p = 0.002). Comparison of PMCA activity yielded a significantly lower
level in GTN group (0.06 ± 0.01 IU/gr) than controls (0.14 ± 0.01 IU/
gr) (p = 0.001). In RBF (0.09 ± 0.01 IU/gr) and RBF + E
(0.12 ± 0.01 IU/gr) groups PMCA activity was higher than it was in
GTN group, though was still lower than in control group (p = 0.001).
Conclusion It has been shown previously that during cortical
spreading depression a derangement in calcium homeostasis takes
place. Our results suggest that riboflavin and vitamin-E improves
deranged calcium homeostasis in glyceryl trinitrate administered rats.
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Patients with thunderclap headache and no signs
of subarachnoidal haemorrhage: examination
of persistent neurological deficits
A. Salih, A.-M. Landblom, A.A. Abdullah, W. Doerfler
Neurology, Linko¨pings University, Linko¨ping, Sweden
Background Thunderclap headache is common and is sometimes a
symptom of subarachnoidal haemorrhage. Benign cryptogenic thun-
derclap headache is however frequent and the causes are unknown. In
our clinics we have encountered several patients with benign thun-
derclap headache who suffer from neurological deficit afterwards.
These have been followed, see below.
Method Seven patients were found. They were initially investigated
according to the clinical routine with an acute CT head and a lumbar
puncture (cell count, absorbance) some patients were also later
investigated with an MRI of the brain.
Results The patients had an initial investigation and clinical inves-
tigation that excluded subarachnoidal haemorrhage, and they were
then followed up at our out patients clinic. All patients except two had
a lumbar puncture. Neuroradiological investigations were completely
negative (four patients have done MRI brain).
In neurological examination there were remaining neurological defi-
cits in the form of for example speech difficulties, sensory and motor
abnormalities, ataxia, and other neurological symptoms. Of interest is
that: 4 / 7 (57% of our patients) have migraine, compared with the
percent of migraine in the general population in Sweden where the
incidence is approximately 20%, 5 / 7 patients had right-sided neu-
rological defect (71%). Moreover, two pat had possible epileptic
symptoms.
Discussion The mechanism behind benign thunderclap headache is
unclear. It is a common condition and patients often come to the
emergency department. Previously such deficits that remains after
benign thunderclap headache has not been studied carefully. We are
interested with the association between thunderclap headache and
migraine. A possible relationship to cerebrovascular constrictions
syndrome is also important to be discussed.
We want to continue to investigate the reason behind the benign
thunderclap headache, and why a small group of patients suffer from
neurological sequelae despite negative investigation.
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Illicit drug use in males with cluster headache
compared with that in the general population:
a cross sectional survey
P. Rossi1, M. Allena2, G. Sances2, C. Tassorelli2, G. Nappi2
1Headache Centre, INI Grottaferrata, Grottaferrata, Italy;
2Headache Science Centre, IRCCS ‘‘National Neurological Institute
C. Mondino’’ Foundation and University Consortium for Headache
and Adaptive Disorders (UCADH), University of Pavia, Pavia, Italy
The aim of this study was to examine the rate of illicit drug use in a
clinic sample of CH male patients, compared with that in the general
population and in a sample of headache patients in the same period.
Methods. One-hundred and sixty-two CH patients (85.8 % episodic
form, 14.2% chronic form) attending two headache clinics were asked
to fill in a questionnaire designed to gather information about the
lifetime use (once or more in their life, LTU), the recent use (once or
more in the last year, RU), the current use (once or more in the last
30 days, CU) of cannabis, cocaine, opioids, hallucinogen, amphet-
amine, ecstasy. In addition, for each drug, information was obtained
about the age of first use, the frequency of use in the last 30 days and
the frequency of use lifetime. The control groups were represented by
a population of 170 headache patients matched for socio-demographic
variables and with the Italian general population (drugs use,
IPSADItalia2007-2008).Results. In the age group 25-34 years, LTU
of amphetamines and ecstasy and CU of cannabis was significantly
higher in CH patients than in control groups. In the age group
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35-44 years LTU of cannabis, opioids, cocaine, amphetamine and
ecstasy, RU and CU of cannabis and cocaine was significantly higher
in CH than in control groups. In the age group 45-54 years LTU use
of cocaine was significantly higher in CH patients than in headache
patients and general population. Age of first use of cannabis, cocaine
and opioids was significantly lower in CH than in control groups.
Current intensive users of cannabis were more prevalent in CH than in
control groups. CH.Conclusion. Our study indicate that CH patients
are prone to overindulge in addictive behaviour, probably for a
common biological susceptibility that predispose to CH and
addiction.
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Does the presence of cutaneous allodynia in Hemicrania
continua predict a favorable treatment response
to indomethacin?
A. Lettich, S.Y. Markowitz, M.S. Robbins, U. Napchan,
B.M. Grosberg, D.C. Buse, R.B. Lipton
Neurology, Montefiore Headache Center, Albert Einstein College
of Medicine, Bronx, NY, USA
Objective To test the following hypotheses
(1) Patients with hemicrania continua (HC) may experience cuta-
neous allodynia (CA)
(2) Patients with HC and CA are more likely to respond to
indomethacin.
Background CA is best described in primary headache disorders
including chronic migraine (CM); anecdotal reports suggest that CA
may occur in HC. Indomethacin response as it pertains to the
presence of CA in HC may help elucidate the etiology and patho-
genesis of HC.
Design and methods A chart review of patients seen at the Monte-
fiore Headache Center from 6/2008 to 1/2010 was conducted. Eligible
patients had a putative diagnosis of HC, an indomethacin trial and
received the validated Allodynia Symptom Checklist.
Results Of 18 patients, 12 (66.7%) had CA, classified in 3 as mild
(25%), in 4 (33%) as moderate and in 5 (41.7%) as severe. Of the 6
patients with no CA, 4 (66.7%) responded to indomethacin, 1 (16.7%)
had an indeterminate response and 1 (16.7%) had no response. Of the
3 patients with mild CA, 2 (66.7%) responded to indomethacin and 1
(33.3%) had no response. Of the 4 patients with moderate CA, 3
(75%) responded to indomethacin and 1 (25%) had an indeterminate
response. Of the 5 patients with severe CA, 3 (60%) responded to
indomethacin, 1 had an indeterminate response and 1 had no
response. Of the patients with moderate to severe CA, 88.9% (8/9)
had at least two of nausea/vomiting, photophobia and phonophobia;
whereas, among the patients with no CA, 33% (2/6) had at least two
of nausea/vomiting, photophobia and phonophobia. The indomethacin
non-responder with severe CA had nausea/vomiting, photophobia and
phonophobia.
Conclusions CA is common in patients with putative hemicrania
continua, including those who respond to indomethacin. The patient
with severe CA, prominent migraine features and no response to
indomethacin may have chronic migraine.
Conflict of interest Dr. Buse has acted as a consultant or received
research support from Allergan Pharmaceuticals, MAP Pharmaceu-
ticals, Merck Inc., and Iroko Pharmaceuticals.
Dr. Grosberg serves on a scientific advisory board for Kowa Phar-
maceuticals American Inc. and Merz Pharmaceuticals; has received
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Merck and Nautilus Pharmaceuticals; and received institutional
research support from Allergan Inc., Merck, GlaxoSmithKline, Endo
Pharmaceuticals, Boston Scientific, Neuralieve Inc., Advanced Bio-
nics, ProEthics, Minster Pharmaceuticals, and Capnia.
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and the Migraine Research Fund; serves on the editorial boards of
Neurology and Cephalalgia and as senior advisor to Headache, has
reviewed for the NIA and NINDS, holds stock options in Neuralieve
Inc. and Minster Inc; serves as consultant or has received honoraria
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An audit in to the efficacy and tolerability of flunarizine
in the treatment of childhood migraine
P. Prabhakar1, B.P. Mohammed2, P.J. Goadsby3
1Neurology, Great Ormond Street Hospital, London, UK;
2Paediatrics, Royal London Hospital, London, UK;
3Neurology, University of California, San Francisco,
San Francisco, CA, USA
Background Flunarizine is unlicensed in the UK. It is prescribed on a
named basis in our headache clinic for children with migraine.
Methods Retrospective analysis of clinical records of all patients
treated with flunarizine in a tertiary paediatric neurology unit between
1998 and 2010.
Results 102 patients were identified, 30 were excluded - outcome data
not available (13), non-migraineurs (9), No records (4), inadequate
duration of treatment (4). Of the 72 patients in the final cohort, 44 had
migraine without aura, 16 migraine with aura and childhood migraine
equivalents, 7 sporadic hemiplegic migraine and 5 familial hemiple-
gic migraine.Mean age of the cohort was 12 years (Range: 1.5 to
17 years) and the mean duration of migraine prior to starting flu-
narizine was 61 months. Usual starting dose was 5 mg and escalated
in 43 patients up to 15 mg per day. Average treatment duration was
14 months.Effective treatment was defined as a reduction in the fre-
quency of individual attacks by at least 50% and this was observed in
55.5% (40/72). There was \ 50% reduction in 6 patients, while there
was no change in 25 patients and worsening in 1 patient. On sub-
group analysis, the reduction in frequency was highest among
hemiplegic migraineurs ([ 50%10/12, [ 30%2/12). Flunarizine was
discontinued in 16 patients (22%) after an average trial period of
9.5 months (range 3 to 24 months). In 5 patients (6.9%), flunarizine
was withdrawn on remission of the attacks. Average duration of
flunarizine use in this group was 14.6 months (Range 6 to
21 months). Adverse effects were noted in 15 (20.8%) patients:
Depression (6), weight gain/increased appetite (5), tiredness/sedation
(3), worsening headache (2). This led to discontinuation of the drug in
13 patients (18%).
Conclusion Flunarizine appears to be more effective in the hemi-
plegic migraine group.
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Greater occipital nerve injection (GONI) for chronic
headache in children
E. Renaudon-Smith1, C. Toolis2, P.J. Goadsby3, P. Prabhakar2
1University College London Medical School, London, UK;
2Neurology, Great Ormond Street Hospital, London, UK;
3Neurology, University of California, San Francisco,
San Francisco, CA, USA
Background It has become increasingly clear that greater occipital
nerve injection (GONI) is effective in treating several primary
headache disorders including migraine and cluster headache. Its use in
children is not well documented.
Aim GONI has been offered at the Childrens headache clinic at Great
Ormond Street since 2008. We set out to analyse its efficacy and side
effect profile in our practice.
Methods Children with chronic, medication refractory migraine were
consented and underwent GONI at GOSH between October 2008 and
April 2010. Feedback forms and clinic notes were used to obtain
outcome data.
Results A total of 17 patients - 5 Male and 12 Female(2008-1, 2009-
10, 2010-6), age range 14 to 18 years had 23 injections. The average
duration of migraine in this cohort was 7 years. The number of adequate
therapeutic trials with migraine prophylaxis varied from 4 to 10. All
patients and careers were consented for the procedures. One patient had 4
and 3 patients had 2 injections.The authors PP (18) and PJG (5) undertook
the procedure. A combination of Methylprednisolone and Lidocaine was
injected as infiltration around the Greater Occipital Nerve on the most
tender site, identified by palpation. The procedure was tolerated well in
all. The left was injected in 15 and the right in 7.
Outcome Complete resolution of headache at 2 weeks which sus-
tained up to 12 weeks in 16/23, partial response 2/23 and no response
5/23. 5 patients reported local soreness and tenderness (3 days to
1 week). Out of which 3 went on to have a second injection. 1 patient
felt dizzy and unsteady which resolved. 3 patients reported increased
headache up to 4 weeks. None had alopecia.
Conclusion GONI is a safe procedure which appears to be effective in
this cohort of children with chronic migraine.
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Headache as the only neurological sign of cerebral
venous thrombosis: a series of 11 cases
R. Kallel, M. Dammak, E. Chtourou, A. Boukhriss, M.I. Miladi,
I. Feki, C. Mhiri
Neurological Department of Habib Bourguiba Hospital, Sfax, Tunisia
Background Headache is the most frequent symptom in cerebral
venous thrombosis (CVT), and usually the first. However, it has rarely
been reported as the only symptom of CVT.
Objectives To study the characteristics of patients in whom headache
was the only presentation of CVT in the absence of intracranial
hypertension, subarachnoid hemorrhage or meningitis.
Methods From a prospective study of 73 consecutive patients with
CVT, only 11 patients with isolated headache were included in the
present study. Among whom, we identified 9 adults and 2 children.
All patients underwent an extensive systematic etiological work-up
and were given intravenous heparin followed by oral anticoagulants
with the exception of two patients.
Results Headache was the only sign of CVT in 11 patients. The mean
age was 33 years (13 to 51 years) and the female/male sex ratio was
1.2. Onset of headache was progressive in 7, acute in 2, and thun-
derclap in 2 patients. The location of headache was reported as
localized (frontal, occipital, and neck) in 3 cases (27%), usually
ipsilateral to the occluded lateral sinus and diffuse (whole head) in 8
cases (73%). Nine (82%) patients have abnormal findings on neuro-
logical examination including papilledema 8 (72%) patients, and
focal neurological deficit 2 (18%) patients. The lateral sinus was the
most frequently involved sinus (n = 7). Numerous causes or predis-
posing factors were identified: infectious causes in 36% and non
infectious causes in 27%. Cause was unknown in 36 % of cases.
Treatment consisted of anticoagulation in all but two patients. All had
a favorable evolution.
Conclusion Headache is the most frequent symptom of cerebral
venous thrombosis. They don’t have particular characteristics and can
mimic other numerous varieties of headache. They are sometimes
isolated, so radiological investigations are justified in all recent and
unusual headaches.
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Automatic thoughts in different headache groups
L. I˙nan1, S. U¨c¸ler1, O. Coskun1, U. Meric¸li2
1Ankara Research and Training Hospital Neurology, Ankara, Turkey;
2Psychiatry, Ankara Oncology Research and Training Hospital,
Ankara, Turkey
Cognitive processing may have a role in the etiology of headache. As a
result, cognitive behavioral therapy may be helpful in the treatment. So
we decided to search cognitive processing in different types of headache
and control group. Automatic thoughts may give ideas about cognitive
processing. So, automatic thoughts scale and Beck depression scale were
given to migraine, tension type headache, medication overuse headache
and control group. The diagnosis of headache type were given according
to IHS-2004 classification. The study were conducted in Ankara
Research and Training Hospital Headache Unit. Twenty migraine
without aura, 20 tension type headache, 19 medication overused head-
ache patients and 20 controls were given these scales. There were no
significant difference in terms of age and gender among all patient groups
and controls. There was no significant difference in automatic thoughts
scale in patient’s groups compared to the controls (p[ 0.05). Beck
depression scale was significantly higher in patients with tension type
headache compared to the controls (p\ 0.05). According to the results,
tension type group were different than control group in terms of beck
depression scale but not in automatic thoughts scale. This significant
difference may not be related with cognitive processing pathology in
tension type headache or automatic thoughts scale may not be useful in
evaluating patients with headache.
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Acute cervical headache by puncturing regular
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M. Cesar-Komar1, Z. Turk2
1Department of Anaesthesiology and Intensive Care Medicine,
General Hospital Slovenj Gradec, Slovenj Gradec, Slovenia;
2Institute for Physical Medicine and Rehabilitation, University
Clinical Centre Maribor, Maribor, Slovenia
S76 J Headache Pain (2010) 11 (Suppl 1):S1–S150
123
Aims Acute cervical headache because of the sprain of the cervical
spine is commonly seen in pain clinic. The authors of this paper has
treated patients, a total 60, of acute cervical headache with regular
acupuncture points. The points were mainly from Urinary Bladder,
Du, Large intestine, Spleen, Sanjinjao, Hart meridian, and in the other
group, added points from the extra meridians. Satisfactory results
were achieved in both groups.
Methods The patients were randomly devided in two groups;
(A) 30 patients using regular points
(B) 30 patients using regular and extra points.
Patients were treated ten times with acupuncture method .
Results
(A) 15 were completely cured (50 %); 8 good improved (26,7 %); 6
improved (20,0 %) and only in 1 case there was no effect (3,3
%).
(B) 19 cases completely cured (63,3 %); 8 good improved (26,7 %);
2 improved (6,7 %) and 1 (3,3) no effect.
The male number complaining acute cervical headache is larger that
of female (72 %). The better effect in male is higher than that in
female (81,1 %, 73 %). The age of patients was 18-60 years. The
duration of acute cervical headache was between 1-20 days. The
history of cervical cephalea was 6 months till 2 years. The complete
cure in the group A covered 50 %, in the group B was 63,3 %. The
group B produces a better therapeutic effect. The effect was better if
the cervical headache occurred with the sprain on one side of the
cervical spine (72 %), in the contrast to having sprain on both sides
(60%).
Conclusion Combination of distal and local regular points was used
for easing tendons and muscles, for activating blood circulation and
ceasing pain. The better effect is using regular and extra points
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Utility of LevadexTM in situations where early
intervention paradigm is impractical
S. Kori1, S. Tepper2, P. Goadsby3, P. Winner4, M. Wang5,
S. Silberstein6
1Clinical, MAP Pharmaceuticals, Mountain View, CA, USA ;
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Background Several well-controlled studies have shown that the
efficacy of triptans is reduced significantly when treatment is delayed
well beyond the start of the migraine. Surveys have also shown that
some patients are unable and unwilling to treat their migraine early,
leading to treatment failure and dissatisfaction with their acute
treatment. LEVADEX, a novel orally inhaled form of DHE in
development, may reverse central sensitization and hence should
work well even when used late in a migraine attack.
Methods Post-hoc analysis of a randomized, double-blind, placebo-
controlled phase 3 study. Two-hour pain-relief (PR) and pain-free
(PF) rates were compared between those who treated their migraine in
less than 1 hr, within 1-4 hrs, within 4-8 hrs and more than 8 hrs of
the start of their migraine.
Results 903 subjects randomized; 771 subjects treating a single attack
included in efficacy analysis. When treated less than 1 hr after
migraine start, the 2hr PR and 2hr PF rates were 66% and 38% for the
LEVADEX group and 41% and 13% for placebo. When treated
1-4 hours after the start, the 2hr PR and PF rates were 60% and 28% for
LEVADEX and 35% and 10% for placebo, respectively. When treated 4-
8 hours after the start, the 2hr PR andPF rates were 53% and 22% for
LEVADEX and 30% and 30% and 8% for placebo, respectively. When
treated even after 8 hours, the 2 hr PR and PF rates were 49% and 19% for
LEVADEX and 24% and 9% for placebo.
Conclusions In this post-hoc analysis, LEVADEX showed efficacy in
treating a moderate or severe acute migraine attack even when it was
administered as late as 8 hours after the start of a migraine. Thus,
LEVADEX may help many migraineurs who are unable to treat their
migraine early due to practical real life limitations.
Conflict of interest Dr. Silberstein has acted as a consultant, speaker
or received research support from Allergan Pharmaceuticals.
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Migraine induced disability and migraine treatment
A. Roceanu, M. Vasile, C. Dumitrache, O. Bajenaru
Neurology Department, University Hospital, Bucharest, Romania
Introduction Migraine is a public health problem that has an impact
on both the individual sufferer and on the society. Migraine has been
found to rank in the top 20 of the world’s most disabling medical
illnesses, based on the 2001 WHO’s World Health Report.
Objective Evaluation on migraine induced disability in migraine
patients.
Methods We evaluated 30 migraine patients in our outpatient clinic.
A secondary cause of headache was rule out by clinical examination
and appropriate diagnostic tests.
Demographic data were collected for each patient, as well as data
regarding migraine characteristics. Patients were asked about
migraine preventive treatment use in the last 3 months and also about
specific antimigrainous acute therapy use (triptans).
We measured migraine disability by asking each patient to fill a
MIDAS and HIT test.
Results MIDAS score revealed severe disability in 43% patients
MIDAS C 21, moderate disability in 30 % patients, mild disability in
17% patients and little disability in 10% patients..
HIT test was modified in accordance with MIDAS (57% patients with
HIT [ 60 points; 23% patients had HIT 56-58; 13% patients had HIT
of 50-54 and 7% patients had HIT scor \ 48).
Conclusions In or study mostly the patients with high disability due
to migraine were asking for a medical advise.
Although MIDAS score of III-IV was found in 75% patients, only 6%
of patients used specific antimigrainous acute therapy (triptans). Only
13 % of patients had a preventive treatment, although most of our
patients had a moderate-severe migraine induced disability.
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The aim of this study was to review the medical record of all patients
having received a diagnosis of headache secondary to psychiatric
disorder (ICHD code 12 and A12) when consulting in a headache
emergency department during 2009. Out of a total of 8479 patients
seen during this year, 25 men and 62 women received this diagnosis
(1.02 %), mean age 40.3 ± 14 years. The psychiatric disorders con-
cerned were: depressive disorder (n = 37), generalized anxiety
(n = 25), panic disorder (n = 5), psychotic disorder (n = 5) undif-
ferentiated somatoform disorder (n = 4), somatisation disorder
(n = 1) and post traumatic stress disorder (n = 1). Data was missing
for 10 patients. The fact that headache had occurred only during the
evolution of a psychiatric disorder was not recorded for any of the
patients. Headache description was tension type (n = 45), atypical
(n = 23), migraine (n = 19). One-fourth of the patients suffered from
pain in other parts of the body (n = 21), 40% had already had
complementary investigations and consulted for their headache. The
most usual prescription proposed to the patients were antidepressants
(n = 45), i.e. amitriptiline and tranquillizer (n = 43), i.e. clonaze-
pam. Patients were sent to a psychiatrist in 45 cases and
complementary investigations were ordered in 21 cases.
This study shows that, in practice, ICHD code 12 and A12 are rarely used.
When used, criteria are not strictly applied. The criterion ‘‘headache
occurring only during the evolution of the psychiatric disorder’’ is not
checked. Not only are atypical headaches considered but, in the majority
of cases, code 12 or A12 is given with tension type or migraine type
headache. Even though psychotic disorder and somatisation disorder are
the only psychiatric disorders accepted for HSPD in the classification
itself, in clinical practice they are not frequently involved whereas
depression and generalized anxiety are. It calls for the removal of those
appendix diagnoses in the classification itself.
Conflict of interest Radat F. Research grants :UPSA. Consulting fees or
other remuneration received for presentations : Lilly France- Menarini-
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Introduction Idiopathic intracranial hypertension (IIH) is character-
ized by high cerebrospinal fluid CSF) pressure with no underlying
structural or systemic cause. Papilledema is a cardinal feature of IIH,
however in rare cases IIH may occur without papilledema.
Case report A -25 year old women, gravida 1, para 1, eight days post
partum presented to the neurologic department with a chief complaint
of headache. Past medical history was unremarkable. The pain was
holocranienne. It was accompanied by nausea without vomiting,
neurological examination and brain MRI was normal.
A lumbar puncture was performed which reveled: CSF opening pres-
sure = 400 mmH2O, white blood cells = 4, protein = 35 mg/100 dl
and sugar = 55 mg/100 dl (concomitant blood sugar = 95 mg/dl)
The patient was diagnosed with IIH and received a lumbar puncture
2 days after. The headache was disappeared.
Discussion Headache is one of the most common symptoms that
encountered in the post partum period. IIH, in its classic form present
as headache and pappilledema. Although pappilledema is acardinal
feature of IIH, in rare case it may occur without papilledema. It is
there for advised that in the presence of obesity, post partum headache
and, a spinal tap may be indicated to exclude the presence of IIH
without papilledema.
Conclusion In post partum condition, the diagnosis of IIH shoud be
considered even in the absence of papilledema .A lumbar puncture is
helpful both diagnostically and therapeutically.
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Iowa gambling task (IGT) in medication overuse
headache (MOH) patients: a neuropsychological study
of the orbitofrontal cortex functioning
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It has been proposed that MOH could be related in some patients to
dependence-related behaviours. Such behaviours are connected to the
orbitofrontal cortex (OFC) which exerts an inhibitory control on sub-
stance craving. The aim of this study was to explore the functioning of the
OFC of MOH patients through neuroimaging techniques (18FDG-PET
and f MRI) and through neuropsychological assessment (IGT). The data
presented here concerned the IGT results from 12 MOH patients com-
pared with 8 episodic migraineurs without prior MOH. IGT is a test
aiming to detect decision-making impairment as it is observed in patients
with OFC damage and in drug-addicts. It is a test where the subject is
confronted with a decision that involves a conflict between an immediate
reward and a long term negative consequence. Six MOH patients were
overusing triptans, 4 were overusing acute headache medications con-
taining opiate-derivatives, one was overusing simple analgesics and one
was overusing combinations. The mean number of acute headache
medication taken per month was 91.9(+/-50) for the MOH group and
5(+/-2) for the migraine group (p = 0.008). MDH-Q is a questionnaire
measuring dependence behaviours in headache patients. Mean MDH-Q
score was significantly higher in the MOH group than in the migraine
group (86.9 +/- 20 versus 35.1 +/- 4, p = 0.01), whereas mean BIS score,
a measure of impulsivity, is not different between the two groups
(58.4 +/-5.7 versus 62.7 +/-10.2). Mean ITG score did not allow differ-
entiating MOH patients from episodic migraineurs, whereas it was
significantly different between opiates abusers and other medication
abusers (45 +/-5.7 versus 57.1 +/-8.2, p = 0.019). Those results must be
interpreted with caution due to the low number of subjects. They, nev-
ertheless, are in favour of a deficit in decision making processes,
underlying behavioural dependence in MOH patients who overuse
medications that contain psychoactive substances like opiates.
Conflict of interest Radat F. Research grants :UPSA. Consulting fees
or other remuneration received for presentations : Lilly France- Menar-
ini- Pfizer- MSD- Allergan. Board member : Lilly France – Allergan.
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Migraine is the most common cause of recurrent acute headaches in
childhood (5 to 10%). The study was conducted by the Migraine
Center (MC) of Trousseau University Hospital in Paris and the pain
management health care network LCD-Paris.
The aim was to assess the management of pediatric migraine before
the first consultation at the Migraine Center.
Parents of cephalalgic children had to answer a questionnaire
before the first consultation at the MC. During the consultation, the
physician classified the headache according to IHS classification
ICHD-II.
177 questionnaires were analysed over a six month-period (September
2007- February 2008).
The mean age of the children was 9.91 years (± 2.8 years), 20.9%
were under 7 years and 33.8% were over 12 years.
At the end of the consultation in MC, 171 children (96.6%) were
diagnosed with migraine, isolated or associated with another
headache.
The first physician consulted (before MC) for the headache was the
general practitioner (56.5%), the pediatrician (28.8%) or another
specialist (7.3%).
That first consultation in primary care was mainly motivated by the
headache in 58.2%. In 34.4 % of case, headache was discussed during
a consultation for another problem.
Migraine diagnosis had already been mentioned for 91% of children.
In 41.8%, migraine was evocated by the parents.
31.6% of parents decided to consult by themselves at the MC.
In primary care, 66.1% of children consulted the ophthalmologist,
25.4% the neurologist and 21% the ENT specialist; 46% of children
had a brain imaging: CT scan (29%) and MRI (24%).
Given the prevalence of migraine, physicians in primary care should
be better trained to recognize and to treat pediatric migraine.
Specialist centers should be consulted in a second phase, for children
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Introduction Migraine with aura affects about 30% of all migraine
patients. Prolonged auras are defined as those lasting more than
60 minutes in typical or basilar migraine, and more than 24 hours but
less than one week in hemiplegic migraine (ICHD-II). Although rare
they may pose a diagnostic challenge and its natural history is not
completely understood.
Aims Clinical characterization and prognostic definition of prolonged
migraine auras.
Methods Retrospective review of clinical files and prospective per-
sonal assessment according to a standardized form, of all patients
admitted or followed in a headache outpatient clinic with the diag-
nosis of prolonged migraine aura, between January/1999 and May/
2010. Structural lesion was excluded by brain MRI with DWI in all
patients.
Results 30 patients included, 25 females, mean age 33.7 ± 9.3 years.
15 patients used to have migraine without aura (1.1 ICHD-II), 14 had
migraine with aura (1.2 ICHD-II) and one patient had no previous
history of migraine. Prolonged aura was sensitive in 11 patients,
visual in 3 and mixed in 16 (7 with motor symptoms). In 18 patients
the aura lasted less than 24 hours. Headache had the usual features in
25 patients. Prolonged aura symptoms were similar to the previous
typical auras in 9 patients and different in 5. Recurrence occurred in
11 patients, 2 of these with distinctive characteristics.
Conclusions Prolonged aura was often the first aura episode, making
diagnosis challenging. Moreover they were frequently complex and
with motor symptoms, which are less frequently recognized as aura
manifestations. However the frequent maintenance of previous
headache and aura features may help in differential diagnosis.
Recurrence of prolonged aura symptoms occurred in 36.7%, having
thus a favorable outcome in most patients.
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The prevalence and burden of primary headaches
in china: a population-based door-to-door survey
S. Yu1, R. Liu1, G. Zhao2, X. Yang3, X. Qiao4, J. Feng5, Y. Fang6,
X. Cao1, T.J. Steiner7
1Chinese PLA General Hospital, Beijing, China;
2The Fourth Military Medical University, XiAn, China;
3Xiangya Hospital of Centre-South University, Changsha, China;
4Affiliated Huashan Hospital of Fudan University, Shanghai, China;
5The First Hospital of Jilin University, Changchun, China;
6The First Affiliated Hospital of SunYat-sen University, Guangzhou,
China;
7Division of Neuroscience and Mental Health, Imperial College
London, London, UK
Objective A population-based door-to-door survey on the prevalence
and the burden of primary headaches in the mainland of China was
initiated by Lifting the Burden: the Global Campaign to Reduce the
Burden of Headache Worldwide.
Method The 5041 respondents were sampled based on population
using random sampling software, according to EPI method estab-
lished by WHO. The questionnaire was structured from English
version of that developed by Lifting the Burden to be translated to
Chinese and fitted to Chinese culture after pre-pilot study.
Results The 1-year prevalence of primary headaches is 23.8% in
China. The 1-year prevalence of migraine is 9.3%, and that of
tension-type headache is 10.77%. The heavy social and economic
burden was caused by primary headache, which lose 121.4 billion
yuan (RMB) per year, 3.9 % of GDP, according to population
modified by age. 66.7 billion yuan per year was cost for migraine,
which is 3% of annual income every family.
Conclusion Primary headaches are not only pain for patients, but also
disable their work, study and daily activities.The 2nd edition Inter-
national Classification of Headache Disorders (ICHD-2) formulated
by International Headache Society.In accordance with the Lifting the
Burden translation protocol for hybrid documents, the Chinese version
of the questionnaire was first evaluated by the chief investigators of six
regions, who are fluent in both languages, and then assessed for
comprehensibility by 20 outpatients at every department of neurology
of the hospital which the chief investigator of region worked.
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Countrywide population-based survey in Russia reveals
high prevalence of chronic daily headache and its
association with low socioeconomic status
I. Ayzenberg1, Z. Katsarava2, M. Chernysh3, A. Sborowski2,
R. Mathalikov4, V. Osipova4, G. Tabeeva4, T. Steiner5
1Department of Neurology, University of Bochum,
Bochum, Germany;
2Department of Neurology, University of Essen, Essen, Germany;
3Institute of Sociology, Russian Academy of Sciences, Moscow,
Russia;
4Moscow Medical Setchenov Academy, Moscow, Russia;
5Division of Neuroscience and Mental Health, Imperial College
London, London, UK
Objective To estimate the current (1-year) prevalence of chronic
daily headache (CDH), defined as headache occurring on C 15 days/
month, and identify risk factors, in the general population of Russia.
Methods By door-to-door unannounced visits, and follow-up visits
when necessary, trained lay interviewers randomly sampled biologi-
cally unrelated adults aged 18-65 years from 35 cities and nine rural
areas of Russia. The sample was thus drawn from all but one of the
seven federal districts of the country, and was representative of the
population of Russia in terms of age, gender, socioeconomic status
and settlement type. A previously validated structured diagnostic
questionnaire based on ICHD-II criteria was applied. Quality of life
(QoL) was assessed using WHOQoL-8.
Results Of 2,725 eligible adults contacted, 2,025 (74.3%) responded,
of whom 1,065 (52.6%) were female and mean age was 39.5 ±
13.4 years. Episodic headache (\ 15 days/month) was reported by
1,060 (52.3%; 95%CI50.2-54.5) respondents and CDH by 213
(10.5%; 95%CI9.2-11.9). Of the latter, 145 (7.2%; 95%CI6.0-8.3)
were overusing acute headache medication and therefore had proba-
ble medication-overuse headache.
Female gender (OR2.7; 95%CI1.8-4.2), low income (OR2.4;
95%CI1.6-3.8), increasing age (OR2.1; 95%CI1.4-3.2) and obesity
(OR1.8; 95%CI1.2-2.8) were risk factors for CDH. Average income
was 36% lower in people with CDH than in those with episodic head-
ache. QoL was lower in people with headache than in people without,
and lowest in those with CDH.
Conclusion This first population-based countrywide study in Russia
revealed a very high prevalence of CDH. Whilst this result is in line
with our previous findings in the Republic of Georgia, another
country of the former USSR, in that country there was much less
MOH. The Georgian population is not Slavic, and is therefore
genetically different. The survey unmasks high unmet needs of people
with headache in Russia and confirms the importance of poverty as a
risk factor.
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Comorbidity of depression in a clinical population
of migraine patients: report from lumina
M.A. Louter1,2, G. Veen2, F.G. Zitman2, M.D. Ferrari1,
G.M. Terwindt1
1Department of Neurology, Leiden University Medical Centre,
Leiden, The Netherlands;
2Department of Psychiatry, Leiden University Medical Centre,
Leiden, The Netherlands
Objective To study the prevalence of depression in a clinical popu-
lation of migraineurs.
Introduction There is a bidirectionally increased comorbidity of
migraine and depression, suggesting shared pathophysiological
mechanisms. This association, in particular for migraine with aura,
can be partly explained by shared genetic factors. We studied the
prevalence of depression in a large clinic based population of
migraineurs with (MA) and without aura (MO).
Methods Migraineurs were identified as follows: patients were
enrolled via the LUMINA (Leiden University MIgraine Neuro-
Analysis) website and answered validated screenings questions.
Screen-positives were automatically directed to an extended validated
web-based questionnaire on headache and aura symptoms, and indi-
vidual diagnoses were calculated using an algorithm based on criteria
of the International Headache Society (ICHD-II). Depression was
measured using a web-based validated questionnaire about current
and lifetime mood status. Descriptive statistics were used to describe
the demographic data for age, sex, and the prevalence of migraine and
depression. To evaluate the difference in prevalence between the
group of MA and MO, a v2 test and a logistic regression analysis were
performed with adjustment for age, gender and current anxiety
disorder.
Results For the depression questionnaire 2600 migraineurs were
approached. The response rate was 89.2%. A number of 2313
patients (86.5% female) was suitable for analysis. MO was seen in
59.7% of these patients. In total, 44.0% of all migraine patients
fulfilled the criteria for a lifetime diagnosis of depression. There
was no significant difference between MA and MO for comorbidity
of depression.
Discussion This is the first large study investigating the comorbidity
of migraine and depression in a large clinic based population of
migraineurs. It confirms findings from previous population-based
studies, showing that a considerable number of migraine patients fulfil
the criteria of a lifetime depression. Remarkably, we found no dif-
ference in prevalence between MA and MO.
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Central facilitation of trigeminal nociceptive processing
in episodic and chronic cluster headache
D. Holle1, C. Gaul1, S. Zillessen1, H.-C. Diener1, H. Kaube2,
Z. Katsarava1, M. Obermann1
1Neurology, University of Duisburg-Essen, Essen, Germany;
2University of Freiburg, Freiburg, Germany
Background Central facilitation of trigeminal pain processing was
demonstrated in different primary headache and facial pain disorders.
Whether this overactivity is also part of the pathophysiology of
cluster headache (CH) is intensively discussed due to inconsistent
study results.
Objective To investigate the function of the trigeminal nociceptive
system in patients with episodic and chronic CH.
Methods Sixty-six patients with CH (18 episodic CH inside bout, 28
episodic CH outside bout, 20 chronic CH) according to the IHS-
classification, as well as 30 healthy controls were investigated using
simultaneous recordings of a the nociceptive blink reflex (nBR) and
pain related evoked potentials (PREP) following nociceptive electri-
cal stimulation on both sides of the forehead (V1).
Results NBR latency ratio (headache side/non headache side) was
decreased in all CH patients independently of CH subtype com-
pared with healthy controls. Area-under-the-curve (AUC) ratio was
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increased in patients with episodic CH inside bout only. PREPs
showed decreased N latency ratio in patients with chronic CH.
Conclusion Side shift of trigeminal nociceptive processing can be
detected in patients with CH predominantly on brainstem level and
most pronounced in the acute pain phase of the disease, but
appears to persist in remission periods. These data support the
hypothesis of neuronal alteration of the trigeminal nociceptive
system in CH. PREPs show central facilitation only in chronic CH
prompting to additional supraspinal alterations of pain processing
in regard to chronic pain that exceeds changes observed in episodic
CH.
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Migraine true disease state estimates (MTDSE):
improving sensitivity in migraine definition
and drug-efficacy detection
D. Serrano1, D.C. Buse2,3, M.L. Reed1, C.M. Runken4, R.B. Lipton2,5
1Vedanta Research, Chapel Hill, NC, USA;
2Neurology, Albert Einstein College of Medicine, Bronx, USA;
3Montefiore Headache Center, Bronx, NY, USA;
4USP Health Outcomes, GlaxoSmithKline, Research Triangle Park,
NC, USA;
5Neurology, Montefiore Headache Center, Bronx, NY, USA
Background Migraine is defined by a constellation of inter-related
symptoms which vary among and within individuals over time. For
acute treatment trials the FDA requires separation from placebo on 4
co-primary measures of migraine pain intensity, nausea, photophobia,
and phonophobia. This approach is inconsistent with true-disease-
state theory, dramatically increases sample size requirements, and
fails to measure the migraine symptom complex.
Objective To develop scoring procedures capturing estimates of the
true disease state, thereby increasing precision and sensitivity in
migraine definition and drug efficacy detection.
Methods In 2005, we assessed a representative sample of 14,936
respondents who met ICHD-2 criteria for episodic headache. Latent
class models were employed to identify natural subclasses of head-
ache sufferers with migraine-dominant symptom patterns. Item
Response Theory (IRT) models were used for assessing item quality.
IRT parameters were employed to obtain adjusted true-disease-state
scores corresponding to all possible ICHD-2 sum scores.
Results A four class model revealed two migraine-dominant clas-
ses. A single-factor IRT model optimally fit the data. The ICHD-2
items strongly measured the underlying disease state, with loadings
ranging from 0.28 to 1.2. The odds of endorsing the items given
the MTDSE ranged from 1.32 to 3.32. These underlying disease
state score estimates are model-based, free of measurement error
and asymptotically normal. MTDSE scores were obtained by cal-
culating the mean of the posterior distribution of the IRT model
corresponding to each sum score. Scores were rescaled to have
mean of 2 and SD of 1.22, yielding 21 scores ranging from 0 to
4.17.
Conclusions ICHD-2 migraine-defining features can be scaled to
produce an MTDSE capturing severity of migraine pain and associ-
ated symptoms. MTDSE scores are normally distributed with fixed
mean and SD. Statistical tests using this scoring method should more
powerfully detect the benefits of migraine treatments both in clinical
trials and clinical practice.
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Greater occipital nerve infiltration with cortivazol
for cluster headache (CHCI): a double blind
randomized controlled trial
E. Leroux1, A. Ducros2, E. Vicaut3, C. Roos2, I. Taifas2, D. Valade2
1Neurology, CHUM Notre-Dame, Montreal, QC, Canada;
2Emergency Headache Center, APHP Lariboisie`re, Paris, France;
3Clinical Research Unit, APHP Lariboisie`re Fernand-Widal,
Paris, France
Cluster headache (CH) bouts are highly disabling. Greater occipital
nerve infiltration (GONI) has been used for CH with different sub-
stances and protocols. This randomized placebo-controlled trial
included 43 CH patients, 15 chronic and 28 episodic, all having [ 2
attacks daily preceding inclusion. Patients had three GONI, 48 to 72 h
apart, performed in a double-blinded fashion either with normal saline
(PL, n = 22) or with cortivazol 3,75 mg (CVZ, n = 21). Patients
were followed for 90 days after inclusion. The primary endpoint was
the number of patients in each group with a mean of 2 attacks or less
per day on the second, third and fourth day after the third injection
(between day 9 and 12 following inclusion). All the patients (100%)
of the CVZ group reached this endpoint, compared to 65% of the PL
group (p 0,0045). Cortivazol also was superior to placebo on various
secondary endpoints: the mean number of attacks over the first
15 days was 7,24 vs 23,3 for CVZ and PL respectively (p = 0,0005).
The delay to remission was 9,1 vs 16,8 days (p \ 0,0001). At day 15,
a 50% decrease in attack frequency was seen in 94,7% vs 72,2%
(p = 0,05). No severe side effects were reported. Minor side effects
were reported by 90% of CVZ vs 66% of PL groups (p = 0,07), the
commonest being neck pain (65% CVZ vs 47% PL, p = 0,26)
Repeated GONI with cortivazol can shorten a CH bout or exacerba-
tion rapidly, decreasing the daily frequency of attacks and inducing a
lasting remission, both in episodic and chronic patients. It is safe and
well-tolerated, can be added to the standard prophylaxis, and should
be considered early in the treatment algorithm of a CH period or
exacerbation.
This study has been registered on clinicaltrials.org under the number
NCT00804895.
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Refractory migraine in an outpatient neurology
headache unit
R. Fernandez-Torron, J.-A. Palma, E. Martinez-VIla, P. Irimia
Neurology, Clinica Universidad de Navarra - University of Navarra,
Pamplona, Spain
Introduction Certain migraines are labeled as refractory, and oper-
ational criteria have been recently proposed. However, epidemiology
is poorly characterized, and there is a lack of data on prevalence and
incidence. In this study, we aimed to determine the prevalence of
refractory migraine in patients attended on the Headache Unit in a
tertiary care center.
Methods The study population consisted of a consecutive sample of
370 patients (60,8% females) with a mean age 43 years (range 14-86;
SD: 15) evaluated for the first time in the Headache Unit over a 1-year
period (between October 2008 and October 2009). We recorded
information on clinical features, previous treatments, Migraine Dis-
ability Assessment Score (MIDAS), diagnosis and outcome.
Results Overall migraine (chronic and episodic) and tension-type
headache (chronic and episodic) were respectively found in 54.6%
and 21.8% of patients. Chronic migraine was found in 7.3% of
patients (13.4% of all migraineurs). Refractory migraine was found in
7.1% of patients (62% of whom were chronic migraineurs) according
to the proposed criteria by Schulman. The mean MIDAS score was
71.8 (range 15-180). 52% of refractory migraineurs were medication-
overusers.
Conclusion Refractory migraine has a prevalence of 7.1% in our
headache clinic. New therapeutic strategies are needed to improve the
quality of life of these patients.
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Migraine associated with arterial hypertension: clinical
features and difficulties of diagnosis
O. Grosu, I. Moldovanu
Neurology, State Medical and Pharmaceutical University,
Chisinau, Moldova
Introduction Migraine and arterial hypertension are both well known
entities in the general population and important cardiovascular risk
factors. Association between headache and hypertension is old and
contradictory issue.
Objectives Analysis of clinical features of migraine associated with
arterial hypertension and estimation of cardiovascular risk.
Methods The study included 30 consecutive patients referred to the
Headache Center with headache (according to ICHD-2004) and
arterial hypertension (BP [ 140/80 mmHg). Patients underwent a
clinical interview, a physical and neurological examination including
the assessment of BP. Data were analyzed by means of EpiInfo for
Windows. For ten patients was calculated Systematic Coronary Risk
Evaluation (SCORE).
Results Headache sample consist of chronic migraine (18p), episodic
migraine (7p) and tension type(5p). Average age was 50.2, 50% of
them in the 50-60 age interval. Was some common clinical features:
the headache history 10-30 years (30%), headache before hyperten-
sion diagnosis (90%), bilateral (50%), phonophobia (90%), other pain
16p (55%). 11 patients (40%) reported another type of headache
fulfilling the criteria for ‘‘Headache attributed to hypertensive crisis
without hypertensive encephalopathy’’, 18 patients(60%) did not fill
when there blood pressure arise, 40% of the patients(12p) presented
dyslipidemia, 26.7% (8p) obesity, 16.7% (5p) diabetes mellitus,14%
of the patients presented stroke. For 10 patients was performed Sys-
tematic Coronary Risk Evaluation (SCORE): 2p (20%) = 1%, 4p
(40%) = 2%, 3p (30%) = 3-4%, 1p (10%) = 5-9% risk for fatal
cardiovascular event for 10 years.
Conclusion Patients with headache and hypertension raise problems
in diagnosis and management. From the moment they were told about
the hypertension they interpret every headache as due to raised blood
pressure. Both diseases are important cardiovascular risk factors and
can produce white matter changes.
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Preliminary clinical data from a new headache
outpatients service in the Republic of Ireland
R. Bhola1, K. Mc Carthy2, K. O’Rourke2, T. Lynch2, M. Ruttledge2,3
1National Hospital for Neurology and Neurosurgery, London, UK;
2Dublin Neurological Institute, Mater Misericordiae University
Hospital, Dublin, Ireland;
3Neurology, Beaumont Hospital, Dublin, Ireland
A new headache out-patient clinic was established in January 2010 at
the Dublin Neurological Institute in Dublin, Ireland. The goal is to
manage headache patients in a specialist setting and minimise waiting
time to first consultation. It is the third specialist headache clinic in
the Republic of Ireland (total population of more than 4 million
people). During the first five months, 70 new patients were seen. Of
these, 63 patients had migraine (47 chronic/16 episodic). 34 of these
patients fulfilled the criteria for medication overuse headache. Only
30% of the migraine patients (20/63) had previously been treated with
a preventative agent, and in many cases with sub-optimal doses or for
too short a period of time. The waiting time for the clinic was between
3 and 14 months. Our data strongly supports the need for further
specialist headache services in the Republic of Ireland.
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Is there an effect of functional electrical stimulation
for inhibition of muscle contractions during sleep?
N. Caspersen, J.R. Hirsvang, B.K. Madsen, R. Jensen
Danish Headache Center, Department of Neurology, Glostrup
Hospital, University of Copenhagen, Glostrup, Denmark
Background Temporomandibular disorders (TMD) and tension- type
headache (TTH) are both characterized by increased tenderness in the
pericranial muscles. Functional Electrical Stimulation (FES) is
developed to cause local relaxation of specific muscles by means of
low electrical stimulation but the effect on headache is not known.
Objectives To investigate the effect of biofeedback system based on
FES during sleep on symptoms and signs of tension- type headache.
Methods 50 patients from a multidisciplinary headache center, who
fulfilled the IHCD-2 criteria for frequent episodic or chronic TTH
were included in a randomized, double- blind placebo-controlled
study of FES. All patients used the biofeedback system during sleep
over 11 weeks period and completed questionnaires regarding sleep,
headache and quality of life three times. Examination of TTH, jaw
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and muscles was examined by a blinded observed by means of The
Research Diagnostic Criteria for Temporomandibular Disorders
(RDC/TMD), and, McGill Pain Questionnaires (MPQ) and Sleep
quality questionnaire. Total tenderness scores (TTS) were evaluated
at baseline, after 7 weeks and after 11 weeks.
Results At present, 32 patients (24F,8 M) with a mean age of
38 years have completed the study. So far the treatment with FES did
not cause any changes in the total TTS-score as the total values are
unchanged from baseline (693), after 7 weeks (730) and after
11 weeks (691),
Conclusion At present only patients who has completed the study
have been analysed in total and the randomization code is protected.
However, the total outcome of TTS is completely unchanged indi-
cating that the possible effect of FES is not directly linked to muscle
tenderness and other mechanisms must be searched. Detailed results
will be presented as the last patient is expected to complete the study
in august 2010.
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Patent foramen ovale (PFO) closure reverses abnormal
habituation of early contingent negative variation
(ECNV) in chronic migraine
M. Guido1, E. Pestrichella2, L.M. Specchio1
1Nerological Institute of Foggia University, Foggia, Italy;
2Cardiologic Division of S. Maria Hospital, Bari, Italy
Purpose Retrospective studies have shown improvement in migraines
after PFO closure. To date, no study has evaluated the role of PFO
closure on neurophysiologic marker of migraine. Lack of habituation
of evoked potentials to repetitive sensory stimuli procedures, such as
CNV, is the main neurophysiological finding in migraine.
The aim of the study was to detect any change in habituation of eCNV
after transcatheter PFO closure in chronic migraineurs that were
positive for moderate-severe shunt at transcranial Doppler examina-
tion (TDe).
Materials and methods Fourteen chronic migraineurs (8 without aura;
8 females; mean age 37 ± 4,2 years; mean duration of illness:
10 ± 3,8 years; mean headache frequency: 18 ± 2,7 days/month)
diagnosed according IHS-2004 criteria were recruited. They were all
resulted positive for moderate-severe PFO at TDe in the previous
3 months; ten of them had assumed prophylactic drugs in the six pre-
vious months with moderate and inconstant efficacy. The eCNV
habituation was assessed by Cz/A1-A2 derivation recordings, accord-
ing to standard odd-boll acoustic paradigm, during inter-ictal phase, in
the basal condition (T0) and after 2 months (T1) from PFO closure.
Results A significant reduction in migraine frequency (p \ 0,05) and
reversing of abnormal habituation pattern (p \ 0,01) respect to T0
was observed in migraneurs at T1. There was a significant correlation
between migraine frequency reduction and normal eCNV habituation
at T1 (p \ 0,01).
Discussion Our study suggests a possible link between moderate-
severe PFO and reduced eCNV habituation in chronic migraine
patients. The possible role of right to left shunting in predisposing to
chronic migraine and consequently to eCNV habituation lack could
be explained by paradoxical embolism. The persistent paradoxical
embolism could led to abnormal cortical information processing that
is considered the main neurophysiologic finding of reduced habitua-
tion migraineurs. Finally migraine relief after PFO closure could
suggest to perform this technique in selected chronic migraine
patients.
342
Magnetic resonance imaging in medication overuse
headache (MOH) a report in a tertiary center
in Argentina
M.T. Goicochea, L. Bonamico, F. Salvat, J.A. Leston
Neurology, FLENI, Capital Federal, Argentina
Some reports have detected MRI brain changes in migraine and
tension type headache. The objective of this presentation is to analyze
and correlate the presence of white matter lesions in chronic headache
patients with medication overuse.
Methods We had studied retrospectively brain MRI in a MOH group,
correlating them with some clinical data.
Result We studied 100 consecutive chronic headache patients,74 of
them had MOH, according to the IHS classification, mean age was
36 years, 87% were females. The medication used were ergotamine
compounds : 58,11%, simple analgesics :29,73 %, . As vascular risk
factor, 2 patients were smokers, 1 used oral contraceptive treatment.
Mean period of chronification headache: 51 months Hypertension
was not detected in the group. MRI studies that were done in 51
patients shown white matter abnormalities in 8 of them, 5 overusing
AINES and 3 ergotamine in combination.
Conclusions Although a correlation between migraine and white
matter lesions has been discussed, these preliminary data shows a low
percentage of brain changes in chronic headache patients overusing
medication. Including those patients overusing ergotamine. Analyzing
more clinical and radiological data may give us the possibility to
deeply study risk factors that may be related to this unresolved
headache disorder.
Supported by COMOESTAS Project - EC contract number 215366
(COMOESTAS) FP7 - Thematic priority ICT.
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Gender and headache: no difference in the therapeutic
efficacy of drugs in emergency department settings
E.V. Dermitzakis, C. Karakasis, E. Markousi, D. Nikiforidou,
E. Kyriazopoulou, I. Tsiptsios
Department of Neurology, Papageorgiou General Hospital,
Thessalonı´ki, Greece
Introduction The aim of this study is to evaluate the effectiveness of
pharmacological treatment for acute headache in Emergency
Department (ED) settings, as well as the difference in the therapeutic
outcome among the genders.
Methods Data were collected by the ED neurologists of all patients
that reported headache in the ED for a period of 6 months. A variety
of drugs were used for the acute treatment of headache in the ED such
as analgesics, NSAIDs, acetylsalicylic acid, triptans and antiemetics.
The intensity of the headache for both genders and for every subtype
of headache was estimated on a Visual Analogue Scale before and 45-
60 minutes after treatment.
Results A total of 419 headache patients were examined in the ED
and 190 of them were given some kind of analgesic medication. 147
(77,4 %) of these patients were female and 43 (22,6%) male. The
medication was well tolerated and effective for every headache sub-
type and there wasn’t any statistically significant relation between the
positive effect of any medical option and gender.
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Discussion Our study confirms the efficacy of specific acute phar-
macological treatment in ED settings. All the given medications were
well tolerated and equally effective to both genders.
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Duloxetine prophylaxis in chronic tension type
headache
P.E. Bermejo1, M.E. Toribio-Diaz2, M.A. Zea-Sevilla2
1Hosital Universitario Puerta de Hierro, Madrid, Spain;
2Hospital del Henares, Madrid, Spain
Objectives Duloxetine is a serotonin-norepinephrine reuptake inhib-
itor, effective for major depressive disorder and generalized anxiety
disorder. As known, anxiety is frequently associated with tension type
headache. The aim of this study is to evaluate the efficacy and
tolerability of duloxetine for patients with refractory chronic tension
type headache and anxiety.
Methods Thirty two patients with refractory chronic tension type
headache according to International Headache Society criteria and
anxiety were enrolled in this study. Headache frequency (days per
month), headache severity (according to the Visual Analogical Scale)
and anxiety (according to Hamilton Scale) associated before and after
treatment initiation with duloxetine were compared. The patients had
failed an average of 3.3 prophylactic drugs prior to duloxetine. The
average duloxetine daily dose was 57 mg and the average duration of
treatment was 121 days.
Results The average number of days with headache per month was
reduced in the entire study population from 19.4 before duloxetin
treatment to 15.1 after its initiation; headache severity was reduced
from 7.3 to 5.4, and anxiety was reduced, from 22.3 to 17.6.
Duloxetine was well tolerated, the principal adverse event was
somnolence and none patient abandoned the treatment for that
reason.
Conclusion Duloxetine has efficacy in tension type headache and
anxiety reduction. According to our results, this drug may be a safe
and effective agent in patients with tension type headache and
anxiety. Double-blind studies are warranted to confirm these
findings.
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Determining of migraine prognosis using latent growth
mixture models
B. Tasdelen1, A. Ozge2, S.H. Kaleagasi2, S. Erdog˘an1, T. Mengi1
1Biostatistics, Mersin University School of Medicine, Mersin,
Turkey;
2Neurology, Mersin University School of Medicine, Mersin, Turkey
This paper presents a retrospective study results to classify patients
into subtypes of the treatment according to baseline and longitudinally
observed values considering heterogeneous in migraine prognosis.
Then, to identify risk factors affecting the success of treatment for each
subgroup will be more appropriate. In the classical prospective clinical
studies, participants are classified with respect to baseline status and
followed within a certain time period. However, latent growth mixture
models, for statistical analysis of this type of longitudinal data, con-
sider variation on the response of the treatment. The study data has
been based on a 10-year computer-based follow-up data of Mersin
University Headache Outpatient Department. The developmental tra-
jectories within subgroups were described for the severity, frequency,
and duration of headache separately and the probabilities of each
subgroup were estimated by using latent growth mixture models. SAS
PROC TRAJ procedures, semiparametric and group-based mixture
modeling approach, were applied to define the developmental trajec-
tories. Bayesian Information Criteria was used to determine the
number of subgroups. While the three-group model for the severity
(mild, moderate, severe) and the frequency (low, midium, high) of
headache appears to be appropriate, the four-group model for the
duration is more appropriate (low, medium, high, extremely high). As
a result, nausea, vomiting and photophobia were the most significant
factors to identify developmental trajectories and the recovery time
was not the same for the severity, frequency, and duration of headache.
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Trigeminal sensory and neuroimaging findings in a case
of Parry Romberg syndrome
M. Viana1,2, C.M. Glastonbury3, T. Sprenger1, P.J. Goadsby1
1Headache Group - Department of Neurology,
University of California, San Francisco, CA, USA;
2Headache Center - Department of Neurology, University of Eastern
Piedmont ‘A. Avogadro’, Novara, Italy;
3Department of Radiology, University of California, San Francisco,
CA, USA
Background Parry-Romberg syndrome (PRS) is characterized by a
slowly progressive atrophy of one side of the face. The cause of the
syndrome is unknown. There have been reports of neurological
complications, such as migraine, trigeminal neuralgia, facial palsy
and epilepsy. Among these, facial pain is frequently reported.
Methods This is a case report with quantitative sensory testing
characterizing the somatosensory phenotype and neuroimaging of a
new patient with Parry Romberg syndrome and facial pain. We
review the literature of cases where at least part of the somatosensory
phenotype has been reported to identify possible shared mechanisms
of pain generation.
Results We describe a 37 year-old African-American woman with
progressive hemifacial atrophy and strictly left-sided facial pain
starting about twelve years ago. There was continuous pain in V1 and
V2, and intermittent sharp shooting pains in V3. The sensory exam
showed areas of pinprick hyperalgesia, cold and heat hyperalgesia, as
well as dynamic mechanical allodynia indicating peripheral as well as
central sensitization. In the literature review, we found four case
reports with a detailed clinical description of the facial pain. Similar
to our case, a constant component of the pain was always part of
the phenotype, positive or negative trigeminal sensory signs were
frequently described.
Conclusions The phenotype of our patient is suggestive of tri-
geminal neuropathic pain involving all three branches of the
trigeminal nerve and the patient fulfils newly defined stricter cri-
teria for neuropathic pain. Similar to our case, the phenotype of the
other published cases seems to be in line with trigeminal neuro-
pathic pain rather than trigeminal neuralgia specifically. Electron
microscopy findings suggest that PRS involves chronic cell-medi-
ated vascular injury and incomplete endothelial regeneration along
branches of the trigeminal nerve (lymphocytic neurovasculitis).
This again supports the view that patients with PRS are suffering
from trigeminal neuropathic pain.
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Pharmacological treatment of headache patients
in the emergency department and effectiveness
in relation with patient’s age
E.V. Dermitzakis, C. Karakasis, A. Mastrokosta, A. Safouris,
I. Tsiptsios
Department of Neurology, Papageorgiou General Hospital,
Thessalonı´ki, Greece
Introduction The aim of this study was to estimate the effectiveness
of pharmacological treatment of headache in Emergency Department
(ED) settings for patients younger and older than 50 years.
Methods Data were collected by the ED neurologists of all patients that
reported headache in the ED for a period of 6 months. A variety of drugs
were used for the acute treatment of headache such as analgesics, NSAIDs,
acetylsalicylic acid, triptans and antiemetics. The intensity of the headache
for both age groups and for every subtype of headache was estimated on a
Visual Analogue Scale before and 45-60 minutes after treatment.
Results 419 headache patients were examined in the ED and 190 of
them were given some kind of analgesic medication. 160 (84%) of
these patients were younger than 50 years and 30 (16%) older. 46%
from the younger group suffered from tension type headache (TTH),
41% from migraine and 13% from secondary headache. From the
older group, 57% suffered from TTH, 27% from migraine and 16%
from secondary headache. For both groups the medication, chosen by
the ED neurologist, was well tolerated and effective for every head-
ache subtype and there was no important relation between the positive
effect of any medical option and age.
Discussion All the given acute medications for ED headache patients
were well tolerated and equally effective to both age groups (younger
than 50 years and older than 50 years).
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Tilt test results in patients with migraine associated
with syncope
G. Corcea1, I. Moldovanu1,2
1Neurology, Institute of Neurology and Neurosurgery,
Headache Center, Moldova;
2State Medical and Pharmaceutical University ‘N. Testemitanu’,
Chisinau, Moldova
Background and aims Migraine (M) is frequently associated with
syncope (S). One of the clinical tests of cardiovascular autonomic
function is the tilt-table test (TTT).
The aim of the study was to estimate the prevalence of positive
response at TTT and the mechanism (vasodepressive, cardioinhibitory
or mixed) by which syncope occurs.
Methods Ninety three patients were included in the study, being
distributed into 3 groups: I group - 63 patients with M associated with
S, II - 15 with M without S and the III group- 15 with S without M.
All patients performed TTT.
Results A positive response at TTT was present in 36 (57.1%) sub-
jects in the I group, in 3 (20%) in the II and 11 (73.3%) patients in the
III group. The mixed mechanism of syncope was the most common:
in 28 (77.8%) in the I group, 3 (100%) in the II and 0 patients in the
III group (p1-2 \ 0.01; p1-3 \ 0.001; p2-3 \ 0.01). The heart rate
decreased during TTT by 8.82 bpm in the I group and 7.33 bpm in the
III (p1-2 \ 0.05; p2-3 \ 0.01). Systolic blood pressure decreased at S
by 34.46 mm Hg in the I group, by 3 mm Hg in the II and by
37.8 mm Hg in the III group (p1-2 \ 0.05; p2-3 \ 0.01). Diastolic
blood pressure decreased at S by 7 mm Hg in the II group and by
25 mm Hg in the III (p2-3 \ 0.05).
Conclusion In two thirds of patients with migraine associated with
syncope the TTT was positive, having a mixed mechanism. During
the syncope migraine patients had a reduced heart rate and systolic
blood pressure, thus indicating the presence of a sympathetic adren-
ergic dysfunction.
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Migraine with aura and TCD bubble test
A.L. Sundic1, J.J. Zidverc-Trajkovic1, Z.B. Jovanovic2,
A.P. Radojicic1, A. Pavlovic2, M. Mijajlovic2, N.M. Sternic2
1Headache Center of Institute of Neurology, Belgrade, Serbia;
2Institute of Neurology, Clinical Center of Serbia, Belgrade, Serbia
Background According to results of several studies in which
Transcranial Doppler (TCD) ultrasound was used for detection of
right-to-left shunt, its prevalence is higher in patients with migraine
with aura (MA), comparing with migraine without aura patients and
healthy subjects. There is no data about some clinical feature of
headache or aura whose presence would suggest existence of right-to-
left shunt. The aim of this study was to analyze clinical features in
patients with MA, in those with positive or negative TCD bubble test.
Methods During the period of two years, TCD-Bubble test with agitated
saline was performed in 62 consecutive patients with MA. Detection of
microembolic signals in the spectra of medial cerebral artery in the period
shorter then 20 seconds from the beginning of injection, was considered
as positive result. The demographic features, the characteristics of aura
and headache were collected in all patients and then compared between
groups with and without positive TCD Bubble test.
Results In the group of 62 patients (83,9% female, 35,8 ± 12,7 years
old), 46 (74,2%) of them had positive TCD bubble test. Differences
between demographic features (age at the time of examination and
headache onset, gender), characteristics of headache (frequency,
localisation, intensity, pain quality, duration, accompanying symp-
toms) and aura (symptoms, duration, time - relation to headache), in
these two groups were not significant.
Conclusion Three quarters of examined MA patients had positive
TCD Bubble test. According to our results, clinical features of MA
patients could not predict the result of TCD bubble test.
Keywords Migraine with aura, bubble test
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Cerebral hemodynamic parameters in patients
with hemodialysis headache
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There are data implicating arterial blood pressure and/or equilib-
rium changes during hemodialysis (HD) session could be important
for pathophysiology of dialysis headache (DH).
The aim of this study was to compare mean cerebral blood flow
velocities and vasomotor reactivity in patients on HD with and
without DH measured by transcranial ultrasound examination.
In the cohort of 318 patients undergoing chronic HD, the diagnosis of
DH was established in 21 (6.6%) patients. Mean flow velocities
(MFV) and vasomotor reactivity (VMR) were measured at the
beginning and at the end of HD session on medial cerebral arteries on
the right (R) and on the left (L) side in 10 HD patients with DH and
19 HD patients without DH, matched by age and gender.
A mild MFV decrease was recorded during HD session in all patients.
No significant differences were recorded in MFV between patients
with (MFVR 47.2 ± 23.5; MFVL 50.3 ± 18.2) and without DH
(MFVR 52.2 ± 16.0; MFVL 55.6 ± 15.3) at the beginning of HD
session (pR = 0.508; pL = 0.419). MFV were significantly lower in
patients with DH (MFVR 37.1 ± 11.2; MFVL 35.9 ± 11.2) than in
patients without DH (MFVR 49.1 ± 11.4; MFVL 49.0 ± 13.2) at the
end of the HD treatment (pR = 0.012; pL = 0.014). There were no
differences in VMR between the two groups neither at the beginning
nor at the end of HD session. Hematological and biochemical
parameters, values of systolic and diastolic blood pressure at the
beginning and at the end of HD session, as well as dialysis adequacy
were not significantly different between the two groups.
The results of our study indicate that significant cerebral flow
decrease during the course of HD session could be important in
pathophysiology of DH.
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Migraine in iranian children;which criteria are the best
diagnostic criteria?
H. Derakhshanfar
Pediatric, Mofid Children’s Hospital, Tehran, Iran
Objective The aim of this study was to identify the best criteria for
diagnosis of migraine in our pediatric population.
Materials and methods A total of 85 children aged below 14 years
who had been referred to the pediatric neurology clinic of Mofid
Children0s Hospital with headache as their complaint, were
enrolled.Validated questionnaires were completed by them. The
patients were evaluated using five sets of diagnostic criteria including
the Vahlquist, the Prensky,the International Headache Society
(IHS),the IHS-Revised (IHS_R),and the Maytal criteria, the sensi-
tivity of each set of criteria was assessed.
Results Of the 85 children,clinically diagnosed as having migraine,
61(72%), 73(86%), 75(88%), 76(89.5%), and 76(89.5%) met the
criteria of IHS, Vahlquist, PrenskyIHS-R, and Maytal respec-
tively.Both the IHS-R and Maytal criteria had the highest,while the
IHS criteria had the lowest sensitivity.Fifty-four children (63.5%)
were positive for all five sets of criteria.The application of HIS cri-
teria for diagnosing pediatric migraine led to a smaller percentage of
children with migraine being identified.
Conclusion Assessment of the sensitivity of the five sets of criteria
for the diagnosis of migraine revealed the inadequacies and limitation
of the IHS criteria in the diagnosis of pediatric migraine.
Keywords Migraine, Child, Headache
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Morning headaches in snorers and their bedpartners -
preliminary results of a diary-based study
S. Seidel1, G. Klo¨sch1, E. Pernicka2, T. Bauer1, P. Oberhofer1,
N. Scheibel1, T. Nakuz1, J. Zeitlhofer1, C. Wo¨ber1
1Department of Neurology, Medical University of Vienna,
Vienna, Austria;
2Department of Medical Statistics, Medical University of Vienna,
Vienna, Austria
Background Morning headache (MH) is common in the general
population, in patients with obstructive sleep apnoea syndrome
(OSAS) and in women living with heavy snorers. MH is poorly
defined and was recorded by means of retrospective questionnaires in
all previous studies. To provide more reliable data we performed a
diary study to elucidate prevalence, characteristics and predictors of
MH in snorers and non-snoring bedpartners.
Patients and methods Up to now, 62 volunteers completed the study.
All subjects completed a 90-days headache and sleep diary, a struc-
tured questionnaire, the Pittsburgh Sleep Quality Index (PSQI),
Epworth Sleepiness Scale (ESS), Self-rating Depression Scale (SDS)
and Self-rating Anxiety Scale (SAS). Snorers underwent ambulatory
OSAS screening. MH was defined as headache present upon awak-
ening and differentiated from nocturnal headache (NH) and diurnal
headache (DH).
Results We analysed 5580 subject days of 41 snorers aged
46 ± 11 years (13 female) and 21 bedpartners aged 42 ± 12 years (5
female). The number of subjects reporting MH, DH, and NH was
similar in snorers and bedpartners. The three headache types occurred
on 8 %, 9 % and 5 % of all days in snorers and on 6 %, 14 % and 5 %
of all days in bedpartners. MH was associated with poorer sleep
quality in snorers (p \ 0.001) and bedpartners (p = 0.004). Snorers
and bedpartners without MH differed significantly regarding PSQI
(4 ± 3 vs. 7 ± 3, p = 0.004) and ESS (10 ± 4 vs. 7 ± 3,
p = 0.009). Occurrence of MH was predicted in snorers by con-
sumption of alcohol before bedtime (p = 0.003) and in bedpartners
by subjective disturbance due to nocturnal recurring leg movements
of their snoring partner (p = 0.01).
Conclusion MH is associated with reduced sleep quality in snorers
and in their bedpartners. In the first, it is related to alcohol con-
sumption, in the latter to recurring leg movements of the
bedpartner.
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Sleep in migraine and tension type headache:
preliminary study
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Background A relationship between migraine headaches and sleep
disturbances has been suggested in both children and adults. Clinical
studies performed in adult populations indicate that certain headache
types may be related to specific sleep stages, but there is a lack of
research examining the relationship between primary headache and
sleep in children. The aim of the study was to evaluate sleep in
children with migraine and tension type headache (TTH).
Methods 450 children and adolescents with headache (16% of migraine
and 84 % TTH) seen in the neurology clinic in 2 year were screening for
sleep problems. Parents completed the sleep questionnaire and a stan-
dardized questionnaire regarding headache characteristics. Only 29
agreed to undergo nocturnal polysomnography (21 migraine and 8
TTH).
Results There were no significant differences between the sleep
habits between children with TTH and migraine. Snoring was
reported more frequently in children with TTH (24.9%) than in
migraine patients (13.7%) (p = 0.037). The parents of children with
migraine reported more frequent day time naps: 37% vs. 24.4% in
TTH (p = 0.026); daytime sleepiness 26% vs. 11.7% (p = 0.001);
learning difficulties 30.1% vs. 19.6% (p = 0.045). On polysomnog-
raphy, slow-wave sleep was significantly lower in children with
migraine (20.6%) than in TTH (24.6%) (p = 0.03), and slightly more
REM time: 122.3 min in migraine vs. 101.8 min in TTH (p = 0.03)
with no significant difference in total sleep time (461 min vs.
480 min). The children with migraine had a mean of 5 REM periods
vs. 4 periods in TTH.
Conclusion The difference in sleep macrostructure with reduced
slow-wave sleep in migraine and REM in TTH may influence daytime
performance in children with headache. It is necessary to conduct
further research on a larger group of patients with headaches in order
to better correlate the prevalence of sleep disorder symptoms with the
type of primary headache and daytime functioning.
358
Efficacy of cinnarizine and sodium valproate
in migraine prophylaxis: a clinical trial
Z. Adwan
Private Practice, Swaida, Syria
Background Calcium-antagonists (CA) are heterogeneous group of
drugs with different efficacy in migraine prophylaxis. Several studies
have firmly demonstrated flunarizine (FLU) and verapamil as the
proven calcium-antagonists for migraine prophylaxis. Cinnarizine
(CIN), is another CA with less complications and less antihistaminic
action. There is very few studies to show the effect of this drug on
migraine. The current study evaluates the efficacy and safety of
cinnarizine on migraine in comparison to sodium valproate, an
acceptable drug in migraine prophylaxis.
Methods The current study is a randomized double blind clinical trial
on 133 participants with intractable migraine headache to evaluate the
positive effect of cinnarizine in comparison to sodium valproate. The
data was collected and analyzed by SPSS software.
Results The mean age of cases was 34.3 ± 10 years in Cinnarizine
group and 33.4 ± 11 in Sodium Valproate users. The headache fre-
quency decreased to about 50% and its severity to about 30% in both
groups. Although the effect of Cinnarizine was started earlier than
sodium valproate, there was no significant difference between two
groups of cases in improvement of headache attacks. Statistically
significant difference was noted in drug’s complication led to dis-
continuation of treatment, 5.2% in Cinnarizine users in respect to 14%
in valproate group.
Conclusion The patients who received Cinnarizine, similar to the
patients on sodium valproate showed significant improvement in
headache attacks, frequency, duration and severity. Cinnarizine such
as sodium valproate is an effective drug in migraine prophylaxis even
in intractable headache, but with lesser severe complication.
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Neuromodulation for facial pain and headache
A. Koulousakis, D. Lenartz
Stereotactic and Functional Neurosurgery, University of Cologne,
Ko¨ln, Germany
Introduction During the last 40 years there was an extension of
neuromodulating treatments for many disciplines, now also for spe-
cial forms of neuropathic facial pain and headache. Weiner reported
in 1999 on peripheral nerve stimulation for occipital neuralgia and
Popney and Alo in 2003 on the therapy of migraine.
Patients and methods In the five years past, we treated 5 patients
with neuropathic facial pain, 6 patients with occipital neuralgia and 1
patient with central thalamic pain high parietal, with peripheral nerve
field stimulation. For that 2 electrodes were implanted subcutaneously
to each border of the pain area, After a test phase of 1-2 weeks and
pain reduction of more than 50%,the electrodes were connected to a
stimulator.
Results Except 1 patient with postherpetic neuralgia in V1 left, all
patients achieved a pain reduction of more than 60 % during a follow-
up of 5 years and improvement of their quality of life.7 patients had a
significant reduction in pain medication.
Conclusion Neuromodulation such as cervical spinal cord stimula-
tion,deep brain stimulation and peripheral nerve field stimulation can
be successfully applied with minimal risk in special forms of facial
pain and headache.
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Obligatory use of the modern medicinal,
complementary, integrated medicine for the effective,
gentle fighting the medicine induced duration
headaches
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The headaches belong to the most frequent complaints in Germany:
Headaches have 66.7 per cent of the women (24 million) and 53.2 per
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cent of the men (18,5 millions) within a year at least one times. Costs
in the amount of 462 million euros/year arise from it. The indirect
costs amount to 2.3 billion euros. Fifteen million people have
migraine. The time period in which a medicine induced duration
headache develops is 4.7 years for free saleable painkillers for Trip-
tane at 1.7 years. 2% (1,64 millions) have for the German medicine
induced duration headaches. With the retention of the usual Tristan
and others migraine means into combination with acupuncture,
therapeutical local analgesia after Trang (TLA after Trang) could
medicine induced duration headaches be reduced except for 0%.
The TLA after Trang, physiotherapy, phytotherapy, TENS, Moxi-
bustion, which are saving acupuncture analgesia with the Anaesthetic
and pain poor, side effect free, bleeding after the step scheme after
Trang can soothe or cure the duration headaches. If the effect of the
combination therapy is not sufficient, the pain infusion still can
improve the pain fighting with Procain, Novaminsulfon and aspirin
between the treatment appointment of 1 week. Blockade of the spinal
nerves, of the plexus cervicalis, the Ganglions stellatum, the Gan-
glions pterygopalatinum and become the demonstrates the PDA in the
C2-C7 area with contrast medium pictures.
Patients with unbearable duration headaches can be happy which can
to improve her quality of life help them that they have found therapy
methods finite. The patients despite side effect rich and not suffi-
ciently pain medicine with unbearable pains until her death without
the effective therapy after Trang is more refraining to set at once from
a rejection of the therapy after Trang by any institution for aid and
bodily injury because must bear.
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Primary headaches in multiple sclerosis: comorbidity
or symptom?
A. Avetisyan1, H. Vekilyan1, H. Hambardzumyan1, A. Karapetyan1,
A. Karapetyan2, E. Gevrorgyan3, H. Manvelyan1
1Neurology, YSMU, Yerevan, Armenia;
2Family Medicine, YSMU, Yerevan, Armenia;
3Neurology, NIH Armenia, Yerevan, Armenia
Aim The aim of this study was to investigate the prevalence of pri-
mary headaches and neuralgic pain (according to International
Headache Society criteria) in patients with Multiple Sclerosis (MS).
Study design We studied 33 patients with clinically definite MS
(diagnosis was confirmed by MRI criteria), and 24 (72.7%) of them
had complains on headaches. Only 6 (18.2%) of them reported that
headaches developed after diagnosis of MS, the rest reported the
presence of premorbid headaches.
Results The distribution of different types of headaches were like fol-
lowing: Tension Type headaches had 15 patients, or 62.5% out of 24,
Migraine - 6, or 25% out of 24 patients, Cluster headache was found in 1
patient (4.2%) and Trigeminal neuralgia was found in 2 patients (8.3%).
The association between different types of headaches and types of the
MS was following: neuralgia was found in two youngsters with
relapsing-remitting MS, the Tension type headaches had prevalence
in secondary progressive MS (12 out of 15 patients) and migraine was
associated again with relapsing-remitting MS, but in age group of late
20-ies - mid 30-ies.
Conclusion Primary headaches are common in MS patients. Despite
on many investigations, further analysis must be done toward
understanding of the connections between the type of MS and type of
headaches and if the headache or pain syndrome is the part of the MS
or is coincidencing with the demyelinating disease. Another studies
are needed to clarify the mechanisms underlying the association
between migraine and relapsing-remitting MS, and tension type
headaches and secondary progressive MS.
This is first report in the framework of undergoing research of Pain
Syndrome and clinical features of MS in Armenia.
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Brain-derived neurotrophic factor gene VAL66MET
polymorphism modulates reversible cerebral
vasoconstriction syndromes
S.-J. Wang1,2, S.-P. Chen1,2, J.-L. Fuh1,2
1Department of Neurology, Neurological Institute, Taipei Veterans
General Hospital, Taipei, Taiwan ROC;
2Department of Neurology, National Yang-Ming University School
of Medicine, Taipei, Taiwan ROC
Objective Brain-derived neurotrophic factor (BDNF) could affect
endothelial function and sympathetic activities, which constitute a
potential pathogenesis of reversible cerebral vasoconstriction syn-
dromes (RCVS). Here we investigated whether the functional BDNF
Val66Met polymorphism was associated with RCVS disease severity.
Methods Patients with RCVS and normal controls were prospectively
recruited and genotyped for the BDNF Val66Met polymorphism.
Consecutive magnetic resonance angiography (MRA) and transcra-
nial color-coded Doppler sonography were employed to evaluate
patient vasoconstriction. Genotyping results, clinical parameters,
vasoconstriction scores, mean flow velocities of the middle cerebral
artery (VMCA), and Lindegaard indices were analyzed.
Results Fifty-four patients with RCVS (M/F = 7/47; mean age:
47.3 ± 11.0 years) and 104 age- and gender-matched normal controls
finished the study. Three patients (5.6%) developed posterior
reversible encephalopathy syndromes (PRES) and three (5.6%)
developed ischemic stroke. The genotype frequencies for the BDNF-
gene Val66Met polymorphism did not differ comparing patients and
control subjects. Compared to Met/Met homozygotes, Val carriers
had higher mean vasoconstriction scores of M1 (1.36 ± 1.07 vs.
0.58 ± 0.67, p = 0.002), A1 (1.43 ± 0.84 vs. 0.89 ± 0.78, p =
0.024), and the basilar artery (0.78 ± 0.96 vs. 0.28 ± 0.67, p =
0.031), and higher VMCA values (110.5 ± 34.9 vs. 82.2 ± 20.8 cm/s,
p = 0.002). None of the Met/Met homozygotes, but 34.4% of the Val
carriers, had VMCA values of [ 120 cm/s. Clinical features and risk of
PRES or ischemic stroke were not associated with the polymorphism.
Conclusions BDNF Val66Met polymorphism is unlikely to play a
role in the genetic susceptibility to RCVS but may be associated with
increased vasoconstriction severity.
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Objective Seminal studies in small and selected groups of migraine
patients suggested an involvement of the white matter (WM) and gray
matter (GM) beyond the resolution of conventional imaging. Aim of
this study was to assess the patterns of regional distribution of damage
in the normal-appearing WM (NAWM) and GM in a large group of
migraine patients with different clinical (aura [MWA] vs. no aura
[MWoA]) and radiological (presence vs. absence of WM hyperin-
tensities [WMHs]) characteristics, using tract-based spatial statistics
(TBSS) and voxel-based morphometry (VBM).
Methods Using a 3.0 T scanner, high-resolution T1-weighted and
diffusion tensor MRI scans were acquired from 82 migraine patients
(40 with aura, 34 with WMHs) and 27 matched healthy controls.
Lesion probability maps (LPMs) were created averaging WHMs
maps. VBM analysis was performed using SPM5 and an ANCOVA
model, including age, gender and intracranial volume as nuisance
variables. TBSS analysis was performed using FMRIB0s Diffusion
Toolbox.
Results WMHs were mostly located in the WM subcortical areas with
an aspecific pattern. No abnormalities of the brain WM were detected
in patients with migraine (considered as a whole and subdivided in the
different study groups). In MWA GM loss involved, predominantly,
the posterior brain regions (parieto-temporo-occipital regions). In
migraine patients, the presence of WMHs was related to a more
complex and diffuse pattern of GM loss (frontal, occipital, temporal
cortex). The factorial analysis showed no interaction between aura
and lesions.
Conclusions and discussion The regional pattern of GM involvement
differs among migraine patients according to their clinical and
radiological characteristics. The absence of interaction between aura
and WMHs support the notion of different pathogenetic mechanisms
underlying the pleomorphic manifestations of migraineours.
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Functional connectivity of the visual network
in patients with migraine and different disease
phenotypes
M. Absinta1, M.A. Rocca1, B. Colombo2, P. Misci1, A. Falini3,
G. Comi2, M. Filippi1
1Neuroimaging Research Unit, Institute of Experimental Neurology,
Milan, Italy;
2Department of Neurology, Scientific Institute and University
Ospedale San Raffaele, Milan, Italy;
3Department of Neuroradiology, Scientific Institute and University
Ospedale San Raffaele, Milan, Italy
Objective To explore alterations in the visual network at rest (i.e.,
without external stimuli) in a large group of migraine patients, outside
the attack, with different clinical (aura [MWA] vs. no aura [MWoA])
and radiological (presence vs. absence of white matter hyperintensi-
ties [WMHs]) characteristics.
Materials Resting state (RS) functional MRI data were acquired from
87 migraine patients (43 with aura, 38 with WMHs) and 25 matched
healthy controls (HC). FC was investigated by examining the corre-
lation between the primary visual cortex (V1) and any other area in
the brain using REST software. The cross correlation spatial maps
obtained from each subject entered in a factorial analysis, corrected
for age and sex, to assess the within-group differences as well as the
selective effect of aura and lesions. The correlations between RS
changes and clinical data were assessed using linear regression
analysis.
Results Compared to HC, the whole sample of migraine patients had
an increased FC between V1 and the bilateral dorsolateral prefrontal
cortex (DLPFC), the bilateral intraparietal sulcus (IPS), and the
bilateral inferior frontal gyrus (IFG). Compared to MWoA, MWA had
an increased connectivity between V1 and the anterior cingulate
cortex (ACC). FC did not differ between patients with vs. those
without WMHs. The factorial analysis showed no interaction between
aura and lesions. In the entire sample of patients, no correlations were
found between FC changes and disease duration and frequency of
attacks.
Conclusions Abnormalities of FC within the visual network do occur
in patients with migraine. Such abnormalities are likely to reflect a
central dysregulation of visuo-spatial attention and short-term spatial
memory. MWA patients had a selective abnormal connection between
the visual network and the ACC, which is involved in intentional
motivation of eye movements, whereas the presence of WMHs is not
likely to modulate visual network rewiring.
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Chronic paracetamol treatment increases
the endothelial cell ultrastructural changes evoked
by cortical spreading depression
W. Supronsinchai1, S.M. le Grand2, A. Srikiatkhachorn1
1Department of Physiology, Faculty of Medicine Chulalongkorn
University, Bangkok, Thailand;
2Department of Pathology, Faculty of Medicine Chulalongkorn
University, Bangkok, Thailand
Background Chronic paracetamol administration increases the fre-
quency of cortical spreading depression (CSD) and Fos expression in
the somatosensory cortex suggesting increased cortical excitability
and trigeminal nociception (Supornsilpchai et al., 2010). This study
was conducted to determine whether chronic paracetamol exposure
affects the endothelial cell ultrastructural changes evoked by CSD.
Methods Male Wistar rats were separated into acute and chronic
paracetamol and control groups (8 rats each). Paracetamol (200 mg/
kg body weight, intraperitoneally (i.p.) was administered 1 hour and
30 days before CSD induction in acute and chronic paracetamol
group, respectively. 1,2-Propanediol (12.5% in 0.9% saline i.p.) was
administered to control rats. CSD was induced by topical application
of 3 mg of KCl to the frontal cortex. The endothelial cell ultra-
structural changes were examined using electron microscopy.
Results Changes in the ultrastructure of cerebral microvessels were
evident in the KCl-treated group. These changes were characterized
by an increase in microvilli and pinocytic vesicle formation. The
number of microvilli in capillaries and arterioles were 1.27 ± 0.56
and 10.75 ± 5.28 microvilli per vessel in the chronic control group
and 3.26 ± 1.33 and 23.75 ± 9.03 microvilli per vessel in the chronic
paracetamol treated group, respectively. The average density of
pinocytic vesicles in capillaries and arterioles were 34 ± 9 and
44 ± 7 vesicle per lm2 in the chronic control group and 32 ± 6 and
59 ± 11 vesicle per lm2 in the chronic paracetamol treated group,
respectively. The number of microvilli and pinocytic vesicles in
capillaries and arterioles in chronic paracetamol treated group and
chronic control groups were statistically different. No significant
change in endothelial cell ultrastructure was observed between the
acute paracetamol treated group and the acute control group.
Conclusion Chronic paracetamol exposure may increase the fre-
quency of headache by causing vascular changes in the cerebral
cortex.
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A novel mutation in SLC1A3 associated with pure
hemiplegic migraine
T. Freilinger1,2, J. Koch3, M. Dichgans1,2, H. Mamsa4, J.C. Jen4
1Department of Neurology, Ludwig-Maximilians-Universita¨t
Mu¨nchen, Klinikum Großhadern, Munich, Germany;
2Institute for Stroke and Dementia Research, Klinikum der
Universita¨t Mu¨nchen, Munich, Germany;
3Department of Paediatrics, Salzburger Universita¨tsklinikum,
Salzburg, Austria;
4Department of Neurology, UCLA School of Medicine,
Los Angeles, CA, USA
Introduction Hemiplegic migraine, either familial (FHM) or sporadic
(SHM), is a severe subtype of migraine with aura characterized by
hemiparesis during the aura. Mutations in three genes involved in ion
translocation (CACNA1A, ATP1A2 and SCN1A) have been identified
in FHM and rare individuals with SHM. Enhanced glutamate release
facilitating cortical spreading depression has been observed in murine
FHM models and proposed to underlie migraine with aura. Here, we
describe a 16-year-old boy with SHM, in whom a novel mutation was
identified in the gene SLC1A3 encoding a glial glutamate transporter
EAAT1.
Clinical and genetic findings Since age 11, the patient has suffered
several episodes of right-sided hemiparesis with aphasia, followed by
migrainous headache; of note, no (episodic) ataxia or epileptic sei-
zures were observed, and family history for HM was negative.
Mutation testing in the known FHM genes was negative. Based on the
previous finding of a mutation in SLC1A3 in a child with episodic
ataxia, hemiplegia, migraines, and seizures, we sequenced SLC1A3 to
find a heterozygous nucleotide change c.1159A [ C (NM_004172).
Analysis of the parental DNA revealed presence of the variant in the
father (who is affected by migraine without aura), suggesting incomplete
penetrance.This variant was not detected in 100 control chromosomes. It
alters a highly conserved residue (T387P) in the functional motif
important in transport, as confirmed by in vitro glutamate uptake assays
demonstrating a 70% decrease in the mutant protein.
Conclusions We discovered in a boy with SHM a novel nucleotide
variant in SLC1A3 which likely represents a pathogenic mutation
because of evidence of strong evolutionary conservation for the wild
type residue and marked deleterious impact on glutamate transport by
the mutant protein. Our observation suggests that, similar to muta-
tions in CACNA1A that enhance glutamate transmission, mutations in
SCL1A3 that impair glutamate reuptake can be associated with HM.
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Adolescent’s primary headache: epidemiology
and socio-economic factors
A. Januskeviciene, E. Vaitkaitiene, A. Zaborskis, I. Lenciauskiene
Social Paediatrics, Institute of Biomedical Researches of Kaunas
Medical University, Kaunas, Lithuania
Background Headaches are one of frequent complaints diagnosed in
children and adolescents. The objective of this study is to evaluate the
prevalence rates for headache among the Lithuanian sample of early-
adolescents and the role of possible related socio-economic factors.
This study is a part of the Cross-National Survey on Health Behavior
in School-aged Children - World Health Organization Collaborative
Study (HBSC).
Methods In total, 5,557 students (2,904 (51.6 %) boys and 2,728
(51.6 %) girls aged 11, 13 and 15 years old from Lithuania were
surveyed in the 2005–2006 school-year. The research was carried out
according to the methodology of the HBSC study using the anony-
mous standardized questionnaire The response rate was 90 %. The
evaluation an impact of socio-economic factors was based on 8 items:
(1) family income,




(6) spending time with friends,
(7) being bullying at school.
Results The overall prevalence of frequent headache (at least once a
week) was 30.9%. Boys are less at risk than girls (c2 = 163,048;
df = 1; p \ 0,000) and the prevalence increases with age. Family
income had a strong association with adolescent’s headaches and
significantly more prevalent among girls from low income families
(c2 = 13,889; df = 2; p \ 0,001). Adolescents who lived in two-
parent families and had good relationships with their parents expe-
rience less headache cases (c2 = 20,415; df = 3; p \ 0,000). The
school environment (pressure at school, peers relationship) showed a
significant association with the headache prevalence.
Conclusion The findings underline the role of family and school
social support in the prevalence of adolescent’s headache, which
should be considered by health promoters.
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Unilateral and bilateral trigeminal autonomic
symptoms in cluster headache
N. Christmann, D. Holle, Z. Katsarava, M. Obermann, C. Gaul
Headache Center, Department of Neurology,
University Duisburg-Essen, Essen, Germany
Aim To investigate prevalence of unilateral and bilateral trigeminal
autonomic symptoms in cluster headache (CH).
Methods Hundred and seventy patients with CH according to the
ICDH-II were studied using a standard questionnaire with regard to
the clinical features with special interest on accompanying trigeminal
autonomic symptoms.
Results Hundred and seventeen patients had episodic, 49 patients had
chronic CH and 4 patients fulfilled criteria for probable CH. The
male-to-female ratio was 3.6:1, mean age 44 years. The vast majority
of the trigeminal autonomic symptoms occurred on the headache side.
The most frequent reported trigemino autonomic symptom was lac-
rimation (92%) followed by nasal congestion (64%), rhinorrhea
(70%), conjuctival injection (62%), ptosis (54%), lid edema (34%),
miosis (29%) reddening of the face (25%) and sweating of the fore-
head (24%) or face (24%). Rarely, autonomic symptoms occurred
bilaterally: rhinorrhea (6%), sweating of the forehead (6%) or of the
face (4%), reddening of the face (4%) miosis (1%) and lacrimation
(\1%). Interestingly, 20% of the patients reported a side shift of the
cluster attacks and in this case the side of the trigeminal autonomic
symptoms followed the pain. Most of the patients (78%) suffered
from more than three accompanying symptoms.
Conclusions The data suggest that a thorough and systematic
observation reveals bilateral trigeminal autonomic symptoms in
cluster headache.
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Migraine and progenitor endothelial cells
X. Rodrı´guez Osorio, T. Sobrino, R. Leira, M. Blanco,
M. Rodrı´guez Ya´n˜ez, S. Arias Rivas, J. Castillo
Department of Neurology, Clinical Neuroscience Research
Laboratory, Hospital Clı´nico Universitario, University of Santiago de
Compostela, Santiago de Compostela, Spain
Purpose Endothelial dysfunction in migraine (investigated by ultra-
sound imaging and biological markers) has been shown in several studies.
Endothelial progenitor cells (EPC) indicate endothelium regeneration
ability. The purpose of this study is to quantify the number of EPC
colonies in migraine patients and its relation with clinical parameters.
Methods Prospective study of 47 patients with migraine (33
migraines without aura and 14 migraines with aura, according to IHS
2004 criteria) and 23 healthy controls. We excluded subjects with
known vascular risk factors and acute or chronic inflammatory/
infectious conditions. The main characteristics of migraine attacks
(frequency, severity and duration) and the duration of the disease
were recorded. EPC counts (colonies/106 cells cultured) were deter-
mined in peripheral blood during intercritical periods.
Results Migraine patients had lower EPC colony counts than controls
(17.9 ± 6.0 vs 9.4 ± 5.0; p \ 0.0001). No significantly differences
were found between migraine with or without aura (9.1 ± 4.8 vs
10.2 ± 5.7; p 0.701). EPC colony counts B 10 correlated with clin-
ical diagnosis of migraine with a sensitivity of 91% and a specificity
of 73%. Inverse correlation between counts of EPC colonies and time
of evolution of migraine was observed (p \ 0.0001). No correlations
were found among EPCs and other clinical parameters of migraine
(frequency, severity or duration of attacks).
Conclusion EPC counts are lower in migraine patients and correlate
with the duration of the disease. These findings suggest the persis-
tence of an altered endothelial function in patients with migraine.
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Feasibility of a brief intervention for medication-
overuse headache: a pilot study
E.S. Kristoffersen1,2, J. Straand1, M.B. Russell3,4, C. Lundqvist2,3,5
1General Practice Research Unit, Section of General Practice,
Institute of Health and Society, University of Oslo, Oslo, Norway;
2HØKH, Akershus University Hospital, Lørenskog, Norway;
3Head and Neck Research Group, Research Centre, Akershus
University Hospital, Lørenskog, Norway;
4Institute of Clinical Medicine, Akershus University Hospital,
University of Oslo, Nordbyhagen, Norway;
5Department of Neurology, Oslo University Hospital Ulleva˚l,
Oslo, Norway
Background We have previously demonstrated that people with
medication-overuse headache (MOH) in the general population can
be identified by using a short screening instrument for behavioural
dependence, the Severity of Dependence Scale (SDS). Short simple
information was enough to detoxify the majority of those with MOH.
We have used this background information to adapt the ‘‘brief
intervention’’ (BI) scheme to be used for MOH in general practice.
Methods The method involves a simple approach for identifying
patients with high likelihood of MOH using only one question about
headache frequency and the SDS score. The structured BI involves
giving feed-back to the individual patient on his/her score and con-
sequences this might have regarding the individual risk of medication
overuse contributing to the headache. Finally, advice is given
regarding measures to be taken, how the patient should proceed and
the possible gains for the patient.
A course for structured intervention based on the BI principles was
offered to a pilot group of six general practitioners (GPs). The screening
question for headache frequency was sent by mail to all 18–50 year old
patients on the GPs list. Those who reported chronic headache were then
examined by GPs who performed the BI on MOH suspected cases. The
pilot study was undertaken in order to focus on the logistics and meth-
odology and did not involve a control group. Follow up with interviews of
the patients was performed one month later.
Results and conclusion The GPs involved reported that the BI was
feasible to implement within a busy practice and that the BI repre-
sented a new instrument for communication with these patients.
Results regarding the patients are currently being analyzed and will be
presented at the meeting.
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Primary chronic headache; treatment patterns
and health service contacts the akershus study
of chronic headache
E.S. Kristoffersen1,2, R.B. Grande2,3, K. Aaseth2,3, C. Lundqvist2,4,5,
M.B. Russell2,3
1General Practice Research Unit, Section of General Practice,
Institute of Health and Society, University of Oslo, Oslo, Norway;
2Head and Neck Research Group, Research Centre, Akershus
University Hospital, Lørenskog, Norway;
3Institute of Clinical Medicine, Akershus University Hospital,
University of Oslo, Nordbyhagen, Norway;
4HØKH, Research Centre, Akershus University Hospital,
Lørenskog, Norway;
5Department of Neurology, Oslo University Hospital Ulleva˚l,
Oslo, Norway
Objective To investigate use of health services and pharmacological
and non-pharmacological treatment for primary chronic headache
from the general population.
Background Primary chronic headaches are associated with disability,
frequent use of health services and various treatments. Patients in spec-
ialised headache clinics, general practices and the general population
differ. Most current knowledge about primary chronic headache is from
selected specialised clinics. Knowledge of pattern of medication use and
use of alternative treatments is also important.
Methods An age and gender stratified cross-sectional survey included
30,000 persons aged 30-44 years from the general population. A
posted questionnaire screened for chronic headache. Those with self-
reported chronic headache were interviewed. The International
Classification of Headache Disorders was used. Participants with
primary chronic headache were asked about previous physician
contacts, medication usage including the Severity of Dependence
Score (SDS) and alternative treatment.
Results The questionnaire response rate was 71%, the interview
participation rate 74%.
Of primary chronic headaches, 19% had never consulted a physician,
63% had consulted their GP, and 17% consulted both GP and neu-
rologist for headache. Those with chronic tension-type headache
(CTTH) and medication-overuse headache (MOH) had similar con-
sultation pattern. Co-occurrence of migraine significantly increased
consultations with GP and neurologist.
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87% used acute medications for their headache and 46 % overused
medication.
9 % used acute medication daily. The SDS score was significantly
higher for MOH than CTTH for all levels of physician contact. Pri-
mary chronic headache subjects in contact with physicians had
significantly higher SDS than those without such contact. Only 4 % of
primary chronic headaches used prophylactic treatment.
63% had used alternative treatment, mostly physiotherapy, acupunc-
ture and chiropractic. Use of alternative treatment differed between
different physician contact levels.
Conclusions The use of headache medication, neurologist contact and
alternative treatments for headache increases the more complex the
headache is.
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Antialgic effect of low intensity laser in the treatment
of cervicogenic headaches
R. Pizzo1, J.G. Speciali1, F. Dach1, C.A. Bordini1, R.Z. Lizarelli2
1Neuroscience - Division of Neurology, Medicine School of Ribeira˜o
Preto - University of Sa˜o Paulo, Ribeira˜o Preto;
2Physics Institut, Optics Group, Biophotonics Laboratory - University
of Sa˜o Paulo, Sa˜o Carlos, Brazil
Background and aims Cervicogenic headache (CH) is any type of
headache originating in low neck structures. It is characterized by
nuchal and/or frontotemporal pain triggered by disturbances in the
neck region at the C1, C2 or C3 level. Blockade of the major and
minor occipital nerves is performed for therapeutic and diagnostic
purposes. To determine the effect of low intensity laser (GaAlAs)
applied to the region of the major and minor occipital nerves and/or of
the C2 root on the symptomatic side for the treatment of cervicogenic
headaches, as an alternative procedure to conventional blockade.
Methods Twenty patients from the Headache Outpatient Clinic of the
University Hospital of FMRP/USP were submitted to the procedure.
Each patient was evaluated by a neurologist, who made the diagnosis
of CH (SJAASTAD, 1990). The patients were submitted to laser
applications (780 nm,70mW, continuous) on the symptomatic side at
8 trigger-points located by palpation in the region of the major and
minor occipital nerves, with one D = 157,5 J/cm2 per point being
applied once a week for 4 weeks. The patients filled out a pain diary
(scores of 0 to 10) and were evaluated on four occasions: A0 (before
the 1st application), A1 (immediately after the last application), A2
and A3 (30 and 60 days after the last application).
Results The weekly mean pain score was calculated (AO = 9.635;
A1 = 2.638; A2 = 2.788; A3 = 2.937) and analysis of the results
identified statistically significant differences (p = 0.001, paired t-test)
between A0 and A3 regarding pain intensity.
Conclusion On the basis of the above data, we may suggest that low
intensity laser promoted a reduction of the intensity and frequency of
symptoms.
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Manipulation of vision by prismatic spectacles blunts
migraine in meniere patients
E. Vente
Balance & Orientation, Utermo¨hlen Institute, Alphen aan den Rijn,
The Netherlands
The chronic use of weak asymmetric base-in prism spectacles
(WABIPS) developed by Utermo¨hlen in 1941 1 is a non-invasive
treatment of Me´nie`re vertigo, also reported to be effective against
motion sickness 2. We evaluated this treatment in a cohort study of
336 unilateral Me´nie`re patients (according to AAS) with 97% sub-
jective satisfaction and reduction of vertigo symptomatology, and
57% significant reduction and stopped concomitant medication. We
found also that before treatment 137 (40.8%) of patients with Me´nie`re
also had migraine episodes (according to IHS). After 12 months
treatment 59 (17.6 %) had still migraine episodes. Migraine lifetime
prevalence is 17% 3. From this report, it seems reasonable to suspect
that Me´nie`re and migraine constitute a heterogeneous population 4.
Apart from this effect, data shows that migraine can be influenced by
visual factors 5, such as induced by WABIPS which may have con-
sequences for the presenting dynamic visual images to people
sensitive to migrainous phenomena. Further studies might include
WABIPS for patients with migraine presenting dynamic visual
images.
1. Utermo¨hlen GP. Het prisma effect bij de Ziekte van Me´nie`re.
Nederlands Tijdschrift Geneeskunde 1941; 85:1183-8.
2. Vente PEM, Bos JE, de Wit G. Motion Sickness Amelioration
induced by prism spectacles. Brain Research Bull, Vol.47.no5.pp
503-505, 1998.
3. Stewart WF, Lipton RB, Celentano DD, Reed MD. Prevalence of
migraine headache in the United States: relation to age, income,
race and other sociodemographic factors. JAMA 1992;267:64-69.
4. Radtke A, Lempert T, Gresty MA, et al. Migraine and Me´nie`res
disease; Is there a link? Neurology 2002;59:1700-1704.
5. Harle DE, Shepherd AJ, Evans BJ. Visual stimuli are common
triggers of migraine and are associated with pattern glare.
Headache. 2006 Oct;46(9):1431-40.
Conflict of interest Vente E. In the last 5 years we have received
sponsoring to attend congress from Menarini, Teva Pharma, Almirall
and MSD. Part of the statistical analysis of this work has been
financed with help of The Uterm¼hlen Stitching and Instituut voor
Zintuigfysiologie, TNO, Soesterberg, The Netherlands. The registra-
tion fees has been paid for 50% by Menarini this time.
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Efficacy of intravenous magnesium sulfate in acute
attacks of migraine
A.A. Abrishami Zadeh
Neurology, Hormozgan Medical University, Bandarabbas, Iran
Attacks of migraine are one of the common causes for emergency
ward admissions.despite effective abortive treatments a completely
safe,cheap and effective drugs seems to be lacking.some of these
drugs have distressing side effects or contraindicated in some medical
conditions.during recent years some investigators has attached a great
importance to the role of magnesium in migraine.
Materials and methods In this double blind randomized placebo
controlled study among patients admitted in emergency ward with
attack of headache, 30 migraine patient (IHS criteria) was selected
and randomized to two groups, receiving either iv 10 cc normal saline
or magnesium sulfate 2gr iv slowly over 5 min. if after 30 minutes no
headache relief was‘ noted in both groups, in the second phase
magnesium sulfate and normal saline was administered in a cross over
manner eg:placebo group received mg (2gr) and active arm received
normal saline. both groups were visited immediately after injection
and at 30 min, 2 hr and 24 hr intervals to monitor probable side
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effects and relief of headache and associated symptoms. Statistical
analysis was performed between two groups with t-test and p-value.
Finding and results In 14 out of 15 (93.3%)patients in active group
there was significant relief of headache (13 complete relief and 1
partial relief and 1 got no relief but in all of them there was complete
relief of nausea,vomiting, photophobia and phonophobia. none of 15
pts(0%) in placebo arm report headache relief but associated symp-
toms was relieved in 2 pts. interestingly in second phase after
magnesium administration to placebo group in 14 pts out of 15
(93.3%) there was significant relief of both headache and associated
symptoms. no significant side effect of mg except flushing was
noted.our study showed a clear cut efficacy of 2gr mgso4 in acute
migraine but large scale study is recommended.
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Quantative electroenecephalographic (QEEG)
parameteres in children with postraumatic chronic
headache (PCH)
N. Kapanadze1, S. Bakhtadze2, N. Geladze1, N. Khachapuridze2
1Pediatric Neurology, Tbilisi State Medical University,
Tbilisi, Georgia;
2Neuromedicine, Tbilisi State Medical University, Tbilisi, Georgia
Objective It is known that posttraumatic chronic headache is very
frequent condition in childhood population (6-12 year of age). The
precise assessment of this condition by neurometric tools is extremely
important. The aim of our research was to study children with PCH
and assess their QEEG changes connected to different cognitive
processes.
Method We have investigated 24 children with PCH (Age range 9-
12 year, 18 boys, 6 girls) and 31 normal children of the same age
without PCH (20 boys and 11 girls). All children with other comor-
bidity and with low IQ were excluded from study. QEEG was
conducted on Neurotravel device (version 6.12). Spectral analysis and
frequency bands were identified in all of them. Assessment of cog-
nitive processes were done by simplest Raven’s test. 2 correct answer
from 7 Raven’s sample was recognized as normal.
Results In children with PCH the power and amplitude of low
frequency delta activity (0.5-1 Hz) known as mental activity delta
was significantly lower (* 40%) than in control ones. This opinion
was confirmed from spectral analysis evidences and by frequency
bands mapping. Besides, the errors when making Raven’s tests
were more frequent in PCH children (4 and more) then in control
group.
Conclusions Cognitive processes in children with PCH is more
handicapped compared with their normal teenagers. Thus, the basic
management of such patients needs to be supported with cogniceu-
ticals in order to prevent different, even slightly expressed cognitive
declines linked with the PCH.
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Association of obesity and migraine in children
T. Eidlitz-Markus, Y. Haimi-Cohen, D. Steier, A. Zeharia
Day Hospitalization Unit, Schneider Children’s Medical Center
of Israel, Sackler Faculty of Medicine, Tel Aviv University,
Petach-Tikva, Israel
Objective To determine the possible relationship of obesity and
migraine in Israeli children and to compare the findings to an earlier
study from Turkey.
Background The possible association of migraine and obesity has
been investigated in adults, but only one study, from Turkey, has been
conducted so far in children.
Methods The files of all children with a diagnosis of migraine
who attended the day care department of a tertiary university-
affiliated pediatric medical center in Israel from 2004 to 2009
were reviewed. Data were collected on patient background (age,
sex, weight, height, ethnicity, religion) and migraine symptoms,
frequency, and duration. Body mass index (BMI) and BMI stan-
dard deviation score (SDS) were calculated according to the CDC
criteria, and patients were divided as follows: normal weight
(BMI SDS -1 to +1), overweight (BMI SDS -1 to \ 2), obese
(BMI SDS C 2).
Results The study group included 132 patients, 56 male and 76
female, aged 3-18 years. Ninety-seven (73.5%) were normal weight,
27 (20.5%) were overweight, and 8 (6%) were obese. There were no
significant differences among the weight groups in migraine symp-
toms, attack frequency, disease chronicity, or disease duration. By
contrast to the earlier study from Turkey, no significant association
was found between pediatric migraine and obesity.
Conclusions The link between migraine and obesity in children
remains controversial. The difference in results between our study and
those in a group of Turkish children highlights important factors that
researchers should focus on in further studies of this issue, such as
age, disease duration before admission, frequency of attacks per
month, and degree of overweight. Importantly, ethnicity and genetic
background may also play an influential role.
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Role of RBC-MG and visual aura intensity in (FSS
and complex partial seizure) epilepsy and migraine
with aura patients
A. Ibadi1, A. Fredman2, M. Czeczko1
1Neurology, Sochaczew District Hospital, Sochaczew, Poland;
2Neurology, Warsaw Medical University Hospital, Warszawa, Poland
Objectives RBC-Mg concentrations influence on visual aura in
(FSS and complex partial) epilepsy and migraine with aura
patients.
Introduction Magnesium is a potential modulator of seizure activity
and development of cortical spreading depression (CSD) through
enhance the sensitivity of the N-methyl-D-aspartate(NMDA) recep-
tors to glutamate. Visual phenomena : lightnings, disturbed contours
of objects, or skotoma, can be due to ophthalmological diseases, but
can also occur as symptoms generated by the central nervous system
(‘‘aura’’) in migraine or epilepsy. Aura is a brief subjective symptom
that may represent the initial manifestation of a partial epileptic sei-
zure with objective signs or constitute the entire epileptic attack (focal
sensory seizure (FSS). The visual aura of the migraine attack has been
explained by the cortical spreading depression (CSD), neuroelectric
event beginning in the occipital cortex and propagating into contig-
uous brain region.
Materials Twenty patients with migraine with aura(MA)(12 females
and 8 males, mean age :30) and ten patients with FSS and Complex
Partial epilepsy (5 females and 5 males, mean age:30,9) were diag-
nosed according to the classification of IHS and ILAE. FSSs were
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subdivided according to the type of sensation in somatosensory,
simple visual or oculosensory, viscerosensory, and experiential sen-
sations,who have definitive epileptogenic EEG activity in the
temporal-parietal-occipital area.10 ml of venous blood sample was
collected and measured red blood cells magnesium concentrations by
atomic absorption spectrometry(850 nm, Perkin-Elmer 3030).
Results Low RBC-Mg concentrations were found in 42% patients of
MA and 55% in FSS and complex partial epilepsy patients during
aura seizures.
Patients with lower RBC-Mg concentrations (\1.80-/+ 0.24) had in
93% aggravation of visual aura intensity during attacks.
Conclusions Low RBC-Mg could be a peripheral expression of the
reduced brain magnesium concentration observed in MA and (FSS
and complex partial) epilepsy patients. Magnesium supplements
could be benefits in reduction the intensity of visual aura in both
groups.
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Adverse events related to the NTI splint: report
from the headache hope study
A. Blumenfeld
The Headache Center of Southern California, Encinitas, CA, USA
Background Migraine is a prevalent and disabling condition, for
which treatment options remain limited. Many patients do not wish to
take oral preventive medications. The NTI splint is FDA approved for
the treatment of migraine. However, the use of this option amongst
headache experts is limited in part due to fear of potential dental,
rather than systemic, adverse events.
Objectives This study used a web based questionnaire to collect data
from dental providers on the methods of use and observed adverse
events of the NTI splint in their practices.
Methods A web-based questionnaire was e mailed to dental providers
in the United States.
Respondents were identified from dental laboratory and distributor
records of documented NTI splint providers.
Questions on the methods of use of the NTI splint and outcomes were
asked.
Analysis of the data is expressed as a percentage of total respondents.
Results Of 6,312 panelists contacted, 567(9%) responded.
Respondents were largely male (506/567: 89%) and had on average
prescribed 160 NTI splints each.
The total number of NTI splints provided by this group of dental
professionals was 90,720.
512/567 responded to the question regarding changes in occlusion
secondary to NTI splint use.
The number of patients reported to develop a clinical observation of
abnormality of occlusion with an anterior open bite as a result of NTI
splint use was reported at: 1.6% of 78,711 cases.
Only 0.3% of patients reported aspirating the device; however 0%
reported documented aspirations on X ray.
The dental providers rated the NTI splint as an effective treatment for
headache in the majority (over 90%) of the patients they treated.
Conclusions Headache can be effectively and safely treated with the
NTI splint in dental practices.
Sponsor: National Dentex Corporation.
Conflict of interest Dr. Blumenfeld has acted as a consultant, speaker
or received research support from Allergan Pharmaceuticals.
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Headache in 25 consecutive patients with atrial septal
defects before and after percutaneous closure:
a prospective case series
F. Riederer1, H. Baumgartner2, P.S. Sa´ndor1,3, P. Wessely4,
C. Woeber4
1Neurology, University Hospital Zurich, Zurich, Switzerland,
2Congenital and Valvular Heart Disease Center, Medical University
Mu¨nster, Mu¨nster, Germany;
3Neurology, Kantonsspital Baden, Zurich, Switzerland;
4Neurology, Medical University Vienna, Vienna, Austria
The effect of atrial septal defect (ASD) closure on headache and
migraine remains a matter of controversy. The objectives of the study
were (i) to determine headache prevalence in consecutive patients
with ASD scheduled for percutaneous closure using the classification
of the International Headache Society and (ii) to compare headache
characteristics before and after closure of ASD. Twenty-five patients
were prospectively included over 27 months. Mean duration of fol-
low-up was 12 ± 4 months. Prevalence of active headache was
increased compared to general population: Any headaches 88%,
migraine without aura 28%, migraine with aura 16%. After ASD
closure, we observed a trend towards a lower headache frequency
(median frequency 1.0; IQR 2.6 vs. 0.3; IQR 1.5 headaches per
month; p = 0.067). In patients with ongoing headaches, a decrease in
headache intensity (median VAS 7; IQR 3 vs. 5; IQR 3.8; p = 0.036)
was reported. Three patients with migraine with aura before the
intervention reported no migraine with aura attacks at follow-up, two
of them reported ongoing tension-type headache, one migraine
without aura. In summary, this prospective observational study con-
firms the high prevalence of headache, particularly migraine, in ASD
patients and suggests a possible small beneficial effect of ASD
closure.
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Headache and BOTOX: a case report of hemicrania
continua responsive to botulinum toxin type-A
S. Ramdas1, M. Prasad1,2, I. Abu-Arafeh2,3
1Tayside Childrens Hospital, Dundee, Scotland;
2Department of Paediatrics, Stirling Royal Infirmary,
Stirling, Scotland;
3Fraser of Allander Neuroscience Unit, Royal Hospital for Sick
Children, Glasgow, UK
Introduction Hemicrania continua (HC) is a rare headache disorder
characterized by a continuous unilateral headache that varies in
intensity, without disappearing completely. HC is typically responsive
to Indomethacin, although patients resistant to this drug have been
described. We present a case of HC who has shown remarkable
response to Botulinum Toxin type A (BT-A).
Case presentation A 12-year old boy presented with a 2-year history
of pain over the right side of his head, worst behind his right ear. The
pain was constant, dull aching in nature with periods of exacerbation.
The exacerbations were mostly nocturnal with bursts of fireworks like
pain, occurring in clusters many times over a period of 3-4 days.
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During these clusters, he cries, grabbing his right ear and develops red
marks in front of this ear with ipsilateral facial pallor. The longest
pain free period was not more than 2 weeks. Clinical examination
including ENT and Maxillofacial assessments were normal. Investi-
gations including a MRI brain were unremarkable.
The symptoms failed to respond to treatment with various medications
including analgesics, Carbamazepine, Gabapentin, Amitriptyline or
Pizotifen. Indomethacin test, trial treatment with Indomethacin and
Occipital nerve block with Lidocaine were also unsuccessful.
Behavioural therapy was also tried with no benefit.
Subsequent treatment with BT-A into the Occipitalis muscle has
shown a remarkable and sustained response for 3 months but required
further injection after 3 months for recurrence which has maintained
his symptom relief, allowing the child back to full time school after a
2-year period.
Conclusions BT-A injections have been shown to be beneficial in
adults with chronic migraines. However literature reports of its use in
Paediatric cases are limited with none found on HC. Our case sup-
ports further trials of BT-A in children with HC poorly responsive to
medications.
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Menstrual headache: subtypes, clinical features
and treatment
M.E. Toribio-Diaz1, V. Medrano-Martinez2, J.M. Molto-Jorda3,
J. Morera-Guitart4, A. Perez-Sempere5, G. Mas-Sese6,
S. Palao-Duarte5, I. Beltran-Blasco7, J.M. Callejo-Dominguez8,
P.E. Bermejo9, M.A. Zea-Sevilla1
1Neurology, Hospital del Henares, Madrid, Spain;
2Neurology, Hospital Virgen de la Salud, Elda, Spain;
3Neurology, Hospital Virgen de los Lirios, Alcoi, Spain;
4Hospital La Pedrera, Denia, Spain;
5Neurology, Hospital General Universitario, Alicante,
Spain;
6Neurology, Hospital Francisco Borja, Gandia, Spain;
7Neurology, Clı´nica Benidorm, Benidorm, Spain;
8Neurology, Hospital Vega Baja, Orihuela, Spain;
9Neurology, Hospital Universitario Puerta de Hierro,
Madrid, Spain
Introduction Menstrual migraine has been included in the second
edition of IHS. Menstrual tension-type headache has not been
recognised yet . Our aim is to evaluate the prevalence of different
subtypes of menstrual headache, to analyze their clinical features and
the treatment prescribed.
Material and methods We prospectively included women attending
several neurology outpatient clinics (January-November 2008).
Women included should be of child-bearing age, their reason for
seeking neurologic care was headache and their headache appeared
during the menstrual period. Their headache was classified: pure
menstrual migraine (PMM), menstrual-related migraine (MRM), pure
menstrual tension-type headache (PMTH) and menstrual-related
tension-type headache (MRTH). Clinical features of each type and
medication prescribed before/after neurological evaluation were
analyzed.
Results 133 patients were included (mean age 34.8 ± 8.9 years).
29.3% suffered from PMM, 58.7% MRM, 4.5% PMTH and 7.5%
MRTH. Clinical features: 75% slow onset; 56.4%PMM,
57.7%MRM hemicranial location; 84%PMTH, 50% MRTH hol-
ocranial/posterior; 87.2% PMM, 71%MRM pulsatile quality, 100%
tensional type oppressive quality; 71.8% PMM, 60.3% MRM
severe intensity, 50%PMTH, 60%MRTH moderate intensity.
Before neurological evaluation 50% were not receiving prophy-
lactic treatment (PMM 69%, MRM 37.9%, PMTH 80%, MRTH
60%). Amitriptyline in MRTH (33.4%), betablockers/amitriptyline
in MRM (20.8%/13.8% respectively). 100% of tension-type head-
ache were treated with NSAIDs. Migraine patients: NSAIDs alone
(58%), associated with triptans (10.2%), with triptans alone
(31.8%). After neurological evaluation prophylactic treatment was
prescribed in 83.5% MRM (42.3% topiramate), 58.4% PMM
(16.7% topiramate, 8.9% betablockers). Amitriptyline in tension-
type headache (33.4% PMTH, 40% MRTH). Symptomatic treat-
ment prescribed: NSAIDs in tension-type headache (83.3% PMTH,
70% MRTH), triptans with NSAIDs (48.7%) or alone (33%) in
migraine patients.
Conclusion Our data suggest that menstrually related tension-type
headaches exists with a prevalence about 12%. Evaluation by a
neurologist allows to easily recognise and classify these types of
headaches. This parameter has a great influence in therapeutic final
decision.
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Immunoreactivity of calcitonin gene-related peptide
(CGRP) and its receptor components in human
and rat spinal trigeminal nucleus
S. Eftekhari, L. Edvinsson
Department of Clinical Sciences, Division of Experimental Vascular
Research, Lund University, Lund, Sweden
Calcitonin gene-related peptide (CGRP) has a key role in the migraine
pathophysiology and is associated with activation of the trigemino-
vascular system. The trigeminal ganglion, storing CGRP and its
receptor components project peripheral to the intracranial vasculature
and central to different regions in the brain stem with Ad- and C-
fibers; this constitutes an essential part of the pain pathways activated
in migraine attacks. Therefore it is of importance to identify the
regions within the brainstem that processes nociceptive information
from the trigeminovascular system, such as the spinal trigeminal
nucleus (STN).
Immunofluorescence method was used to study the distribution of
CGRP and its receptor components, calcitonin like receptor (CLR)
and receptor amplifying peptide 1 (RAMP1), in human STN (Sp5C),
and compare that of rat, using a set of newly characterized antibodies
(Eftekhari et al. 2010).
We observed immunoreactivity for CGRP and its receptor compo-
nents in the STN. The highest density of CGRP immunoreactive
fibers were found in a network around fiber bundles in the superficial
laminae. Except immunoreactive fibers, CGRP positive neurons were
found in the rat brainstem (on the level of the inferior olive and the
hypoglossal nucleus). However, no positive neurons were found in the
human brainstem. The CLR and RAMP1 expression were predomi-
nately found on fibers in the spinal trigeminal tract (Sp5), with some
fibers spanning into the superficial laminae. Co-localization between
CGRP and its receptor components were rarely noted. Interestingly,
RAMP1 and CLR positive fibers were also detected close to the
central canal of the brainstem of both human and rat.
This study demonstrates the expression of CGRP and its receptor
components in the STN, and for the first time indicating the possi-
bility of CGRP signaling in the human STN. Our results suggest STN
as a possible site of action for the recently developed CGRP receptor
antagonists.
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Migraine in patients with colonic sensorimotor activity
and irritable bowel syndrome
E. Pucci1, M. Di Stefano2, F. Racca2, R. Fasulo2, G. Sandrini3,
G.R. Corazza2, G. Nappi4
1Headache Science Centre, IRCCS ‘National Neurological Institute
C. Mondino’ Foundation and University of Pavia; University
Consortium for the Study of Adaptive Disorder and Headache
(UCADH), Pavia, Italy;
2First Department of Medicine, University of Pavia, IRCCS ‘S.
Matteo’ Hospital, Pavia, Italy;
3Headache Science Centre, IRCCS ‘National Neurological Institute
C. Mondino’ Foundation and University of Pavia. University
Consortium for the Study of Adaptive Disorder and Headache
(UCADH), Pavia, Italy;
4Headache Science Centre, IRCCS ‘National Neurological Institute
C. Mondino’ Foundation and University of Pavia; University
Consortium for the Study of Adaptive Disorder and Headache
(UCADH), University La Sapienza, Rome, Pavia, Italy
Background and aims We have recently shown that in patients with
migraine and functional dyspepsia an alteration of postprandial gas-
tric sensorimotor function is evident. Alterations of both visceral
sensitivity and motor activity are also described in irritable bowel
syndrome (IBS) due to alterations of serotoninergic pathways, which
proved to be also responsible for migraine pathophysiology. An
association between IBS and migraine was previously described and
the aim of this study was the evaluation of recto-sigmoid sensori-
motor activity in IBS patients with and without migraine.
Patients and methods Twelve patients with migraine without aura
(ICHD-II criteria) and IBS (39 ± 10 yrs, range 28-60, 11 female, 5
constipated), 18 patients with IBS (42 ± 13 yrs, range 29-72, 14
female, 7 constipated) and 10 healthy volunteers (28 ± 6 yrs, 9
female) underwent the recto-sigmoid barostat test as previously
described. IBS diagnosis was made according to Rome III criteria.
During the test, postprandial modification of rectosigmoid tone, as the
difference between mean 60-min postprandial volume and mean
30-min fasting volume was also evaluated.
Results In IBS patients discomfort threshold was significantly lower
than in HV, but no difference was found between patients with and
without migraine.
Postprandial rectosigmoid tone modification was more profoundly
impaired in IBS patients with migraine than patients without migraine
(p \ 0.05).
Conclusions In IBS patients, the presence of migraine is associated to
a more severe alteration of postprandial motor activity.
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Benign intracranial hypertension associated
to progesterone utrogestan: about one case
A. Elrherbi1, M. Sodqi2, H. Filali1, F. Hakkou1
1Service de Pharmacologie Clinique et de Toxicologie,
Casablanca, Morocco;
2Service des Maladies Infectieuses, CHU IBN ROCHD,
Casablanca, Morocco
Objective Reporting a case of benign intracranial hypertension which
occur with an hormonal therapy by progesterone utrogestan.
Patients and methods A 27 years old woman pregnant in her 16th
week of amenorrhea received for two months 200 mg/day of
progesterone utrogestan indicated for first trimester bleeding
presented headache, vomiting, and a bilateral papilloedema grad
III at the eyeground. An exhaustive biologic and morphologic
assessment allows to eliminate infectious, vascular, and tumoral
causes of this ICHT and to suspect the role of progesterone
therapy. After utrogetan discontinuation the evolution was
spectacularly favorable with disappearance of all neurologic
symptoms without any corrector treatment. The case was reported
to the pharmaco-vigilance unit where it was analyzed, discussed
and recorded.
Results Using the WHO’s method of drug side effects imputability to
analyze this Adverse event, we found I3 score for the intrinsic
imputability and B2 score for extrinsic imputability.
Conclusion Benign Intracranial Hypertension BICH or pseudotu-
mor cerebri is defined as an elevation of the cerebrospinal liquid
pressure in the absence of an expansive intracranial processus, a
cerebral venous sinus thrombosis or a hydrocephaly. It might be
drug induced as in the case reported here, where the progesterone
therapy was incriminated. A severe evolution is possible with
vision loss by an optic atrophy. The treatment consists of drug
discontinuation with an eventual excess weight reduction and high
dose corticotherapy. The evolution is characterized by a rapid
recovery; surgical treatment is reserved to the rare rebellious
cases.
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Optimal medication use in headache: a new
conceptualization of acute headache medication
adherence
E.K. Seng, K.A. Holroyd, K.N. Lewis, C.S. Barnhouse
Psychology, Ohio University, Athens, OH, USA
Background Research has extensively examined adherence with
medications taken on a daily basis; however, this literature provides
little relevant information regarding adherence with acute medica-
tions that are essential to the management of migraine as well as other
disorders, such as asthma. Self-efficacy, or confidence in one’s ability
use medication optimally, is key to fostering medication adherence,
but is behavior-specific. We argue that the behaviors necessary to
optimally use acute medications differ from the behaviors necessary
to optimally use daily medications. A new model that accounts for
key variables associated with optimal use of acute medications is
needed.
Methodology Literature review revealed information regarding daily
medication use. Phenomenological interviews with headache suffer-
ers (n = 10) and health care providers who work with headache
sufferers (n = 14) described medication-taking behaviors required to
optimally manage headache disorders.
Conceptualization Patient behaviors
Acute medication use requires moment-to-moment evaluation of
multiple changing variables that influences behaviors such as tim-
ing, dosage, type of medication, available treatment options, and
circumstances of medication use. Daily medication use requires
taking a set dose of medication at predetermined times. Physician
tasks.
For acute medication, instructions from physicians are insufficient to
describe all aspects of medication use. Therefore, physicians must
provide education about the disorder and the effect of each type of
medication used, enabling patients to make effective in-the-moment
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decisions regarding taking medication. For daily medication,
instructions from physicians should explicitly describe and ensure the
understanding of optimal timing, dosage, and circumstances of
medication use.
Implications Current models of medication adherence may be of
limited utility for acute headache medications. Conceptualizing
acute headache medication adherence as a set of optimal medica-
tion-taking behaviors acknowledges the inherent complexity
involved in taking acute (as opposed to daily) medication, and can
inform targeted interventions for suboptimal medication-taking
behaviors.
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Rizatriptan treatment of acute migraine in patients
taking Topiramate for migraine prophylaxis
D. Valade1, J.L. Seeburger2, R.K. Cady3, P. Winner4,
A. MacGregor5, Y. Ge2, Y. Zhang2, C.M. Hustad2, N. Strickler2,
E. Schaefer2, L. Harper Mozley2, X. Fan2, D. Hewitt2, T. Ho2,
K.M. Connor2
1Centre d’Urgences Ce´phale´es, Hoˆpital Lariboisie`re, Paris, France,
2Merck & Co., Inc., North Wales, PA, USA;
3Headache Care Center, Springfield, MO, USA;
4Palm Beach Headache Center, W. Palm Beach, FL, USA;
5City of London Migraine Clinic, London, UK
Objective To assess efficacy and tolerability of rizatriptan ODT for
treatment of acute migraine in patients utilizing topiramate for
migraine prophylaxis.
Background There are limited data from prospective controlled
trials demonstrating benefit of triptans in patients who continue
to experience migraine attacks while utilizing prophylactic
medication.
Methods This was a worldwide, randomized, placebo-controlled,
double-blind, multiple-attack study in adults with [ 1-year history
of ICHD-2 migraine, taking a stable dose of topiramate for
migraine prophylaxis yet experiencing at least 2 moderate/severe
migraine attacks per month. Patients treated 3 moderate/severe
attacks in crossover fashion (2 with rizatriptan 10-mg ODT, 1 with
placebo) and were randomly assigned to one of three treatment
sequences (1:1:1 ratio). The primary endpoint was pain relief at
2 hours.
Results Of 108 patients randomized to treatment, 100 (93%) treated a
study migraine. The response rate for 2-hour pain relief was signifi-
cantly greater with rizatriptan compared with placebo (55.0% vs.
17.4%, p \ 0.001). Response rates also favored rizatriptan on all
secondary endpoints: sustained pain relief from 2-24 hours (32.6% vs.
11.1%, p \ 0.001), 2-hour pain freedom (36.0% vs. 6.5%,
p \ 0.001), normal functional ability at 2 hours (42.2% vs. 12.7%,
p \ 0.001), and overall treatment satisfaction at 24 hours (60.8% vs.
33.6%, p \ 0.001). Treatment was generally well tolerated, and few
adverse events (AEs) were reported. Overall, 16 (15.8%) patients
reported at least one AE following treatment with rizatriptan, and 3
(3.2%) patients reported at least one AE following placebo (note:
treatment strategy was 2:1, rizatriptan to placebo, across attacks).
Most AEs were of mild severity, and no serious AEs were reported
during the study.
Conclusion Rizatriptan 10-mg ODT was superior to placebo at all
endpoints examined in the treatment of acute migraine in patients
utilizing topiramate for migraine prophylaxis. Rizatriptan was gen-
erally well tolerated in this population.
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Efficacy of rizatriptan for the treatment of acute
migraine in sumatriptan non-responders
F.R. Taylor1, J.L. Seeburger2, L. Newman3, D. Friedman4, Y. Ge2,
Y. Zhang2, C.M. Hustad2, J. LaSorda2, L. Harper Mozley2, X. Fan2,
D. Hewitt2, T. Ho2, K.M. Connor2
1Park Nicollet Clinic, Minneapolis, MN, USA;
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4University of Rochester, Rochester, NY, USA
Objective To assess the efficacy and tolerability of rizatriptan ODT in
the treatment of acute migraine in patients who are non-responders to
sumatriptan.
Background Thirty to forty per cent of migraineurs report dissatis-
faction with sumatriptan treatment. It is unclear whether those who
fail to respond to sumatriptan 100 mg will respond to other triptans.
Methods This was a randomized, placebo-controlled, double-blind,
multiple-attack study in adults with a [1-year history of ICHD-2
migraine who reported that they generally do not respond to suma-
triptan treatment (C50% unsatisfactory response). In the baseline
phase, participants treated a single moderate/severe migraine attack
with open-label generic sumatriptan 100 mg. Those who continued to
experience moderate/severe pain at 2 hours post-dose were eligible to
enter the double-blind treatment phase. In this phase, participants
treated three moderate/severe attacks in crossover fashion (2 with
rizatriptan 10-mg ODT, 1 with placebo) after being randomly
assigned to one of three treatment sequences (1:1:1 ratio). The pri-
mary endpoint was pain relief at 2 hours.
Results Of 109 patients randomized to treatment, 102 (94%) treated a
study migraine. The response rate for pain relief at 2 hours was sig-
nificantly greater with rizatriptan as compared with placebo (51% vs.
20%, p \ 0.001). Response rates also favored rizatriptan on the
secondary endpoint of 2-hour pain freedom (22% vs. 12%,
p = 0.013), as well as on sustained pain relief (38% vs. 14%, p \ 0.001)
and sustained pain freedom (20% vs. 11%, p = 0.036) 2-24 hours
postdose. Treatment was generally well tolerated. Most AEs were of mild
severity, and no serious AEs were reported during the study.
Conclusion Rizatriptan 10-mg ODT was superior to placebo at pro-
viding 2-hour pain relief and 2-hour pain freedom in the treatment of
acute migraine in patients who do not generally respond to suma-
triptan 100 mg. Rizatriptan was well tolerated in this population.
Conflict of interest Taylor F. Merck Honoraria for Migraine Spe-
cialist Advisory Board, Speakero´s Bureau and Scientific Advisory
Committee for this study. Merck Research funded studies with pay-
ments to the Park Nicollet Institute for Research and Education and
none to me directly. No others potentially pertinent to this informa-
tion in past 12 months.
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Headache in a neuro psychiatric clinic
R. Sidana, A. Sidana, N. Chadha, D. Gupta
Tekchand Sidana Memorial Psychiatric Hospital and Deaddiction
Centre, Sriganganagar, India
Aim and objective Present study is being carried out to find
acceptability of headache clinic in a psychiatric hospital & to study
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socio demographic, clinical profile of patients presenting with pri-
mary complaint of headache and to study the psychiatric co-morbidity
and primary diagnosis.
Place The study was conducted in psychiatry OPD of Tekchand Si-
dana Memorial Psychiatrtic Hospital And Deaddiction Centre, Sri
Ganganagar, Rajasthan, India.
Material and methods 100 consecuive patients presenting with chief
complaint of headache were included in the study. The patients were
initially worked up by clinical psychologist using a semi structured
performa for detailed sociodemographic variable psychiatric history &
mental state examination. These patients were seen by the psychiatrist
where history study was reassessed and a detailed physical and neuro-
logical examination was done to reach a provisional diagnosis. The
patients were then advised laboratory investigations, EEG, CT scan and
MRI as & when required. The help of other consultants such as ENT,
physician, ophthalmologists and neurologists were taken in some cases.
Results The study is in progress, so far it is apparent that large
number of patients suffer from primary headache, Migraine (30 %)
and tension induced (40 %) & mixed headache. But more than 50 %
of patients had co-morbid psychiatric diagnosis like major depressive
disorder, generalized anxiety disorder, substance abuse. About 10 %
of patients were diagnosed as secondary headache with various
neurological conditions. The detailed analysis will be presented &
discussed in the light of other similar studies.
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Transcatheter PFO closure among patients
with episodic and chronic migraine
B. Whisenant1, D.W. Dodick2, S.G. Sorensen1, K. Balle1,
J.B. Muhlestein1, B.D. Horne1, T.L. Bair1
1Cardiology, Intermountain Medical Center, Murray, UT, USA;
2Neurology, Mayo Clinic, Phoenix, AZ, USA
Objective To compare the benefit of PFO closure in subjects with
episodic (EM) versus chronic migraine (CM).
Methods 3,300 subjects who underwent transcatheter PFO closure at
least 6 months ago were contacted by mail and directed to an internet
based survey. The survey questioned subjects regarding procedural
indications, device related complications, and migraine frequency
prior to and after PFO closure. Subjects select ed 1 of 5 migraine
frequency categories before PFO closure and recently: 0-1 migraine
days per month (MD/Mo); 2-5 MD/Mo; 6-15 MD/Mo; 16-25 MD/
Mo; or [ 25 MD/Mo.
Results 1,075 patients responded to the survey. 257 patients provided
baseline and recent migraine frequency data and were used for this
analysis. 68% noted migraine as a primary indication for closure.
42.3% reported one or more adverse events including palpitations
31%, chest pain 19%, atrial fibrillation 3.3%, device related stroke
0.4%, and transfusion 0.4%. The distribution of migraine frequency
prior to PFO closure was: 0-1 MD/Mo 5.9%; 2-5 MD/Mo 30.5%; 6-
15 MD/Mo 33.2%; 16-25 MD/Mo 23.8%; and [ 25 MD/Mo 6.6%.
75% of subjects with EM reported improvement of at least 1 frequency
category while 4 patients (4.8%) reported an increased frequency of
migraine yielding a mean reduction of 1.1 frequency categories for the
group. 94.8% of the CM group reported improvement of at least 1 fre-
quency category with a mean reduction of 2.2 frequency categories.
Subjects with CM were more likely to respond (drop of C 1 frequency
category) to PFO closure than those with EM (p = 0.0006).
Conclusion These preliminary results suggest that while both
groups respond, patients with CM are more likely to experience a
reduction in migraine frequency compared to those with EM. A
controlled study is warranted to evaluate the benefit of PFO closure
in patients suffering with CM, a group with a large unmet treat-
ment need.
Conflict of interest Dr. Dodick has acted as a consultant, speaker or
received research support from Allergan Pharmaceuticals.
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Psychometric properties of the Lithuanian version
of the migraine disability assessment questionnaire
K. Ryliskiene1,2, D. Jatuzis1,2
1Neurology, Vilnius University Hospital Santariskiu Clinic,
Vilnius, Lithuania;
2Vilnius University, Faculty of Medicine, Neurology
and Neurosurgery Clinic, Vilnius, Lithuania
Background Migraine is a common neurological disorder with high
levels of pain and disability. There is no valid migraine disability
assessment tool in Lithuania. Development of one more new instrument
for small country is unnecessary. Original Migraine Disability Assess-
ment (MIDAS) questionnaire is reliable and valid instrument to determine
the degree of migraine-related disability, to improve patient-physician
communication, and to identify patients with high treatment needs.
Objective To perform cross-cultural adaptation of MIDAS and to eval-
uate psychometric properties of the Lithuanian version (MIDAS-LT).
Materials and methods Cross-cultural adaptation of questionnaire
for Lithuanian speaking population was performed following Interna-
tional Society for Pharmacoeconomics and Outcomes Research
recommendations. Psychometric properties were tested on Vilnius uni-
versity hospital Santariskiu clinics out-patients with active migraine.
Internal consistency, test-retest reliability and construct validity were
assessed. Test-retest examination was done in two weeks after initial
evaluation of disability. Nine hypothesis according 90-day headache
diaries’ and Lithuanian Short Form-36 version 2 (SF-36v2) data were
constructed for the evaluation of construct validity.
Results 145 patients (mean age 36.04 ± 10.02; 80.7% females and
19.3% males; 82 patients had migraine without aura and 63 with aura)
participated in the study. MIDAS-LT demonstrated acceptable
internal consistency (Cronbach alpha 0.81 [95% CI; 0.76 - 0.85], item
total correlations 0.36 - 0.83), and test-retest reliability (interclass
correlation coefficient 0.90 [95% CI; 0.82 - 0.94]). Correlations for all
constructed hypothesis according headache diary data and SF-36v2
assessment were significant (p \ 0.001).
Conclusions MIDAS-LT can be used as migraine disability self-
assessment instrument in Lithuanian speaking population.
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Prevalence and impact of headache in children
with medically unexplained neurological symptoms
(MUNS) presenting to a tertiary paediatric neurology
centre
K. Vijayakumar, P. Prabhakar
Neurology, Great Ormond Street Hospital, London, UK
Background Pain syndrome, particularly headaches are common in
children presenting with medically unexplained neurological syn-
drome (MUNS).
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Aim To study the frequency and provide disability data on headache
syndrome among our cohort of MUNS and the factors influencing
their condition.
Methods Of the 652 admissions to tertiary paediatric neurology
service over 3 year period (2007–2009), 82 episodes of admissions
(12.6%) in 55 children, documented to have MUNS were identified.
52 were studied retrospectively for data on predominant neurological
manifestations, pre-existing clinical diagnosis of headache syndrome,
and their impact on mobility and school attendance.
Results 18/52 (35%) - six males and twelve; median age of 13y 6 m
and range of 6 to 16y within MUNS cohort had diagnosis of a
headache syndrome. In 5/18 headache was the predominant present-
ing feature. In 10/18, the headache was contributory to the presenting
feature. In the rest it was not symptomatic at the time of MUNS
presentation. The headache diagnoses according to IHS classification
was: Migrane without aura (7), Migrane with aura (1), secondary
headache (5), tension type headache (1), sporadic hemiplegic migrane
(1), unspecified (3). School attendances were poor (10) /variable (3);
mobility was poor (crutches/wheelchair) (5) and fluctuating (4) in
those presenting with headache within MUNS cohort. 5 each were
either on migraine prophylaxis or other treatments for headache. The
co- morbidity included: weight problems (5), nutritional deficiency
(2), psychiatric issues (5), others (7). Ongoing mental health(10) and
social services (4) input were recommended at discharge.
Conclusion Headache was presenting feature in 28% (15/52) within
MUNS cohort. The diagnosis of pre existing headache syndrome does not
seem to influence the presenting MUNS symptamatology. However, the
educational, medical and psychosocial co- morbidity is high in this group.
Early integrated multi-disciplinary approach addressing the environ-
mental/personal influences may help in improving outcome.
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3-year follow-up of secondary chronic headache:
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5Department of Neurology, Ulleva˚l University Hospital, Oslo, Norway
Objective To investigate the 3-year course of a population based
sample of secondary chronic headaches.
Methods This is a cross-sectional epidemiological study with follow-
up. An age and gender stratified random sample of 30,000 persons
aged 30-44 years from the general population received a mailed
questionnaire. Those with a self-reported chronic headache were
interviewed by neurological residents. The questionnaire response
rate was 71%. The participation rate of the initial interview was 74%
and it was 87% at the 3 years follow-up. The International Classifi-
cation of Headache Disorders was used.
Results Of those followed-up, 36% had chronic headache attributed
to head and/or neck trauma (chronic post-traumatic headache), 20%
had cervicogenic headache (CEH) and 44% had headache attributed
to chronic rhinosinusitis (HACRS). The headache index (frequency x
intensity x duration) was significantly reduced in chronic post-
traumatic headache and HACRS, 26% and 45% respectively, while it
was unchanged in CEH.
Conclusions Secondary chronic headaches have various courses depen-
dent on the diagnosis. Recognizing the different types of secondary chronic
headaches is of importance and might have management implications.
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with chronic tension-type headache: the akershus study
of chronic headache
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4Norwegian Knowledge Centre for the Health Services, University
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Objectives To investigate personality traits and level of psychologi-
cal distress in persons with chronic tension-type headache (CTTH)
from the general population.
Methods An age and gender stratified random sample of 30,000 persons
aged 30-44 years from the general population received a mailed ques-
tionnaire. Those with a self-reported chronic headache were interviewed
by neurological residents. The questionnaire response rate was 71% and
the participation rate of the interview was 74%. The International Clas-
sification of Headache Disorders was used. To assess personality traits and
level of psychological distress, the Eysenck0s Personality Questionnaire
(EPQ) and the Hopkins Symptom Checklist-25 (HSCL-25) was used.
Results Persons with CTTH had a significantly higher neuroticism
score and had a significantly higher level of psychological distress
than healthy controls from the general population. Headache- or
medication days per month had no significant influence on the neu-
roticism- and lie scores or the HSCL-25 score.
Conclusions Persons with CTTH revealed higher level of neuroticism
and psychological distress than healthy persons. Whether this is due
to premorbid psyche and/or secondary to the chronic pain is a
question that future studies should address.
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Background There are striking individual differences in treatment
response to topiramate as a preventive treatment for migraine.
Glutamatergic neurotransmission is known to be associated with
migraine.
Objective To evaluate whether polymorphisms in GRIK4, a gene
coding for a glutamate receptor, are associated with outcome in the
preventive treatment of migraine with topiramate.
Methods We analyzed data from a randomized, double-blind, pla-
cebo-controlled study of adult subjects with high frequency episodic
migraine. Subjects were randomized in a 1:1 ratio to treatment with
either topiramate 100 mg daily or matching placebo for a 20 week
double blind treatment phase. Responders were defined as subjects
who had a reduction of 50% or more in the number of migraine days
relative to baseline for weeks 17-20. We assessed association of
selected 61 tag-SNPs of the GRIK4 for genotyping, covering nearly
the whole gene.
Results A total of 385 subjects were randomized to study treatment. We
had genotypes on 304 subjects, and, of these, 262 were in the efficacy
evaluable population (128 in the topiramate group and 134 in the placebo
group). The topiramate and placebo treatment groups were comparable in
baseline headache characteristics. After 20 weeks of treatment, the
responder rate for the topiramate group (78/128, 60.94%) was higher than
for the placebo group (60/134, 44.78%). Genotype-wise analysis
revealed an association of rs6589833 (p = 0.012), rs2155258
(p = 0.047) and rs1939630 (p = 0.008) with topiramate response. In the
additive model-wise analysis, rs6589833 (p = 0.005), rs951370
(p = 0.025), rs948029 (p = 0.026), rs6589845 (p = 0.047) and
rs493656 (p = 0.047) showed association with topiramate response. In
addition, rs6589833 (p = 0.007) and rs49356556 (p = 0.047) showed
association in the dominant model analysis and rs1939670 (p = 0.0.32)
showed association in the recessive model analysis.
Conclusions These preliminary results suggest that sequence variations
in GRIK4 may be associated with topiramate treatment response in the
preventive treatment of subjects with high frequency episodic migraine.
Conflict of interest Dr. Lipton receives research support from the
NIH [PO1 AG03949 (Program Director), PO1AG027734 (Project
Leader), RO1AG025119 (Investigator), K23AG030857 (Mentor),
K23NS05140901A1 (Mentor), and K23NS47256 (Mentor)], the National
Headache Foundation, and the Migraine Research Fund; serves on the
editorial boards of Neurology and Cephalalgia and as senior advisor to
Headache, has reviewed for the NIA and NINDS, holds stock options in
Neuralieve Inc. and Minster Inc; serves as consultant or has received
honoraria from: Allergan, Autonomic Technologies, Boston Scientific,
Bristol Myers Squibb, Eli Lilly, Endo, GlaxoSmithKline, Minster, Merck,
Nautilus Neuroscience, Neuralieve, Novartis, and Pfizer.
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Background Obesity is known to be an exacerbating factor of
migraine. ADIPOQ codes for adiponectin, a protein involved in both
obesity and migraine.
Objective To determine if ADIPOQ polymorphisms predict migraine
response and body weight (Bwt) change in the preventive treatment of
migraine with topiramate.
Methods We analyzed data from a randomized, double-blind (DB),
placebo-controlled study of adult subjects with high frequency epi-
sodic migraine. Subjects were randomized in a 1:1 ratio to treatment
with either topiramate 100 mg daily or matching placebo for a 20-
week DB treatment phase. We assessed association of six candidate
SNPs of the ADIPOQ gene and change of the 28-day rate of migraine
days using a linear regression model. In additional, we evaluated the
association between Bwt change and ADIPOQ polymorphisms.
Results A total of 385 subjects were randomized to study treatment.
Genotypes were analyzed for 304 subjects and, of these, 262 were in
the efficacy evaluable population (128 in the topiramate group and
134 in the placebo group). The topiramate and placebo groups were
comparable in baseline Bwt and headache characteristics. After
20 weeks of treatment, the topiramate group showed significant
reductions in both the number of migraine days from baseline to the
DB treatment phase (-6.6 ± 3.8 vs. -5.3 ± 3.6; p = 0.000) and Bwt
change (-3.0 ± 6.6% vs. 0.48 ± 3.7%; p = 0.001) comparing to
placebo group. Three SNPs [rs822396 (p = 0.029), rs1501299
(p = 0.008) and rs37674261 (p = 0.009)] showed association with
change in the 28-day rate of migraine days. No evidence showed the
association between Bwt change and the change in the 28-day rate of
migraine days or association between Bwt change and the 6 SNPs of
ADIPOQ gene.
Conclusions These results suggest that sequence variations in ADI-
POQ may be associated with topiramate response in the preventive
treatment of subjects with high frequency episodic migraine,
regardless of body weight change during treatment.
Conflict of interest Dr. Lipton receives research support from the
NIH [PO1 AG03949 (Program Director), PO1AG027734 (Project
Leader), RO1AG025119 (Investigator), K23AG030857 (Mentor),
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Background We and others identified migraine to be a risk factor
for subclinical cerebellar infarction, deep white matter lesions
(WMLs) and brainstem lesions (1-3). Microbleeds are considered
another type of small vessel damage, which have not been studied
in migraine yet.
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Methods We diagnosed 63 participants of the PROspective Study
of Pravastatin in the Elderly at Risk (PROSPER; 4) to have a
lifetime history of migraine (25 with aura [MA], 35 without aura
[MO], 3 aura status unknown). There were 359 headache-free
controls (age range 73-85 years). Microbleeds were scored on T2*-
weighted MRI images using established criteria (5), blinded for
clinical history. We a priori stratified for supra- and infratentorial
microbleed location, based on suggested increased vulnerability of
cerebellum and brainstem in migraine. Infarcts were scored and
WML volumes were calculated automatically. Logistic regression
models were run controlled for age, gender, cardiovascular risk
factors, aspirin and pravastatin use.
Results Overall prevalence of microbleeds was not different across
groups: MA 24%, MO 31%, controls 24%. Stratified by location
however, infratentorial microbleeds were more frequent in MO vs.
controls (14% vs. 3.9%; OR 3.7; 95% CI 1.1-12), especially in men
(25% vs. 3.5%; OR 16 [2.2-114]). Among migraineurs, those with vs.
those without microbleeds had far more often any infarct (65% vs.
20%; OR 5.8 [1.5-23]), especially lacunar infarcts (41% vs. 8.9%; OR
5.8 [1.3-26]) and infratentorial infarcts (35% vs. 6.7%; OR 5.5 [1.0-
30]). Moreover, migraineurs with microbleeds tended to have higher
WML-loads than those without microbleeds.
Conclusion A history of migraine without aura is an independent risk
factor for infratentorial microbleeds in lifetime migraineurs. Micro-
bleeds in migraineurs are strongly correlated with lacunar and
infratentorial infarcts, and WMLs (trend). Small vessel vulnerability








Pilot trial: computerized mobilization of the cervical
spine for the treatment of chronic neck pain
and associated headache
Y. River
Neurology, Hillel Yaffe Medical Center, Hadera, Israel
Background Physical therapy has been successfully used for the
treatment of chronic neck pain. However, manual treatment inter-
ventions share a common disadvantage, they are imprecise and
inconsistent.
Objective Investigate the safety and efficacy of computerized
mobilization of the cervical spine for the treatment of chronic neck
pain.
Methods Pilot, open, trial utilizing a device capable of precise three
dimensional mobilization of the neck. We recruited patients with
chronic neck pain over a period of 6 months. We excluded patients
with myelopathy, radiculopathy, and discopathy. Treatment sessions
lasted 20 minutes, twice a week, for 6 weeks. Parameters of treat-
ment: continuous mobilization in the sagittal plane with a range of
zero to 408. The angular velocity allowed 0.5 to 28/sec. We evaluated
patients with weekly visual analogue score (VAS), neck disability
index (NDI), muscle algometry, neck range of motion, surface EMG
of the Trapezius muscles and SF-36 quality of life questionnaire.
Results We recruited 10 patients, 8 women and two men, with a mean
age of 50.5 ± 13.5 years. Nine patients reported significant headache
with neck pain. Seven patients with Tension type headache and two
patients with cervicogenic headache. Treatment was not associated
with any significant adverse effects. Pain scores dropped by 2 ± 0.5
VAS points at the end of the study. Composite Neck range of motion
(in the sagittal, horizontal, and coronal planes) showed a significant
improvement at the end of the study (p = 0.034). NDI showed
marked improvement by the forth week with a p \ 0.05, this
improvement remained significant at the end of the study and two
weeks after the completion of the study. The headache NDI subscale
showed marked reduction of headache intensity.
Conclusions Preliminary results show that computerized mobilization
is safe. The data suggests that this method is effective for both the
neck pain and associated headache.
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The nucleus raphe magnus contributes
to the production of morphine antinociception
in the acute pain
E. Abzianidze1, T. Gorgiladze1, V. Berishvili1, T. Tkemaladze1,
G. Gurtskaia2, M. Tsagareli2
1Tbilisi State Medical University, Tbilisi, Georgia;
2I. Beritashvili Institute of Physiology, Tbilisi, Georgia
Aim of Investigation Our studies was examined whether pretreat-
ment of naloxone, opioid receptor antagonists into the PAG
would alter antinociception elicited by electrical stimulation of the
NRM.
Methods The experiments were carried out on white male rats by the
models of tail-flick (TF) and hot plate (HP) tests using standard
electrophysiological techniques. Latency increase of these reflexes
indicated the degree of antinociception. Steel Electrodes was stereo-
taxically implanted into Nucleus Raphe Magnus (NRM) according to
Paxinos and Watson atlas coordinates. An agonist (morphine,
0.5-3 mg/kg) and antagonist (naloxone, 0.3-2.5 mg/kg) of opioidergic
receptors were used for neuropharmacological analysis. Same volume
of saline was injected for control animals.Experiments was performed
in accordance with the standards of the International Pain Society.
Results Stimulation of the NRM elicited a potent antinociceptive
response on the tail-flick and hot-plate tests. Pretreatment with the
naloxone, at doses between naloxone(0.3-2.5 mg/kg)produced dose-
dependent inhibition of antinociception elicited from the NRM on
the tail-flick and hot-plate tests. Subthreshold stimulation of the
NRM against a background of subanalgesic dose morphine 0.5 -
0.8 mg/kg induced potentiation of morphine effect.
Conclusions Our date indicate functional interactions between opioid
and nonopioid antinociceptive systems and modulation of the pain is
mediated by a set of neural circuits.
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Visual aura is the most common type of aura. However, a late onset of
aura is usually symptomatic. We report the case of a 72 year old
woman who developed migraine with aura in her seventies which
completely resolved after carotid endarterectomy.
This patient had a past medical history of arterial hypertension, cor-
onary angioplasty and migraine without aura since adolescence. In
May 2006 she presented with frequent migraine attacks and, for the
first time in her life, visual aura. The visual auras were always left
homonymous hemianopsia followed by severe migrainous headache,
with frequent migraines without aura in between. She was already
regularly followed for asymptomatic right internal carotid artery
stenosis, estimated at 60%.
She was started on maintenance dose of 250 mg Aspirin daily with
increase to 1 g during the attacks. Although this regime decreased the
frequency of attacks, she still had one migraine with aura every month
and two severe attacks without aura every week. In October 2007 she
experienced a regressive ischemic stroke in right carotid artery territory.
Ultrasounds and MR angiography showed a nearly occluded carotid
artery. She underwent a right carotid endarterectomy. Since then, with a
follow-up more than 2 years, she has no more any visual aura.
The aura is linked to the phenomenon of cortical spreading depression
(CSD). Recently it has been suggested in a mouse model that mic-
roemboli may trigger CSD, often without causing microinfarction.
We hypothesize that this patient experienced late onset of visual aura,
initially without ischemic stroke, due to the severe carotid artery
stenosis.
Conflict of interest C. Lucas has perceived personal fees for activ-
ities (consulting, clinical research) with Allergan, Almirall SAS,
Astra Zeneca Pharmaceuticals, Boehringer Ingelheim, Bouchara
Recordati, Glaxo-Smith Kline Inc, Menarini, Merck, Pfizer Inc,
Sanofi-Aventis, Servier.
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notch 3 positive siblings
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Purpose Cerebral autosomal dominant arteriopathy with subcortical
infarct and leukoencephalopathy (CADASIL) is hereditary arteriop-
athy caused by mutation NOTCH3 gene on chromosome 19. Its
cardinal clinical features included headache, strokes in the young age
and vascular dementia in persons with positive family history. In
CADASIL patient is headache usually referred as migraine mostly
migraine with atypical or prolonged aura. Migraine, as the first symptom,
can precede the stroke and neuropsychiatric disorders by a mean of
10 years. The Head magnetic resonance imaging (MRI) with diffuse
leukoencephalopathy prominent in temporal lobes is pathognomic.
Case report We present a clinical, neuroradiological features, skin
biopsy and pedigree in three NOTCH 3 positive siblings (2 sisters - 45 and
43 years old and brother 33 years old). Their clinical picture includes
migraine with prolonged aura. Magnetic resonance imaging (MRI)
revealed diffuse leukoencephalopathy with involvement of bilateral
anterior temporal lobes. Skin biopsy demonstrated granular osmiophilic
material deposits in dermal arterioles, diagnostic for CADASIL. Both
sisters additionally manifest Raynauds syndrome with paroxysmal white-
blue-red discoloration of the fingers and toes induced by cold or stress.
Conclusion In CADASIL person with migraine as initial symptom
can be helpful the head MRI. The leukoencephalopathy presentation
is pathognomic to distinguish headache attributed to genetic disor-
ders, CADASIL especially.
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Objective To evaluate the efficacy and tolerability of the CGRP
receptor antagonist telcagepant when co-administered with ibuprofen
or acetaminophen for the acute treatment of migraine.
Background Combining telcagepant with analgesics that have a
different mechanism of action could produce greater efficacy.
Methods Pilot randomized, double-blind, placebo-controlled trial.
Patients were randomized to treat a moderate/severe migraine with
either telcagepant 280 mg + ibuprofen 400 mg (N = 171), telcage-
pant 280 mg + acetaminophen 1000 mg (N = 171), telcagepant
280 mg (N = 170), or placebo (N = 171). The primary efficacy
endpoint was 2-hour pain freedom. The study had 80% power to
detect an additive effect of C 15 percentage points (telcagepant
combination versus telcagepant alone) and 48% power to detect an
additive effect of C 10 percentage points.
Results The percentages of patients with 2-hour pain freedom were
greater in each active treatment group compared to placebo
(p \ 0.001): telcagepant + ibuprofen = 35.2%, telcagepant + acet-
aminophen = 38.3%, telcagepant = 31.2%, placebo = 10.9%. No
significant differences were seen for the combinations versus tel-
cagepant, but both combinations were numerically better than
telcagepant alone. All active treatments were generally well-tolerated.
The percentage of patients reporting any adverse event within
48-hours was higher in the active treatment groups than placebo:
telcagepant + ibuprofen = 30.3%, telcagepant + acetaminophen =
31.6%, telcagepant = 24.8%, placebo = 18.2%. Adverse events
reported by C 4 patients in C 1 of the groups that included telcage-
pant were fatigue, nausea, dizziness, somnolence, dry mouth, and
tremor. One patient in the telcagepant group, who had also been
taking their own non-study acetaminophen, had ALT and AST ele-
vations C3 times the upper limit of normal.
Conclusions The combination of telcagepant 280 mg with either
ibuprofen 400 mg or acetaminophen 1000 mg showed numerically
greater treatment effects than telcagepant 280 mg alone, but the dif-
ferences were not significant in this pilot study. The active treatments
were generally well tolerated although the combination treatments
were associated with a higher percentage of adverse events. Tel-
cagepant combination treatments may merit further evaluation in
studies powered to detect smaller additive benefits.
Conflict of interest Dr. Lipton receives research support from the
NIH [PO1 AG03949 (Program Director), PO1AG027734 (Project
Leader), RO1AG025119 (Investigator), K23AG030857 (Mentor),
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in patients with exercise induced myocardial ischemia
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Objective To determine if telcagepant adversely affects exercise
parameters of myocardial ischemia.
Background CGRP is a potent vasodilator. Telcagepant is a CGRP
receptor antagonist being evaluated for treatment of acute migraine. It
is unknown whether a CGRP receptor antagonist reduces compen-
satory vasodilatory capacity during myocardial ischemia.
Methods Double-blind, placebo-controlled, 2-period, single-dose
crossover in 61 patients with reproducible exercise induced angina
and treadmill exercise time. In each period, patients received a single
oral dose of telcagepant (N = 14, 900 mg or N = 46, 600 mg) or
placebo. Patients were randomized to treatment and in each period
performed a Bruce treadmill exercise test at Tmax post telcagepant.
The primary endpoint was designed to test the lower bound of the 2-
sided 90% confidence interval (equivalent to a 1-sided lower 95%
confidence interval) for a total exercise duration treatment difference
(telcagepant - placebo)[ -60 seconds.
Results Data were analyzed for all subjects and stratified by dose.
Mean total exercise duration for telcagepant was 405.38 seconds
(95% CI: 375.91, 434.85) and for placebo was 412.28 seconds (95%
CI: 382.72, 441.85); mean treatment difference (telcagepant - pla-
cebo) was -6.90 seconds (90% CI: -17.66, 3.86). The mean treatment
difference in total exercise duration (600 mg telcagepant - placebo)
was -10.61 seconds (90% CI: -22.94, 1.72). The mean treatment
difference in total exercise duration (900 mg telcagepant - placebo)
was 4.75 seconds (90% CI: -16.69, 26.20). There were no significant
between-treatment differences in exercise time, maximum exercise
heart rate, maximum ST segment depression (STD) or time to 1 mm
STD among pooled data or upon stratification for dose.
Conclusions The findings suggest that antagonism of the CGRP
receptor has no statistically significant effect on compensatory va-
sodilatory capacity during myocardial ischemia as assessed by
exercise duration, chest pain, or STD in patients with chronic angina
and limiting exercise-induced cardiac ischemia.
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in secondary chronic headaches: the akershus study
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Objective To investigate personality traits and level of psychological
distress in a population based sample of secondary chronic headaches.
Methods An age and gender stratified random sample of 30,000
persons aged 30-44 years from the general population received a
mailed questionnaire. Those with a self-reported chronic headache
were interviewed by neurological residents. The questionnaire
response rate was 71% and the participation rate of the interview was
74%. The International Classification of Headache Disorders was
used. To assess personality traits and level of psychological distress,
the Eysenck’s Personality Questionnaire (EPQ) and the Hopkins
Symptom Checklist-25 (HSCL-25) was used.
Results The data are currently being analyzed, and will be presented
at the congress.
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Childhood migraine: a sign of social discomfort
D. Moscato, F.R. Moscato
Childhood Headache Centre, San Charles IDI Hospital, Roma, Italy
Introduction In recent years the occurrence of migraine in growing
up age has reached high peaks. Several cause have been mentioned,
such as, family environment problems and greater difficulties for
young people to cope with the events of life.
Materials and methods In order to evaluate the truthfulness of these
statements the reports of headache suffering boys and girls who had
witnessed in the last 5 years (2006-2010) the occurrence of headache
in the months of greater suffering (January, February, March) were
re-evaluated.
The parameters taken into consideration were the loss of a family
figure (separations, divorces, death of a parent or a brother or sister),
problems in the relationships with the rest of the family, school
problems and in the group of peers.
The characteristics of migraine (intensityxduration (Pain Index), days
of headache/month) were compared among subjects showing the
preceding characteristics and those who did not.
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The first group was made up of 286p.(MwoutA251, MwA34;
178 f.108 m. average age 10,8 +/-3 range 6-18 years), the second of
246p.(MwoutA231, MwA15;149 f.97 m. average age10,9 +/-3,3
range 6-17 years).
The presence of psychiatric disturbances evaluated by means of the
CDI and FABC anxiety scale was also evaluated.
Results In the first group greater values were found for migraine (P.I.6 +/-
2,1vs.5,2 +/-1,9 p\ .05, g/month 5,7 +/-6,7vs.5,24 +/4,3 p\ .05).
Also the concurrent existence of other pathologies were different
(CDI 16,9 +/-6,2vs13,3 +/-3,4 p \ .05; anxiety FABC 6,4 +/-1,8
vs.4.9 +/-1.3 p \ .05).
Conclusions The presence of the loss of a family figure is very high
(from 15% 2006–to 44% 2010), followed by school problems (17%–
24%), family problems (7%–22%), problems with the peers (10%–19%).
The close relationship between migraine and social discomfort must
stimulate us to paying greater attention to such problems, as well as
taking over the entire family nucleus, albeit supporting through
behavioral courses in therapy the migraine suffering child.
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The inhibition of monoacylglycerol lipase by URB602
shows anti-nociceptive effects: study in animal models
of hyperalgesia
R. Greco1, A.S. Mangione1, G. Levandis1, G. Sandrini1,2,
M. Maccarrone3, G. Nappi1,2,4, C. Tassorelli1,2
1IRCCS Neurological Institute ‘‘C. Mondino Foundation, Pavia, Italy;
2University Consortium for the Study of Adaptive Disorder
and Headache (UCADH), Pavia, Italy;
3Department of Biomedical Sciences, University of Teramo,
Teramo, Italy;
4Chair of Neurology, University of Rome ‘‘La Sapienza’’, Roma, Italy
Endocannabinoids, such as anandamide (AEA) and 2-arachidonoyl
glycerol (2-AG), are promising pain modulators. It has been clearly
demonstrated that endocannabinoids are hydrolysed by specific
enzymes: fatty-acid amide hydrolase (FAAH) is an intracellular
hydrolase that catalyzes the cleavage of bioactive of several
endogenous fatty acid amides, such as anandamide (AEA), while
the hydrolysis of 2-arachidonoylglycerol (2-AG), another important
endocannabinoid, is mainly catalysed by the monoacylglycerol
lipase (MAGL). The development of MAGL inhibitors could offer
an opportunity to study the anti-inflammatory and anti-nociceptive
role of 2-AG, which have not yet been elucidated. In this study we
evaluated whether systemic inhibition of MAGL, may alter noci-
ceptive responses in a well-known animal model of migraine based
on the hyperalgesia induced by nitroglycerin administration at the
tail flick test and formalin test (4 hours after its administration).
The analgesic effect of URB602 (a MAGL inhibitor, 2 mg/Kg, i.p.)
was evaluated in male Sprague-Dawley rats. The animals under-
went tail-flick and formalin tests, both performed in baseline
conditions and after nitroglycerin-induced hyperalgesia. Rats were
pre-treated with nitroglycerin (10 mg/kg, i.p.) and treated with
URB602, 60 minutes before the tail flick test and formalin test.
URB602 did not shown any analgesic effect per se at tail flick test,
but it inhibited nitroglycerin-induced hyperalgesia. In the formalin
test, URB602 inhibited the behaviour nociceptive only in the phase
I in baseline conditions and in the phase II in nitroglycerin-induced
hyperalgesia. The present data suggest that inhibition of MAGL
activity, with the theoretical consequent increase in spinal content
of 2-AG, may modulate pain perception in a specific animal model
of migraine.
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Effect of cortical spreading depression on basal
and evoked traffic in the trigeminovascular sensory
system
G.A. Lambert, L. Truong, A.S. Zagami
Prince of Wales Clinical School, UNSW, Kensington,
NSW, Australia
We monitored the spontaneous and evoked activity of second-order
trigeminovascular sensory neurons in rats to test whether afferent
traffic increased following a potential migraine trigger and by what
mechanism any such change was mediated. Neurons responded to
both electrical and mechanical stimulation of the dura mater and
facial skin with a-delta latencies. The neurons (N = 9) were spon-
taneously active with a basal discharge rate of 10.7 ± 2.3 discharges
per second. Injection of 5 mL of 2 mg ml-1 xylocaine (total amount
10 mg) into the trigeminal ganglion produced a fully reversible
reduction of the spontaneous discharge rate of neurons to 40% ± 7%
of control. Spontaneous activity had returned to normal
(106% ± 21%) by 90 minutes post-xylocaine injection. Xylocaine
reduced the evoked responses of neurons to dural stimulation to
37% ± 17% and to facial skin stimulation to 53% ± 15% of control.
Induction of cortical spreading depression (CSD, a possible migraine
trigger) by local cortical injection of 50 nL of potassium chloride
increased the spontaneous discharge rate of responsive neurons from
2.1 ± 0.7, (N = 10) to 6.5 ± 1.2 discharges per second at 20 min-
utes post-CSD initiation. Injection of 10ug of xylocaine into the
trigeminal ganglion at this time failed to reverse or arrest this increase
in discharge rate; discharge rates continued to rise to 8.7 ± 1.9 dis-
charges per second at their peak. These results suggest that there is a
continuous resting traffic in trigeminovascular sensory fibres and that
CSD probably does not act to increase this traffic- rather it must
produce its effect on trigeminovascular sensation by a mechanism
intrinsic to the CNS. The results therefore suggest that the pain of
migraine in humans may not be the result of peripheral sensory
stimulation, but may arise by a central mechanism.
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A role for both the PAG and the NRM
in craniovascular sensation
G.A. Lambert, L. Truong, A.S. Zagami
Prince of Wales Clinical School, UNSW, Kensington,
NSW, Australia
In experiments on rats, we demonstrated that chemical and elec-
trical activation of the periaqueductal grey matter (PAG) or the
nucleus raphe magnus (NRM) selectively inhibits the responses of
second-order craniovascular neurons to electrical or mechanical
stimulation of the dura mater, compared with stimulation of the
facial skin. Injections of local anaesthetic (xylocaine) into the
NRM selectively potentiated the responses of craniovascular neu-
rons to electrical or mechanical stimulation of the dura mater
(178 ± 28%), compared with stimulation of the facial skin
(119 ± 7%). There was no significant effect of the injection of
xylocaine into the PAG on responses to trigeminal stimulation.
Injections of sodium glutamate into either the NRM or PAG
selectively inhibited the responses of trigeminovascular neurons to
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electrical or mechanical stimulation of the dura mater (NRM to
72 ± 10%; PAG to 60 ± 8%), compared with stimulation of the
facial skin (NRM to 93 ± 7%; PAG to 97 ± 12%). Additionally,
injections into either the NRM or the PAG of glutamate reversed
the increase in discharge rate neurons produced by the potential
migraine trigger cortical spreading depression (NRM 100% a`
289 ± 92 %, a` 109 ± 13%; PAG: 100% a` 488 ± 77 %, a`
159 ± 25%). Such injections also reversed or reduced the increase
in discharge rate produced by another potential migraine trigger,
bright flashing light (NRM 100% a` 236 ± 27 %, a` 92 ± 7%; PAG:
100% a` 376 ± 97 %, a` 220 ± 50%). These results suggest that
trigeminovascular sensation is under tight control by brainstem
nuclei, whereas other trigeminal sensation is not. Modification of
the activity of neurons in these two brainstem nuclei can modulate
the effect of potential migraine triggers on trigeminal sensation.
These nuclei could be relay points in an hypothesised cortico-
brainstem-trigeminal pathway responsible for triggering migraine.
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Prospective analysis of factors related to migraine aura
- the pamina study
S. Salhofer1, S. Frantal2, W. Brannath2, S. Seidel1, C. Wo¨ber-Bingo¨l3,
C. Wo¨ber1
1Department of Neurology, Medical University of Vienna,
Vienna, Austria;
2Department of Medical Statistics, Medical University of Vienna,
Vienna, Austria;
3Department of Child and Adolescent Psychiatry, Medical University
of Vienna, Vienna, Austria
Objectives To examine factors increasing and decreasing the risk of
occurrence of migraine with aura prospectively by means of a daily
diary.
Patients and methods Out of 327 patients with migraine completing
a comprehensive 90 days diary, we selected all patients who recorded
at least one episode of migraine aura. To find risk indicators for
migraine aura we calculated univariate and multivariate generalized
linear mixed models (random factor patient) using bias-corrected
sandwich estimators for the covariance matrix. In the univariate
analyses, a total of 56 variables were included. Factors which showed
a p-value \0.05 were included in the multivariate analysis.
Results We included 54 patients (50 female) aged 40 ± 12 years and
analysed a total of 4485 patient days. Migraine aura was recorded on
354 days. Visual aura was present on 317 days and additional or other
aura symptoms on 127 days. In the univariate analysis, the risk of
migraine aura was increased statistically significantly on days 1-3 of
menstruation (odds ratio (OR) 2.41) and by following factors recor-
ded on the day before aura: smoking (OR 2.45), glaring lights (OR
2.37), disturbing smells (OR 2.29), disturbing noise (OR 1.99),
physical exhaustion (OR 1.96), tiredness (OR 1.88), hunger (OR
1.78), psychic exhaustion (OR 1.74) and psychic tension (OR 1.69).
In contrast, the risk of aura was decreased by progesterone-only
contraceptives (OR 0.40), holidays and days off (OR 0.40) and
relaxation after stress (OR 0.48). In the multivariate analysis, smoking
(OR 2.29), menstruation (OR 2.23), hunger (OR 1.66) and holidays
and days off (OR 0.42) remained statistically significant.
Conclusion Smoking and menstruation are the most prominent fac-
tors increasing the risk of occurrence of migraine aura, whereas
holidays and days off decrease the risk. This is the first prospective
study suggesting that smoking is a risk factor for migraine aura.
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Successful treatment of cluster headache
with the antihistamine terfenadine
M. Indoe1, N. Giffin2
1Bristol University Medical School, Bristol, UK;
2Neurology, Royal United Hospital, Bath, UK
Episodic cluster headache is a well documented and debilitating
condition. There is no absolute treatment for cluster headache, only
symptomatic medication. The pathophysiology of cluster headache is
still unclear though a number of hypotheses, including histamine
involvement, have been proposed in an effort to explain the aetiology
of this condition. Research into the association of histamine is
minimal.
This case study reports a 59 year old man who suffered with episodic
cluster headaches for 16 years, from the age of 25 to 41. The attacks
lasted for 3 hours, occurring up to 6 times a day, with an average of
2–3 bouts a year, each lasting 2 to 3 months. Standard cluster treat-
ment including oxygen, triptans, oral and rectal ergotamine, intranasal
lidocaine, lithium and corticosteroids proved to be of minimal use.
Prophylaxis with the antihistamine Terfenadine 60 mg proved very
effective. The first dose was taken at the onset of a cluster attack and
aborted the attack; the patient continued taking Terfenadine 60 mg
twice daily for 3 days and had no further attacks during this period.
He had no further cluster attacks until 4 weeks later when again he
took Terfenadine 60 mg at the onset of a cluster attack, again with
complete resolution of his symptoms. Only 3 doses of Terfenadine
were required on this occasion to abort the bout and no further attacks
have been suffered since then.
It is proposed that antihistamine prophylaxis for cluster headache
should be a considered as a recognised treatment for patients unre-
sponsive to standard treatment. A wider breath of evidence through
prospective and randomised control trials should be sought.
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Migraine burden in an Albanian patients cohort
D. Naco1, J. Kruja2
1Specialist’s Polyclinic Nr 2, UHC Mother Theresa, Tirana, Albania;
2Neurology, UHC Mother Theresa, Tirana, Albania
Purpose To find the correlation between migraine and work ability by
using the MIDAS questionnaire.
Methods We studied the data of 106 migraine patients randomly
presented at the Specialist’s Polyclinic Nr 2 of Tirana. The diag-
nosis is made according ICHD IIR1 criteria (2005). The MIDAS
questionnaire, Albanian variant, evaluated in a previous study
(2000, MK, JK) is used. The age of patients, age of headache,
gender, education and the drug treatment are used as variables of the
study. The neurological examination and possibly the laboratory
exams are required. The SPSS 17.0 program is applicated to get the
statistical data.
Results The mean age of patients was 34.57 years old (SD 11.22).
There were 83 (78.3%) female and 23 (21.7%) male. 71.7% of
patients were suffering of migraine without aura. 58 patients (54.7%)
had finished the high school and 23 (21.7%) the undergraduate
studies. There were 38 patients (35.8%) under correct treatment and
68 (64.2%) using wrong treatment regimen. There is a statistically
significant correlation between the age of disease and the treatment
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and between the treatment and MIDAS degree. No significant cor-
relation between migraine form and age of patients and migraine form
and gender or education is found.
Conclusion The correct treatment of migraine is an important factor
in diminishing the burden of migraine especially in the newly diag-
nosed patients.
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The neural basis of decision-making under risk
in medication overuse headache patients:
an FMRI study
S. Ferraro1, L. Grazzi2, M.G. Bruzzone1, G. Bussone2, S. Nava1,
F. Di Salle3, L. Chiapparini1
1Neuroradiology, Istituto Neurologico Carlo Besta, Milan, Italy;
2Headache Centre, Istituto Neurologico Carlo Besta, Milan, Italy;
3Maastricht University, Maastricht, The Netherlands
Introduction Medication overuse headache (MOH) represents one of
the common disorders associated with chronic substance use and it
can be speculated that MOH shares some pathogenetic mechanism
with other kinds of drug addiction (Calabresi et al., 2005). A PET
study supports the link between MOH and addiction showing, in
MOH patients, a persistent orbitofrontal hypofunction, known to
occur in drug dependence (Fumal et al., 2006). The abnormal acti-
vation within the neural basis of decision-making under risk seems to
underlie the maladaptive behaviour of substance abuse, including
impaired decision making (Tom et al., 2007).
Subjects and methods To test the hypothesis of a dysfunction of the
neural circuit of decision-making under risk in MOH patients, we
investigated with functional Magnetic Resonance Imaging (fMRI) 8
female MOH patients (MOH group) (mean age: 32 ± 9 ys) and 8
female control subjects (C group) (mean age: 36 ± 6 ys), during the
execution of a decision utility paradigm, while subjects decided
whether to accept or reject gambles that offered a 50/50 chance of
either gaining one amount of money or losing another amount . We
used the paradigm by Tom et al. (2007) that successfully identified a
diminished neural sensitivity to losses among individuals who were
less loss averse and thus more risk seeking, a feature of substance
abusers.
Results We observed activations in the targets of the mesolimbic and
mesocortical dopamine systems in both groups. Moreover MOH
patients showed, in comparison to C group, an hypoactivation in the
ventral tegmental area (VTA) and in substantia nigra (SN) and an
hyperactivation in (p \ 0.001 uncorrected) in superior medial frontal
gyrus.
Conclusion Our results seem to support the hypothesis of a dys-
function in the neural basis of decision-making under risk in MOH
patients.
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Cardiac cephalalgia: heartache to headache
R.B. Halker, B.B. Vargas, D.W. Dodick
Neurology, Mayo Clinic, Phoenix, AZ, USA
Cardiac cephalalgia is recognized by the ICHD-II, with cardiac
disease manifesting as headache.
Patient 1 A 70-year-old woman with migraine, coronary artery
disease (CAD), hyperlipidemia, hypertension, and stroke presented
with a 2-year history of positional headache. It occurred daily,
developed with standing and intensified after walking or Valsalva.
The headache would immediately improve with activity cessation,
and disappear completely if she lay down. She denied migrainous/
autonomic features or systemic symptoms. General medical and
neurological examinations, cerebral MRA/MRV, orthostatics, labs,
tilt table, and radionuclide cisternogram were unremarkable. Brain
MRI revealed a chronic left caudate lacunar infarction. Stress echo-
cardiogram was mildly positive for myocardial ischemia; she
experienced the same headache during exercise, but no chest pain.
Her headache resolved with isosorbide dinitrate. Cardiology contin-
ued medical management of her CAD, as she had mild
echocardiogram abnormalities and good functional aerobic capacity.
Patient 2 A 79-year-old woman with CAD, hypertension, hyper-
lipidemia, and migraine presented with thunderclap headache. She
had slowed speech, but no aphasia or other neurological symp-
toms, no complaints of dyspnea, chest pressure/pain. Cardiac,
neurologic, and general medical exams were normal, with no
signs of heart failure. Head CT was negative. CTA revealed 40%
stenosis in left-ICA, 75% stenosis in right-ICA, and no vertebral
or intracranial stenosis. EKG showed nonspecific ST-segment
abnormalities. Initial troponin-T was \ 0.01; 8 hours later, it was
0.11 and CK-MB was 6.9. Coronary angiography showed high-
grade stenosis of mid-RCA distal to previously placed bare-metal
stent. A drug-eluting stent was placed, with no residual stenosis
and excellent distal flow. The headache resolved with oxycodone/
acetaminophen.
Myocardial ischemia can present solely with headache. Cardiac
cephalalgia should be considered in patients with a new/different
headache and cardiac risk factors. In these patients, investigations to
exclude myocardial ischemia should be pursued. Failure to recognize/
treat cardiac cephalalgia can have serious consequences.
Conflict of interest Dr. Dodick has acted as a consultant, speaker or
received research support from Allergan Pharmaceuticals.
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Frequencies of genetic polymorphisms related
to triptans metabolism in chronic migraine
M. Simmaco1, G. Gentile1, M. Borro1, S. Missori2, A. Sebastianelli2,
P. Martelletti2
1Biochemical Sciences, Advanced Molecular Diagnostic Unit,
Roma, Italy;
2Medical and Molecular Sciences, Sapienza, Roma, Italy
Migraine is a common type of headache, and the most aggressive
form is usually treated with triptans, whose efficacy is extremely
variable. A genetic basis for migraine is evident and many suscepti-
bility genes have been described, as well as gene polymorphisms
possibly implied in therapy response. During a study aimed to found
relations between genotype and response to triptans administration,
we characterized a migraineurs population for polymorphisms in the
genes coding for monoamine oxidase A, g-protein beta 3 and the
cytochromes CYP3A4 and CYP1A2. Alleles and genotypes distri-
butions were compared with known frequencies of healthy Caucasian
populations. A significant association with chronic migraine was
found for the long allele of monoamine oxidase A 30 bp VNTR and
CYP1A2*1F variant.
Thus, the study of functional interaction between CYP and MAO A
SNPs might be of striking impact for tailored drug selection in
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chronic migraine in order to skip the misuse/overuse of triptans
leading to a superimposed medication overuse headache.
Reference
Gentile G, Borro M, Missori M, Sebastianelli A, Simmaco M, Mar-
telletti M (2010) J Headache Pain 11(2):151–6
433
Genetic polymorphisms related to triptans efficacy
and overuse in chronic migraine
M. Simmaco1, S. Missori2, M. Borro3, G. Gentile1, N. Lala4,
P. Martelletti4
1Biochemical Sciences, Advanced Molecular Diagnostic Unit,
Sapienza, Roma, Italy;
2Medical and Molecular Sciences, Sapienza Rome University, II
School of Medicine, Rome, Italy;
3NESMOS Department, Advanced Molecular Diagnostic Unit,
Roma, Italy;
4Medical and Molecular Sciences, Sapienza, Roma, Italy
Migraine is widespread form of headache, and triptans are usually the
best therapeutic acute option, although efficacy is extremely variable.
Several SNPs in genes involved in metabolism and target mechanisms of
triptans have been described. In order to define an association between
genetic profile and triptans response, we classified a migraineurs popu-
lation on the basis of triptans response and characterized it for
polymorphisms in the genes coding for monoamine oxidase A, G-protein
beta 3 and the cytochrome CYP1A2. Analysis of association between
genotypic and allelic frequencies of the analyzed SNPs and the grade of
response to triptans administration showed a significant correlation for
the MAOA uVNTR polymorphism. The further stratification of patients
in abuser and non-abuser groups revealed a significant association with
triptans overuse and, within the abusers, with drug response for
CYP1A2*1F variant.
These data contribute to determine the triptans treatment outcome,
which frequently prompts to triptans overuse risk and then to Medi-
cation Overuse Headache (MOH).
Reproducibility and validation of genetic association studies in the
research area of CM ± MOH management strongly need of stan-
dardized and more accurate methods for unambiguous classification
of therapy efficacy, till now based on patient self-reports.
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Psychiatric comorbidity and suicide risk in patients
with chronic migraine
M. Pompili1,2, S. De Filippis3, G. Serafini4, D. Di Cosimo5,
N. Girardi5, M. Innamorati5, R. Tatarelli5, D. Lester6, P. Martelletti7
1MC Lean Hospital, Harvard Medical School, Boston, MA, USA;
2Psychiatry, Suicide Prevention Center, Sapienza, Italy;
3Medical and Molecular Sciences, Sapienza, Roma, Italy;
4Psychiatry, Suicide Prevention Center, Sapienza, Rome, Italy;
5Psychiatry, Suicide Prevention Center, Sapienza, Roma, Italy;
6Psychiatry, The Richard Stockton College, New Jersey, NJ, USA;
7Medical and Molecular Sciences, Sapienza, Rome, Italy
The aim of this study was to explore the impact of mental illness
among patients with migraine. We performed MedLine and
PsycINFO searches from 1980 to 2008. Research has systematically
documented a strong bidirectional association between migraine and
psychiatric disorders.
The relationship between migraine and psychopathology has often
been clinically discussed rather than systematically studied. Future
research should include sound methodologically-based studies
focusing on the interplay of factors behind the relationship between
migraine, suicide risk, and mental illness.
Reference
Pompili M, Serafini M, Di Cosimo D, Dominici G, Innamorati M,
Lester D, Forte D, Girardi N, De Filippis S, Tatarelli R, Martelletti P
(2010) Psychiatric comorbidity and suicide risk in patients with
chronic migraine. Neuropsychiatric Disease and Treatment 6:81-91
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Patient outcome in migraine prophylaxis: the role
of psychopharmacological agents
M. Pompili1,2, P. Girardi2, R. Tatarelli2, D. Lester3, P. Martelletti4
1MC Lean Hospital, Harvard Medical School, Boston, MA, USA;
2Psychiatry, Suicide Prevention Center, Sapienza, Rome, Italy;
3Psychiatry, The Richard Stockton College, New Jersey, NJ, USA;
4Medical and Molecular Sciences, Sapienza, Roma, Italy
Migraine is a serious illness that needs correct treatment for acute
attacks and, in addition, a treatment prophylaxis, since patients with
migraine suffer during acute attacks and also between attacks.
A systematic review of the most relevant clinical trials of migraine
headache and its epidemiology, pathophysiology, comorbidity, and
prophylactic treatment (medical and non-medical) was carried out
using ‘‘Medline’’ and ‘‘Psych-info’’ from 1973 to 2009.
Approximately 110 trials met our inclusion criteria and were included
in the current retrospective study.
The most effective pharmacological treatment for migraine prophy-
laxis is propranolol and anticonvulsants such as topiramate, valproic
acid, and amitriptyline. Non-medical treatments such as acupuncture,
biofeedback, and melatonin have also been proposed. Peripheral
neurostimulation has been suggested for the treatment of chronic
daily headache that does not respond to prophylaxis and for the
treatment of drug-resistant primary headache. The majority of the
pharmacological agents available today have limited efficacy and may
cause adverse effects incompatible with long-term use.
This study was limited by the highly variable and often insufficient
reporting of the complex outcome data and by the fact that migraine
prophylaxis trials typically use headache diaries to monitor the course
of the disease. The results of the different studies were also presented
in different ways, making comparison of the results difficult.
Reference Pompili M, Serafini G, Innamorati M, Serra G, Dominici G,
Fortes-Lindau G, Pastina M, Telesforo L, Lester G, Girardi P, Tatarelli R,
Martelletti P (2010) Patient Related Outcome Measures 1:1–12
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Rehabilitating chronic migraine complicated
by medication overuse headaches: how can we prevent
migraine relapse?
I. Farinelli, I. Dionisi, P. Martelletti
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Headache is among the most common neurological symptoms in clinical
practice. In some cases of episodic migraine, the headache intensifies into
a chronic form, defined as chronic migraine (CM) and such a condition
encompasses a headache frequency of 15 days/ month, with features
similar to those of migraine attacks. The assessment of CM in the US
general population ranges around 1.3ndash;2%. Migraine progression
from an episodic into a chronic form is realized through a period of time
involving several months or years, during which an increase attack fre-
quency occurs. Both Topiramate and OnabotulinumtoxinA can be
considered to be safe as well as effective medications, therefore, repre-
senting a treatment choice. Regarding drug abusers, the initial relief step
always consists of drug interruption. Only after detoxification can a new
prophylaxis therapy be commenced, which otherwise would be useless
from the start. The feasible diagnostic setting for the tailored treatment of
CM based on the application of pharmacogenomics will allow us in
predetermining the efficacy of a single old and new drugs by avoiding
abuse due to non-responsivity of the abused drug.
Reference Farinelli I, Dionisi I, Martelletti P (2010) Rehabilitating
chronic migraine complicated by medication overuse headaches: how
can we prevent migraine relapse? Intern Emerg Med DOI 10.1007/
s11739-010-0410-9
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Efficacy of stellate ganglion block on new daily
persistent headache
D. Danno, H. Tachibana, T. Yamanishi, M. Hashimoto, K. Matsui,
T. Oku, K. Kawabata
Division of General Medicine, Department of Internal Medicine,
Hyogo College of Medicine, Nishinomiya-shi Hyogo, Japan
Aim New daily persistent headache (NDPH) is a primary headache
that is characterized by sudden onset in a person with no past history
of headache and is followed by a shift to a persistent headache within
several days. NDPH has been considered as one of the most refractory
headaches. In this study, we performed stellate ganglion block (SGB)
on NDPH patients to assess its possible efficacy.
Method Four NDPH patients were investigated. They were diagnosed
based on the NDPH diagnostic criteria set forth in the ICHD-II. SGB was
performed three times per month to everyday dependingon the symptoms.
Results
Case 1 A 37-year-old woman had a non-pulsating headache that
developed in the whole head since last year. The degree of the
headache was moderate. Triptans, NSAIDs, antiepileptic drugs, and
muscle relaxants provided ineffective relief. Tricyclic antidepressants
were slightly effective whereas SGB was effective.
Case 2 A 17-year-old woman had a right side non-pulsating headache
that developed 6 months ago. The degree of the headache was
moderate to severe. NSAIDs, tricyclic antidepressants, anxiolytics,
and triptans provided ineffective relief whereas the headache was
relieved following SGB.
Case 3 A 68-year-old man had a throbbing headache that developed in the
whole head from the age of 64 years. The degree of the headache was
moderate. Various oral administrations and SGB provided ineffective relief.
Case 4 A 35-year-old man experienced a sudden onset of a non-
pulsating headache in the whole head 4 months ago. The headache
continued to persist. The degree of the headache was moderate.
Triptans, NSAIDs, anxiolytics, muscle relaxants, and tricyclic anti-
depressants were ineffective, but SGB was effective.
In 3 of the 4 cases, SGB administration provided effective relief of the
headache in NDPH patients.
Conclusions The present study suggests that SGB may be useful for
the treatment of drug-resistant NDPH.
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Hemicrania continua-like syndrome after ipsilateral
lateral medulla infarction with significant painrelief
on occipital nerve stimulation
H. Ter Berg1, N. Bouwman1, F.J. Hulsmans1, O. Teernstra2
1Orbis Medical Center, Sittard-Geleen, Geleen, The Netherlands;
2Maastricht University Medical Center, Maastricht, The Netherlands
In a 50-year-old female, smoker, match to clinical, MRI, SSEP,
blinkreflex and quantative sensory testing (QST) data a right-sided
lateral medulla infarction (LMI) on the level of the pars interpolaris
trigeminal nucleus.
Remarkable features: initiating intolerable exploding headache com-
bined contralateral absent and impaired pain/temperature and touch/
vibration sense respectively (because of lesioned sensory fibres within
spinothalamic tract?) with an intact medial lemniscus (normal SSEP).
The lesioned 2nd trigeminal branch (QST) is more compatible with
pars interpolaris than caudalis V nucleus involvement.
After one week a persistent ipsilateral hemicranial pain with nasal
congestion, mild lacrimation and partial ptosis during exacerbations
(VAS 6 to 8–9) occurs. A negative response on indometacin 150mgr/
day exists. Subsequently a diagnosis of a close temporally event-
related and side concordant hemicrania continua (CH) phenotype is
made. Migraine features does not exist. No effect exists on betab-
lockers, dopaminergics, morfinominetics, oxcarbamazepin, lamotrigin
and nortriptylin. Occipital steroids injection causes painfreedom
during 1 day.
Twenty months later (november, 2007) the patient is added to a pilot
study with occipital nerve stimulation on 3 patients with treatment re-
sistent chronic cluster headache in our centre resulting in a persistent
significant painrelief to VAS 2 to 6–7 with disappearance of autonomic
signs until now. On non-stimulation all features recur. Definite anatomic
and pathophysiological conclusions can not be made. A variable affected
trigeminal and extracranial touch/pain sensation exist in LMI.
Inconsistent indomethacin response is reported in secondary HC.
Validation of the indotest has been proposed.
In LMI autonomic features doesn’t occur besides sympathic Horner’s
syndrome and headpain is mostly mild/absent. The superior salivatory
nucleus with many regulative parasympathic connections may be
involved.
Literature
– Kim JS et al. Patterns of sensory dysfunction in lateral medullary
infarction. Neurology 1997;49:1557–1563
– Prakash S et al. Secondary hemicrania continua: case reports and
literature review. J Neurol Sci 2009;280:29–34
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Clinical and electroencephalographic profile
of posttraumatic headache in children and adolescents
M. Lemka, E. Pilarska, K. Pienczk Renclawowicz
Department of Developmental Neurology, Medical University
of Gdan´sk, Gdansk, Poland
Purpose To present the clinical characteristic and electroencephalo-
graphic profile of posttraumatic headache in children and adolescents.
Method In a prospective hospital - based study, 100 children (29 girls
and 71 boys), aged 3-14 years old, 90 after brain concussion and 10
after contusion were studied. The children were examined within one
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week after trauma, and then after 3, 6 and 12 months. EEG was
performed in all patients and repeated in children with persistent
headache. The evolution of EEG recordings in children with chronic
headache was presented.
Result 83% of children complained of headache after brain concus-
sion and contusion. The majority had acute posttraumatic headache,
but 27% had chronic headache, mainly tension type. EEG was normal
in 48 (48%) patients. The pathological EEGs showed general slowing,
focal findings with localized slowing, spike - wave complexes.
Conclusion The important risk factor for the occurrence of post-
traumatic headache were the age of child at the moment of injury and
the period of unconsciousness. The routine performance of an EEG in
children with posttraumatic headache is not indicated because in most
of the cases it is unrevealing. Children should be closely monitored
for possible clinical complication and neurological deterioration.
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The pharmacological effect of BGC20-1531, a novel
prostanoid EP4 receptor antagonist, in prostaglandin
E2 human model of headache
M. Antonova1, T. Wienecke1, K. Maubach2, E. Thomas2, J. Olesen1,
M. Ashina1
1Danish Headache Center and Department of Neurology, Glostrup
Hospital, Faculty of Health Sciences, University of Copenhagen,
Glostrup, Denmark;
2BTG International Ltd, London, UK
Background and objective Using a human Prostaglandin E2 (PGE2)
model of headache we examined whether a novel selective and potent
and selective EP4 receptor antagonist, BGC20-1531, may prevent
headache and dilatation of the middle cerebral (MCA) and superficial
temporal (STA) artery.
Methods Eight healthy volunteers were randomly allocated to
receive 200 and 400 mg BGC20-1531 and placebo, followed by a
25-min infusion of PGE2 (0.40 lg/kg/min). We recorded headache
intensity a 10-point verbal rating scale, and measured blood flow
velocity in the MCA (VMCA) and the diameter of the STA by
ultrasonography.
Results A large variation in the severity of the PGE2-induced headache
between the subjects on placebo day had been observed. Five out of eight
subjects did not reach the therapeutic plasma concentration of BGC20-
1531. We found no difference in headache responses between both
pretreatment days and placebo day (P [ 0.05). Both doses of BGC20-
1531 did not prevent dilation of the MCA and the STA (P [ 0.05).
Conclusion The EP4 receptor antagonist, BGC20-1531 did not pre-
vent PGE2-induced headache and dilatation of cranial arteries.
However, insufficient exposure to BGC20-1531 and variability in
headache response has confounded the outcome of the study and
further investigations are needed.
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Dizziness as a discriminating feature in children
with primary headaches
E. Pilarska, M. Lemka, K. Pienczk-Renclawowicz, A. Olszewska
Department of Developmental Neurology, Medical University
of Gdan´sk, Gdansk, Poland
Purpose Even though there are separate and clear criteria for the
diagnosis of migraine and tension type headaches established by the
International Headache Society, the diagnosis of aforementioned may
be troublesome especially in pediatric population. The purpose of the
study was to find out the discriminating features between migraine
and tension-type headaches focusing mainly on dizziness (the fre-
quency of dizziness in paediatric migraineurs and in children
suffering from tension-type headaches (TTH), evaluation if dizziness
was a part of migraine aura, migraine headache or a separate symp-
tom e.g in benign paroxysmal vertigo of childhood.
Material and methods Study group consisted of 60 children aged
from 6 to 18 years old (30 migraineurs and 30 TTH patients) hospitalised
in Developmental Neurology Department, Medical University of Gdansk
between 2004–2009 due to migraine with or without aura or TTH. The
type of aura was visual (10 children) and sensory (4 children). Children
suffering simultaneously from migraine and TTH were excluded from
the survey. In all children paediatric, otorhinolaryngological, ophthal-
mological, psychological examinations, electroencephalogram and
neuroimaging were performed.
Results Dizziness was diagnosed in 52 % children with migraine and
31 % with TTH. Benign paroxysmal vertigo was diagnosed in 12% of
migraineurs. In 10 % dizziness was the symptom of migraine attacks,
more often it was a sign of an aura (25%). We did not find statistically
significant difference in frequency of dizziness between patients with
visual and sensory aura. Dizziness in children with TTH was much
milder than in children with migraine.
Conclusions Occurrence of dizziness coexisting with a headache is
supportive for the recognition of migraine in pediatric population, but
does not exclude the recognition of TTH.
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Primary idiopathic stabbing headache with a possible
seasonal pattern
S. Fernandes Machado, C. Costa, E. Parreira
Neurology, Hospital Fernando Fonseca, Amadora, Portugal
Introduction Primary Stabbing Headache is recognized as an intense
pain with preferential localization in the cutaneous area of the first
division of the trigeminal nerve, with no autonomic symptomatology
and lasting a fraction of seconds. Its cause is not completely under-
stood but some features possibly reveal a common physiopathology
with TACs. There are no robust descriptions of a seasonal variation
and those anecdotal case reports relate to recurrences of pain occur-
ring only during winter and in patients with previous respiratory tract
infections.
Clinical report A 70 year old woman recurred to our Neurology
Department due to a 30 year old history of headache, described as
‘‘stabbing’’, with preferential parietal localization, occasionally with
auricular irradiation, occurring several times a day, lasting a few
seconds and returning every 7 months, exclusively ‘‘in Spring and
Autumn’’. Actually it interferes with sleep. She has no accompanying
symptoms, namely disautonomic ones. She had already been observed
by several doctors, with subsequent several different diagnoses, but
without successful treatments. In our department the neurological
observation and the cranial MRI were unremarkable. The diagnostic
hypothesis of Primary Stabbing Headache was made and we started
indomethacin (25 mg tid) with a good response.
Conclusion Primary Stabbing Headache is an infrequent entity and its
correct diagnosis has obvious therapeutic implications. In this case,
the reappearance of the episodes with a seasonal pattern and its
occurrence by night suggest a possible common physiopathology with
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TACs. This might be the reason why there are descriptions of
favorable responses to melatonin in patients with Primary Stabbing
Headache. To our knowledge there are no such cases with a well
established chronic seasonal pattern.
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A dependency scale predicts prognosis of medication
overuse headache the akershus study of chronic
headache
C. Lundqvist1,2,3, R.B. Grande1,4, K. Aaseth1,4, M.B. Russell1,4
1Head and Neck Research Group, Research Centre, Akershus
University Hospital, Lørenskog, Norway;
2HØHK, Research Centre, Akerhus University Hospital,
Lørenskog, Norway;
3Department of Neurology, Ullevaal University Hospital,
Oslo, Norway;
4Institute of Clinical Medicine, University of Oslo,
Nordbyhagen, Norway
Medication overuse headache (MOH) is common in the general
population. It has several characteristics similar to drug dependency.
The objective of this study was to test the hypothesis that the severity
of dependence scale (SDS) can predict MOH prognosis regarding
medication overuse and headache frequency.
A cohort of 151 people with chronic headache and medication
overuse from the general population were followed-up after 2–
3 years. SDS scores, information on headache frequency and medi-
cation use were collected at baseline and follow-up. Main outcomes
were SDS scores, no of days of headache and number of days with
medication overuse at baseline and follow-up. Pearsons c2 tests and
paired Student’s t-tests were used.
Of those with primary or secondary chronic headaches with medi-
cation overuse, 72% and 48% respectively had stopped medication
overuse. Chronic headache was significantly more frequent among
those who continued to have medication overuse (81% v. 49%,
p = 0.002 for primary, 96% v. 60%, p = 0.005 for secondary head-
aches). For participants with primary headaches and medication
overuse, the baseline SDS score was a significant predictor of both
presence of medication overuse and presence of chronic headache at
follow-up. The SDS could not predict similar improvement among those
with secondary headaches. The SDS score was reduced slightly but
significantly in primary headache subjects who had detoxified but not for
secondary headaches. The SDS remained elevated as compared to levels
for subjects who had not had medication overuse at baseline.
Our conclusion is that the SDS score predicts medication overuse
among chronic headache patients and also predicts the probability of
headache and medication improvement over time.
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Migraine and lateral ventricular asymmetry: a clinical
and neuroimaging study
L. Rotaru2, S. Odobescu2, G. Pavlic1,2, I. Moldovanu1,2
1Neurology, State Medical and Pharmaceutical University
‘N. Testemitanu’, Chisinau, Moldova;
2Neurology, Institute of Neurology and Neurosurgery,
Headache Center, Chisinau, Moldova
Objective The purpose of this study was to evaluate the association of
lateral ventricles asymmetry (LVA) with chronic migraine and to
assess its clinical importance.
Materials and methods We have included 95 consecutive chronic
migraine (CM) patients who presented LVA on 1,5T MRI examina-
tion. The measurements of the LVA were made electronically at the
frontal horn level and the degree of ventricular asymmetry was
classified as being minimal (control group), mild, moderate or severe
according to the ratio of the larger frontal horn diameter to the smaller
one (Grosman H.). Patients were evaluated with a detailed structured
questionnaire based on criteria of the International Classification of
Headache Disorders (ICHD), 2nd edition, and collected data were
analyzed.
Results We compared the clinical features of migraine in minimal
and severe LVA patients. The mean age was similar in both patients
groups (41.5 ± 15.7 vs. 38.5 ± 14.92). There was no significant
statistical difference in disease duration (mean duration 19.58, SD
13.26) and migraine attacks frequency (26.2 ± 5.2 headache days per
month). The prevalence of LVA all-out (mild, moderate and severe)
in the study population was 51%. We ascertained a younger age at the
migraine onset in severe LVA patients (14.11 SD 8.11 vs. 21.88 SD
10.28, p \ 0.05), as well as longer attack duration in the same group
(63.3 SD 47.49 vs. 20.5 SD 19.4, p \ 0.01).
Conclusions Asymmetry of the lateral ventricles of the brain is a
relatively common MRI finding in CM patients that has important
clinical correlates and deserves more attention. According to the
results of this study, lateral ventricles asymmetry could be considered
as a factor that may influence migraine severity.
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Chronic migraine: clinical and epidemiological study
and chronification factors
S. Odobescu, L. Rotaru, I. Moldovanu
Neurology, Institute of Neurology and Neurosurgery,
Headache Center, Chisinau, Moldova
Objective About 14% of episodic migraine (EM) patients progress to
chronic (CM) migraine during one year of followup [Katzarava Z.
et al, 2004].
The purpose of this study was to evaluate specific social and demo-
graphic features as well as the comparative clinical picture of CM and
EM in order to define potential factors of chronification.
Materials and methods We performed a randomized epidemiologi-
cal study of primary headaches in Republic of Moldova on 2665
responders, using a detailed structured questionnaire based on criteria
of the International Classification of Headache Disorders (ICHD), 2nd
edition, 2004.
Results Of the total sample, 93 patients (3.5%) suffered from CM and
441 (16.5%) from EM. Mean age of migraine sufferers was
38.5 ± 1.47 vs. 37.8 ± 0.67 years and disease duration - 10.3 ± 0.83
vs. 8.5 ± 0.42 years (p \ 0.05).
We ascertained some specific features of CM patients: the majority
were women (84.9%), from rural area (67.7%), with low level of
education (74.3%), physical workers or not employed (64.5%), and
with poor financial status (72%).
Head or neck trauma has been reported in 33.8% CM vs. 25.1% EM
patients (p \ 0.05), mood disorders - in 54.5% CM vs. 44.3% EM,
and drug abuse in 29.9% CM patients.
Conclusions The results of the current study emphasize that some
factors (sex, low educational and financial level, drug abuse, head or
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neck trauma, and associated mood disorders) may influence migraine
chronification.
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New online tools to monitor migraine headache
M.J. Sorbi1, D. Westhuis1, H.G. van Silfhout1, J.L. van der Zwan2,
Psychology & Health (National Research School)
1Clinical & Health Psychology, Utrecht University,
Utrecht, The Netherlands;
2Hoofdpijncentrum MiddenNederland, Amersfoort, The Netherlands
A headache diary - based on the IHS classification criteria - is
mandatory in clinical practice and research, given the consistent
discrepancy between retrospective questionnaires or inquiry and
daily state reporting. Uniformity between centers and countries, as
well as clarity and user-friendliness, are highly desirable. In
addition, electronic diaries are more reliable than paper-and pencil
forms and when accessed safely through the internet have numer-
ous advantages.
We will present two tools to monitor migraine according to the IHS
through the internet.
(1) An online headache diary with migraine monitor - the direct
graphical representation over time of headaches, migraine
attacks and medication use per day, as well as the menstruation
in women.
(2) A real-time diary, employed through smartphone by prompting
the user in daily life, which captures migraine headache,
prodromal features of migraine, and current health behavior.
This application also allows for tailored coaching of health behavior
in response to the diary entry, which the user receives directly through
the smartphone.
The technical feasibility, acceptance and utility of both tools were
successfully tested. The online diary with migraine monitor was
recently employed in a Dutch headache center by 28 migraine patients
who kept it for 80 days at average, as well as by the neurologist, who
used it before, within and between consultations. The real-time diary
was tested in 47 migraine patients. In five of them this was done
recently as part of an advanced software application with an extended
‘back office’ for data management.
Both tools can be easily used in clinical practice and in research. We
want to share these developments also with the aim to contribute to
the issue of usability and best practice in migraine monitoring, and to
the convergence in headache diary use.
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Epidemiology, etiology and study of clinical findings
of headache
Z. Adwan
Neurology, National Hospital, Swaida, Syria
Background and methods In a cross-sectional epidemiological
study of headache disorders in neurology clinic (August 22-
November 20.2009), information on types of headaches, quality,
severity, location, duration, frequency, precipitating factors, age of
onset, influence of menstruation and pregnancy, positive familial
history, use of oral contraceptive pills and other epidemiological
factors including socioeconomic and age/sex composition was
collected. Any types of headaches was ascertained by a clinical
interview and examination using the operational diagnostic criteria
of the International Headaches Society. The prevalence of migraine
and tension type headache was also analyzed in relation to vari-
ables of life style (physical activity and sleep pattern) and
associated signs and symptoms (nausea, vomiting, photophobia and
phonophobia).
Results In this study migraine and tension headache were also
compared in variable aspects with each other.
(1) Headache was more prevalent in women than men (F/M = 3/1).
(2) The most common types of headache included: tension type
headache T.T.H (41.4%), migraine (31.2%) and unclassified
headaches (17.2%).
(3) Migraine and T.T.H were more prevalent in early adult life and
middle ages.
(4) In both migraine and tension type headache the time profiles
(duration, frequency, age of onset), quality and location were
like that noted in textbook and previous studies.
(5) In both migraine and tension type headache the most conspic-
uous precipitating factor was stress and mental tension and
frequent headaches were accompanied with psychiatric prob-
lems (e.g. depression and or anxiety).
(6) Nausea, vomiting, phonophobia and photophobia were the most
common associated symptoms in both of them.
(7) Positive familial history and aggravation of headache in
premenstrual period were more commonly seen in patients with
migraine than tension type headache.
In conclusion using the operational diagnostic criteria of International
Headache Society in clinical practice, treating, teaching, clinical and
epidemiological research is very useful and must also be applied for
patients.
449
Epidemiologic and clinical characteristics of migraine
and tension-type headaches among hospitals staffs
S. Al Faqih
Baghdad University, Baghdad, Iraq
Background Headache is a common symptom that constitutes a
major health problem to all countries in the world. This study was
conducted to estimate the prevalence of migraine and tension -type
headaches (TTH), its associated occupational risk factors among
hospitals staffs, and to report on clinical characteristics of migraine
and TTH with using the International Headache Society (IHS) diag-
nosis criteria.
Method A random sample of 1,023 staffs constituting a 20% sample
of the hospitals staff population was selected. Sampling method was
categorical random sampling. Within each group sampling was
carried out systematically. Data were collected by screening ques-
tionnaire followed by clinical interviews, general physical and
neurological examination, and diagnostic criteria of IHS. Prevalence
of migraine, TTH and coexisting migraine and TTH were estimated
as 11.2% (115 cases), 19.5% (199 subjects) and 3.2% (33 subjects)
respectively. In this study, clinical characteristics of headache
including type, site, number, intensity, concomitant symptom of
headaches had been surveyed.
Result TTH and migraine headaches were significantly associated
with self reported abnormal sleep pattern and female gender
(P \ 0.001). Also TTH was negatively associated with total 24hr
duration of sleep and history of involvement in second job
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significantly (P \ 0.026). The average of prevalence of migraine and
TTH were lower than their counter parts in western countries but
higher than previous studies conducted in other Asian countries.
Conclusion Clinical characteristics were almost parallel with IHS
criteria, headache- related missed work rates were higher for subjects
with migraine headache, and also TTH and migraine were separate
disorders and were not as a part of a continuum of headache disorders.
Headache disorders deserve more attention, especially concerning
strategies leading to adequate primary prevention, diagnosis and
treatment.
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Effect of migraine on economic status and quality
of life of patients
S. Al Faqih
Baghdad University, Baghdad, Iraq
Background Migraine as one of the most common types of head-
aches with high intensity and prevalence, affects life significantly.
This study was devised to determine the effects of migraine on eco-
nomic status and life quality of suffers.
Methods ‘‘Pain database questionnaire’’, prepared by the Interna-
tional Association for the Study of Pain (IASP) in the year 1995, was
translated to Arabic. Then we modified it regarding cultural, geographical
and social characteristics of Syria . 65 patients (55 women and 10 men)
were recruited form neurology clinic consultants. Those patients who met
the International Headache Society. (IHS) criteria for migraine were
interviewed using IASP questionnaire. Pain effects on sleep, marital life,
social, recreational and sexual activities, quality and quantity of drug
consumption as well as using paraclinic procedures were considered.
Results Significant decrease in sleep duration was seen during
pain (7.4 ± 1.9 h) compared to pain-free conditions (6 ± 3.7 h)
(P \ 0.001). The effects of pain on marital life, social, recreational
and sexual activities during pain were compared with pain-free con-
ditions based on a zero to ten ranking schedule,. Wilcoxon test
showed statistically significant (P \ 0.02) differences.
Conclusion We concluded that the economic effect of migraine and
its impact on patients0 quality of life are significant and should be
considered in health planning and disease management.
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Headaches and ischemic stroke in spontaneous
dissection of the intracranial vertebral artery
M. Shiraishi, H. Akiyama, T. Shimizu, Y. Hasegawa
Neurology, St. Marianna University School of Medicine,
Kawasaki, Japan
Background and purpose Recent progress in magnetic resonance
imaging (MRI) technique enables us to diagnose intracranial vertebral
artery dissection (IVAD) noninvasively. IVAD has been rarely
reported but it may be under diagnosed. We sought to determine the
clinical features of IVAD.
Methods Japanese guideline was used for the diagnosis of IVAD based
on the MR imaging. We retrospectively determined clinical features of
headache, neurological deficits, and MRI findings in 20 patients with
ischemic stroke caused by IVAD admitted from April 2007 to December
2009 (mean age, 54 ± 19 years old; 16 males, 80%).
Results In 8 patients (40%), no episode of headache or neck pain
coincided with ischemic stroke was found. There was no traumatic
episode except one patient with minor trauma in the neck. Headache
was observed in 12 patients (60%), headaches in the unilateral
occipital; 3, in the bilateral occipital; 3, in the bilateral temporal;
2, and in the whole skull; 4. Pulsatile headache was observed in 4
patients (33%) and the intensity of headache was ranged from slight
or trivial in 9 (88%) to moderate in 4 (12%). The neurological deficits
were so slight in 12 patients (NIHSS score ranged from 0 to 3) that
significant delay of the onset to admission was observed (ranged from
6 hour to 24 hour).
Conclusion Majority of patients with IVAD may not have headache
and neck pain. Such a slight symptom may result a delay of hospital visit.
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Impact of hormonal contraception on the risk
of migraine: cross-sectional study including
1613 French women
L. Maitrot-Mantelet1, H. Massiou2, A. Gompel1, M.-H. Horellou3,
G. Plu-Bureau1
1Unit of Gynecological Endocrinology, Hotel Dieu Hospital,
University Paris Descartes, Paris, France;
2Neurology, Lariboisie`re Hospital, Paris, France;
3Unit of Hemostasis, Hotel-Dieu Hospital,
University Paris Descartes, Paris, France
Migraine is a common neurologic disorder which concerns more often
women than men. Its occurrence may be influenced by the events of
endogenous or exogenous hormonal life. Risk assessment of hormonal
contraceptives on migraine is important because of higher risk of
ischemic stroke among migrainous women using combined estrogen-
progestin contraceptives. While many studies have assessed the impact of
combined estrogen-progestin contraceptives on migraine, studies on
progestin only contraceptives remain scarce. In particular, there is no
published data on the risk of migraine among women using progestin
with antigonadotropic effect. The aim of this cross-sectional study
including 1613 childbearing women is to assess the impact of hormonal
contraceptives on the risk of migraine, targeting especially the impact of
progestin-only contraceptives. In our study, the risk of migraine was
significantly associated with family history of migraine (OR = 4,38, CI:
3,38-5,68). In addition, the earlier age of first contraception is associated
with higher risk of migraine (p trend = 0.03). Our results suggest that the
risk of migraine is increased among current users of 3rd generation
estrogen-progestin contraception or pills that have a high estrogen
potency (OR = 2.66, CI: 1.11-6.37), compared to never users of hor-
monal contraception. In contrast, no significant association was found
between migraine and current use of antigonadotropic doses of progestin
(OR = 1.84, CI: 0.80-4.26) or use of progestin only pills (OR = 2.11,
CI: 0.95-4.70). These results obtained with cross-sectional study need to
be confirmed by prospective or randomized studies.
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Skull base metastasis presenting as positional headache
C. Duncan1, C. Dent2, S. Olson3, G. Linklater2
1Department of Neurology, NHS Grampian, Aberdeen, UK;
2Department of Palliative Care, NHS Grampian, Aberdeen, UK;
3Department of Radiology, NHS Grampian, Aberdeen, UK
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This 78 year old man was admitted with a short history of continuous
headache. Neurological examination, MRI brain without contrast and
lumbar puncture were normal. Further investigations of deranged
LFTs revealed metastatic renal carcinoma and he was transferred to
the palliative care hospital for symptom management. He continued
to have severe headache and a neurology opinion was sought.
He was most comfortable on his right side, and was unable to sit or
stand for more than a few minutes because of severe global headache.
This improved to a bearable level on lying on his right side again.
Neurological examination was normal. Intracranial hypotension was
considered. A repeat MRI brain with contrast was considered to be
normal. CSF was again normal (opening pressure marginally reduced;
8 cm CSF). Because he was unable to sit or stand a blind lumbar
blood patch was performed. This was unhelpful and a second blood
patch was considered.
While waiting for this he was assessed by the palliative care phys-
iotherapist. On elongation and retraction of the cervical spine into
postural alignment whilst in the sitting position he became transiently
headache free. An MRI of his cervical spine showed an abnormality
of his skull base, which in retrospect was evident on both previous
MRI’s. Metastatic tumour tissue was noted to involve the right lower
clivus and foramen magnum. This involved the articulation of C1
with the skull base and the hypoglossal canal. Repeat neurological
examination revealed a right 12th nerve palsy with associated tongue
atrophy. He is now receiving palliative radiotherapy.
Presumably his positional headache is due to instability of the skull
base on C1 or pressure on pain sensitive structures in the skull base.
Not all orthostatic headache is due to low CSF pressure and this case
highlights the importance of considering alternative causes.
455
Machine learning techniques in migraine without aura
R. Malik1, D. Nyholt2, B. Mu¨ller-Myhsok3, M. Dichgans1,4,
T. Freilinger1,4
1Institute for Stroke and Dementia Research, Klinikum der
Universita¨t Mu¨nchen, Munich, Germany;
2Queensland Institute of Medical Research, Brisbane,
QLD, Australia;
3Max-Planck-Institute for Psychiatry, Munich, Germany;
4Department of Neurology, Ludwig-Maximilians-Universita¨t
Mu¨nchen, Klinikum Großhadern, Munich, Germany
Background and goals Epidemiological studies have provided evi-
dence for a genetic component in migraine without aura (MO). However,
no variants convincingly associated with MO have been reported, and its
genetic basis remains largely unclear. In the context of a genome-wide
association study (GWAS) in MO (performed in the setting of the
International Migraine Genetics Consortium; IMGC), we aimed at
implementing different ‘machine learning’ techniques, namely Support
Vector Machines (SVMs), Bayesian Network Learning (BNL) and a
technique to retrieve aggregate effects from GWAS data.
Methods and preliminary results For SVMs, we used a set of 628
SNPs derived from our MO GWAS (p \ 1*10–3). When optimizing
the procedure, we found that a polynomial kernel performed best to
separate affected / unaffected status. 10-fold cross-validation on the
set of 628 SNPs resulted in an AUC of 0.914. We are now planning to
apply this model to other migraine datasets available through the
IMGC (including a large population-based Australian MO sample).
Further, BNL can be used to derive correlation between a given SNP
and the phenotype as well as between different SNPs. Both the
structure of the network (parent and child nodes of the phenotype,
direction of arcs in the network) and the probability distribution
behind the network can be learned efficiently from existing data. We
will present first promising results from BNL.
As a final approach, we aimed to transform variation across loci
which were nominally associated in our MO GWAS dataset, into
quantitative scores and relate these scores to disease status. Using
large sets of scored alleles, we could derive aggregate risk scores from
larger sets of SNPs. Our preliminary analysis revealed significant
aggregate scores, although single variants had only smaller effects.
Conclusion Our pilot study emphasizes that ‘machine learning’ can
make a useful contribution to unravel the genetics of migraine.
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A care pathway proforma improves the documentation
of the initial assessment of non-traumatic headaches
in the emergency department
L. Clarke, A. Thomas
University Hospital Coventry & Warwickshire, Coventry, UK
Aim To evaluate the use of a care pathway in the documentation of
the initial assessment of patients who presented to the emergency
department with a non-traumatic headache.
Methods We retrospectively reviewed the medical records of 92
consecutive adult patients who presented to the emergency depart-
ment of a large teaching hospital with a non-traumatic headache over
a three-month period.
Results The current headache care pathway proforma was used in
only nine of the cases; 83 were clerked ‘freehand’. The documentation of
the history and physical examination findings were allocated a score, out
of a maximum of 21, based on the documentation criteria in the care
pathway. Where the care pathway had been used, the scores were con-
sistently much higher (mean score 16.22, p = 0.09) than that of the
freehand clerking (mean score 8.14 p = \ 0.0001). A large proportion of
patients in both groups underwent computed tomography scanning of the
head. Many were subsequently discharged from hospital without a
definitive diagnosis or arrangements for neurological follow-up.
Conclusion Patients with non-traumatic headache could benefit from
the use of a simple care pathway in the emergency department,
however they are under-utilized at present. By emphasizing the cru-
cial elements of history and examination, care pathways improve the
documentation of the clinically and medico-legally significant ele-
ments of the history, encourage thorough examination, and are a
useful tool to guide the decision-making of clinicians in the emer-
gency department. Care pathways facilitate the rapid and accurate
diagnosis of potentially life-threatening secondary headaches, and
expedite the safe discharge of patients with benign headaches, thus
improving the care of this important group of patients.
457
Does migraine improve through ketogenetic diet?
C. Di Lorenzo1, G. Sirianni2, G. Coppola1, S.L. Sava1, M. Gorini1,
C. Davassi1, M. De Micco1, F. Pierelli1
1University Center for Adaptive Disorders and Headache (UCADH),
‘‘Sapienza’’ University of Rome, Polo Pontino - ICOT, Latina,
Rome, Italy;
2Wellness and Aesthetics Medicine, Krom Genetics Institute,
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Introduction Ketogenic diet (low-carbohydrate, high-protein and
lipids diet, inducing ketone bodies hepatic mitochondrial production)
improves drug-resistant epilepsy, maybe by ketonic modulation of
neuronal excitability.
From seventies, low-calorie ketogenic diet, poor in carbohydrate
(\1 g per kg) but rich in proteins (1.2–1.6 g per Kg), is adopted to
achieve rapid adiposity loss in obese persons, producing ketone
bodies by lipid catabolism. This diet, according to WHO suggested
protein intake upper limits (2.5 g per Kg), is usually adopted for
short-time periods (2–4 weeks).
We report two 45 y.o. migraineurs sisters, monozygotic twins, that
have had a headache improvement with a low-calorie ketogenic diet.
Case report Twins were examined for a high frequency migraine
without-aura. Previously they were followed by another Headache-
Clinic, abandoned more than one year before because of absence of
improvement and weight gain (around +20 Kg in less than 2 years).
Fortunately, they continued to fill-in the headache diary.
Both diary analysis evidenced meanly five attacks/month (10–
15 days/month). However, they have had for 3 times, both in the
same periods, a 1-month headache free phase every 3 months, exactly
clashing with 21-days cycles of low-calorie ketogenic diet that carried
them to their ideal weight.
Discussion Ketogenesis was already suggested as useful to improve
several neurologic disorders, but migraine. However, ketogenesis
reduces cortical spreading depression propagation. This mechanism is
maybe involved in our patients headache improvement.
Conclusions We auspicate studies about ketogenic diet influence on
migraine, since it could be useful to reduce both headache burden and the
weight-gain that usually complicates several prophylactic treatments.
458
Cephalgia in multiple sclerosis
N.F. Filipovich1, A.N. Filipovich2, V.I. Novikov1, N.S. Filipovich1
1Belorusian Medical Academy for Post-Graduate Doctors
Training, Belarus, Russia;
2Research Institute of Medical Assessment and Rehabilitation,
Minsk, Belarus, Russia
According to literature data, 25-40% of the population suffer from
cephalgia. It prevails among people of employable age and is associated
with life quality deterioration. In multiple sclerosis (MS), cephalgia
occurs in the cases of brain stem involvement, location of plaques
around the ventricular system. The presence of cephalgia considerably
impedes early diagnosis of MS having no pathognomic clinical signs.
The only reliable modality for MS verification is MRI with high
intensity of magnetic field (1.5T and higher), (F.Barhof‘s criteria).
Objective of the study Evaluating the role of venous disorders in
cephalgia pathogenesis in MS.
Materials and methods The results of the study of 28 MS patients
were summarized.
Results MS duration ranger from 1 to 5 years and more. The course
of the disease was of progressive nature with persistent cephalgesic
syndrome, meteosensivity, events of neurologic symptom fluctuation
which were regarded by outpatient clinic neurologists as recurrent MS
exacerbation.
The findings of initial MRI with low intensity of magnetic field in the
28 patients suggested multifocal affection of the white substance of
the brain. Given persistent cephalgia in the 11 patients, MRI was
repeated using a vascular program on a unit with magnetic field
intensity of 1.5T. the analysis of MRI scans demonstrated that blood
filling of cerebral vessels of the carotid and vertebrobasilar system
was intact in all examined patients. At the same time, the net of
venous vessels was affected, mainly on cephalgia side: delated,
twisted veins with dominant transverse sinus in the right (7 patients)
or in the left (4). The administered venotonic and dehydrating therapy
with correctors made it possible not only to control cephalgia but also
to rule out MS exacerbation, as well as to avoid groundless pre-
scription of expensive immunomodulating therapy.
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DNA sequencing of mitochondrial complex i predicts
riboflavin efficacy in migranie
C. Di Lorenzo1, F. Pierelli1, G. Coppola1, M. Gorini1, C. Davassi1,
M. De Micco1, C. Casali1, G.S. Grieco2, M. Ciccolella3,
F.M. Santorelli4
1University Center for Adaptive Disorders and Headache (UCADH),
‘‘Sapienza’’ University of Rome, Polo Pontino - ICOT, Latina,
Rome, Italy;
2Experimental Neurobiology, IRCCS ‘‘C. Mondino Institute
of Neurology’’ Foundation, Pavia, Italy;
3Molecular Medicine, IRCCS ‘‘Bambino Gesu`,’’, Rome, Italy;
4Molecular Medicine and Neuroscience, IRCCS ‘‘Stella Maris’’,
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Introduction Daily high-dose riboflavin supplementation is a useful
treatment in mitochondrial disorders and migraine. This effectiveness
is higher in carriers of mutations in Complex I of mitochondrial
respiratory chain, an enzymatic complex involved in oxidative
phosphorylation, synthesized by mitochondrial DNA (mtDNA).
However, although some mtDNA mutations were occasionally
described in migraineurs, Complex I mutations were never detected in
migraine. Aim of this study is to look for Complex I mtDNA muta-
tions in a group of migraineurs treated with high-dose riboflavin and
compare mutations of responders with non-responders.
Materials Complex I genome and mtDNA control region (as control)
was sequenced in 67 migraineurs treated with riboflavin, blind for
treatment efficacy.
Results Complex I mutations were found in 4 patients, all responders
to riboflavin. Control region mutations were found in 5 patients, only
1 resulted to be responders to riboflavin. At two-tailed Fisher exact
test, groups resulted to be statistically different (p = 0.048).
Discussion In our patients, Complex I mutations could account for an
enzymatic dysfunction, improved by riboflavin.
Conclusions Our findings support hypothesis that it will exist a
relationship between migraine and mitochondria.
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The major metabolite of dihydroergotamine (dhe)
after oral inhalation and iv administration does
not significantly contribute to the pharmacologic
activity
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DHE has been used to treat migraine for over 60 years. Early phar-
macokinetic (PK) studies were performed using relatively non-
specific assays following oral administration. It has been suggested
that part of the reason for the long duration of action of DHE is its
potent and long-lasting metabolite, 80-hydroxy-DHE (80-OH-DHE). A
sensitive (20 pg/ml) LC-MS-MS method for analyzing 80-OH-DHE
was developed, and results from two PK studies where DHE was
administered by IV or oral inhalation are reported here. Receptor
binding studies were also performed on some serotonin subtype
receptors using the maximum 80-OH-DHE concentrations found in
the first study.
In the two studies, 30 healthy subjects (17 males, 13 females)
received 1.0 mg IV or orally inhaled DHE and had measurable con-
centrations of 80-OH-DHE at 12 hours following IV administration
that allowed for calculation of the 80-OH-DHE half-life. In most
subjects, there were insufficient samples above the limit of quanti-
tation from orally inhaled DHE to allow accurate calculation of the 80-
OH-DHE half-life.
Results Mean Cmax concentrations after IV administration for DHE
and 80-OH-DHE were 45,289 pg/ml and 424 pg/ml respectively for
the first study (n = 16) and 42,201 pg/ml and 335 pg/ml respectively
for the second study (n = 14). After IV administration, the average
elimination half-life from both studies of 9.4 hours for 80-OH-DHE
was not significantly different from that calculated for DHE
(10.2 hours). Receptor binding studies showed that there was little or
no receptor occupancy/activation at serotonin subtype receptors when
the Cmax concentration of the 8
0-OH-DHE from the first study was
tested.
Conclusions The results of these two studies suggest that the 80-OH-
DHE metabolite does not have a longer half-life than the parent
compound and its contribution to the pharmacologic activity when
given via IV or oral inhalation is minimal.
Conflict of interest Dr. Silberstein has acted as a consultant, speaker
or received research support from Allergan Pharmaceuticals.
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LevadexTM, a novel orally inhaled treatment for acute
migraine: efficacy and tolerability results
of a phase 3 study
S. Kori1, S. Silberstein2, S. Aurora3, S. Tepper4, S. Borland5,
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Background Triptans are known to have inconsistency of response,
high recurrence rates, slow onset of action and potential for medi-
cation overuse headaches (MOH). IV DHE provides rapid relief,
low recurrence rates and no reported MOH. However, IV DHE is
difficult to administer and has poor tolerability. LEVADEX is a self
administered, novel inhaled formulation of DHE in development.
Methods Randomized, double-blind, placebo-controlled, two-arm,
multicenter study. The co-primary efficacy endpoints were pain relief,
photophobia, phonophobia, and nausea free at 2 hrs post dosing.
Secondary endpoints also were evaluated. Safety evaluations: clinical
assessments, laboratory evaluations, pulmonary function, and cardiac
evaluations.
Results 903 subjects randomized, 792 (mITT population) included
in the primary analysis. 59% of LEVADEX treated subjects had
pain relief at 2 hours compared to 35% for placebo (p \ 0.0001).
Subjects who were nausea free, photophobia free and phonophobia
free at 2 hours 67%, 47%, 53% respectively for the treatment
group and 59%, 27%, and 34% for the placebo group (p values of
0.02, 0.0001 and 0.0001, respectively). The pain relief rate at
10 minutes was 9% for active group compared to 6% for placebo
(p = 0.15). Sustained pain relief, 2–24 an 2–48 hours for the active
arm 44% and 36% and 20% and 17% for the placebo (p \ 0.0001
and 0.0001 respectively). The drug was well tolerated. No drug
related SAEs. Most common adverse event was drug aftertaste (6%
vs 2%).
Conclusions In this trial, LEVADEX demonstrated rapid and sus-
tained efficacy in treating acute migraine. LEVADEX was well
tolerated with an AE profile similar to that of placebo.
Conflict of interest Dr. Silberstein has acted as a consultant, speaker
or received research support from Allergan Pharmaceuticals.
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Efficacy evaluation of LevadexTM in treating a broad
spectrum of acute migraine attacks
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M. Wang5, B. Hu5, J. Brandes6
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Objectives To evaluate efficacy and safety of LEVADEX, a novel
orally inhaled formulation of dihydroergotamine (DHE) in devel-
opment, in treatment of a broad spectrum of acute migraine
attacks.
Background Migraine patient treatment needs often are unmet due in
part the inability of existing therapies to relieve symptoms consis-
tently across a broad spectrum of acute migraine attacks.
Methods This is a post hoc analysis of a randomized, double-blind,
placebo-controlled, two-arm, multicenter study. Efficacy rates at 2 hrs
were compared between patients with moderate vs severe migraine,
with aura and without, and with nausea and vomiting and without.
Comparison was also made between patients using triptans at the time
of entry and not using them.
Results 903 patients randomized; 792 patients in MITT were included
in primary analysis. PR and PF for migraine with moderate intensity
and severe intensity were 70% and 32% compared to 45% and 24%.
PR and PF for migraine with nausea were 54% and 26% compared to
69% and 32% for those without. PR and PF for those with vomiting
were 42% and 28% compared to 60% and 29% for those without.
Migraine with aura had a PR and PF of 55% and 27% compared to
62% and 29% for those without. 43% of patients reported using
triptans and 57% not using triptans. 58% and 26% of patients using
triptans had pain relief and were pain free at 2 hrs (PR,PF), respec-
tively, compared to 59% and 30% of patients not using triptans.
Conclusions In this Phase 3 trial, LEVADEX was effective in
treating acute migraine with moderate and severe intensity, migraine
with nausea and vomiting and those without, migraine with aura and
those without, and migraine in patients currently using triptans and
patients not using triptans. LEVADEX has the potential to treat a
broad range of migraine.
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Efficacy evaluation of levadexTM in treating resistant
migraine including migraine with allodynia, morning
migraine, disabling migraine and migraine treated late
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S. Borland7, M. Wang7, B. Hu7, S. Silberstein8
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Background Triptans are not likely to relieve migraine associated
with cutaneous allodynia, morning migraines and migraine attacks
late in their course. Injectable DHE has been used to treat nonre-
sponsive migraines for decades, however it is inconvenient to
administer and is often associated with nausea. LEVADEX is a self-
administered, novel inhaled form of DHE in development, 1.0 mg
nominal (* 0.5 mg systemic) dose, with Tmax and AUC similar to IV
infusion, but with markedly lower Cmax.
Methods This is a post-hoc analysis of a large randomized, double-
blind, placebo-controlled, two-arm, multicenter study. The presence of
allodynia at the time of drug administration was determined by a standard
questionnaire. Time to treatment was determined using an electronic diary.
Morning migraine was defined as headache occurring prior to 7 AM.
Results 903 patients randomized; 792 patients treating at least one
qualifying headache were included in primary analysis. At baseline, 53%
of patients reported allodynia. 57% with allodynia at baseline reported
pain relief at 2 hrs (34% placebo(PL), p \ 0.0001) compared to 60% of
those that were non-allodynic (35% PL, p \ 0.0001). 30% were pain free
at 2 hrs (8% PL, p \ 0.0001) compared to 27% non-allodynics (12% PL,
p = 0.0002). The pain free rate at 2 hrs for morning migraines was 21%
(4% PL, p = 0.004) compared to 30% for rest of the day migraines (12%
PL, p \ 0.0001). There was no correlation between time to treatment of
migraine and pain relief or pain free rates at 2 hrs. LEVADEX was
equally effective in severely disabled and less disabled migraine patients.
Conclusions In this trial, LEVADEX was statistically similar in each
case in treating migraine with and without allodynia, morning
migraine, disabling migraine and migraine treated late in its cycle.
LEVADEX has the potential to treat migraines that often are resistant
to other acute migraine therapies.
Conflict of interest Dr. Silberstein has acted as a consultant, speaker
or received research support from Allergan Pharmaceuticals.
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(MAP0004) in treating acute menstrual migraine
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Objective To evaluate the efficacy and safety of LEVADEXTM
(MAP0004), a novel orally inhaled formulation of dihydroergotamine
(DHE) in development, in the treatment of an acute menstrual
migraine.
Background Menstrual migraines are reported to be more disabling,
longer lasting, and less responsive to traditional treatments than
nonmenstrual migraines. MAP0004, 1.0 mg nominal dose (approxi-
mately 0.5 mg systemic equivalent dose), has tmax and AUC similar to
IV infusion, but with lower Cmax. Results from a large Phase 3 study
were analyzed to evaluate MAP0004 in the treatment of menstrual
migraine.
Methods This is a post hoc analysis of a randomized, double-blind,
placebo-controlled, two-arm, multicenter study. Menstrual migraine
was defined as a migraine occurring within the period 2 days prior to
3 days after the onset of menstrual flow. Pain relief and sustained pain
relief (SPR) at 2–24 hours and 2–48 hours were compared between
MAP0004 and placebo in menstrual migraines.
Results 903 patients were randomized; 792 patients treating at least
one qualifying headache were included in efficacy analysis. Infor-
mation about last menstrual period was available in 318 patients. 97
(31%) of them had menstrual migraine. For the 97 patients with
menstrual migraine, the 2 hour pain relief rate was 62% for MAP0004
and 34% for placebo. 2-24 and 2-48 hour SPR were 51% and 39% for
MAP0004 and 20% and 17% for placebo, respectively. In all the
measures, the response to MAP0004 was statistically superior to
placebo (p \ 0.05). MAP0004 was well tolerated.
Conclusions In this Phase 3 trial, MAP0004 was effective in treating
acute menstrual migraine.
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Evaluation of efficacy and safety of levadexTM
(MAP0004) in reversing central sensitization
and treating migraine in established allodynic patients
S. Kori1, S. Tepper2, S. Borland3, M. Wang3, B. Hu3, S. Silberstein4
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Objective To evaluate the efficacy and safety of LEVADEX
(MAP0004), a novel orally inhaled formulation of dihydroergotamine
(DHE), in treating acute migraine in allodynic patients.
Background Current migraine treatments may not relieve symptoms
in patients who have established central sensitization (CS), clinically
manifested by cutaneous allodynia. Intravenous DHE has been
shown, in animal studies, to reverse established CS. This analysis of a
large Phase 3 study was undertaken to evaluate the efficacy of
MAP0004 in reversing CS and treating acute migraine attack in
patients with cutaneous allodynia.
Methods This is a post-hoc analysis of a large randomized, double-blind,
placebo-controlled, two-arm, multicenter study. The presence or absence
of allodynia at the time of drug administration and at 2 hours post
administration was determined by a standard questionnaire. Pain mea-
sures were compared between allodynic and non-allodynic patients.
Results 903 patients were randomized; 792 patients treated at least
one qualifying headache were included in efficacy analysis. At time
of treatment, 57% of patients reported allodynia. 53% of these had
resolution of allodynia at 2 hours with MAP0004 compared to 41% in
the placebo group (p = 0.02). 57% of MAP0004 patients with allo-
dynia at time of treatment reported pain relief at 2 hours compared to
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34% of placebo patients with allodynia (p \ 0.0001). The SPR rate at
2-24 hours was 45% for the allodynic MAP0004 population com-
pared to 20% for the placebo allodynic population (p \ 0.001). There
was no statistically significant difference in MAP0004 response
between the allodynic and non-allodynic groups.
Conclusions In this Phase 3 trial, MAP0004 was equally effective in
treating migraines with and without allodynia and was effective in
reversing established allodynia.
Conflict of interest Dr. Silberstein has acted as a consultant, speaker
or received research support from Allergan Pharmaceuticals.
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inhaled DHE) for the treatment of migraine in subjects
with concomitant asthma
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Objective To evaluate the efficacy and tolerability of LEVADEX
TM
for the treatment of migraine in subjects with asthma.
Background Asthma can be a common concomitant disorder for
patients with migraine. Since individuals with asthma can sometimes
have problems with tolerability of inhaled medications and absorption
may be different, we evaluated the efficacy and tolerability of
LEVADEX in a subgroup of patients from a large Phase 3 migraine
trial (previously reported Silberstein et al 2009) who reported to have
concomitant asthma.
Methods Of 792 subjects who treated a migraine headache with
Placebo (P) or LEVADEX (L), 80 reported having a diagnosis of
asthma (L = 44, P = 36). In this subgroup, we analyzed the key
efficacy parameters (2 hr pain relief, photophobia-free, phonophobia-
free, and nausea-free), as well as the occurrence of adverse events
(AEs), and pre-study and post-study spirometry. P-values were cal-
culated without adjustment for multiple comparisons.
Results For efficacy parameters at 2 hours, the following results were
observed in subjects with asthma for L or P. Pain relief: L66% P39%
p = 0.02, Photophobia free: L48% P25% p = 0.04, Phonophobia
free: L57% P39% p = 0.11, Nausea free: L71% P50% p = 0.11.
Mean change from baseline in FEV1 was +60 ml for L and -20 ml
for P. 34% of subjects reported AEs: L32% P36%. The most common
AEs in the body system were infections and infestations (L16%,
P19%). No serious adverse events were reported.
Conclusion In this subgroup analysis, LEVADEX was effective and
well-tolerated in subjects with migraine and concomitant asthma.
A long term study evaluating safety of LEVADEX in subjects with
migraine and concomitant asthma is ongoing.
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Carissa congesta wight: a magical ethnomedicinal
plant for migraine
T.P. Mall
Post Graduate Department of Botany, Kisan P.G. College,
Bahraich, India
During survey for ethnomedicinal flora of Bhinga forest range rep-
resenting north central Tarai forest of UP on May 01, 2010 we met
Mr. Tilak Ram Varma, the forest watchman in Gulra Beet (Mohak-
ama Rihar) on the bank of Cane River. He told us that 15 years ago
when he was nursery gardener and suffering from migraine for last
five years. Once he was sitting in the forest and saw number of young
lateral branches of the Carissa congesta Wight (syn. C. carandes
Auct.: C. carandes L.) plant and spontaneously he reached there and
took out four young twigs and chewed. After half an hour he felt some
irritation in his nose and immediately sneezed for three or four times.
Later on he felt that there is something thread like in his nose. He
wanted to remove it. He found about five meters of fine thread coming
out of his nose in one stretch. He felt lightness in his head and
immediately no pain. Till date he never felt any pain. He told that he
has prescribed several people to get rid off from headache and always
successful. This thread like substance deposited in head may be the
causal reason for pain. He told that the plant is now a magical eth-
nomedicine for the locality. Further intensive research on biochemical
and pharmaceutical study for the same is warranted.
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Migraine recurrence rates: case for standardization
of the definition
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Background Many physicians prefer to refer to recurrence rates to
assess extended migraine relief. However, recurrence rate endpoints
differ widely in definition. Several different definitions are presented
below to illustrate variability in these assessments.
Methods Post-hoc analysis of a Phase 3 study comparing LEVA-
DEXTM (orally inhaled DHE) to placebo. Four different previously
published recurrence rate definitions were used:
a. Numerator: subjects with 2 h pain relief and moderate or severe
pain during 2–24 or 2–48 hours. Denominator: subjects with 2 h
pain relief.
b. Numerator: includes in addition to (a), subjects with pain relief
who used rescue medication during 2-24 or 2-48 hours. Denom-
inator: same as (a)
c. Numerator: same as (a). Denominator: number of subjects in
MITT population
d. Numerator: same as (b) Denominator: same as (c).
These same endpoints can be calculated for pain free criteria.
Results Of 903 subjects randomized; 792 subjects treating C 1 attack
are included in the efficacy analysis. The recurrence rates for the
LEVADEX treatment group during 2–24 h were 6.5%, 22.4%, 3.8%, and
13.2% for definitions a,b,c, and d, respectively. Corresponding rates for
the placebo group were 15.3%, 39.4%, 5.3%, and 13.6%, respectively.
During 2–48 h, the recurrence rates in the LEVADEX treatment group
were 10.3%, 30.2%, 6.1%, and 17.7% and in the placebo group were 18.2
%, 41.6%, 6.3%, and 14.4%for definitions a,b,c, and d, respectively.
Conclusion Recurrence rate, often used to assess sustained effects of
acute migraine therapies, can vary widely in definition and can be
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misleading, depending on the specific one applied. A standardized
definition should be developed to make such comparisons easy and
more meaningful. In a Phase 3 study, LEVADEX demonstrated low
recurrence rates regardless of the definition used.
Conflict of interest Dr. Lipton receives research support from the
NIH [PO1 AG03949 (Program Director), PO1AG027734 (Project
Leader), RO1AG025119 (Investigator), K23AG030857 (Mentor),
K23NS05140901A1 (Mentor), and K23NS47256 (Mentor)], the
National Headache Foundation, and the Migraine Research Fund;
serves on the editorial boards of Neurology and Cephalalgia and as
senior advisor to Headache, has reviewed for the NIA and NINDS,
holds stock options in Neuralieve Inc. and Minster Inc; serves as
consultant or has received honoraria from: Allergan, Autonomic
Technologies, Boston Scientific, Bristol Myers Squibb, Eli Lilly,
Endo, GlaxoSmithKline, Minster, Merck, Nautilus Neuroscience,
Neuralieve, Novartis, and Pfizer.
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Analysis of plasma levels of metalloproteinases
in patients with migraine
J. Ferna´ndez Morales1,2, P. Pozo Rosich1,3, I. Ferna´ndez Cadenas2,
A. Penalba Morenilla2, M. Navarro Sobrino2, M. Vila Pueyo1,
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Research Group and Laboratory of Neurovascular Investigation
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2Laboratory of Neurovascular Investigation, Research Institute
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3Neurology Department, Vall d’Hebron University Hospital,
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Objective The metalloproteinases (MMPs) are involved in neuroin-
flammation and neurodegenerative disorders. MMP-9 levels are
increased in migraine during cortical spreading depression. We ana-
lyzed the plasma levels of the most important families of MMPs in
patients with migraine.
Material and methods A sample of blood using EDTA tubes was
centrifuged at 3500 rpm (4C) to obtain plasma and it was frozen at -
80C. The quantitative determination of plasma levels of MMPs was
performed using SearchlightTM technology (Aushon, Pierce) with the
kit Array Matrix Metalloproteinase 9-PLEX (MMP-1, MMP-2,
MMP-3, MMP-8, MMP-9, MMP -10, MMP-13, TIMP-1 and TIMP-
2). We analyzed the plasma of 80 migraineurs (40 chronic and 40
episodic, with and without aura) interictally and 40 healthy volun-
teers. Most of the patients with chronic migraine were taking
prophylactic drugs, in contrast with episodic migraineurs.
Results Higher plasma levels for MMP-2: 439.3 (264.9-1287.2) vs.
253.72 (223.1-317.8) ng/ml, p \ 0.001; MMP-3: 6.1 (2.5-9.5) vs. 2.5
(1.8-5.3) ng/ml, p \ 0.05; MMP-10: 0.6 (0.3-1.2) vs. 0.28 80.1-0.7) ng/
ml, p \ 0.05; MMP-13: 0.88 (0.43-3.0) vs. 0.43 (0.4-1.6) ng/ml,
p \ 0.05; TIMP-1: 95.85 (57.3-136.7) vs. 59.17 (45.7-66.2) ng/ml,
p \ 0.001; and TIMP-2: 89.14 (64.1-111.6) vs. 59.41 (53.4-71.8) ng/
ml, p \ 0.001 were found in migraineurs versus healthy controls. In
these cases, the presence of aura was associated with even higher levels
of MMP-3, MMP-10 and TIMP-2 in a statistically significant way.
There were no differences between episodic and chronic patients or
amongst those taking or not preventative treatment.
Conclusions Levels of gelatinases (MMP-2), stromelysin (MMP-3
and MMP-10) and collagenase (MMP-13) and its inhibitors (TIMP-1
and TIMP-2) were higher in migraineurs, suggesting a dysfunction of
the cerebrovascular system that predisposes to the development of
neuroinflammation.
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The treatment of parietal headache and atypical facial
pain with peripheral nerve field stimulation (PNFS):
a clinical case report
C. Reverberi
Pain Therapy Centre, Oglio-Po Hospital, Casalmaggiore, Italy
Introduction We report the case of a patient with parietal headache
associated to atypical facial neuralgia successfully treated with PNfS.
Clinical case A caucasic 55-year old man affected by serious atypical
right facial neuralgia unsuccessfully treated both with drugs and with
retrogasserian neurolysis came to our hospital for debilitating facial
pain extended to right auricular and parietal area.
Pain did not improve even with high dosage of carbamazepine
(1,200 mg/die). The pain was continuous and it expanded from the
trigger facial point to the auricular and parietal area with frequent
peaks, causing strong crisis that forced the patient to bed.
A Medtronic (Minneapolis, USA) octopolar lead was inserted through
a 2 cm-long incision in front of the tragus, directed caudally and
medially towards the right labial incisure and placed subcutaneously.
During the 45-day period of test stimulation, the patient reported no
painful peaks of pain, persistency of continuous but completely tol-
erable pain (NRS improved from 10 before PNfS to 4 after PNfS) and
a reduction in the assumption of carbamazepine (from 1200 mg/die
before PNfS to 400 mg/die after PNfS). The patient was then
implanted with a Medtronic neurostimulator mod. Synergy Versitrel,
placed in the right abdominal subcutaneous pocket.
Conclusion As reported in literature, this case report confirms that
PNfS is an effective approach to treat frontal, parietal, cervicogenic
and cluster headaches, even when associated to atypical or trigeminal
neuralgia refractory to optimal medical therapy.
Keywords Frontal and parietal headache, atypical facial neuralgia,
cervicogenic headache, trigeminal neuralgia.
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A case of sporadic hemiplegic migraine with prolonged
neurological deficit
S. Aurangzeb, A. Ali
Stroke Unit, Diana Princess of Wales Hospital, Grimsby, UK
Background Migraine in older age groups has been neglected. In
2-3% of all cases of migraine, the first attack occur at C 50 years of
age. The focal deficit in sporadic hemiplegic migraine usually lasts
for less than 24hours.
Case report 52 year’s female presented with frontal headache which
increased in intensity overnight and the next morning, she developed
slurring of speech and left sided weakness.
She was diagnosed to have two strokes in last 2 years. She has spinal
stimulator device for nerve damage secondary to avulsion.
She has no personal or family history of migraines.
On examination, she had expressive dysphasia and left hemiparesis.
CT brain and carotid Doppler were normal. MRI could not be per-
formed due to spinal stimulator device. Echocardiography ruled out
cardiac pathology and EEG showed no dysrhythmia. ESR, Serum
B12, Folate, TSH, autoimmune and thrombophilia screen was normal.
A diagnosis of hemiplegic migraine was made and she was started on
topiramate. She made complete recovery in 12 days.
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Two weeks after the discharge she presented with stereo typed
symptoms. Repeat CT scan was normal. She improved over the next
couple of days and was mobile at discharge.
On her follow up visit six weeks later, she described three episodes of
severe headache, left sided weakness and expressive dysphasia, each
time resolving spontaneously within few hours. She was very clear
that each episode was preceded by loud noise. The dose of topiramate
was increased.
She is asymptomatic on following visits.
Conclusion The focal deficit in sporadic hemiplegic migraine can last
for several days. Good history is, of course, most important in
establishing the correct diagnosis, coupled with repeated normal
neuroimaging.
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Is there an increased cardiovascular risk in pediatric
migraineurs?
M.K. Farkas, A´. Cseh, E´. Pa´llinger, B. Va´sa´rhelyi, V. Farkas
Semmelweis University, Budapest, Hungary
Several studies suggested that the migraine disease in adults increases
the risk of cardiovascular events. The aim of our study was to
investigate different cardiovascular cytokine levels and lymphocyte
populations in the peripheral blood of pediatric migraineurs and
healthy controls.
We have investigated 94 migraine patients (M) (age (median, range)
15 [13 - 19] years), 15 hemiplegic migraineurs (HM) (15 [15 - 18]
years), 29 migraine with aura (MA) (17 [14 - 18] years) and 50
migraine without aura (MO) 13 [11 - 16] years) patients and 51
controls (C) (16 [10 - 24] years). The prevalence of lymphocyte
subsets (CD4, CD8, Th1 (CXCR3), Th2 (CCR4)), regulatory T cells
(CD4, CD25, CD127), iNKT, NKT and NK cells (CD3, CD161,
6B11) and the plasma levels of sCD40L, t-PA, MCP-1, IL-8, sP-
selektin, sVCAM-1 were measured by flow cytometry method in the
peripheral blood of the migraineurs during the interictal phase.
The prevalence of the CD8 cells were decreased in all migraine
subtypes compared with controls. The plasma level of the cardio-
vascular risk cytokine sCD40L showed an increase in the M and HM
groups compared with controls and in the HM subtype vs MO. The
plasma level of the t-PA was higher in the M, MO and HM groups
than in the controls. The sVCAM-1 concentration was elevated in all
migraine subtypes compared with controls and showed higher level in
the HM group than in the MO patients.
Recent studies proved that the migration of CD8 cells plays an
important role in the atherogenesis. The decreased prevalence of the
CD8 cells in the peripheral blood might be connected to the devel-
opment of atherosclerotic lesions. The elevated plasma concentrations
of the cardiovascular cytokine sCD40L, t-PA and sVCAM might
indicate an increased cardiovascular risk in pediatric migraineurs.
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Diagnostic delay and misdiagnosis of cluster headache
V. Mateos1, R. Garcı´a-Rodrı´guez1, J. Ferna´ndez-Domı´nguez1,
D. Santirso2, M. Gonza´lez-Delgado2
1Neurology, Centro Medico Asturias, Oviedo, Spain;
2Neurology, Hospital Universitario Central de Asturias,
Oviedo, Spain
Objectives Cluster headache (CH) diagnostic criteria are clearly
defined, as well as therapeutic guidelines, specially those referred to
symptomatic treatment. We intend to evaluate the translation of this
consensum to the clinical practice.
Methods We retrospectively reviewed the clinical historys’ of all
patients diagnosed of CH (IHS-II criteria) who had attended in the
specialized Headache Unit in ‘‘Hospital Central de Asturias’’ and
‘‘Centro Me´dico de Asturias’’ in the last ten years. We analyzed
several parameters, especially those related to diagnostic and thera-
peutic aspects.
Results The total number of patients was 106 (94 men and 12
women) with a mean age of 43 (22-74). First-degree familial history
of CH was found in 13% of patients . CH was chronic in 16% of
patients, while the rest had an episodic form. The mean age of onset
was 32 years old (15-63). There was a diagnostic delay between the
first symptoms and a well-established diagnosis of 5,3 years. Up to
35% of patients had been initially diagnosed of migraine. Before the
consult in our Headache Unit, only 18% of patients had been treated
with subcutaneous sumatriptan or intra-nasal triptans during the
attacks.
Conclusions It is highly surprising that CH in which clinical features
are so eloquent, support such a significant diagnostic delay. It is also
striking that many patients who had been correctly diagnosed were
receiving completely nonspecific medication while ineffective. It
seems necessary to implement the knowledge of this primary head-
ache in those health care levels involved (primary and emergency
care, mainly).
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Secondary headache in periodontitis
N. Kapanadze1, M. Natriashvili2, G. Natriashvili3, T. Abuladze2
1Tbilisi State Medical University, Tbilisi, Georgia;
2Dental Clinic of Tbilisi State Medical University, Tbilisi, Georgia;
3SEU Clinic, Tbilisi, Georgia
Background Headache is a very common disease, symptom with
high lifetime prevalence. Often it is difficult to differentiate primary
and secondary headaches, especially when main disease’s clinical
symptoms of is not significant.
Aim It was our aim to describe and classify headaches associated with
inflammatory disease of oral cavity, especially with periodontitis. We
have notice, that sometimes inflammatory and dystrophic diseases of
oral cavity have poor clinical symptoms and they are not diagnosed.
In spite of types of headaches such as migraine, cluster etc, headache
associated with periodontitis is secondary headache.
Objective/methods 83 patients were observed (39 M/44F, age range
14-45 years) to have several types of headaches associated with
periodontitis. Periodontitis was diagnosed primarily by detailed
clinical observations. Mild form of periodontitis was diagnosed in 13
cases, moderate in 21 and severe form in 51 cases. Moreover, 55
patients had other neurological syndromes like hypothalamic(37) and
brain stem syndrome (18). Periodontitis in those patients was diag-
nosed several years earlier. 13 patient had acute form of periodontitis,
21 patients had chronic form and 49 patients - chronic form with
aggravation. Patients had different types of headaches: 24 patients had
trigeminal neuralgia, tension headache - 39, migraine 9, paroxysmal
hemicranias 5, cluster headache 16. In some cases patients had several
types of headache. 35 patients had been treated as patients with pri-
mary headache, until periodontitis was diagnosed. There was
statistically significant correlation between effective treatment of
pariodontitis and improvement of headache.
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Conclusions
1. Periodontitis might be associated with several types of headaches.
2. Patients with headache also need dentist consultation.
3. Oral cavity sanitation is necessary to prevent some aggravations
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Migraine in adolescent females
N. Kapanadze1, G. Natriashvili2, D. Chkhartishvili2,
E. Chkhartishvili2
1Tbilisi State Medical University, Tbilisi, Georgia;
2SEU Clinic, Tbilisi, Georgia
Background Migraine occurs in 3 to 10% of children and adolescents
and causes a considerable impact on quality of life. There is little dif-
ference between gender before puberty. After age of 11 there is
predominance in females. There are epidemiological studies confirming
the correlation between migraine and menarche. Severe headaches
associated with menstruation are often not recognized as migraine.
Sometimes menstrual migraine is correlated with dysmenorrhea. At the
same prolactin is a main factor which defines normal function of ovary.
Aim
(1) to distinguish correlation between migraine and a level of
prolactin in adolescent girls;
(2) to provide some recommendations for relevant treatment.
Methods We observed 65 outpatient females (aged from 10 to
16 years) with menstrual migraine. 45% of them had their first
headache during menarche. 55% of patients had dysmenorrheal.
Patients productivity was reduced by half or more from 1 to 6 days in
a month due to headache. Only 7 patients had severe headaches with
visual disturbances. Others had migraine without aura.
Results We determined level of prolactin in all cases. Level of pro-
lactin was normal in 13 patients, while in others it was increased. 35%
of patients had genetic risk factors - mothers or/and grandmothers had
migraines also. Lifestyle modification and prevention of trigger fac-
tors was sufficient in 26 % of patients. 45 patients with high level of
prolactin received: I group- dopamine agonists in addition to migraine
therapy, II group only migraine therapy and III group - only dopamine
agonist. There was statistically significant correlation between
decrease in prolactin level and improvement of headache.
Conclusion Management of migraine in adolescent females requires
to determine prolactin level. Lifestyle modification and pathogenic
treatment is recommended.
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Improvement of migraine headache after transcatheter
closure of patent foramen ovale in cryptogenic stroke
patients
K. Spisak-Borowska1, E. Konarska-Kuszewska2, P. Weglarz2,
J. Machowski1, A. Drzewiecka-Gerber2, J. Drzewiecki2,
M. Trusz-Gluza2, G. Opala3
1Neurology Department, Oswiecim, Poland;
2I Department of Cardiology, Silesian University of Medicine,
Katowice, Poland;
3Department of Neurology, Aging, Degenerative and Cerebrovascular
Diseases, Silesian University of Medicine, Katowice, Poland
Background Patent foramen ovale (PFO) is considered a cause of
migraine headache (MHA) in young patients (pts). The prevalence of
MHA is higher in cryptogenic stroke patients with PFO than in the
general population. The reason of such a dependence is still unclear.
The goal of this study was to analyze the effect of percutaneous
closure of PFO on MHA in patients with neurological events.
Methods 149 pts at a mean age of 38 +/- 12 years underwent catheter
closure of their PFO for prevention of recurrent crypogenic stroke or
TIA. 50 pts had ischemic stroke, 81 pts had TIA and 18 pts had C1
neurological events. A one year analysis of migraine symptoms
before and after PFO closure were performed at 62 patients (46 pts
with MHA with aura). Migraine severity was assessed before PFO
closure and next 6 and 12 month after PFO closure -number, inten-
sity, duration of episodes, The Migraine Disability Assessment Test
(MIDAS), migraine severity scale.
Results MHA was completely abolished in 14 pts (22,5%) after
6 months and in 24 pts (38,7%) after 12 months. At the end of follow
up period a significant reduction of duration, number and intensity of
MHA and decrease points in the MIDAS and migraine severity scale
was observed (p‹0,001).
Conclusions Transcatheter closure of PFO can result in complete
resolution or marked reduction in number, intensity and duration of
MHA.
486
Association between migraine and sleep apnea
in the general population
H.A. Kristiansen1,2, K.J. Kværner3,4, H. Akre5, B. Øverland5,
M.B. Russell1,2
1Head and Neck Research Group, Research Centre, Akershus
University Hospital, Lørenskog, Norway;
2Faculty Division, Akershus University Hospital, University of Oslo,
Lørenskog, Norway;
3Department of Research and Education, Oslo University Hospital,
Oslo, Norway;
4Institute of Health Management and Health Economics, University
of Oslo, Norway;
5Sleep Unit, Department of Otorhinolaryngology, Lovisenberg
Diakonale Hospital, Oslo, Norway
Objective To investigate the relationship between migraine and
obstructive sleep apnea in the general population.
Method A cross-sectional population based study. A random age and
gender stratified sample of 40,000 persons aged 20-80 years residing
in Akershus, Hedmark or Oppland County, Norway were drawn by
the National Population Register. A postal questionnaire containing
the Berlin Questionnaire was used to classify respondents to be of
either high or low risk of obstructive sleep apnea. 376 persons with
high risk and 157 persons with low risk of sleep apnea aged 30-
65 years were included for further investigations. They underwent an
extensive clinical interview, a physical and a neurological examina-
tion by physicians, and in-hospital polysomnography. Those with
apnea hypopnoea index (AHI) C 5 were classified with obstructive
sleep apnea. Migraine without aura (MO) and migraine with aura
(MA) was diagnosed according to the International Classification of
Headache Disorders.
Results MO and MA occurred in 12.5% and 6.8% of the partici-
pants with obstructive sleep apnea. The logistic regression analyses
showed no relationship between the two types of migraine and
obstructive sleep apnea, with adjusted odds ratios for MO 1.15
(0.65-2.06) and MA 1.15 (0.95-2.39). Further, estimates using cutoff
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of moderate (AHI C 15) and severe (AHI C 30) obstructive sleep
apnea, did not reveal any significant relationship between migraine
and the AHI.
Conclusions Migraine and obstructive sleep apnea are unrelated in
the general population.
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Development and validation of a cognitive impairment
scale for migraine attacks - the MIG-COG
R. Gil-Gouveia1,2, I.P. Martins1, A. Gouveia3
1Department of Clinical Neurosciences (UNIC), Instituto de Medicina
Molecular (IMM), Lisbon Faculty of Medicine, Lisboa, Portugal;
2Headache Outpatient Clinic, Hospital da Luz, Lisoa, Portugal;
3Department of Biostatistics, Faculty of Medical Sciences,
Lisboa, Portugal
Background The burden of migraine, both to the individual and to
society, is determined by the ability to function during attacks.
Impairment during attacks is caused not only by pain, but also by
associated migraine symptoms, such as cognitive dysfunction.
Objective To develop a self-administered questionnaire for measur-
ing cognitive impairment during migraine attacks.
Methods Item generation was patient-centered and optimized by a
panel of experts. The initial questionnaire, based on 43 candidate
items, was administered to consecutive migraine patients. Item
reduction used exclusion of items with high non-responder rates and
factor analysis. Convergent and construct validity was assessed by
correlation with the number of spontaneous cognitive complaints and
with the scores of the 43-item and Cognitive Failures Questionnaires.
Results Ninety-three patients were included (86 females), with mean
age of 39 years, mean disease duration of 18 years. The reduced
9-item questionnaire identified two domains - executive functions and
language, taking 1 minute to complete. Cronbachs’ alpha was 0,83.
Its scoring correlated with the number of spontaneous cognitive
complaints (p \ 0,001), with the 43-item (p \ 0,001) and the Cog-
nitive Failures Questionnaires (p \ 0,01). Its scoring is not influenced
by gender, age, disease duration, aura, attack frequency, duration and
intensity, nor current migraine prophylaxis. Test-retest Cohen’s kappa
was 0.55.
Conclusions MigCog questionnaire is a valid, reliable, consistent and
fast self-application tool than can be used in clinical practice and in
research settings. It profiles and quantifies cognitive difficulties dur-
ing attacks, providing a measure of another dimension of the migraine
burden and eventually, of the efficacy of acute treatment on cognitive
dysfunction during attacks. It also offers patients a quantifiable way to
illustrate ill-characterized, but disabling symptoms to their attending
physicians.
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Comorbidity of migraine with symptoms of anxiety
and depression in adolescents: a review of the literature
B. Todorov, K. Holroyd
Ohio University, Athens, OH, USA
Purpose of this paper is to review the prevalence and magnitude of
anxiety and depression among adolescents with migraine.
Publications in the area of adolescent migraine related to anxiety and
depression were identified by Medline (1966–2009), PubMed
(1991–2009) and PsychInfo (1967–2009). 19 studies were identified.
Mean levels of anxiety and depression symptoms as reported by the
adolescent or their parent/ caregiver were modestly elevated relative
to established norms or healthy controls (12 of 19 studies), but below
established cutoffs for diagnosis of a DSM-IV mood or anxiety dis-
order. These modest elevations in symptom reports were reported in
both clinical samples and in random samples from school populations.
Such elevations in symptom reports are consistent with either (or
both):
(a) affective distress in healthy adolescents that results from living
with migraine, or
(b) an elevated prevalence of DSM-IV mood and/or anxiety
disorders in adolescents with migraine.
However, inadequate diagnostic information was available from
studies of school samples to know if this finding generalized beyond
the clinic. In clinical samples, some evidence suggests that hypothesis
(b) is an important factor, with some studies reporting 25% or more of
their headache participants receiving a mood or anxiety disorder
diagnosis based on clinical interview or established cut off scores on
standardized tests (5 studies).
The existing literature allows only tentative conclusions about the
association of anxiety or mood disorders with adolescent migraine.
Conclusions are limited by small samples, the practice of reporting
data only for combined samples of adolescents and young children,
and for migraine and other headache types, use of diagnostic proce-
dures of uncertain validity for identifying migraine and for diagnosing
mood and anxiety disorders, and the lack of true population data.
Additional research that employs population sampling, reliable
diagnostics and targets exclusively adolescents with migraine is
needed.
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Impact of migraine characteristics and psychological
variables on health related quality of life
among adolescents with migraine
B. Todorov1, K. Holroyd1, A. Pakalnis2, C. Cottrell3
1Psychology, Ohio University, Athens, Greece;
2Nationwide Children’s Hospital, Columbus;
3Ohio University, Athens, OH, USA
The following study aims to estimate how migraine characteristics
(frequency and severity of migraines and associated symptoms of
migraines) and psychological variables (symptoms of anxiety and
depression and catastrophizing) affect health related quality of life of
adolescents.
A sample of 62 adolescents aged 12 to 17 years (44 female; mean
age = 14.3), averaging 1 to 14 (mean = 4) migraines (ICHD-2 cri-
teria) and 1 to 22 migraine days (mean = 5.6) per 30 days was
obtained from two outpatient headache clinics in Columbus, OH.
Migraine frequency and severity and the severity of the associated
symptoms of migraine were obtained through 4-week electronic
headache diary. Symptoms of anxiety and depression were measured
by the Internalizing scale on the Youth Self Report. Catastrophizing
was measured through the Pain Catastrophizing scale. Quality of Life
was measured through the Migraine Specific Quality of Life-Adoles-
cent Form (MSQL-A). Poorer quality of life was associated with a
greater number of migraine episodes per 30 days (r = .34, p \ .01),
greater migraine severity (r = .28, p \ .03) and associated symptom
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severity (r = .34, p \ .01). Poorer quality of life was also associated
with greater catastrophizing in response to pain (r = .3; P \ .02).
Migraine severity and associated symptoms were highly correlated
(r = .82, P \ .01). Regression analysis revealed that either migraine
severity alone or migraine associated symptoms alone accounted
for the observed migraine-related impairments quality of life.
Although the independent variance in quality of life accounted for by
catastrophizing was not statistically significant this may reflect the
relatively small sample size. Both migraine characteristics and psy-
chological variables were associated with impairments in quality of
life in adolescents with migraine. However, we could not demon-
strate that psychological variables were associated with significant
variance in quality of life that was independent of variance
accounted for by migraine severity or severity of migraine asso-
ciated symptoms.
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Neonatal capsaicin treatment inhibits inflammatory
soup induced release of calcitonin gene-related peptidex
J. Hoffmann1,2, S. Wecker1, L. Neeb1, U. Dirnagl1, U. Reuter1
1Department of Neurology, Charite - Universitaetsmedizin
Berlin, Berlin, Germany;
2Department of Neurology, University of California,
San Francisco, CA, USA
Calcitonin gene-related peptide (CGRP) is released during the acti-
vation of the trigeminal nerve system and centrally modulates
neuronal activity in the trigeminal nucleus caudalis (TNC). Clinical
studies indicate that CGRP is released during a spontaneous migraine
attack. CGRP receptor antagonists are effective for the acute treat-
ment of migraine.
Sensitization, the pathophysiological correlate of cutaneous allodynia,
probably influences the efficacy of triptans. In experimental migraine
models trigeminal sensitization can be induced with inflammatory
soup (IS). We recently demonstrated a possible link between tri-
geminal sensitization and CGRP. We hypothesize that CGRP release
by IS administration originates in the peripheral and central parts of
the trigeminal system.
In Sprague-Dawley rats flexible catheters were placed in the cisterna
magna and the jugular vein for blood sample collection. IS was
injected into the cisterna magna and blood samples or CSF were
collected for analysis of CGRP concentration. To demonstrate the
trigeminal origin of the IS-induced CGRP release a second group of
animals received neonatal subcutaneous capsaicin treatment to
destroy trigeminal c-fibers. To further investigate the origin of the
CGRP release RT-PCR for CGRP-mRNA of the trigeminal ganglion
and the TNC was performed in both groups.
Our results show, that neonatal capsaicin treatment leads to a striking
inhibition of IS-induced CGRP release in plasma and in CSF indi-
cating that CGRP release originates from the trigeminal nerve system.
The selective reduction of CGRP mRNA in the trigeminal ganglion
but not in the trigeminocervical complex and data from the functional
study indicate that peripheral trigeminal neurons significantly con-
tribute to CGRP release. The contribution of central trigeminal
neurons to CGRP release is likely as capsaicin treated animals still
exhibit higher amount of CGRP release due to IS administration as
compared to vehicle studies.
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Electronic headache diary for monitoring headaches:
better than the paper one?
M. Allena1,2, F. Antonaci2,3, C. Tassorelli1,2, E. Guaschino1,3,
G. Nappi1,2,4
1Headache Science Centre, IRCCS ‘‘National Neurological Institute
C. Mondino’’ Foundation, Pavia, Italy;
2University Consortium for Adaptive Disorder and Headache
(UCADH), University of Pavia, Pavia, Italy;
3Headache Medicine Center, Policlinic of Monza, Monza, Italy;
4University of Rome ‘La Sapienza’, University of Rome, Rome, Italy
Patients suffering from headache usually are asked to fill in regularly
monitoring charts for their disease. These diaries become crucial in
the diagnosis and management of headache disorders because provide
further information concerning the frequency and the temporal pattern
of attacks, the drug intake, the trigger factor, and the response to the
treatment.
Objective To compare an electronic version of the headache paper
diary used in our Clinic in a group of headache in-patients with
medication overuse headache (MOH).
Methods 85 hospitalized MOH patients received an user-friendly
electronic headache diary (Palm devise) developed according the
ICHD-II criteria. Our electronic diary was structured as a calendar in
which the dates were already printed. For each headache day, the
patient was required to note sleep time (hours), presence of aura
symptoms, time of pain onset and its features (intensity, side, type,
presence of associated symptoms). An further section of the diary
investigated intake of painkillers (the type of drug, the time of intake
and the total number of doses taken during the 24 hours). When
discharged, patients were asked to compare the two versions of the
diary, through a numerical Rating Scale.
Results Our patients responded very well to the electronic headache
diary (easy to understand, easy to fill in) and the patients’s level of
compliance was good. Most of the patients considered the Palm
device handier than the traditional paper version.
Conclusions These preliminary data show that the electronic version
could be a really practical and helpful instrument for clinical head-
ache monitoring. Paper diaries are easy to employ, but electronic
diaries, programmed into a pocket computer, could be preferable and
should be employed if possible. A forthcoming step in the improve-
ment of headache management will be to set up and release an ad hoc
software for palm device, smartphone and PC.
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Do travels and holidays worsen migraine?
M. Huerta-Villanueva1, A. Martı´nez-Ye´lamos1, J. Prat-Rojo2,
L. Gonza´lez-Mera1, M. Moragas-Garrido2, M. Jato de Evan1
1Neurology, Hospital de Viladecans, Viladecans, Spain;
2Neurology, Hospital Universitari de Bellvitge,
L’Hospitalet de Llobregat, Spain
Background and aims Some patients complain about worsening of
their migraine in trips and holidays. Aims To characterize the patients
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and factors related to the appearance of migraine in trips and
vacations.
Methods Eighty nine consecutive patients diagnosed of migraine with
and without aura were studied. We analyzed demographic variables,
frequency and intensity of attacks, history of anxiety, depression and
stress. A structured questionnaire was supplied to evaluate if during
holidays, weekends and trips there were changes in frequency or
intensity of the migraine attacks, recognized triggers and motion
sickness.
Results Migraine impairs with travels in 34 (38.6%) patients
(p \ 0,01) - in 29.5% increases frequency and 21.6% intensity - while
37.5% of migraineurs worsens on weekends (p \ 0,01) and only
26.1% on holidays (p = NS). Patients related their attacks with
travelling by car (41.6%), and plane (24.7%), and with the hot
(25.9%) and windy (19.1%) destinations. Stress (59.1%), sleep
changes (42%), sun exposure (31.8%) and bad positions during travel
(28.4%) were considered triggers of travel headaches. 37 migraineurs
(41.6%) suffer motion sickness and 34.1% have been unable to treat
some attacks during trips. Travel migraine was related to older age
(p = 0,023) and travel stress (p = 0,024) that increases the frequency
of headaches (p \ 0,001).
Conclusions An important proportion of migraineurs worsens their
migraine during trips or suffers motion sickness. The travel induced
stress is important for the impairment of migraine in trips.
Conflict of interest In reference to abstract No.493, the work was
supported by a Merck research grant.
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Sinonasal computed tomographic findings in migraine:
clinicopathological correlation
Y.A. Nour
Otorhinolaryngology Department, University of Alexandria,
Alexandria, Egypt
Introduction Migraine is often misdiagnosed as sinus headache
either by the patient or primary care physician. Computed tomogra-
phy is the most widely used modality for diagnosis of sinus headache.
However, several studies have emphasized the prevalence of inci-
dental radiological abnormalities in asymptomatic individuals. The aim
of this study is to analyze the computed tomographic sinonasal abnor-
malities in patients with migraine who were previously misdiagnosed as
sinus headache with special emphasis to the clinicopathological corre-
lation between such abnormalities and migraine.
Material and methods A retrospective review of the medical records
of patients who met the IHS criteria of migraine and who were pre-
viously misdiagnosed as sinus headache was undertaken. Only
patients who underwent computed tomographic imaging were inclu-
ded in the study. CT scans were assessed for sinus abnormalities using
the Lund-Mackay score. Other evaluated findings included septal
abnormalities and pneumatization of the middle or superior turbinate.
Results Two hundred and four patients were included in the study.
Sinonasal radiological abnormalities were detected in 116 patients
(57%). Septal abnormalities included septal deviation (31 patients)
and septal impaction (23 patients). Concha bullosa of the middle or
superior turbinate was reported in 29 patients. Lund-Mackay score
was B5 in 49 patients and C5 in 22 patients. The correlation between
the sidedness of headache and intranasal pathology was only statis-
tically significant in patients with septal impaction and in those with
concha bullosa with proven contact with the nasal septum. The effect
of medical or surgical treatment of intranasal pathological conditions
on the severity and frequency of migraine was analyzed.
Conclusions Sinonasal abnormalities are common in patients with
migraine. However, precise correlation between the clinical presen-
tation and radiological findings is important to select those patients
with possible intranasal triggering factors for migraine that might be
corrected by medical or surgical treatment.
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Differential effects of selective PDE5 inhibitors
in rat cerebral arteries in vitro and in vivo
C. Kruuse1,2, S. Gupta2, E. Nilsson3, L.S. Kruse1, J. Olesen1,2,
L. Edvinsson2,3,4
1Danish Headache Center, Dept. Neurology, Glostrup, Denmark;
2Lundbeck Foundation Center for Neurovascular Signaling, Glostrup
Hospital, University of Copenhagen, Glostrup, Denmark;
3Division of Experimental Vascular Research, Dept of Internal
Medicine, University Hospital of Lund, Lund, Sweden;
4Departments of Clinical Experimental Research, Glostrup Hospital,
University of Copenhagen, Glostrup, Denmark
Sildenafil and tadalafil inhibit the cGMP degrading enzyme phos-
phodiesterase type 5 (PDE5) and are implicated in migraine
pathophysiology as well as stroke recovery. In humans, PDE5
inhibitors do not dilate cerebral arteries or change cerebrovascular
reactivity. Such findings may, however, relate to technical difficulties
of measuring artery changes in human. We investigated the vascular
response to selective PDE5 inhibitors in rat middle cerebral arteries in
vitro and meningeal arteries in vivo.
Rat middle cerebral arteries were investigated using pressurised ar-
teriograhy, applying UK 114-542, sildenafil and tadalafil either
intraluminally or extraluminally. Effects of sildenafil and tadalafil on
dural arteries were investigated in a closed cranial window model.
Abluminal sildenafil induced dilatation at concentrations above
0.1 lM (pEC50, 6.62 ± 0.09 and Emax 40.32 ± 7.65) (n = 5). UK
114542 was slightly more potent (n = 6). Abluminal tadalafil (n = 5)
showed no dilatory effect. When applied luminally all PDE5 inhibi-
tors elicited a minor contraction of 4-10 % at high concentrations
(n = 5). In vivo sildenafil dilated dural arteries concomitant to a
significant reduction of blood pressure in a dose dependent manner
(0.5 to 3 mg/kg), with 1 mg/kg inducing 60 ± 14 % dilatation
(n = 6). Tadalafil failed to elicit significant dilatations in vivo.
In conclusion, only when applied abluminally in concentrations where
unspecific effects may prevail, did sildenafil, but not tadalafil, induce
dilatation. Further, in meningeal arteries sildenafil induced dilatation
above normal therapeutic range. Thus, the current results do not support a
vasodilatory origin of the PDE5 inhibitor induced headache; although a
relation to cerebral artery sensory signalling cannot be ruled out.
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Tolosa hunt syndrome - clinical case
D.M.D.C.B.e. Gala1, A. Antunes1, C. Borges1, P. Dias2, O. Gomes1,
J. Leite1, C. Fernandes1
1Servic¸o de Medicina Interna II, 2Servic¸o de Neurologia, Hospital
de Santo Andre´, Leiria, Portugal
Tolosa Hunt syndrome consists of retro or unilateral periorbital pain
associated with ophthalmoparesis of the III, IV or VI cranial nerves
with pain relief after corticotherapy.
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It is a diagnosis of exclusion.
The authors present the following clinical case: a 56 year old woman
with hypertension, depressive syndrome, right facial nerve paralysis
three years ago and left facial nerve paralysis two years ago. The
patient was observed in the emergency room due to right periorbital
and supracilliar pain associated with ipsilateral diplopia and ptosis
with four days of evolution. The neurological exam showed incom-
plete paralysis of the III right cranial nerve: ptosis, medial rectus palsy,
left looking diplopia with pupil constriction and dilation preserved.
Magnetic resonance imaging identified asymmetric cavernous sinus,
with right cavernous sinus signal enhancement after contrast, tra-
ducing an inflammatory process.
The blood and CSF tests were normal.
Treatment with 1 mg/Kg/day of prednisolone was initiated with pain
remission after 48 hours.
After six months the magnetic resonance imaging showed resolution
of the inflammatory process.
After analytical and imagiological studies, the excellent response to
the beginning of corticotherapy and exclusion of other differential
diagnosis, Tolosa Hunt syndrome diagnosis was established.
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Thunderclap headache secondary to acute
sphenoid sinusitis
M. Goggins1, P. Leyden2, G. Briggs3, R. Forbes4
1Medicine, Craigavon Area Hospital, SHSCT, Portadown, UK;
2ENT Surgery, Craigavon Area Hospital, SHSCT, Portadown, UK;
3Radiology, Craigavon Area Hospital, SHSCT, Portadown, UK;
4Neurology, Craigavon Area Hospital, SHSCT, Portadown, UK
We describe a 25 year old pregnant female with a thunderclap
headache. She had no previous headache history. She did not have,
nor develop, any focal neurological signs. Computerised Tomography
of her Head identified an air-fluid level in the Sphenoid Sinus, in
keeping with Acute Sphenoid Sinusitis. A light-protected sample of
her Cerebrospinal Fluid did not show any blood breakdown products,
nor any evidence of infection. Her sinusitis was successfully treated
with intravenous antibiotics and intra-nasal decongestants. Acute
Sphenoid Sinusitis is not recognised to present with abrupt onset
severe headache in the absence of localising neurologic signs. Acute
Sphenoid Sinusitis should now be considered in the differential
diagnosis of thunderclap headache. Clinicians should be aware of the
need to review images of the paranasal sinuses in presentations of
thunderclap headache.
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Comoestas project: preliminary data on the usefulness
of an informatic tool in the management of medication
overuse headache
C. Tassorelli1,2, M. Allena1, R. Jensen3, Z. Katsarava4, M. Lainez5,
R. Fadic6, J.A. Leston7, S. Spadafora8, M. Pagani9, G. Nappi10,11,12,
and the COMOESTAS Consortium
1Headache Science Centre, IRCCS ‘‘National Neurological Institute
C. Mondino’’ Foundation and University of Pavia, Pavia, Italy;
2University Centre for the Study of Adaptive Disorder and Headache
(UCADH), University of Pavia, Pavia, Italy;
3Danish Headache Centre, Glostrup Hospital, University
of Copenhagen, Copenhagen, Denmark;
4Department of Neurology, University Hospital of Essen, Essen,
Germany;
5Department of Neurology, Clinical University Hospital of Valencia,
Valencia, Spain;
6Department of Neurology, Ponitificia University of Chile, Santiago,
Chile;
7Department of Neurology, FLENI Institute, Macon, USA;
8Isalud University, Buenos Aires, Argentina;
9Consortium of Bio-Engeneering and Medical Informatics, Pavia,
Italy;
10Headache Science Center, IRCCS ‘‘National Neurological Institute
C. Mondino’’ Foundation and University of Pavia, Pavia, Italy;
11University Consortium for the Study of Adaptive Disorder
and Headache (UCADH), University of Pavia, Pavia;
12‘La Sapienza’ University, Rome, Italy
COMOESTAS is an e-health project funded by the European Com-
mission and conceived with the aim of offering an innovative
approach for the management of Medication Overuse Headache
(MOH), a chronic and disabling disease.
The core of the project is an informatic tool, called Interactive
Electronic Patient0s Record (IEPR). IEPR is an ‘‘all-in-one’’ system that
integrates people involved in the network through an electronic patient0s
data record (for defining the diagnosis, the process of detoxification and the
subsequent therapy), an electronic headache diary (filled in by the patient,
that allows constant monitoring of clinical condition) and an advanced
Alerting and Decision Support System (that supports physician in managing
the therapy and in controlling relevant events impacting on patient safety).
The clinical study is divided in two sections: the traditional approach,
based on the classic management of MOH, and the approach of the
COMOESTAS system (i.e. IEPR approach).
Patient’s enrolment in the traditional arm has been completed in all
centers involved (Copenhagen, Essen, Valencia, Buenos Aires e Santiago
del Cile), for a total of 389 patients included, and 57.3% of them com-
pleted the study, after 6 months from the detoxification.
An interim analysis of the classic arm data shows an initial high level
of compliance that decreased during the follow-up period (especially
in Latin America countries), but also a good percentage of patient’
satisfaction with the headache pattern after the detoxification and with
the management of the disease (62.7% and 79.6%, respectively).
Presently 149 patients were included in the IEPR arm and they are com-
pleting the study. A very preliminary analysis shows that the constant
monitoring based on the electronic diary and the alert-system of the
COMOESTAS strategy permits a further improvement of the management
of these patients, through a better interaction between patient and physician.
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Use of cannabis among cluster headache sufferers:
frequency and effect on attacks
E. Leroux1, D. Valade2, I. Taifas2, A. Donnet3, A. Ducros2
1Neurology, CHUM Notre-Dame, Montreal, QC, Canada,
2Emergency Headache Center, APHP Lariboisie`re, Paris, France;
3Neurology, Hopital la Timone, Marseille, France
Objectives To describe the frequency of cannabis use in a group of
cluster headache (CH) sufferers and to determine the effect observed
by users of this drug on the CH attacks.
Background Cluster headache attacks are severe and may not
respond to sumatriptan or oxygenotherapy. Cannabis contains delta-
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tetrahydrocannabinol, an agonist of cannabinoid receptors, which
have antinociceptive properties and effects on the cerebral arteries.
CH patients are heavy smokers, and there is no data about cannabis
use in this population.
Methods We obtained questionnaires from CH patients in two spe-
cialized headache centers to document the frequency of cannabis use
and observed effect on CH attacks according to users.
Results Among 139 patients (116 men and 23 women), 103 (74%)
were active tobacco smokers, 63 (46%) had a history of cannabis use,
and 27 patients (19% of the total cohort) had tried cannabis for CH
attacks. The male to female sex-ratio was 5 in the cohort, and 15 in
cannabis users. Among cannabis users, 25,9% had found some effi-
cacy of cannabis, 51,8% claimed that the effect was variable or
uncertain, and 22,3% saw a negative effect. During an active period,
43% of users tended to avoid cannabis, and 27% found that cannabis
could trigger attacks.
Conclusions Cannabis use in CH patients is frequent, especially in
men, and has legal implications, lifestyle repercussions, and potential
cerebro-vascular risks. The therapeutic potential of cannabis for CH is
to be considered on a scientific basis, but mixed results observed by
patients suggest that structured trials with synthetic, selective can-
nabinoids should be the way to investigate this topic further.
Conflict of interest Dr. Donnet has perceived personal compensation
for activities (consulting, clinical research) with Almirall SAS,
Merck, Pfizer Inc.
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Twenty years of mid-face cluster headache diagnosed
as ‘‘TMJ’’
S.A. Mehta
University of British Columbia, Vancouver, BC, Canada
Headache is one of the more common medical complaints and a frequent
reason to consult general practitioners as well as headache specialists.
Facial pain to the mid-face most commonly would be referred to oto-
laryngology while mid-face and lower third of face pain may be more
frequently dealt with dentists. Complex facial pain may require multiple
specialists for best care practices and to eliminate diagnostic entities
according to area of expertise.
A 52 year-old male presents to a university-based facial pain clinic
with a twenty-plus year history of ‘‘TMJ’’ disorder. He describes a
severe and lancinating pain to the left mid-face clearly outlining the
temporomandibular joint. History is noted for multiple medication
trials of anti-inflammatories. He understood after consulting multiple
providers including general physician, otolaryngology, neurology and
multiple dental specialists including maxillofacial surgery and oral
medicine that his temporomandibular joint pain required splint or oral
appliance therapy. On more in depth history and interview he notes
unilateral jaw pain with jaw function as well as at random. He
endorses unilateral tearing of the eye combined with sensitivity to
sounds when severe left-sided jaw pain is present.
Complicating factors include a bilateral disc displacement with
reduction along the temporomandibular joints which is in fact not
associated with pain. The history was challenged by language barrier
between patient and multiple health care providers. He was able to
outline specifically the temporomandibular joint as the region of pain
however the site was not the source of pain.
This gentleman’s severe, unilateral pain associated with tearing of the
eye and phonophobia, associated with benign jaw joint clicking
sounds, jaw pain with function and labelled as a TMJ disorder with
poor outcomes for twenty years ultimately found benefit from well
established treatment algorithms for cluster headache.
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Acid-sensing ion channel 1- A potential site of action
of amiloride in migraine with aura
A.P. Andreou1, O. Summ1, P.R. Holland2, S. Akerman3,
A.M. Wunsch4, J. Wemmie4, P.J. Goadsby1
1Department of Neurology, University of California San Francisco,
San Francisco, CA, USA;
2Centre for Cognitive and Neural Systems, University of Edinburgh,
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3Pain and Migraine DHT, Lilly Laboratories, Surrey, UK;
4Department of Psychiatry, Roy J and Lucille A Carver College
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Amiloride, a common diuretic, blocks all epithelial sodium channels
(ENaC) and has been shown to be effective in attenuating trigemi-
novascular activation in animal models of migraine including
blockade of cortical spreading depression (CSD), the experimental
correlate of aura. Open label clinical experience suggests amiloride
may be useful in migraine with prolonged aura. We aimed to study
the potential actions of amiloride on a subtype of ENaC, the acid-
sensing ion channel 1 (ASIC1), blockade of which reduces the
occurrence of CSD in animal models. Eight male ASIC1 knockout
mice raised on a C57BL/6 J background and 10 wild type age-mat-
ched controls were anesthetized with sodium pentobarbitone (80
mgkg-1). Mice were cannulated for administration of test compounds
and cortical steady state DC potentials were recorded to identify
waves of spreading depolarization. Further anesthesia was maintained
with isoflurane inhalation (1.5-2.5%) in oxygen-enriched air. Fol-
lowing a mechanically induced CSD at baseline conditions, amiloride
was then administered (20 mgkg-1 iv), followed by CSD initiation at
15 minutes and every twenty minutes onwards. Amiloride blocked CSD
in 6 of 10 wild type mice. At the same dose amiloride failed to block CSD
in 7 of 8 ASIC1 knockout mice. The study demonstrates that part of
amiloride’s pharmacology includes interactions with the ASIC1 channel,
which may contribute to the induction of CSD. Targeting ASIC1 chan-
nels might prove essential in treating migraine aura.
Conflict of interest Oliver Summ received a fellowship by the Eur-
opean Federation of Neurological Societies and fellowship by MSD.
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Prevalence and clinical characteristics of primary
headaches among school children in South Korea:
a nation-wide survey
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Purpose To determine the 1 year prevalence of headache and clinical
characteristics of primary headaches among school children in South
Korea.
Methods We conducted a cross-sectional school-based study of a ran-
domized and proportional sample of 5,360 male and female students. The
questionnaire collect demographic data, in addition to specific questions
about headache according to International Classification of Headache
Disorder II (ICHD-II) criteria. Valid questionnaires were returned by
94.1% of the sample. Modified criteria changed the item 0duration0 in
migraine ([1 hour instead of 4 hours).
Results The total sample size was 5,039 children aged 7-18 years. The
overall 1 year prevalence of recurrent headache was 29.1% (boys 24.4%,
girls 33.3%). Mean age for children complaining of headache
(14.02 ± 3.03 yrs) was significantly higher than that of those without
headache (12.73 ± 3.36 yrs). Migraine was 8.7% (boys 7.0%, girls
10.3%), 13.7% in tension type headache (TTH) (boys 10.7%, girls
16.3%), and 6.7% in non specific headache. Chronic daily headache was
3.1%. The prevalence of headache according to the age was 20.8% in 6-
12 years, 32.0% in 13-15 years, and 38.2% in 16-18 years.
Conclusions Recurrent primary headache is quite prevalent among
school-aged children and adolescents in South Korea, and the prev-
alence rates are similar to those reported elsewhere. TTH was more
common than migraine. The prevalence of migraine headache
increased with age. Students with headache in city and suburban were
significantly higher than in rural.
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Genetic and phenotypic analysis of migraine
D.R. Nyholt1, G.W. Montgomery2, N.G. Martin3
1Neurogenetics Laboratory, Queensland Institute of Medical
Research, Herston, QLD, Australia;
2Molecular Epidemiology Laboratory, Queensland Institute
of Medical Research, Herston, QLD, Australia;
3Genetic Epidemiology Laboratory, Queensland Institute
of Medical Research, Herston, QLD, Australia
Although common migraine is highly prevalent in our society, its
aetiology remains relatively obscure and there are no laboratory based
diagnostic tests that identify those who suffer from the disorder. Twin
studies indicate that migraine has a significant genetic component,
with heritability estimates of 33-65%. Therefore, in an effort to
identify the molecular mechanisms underlying the disorder, we have
performed a genome-wide association (GWA) study of migraine in a
large homogenous sample of Australian twin families.
Analysis of the Australian Twin Migraine (ATM) GWA cohort encom-
passing 1851 unrelated cases and 4008 unrelated controls revealed one
genome-wide significant association [odds ratio (OR) = 1.28;
P = 1.9 9 10-8]. A sibling-TDT (‘S-TDT’) analysis utilising 739 (of
the 1851) cases whom had a non-migraine sibling, confirmed association
to this locus, with an OR of 1.44 (P = 0.023). Tantalisingly, the genome-
wide significant variant is in a gene with Na +/K + transporting activity
and whose protein is known to interact with the protein of one of the three
identified familial hemiplegic migraine (FHM) genes.
Extending our ‘unrelated’ GWA analyses to include 665 affected
siblings of the unrelated cases and 865 non-migraine siblings of the
unrelated controls identified additional loci significantly associated
with migraine.
In addition to results from our ATM GWA study, we present results
from additional replication studies in independent cohorts and
detailed examination of the relationship between associated variants
and migraine symptomatology.
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Long term use of botox (onabotulinum toxin a)
for the prophylaxis of migraine in clinical practice
in Switzerland
R.M. Agosti1,2, S.J.K. Rauber1,3, A. Bumb1
1Headache Center Zurich Hirslanden, Zurich, Switzerland;
2Swiss Neuro Institute, Klinik Hirslanden Zu¨rich,
Zurich, Switzerland;
3Kantonsschule Wiedikon Zurich, Zurich, Switzerland
Aims Botox (onabotulinum-toxin A) has been applied against
migraine for approximately 10 years, strictly off label. However,
several headache specialists have used botox against migraines. Here
we present migraine botox data of 529 patients in the long term
course.
Methods Retrospective data analysis of patients treated with botox
for migraine in a tertiary care headache center Zurich, Switzerland.
Demographics, efficacy and tolerability were analysed.
Results 418 women and 111 male patients received botox against
migraine from 2002 to 2009, mainly 100 Units of BoTox (Allergan)
in a mixed protocol (fixed dose fixed site and follow the pain) to
pericranial muscles commonly treated with botox for migraine. Mean
age (both sexes) was approx 50 years (bell shaped distribution), i.e.
49.4 years (range 17 to 79) in women and 51.2 in men, (range 17 to
88) with proportionally more younger males and more older women.
Distribution of number of treatments per person: 259 once, 111 twice,
51 three times, 34 pts 4 times, 74 pts 5 times and 46 pts 6 to 21
treatments. We considered responders patients who underwent three
or more treatments, N = 159, 30.1% of all migraineurs. Gender
distribution of responders was 10% male, 90% female, in comparison
to 24% male and 76% female in non responders (one to two treat-
ments). Tolerability was overall excellent and only occasionally mild
and fully reversible side effects were reported. No factors were found
that would predict responders but middle aged women seem to be
more susceptible.
Conclusions The current analysis represents the longest yet published
data on botox migraine prophylaxis. The response rate of approx.
30% was similar to other experiences worldwide with women around
50 years old found to be overrepresented in comparison to the normal
migraine population. Tolerability and safety were excellent. No
problems with long term application were observed.
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Comparison of pain detection thresholds in patients
with migraine, tension type headache
and asymptomatic controls: generalized or peripheral
pain sensitization?
W. De Hertogh1,2, J. Nijs3, A. De Smedt2, C. Dielman2, P. Vaes4,
J. De Keyser2, J. Versijpt2
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Background Sensitization is a key phenomenon in headache patho-
physiology. To determine the presence of sensitization, pain detection
thresholds (thermal and pressure stimuli) of patients with migraine
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(n = 39) and tension type headache (TTH, n = 21) were compared
with those of asymptomatic controls (n = 50 for pressure stimuli,
n = 30 for thermal stimuli). All patients were diagnosed by an
experienced neurologist according to the 2004 criteria of the Inter-
national Headache Society. Patients mean age and Headache Impact
Test score (HIT-6) were 33.9 y. ± 11.7 years and 66.4 ± 5.6 points,
respectively.
Pain detection thresholds were assessed by means of the ‘method of
limits’. All measurements were performed bilaterally, both on
cephalic and extracephalic sites. Cephalic sites were the temple and
mastoid process, extracephalic sites were the index and anterior tibial
muscle (pressure stimuli) or thenar (thermal stimuli).
Results In comparison with asymptomatic controls, both migraine
and TTH patients showed lower pain detection thresholds (both for
pressure as well as for thermal stimuli) on cephalic sites but not on
extra-cephalic sites.
No significant differences in pain detection thresholds were found
between patients with migraine and TTH.
Patients with more than 15 headache days per month showed no
statistically significant additional lowered pain detection thresholds,
although a trend could be observed for migraine patients only.
Conclusions Reduced pain detection threshold on cephalic sites was
found in patients with migraine and TTH. This indicates sensitization
of polymodal receptors which, from this study, appears to be
peripheral rather than central. The trend for an additional lowered
pain detection threshold in chronic migraine patients needs clarifi-
cation in larger patients samples.
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Predictive factors of migraine outcome
in postmenopausal women
L. Savi1, C. Condello1, M.B. Anoaica1, E. Novelli2, L. Pinessi1
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Throughout reproductive life cycle, as hormonal levels are changing,
many women experience significant headache changes. Although
migraine prevalence decreases with advancing age, migraine can
either regress or worsen or remain unchanged at menopause.
Up to now, no certain data exist, predicting the illness’ outcome after
the onset of menopause. The possibility to predict this outcome could
be very useful.
In order to find out some other predictive factor about the develop-
ment of the illness, we studied the course of postmenopausal migraine
focalising the attention on the existence of a possible link between the
evolution of migraine after menopause and particular features during
reproductive life.
367 post-menopausal women (291 natural and 76 surgical menopause)
suffering from migraine according to ICHD-II criteria, were studied.
They were asked if and how the characteristics of migraine changed after
menopause, and different aspects that were though to be possible pre-
dictive factors of the outcome of the illness after menopause
In 48 (16.5%) natural menopause patients migraine improved after
menopause, in 243 (83.5%) worsened or remained unchanged.
44 (91.7%) of the 48 patients whose migraine improved after men-
opause had migraine attacks correlated to the menstruation, while
only 174 (71.6%) of the patients whose migraine worsened or
remained unchanged had this correlation (p \ 0.05). The outcome of
migraine after menopause in the majority of cases followed the one of
the patients’ mothers.
On the basis of these data correlation of migraine attacks with men-
struation during reproductive life and the improvement of migraine
after menopause in the patient’s mother seem to predict a migraine
improvement after menopause.
Since at present there are little or no data on this particular aspect of
the illness, more studies are needed. If these data will be confirmed
this will be a very useful indication for many women approaching the
menopausal period.
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Genome-wide association study of 5,957 migraine
patients and 50,809 controls identifies a variant
on 8Q22.1 with potential glutamate regulatory effects
V. Anttila
International Headache Genetics Consortium,
Wellcome Trust Sanger Institute, Cambridge, UK
We report the results of the first genome-wide association study in
migraine, with an initial genotyping phase consisting of 2,748 migraine
patients and 10,747 population-matched controls from Finland, Ger-
many and the Netherlands. The initial study was followed by a
replication study in 3,209 patients and 40,062 similarly matched con-
trols from Iceland, Denmark, Germany and the Netherlands. In the
study, we detected the first common variant associated with migraine,
with a genome-wide significant p-value of 5.12 9 10-9, and OR of 1.23
(95% CI 1.150-1.324). Overall meta-analysis showed a p-value of
1.60 9 10-11. Patients whose attacks are always accompanied by aura
showed the strongest effect size (meta-analysis OR 1.29), and patients
without aura the least effect sizes (meta-analysis OR 1.12). The fre-
quency of having migraine among carriers of the variant was increased
compared to the general population in ten out of eleven replication study
samples (differentiated based on country of origin and migraine type),
and the association successfully replicated in six. The variant was found
to account for 2.5% of total migraine heritability and 10.7% of the
population attributable risk of migraine. A follow-up expression quan-
titative trait linkage (eQTL) showed that the associated variant shows
significant correlation to the expression level of a nearby regulatory
gene, MTDH/AEG-1, which in turn is known to down-regulate levels of
EAAT2, the primary glutamate reuptake transporter in the brain. Our
hypothesis is that inappropriate down-regulation of EAAT2 causes
glutamate build-up in the brain synapses of a migraine patient, leading
to a progressively increasing central sensitisation. Overall, we have
detected the first gene for common migraine, estimated to account for a
moderate portion of the population attributable risk. This finding pro-
vides a potential functional explanation for the association, and provides
an interesting hypothesis for a new biological mechanism in migraine.
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Background In the last decades, numerous population-based and
hospital-based studies have demonstrated a relationship between
migraine or headache and psychopathology in children.
Objective To describe and assess all clinical studies on the preva-
lence and manifestations of psychological functioning and psychiatric
comorbidity in children with migraine, and to provide recommenda-
tions for its diagnosis and treatment.
Methods A literature search was made in Medline, Embase, Psy-
cINFO and the Cochrane database to identify clinical studies that
assessed psychological functioning and/or psychiatric comorbidity in
children with migraine. Trial quality was assessed trial for quality
according to a standardized and validated set of criteria.
Results Seven studies met the inclusion criteria. Evidence assessment
was performed using the best-evidence synthesis method of Slavin. Based
on this method, we found strong evidence that children with migraine in a
clinical setting do not exhibit more withdrawn behaviour, do not have
more thought problems, do not have more social problems and do not
exhibit more delinquent or aggressive behaviour than healthy children.
Furthermore, there is strong evidence that children with migraine have
more somatic complaints and exhibit internalizing behaviour which is,
given the construct of the outcome measure used, a consequence of the
nature of their disease rather than a sign of psychological dysfunctioning.
Finally, compared with healthy children, there is limited evidence that
children with migraine in a clinical setting are more frequently diagnosed
with oppositional defiant disorder and they are not more frequently
diagnosed with ADHD, conduct disorder, dysthymia and depression.
Conclusions Based on this review, we conclude that children with
migraine at referral to a specialist do not exhibit more psychological
dysfunctioning, and (to a lesser extent) do not exhibit more psychi-
atric comorbidity compared with healthy controls.
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Information to patients with medication overuse
headache - pilot study
A.V. Rasmussen, A.F. Jonasson, H. Rasmussen
The Danish Headachecenter and Department of Neurology,
Glostrup Hospital, University of Copenhagen, Glostrup, Denmark
Background At the multidisciplinary Headache center specialist
nurses provide detailed education to out-patients with Medication
Overuse Headache (MOH) in groups of 6-7 patients or individually
before a scheduled 2 months detoxification period. Information is
needed on the extent of patients’ satisfaction with the given infor-
mation and applicability.
Aim To evaluate the given information in 2 different strategies, the
group sessions (STR1) and the individual approach (STR2).
Method 2 questionnaires on relevance and applicability were created
and validated. Patients in both strategies answered 10-14 questions to
their readiness before the detoxification and to their satisfaction with
the detoxification period and the applicability of the information.
Fifty-two STR1 patients and 47 STR2 answered the 1st questionnaire.
After the detoxification, 32 STR1 and 21 STR2 answered the 2nd
questionnaire. Differences from 1st to 2nd were due to drop-outs, lack
of attendance or for detoxification still being active.
Results Overall, 96% of all patients expressed to be Satisfied or Very
Satisfied with the information, and 4% reported neither/nor.
Seventy-nine percent of STR1 and 95% of STR2 expressed that they
were Satisfied or Very Satisfied with the detoxification period. So far,
97% of STR1 and 100% of the 21 completed STR2 claimed that they
were Satisfied or Very Satisfied with the applicability of the given
information.
Conclusions The vast majority of our MOH-patients were Satisfied or
Very Satisfied with the given information and applicability. To
motivate patients for treatment, clear and thorough information about
MOH and the detoxification period is important.
Both Strategies were positively evaluated. Group sessions are suitable
and less demanding with regards to resources. Comparative outcome
studies for STR1 and STR2 are important for future MOH-treatment.
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What are the chronic primary headache patients
want?The biophysicosocial perspective
R.T. Pinzon
Neurology, Bethesda Hospital Yogyakarta Indonesia,
Yogyakarta, Indonesia
Aim Chronic primary headache is very common in population. The
previous studies showed there is complex psychobiology interaction
in chronic headache. This study describe the wants of chronic daily
headache patients.
Method The data was collected using qualitative method. The sub-
jects of this study were all patients with chronic headache (last more
than 3 months), neurological normal, and have not ben investigated
by suppoting laboratory and radiology examination in our hospital.
The author ask a very simple question ‘‘ what do you wants with your
headache?’’
Result There were 18 patients meet the criteria, consist of 16 female
and 2 male. The mean age was 23,4 years old. Sixteen of 18 patients
answered ‘‘I want to know whats wrong with my head’’, ‘‘I want to
know what is the cause of my headache’’, ‘‘I am worried there is
something wrong with my head’’. All of this patients willing to be CT
scanned and EEG recording. The result of CT scan were normal for
all of them. Only 12 from 18 patients answered ‘‘I want to be cured’’,
‘‘I want to be free from pain medication’’. ‘‘Do normal CT Scan has
placebo effect in this group of patients?’’ There is a strong need for
performing further studies.
Conclusion Most of the chronic headache patients want to know the
origin of the pain. The searching of the origin can be very costly in
some cases. There is a need of further explorative study.
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Significant headache pain reduction
after the application of a special neck massage
and manipulation technique in primary headache
acute attacks
Y. Jahangiri Noudeh, N. Vatankhah
Iran University of Medical Sciences, Tehran, Iran
Introduction Migraines and tension type headaches constitute the
main part in primary headache states. These headache types impose a
great suffering to the societies health state and their treatment faces a
challenge. The application of simple physical non-pharmacological
techniques could greatly reduce the therapeutic costs and side effects
in acute onsets of these headache states.
Materials and methods Patients with acute onset of a primary
headache according to IHS-2004 diagnostic criteria enrolled in the
study. Their headache pain intensity assessed primarily using a verbal
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10-point pain assessment scale. A special neck massage and manip-
ulation technique was done as shoulder and neck massage and
relaxation and a cervical and upper thoracic intervertebral joints
cracking. The pain intensity assessed again after the completion of the
therapeutic session.
Results Thirty patients with the complaint of a primary headache
onset enrolled in the study. Their mean age was 28.23 ±
9.36 years and just one of them was female. Their post-therapeutic
mean headache pain intensity was significantly reduced compared
to the primary values (1.72 ± 1.28 vs. 5.28 ± 1.78, P \ 0.0001,
paired t-test). Average pain reduction value was 67.14 ± 24.36%.
None of the measured variables including the headache diagnosis
associated with the pain reduction value. No side effects were
reported and all of the patients were satisfied with the therapeutic
method.
Discussion Our study results showed that the applied cervical and
upper thoracic massage and manipulation technique could signifi-
cantly reduce the headache attack pain intensity in patients with
primary headaches. The application of this simple manual technique
could reduce significantly the headaches attacks burden. On the other
hand, these results more corroborate the role for cervical nerve roots
in the arousal of headaches.
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The description of relpax medicine’s efficiency
dependent of time taking
L.S. Sahradyan1, G.A. Hovhanessian2
1Neurology, Assistant Chair Neurology National Institute of Health,
Yerevan, Armenia;
2Head of Neurology Department, National Institut of Health, Medical
Center ‘Saint Grigor Lusavorich’, Yerevan, Armenia
Migraine is clinically expressed by periodical repeated acute head-
ache, mostly in one hemisphere of head, which is accompanied by
nausea, vomiting,badly bearing of light colors and loud voice.
Since 2008-2009 in medical centre of ‘‘Grigor Lousavorich’’ there
have been carried complex studies and treatment of patients suffering
from different forms of Migraine.
The aim of investigations were the study of Relpax medicine
dependent of time taking on the onset of attack. About 50 people
between the age of 30 - 50 were examined, from them 30 women and
20 man, who were suffering from paroxysmal headache, according to
diagnostic criteria of migraine.
There were included 22 people in the first group, who had the diag-
nosis of proved migraine and 28 people created the second group,
who had mixed types of headaches (Migraine and Headache of ten-
sions). All the patients got Relpax 40 mg. The first group got the
medicine on the onset of headache (1-4 hours). The second group got
it between 4-8 hours. The comparative analyze of dates observed that
positive results were achieved among the patients of first group
between 1-1.5 hours after taking the medicine. It was expressed by
improved feeling and opportunity to return to daily life. The
improvement was observed among 20% of patients in the second
group. The repeated taking of the medicine didn’t succeed. Later the
patients were given Diazepam 2.0 mg intramuscularly to achieve a
deep sleep, after which the attack disappeared.
Conclusion Relpax is mostly effective, when it is taken during the
first four hours among the patients, who are surely suffering from
Migraine. It helps people to return to their daily activity and improves
life quality of patients.
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Photic EEG-driving responses are depressed
in migraine without aura within a true interictal
interval
M.H. Bjørk1, L.J. Stovner2, K. Hagen2, T. Sand3
1Department of Neuroscience, Norwegian University of Science
and Technology, Trondheim, Norway;
2Norwegian National Headache Centre, Trondheim, Norway;
3Department of Neurology and Clinical Neuophysiology, St. Olavs
Hospital, Trondheim, Norway
Introduction Increased photic driving has been reported in migrai-
neurs between attacks, but it has not been studied specifically in the
preictal interval. Neuropsychological abnormalities tend to accumu-
late before attacks. Photic responses might have been overestimated
in migraineurs as most previous studies have included patients in the
preictal phase.
Aim To investigate steady state visual evoked EEG-responses
(SSVEPs) in migraineurs before, after, during and between attacks
with a blinded and controlled design.
Method We recorded SSVEP for 6, 12, 18 and 24 Hz flash stimuli at
three random days from 33 migraineurs without aura, 8 migraineurs
with aura and 32 controls. Recordings were retrospectively classified
as preictal, ictal, postictal or interictal (more than 72 hours from any
attack). Interictal responses were compared pairwise with preictal,
ictal and postictal responses and with responses from controls.
Results 12 Hz driving power was increased within 72 hours before
the attack (p = 0.02). However, driving responses to 18 and 24 Hz
were attenuated in migraineurs without aura between attacks com-
pared to controls (p \ 0.02).
Conclusion Medium-frequency photic responses seemed to be
depressed rather than increased in migraineurs without aura in a true
interictal interval. Earlier studies may have overestimated the
response due inclusion of recordings during the preictal interval and/
or habituation among controls. Our results indirectly support the
hypothesis of hypoecitable visual cortices in migraine.
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The effectiveness of using the combined therapy
of BOTOX injection and cervical pulsed
radiofrequency in the treatment of cervicogenic
headache
Z. Elchami1, A.R. Cooper2, Pain & Headache Management CoE
Team, IMC Hospital, Jeddah, Saudi Arabia
1Pain & Headache Management Center of Excellence,
International Medical Center, Jeddah, Saudi Arabia;
2Pain Relief Clinic, Causeway Hospital, Coleraine, UK
Introduction The treatment of cervicogenic headache is considered a
challenge for most clinicians, as symptoms can be similar to migraine,
due to its anatomic and pathophysiologic complexities. Successful
treatment of cervicogenic headache usually requires multi-faceted
approach using pharmacologic, interventional procedures, and others.
Objective To evaluate the effectiveness of using the combined
therapy of BOTOX Injection and cervical pulsed radiofrequency
(cervical PRF) in the management of cervicogenic headache.
Design In an attempt to evaluate the best management for treating cer-
vicogenic headache, 64 patients were evaluated according to the IHS
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Classification of Secondary Headaches, randomly allocated to receive
either BOTOX injection alone, cervical PRF alone, or combination of
both. The standard dose of BOTOX was 100 units were injected to
cervical muscle region, while cervical PRF was applied to cervical facets,
settings including temperature: 42C, pulse count: 480, rate: 2pps, width:
20 ms, and set: 45v were used. Trial was conducted over an 8-month
period in the headache clinic at the International Medical Center, KSA.
Patients received single treatment of either BOTOX or cervical PRF, or
both. Inclusive criteria including 16 males and 59 females, ages ranged
were 17-70 with the mean of 44. Exclusive criteria were Pediatric patients
or patients older than 70 with uncontrolled diabetes and blood pressure
and other neurological deficits. One-third of these patients had associated
migraine symptoms as per IHS criteria. Sample showed that cervicogenic
headache was three times more prevalent in females and the mean of age
of these patients was 45.
Results An average improvement of 55%, 53%, and 65% had been
seen in these patients who were treated with BOTOX, cervical PRF,
or combination, respectively.
Conclusion Patients who received combined therapy of BOTOX
and cervical PRF showed more significant improvement compared to
the patients who received either BOTOX or cervical pulsed radio-
frequency alone.
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Sensory hypersensitivity is associated with increased
resting eeg relative power and decreased photic
responses in the theta-alpha range
M.H. Bjørk1, K. Hagen2, L.J. Stovner2, T. Sand3
1Department of Neuroscience, Norwegian University of Science
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2Norwegian National Headache Centre, Trondheim, Norway;
3Department of Neurology and Clinical Neuophysiology,
St. Olavs Hospital, Trondheim, Norway
Background Migraineurs have increased photosensitivity during and
between attacks. Sensory stimuli such as bright light or noise frequently
trigger migraine attacks in some patients. The origin of photophobia and
the mechanisms behind migraine triggers is unknown.
Aim To study if photophobia and trigger sensitivity in relation to
resting quantitative EEG (QEEG) and steady state visual evoked
responses (SSVEPs).
Method 41 migraineurs were included (8 with aura, 33 without aura).
Resting QEEG and occiptoparietal SSVEPs to 6 Hz, 12 Hz, 18 Hz
and 24 Hz flash stimuli were recorded in the interictal phase.
Spearman’s rho was used to correlate relative resting power and
SSVEP components with self-reported photophobia (0-2) and trigger
sensitivity (0-4; headache triggered or worsened by light, sound, smell
and physical activity, each given one point and summed).
Results Trigger sensitivity correlated negatively with 6 Hz and 12 Hz
photic driving (rho = -0.7, p = 0.00005, rho = -0.4, p = 0.04),
positively with interictal temporal theta power and frontocentral alpha
power (rho = 0.4, p = 0.05 and 0.04) and negatively with fronto-
central beta and delta power (rho = - 0.4 p = 0.02, rho = - 0.03
p = 0.05). Photophobia correlated negatively with 6 Hz driving
(rho = - 0.4, p = 0.03) and positively with theta power in fronto-
central and temporal regions (rho = 0.4, p = 0.02 and 0.01).
Conclusion Increased sensory hypersensitivity is associated with
attenuated photic driving and increased resting activity in the theta-
alpha range. Possibly, increased synchronization in thalamocortical
connections predisposes towards aberrant sensory processing.
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A study of the neuroimaging profile of patients referred
to a specialist headache clinic
S.A. Ellawela, S. Miller, M. Mckenzie, G. Gorrie, A. Tyagi
Institute of Neurological Sciences, Southern General
Hospital, Glasgow, UK
Introduction Referrals to headache clinics may be for the diagnosis
or management of patient with headache disorders and there has been
an increase in the number of referrals to such clinics in the UK. There
has also been a significant increase in the access to neuro-imaging for
GPs in the UK. As part of a larger audit of neuroimaging referrals
from the outpatient headache clinic based at the regional headache
service in the West of Scotland, we looked at the pre-referral neu-
roimaging profile of patients seen at the headache clinic.
Methods A prospective study was carried out for 4 months between
December 2009 and April 2010. A record of the imaging carried out
prior to referral to the clinic was kept in addition to details of the
study requested, the date of the study and its results.
Results A total of 400 new referrals were seen at the clinic during the
4 month study duration. 180 of the 400 (45%) had imaging carried out
before being referred to the clinic. A CT brain was done in 136 (67%),
while an MRI brain was carried out in 63 patients (31%). The imaging
had been done from between 3 weeks and 18 years prior to referral at
the clinic. 35 (19%) patients had scans within the previous 3 months
and 92 (51%) had neuroimaging done in the year prior to referral.
143/180 (79%) of the scans were normal whereas 32/180 (17.7%)
showed abnormal findings. 42 of the 180 brain scans (23%) were
carried out via the open access service available to GPs.
Conclusions A significant proportion of patients referred to our
specialist headache outpatient clinic had neuroimaging studies done
prior to referral. Open access CT for GPs is necessary but should be in
addition to, not instead of, specialist headache services.
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Surgery for sunct headaches
G. Cummins1, D. O’Rourke2, E. Chaila2, D. Rawluk2,
M. Hutchinson3, M. Ruttledge2
1Mater Misericordiae University Hospital, Dublin, Ireland;
2Beaumont Hospital, Dublin, Ireland;
3St. Vincents Hospital, Dublin, Ireland
Short-lasting, unilateral neuralgiform headaches with conjunctival
injection and tearing (SUNCT) is a rare primary headache disorder
that is often refractory to medical treatment. The role of surgery for
treating SUNCT is controversial. There have been a number of case
reports of SUNCT in association with vascular compression of the
trigeminal nerve which have responded to surgical intervention. We
present two patients who have had complete relief of their symptoms
for more than one year after microvascular decompression surgery of
the trigeminal nerve. Both patients were males in their fifties with
several years of intermittent, often provoked, near daily pain. The
pain was strictly unilateral, lasted seconds and was associated with
both conjunctival tearing and conjunctival injection. They had both
tried a number of different medications, including indomethacin and
lamotrigine. Both patients were completely headache free within days
of surgery. This data, together with previous reports, suggests that
surgery may be an option in some SUNCT cases. All patients with a
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likely diagnosis of SUNCT should have an MRI brain scan with
particular emphasis on the brainstem and trigeminal nerve as part of
their evaluation. If there is evidence of a vascular loop adjacent to the
trigeminal nerve and they are refractory to medical therapy, then
surgical decompression should be considered.
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The effect of riboflavin and vitamin-E on hippocampal
NMDA receptors in rats with gliceryl trinitrate-induced
headache
A. Butun1, S. Demirci1, M. Naziroglu2, C. Uguz2, R. Sutcu3,
B. Mermi3
1Neurology, Suleyman Demirel University, Isparta, Turkey;
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Objective NMDA receptor activation is a potent stimulus with a
depolarizing effect and may stimulate the initiation and propagation
of cortical spreading depression.
Methods Sixty rats were administered into 4 groups:
Group I: sham control (saline),
Group II: Glyceryl trinitrate (GTN) administered,
Group III: GTN and riboflavine (RBF); and
Group IV: GTN, riboflavin and vitamin-E group (RBF + E)
Group I and II were given no drugs. Group III was given riboflavin
100 mg/kg/d p.o and Group IV riboflavin 100 mg/kg/d p.o. and 100 mg/
kg i.p on alternate days for a ten day course. Twenty-four hours after the
last drug treatment, group I infused with saline and the remaining groups
with GTN 10 mg/kg i.p. for 3 hours. After slowing of movements and
reaction to tail test was observed, rats were decapitated under ketamin
HCl (50 mg/kg) and xylacine (5 mg/kg) i.p. anesthesia. Hippocampal
NMDA-NR2A and NMDA-NR2B expression levels were measured with
SDS-page and western blotting method.
Results Hippocampal NMDA-NR2A levels was significantly higher
in GTN administered group (435 ± 19%) compared to the control
group (100 ± 19%) (p = 0,005). NMDA-2A levels were signifi-
cantly lower in RBF (218 ± 99 %) and RBF + E (88 ± 98%) groups
compared to GTN group (for both p \ 0.05). Hippocampal NMDA-
2B levels were also significantly higher in GTN group (180 ± 20%)
compared to normal (100 ± 38%), RBF (95 ± 30%) and RBF + E
(119 ± 16%) groups. Differences was significant only for GTN-
control, GTN-RBF and GTN-RBF + E groups (p \ 0.05).
Conclusion NMDA receptor activation is reported as an important
factor for initiation of cortical spreading depression. It has also been
reported that cortical spreading depression propagates amygdala
rather than hippocampus. Our results may suggest that exogen nitric
oxide exposure activates hippocampal NMDA receptors, and ribo-
flavine and vitamin-E may ameliorate its effect.
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Access to care for headache sufferers, data
from the european headache alliance questionnaire
in three italian headache centres
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1University Consortium of Adaptive Disorders and Headache
(UCADH), C. Mondino Foundation, Pavia, Italy;
2Headache Science Centre, Policlinic of Monza, Monza, Italy;
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(UCADH), University of Insubria, Varese, Italy;
4Headache Science Centre, IRCCS National Neurological Institute
C. Mondino Foundation and University of Pavia, Pavia, Italy;
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Introduction It’s known that primary headaches, especially migraine,
do not always receive an appropriate diagnosis and that people with
headache have to face, a rather frequent, incorrect diagnostic and
therapeutic approach.
Methods 214 patients suffering of headache, having first visit at
headache centre of Policlinic of Monza, C.Mondino Foundation,
Pavia and University of Insubria, Varese filled a ten items question-
naire, conceived by European Headache Alliance, aimed to collect
patients’ valuations and observations about the level of knowledge of
their disease, the use of drugs and the level of satisfaction with the
management and treatment of their condition. Forty-one M (19%) and
173 F (81%) completed the questionnaire.
Results The responders suffered of migraine without aura (45.1%),
tension type headache (15.5%) and medication overuse headache
(9.2%). Twenty four percent of the patients had more than one type of
headache, 58% of the patients used to see regularly a specialist
(34.1% of them a neurologist, 31.6% headache clinic staff and 29.7%
general practitioner); 62% of patients were not satisfied with the
management and treatment of their condition. The reasons were:
ineffective treatment (64%), insufficient explanation (17%), next
appointment too long ahead (14%) and difficulty to reach a specialist
(8%). Patients got to know about the existence of headache centre in
41% of cases by medical experts, in 22% by media and in 17% by
other people suffering of headache. These results are partially in
consort with those collected by the EHA survey in Europe.
Discussion The questionnaire shows that most of headache patients,
visited for first in a headache centre, are not satisfied with their
therapeutic treatment and only 31.6% of them are followed by a
headache specialist. These results may contribute to focus the
necessity to improve the access and quality of care and to spread
information in a suitably way.
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Phosphorylation of extracellular signal-regulated
kinase occurs in trigeminal ganglion neurons by noxious
stimuli
T. Iwashita, T. Shimizu, M. Shibata, H. Toriumi, M. Funakubo,
N. Suzuki
Neurology, Keio University, School of Medicine, Tokyo, Japan
Introduction The activation of the meningeal nociceptors is con-
sidered to play an important role in migraine. Expression of
phosphorylated extracellular signal-regulated kinase (pERK) in sen-
sory neurons by noxious stimulation is known to contribute to short-
term pain hypersensitivity. We have already observed the phosphor-
ylation of ERK in the trigeminal ganglion (TG) after capsaicin
application to the dura mater. In this study, using immunohisto-
chemistry, we investigated the temporal profile of phosphorylation of
ERK and localization of pERK-immunoreactivity (pERK-IR) in TG.
Methods In twelve Sprague-Dawley rats, 10 mM capsaicin was
applied to the dura mater. After several survival times (the survival
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time after capsaicin stimulation: 1, 3, 5 min, n = 3 each group; 3 min
after vehicle application as control, n = 3 each group), the TG were
removed and processed for immunohistochemistry. The sections were
labeled with anti-pERK antibody. To calculate the proportion of
pERK-IR neurons, we counted the total number of TG neurons and
the number of pERK-IR neurons. For double staining, slides were
double-labeled with anti-pERK and anti-NeuN antibody.
Results The proportion of p-ERK-IR cells was 0.6% in the control
animals. Following capsaicin administration p-ERK immunoreactiv-
ity was detectable in 1.9% of all the cells examined at 1 minute after
capsaicin application, 4.2% at 3 minutes and 2.3% at 5 minutes. The
proportions of p-ERK-IR neurons at 3 and 5 minutes after capsaicin
application significantly differed as compared to the control animals
(p \ 0.05). This temporal profile of phosphorylation of ERK was
similar to that of the findings of western blot analysis. The immu-
noreactivity of p-ERK was restricted to neurons identified as NeuN-
IR cells.
Conclusion These findings indicate that we can use the phosphory-
lation of ERK as an early phase pain conducting maker in novel
animal models of migraine headache.
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- case report
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Introduction Reversible cerebral vasoconstriction syndrome (RCVS)
is an entity which is mainly characterized by the association of severe
acute headaches with or without additional neurological symptoms
and diffuse, multifocal, segmental narrowings involving cerebral
arteries. Cortical subarachnoid haemorrhage (cSAH) occurs in 20-
22% of cases and incidental cerebral aneurysm was described.
Methods We presented a case of RCVS physical effort induced,
associated with cSAH.
Results A 51 years old women presented a recurrent thunderclap
headache (TCH) physical exertional induced. She had a history of
COPD, Diabetes, Dyslipidemia. She had no migraine history and she
did not use illicit drug. Her usual treatment consisted in Seretide
(salmeterol/fluticasone), Spiriva (tiotropium bromide), Perindopril,
Duovent (fenoterol/ipratropium), Fenofibratum, Aspirine, Eucreas
(metformin/vildagliptin). Clinical examination was normal. The brain
computed tomography was normal. Magnetic resonance angiography
(MRA) showed abnormal FLAIR high signals in frontal, parietal and
occipital region, suggesting cortical subarachnoid haemorrhage.
Therefore, a lumbar puncture was performed and showed 26 red
blood cells (RBC) with one RBC crenation. Conventional angiogra-
phy demonstrated a small (1,5 mm) unruptured aneurysm of right
internal carotid and multifocal segmental arterial constriction pre-
dominant in parietal, occipital et cerebellar left areas. Reversible
cerebral vasoconstriction syndrome was suspected and Nimotop
treatment was started with clear improvement of headache. A second
angiography (one week later) showed a significant diminution of
vasospasm and a later control angiography (six weeks) demonstrated
the complete disappearance of vasospasm.
Conclusion It is important to recognise cSAH as a complication of
RCVS especially in the presence of a cerebral aneurysm. The finding
of an unruptured cerebral aneurysm in RCVS patients is incidental.
528
Postprandial, but not fasting insulin secretion is
augmented in migraine. are migraineurs at high risk
for future insulin resistance syndrome?
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Background There’s some evidence that glucose metabolism is
altered with impaired insulin sensitivity in migraineurs.
Objective To test the relationship between glucose metabolism,
migraine attacks in otherwise healthy migraineurs.
Design and methods 64 nonobese- nondiabetic, normotensive epi-
sodic migraine(EM) and 33 chronic migraine(CM) patients, 23
healthy volunteers were enrolled (mean ages 33.0 ± 8.6, 36.8 ± 8.5
and 36.7 ± 8.4 years). Patients weren0t on prophylaxis. Total energy
and carbohydrate intake was calculated from a dietary questionniare
completed on three consecutive nonheadache days. After 12hr fasting
period 75 g five-hour oral glucose tolerance test(OGTT) was performed.
Glucose and insulin levels were measured hourly for and areas under the
curve(AUC) were calculated. Symptoms related to reactive hypoglyce-
mia during OGTT were recorded. Homeostatic model assessment insulin
resistance(HOMA-IR) index was calculated to diagnose IR. None had IR
and metabolic syndrome(IRS) according to the ATPIII-criteria and they
didn0t differ from controls in terms of diabetes risk factors.
Results The groups did not differ in terms of components of metabolic
syndrome, as well as HOMA-IR index. In migraineurs, AUC for glucose
was significantly higher compared to controls (p = 0.016) as well as
AUC of insulin (p = 0.042). Total energy intake was significantly dif-
ferent between groups with the highest intake in patients with EM, as well
an increased consumption of carbohydrate containing foods with high
glycemic index (p = 0.036). Despite no biochemically confirmed reac-
tive hypoglycemia, significantly more patients with EM and CM suffered
from hypoglycemic symptoms during OGTT compared to controls.
These symptoms were not correlated with glucose or insulin levels and
headache was not triggered after oral glucose load.
Conclusion EM patients are prone to consume foods with high GI and
energy, which may be a risk for future IRS. Besides, insulin response
to oral glucose load is more pronounced and postload glucose levels
are significantly higher in migraineurs, suggesting an impaired insulin
mediated glucose disposal in migraineurs.
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Clinical features and outcome of headache in a sample
of juvenile patients attending a tertiary headache centre
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Introduction Recurrent headaches are significant problems in pedi-
atric populations. Positive family history and disease severity seem to
increase headache risk for first degree relatives (1). A better knowl-
edge of pediatric headache may help to identify possible factors of
disease progression so this study was conducted to analyze headache
clinical features and outcome of a sample of young outpatients.
Patients and methods 508 pediatric subjects attending the Headache
Centre, Neurological Clinic, University of Bari were enrolled. Inter-
national Headache Society criteria were used for the diagnosis (2).
Control visits were scheduled every 3 months. Data concerning the
drop out group were obtained by a telephone interview. The preva-
lence of the different headache diagnosis, the follow up duration, the
outcome of therapies, the drop out prevalence and reasons were
evaluated.
Results Migraine without aura was the most frequent diagnosis.
Headache onset age was 9,88 ± 3,62 years in the patients with a
positive familial history and 12,03 ± 3,62 years in those with nega-
tive familial history (p \ 0,001). Patient’s headache onset age was
lower than that of their parents. The most frequent drop out reason
was headache improvement or remission. A smaller group dropped
out because reassured by diagnosis.
Discussion The headache onset age lower than parental one is a
further confirm of a genetic predisposition or an increased environ-
mental susceptibility to headache, as stated previously (1). The drop
out reasons show that many patients achieve significant improvement
or remission. Tertiary headache centres seem to be important for
diagnosis, therapy and the educational work since in a not so small
percent of patients dropped out because satisfied by the information
concerning their health.
1. Bigal ME, Arruda MA. Migraine in the Pediatric Population-
Evolving concepts. Headache. 2010 Jun 21.
2. Headache Classification Committee of the International Headache
Society. The International Classification of Headache Disorders.
Cephalalgia (2004), 24, S1:1-160.
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Effect of yoga therapy on migraine: a clinical
and cardiac autonomic function study
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1Neurophysiology, Health Care Global Company, Bangalore, India;
2Neurology, National Institute of Mental Health and Neurosciences
(NIMHANS), Bangalore, India;
3Complementory and Alternative Medicine (CAM),
Health Care Global Company, Bangalore, India
Background Migraine is associated with varied clinical manifesta-
tions including autonomic symptoms. Yoga is a traditional Indian
psycho-philosophical-cultural method that has multiple health bene-
fits and has shown benefits in various pain syndromes possibly due to
its influence on vascular tone.
Objective To study the effect of yoga therapy on clinical and cardiac
autonomic function in migraine patients.
Methods Ten chronic migraine patients (age 32.6 ± 2.3yrs; dura-
tion of illness 13 ± 2.9yrs) fulfilling the International classification
of headache disorders (ICHD) II criteria, were recruited from the
Neurology department, NIMHANS, Bangalore. In addition to the
conventional treatment, patients practiced structured yoga therapy
consisting sookshma vyayama (light exercises), pranayama
(breathing exercises), asana (yogic postures) and vishranti kriya
(relaxation technique) for 60 min daily for 45 days. Patients were
assessed before and after yoga intervention by headache impact test
(HIT), visual analogue scale (VAS) for pain and cardiac autonomic
functions by heart rate variability (HRV) measures. Lead II resting
ECG was recorded for 15 minutes and analyzed offline. Baseline
HRV parameters in migraine patients were compared with 10 age
and gender matched healthy controls to assess autonomic
dysfunction.
Results The migraine patients had significant autonomic dysfunction
at baseline when compared with the healthy controls. Following yoga
therapy, patients exhibited significant improvement in clinical
parameters (HIT pre 69.6 ± 2.5, HIT post 39.8 ± 1.7; VAS pre
8.6 ± 0.5 VAS post 1.6 ± 0.3). Cardiac autonomic function param-
eters also improved significantly (LFnu pre 55.6 ± 4.3, LFnu post
42.2 ± 4.6,; HFnu pre 37.27 ± 4.55, HFnu post 51.05 ± 5.93,; LF/
HF ratio pre 2.94 ± 1.57, LF/HF ratio post 1.43 ± 0.67,).
Conclusion Sympathetic overdrive is integral to migraine and is a
negative prognostic marker. Our study shows that yoga therapy
enhanced the vagal tone in addition to reducing the frequency and
intensity of headaches and thus improving the quality of life in
migraine patients. Yoga therapy can be effectively incorporated as an
add-on therapy in migraine patients.
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Objective To evaluate cardiac autonomic dysfunction in female
migraine patients.
Background Migraine is associated with autonomic symptoms.
However, the extent of autonomic dysfunction in the inter-ictal period
remains controversial. The present study aimed to characterize car-
diac autonomic dysfunction in female migraine patients. Heart rate
variability (HRV) is a noninvasive test for autonomic function.
Methods Twenty nine female migraine patients (aged
35.2 ± 9.2 years), fulfilling ICHD-II criteria were recruited from the
Neurology outpatient department, NIMHANS, Bangalore, India.
Resting lead II ECG was recorded for 15 minute during headache free
intervals (recording day ± 2 days). An artifact free 5 minute segment
of the ECG was analyzed offline to obtain the HRV parameters in
time and frequency domain. The data was compared with 44 age
matched (36.0 ± 10.1 years) healthy females.
Results The mean heart rate was significantly higher in the migraine
patients (78.8 ± 10.4/min vs 73.4 ± 9.2/min) than controls. The time
domain parameters of HRV were significantly reduced in migraine
patients as compared to healthy subjects [standard deviation of nor-
mal to normal intervals (SDNN) 31.4 ± 1.8 ms vs 45.2 ± 3.2 ms;
root mean square of successive differences of standard deviation
(RMSSD) 25.4 ± 2.2 ms vs 38.5 ± 3.8 ms; number of successive
NN intervals [ 50 ms (NN50) 27.1 ± 8.1 vs 54.1 ± 8.0; percentage
of number of successive NN intervals [ 50 ms (pNN50) 7.6 ± 2.4 vs
17.1 ± 2.8]. The frequency domain parameters were also reduced in
migraine patients compared to healthy subjects [Total power (TP)
1023.1 ± 103.9 ms2 vs 2181.2 ± 357.3 ms2; low frequency power
(LF) 220.8 ± 19.6 ms2 vs 467.2 ± 70.7 ms2; high frequency power
(HF) 307.6 ± 51.8 ms2 vs 771.4 ± 185.0 ms2].
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Conclusion Our study demonstrates distinct parasympathetic dys-
function in female migraine patients and supports the hypothesis of a
common neural substrate for migraine and autonomic dysfunction. An
enhanced understanding of the autonomic dysfunction in migraine
may help to diagnose, prevent, and treat migraine
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Vertigo and dizziness: is an associate or a part
of primary headache disorders
G. Akdal1, A. O¨zge2, G. Ergo¨r3
1Neurology, Dokuz Eylu¨l University School of Medicine,
Izmir, Turkey;
2Neurology, Mersin University School of Medicine, Mersin, Turkey;
3Public Health, Dokuz Eylu¨l University School of Medicine,
Izmir, Turkey
The aim of this study is to evaluate the frequency of vestibular
symptoms in primary headache sufferers. Totally 5111 patients with
primary headache disorders seen from 1999 to 2010 in Mersin Uni-
versity Hospital Department of Neurology were selected. There were
3231 patients with tension type headache (episodic and chronic) and
1880 with migraine type headache which were 4149 females and 962
males were included. Patients’ headache characteristics and accom-
panying symptoms were analyzed. Among migraine sufferers 1560
subjects diagnosed as migraine without aura (MWOA) and 320
patients diagnosed as migraine with aura (MWA). Data base were
evaluated for the following symptoms; dizziness, vertigo, motion
sickness, periodical vomiting, abdominal pain and headache relation
to menstrual cycles. Dizziness and vertigo were significantly high in
patients with MWA (50%, 45.2%, respectively). Motion sickness was
also found to be significantly high in patients with MWA (51.4% vs
38.6%, p = 0.007). Periodical vomiting and abdominal pain were
also significantly high in patients with MWA compared to MWOA
(9.7% vs 5.5%, p = 0.001; 10.9% vs 7.4%, p = 0.000, respectively).
All of the associates showed similar frequencies in patients with
MWOA and episodic TTH. The significantly high frequencies of
dizziness and vertigo in patients with MWA in our study are contrary
to the previous studies suggesting that both of the symptoms were
significantly high in patients with MWOA. It could be discussed
whether vertigo and dizziness is a part of aura period or a separate
entity. On the other hand, the continuum hypothesis between MWOA
and ETTH could also be questioned.
In conclusion, dizziness, vertigo and motion sickness are found to be
significantly high in patients with MWA. As far as we know this is the
first study evaluating these symptoms in a tertiary primary headache
center.
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Headache in children with chronic rheumatic disease
D.U. Uludu¨z1, M.E. Tavsanli1, S. Saip1, O¨. Kasapc¸opur2, A. O¨zge3,
G.O¨. Temel4, A. Kanik4, A. Siva1
1Neurology, Istanbul University School of Medicine, Istanbul,
Turkey;
2Pediatrics, Istanbul University School of Medicine, Istanbul, Turkey;
3Neurology, Mersin University School of Medicine, Mersin, Turkey;
4Biostatistics, Mersin University School of Medicine, Mersin, Turkey
Objectives To examine the presence of headache frequency and
associated psychological profiles in children with chronic rheumatic
disease.
Design and methods Patients of 354 children between ages 4 and 16
were recruited from pediatric rheumatology clinic during routine
visits. Among them most frequent types juvenile rheumatoid
arthritis (JRA) and familial mediterranean fever (FMF) were
included to this study. Headache frequency and characteristics have
been recruited using semistructured database by headache special-
ists, in addition to Child Behaviour Checklist (CBCL) for
psychological profile. Patients, reported headache were evaluated
additionally by drawing pictures of their headaches. All data was
consultated with the specialists (art professor, pedagog, child psy-
chiatrist for CBCL, statistician) and required statistical analysis
have been made.
Results Mean age of the subjects was 10.5 ± 3.2 years. Among them
45.4% were boys and 54.6% were girls. Rheumatic disorders diag-
nosis of patients were JRA (104 subjects, 29.3%) and FMF (250
subjects, 70.7%). Headache prevalences were 43.2% in all subjects
without an important gender difference (33.6% for JRA and 42.8% for
FMF). Most frequent headache type was migraine for both groups. A
higher number of parents of these children described headache his-
tory. CBCL showed important frequencies of depressive and anxious
features in headache sufferers among rheumatic disorders with a high
frequency of internalising disturbances supported by drawing head-
ache pictures of the children.
Conclusion It was concluded that apart rom secondary causes of
headache in subjects with pediatric rheumatic disorders, primary
headache disorders is not rare (totally 43.2%) especially in subjects
with FMF and using the following describing features (associated
nausea, vomiting, photophobia, phonophobia and aggravation by
studying) it can differentiate each others. In order to reach best life
quality these subjects should be consultate to neurologist and
psychiatrist for the best performance and diagnostic procedure
include the drawing picture performance in addition to standardised
tests.
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Application of bioinformatics in headache:
the I2B2-pavia project
G. Sances1, C. Larizza2, M. Gabetta2, M. Bucalo2, E. Guaschino1,
G. Milani2, C. Cereda3, R. Bellazzi2
1Headache Unit, IRCCS ‘‘C. Mondino National Institute
of Neurology’’ Foundation, Pavia, Italy;
2Laboratory for Biomedical Informatics, Department of Computer
Engineering and Systems Science, University of Pavia, Pavia, Italy;
3Laboratory of Experimental Neurobiology, IRCCS ‘‘C. Mondino
National Institute of Neurology’’ Foundation, Pavia, Italy
A detailed clinical interview is the basis of a correct diagnosis of
headache disorder, particularly of a primary form; indeed, instru-
mental examinations are required only for the symptomatic forms. All
headache disorders are classified according to the International
Classification of Headache Disorders, in which there are major
groups, each of which is then subdivided one, two or three times into
headache types, subtypes and subforms. To support a diagnosis of
primary headache, details of pain characteristics, time of onset, and
associated symptoms have to be collected; extensive information
about family history, comorbidities and biogenetic markers often
sheds light on the aetiopathogenic basis of different subforms of
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primary headache. However, to analyse all these variables it is
essential to use informatics software.
In order to exploit the information available in discharge summaries,
we exploited a Natural Language Processing (NLP) system that, after
a lexical and syntactical analysis of textual files, is able to extract
different types of clinical concepts, like principal diagnosis, comor-
bidities, therapies, etc. These data are then stored in a database
suitable for a further data exploration and analysis. As the framework
for processing such reports we implemented an NLP system inspired
by the one available within the i2b2 project, with substantial modi-
fications and extensions to cope with the Italian language and with our
specific tasks. We have currently analyzed more than 474 discharge
summaries. To date, system evaluation has been performed on the
principal diagnosis extraction task on the basis of a gold-standard
provided by the physicians composed of 150 documents. The diag-
nosis extraction task has a precision of 96.75% and a recall of
94.25%.
This method showed precision evaluation of simple Word file and
could be an easy method for collecting a great number of clinical data
allowing extension of an analysis to a larger headache population.
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Vitamin D levels in migraine and headache patients
compared with pain patients
J.C. Krusz, W.R. Knoderer
Anodyne Headache & PainCare, Dallas, TX, USA
Objective We measure Vitamin D (25-OH) levels in our migraine
and headache clinic population and compared them with our patients
who had chronic pain disorders without any headache.
Background Vitamin D levels have been found to be low in mus-
culoskeletal, fibromyalgia and other pain pain syndromes. We tried to
separate, as much as possible clinically, headache/migraine patients
from patients with chronic pain syndromes to measure Vitamin D
levels in both groups individually.
Methods Serum Vitamin D levels [total Vitamin D level = D2 + D3]
were drawn on over 1500 migraine and headache patients, as well as
in chronic pain disorders of many types, (fibromyalgia, rheumatologic
disorders and neuropathic pain disorders (TN, CRPS, TMD, lumbar
and cervical radiculopathies). We present data on 100 patients with
migraines/headaches and pain disorders.
Results We compared 100 patients with headache and pain conditions
[55 with migraines/headache, 45 with pain syndromes with regard to
their Vitamin D levels. The average Vitamin D level in patients with
predominantly migraine and mixed headache disorders, including
CDH, was 26.3 ng/ml. Only 15% had any other remote pain disorder
in their history. This compared to Vitamin D levels of 25.2 ng/ml in a
variety of pain patients, with no headache symptoms. No statistical
significance was found between the 2 groups of patients (P \ .8),
Neither group was compared to persons without either of the clinical
conditions.
Conclusions We conclude that Vitamin D levels are low in both
migraine and headache patients and are comparable to low levels seen
in our chronic pain patients. This potential biomarker should be
studied in double-blind trials, both for epidemiological and clinical
reasons, and for potential treatment effects. Vitamin D may play some
yet unknown role in multiple painful and possibly headache and
migraine disorders.
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Overlaping features of migraine and tension-type
headache. new insight to continuum hypothesis
D.U. Uludu¨z1, A. O¨zge2, A. Siva1, G.O¨. Temel3, A. Kanik3,
Turkish Headache Database Study Group
1Neurology, Istanbul University School of Medicine, Istanbul,
Turkey;
2Neurology, Mersin University School of Medicine, Mersin, Turkey;
3Biostatistics, Mersin University School of Medicine, Mersin, Turkey
Objectives To investigate the overlapping features of tension type
headache (TTH) and migraine in tertiary based headache centers
common database.
Background Question of whether TTH and migraine represent two
point of continuum has been debated before. Definitions of Interna-
tional Headache Society attempt to make distinction between
migraine and TTH based on pattern, duration and severity of attacks.
However; patients may present with characteristics of both headache
disorders and continuum concept is a possible key to the under-
standing of this association.
Methods Totally 7184 patients with headache aged between 18 and
67 were included. Information of sociodemographics and clinical
features was gathered in all patients by face to face interviews by
headache specialists using semi-structured web-based questionnaire.
Primary describing characteristics of these two headache disorders
were analyzed using standardised tests and most important discrimi-
nant features were evaluated using classification and regression tree
method.
Results Groups composed of 3317 subjects with migraine and 3,996
subjects with TTH. They showed important difference in the aspect of
headache duration (60 months vs 24 months), frequency of attacks (5
vs 15 per month), duration of attacks (24 hr vs 6 hr), quality of
attacks (pulsating vs pressing), location of attacks (unilateral vs
suboccipital), frequency of associated features (77.2% vs 35.5%). On
the other hand both headache type showed similar frequencies in the
aspect of headache timing (commonly at the evenings), associated
dizziness and nausea in addition to previous positive history of atopic
disorders and travel sickness.
Conclusions Although migraine and tension type headache are con-
sidered two different entities with different pathophysiology, however
these disorders exhibit more similarities than differences. They may
exhibit similar associated features, share similar demographics and
may be more intimately related than would be suggested by their
diagnostic criteria. The most differentiating features of these disorders
are associated nausea and dizziness in contrast to previous reports.
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Injections of the greater occipital nerve in episodic
and chronic cluster headache - efficacy and safety
of 113 injections
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1Department of Neurology, University Hospital Zurich,
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The infiltration of the greater occipital nerve with local anaesthetics
and corticosteroids is a treatment option in patients with cluster
headache. We retrospectively analysed efficacy and safety of 113
consecutive injections in 64 different patients with episodic and
chronic cluster headache. The data was collected from the patients
files from 2005 to 2009 at the headache and pain unit, Department of
Neurology, University Hospital Zurich.
More than 80% of these infiltrations had been effective. The effect
was maintained for 4 weeks on average in chronic cluster headache,
and 6 weeks in episodic cluster headache.
No major side effects have been reported. In 18 infiltrations (14%)
mild to moderate side effects have been reported, all of which have
been transient. Nevertheless, two patients decided to stop the infil-
trations despite the beneficial effect of their previous injections.
Our data shows that GON-infiltration is a valuable and safe option to
treat patients suffering from cluster headache. Especially patients with
the episodic form benefit from an injection of the greater occipital
nerve on the side of pain.
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Primary headaches: epidemiologic and clinical aspects
in the neurology department of the central hospital
Yaounde -Cameroon
Y.F. Fogoum1, A.N. Kongnyuy2, C.K. Tegueu2, J.F. Yundze1
1Neurology, Yaounde Central Hospital, Yaounde, Cameroon;
2Neurology, Faculty of Medicine and Biomedical Sciences,
University of Yaounde I, Yaounde, Cameroon
Introduction Headaches constitute the first presenting complaint in
neurological practice in western countries. However, rather few
studies have been done on headaches in Africa in general and
Cameroon in particular.
Methods To evaluate the frequency and clinical presentation of pri-
mary headaches, 276 patients with headaches were interviewed and
examined based on the 2004 IHS criteria in the Neurology Depart-
ment of the Central Hospital in Yaounde´.
Results/discussion Primary headache was found in 84.42% of the
patients. 65.22% of the patients suffered from tension-type headache
(TTH) and 13.04% from migraine whilst 6.16% had an association of
TTH and migraine. Three patients had and association of chronic
TTH and probable analgesic overuse headache. The mean age of
patients with TTH was 36.40 ± 13.63 years as against 25.47 ±
9.08 years for migraine patients. The F/M ratio of the patients with
TTH was 1.90 as against 5.0 for migraine patients. About  of the
patients with TTH and  of the migraine patients were students.
Among the patients with TTH, 53.2% presented with frequent epi-
sodic TTH and 46.8% with chronic TTH. Of the patients with
migraine, 83.33% had no aura. Insomnia was present in 42.2 % of
TTH patients. Primary headaches affected mainly the active youths,
females dominating.
Conclusion This is the first report of the prevalence of headache in
Cameroon, and shows that primary headaches are frequent in Yao-
unde - Cameroon, TTH been the most frequent. The prevalence of
TTH seems to be higher than in western countries.
Keywords Headache, prevalence, tension-type headache, migraine,
Cameroon.
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Thunderclap headache: the clinical features, diagnosis
and management: a 6 months prospective study
D. Dolezˇil, L. Svoboda, S. Obermannova´, C. Mavrokordatos,
M. Fauknerova´, Z. Svobodova´, R. Sˇiky´rˇ, E. Medova´, A. Bartosˇ
Department of Neurology, Charles University in Prague,Third Faculty
of Medicine and Faculty Hospital Kra´lovske´ Vinohrady, Prague,
Czech Republic
Thunderclap Headache (TCH) is a severe and explosive headache
whose maximal intensity at or within 60 seconds of onset. Primary
thunderclap headache lasts from 1 hour to 10 days and diagnosis
can be made only after exclusion another disorder. First every
thunderclap headache has to be considered as symptomatic head-
ache, such as subarachnoid hemorrhage, cerebral venous sinus
thrombosis, cerebral artery dissection, reversible cerebral vasocon-
striction, meningitis and other primary headache such as cough,
exertional and sexual headache. For diagnosis we used ICHD-II
criteria of International Headache Society and a cerebral CT scan,
lumbar puncture, magnetic resonance imaging, CT angiography,
MR angiography, cervical and transcranial ultrasound examination.
The first step of diagnosis procedure was to obtain a history of
present and previous headaches. We monitored pain intensity,
location of headache, quality of headache, time and duration of
headache. During 6 months we included 21 patients (11 women, 10
men), mean age 52 (standard deviation 17; median age 53) with
clinical pictures of TCH from 211 patients with headache who
were in emergency at our clinic. 10 patients had diagnosis of
primary headache (2 patients had primary TCH, 3 patients had
orgasmic headache, 1 patient had exertional headache, 2 patients
had first attack of migraine with aura). 13 patients suffered from
secondary headache (5 patient suffered from ischemic stroke, 1
patient had hemorrhagic stroke, 2 patients had subarachnoid hem-
orrhage, 2 patients had meningitis, 1 patient suffered from posterior
reversible encephalopathy syndrome, 1 patient had psychosis, 1
patient had lymphadenitis of neck). Mean score of pain intensity on
a pain scale of 0-10 were 8,4 (standard deviation 2,1 median 9)
and mean time of duration of headache was 131 hours (standard
deviation 378, median 24).
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Objective This study aimed to investigate whether the calcitonin gene
related peptide (CGRP) involves in the facilitation of trigeminovas-
cular nociception induced by cortical spreading depression (CSD) in
the serotonin depleted state.
Methods Male Wistar rats were separated into 3 groups of eight
animals each as following: control, cortical spreading depression
(CSD), and low serotonin with CSD groups. Serotonin was depleted
by administration of para-chlorophenylalanine. CSD was used to
activate trigeminal nociception. In all experimental groups, the
immunoreactivity of the calcitonin gene related peptide (CGRP) was
investigated in the sections obtained from the cerebral cortex, tri-
geminal ganglion (TG) and the trigeminal nucleus caudalis (TNC)
using the immunohistochemical technique.
Results The depletion of serotonin caused an increase of the CGRP
immunoreactivity in both TG and TNC as compared with the CSD
group. In the cerebral cortex, the perivascular immunoreactivity of
CGRP after CSD activation was more prominent in the serotonin
depleted group than in the CSD group.
Conclusion The results of this study indicate that the increase of the
CGRP release after CSD activation could be one explanation for the
facilitation of the trigeminal nociception observed in the serotonin
depleted state.
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Lacosamide in the prophylaxis of chronic headache
and migraine disorders
J.C. Krusz, J.P. Albright
Anodyne Headache & PainCare, Dallas, TX, USA
Objectives We studied a new anticonvulsant, lacosamide, in the
prophylaxis of chronic daily headaches [CDH] and mixed chronic
migraine disorders.
Background Lacosamide is a new anti-convulsant with a unique
mechanism of action that enhances the slow inactivation of voltage-
gated sodium channels in nerve.
Because other sodium channel agents have been shown to have
efficacy in the prophylaxis of chronic headache disorders, we chose to
study this agent in our clinic population who had failed multiple other
medication trials for their headaches.
Methods We studied 22 patients who had failed up to 6-7 other
prophylaxis agents for chronic migraines, CDH and mixed head-
ache disorders with neck/TMD pain. 22 Patients were treated with
daily lacosamide in increasing doses, averaging 10-14 days
between dosage changes. Average lacosamide dosage per day was
165 mg. 14 patients (64%) had neck pain or TMD co-existent with
migraines and CDH.
Results Average locosamide treatment was 94 days at the above
dosage. The number of headache and migraine days per month at
onset of lacosamide treatment was 21.4 (12-30 days per month). After
therapy, the average headache and migraine days per month reduced
to 13 per month (p \ .05, 2 tailed t test). 4 patients had no response,
mainly due to side effects such as nausea, cognitive complaints or
drowsiness. 11 of 14 (79%) patient with co-existent pain also reported
a reduction of about 47% of their symptoms.
Conclusions We conclude that lacosamide may offer a newer
approach to prophylaxis of CDH and chronic migraine. It has a novel
mechanism of action on sodium channel function in nerve, and should
be studied rigorously in a double-blind manner.
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IV tramadol treatment for chronic daily headaches
and migraines in the outpatient clinic
J.C. Krusz, J. Cagle, J.P. Albright
Anodyne Headache & PainCare, Dallas, TX, USA
Tramadol is used orally for chronic pain in the USA but no IV form
is available. We prepared an IV sterile preparation of tramadol
for treating chronic daily headaches (CDH) and chronic migraines
(CM).
Method Tramadol was given IV in the headache clinic to
patients with CDH and CM, following failed treatment with usual
medications. 112 patients were treated with IV tramadol (37 had
chronic migraines or migrainous features with CDH), An IV line
with normal saline and with pulse oximetry monitoring and with
monitoring of headache status by the patient on a 0-11 numeric
rating scale (NRS). The study was done in an outpatient headache
clinic setting.
Results All but 4 patients treated had some response to IV tram-
adol. Average dose of tramadol was 499 mg (range = 250-
1,200 mg), given over 108 minutes in the clinic. Average reduc-
tion in severity of CDH (0-11 NRS) was 7.12/10 to 1.65/10 after
treatment [p \ .001 by two-tailed t test]. No side effects other than
transient drowsiness or nausea were noted in 15 patients. 52
patients were subsequently placed on oral tramadol for their CDH.
Headaches returned within 24 hours in 22 patients not treated with
oral tramadol.
Conclusions IV tramadol is very effective in treating CDH/CM and
mixed headaches acutely in the clinic. It has virtually no toxicity
IV and can be the starting point for oral treatment. Tramadol IV
offers a new possibility in treating CDH/CM effectively and safely
and should be studied in a double-blind manner. Tramadol has mu
opioid receptor activity and reuptake blockade of norepinephrine
and serotonin. No other example of a medication administered IV
with these latter mechanisms has ever been shown to be effective
in treating CDH and other headaches with this rapidility and
effectiveness.
546
Evaluation of habituation patterns in cluster headache
S. Naegel, D. Holle, S. Zillessen, C. Gaul, H.C. Diener, Z. Katsarava,
M. Obermann
Department of Neurology, University Duisburg-Essen,
Essen, Germany
Background Cluster headache (CH) is a rare primary headache dis-
order, which is characterized by strictly unilateral severe headache
attacks. Hypothalamic dysfunction and alteration of habituation pat-
terns were suggested to play a pivotal role in the pathophysiology of
CH.
Objective To determine habituation patterns of trigeminal nocicep-
tive processing in patients with CH using the nociceptive blink reflex
(nBR).
Methods Sixty-six patients with CH (18 episodic CH inside bout; 28
episodic CH outside bout, 20 chronic CH) and 30 healthy controls
(HC) were investigated. NBR was performed following nociception
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specific electrical stimulation on both sides of the forehead
(first division of the trigeminal nerve: V1). Habituation of the R2
response was determined by analyzing the mean regression coefficient
(MRC).
Results In healthy controls the MRC was -1.4 following right-sided
stimulation and -1.9 following left sided stimulation. In episodic CH
inside bout the MRC was -2.2 after stimulation of the headache side
(HA) and MRC = -1.2 of the non-headache side (non-HA). Outside
bout the MRC was -1.6 on the HA and MRC = -1.2 on the non-HA.
In chronic CH MRC = -1.4 after stimulation of both sides of the
head. The differences between HA and non-HA as well as CH and HC
were not statistically significant. In episodic CH inside bout the R2-
response was significantly increased on the HA compared to the non-
HA.
Conclusion Our data did not detect a habituation deficit in CH,
regardless of the course of the disease (episodic inside and out-
side bout, chronic) compared with healthy controls. These results
contradict prior studies that showed an even pronounced habitu-
ation deficit of brainstem reflexes in CH compared with
migraineurs. Increased R2 responses on the HA, however, point to
a facilitation of the trigeminal nociceptive processing in CH
patients inside bout.
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Normal levels of circulating trace amines
in tension-type headache
F. Perini1, G. D’Andrea2, A. Bolner2, V. De Riva1, E. Galloni1,
D. Ruggiero1, G. Billo1, A. De Boni1, F. Pignatelli1
1Neurology, St. Bortolo Hospital, Vicenza, Italy;
2Neurology, Villa Margherita, Vicenza, Italy
Trace amines, such as tyramine and octopamine, are neuromodulators
related to classic biogenic amines. They are present in plasma at very
low physiological concentrations. Tyramine, which is derived from
the aminoacid tyrosine through tyrosine decarboxylase enzyme
activity and from tyramine containing food (cheese and chocolate), is
rapidly metabolized by dopamine-b- hydroxylase into octopamine,
which is the most stable among biogenic trace amines. Levels of these
amines are altered in various disorders such as migraine, cluster
headache, psychiatric state and Parkinson’s Disease. There are no
data available in the literature regarding plasma trace amine levels in
tension-type headache.
Therefore we assessed the plasma levels of tyramine and octopamine
in 15 patients affected by chronic tension-type or high frequency
episodic tension-type headaches, without history of migraine, and 15
healthy control subjects. For the detection of tyramine and octopa-
mine levels we used a multi-channel electrochemical HPLC system
(Coulochem II, ESA).
We found detectable levels of octopamine and tyramine in all sub-
jects. Plasma levels of octopamine and tyramine of patients
[octopamine 2,3 ng/ml ± (0,14-8,55) and tyramine 1,17 ng/ml (0,03-
4,1)] were not statistically different from those of controls [octopa-
mine 1,63 ng/ml (0,05-8,8) and tyramine 0,59 ng/ml (0,03-3,1),
p = 0.45 and p = 0.32 respectively].
Our very preliminary results, in contrast to the data in migraine and
cluster headache patients, could indicate that these two neuromodu-
lators do not play a role in tension-type headache. If confirmed, this
different pattern between migraine and cluster headache, on one side,
and tension-type headache, on the other side, may indicate different
biochemical and pathophysiological grounds.
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Vitamin D levels in chronic migraine
L. Norris1, W. Cooper1,2, A. Masih1, M. Serowoky3, K. Bialik2,
S. Eberle1
1Department of Neurology, University of Michigan,
Ann Arbor, USA;
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Ann Arbor, USA;
3Department of Pediatrics, Henry Ford Health System,
Detroit, MI, USA
Chronic migraine affects 3% of persons worldwide (1). The
mechanisms and causes of chronic migraine are not well under-
stood (1). There is a positive relationship between chronic migraine
and greater distance from the equator (2). The importance of
adequate vitamin D has been highlighted recently in the pain lit-
erature (3-7). Several studies suggest vitamin D supplementation is
helpful in the management of chronic pain including non-specific
musculoskeletal pain, back pain and diabetic neuropathy (3-5).
There is evidence that migraine prevalence correlates to northern
latitude and colder climates (2), suggesting that a deficiency of
vitamin D may be involved (2, 7). This study examines the cor-
relation of Vitamin D levels with pain disability measures, age,
sex, BMI, and season of the year, for new patients presenting to a
headache clinic at 42.3 degrees latitude with a diagnosis of chronic
migraine. A retrospective medical record review was done on 882
new patients seen from January 1, 2009 to January 1, 2010. 123
subjects thus far were found to have a diagnosis of chronic
migraine with recorded vitamin D level measures, pain disability
index, and body mass index. These measures were then compiled
into an excel spread sheet. Preliminary data results are average
vitamin D level 25.88, average pain disability index 34 and aver-
age age 43. Vitamin D levels below 20 are usually considered low
and pain disability index scores vary from 0 being no disability to
70 as the maximal disability of pain. Further correlations will be
presented to make the connection between vitamin D levels and
chronic migraine apparent.
Citations available upon request.
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Burden of disease in cluster headache
T.P. Ju¨rgens1,2, C. Gaul3,4, A. Lindwurm2, T. Dresler5,
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6Dept. of Psychiatry, University of Aachen, Aachen, Germany;
7Kiel Pain Center, Kiel, Germany
Introduction Cluster headache (CH) belongs to the most excruciating
headache syndromes known. However, relatively little is known about
the burden of cluster headache regarding its various subtypes (chronic
and episodic CH in and out of the active period). The implications of
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headache can be differentiated into diverse economic (e.g. impaired
work life) and non-economic burdens (e.g. disability and psychiatric
complaints).
Patients and methods In a multicentre prospective study patients
with chronic CH (n = 27), with episodic CH in the active period
(n = 26) and outside the active period (n = 22), migraine patients
(n = 24) and controls without a history of primary headaches
(n = 31) were included. Apart from epidemiological data, the Ger-
man version of the Headache Disability Inventory (HDI) and
screening questions for psychiatric complaints were applied.
Results About 25% of chronic CH patients received invalidity
allowance due to headache. HDI scores (total and the subscales
emotion and function) indicated a statistically significant severe
headache-specific disability in the chronic and active episodic CH
patients. Patients with inactive CH and migraine were less affected
than the former group but still more impaired than healthy volunteers.
Symptoms suggestive of psychiatric comorbidity were found pre-
dominantly in the chronic CH group. Depressive symptoms (56%)
and signs of agoraphobia (33%) prevailed. Interestingly, 22% of the
chronic CH patients reported thoughts about death and suicide.
Discussion In conclusion, a massive headache-specific disability in
patients with chronic and active episodic CH could be found. Job life
was severely affected with a surprisingly high proportion of early
retirement in chronic CH. Lastly, psychiatric comorbidity and suicidal
tendencies were highest in chronic CH. Therefore, patients with
chronic CH have a severe and disabling condition that warrants
special medical and further supportive care.
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Comorbid conditions with migraine
S. Bicakci1, A. Ozge2, G. Seydaoglu3, Y. Sarica1,
Turkish Headache Database Study Group
1Neurology, Cukurova University School of Medicine,
Adana, Turkey;
2Neurology, Mersin University School of Medicine, Mersin, Turkey;
3Biostatistics, Cukurova University School of Medicine,
Adana, Turkey
Background and objectives Comorbidity refers to coexistancy or
concomitancy with an unrelated pathological or disease process of
separate conditions in the same individuals. Migraine may be associ-
ated with various medical, neurological and psychiatric diseases. The
aim of this study was to evaluate the comorbidity in migraine patients.
Materials and methods Patients’ data from Turkish Headache
Database Study Group were evaluated in this retrospective study. The
study group consisted of 3414 cases based on The International Classi-
fication of Headache Disorders, 2nd edn diagnostic criteria. Migraine
comorbidity in the patients were assessed according to their self reports.
Results Mean age was 43,3 ± 12,6 (min14- max90). The patients were
divided into four groups; migraine with aura, migraine without aura,
probable migraine, complications of migraine. Psychiatric comorbidi-
ties (depression in 31.5%, anxiety disorder in 11.7%, obsessive-
compulsive disorder in 1.9%, psychosis in 0.8%), non-headache pain in
31.0%, vascular comorbidities (hypertension in 14.5%, atherosclerotic
heart disease in 8.5%, transient ischemic attack and stroke in 0.3%),
atopic disorder in 1.5%, and epilepsy in 1.1% of patients were detected.
Conclusion Migraine is a complex disease that requires a multidis-
ciplinary disease management approach. Comorbid disorders have
been found to affect migraine progression and treatment strategy. The
presence of these disorders can impose therapeutic challenges and
limit treatment alternatives.
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Migraine and epilepsy - a shared genetic region
on 14Q13-Q23
A. Polvi1, A. Siren1,2, M. Kallela3, V. Artto3, H. Rantala4, E. Sobel5,
A. Palotie6,7, A.-E. Lehesjoki1, M. Wessman1,7
1Folkha¨lsan Institute of Genetics, Department of Medical Genetics
and Neuroscience Center, University of Helsinki, Helsinki, Finland;
2Department of Pediatrics, University Hospital of Tampere,
Tampere, Finland;
3Department of Neurology, Helsinki University Hospital,
Helsinki, Finland;
4Department of Pediatrics, University of Oulu, Oulu, Finland,
5Human Genetics, UCLA, Los Angeles, CA, USA, 6Wellcome Trust
Sanger Institute, Cambridge, UK, 7Institute of Molecular Medicine
(FIMM), University of Helsinki, Helsinki, Finland
Migraine and epilepsy are paroxysmal disorders of the brain. Patients
are typically symptom-free between the attacks. Decrease in level of
consciousness (severe in epilepsy, milder in migraine), presence of
auras, post-ictal drowsiness, aphasia and attacks that may be triggered
by either visual or hormonal stimulus are all characteristics shared by
both migraine and epilepsy. Epidemiological and clinical studies have
demonstrated a high degree of co-morbidity between migraine and
epilepsy. We performed a genome-wide linkage scan in search for
shared loci for migraine and epilepsy.
A large Finnish family with a high prevalence of migraine and epi-
lepsy was identified and clinically characterized. Data on IHS-defined
attack symptoms was collected using the validated Finnish Migraine
Specific Questionnaire for Family Studies. Of 46 individuals, 27 had
migraine and eight generalized tonic-clonic seizures (GTCS). All
GTCS patients had migraine (five patients with and three without
aura). Genome-wide genotyping was performed using 382 microsat-
ellite markers with an inter-marker distance of 9.4 cM. Multipoint
non-parametric linkage and haplotype analyses were performed using
SimWalk v2.96.
A shared region on chromosome 14q13-q23 was identified for
migraine and GTCS. Suggestive evidence of linkage (p-value 0.0018)
was found between migraine and marker D14S70. This marker also
indicated suggestive evidence of linkage to GTCS (p-value 0.0025).
Significant evidence of linkage (p-value 0.0005) between migraine
and marker D14S70 was detected after fine-mapping. A haplotype
analysis identified a shared segment of 21 Mb for both migraine and
GTCS.
Our finding indicates a shared region on chromosome 14q13-q23 for
migraine and GTCS. Furthermore, our study confirms results of two
previous studies indicating linkage of migraine without aura (Soragna
et al., 2003) and epilepsy (Sander et al., 2000) to this locus. Future
work will show whether there are shared or separate susceptibility
variants for migraine and epilepsy in this region.
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Top-down control of visual cortex in migraine
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The pathophysiology of migraine includes a heightened excitability of
visual cortex that persists between headache events and that has been
linked to impaired inhibitory intracortical processes. Here we exam-
ined the implications of this cortical pathophysiology for the top-
down attentional control of visual cortex. We asked two groups of
participants – migraineurs (N = 29) and non-migraine controls
(N = 29) – to perform a probabilistic spatial orienting task as we
measured visual sensory cortical responses via event-related poten-
tials (ERPs). Data were then analyzed as a function of whether the
ERP-eliciting stimulus was in the fovea vs. parafovea, and whether
the stimulus0 location was attended or unattended. In this regard, we
found two key between-groups differences in the effect of attention
on sensory-evoked visual-cortical activity. First, relative to controls,
migraineurs showed a larger attention effect in the visual N1 ERP
component for events at the fovea. Second, unlike controls, migrai-
neurs showed no early-phase attention effect in the P1 ERP
component for events in the parafovea. Taken together, our results
suggest that migraineurs have an abnormal top-down modulation of
visual cortex leading to a lack of normal suppression of unattended
information.
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Headache as a manifestation of spontaneous cervical
artery dissections
A. Radojicic1, I. Berisavac2, L. Beslac-Bumbasirevic2,
N. Covickovic-Sternic1
1Department for Cerebrovascular Disorders and Headache,
Belgrade, Serbia;
2Emergency Neurology Department, Institute of Neurology,
Clinical Center of Serbia, Belgrade, Serbia
Background Spontaneous cervical artery dissection (sCAD) is a well
recognized cause of stroke, particularly in the young, with a wide
spectrum of clinical presentations. Patients may present with local
manifestations, ischemic signs or both. Headache and neck pain are
thought to be frequent symptoms of sCAD.
The aim was to evaluate headache occurrence associated with cer-
vical artery dissections as well as clinical characteristics of headaches
in sCAD.
Methods A study was done on 37 neurological inpatients with
spontaneous internal carotid (sICAD) or vertebral artery dissections
(sVAD) who were treated at stroke unit and department for cere-
brovascular disorders and headache at the Institute of Neurology
Clinical Center of Serbia. Diagnosis of arterial dissection was
established by CT or MR angiography, and confirmed by extracranial
Doppler ultrasound. Headache characteristics (localization, intensity,
duration, pain quality) were analyzed as well as accompanying fea-
tures in patients with headache.
Results In a group of 37 patients with sCAD, 26 were males (75%),
with mean age of 42.5 years. Headache occurred in 17 patients (46%)
and in 2 was the only symptom of disease, lasted from 3 hours to
15 days. Headache was an initial symptom in 9 patients, and preceded
stroke or TIA up to 4 days. Unilateral localization was present in 7
and bilateral in 10 patients. 2 patients with sICAD presented with
intensive continuing retro-orbital unilateral pain with ipsilateral
autonomic signs (semiptosis, miosis, eyelid swelling, lacrimation).
Unilateral throbbing pain in occipital region accompanied with ver-
tigo, nausea and vomiting was found in 4 patients with sVAD.
Conclusion Headache is often the initial sign of sCAD. Clinical
presentation may vary in intensity, duration and localization and it
can mimic primary headache disorders.
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Headaches and medical doctor education in Serbia
S.L. Sretenovic, A.I. Stanic
Headache and Migraine Centre, University Hospital Zvezdara,
Belgrade, Serbia
Introduction Fact that there is insufficient number of Medical Doc-
tors specialized in headaches as well as their insufficient education
often introduces wrong diagnosis, and improper treatment of different
headache entities.
Objective Study is focused in determination of the quality level of
Medical Doctors specialized in different areas in order to make the
proper diagnosis of the different types of Headaches.
Method This retrospective study analyzed referral diagnosis that was
conducted by the group of Medical Doctors of different specializa-
tions, who have referred the patients to a Headache Center. Diagnosis
were compared with the ones provided by the Neurologists special-
ized in headaches and in accordance to the standards specified by the
International Headache Society differentiating the variety of head-
aches. Referral and final diagnosis were compared for 1,200 of
consecutive patients (M:F = 330:870) taken from the specialized
protocols for evaluation used in the Headache Center. 1200 analyzed
patients, are divided into three groups. First group, 976 patients
referred by the General Practitioners, second, 32 patients referred by
the Neurologists, third 192 patients referred by the Medical Doctors
specialized in different areas.
Results Referral diagnosis from General Practitioners were confirmed
in 30.3%, from Specialized Neurologists in 62% and from Medical
Doctors specialized in different areas in 37.5% cases. Biggest prob-
lem to define the proper diagnose, for all the groups was the Cluster
Headache, that has been properly diagnosed just in 16% of all the
cases and Migraine with Aura that has been properly diagnosed in just
23% of all the cases.
Conclusion This study results, indicates the problem of assigning the
right diagnosis for different types of headaches, especially within
the group of patients checked by General Doctors. Organization of the
supplementary education in this area would significantly improve the
way of treatment, and would also impact the economy factor in
reducing the costs.
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Evaluation of sleep disorders among migraineurs
and tension-type headache and control group
G. Jalilzadeh1, S. Shahbeigi2, S. Jalilolghadr3, S.M. Fereshtenezhad4,
N. Mohammadi5
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4Jondishapur Neurology Clinic, Tehran, Iran;
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Headache is one of the most common complaints of patients visiting
neurologists. More than 90% of individuals experience headache at
least once in their life time which may be exacerbated by various risk
factors including sleep disorders. Sleep disorders related to headache
are of different types such as insomnia, polysomnia and circadian
rhythm disturbances. Considering the above, determination of sleep
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disorder pattern among headache sufferers and appropriate approach
to these disorders may remit or cure headache.
This case-control study was conducted on 3 separate groups con-
sisting of migraineurs, tension-type headache and control group in
1388-89 in Tehran. Twenty hundred and ninety eight participants
completed Sleep Disorders’ and Epworth Questionnaires and 8 sleep
disorders including hypersomnia, insomnia, restless leg syndrome
(RLS), excessive daytime sleepiness, somnombolin, sleep talking,
nightmare, and bruxism were evaluated. Chi-square analysis was
performed to compare groups.
Out of the 298 participants 72.1% were female and 27.9% were male.
Mean age of participants was 38.3 years. Ninety two participants
were in the control group and according to HIS criteria 124 indi-
viduals were migraineurs and 82 were classified as having tension-
type headache. Results of this study show significant difference in 3
of the sleep disorders including insomnia (p = 0.036), restless leg
syndrome (p = 0.034) and nightmare (p = 0.027) between headache
and control group. No other significant difference was found between
the two groups. In addition, no significant difference (p [ 0.05) was
found between migraineurs and tension-type headache group.
Considering the results of this study it is suggested that evaluating
risk factors and clinical symptoms and treating sleep disorders, spe-
cially insomnia, restless leg syndrome, and nightmare, can be
effective in migraineurs and tension-type headache sufferers.
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Posttraumatic headache in former military men:
clinical picture and age differences
E. Mikhaylova1,2, A. Rachin2
1Smolensk Regional Hospital for Veterans, Smolensk, Russia;
2Smolensk State Medical Academy, Smolensk, Russia
Posttraumatic headache in former military men: clinical picture and
age differences.
Background Traumatic brain injury (TBI) ranging from 30 to 50% of
all types of injuries and increasing to 60-80% in case of traffic acci-
dents. The number of TBI in warzone is really high and about 80% of
them are mild brain injuries very often leads to posttraumatic head-
ache. Soldiers with TBI often have symptoms and findings affecting
several areas of brain function. Among 5,000 soldiers who returned
from deployment to Fort Lewis, Washington 19% had had a concus-
sion, and more than 90% of this group reported having headaches
during the previous three months (Theeler BJ, Erickson JC, 2009).
Material We had investigated 60 veterans of local wars with post-
traumatic headache. Patient age ranged from 21 to 59 years.
Results Posttraumatic headache could be characterized as bilateral pain
which was mainly located in frontotemporal (42.6%) and occipital region
(24.6%), prompted by a bad dream, accompanied by vertigo (18.0%) and
fluctuating blood pressure (26.2%). 59.0% of patients suffered from it for
ten years or more. Patients were divided into two subgroups are compared
with each other: First subgroup - patients under 40 years, 26 men, mean
age 33.9; Second subgroup - patients older than 40 years, 34 men, mean
age 46.7. The intensity of headache according to visual and analog scale
of pain and other clinical characteristics was not statistically differed in
both subgroups. However, people older than 40 years, significantly more
often complained about the presence of other pain syndromes: 47.1% - for
vertebrogenous pain syndromes, 20.6% - heart pain, 8.8% for joint pain,
5.9% - epigastric pain. 65.4% of men from the first subgroup, and only
38.2% from the second complained only of a headache.
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Cluster headache-like headache in an eight-year-old
girl: case report
D. Petravic´1, N. Barisˇic´ 2, D. Markov3
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Zagreb, Croatia;
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Cluster headache (CH) is a primary episodic headache clinically
characterized by extreme unilateral orbital or periorbital pain, cranial
autonomic symptoms and periodic occurrence. The prevalence of CH
in the general population is 0.1% and is threefold more common in
men. CH mostly occurs in the second and third decade of life;
however, cases of its occurrence in the first decade of life have also
been reported. A case is presented of an 8-year-old girl, previously
healthy, with a one-week history of clinically typical daily CH
attacks, with motor hyperactivity for about one hour of falling asleep,
persisting for hours. The administration of analgesics (paracetamol,
ibuprofen) proved inefficient. The attacks were only interrupted by
cold winter air inspiration. Diagnostic work-up including C-reactive
protein, complete blood count, general biochemistry, neurologic
examination with electroencephalography, and ophthalmologic
examination (vision, fundus, biomicroscopy and tonometry) yielded
normal findings. ENT examination with paranasal cavity x-ray and
sinusoscopy pointed to inflammation of the ipsilateral maxillary sinus
with the respective ostium obstruction. Upon topical endoscopic
treatment with decongestants on two occasions at a week interval and
topical therapy with corticosteroid and antibiotic drops, pain attacks
subsided in severity and frequency, to regress completely in the
second week of therapy. The subsequently obtained magnetic reso-
nance of the head was normal. The case presented points to the need
of additional diagnostic work-up in children with CH irrespective of a
typical clinical picture, in order to exclude the secondary treatable
causes.
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Neck-tongue syndrome: a Turkish patient
L.E. Inan1, N. Inan2, E. Sut2, O. Coskun1, S. Ucler1
1Neurology, Ministry of Health Ankara Research and Training
Hospital, Ankara, Turkey;
2Anesthesia, Ministry of Health Ankara Research and Training
Hospital, Ankara, Turkey
A syndrome, unilateral upper nuchal or occipital pain with or
without numbness in these areas, accompanied by simultaneous
ipsilateral numbness of the tongue is explicable by compression of
the second cervical root in the atlantoaxial space on sharp rotation
of the neck as published justly by Lance JW and Anthony M in
1980. Since then totally 25 papers were published about this syn-
drome. Now we are presenting probably the first Turkish neck
tongue syndrome patient. The patient is 15 years old girl and she
has been suffering from ipsilateral numbness and pain on the neck
and tongue during sharp rotation of the neck for ten years. She has
no history of neck travma.
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Clinical characteristics of primary headaches
and the efficacy of prophylactic therapy in out-patients
M. Jovanovic, N. Buder, P. Simonovic
Department for Clinical Neurophysiology and Epilepsy,
Institute of Mental Health, Belgrade, Serbia
Objectives To asses the clinical characteristics of primary headaches,
prior to initiation of prophylactic therapy as well as the response to
treatment.
Background Successful management of primary headaches -
migraine and tension type headache, a highly prevalent disorder, is
based upon timely and appropriate choice of prophylactic medication.
Method We studied 120 subjects in un out-patient setting using post-
hoc analysis of: the age of occurrence (before or after 30); number of
years with headache (more or less than 10), number of headache days
per month (more or less 15). Diagnosis of headache was made
according to IHS-classification (2004). Clinical diagnosis of depres-
sion (ICD-10) was supported by the BDI-scale. We initiated
prophylactic treatment according to guidelines of headache treatment,
as a step-by step and stratified care.
Results The sample of 120 patients contained 93 females and 27
males, ages 16 - 70. There was low therapeutic efficacy in 23 of 120
patients (19,16%). It was observed that the characteristics of the non-
responders were: headache that started after the age of 30 in 13 out of
50 (26%); headache duration more than 10 years in 19 out of 85 (22%)
and over 15 headache days per month in 16 out of 60 (26%) . We had
low therapeutic efficacy in 6 out of 46 (13%) migraine patients, 10 out
of 33 (30%) with tension type headaches and in 7 out of 41 (17%) with
co-existence of the two types. 16 out of 64 patients (15%) who also
suffered from depression did not respond to prophylactic treatment.
Conclusion We concluded that later onset of headache, more head-
ache days per month (chronic course), tension type headache and co-
existing depression were conditions that led to low therapeutic
response in patients with primary headaches.
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Co-existing depression in primary headaches - clinical
characteristics in un out-patient sample
N. Buder, M. Jovanovic, P. Simonovic
Department for Clinical Neurophysiology and Epilepsy,
Institute of Mental Health, Belgrade, Serbia
Objectives We wanted to study the possible influence of certain
clinical characteristics of primary headaches on the co-existence of
depression.
Background Depression, the most prevalent co-morbid condition in
patients with migraine and tension type headache, worsens the clinical
course and demands much greater therapeutic effort.
Method In the sample of 120 out-patients we followed the age of
onset (before and after 30), duration (more or less than 10 years),
number of headache days per month (more or less than 15) and the
efficacy of prophylactic treatment. Diagnosis of headache was made
according to IHS-classification (2004). Clinical diagnosis of depres-
sion (ICD-10) was supported by the BDI-scale.
Results In the group of 93 females and 27 males, ages 16 - 70 (mean
45,61 yr.) - 64 patients (53,3%) suffered from depression. Depression
was more prominent in those who started headache after the age of 30
yrs. - 32 out of 50 (64%), but similarly distributed in those whose
headache lasted more and less than 10 years, as well as in those with
more and less than 15 headache days per month. Depression co-
existed in 18 out of 46 (39%) migraine patients, 24 out of 33 (73%)
with headache of tension type and 22 out of 41 (54%) that had both
types. Depression was founded in 16 out of 23 patients that did not
respond to prophylactic therapy (69%), and was equally present in the
group of responders.
Conclusion We found more depression in patients with later onset of
headache, while the duration and the number of headache days per
month did not affect the emotional state. Tension type headache and
low therapeutic response to prophylaxis could be signed as the risk
factors of co-morbid depression in primary headaches.
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Adolescent migraine: long-term health outcomes
following treatment with a single tablet formulation
of sumatriptan and naproxen sodium
E.M. Pearlman1, M.C. Runken2, P. Winner3, N. Richard4,
F.J. Derosier4, S.A. McDonald4
1Memorial Children’s Hospital, Mercer University School
of Medicine-Savannah Campus, Savannah, GA, USA;
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4Neurosciences MDC, GlaxoSmithKline, Research Triangle Park,
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Objective To measure long-term patient-reported health outcomes
(B 12 months) in adolescents treating migraines with sumatriptan and
naproxen sodium (SumaRT/Nap).
Methods A prospective, open-label, single-arm, multi-center study
was conducted to evaluate SumaRT/Nap acute treatment of migraine
in adolescents 12-17 years old. Trial design reported elsewhere
(McDonald 2010). Quality of Life (QoL) was measured using the
Migraine-Specific QoL Questionnaire for Adolescents (MSQ-A) at
baseline and at 3 month intervals. Overall medication satisfaction was
measured at baseline and monthly following treatment using the
global subset of items from the Revised Patient Perception of
Migraine Questionnaire (PPMQ-R).
Results The ITT population was used for these analyses and was
defined as subjects taking C 1 dose of SumaRT/Nap and completing
an eligibility-treatment assessment: 591 [12-14 yrs: 273; 15-17 yrs:
318]. Subjects were primarily Caucasian (86%), females (60%), with
a 5-year history of migraine without aura (69%) and experiencing 4
attacks/month. 67 (11%) withdrew due to adverse events or lack of
efficacy. 333/591 subjects remained in the study for at least 6 months
treating on average C 1 attack/month within the first 6 months (6mo-
Completers); 181/591 remained in the study for 12 months treat-
ing C 1 migraine attack/month (12mo-Completers).
In the ITT and 12mo-Completer groups, mean MSQ-A scores
improved significantly from baseline in all three QoL dimensions
(p B 0.0001 for ITT; p B 0.005 for 12mo-Completers) and on aver-
age exceeded the Minimal Clinically Important Differences in the
Role-Restrictive(7) and Role-Emotional(6) dimensions at all time
points. PPMQ-R data indicated that 82%, 84% and 85% of the ITT,
6mo- and 12mo-Completer groups were either ‘Satisfied’ or ‘Very
Satisfied’ with the Overall Efficacy, while 86%, 87% and 89%
respectively, were ‘Satisfied’ or ‘Very Satisfied’ with the Overall
Treatment of SumaRT/Nap.
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Conclusions Adolescents migraineurs using SumaRT/Nap reported
improved quality of life compared to baseline and were generally
satisfied with their treatment.
Conflict of interest M. Chris Runken, PharmD is full time employee
of GlaxoSmithKline, Research Triangle Park, North Carolina, USA.
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Paroxymal hemicrania and visual aura: a case report
E. Guaschino1, F. Antonaci2,3, M.G. Cuzzoni3,4, G. Nappi1
1IRCCS Mondino Foundation, Pavia, Italy;
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Pavia, Italy;
3Headache Medicine Centre Polyclinic of Monza, Monza, Italy;
4University Centre for Adaptive Disorders and Headache (UCADH),
Varese, Italy
A 48 years-old healthy female patient presented to our outpatient
clinic in December 2008. Since the age of 20 the patient had expe-
rienced severe left side orbital, supraorbital and temporal headache
pain lasting about 15-20 minutes, associated with ipsilateral symp-
toms and signs (lacrimation, ptosis and nasal congestion). Attacks had
a frequency above 6 per day and occured in periods lasting about one
month with subsequent pain free period lasting more years. In
December 2008, she experienced another headache period with daily
attacks with average frequency of 8 per day, always characterized by
the same unilateral headache pain and ipsilateral located signs on the
left side. The physical and neurological examination was normal. The
attacks stopped with indomethacin 100 mg BID by injection for
3 days and later with 150 mg orally for maintenance, supporting the
diagnosis of paroxysmal hemicrania.
The patient returned at our observation after 3 months, reporting a
complete remission of headache.
A MRI and angio-RMI of the brain was performed in february 2009,
showing a small, right intracranial carotid artery aneurysm.
In July 2009, she reported a three month history of visual disturbance
tipical for migraine aura (characterized by gradual onset of binocular
scotoma lasting 15-30 minutes) without subsequent headache, oc-
curing four-five times in a month. One month ago she was operated
upon the aneurysm with endovascular coiling; she started treatment
with double antiaggregation drugs after which she referred no other
episode of migraine aura.
This is a case in which two different diagnosis, paroxysmal hemi-
crania and migraine aura without headache, seem coexisting. Since
visual disturbance was clearly reported as binocular and typical for
aura, carotid aneurysm could be considered a casual finding as well as
also episodic unilateral headache pain located in left head seems not
to be related with right carotid alteration.
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Characteristics of headache: a clinico-epidemiologic
study
S. Ben Nsir, M. Damak, I. Ayadi, A. Boukhris, M.I. Miladi, I. Feki,
C. Mhiri
Department of Neurology, Habib Bourguiba Hospital, Sfax, Tunisia
Background Headache disorders are extremely common and are a
common complaint among patients seeking care. The prevalence of
headache has long been a subject of discussion. As with all disorders,
the key to diagnosis is a good history.
Patients and methods The objective of this study was to describe the
epidemiology, clinical presentation of chronic headache in 96
patients.
Results The mean age was 39 years, 61patients were female and 35
were male. The onset of headache is acute in 8%, fast progressive in
20.8%, progressive in 66.1%. The prodromes are vomiting in 17.7%,
anxiety in 5.2%, irritability in 18.7%, others in 29% and without
prodromes in 18%. The headache is localised in 18.7%, diffuse in
8.3%, unilateral in 19.8%, bilateral in 17.7%, holocranial in 114%,
hemicranial in 29%, orbital in 18.7%, occipital in 20.8%, vertex in
26%, frontal in 26%, parietal in 8.3%, temporal in 22.9%, hemi facial
in 2%, cervical-occipital in 2%, a bascule in 6.2%.
The neurological examination was normal in all patients and the
diagnoses were migraine with in 8.3% and without aura in 39.7% and
psychological headache in 52%.
All the patients are treated with analgesics; NSAI, Triptan, Ami-
triptyline, Oxe´torone and the outcome are variable.
Conclusion The different headache symptoms may be causally
related to age, but an influence of medication or other factors must
also be considered. The use of specific coping strategies as well as
non-pharmacological or pharmacological prophylactic therapies
needs further support in daily clinical practice.
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Demographic characteristics of out-patients
with primary headaches and the clinical course
of illness
P. Simonovic, M. Jovanovic, N. Buder
Department for Clinical Neurophysiology and Epilepsy,
Institute of Mental Health, Belgrade, Serbia
Objectives We wanted to esteem the possible importance of the age,
sex, academic level and employment of patients with primary head-
ache for the efficacy of prophylactic medication.
Background Migraine and tension type headache are highly pre-
valent chronic disorders, that affect general population in their most
active and productive period of life, with consequences to their
functioning, also important for economic cost and burden of the
illness.
Method In the sample of 120 out-patients, diagnosed according to
criteria of ICD-10 (2007) and IHS (2004) - as migraine, tension type
headache and co-existence of migraine and tension headache - we
marked demographic characteristics and their possible influence on
the success of prophylactic medication.
Results Patient were both sexes,93 females and 27 males, ages 16 -
70 (mean 45 years). There were 20 patients (16,7%) with elementary,
66 (55%) middle and 34 (28,3%) high education level. 58 patients
(48,3%) were employed, while the other 62 (51,6%) did not work -
pupils, students and retired. There were 31 unemployed persons that
is 26% in the whole sample and 35% among 89 subjects in work
active period. Prophylactic therapy was not successful in 23 out of
120 patients (19,2%), worse in males (8 out of 23 or 34,8%), older
subjects (mean age 52 years), middle education level (16 out of 23 or
69,5%), non-working individuals (14 or 60,8%) and unemployed, but
in work-active period of life 7 or 30%.
Conclusion We found that the factors of worse clinical course of
primary headaches could be: male sex, more than 50 years of age,
middle education level and non-working population, specially
unemployed.
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Quality of life in Tunisian headache suffers
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I. Feki2, N. Zouari1, C. Mhiri2, M. Maalej1
1Psychiatry C Department, Hedi Chaker Teaching Hospital,
Sfax, Tunisia;
2Department of Neurology, Habib Bourguiba Hospital, Sfax, Tunisia
Objective To assess quality of life in Tunisian headache suffers.
Methods We studied 50 consecutive patients presenting with head-
ache and consulting in Neurology department of Habib Bourguiba
Hospital (Sfax, Tunisia). Data collection included patient character-
istics, characteristics of headaches, neurological exam and
radiographic findings. Headaches were diagnosed according to the
New International Classification of Headache Disorder. The quality of
life was assessed using the SF-36 questionnaire, including physical
functioning, social functioning, role physical, role emotional, bodily
pain, vitality, mental health and general health. Fore better interpre-
tation of our results we proceeded to the standardisation of initial
average scores of eight domains to an average of 50 in accordance
with the study in general population (USA 98). According to Lean,
the quality of life was compromised if mean score of eight domains
was B 66.7.
Results Patients included 42 women and 8 men, aged 17-82 years.
Thirty-two percent of headache suffers had a poor quality of life
(mean score B 66.7). They reported diminished functioning and
well-being on all eight domains. The daily frequency of headache
was significantly associated with role physical (p = 0.01), role
emotional (p = 0.01) and vitality (p = 0.035). Throbbing headache
types were correlated with bodily pain (p = 0.02) and vitality
(p = 0.032).
Conclusion Tunisian headache suffers often report compromised
physical, mental and social functioning because pain changes quality
of their lives.
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The effect of incident cranial neuralgia on pre-existing
migraine
H. Sheikh, R.B. Lipton, B.M. Grosberg, M.S. Robbins
Neurology, Montefiore Headache Center, Albert Einstein College
of Medicine, Bronx, NY, USA
Objectives To describe the impact and characteristics of incident
cranial neuralgias (CN) in patients with pre-existing migraine.
Background A subset of episodic migraine (EM) patients progress to
chronic migraine. A variety of risk factors have been identified for this
transition, including comorbid pain conditions and temporomandibu-
lar dysfunction (TMD). A shared mechanism may be the development
of cutaneous allodynia, a clinical marker of central sensitization.
Results Co-existing CN and migraine were identified in 5 patients, all
women. Three patients developed trigeminal neuralgia (TN), 1
developed glossopharyngeal neuralgia (GN), and 1 developed both. In
all patients, migraine onset preceded CN onset, mean time between
the two was 34 years. Comorbidities included TMD in 2 patients,
depression in 1 patient, and anxiety in 1 patient. Three patients
reported worsening of their migraine following incident CN, 2 with
TN and 1 with both TN and GN. In the year following CN onset,
monthly days of headache increased by a mean of 7 days (range 3 to
15 days). In the other 2 patients, headache frequency was unchanged.
After CN onset, patients were started on oxcarbazepine (n = 2), to-
piramate (n = 2), or venlafaxine (n = 1). Allodynia was present in 3
patients, mean ASC score of 6 (range 4-8). Patients with prominent
allodynia had a higher likelihood of developing worsening migraine
after CN onset. All 3 patients who progressed had a history of using of
abortive medications [ 10 days a month, including meperidine, ibu-
profen, and butalbital/acetaminophen/caffeine.
Conclusions Three of five patients reported worsening of long-standing
migraine after the new onset of CN. Migraine worsened despite treat-
ment with preventive medications for CN. We hypothesize that CN may
be associated with migraine progression through the mechanism of
central sensitization. Analytic epidemiologic studies are required in
larger series of patients to further elucidate this relationship.
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for Kowa Pharmaceuticals American Inc. and Merz Pharmaceuticals;
has received honoraria for speaking engagements or educational
activities from Merck and Nautilus Pharmaceuticals; and received
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oSmithKline, Endo Pharmaceuticals, Boston Scientific, Neuralieve
Inc., Advanced Bionics, ProEthics, Minster Pharmaceuticals, and
Capnia.
Dr. Lipton receives research support from the NIH [PO1 AG03949
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tor), and K23NS47256 (Mentor)], the National Headache Foundation,
and the Migraine Research Fund; serves on the editorial boards of
Neurology and Cephalalgia and as senior advisor to Headache, has
reviewed for the NIA and NINDS, holds stock options in Neuralieve
Inc. and Minster Inc; serves as consultant or has received honoraria
from: Allergan, Autonomic Technologies, Boston Scientific, Bristol
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Nautilus Neuroscience, Neuralieve, Novartis, and Pfizer.
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Pathogenic mechanism in familial hemiplegic migraine
2 (FHM2) involves disruption of local and global Ca2+
signaling
I.F. Smith1, C. Shih2, R. Blostein3, I. Parker4, J.J. Gargus5
1Neurobiology and Behavior, University of California,
Irvine, CA, USA;
2Physiology & Biophysics, University of California,
Irvine, CA, USA;
3Medicine & Biochemistry, McGill University,
Montreal, QC, Canada;
4Neurobiology and Behavior and Physiology & Biophysics,
University of California, Irvine, CA, USA;
5Physiology & Biophysics and Pediatrics, Division of Medical
Genetics, University of California, Irvine, CA, USA
Point mutations in the a2 isoform of the Na, K-ATPase (ATP1A2 Na
pump) cause FHM2, an autosomal dominant migraine phenotype
identical to that caused by CACNA1A P/Q calcium channel muta-
tions in FHM1. Although FHM2 alleles produce diverse effects on
pump kinetics, all FHM2 mutants tested, unlike WT, similarly disrupt
intracellular Ca++ signaling in stable transformant human SH-SY5Y
neuroblastoma cells. Ca++ signals evoked by 100 lM carbachol were
diminished in mutants, Ca++ oscillations were suppressed and local
Ca++ puffs, representing quantal IP3R release events evoked by
photoreleased inositol trisphosphate (IP3) occurred with similar fre-
quency, yet lower amplitude than in WT. These effects of FHM2
S144 J Headache Pain (2010) 11 (Suppl 1):S1–S150
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mutations were evident without inhibiting normal endogenous human
Na pumps, simulating the mix of pumps present in the heterozygous
disease state. The changes are observed in the absence of changes in
cellular proliferation, basal calcium levels or ER calcium stores.Given
these mutations affect ATPase kinetics in different ways, yet lead to
similar disease and disruptions in Ca++ signaling, we propose that
regulation of IP3-mediated Ca++ signaling is a critical physiological
function of a2 and that calcium signaling alterations are a central
component of the pathogenic mechanism of FHM.
Supported by grants NIH GM 40871(I.P.) and NIH MH 71433 (J.J.G.)
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Depression in Tunisian headache suffers
I. Abid1, J. Ben Thabet1, A. Boukhris2, M.I. Miladi2, L. Zouari1,
I. Feki2, N. Zouari1, C. Mhiri2, M. Maalej1
1Psychiatry C Department, Hedi Chaker Teaching Hospital,
Sfax, Tunisia;
2Department of Neurology, Habib Bourguiba Hospital, Sfax, Tunisia
Objective To detect depression in headache suffers.
Methods We studied 50 consecutive patients presenting with head-
ache and consulting in Neurology department of Habib Bourguiba
Hospital (Sfax, Tunisia). Data collection included patient character-
istics, characteristics of headaches, neurological exam and
radiographic findings. Headaches were diagnosed according to the
New International Classification of Headache Disorder. Depression
was defined as a Beck scale C 4.
Results Patients included 42 women and 8 men, aged17-82 years.
Depression was observed in 50% of Tunisian patients with headache.
There were correlations between depression and some characteristics
of headache such as its higher frequency (p = 0.05), the existence of
preamble (p = 0.047) and associated blurred vision (p = 0.024).
Moreover, the presence of depression was correlated with persistence
of headache (p = 0.01) despite treatment.
Conclusion Depression is a frequent co-morbidity in Tunisian
headache patients. Therefore, the systematic use of depression scale
in such patients would allow readjusting their treatment and bettering
their management.
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Skeletal scintigraphy of craniovertebral structures:
clinical significance in cervicogenic headaches
H. Knackstedt1,2, G. Zinger3, D. Bansevicius1,2, M.B. Russell2,4
1Department of Neurology, Innlandet Hospital Trust, Elverum,
Norway;
2Head and Neck Research Group, University Hospital Akershus,
Oslo, Norway;
3Department of Nuklear Medicine, Innlandet Hospital Trust, Elverum,
Norway;
4Faculty Division Akershus University Hospital, University of Oslo,
Nordbyhagen, Norway
Objective To investigate the relevance of morphological changes in
the main stabilizing structures of the craniocervical junction in per-
sons with cervicogenic headache (CEH).
Material and methods A case control study of 46 consecutive per-
sons with CEH, 22 consecutive with headache attributed to whiplash
associated headache (WLaH) and 19 consecutive persons with
migraine. The criteria of the Cervicogenic Headache International
Study Group (CHISG) were used for diagnosing CEH, otherwise the
criteria of the International Classification of Headache Disorders
(ICHD II) were applied. All participants had a clinical interview, and
a physical and neurological examination. The skeletal bone scintig-
raphies were evaluated in a blinded Faison.
Results Is analyzed at the time
Conclusion Will be presented at the congress.
Keywords Cervicogenic headache, skeletal scintigraphy, cervical
spine,
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Depression comorbidity in patients with tension-type
headache at the neurology outpatient consultation
in Yaounde-Cameroon
Y.F. Fogoum1, C.K. Tegueu2, V. Sini3, J.Y. Fonsah1, A.K. Njamnshi3
1Neurology Department, Yaounde Central Hospital, Yaounde,
Cameroon;
2Neurology, Faculty of Medicine and Biomedical Sciences,
University of Yaounde I, Yaounde, Cameroon;
3Neurology Department, Faculty of Medicine and Biomedical
Sciences, University of Yaounde I; Yaounde Central Hospital,
Yaounde, Cameroon
Introduction Tension-type headache (TTH) is the most frequent type
of primary headache. In advanced forms, it is associated with psy-
chiatric comorbidities which have a high impact on the quality of life
of patients.
Objectives To determine the frequency, assess the severity and
analyse the symptoms of depression in tension-type headache during
outpatient neurology consultations in Yaounde.
Patients and methods One hundred and thirty-six consenting patients
with TTH (2004 IHS criteria) were recruited and answered the BDI-II
questionnaire (Beck Depression Inventory, 2nd edition).
Results The F/M sex-ratio was 1.68. The main age of the patients was
33.51 ± 11.35 years. Most patients (94.12%) had a formal level of
education of more than 7 years, and the majority lived in an urban
setting. The mean duration of evolution of the headache was
4.14 ± 5.74 years (range: 0.08 to 28). Chronic TTH was found in
70.40 % of the patients while 29.70% of the patients had frequent
episodic TTH. Probable analgesic-overuse headache was associated
to TTH in 14.81% of patients. Severe depression (BDI score of 29-63)
was diagnosed in 35.29% of patients, and moderate depression in
32.35% of them (BDI score of 20-28). The mean depression score was
26 in men as against 23 in women (p = 0.221). Depression was more
present in the chronic form of TTH than in the frequent episodic form
(p = 0.096). The most frequent symptoms of depression were sleep
disorders and concentration difficulties with means sores of 3/6 and
1.53/3 respectively.
Conclusion Depression is a frequent comorbidity in patients with
TTH in Yaounde. An assessment of these patients from an affective
perspective needs to be systematically carried out and integrated in
their management.
Keywords Headache, Tension-type, depression, comorbidity,
Yaounde.
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Three-dimensional analysis of the cervical range
of motion in cervicogenic headache
H. Knackstedt1,2, D. Bansevicius1,2, M.B. Russell2,3
1Department of Neurology, Innlandet Hospital Trust,
Elverum, Norway;
2Head and Neck Research Group, University Hospital Akershus,
Oslo, Norway;
3Faculty Division Akershus University Hospital,
University of Oslo, Nordbyhagen, Norway
Objective To investigate the physical impairment of the cervical
range of motion in persons with cervicogenic headache (CEH).
Material and methods A case control study of 46 consecutive per-
sons with CEH, 22 consecutive with headache attributed to whiplash
associated headache (WLaH) and 19 consecutive persons with
migraine. The criteria of the Cervicogenic Headache International
Study Group (CHISG) were used for diagnosing CEH, otherwise the
criteria of the International Classification of Headache Disorders
(ICHD II) were applied. All participants had a clinical interview, and
a physical and neurological examination. The active and passive
cervical range of motion was evaluated with a 3D ultrasound-based
device.
Results Are analyzed at time
Conclusion Will be presented at the congress.
Keywords Cervicogenic headache, active and passive cervical range
og motion, cervical spine
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Heat pain threshold habituation in migraine
and tension-type headache
T. Sand1,2, M. Engstrøm1, M. Stjern1, G. Gravdahl3, K. Hagen1,3,
L.J. Stovner1,3
1Department of Clinical Neuroscience, NTNU, Trondheim, Norway;
2Department of Neurology and Clinical Neurophysiology,
Trondheim, Norway;
3National Headache Centre, St.Olavs Hospital, Trondheim, Norway
Objectives Sensory allodynia has been reported by some migraine
(MIG) patients. Lack of habituation to sensory stimuli has also been
described for several sensory modalities.. The aim of our study was
to measure pain threshold habituation for thermal stimuli in
migraine compared to tension-type headache (TTH) and healthy
controls (CO).
Materials and methods 60 MIG (mean age 38.4 years, 15 with aura,
46 women), 23 patients with TTH (mean age 39.5 years, 12 women)
and 43 healthy controls (mean age 39.3 years, 27 women) were
recruited. Heat pain (HPT) thresholds were recorded for three con-
secutive stimuli with five second intervals by the method of limits in
frontal and volar hand regions. ANOVA with repeated measures was
applied. Habituation effect was defined as the percentage change in
the third compared to the first threshold.
Results HPT stimulus x group interaction was significant in the frontal
region (p = 0.008), but not in the hand (p = 0.85). Mean frontal habit-
uation effects were 4.5% in controls, 2.5% in migraine and 3.0% in TTH
(Tukey post-hoc test for MIG vs CO: p = 0.01). Frontal HPT-habituation
tended to correlate with photophobia (r = 0.27, p = 0.05).
Conclusion Patients with migraine had less heat-pain habituation in
the frontal region compared to healthy controls. This result supports
the theory about a trigeminal brainstem hypersensitivity in migraine.
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Trigeminal neuralgia as a consequence of temporal
bone epidermoid cyst: case report
S. Ljubisavljevic1, J. Ljubisavljevic2, M. Spasic1, S. Lukic1,
D. Savic1, Z. Peric1, A. Prazic1
1Clinical Center Nis, Nis, Serbia;
2Medical Faculty Nis, Nis, Serbia
Introduction Trigeminal neuralgia has been described to as one of
the most painful conditions of humanity. Heterogenous causes include
traumatic disorders of the trigeminal nerve by neoplastic or vascular
anomalies, infectious agents and intracranial tumors or demyelinating
conditions. Here we report a case of a patient diagnosed with trigeminal
neuralgia to epidermoid cyst at the pyramid part of temporal bone.
Case report Fourthy six years old women, cook, was treated in Clinic
of Neurology of Nis because of headache and eyes movements
impairment, especially during the turning eyes on right side, without
diplopia. Two years ago she had hypacusio and tinitus without
complete recovery. Also, she had a very big pain on temporal and
parietal head side usually by night. In neurological finding it is evi-
dence right hemifacial restricted to the innervations of the areas of all
trigeminal branches. Magnetic resonance finded in the top of temporal
bone on right side sign as a consequence of inflammation process.
Hyperdense structure noted also on a computer tomography scan with
destruction of bone part and bone wall of carotid channel, without
density changes after contrast application. Described structure prob-
ably is genetic cholesteatoma (epidermoid cyst) which is related to
carotid artery. The patient is suited for surgical intervention.
Conclusion Trigeminal neuralgia may be an unique or initial clinical
presenting symptom of epidermoid cyst. It is very important that
appropriate imaging be undertaken to help in identifying the under-
lying cause of the pain and also its management.
Keywords Trigeminal neuralgia, epidermoid cyst
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Cyclical methysergide in the treatment of menstrual
migraine
W. Mowafi1, R. Mir2, A. Al Din2
1Leeds General Infirmary, Leeds, UK;
2Neurology, Pinderfields General Hospital, Wakefield, UK
Menstrual migraine is a recognised clinical diagnosis that is
responsible for 3% of migraines in its pure form and upto 50% of
women with migraine as a menstrually related migraine. The
headaches are more severe, last longer, are more likely to be
associated with nausea, tend not to be associated with aura and are
more resistant to treatment than non menstrual migraine. The role of
cyclical triptans in the acute treatment and prophylaxis of these
headaches has been clinically validated. The use of methysergide
has fallen out of favour to other treatments in recent years due to its
side effects and the clinical monitoring required. We present a
52 year old women who has suffered from menstrual migraines
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without response to a multitude of acute and abortive therapies over
the years, including triptans, who responded to low dose cyclical
methysergide.
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Sleep quality in migraine and tension-type headache
T. Sand1,2, M. Engstrøm1, M. Stjern1, G. Gravdahl3, K. Hagen1,3,
L.J. Stovner1,3
1Department of Clinical Neuroscience, NTNU, Trondheim, Norway;
2Department of Neurology and Clinical Neurophysiology,
Trondheim, Norway;
3National Headache Centre, St.Olavs Hospital, Trondheim, Norway
Objectives Sleepiness and fatigue is reported by migraine (MIG)
patients. EEG studies have suggested a sleep dysfunction in migrai-
neurs. Little is known about sleep in tension-type headache (TTH).
The aim of our study was to measure sleep quality with polysom-
nography (PSG) in primary headache compared to healthy controls
(CO).
Materials and methods Subjects slept unattended in a single-room in
our patient-hotel. 52 patients with migraine (mean age 38.1 years, 15
with aura, 40 women), 20 patients with tension-type headache (mean
age 40.1 years, 10 women) and 37 healthy controls (mean age
39.6 years, 23 women) were analysed. Kruskal-Wallis test was
applied.
Results No differences in age, height, weight, neck circumference,
apnea-hypopnea index, or desaturation was found. Group differences
were found for stage III + IV sleep time (mean MIG 100 min, TTH
106 min, CO 85 min; p = 0.009) and relative stage III + IV sleep in
percent (MIG 23%, TTH 25%, CO 21%; p = 0.04). Differences were
not found for wake after sleep onset or the number of awakenings.
Conclusion Patients with primary headache had more slow-wave
sleep than healthy controls, suggesting prior sleep deprivation or
hyperactivity in thalamic inhibitory networks. Increased headache-
related arousal was not detected in macro-sleep parameters.
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Novel powder device significantly improves nasal
deposition compared to liquid spray; implications
for absorption and clinical effects of nasal sumatriptan?
P.G. Djupesland1, A. Skretting2
1R&D, OptiNose AS, Oslo, Norway;
2Medical Physics, Clinic of Oncology & Radiotherapy, National
Hospital, Oslo, Norway
Objectives Rapid initial rate of absorption across the nasal mucosa is
regarded the main explanation for the faster onset of 20 mg suma-
triptan nasal spray as compared to 100 mg delivered orally. However,
only 10% of the sumatriptan spray is absorbed nasally. Clinical trials
with the OptiNose nasal powder device (Opt-Powder) have shown
faster and more extensive nasal sumatriptan absorption and excellent
clinical efficacy. We compare the deposition patterns of a nasal spray
and Opt-Powder and discuss how deposition patterns may influence
PK-profiles and clinical outcomes
Methods The regional deposition and clearance patterns of the device
used in the Phase I&II studies were compared to a conventional liquid
spray pump in 7 healthy subjects by gamma camera imaging after
administration of either 99mTc-labeled lactose powder or liquid
99mTc-DTPA-aerosol. The gamma camera images were aligned with
sagittal MRI0s to identify nasal regions. Deposition results were
compared to published PK-profiles and efficacy data for the two nasal
sumatriptan formulations.
Results The Opt-powder device achieved a sevenfold larger initial
deposition in the upper posterior third of the nose (Opt-Powder:
18.3% ± 11.5 vs. Spray:2.4% ± 1.8; p \ 0.02) and threefold depo-
sition in the upper posterior 2/3 of the nose (Opt-Powder:
53.5% ± 18.5 vs. Spray: 15.7% ± 13851 p \ 0.02). Cumulative
exposure for 32 minutes following delivery shows a similar pattern.
The ratio for cumulative exposure in the upper posterior third is 3.7
(Powder/Spray), (p \ 0.04) and 2.2 for the upper posterior 2/3rd
(p \ 0.04).
Conclusions The more widespread nasal deposition achieved with the
Opt-powder device compared to a liquid spray is the most obvious
explanation for the faster and greater nasal absorption of sumatriptan.
However, based on efficacy data and recent animal studies we spec-
ulate that the improved deposition of Opt-Powder may contribute to
the clinical effects also by blocking pain signaling in the trigeminal
nerve directly involved in the pathophysiology of migraine.
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Analysis of a relationship between smoking
and headache in working population
S. Simic1, D. Simic2, Z. Jovin1
1Neurology Department, University of Novi Sad, School of Medicine,
Novi Sad, Serbia;
2Integrating Transport and Logistics, University of Novi Sad, Faculty
of Technical Sciences, Novi Sad, Serbia
Smoking represents, to put it mildly, a bad habit, but at the same time
it represents a risk factor for many diseases, and sometimes it can be
viewed as an addictive disease. The aim of this research was to
establish the relationship between smoking and headache occurrence,
as well as the occurrence of certain headache types and sub-types in
working population in our environment. The research has been con-
ducted on a sample of 1022 employed examinees of both sexes and
between 20-65 years of age. The data have been collected via general
questionnaire in which one of the questions was related to nicotinism.
The data that have been collected were processed by corresponding
mathematical-statistical methods. The results show the prevalence of
a non smoking population (59% of examinees) in our working pop-
ulation. Although the number of non-smokers is greater among the
healthy, the difference is not a relevant one, and using the method of a
x2 - test, the correlation between the presence of headaches and
nicotinism has not been proven. In the group of examinees who have
headaches, and who have been divided in those suffering from
migraine, tension-type headache and other types of headaches, the
largest number of smokers was within the group of those with
migraine with very low correlation between the type of the headache
and nicotinism. In relation to observed sup-types of headaches, which
have been divided into migraine with, and without aura, rare episodic
tension-type headache, frequent episodic tension-type headache and
chronic tension-type headache, the greatest number of smokers was
among those with chronic tension-type headache. A very low corre-
lation between nicotinism and sub-type of a headache has been
established. Although low, the correlation between nicotinism and
certain types and sub-types of headaches harms the patients and
quitting the habit would be strongly recommended.
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Correlation between circle of Willis and migraine
E. Harizi1, A. Rroji2,3, X. Doci4
1Neurology, Durres Regional Hospital, Tirana, Albania;
2Radiology, Department of Neurology, Hospital Center Mother
Theresa, Tirana, Albania;
3Hospital Center Mother Theresa, Tirana, Albania;
4Dermatology, Durres Regional Hospital, Durres, Albania
Background Migraine is already classified among the diseases with
cerebrovascular risk, based also on the white matter alterations seen
in the MRI. Relating to the fact that vascular abnormalities can trigger
cerebral hypoperfusion, in this study we assessed the correlation
between the variations of the Circle of Willis and Migraine.
Methods In this study were included 50 patients which underwent CT
angiography or MRI angiography from March 2007 until March 2009.
23 of the patients were diagnosed as migraineurs (46 %) 27 patients
had other neurologic disorders (54 %). In the migraineurs group 12
had migraine without aura and 11 had migraine with aura. In 8 of the
migraine patients were seen abnormalities of the white matter (5 had
migraine with aura and 3 without aura). 60 % of the total number of
the patients presented abnormalities of the Circle of Willis (30
patients), from which 18 belonged to the group of the migraineurs
(60%) and 12 (40%) to the other group. The abnormalities were
related to hypoplasy or aplasy of the posterior communicating artery,
or other vascular abnormalities.
Results It was shown an evident correlation between the abnormal-
ities of the circle of Willis mainly with hypoplasy or aplasy of the
posterior communicating artery with the migraine patients.
Conclusion Our comparative study despite being conducted in a
small number of patients showed a strong correlation between the
abnormalities of the circle of Willis and migraine.
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Clopidogrel (PLAVIX) in the prevention of typical
migraine aura without headaches - a case report
R.M. Agosti, R. Langner
Headache Center Zurich Hirslanden, Zollikon, Switzerland
Aims Treating and preventing frequent migraine auras is known to be
very challenging, be it with frequent auras as part of migraine with
aura attacks or as freestanding auras without headaches . Clopidogrel
may have a relatively specific role in the prevention of migraine
auras. Subanalysis of the Migraine Intervention With STARFlex
Technology (MIST) trial (Dowson et al, 2008) seemed to point to a
relatively specific role of clopidogrel (with and without combination
of acetyl salicylic acid). Wilmshurst reported in 2005 a highly sig-
nificant reduction of migraine with aura attacks after addition of
clopidogrel to aspirin after transcatheter closure of pending foramen
ovale. This case report supports the possible specific role of clopi-
dogrel in the prevention of migraine auras.
Methods Case report.
Results A 74 year old lady with moderate cardiovascular disease was
seen at the Headache Center Zurich Hirslanden for frequent visual
migraine auras without headaches. Her major concern were worries
about pending cerebrovascular infarction. Persistent open foramen
ovale was ruled out by echocardiography. Several migraine prophy-
lactic substances were tried without success until she was switched by
her cardiologist from aspirin to clopidogrel leading to an immediate
disappearance of her visual auras. Auras recurred during three epi-
sodes of several weeks. During each of these episodes clopidogrel had
to be stopped for orthopedic surgery of large joints.
Conclusion Clopidogrel seems to play a relatively specific role in the
prevention of migraine auras, here typical visual auras without
headaches. This case further seems to point to an independent role of
clopidogrel with no need for a combination with aspirin although in
some cases the combination may be needed to prevent auras.
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Subcutaneous occipital nerve neurostimulation;
treatment for refractory headaches
J.M. Salom, J.M. Lainez
Headache Unit, Neurology Department, Hospital Clı´nic Universitari
de Vale`ncia, Valencia, Spain
There are many primary headache in which the involvement of the
trigeminal system in the entire etiopathogenic process has been
identified. We know the importance of such a system and through
intervention on it, we can determine a change in the activation
humbral. There are many articles describing the Occipital Nerve
Stimulation as a treatment for some types of refractory headaches.
Despite the results, which in general are encouraging, we still can not
reach statistically significant conclusions.
In this paper, we analyze the results of our experience in the treatment
by placing occipital stimulation systems in patients with refractory
cluster headache. Data has been collected from 14 patients through pre-
and post-surgery diaries. All of them chronic and refractory to medical
treatment during a previous period of monitoring in our unit for 3 years.
Two subcutaneous electrode system were implanted and located by
anatomical references and looking for a suitable stimulation area as
directed by the patient during surgery. During the first 24 hours the
system was tested and turned on. Monitoring visits were arranged
during the first and third month, biannually and annually, in which the
parameters were adjusted again if needed. The clinical response was
satisfactory in all patients, with a reduction of at least 50% in the
number of crises in all of them. 7 patients had no more seizures after
surgery and medical treatment could be completely removed in 10. The
stimulation parameters used were variable (300-700 cms, 40-80 Hz,
1.5 to 6 mA). During follow-up the most frequent complication was the
rejection and infection of the system, which forced the withdrawal of
the system in three patients. There were no major complications.
Therefore we conclude that occipital nerve stimulation is an effective
and safe treatment for some selected patients with chronic and
refractory cluster headache.
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Onabotulinum toxin, type A, for treating co-morbid
migraine/headaches and TMD symptoms
J.C. Krusz, W.R. Knoderer
Anodyne Headache & PainCare, Dallas, TX, USA
Objectives Onabotulinum toxin, type A, intradermally, [BontA] was
used to treat headaches and migraines of facial origin (IHS criteria)
for migraine in patients with temporomandibular disorders (TMD).
Intradermal application was used, a novel injection technique.
S148 J Headache Pain (2010) 11 (Suppl 1):S1–S150
123
Background Botulinum toxins can play a role in reducing pain and
headache disorders and recent evidence suggests that there is
migration of BontA to the CNS from peripheral injection sites.
Methods 48 patients [35f, 13 m) were entered. All received intra-
dermal BontA, 100 units, given on the side of predominant side of
TMD/migraine involvement. All patients were followed monthly.
Migraine frequency and severity, along with TMD symptom severity,
were assessed monthly.
Results BoNTA showed statistically significant reductions of
migraine frequency and severity both at 1 month and at 3 months.
Headache/migraine frequency was 17.2 headaches per month, as
compared with 3.6 headaches per month after BontA treatment.
(p \ .001, 2-tailed t test). Reductions in migraine severity continued
at p \ .002 compared to baseline data after 3 months. TMD pain
reduced 73% VAS) after BoNTA treatment for an average of
12.6 weeks (6.4-21.7). Reductions in migraine severity continued at
p \ .002 compared to placebo over 12.5 weeks. No side effects were
noted with BontA, other than minor discomfort at injection sites.
Safety and tolerability of intradermal BontA were excellent.
Conclusions Intradermal dosing may involve mechanisms of action
that do not utilize cholinergic motor nerve elements and may involve
alterations in pain transmission pathways.
Intradermal BontA reduced significantly the frequency and severity of
migraines and TMD symptoms, including pain. Safety and tolerability
of intradermal BoNTA was excellent. Intradermal BontA dosing may
involve mechanisms of action that do not utilize motor nerve elements
and may involve alterations in pain transmission. Double-blind
studies are needed for intradermal BontA for face pain and migraine
disorders.
592
A randomized controlled trial evaluating the efficacy
of tailored migraine self-management tools
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Background Migraine is a chronic disease with attacks that vary in
frequency. A hallmark of chronic disease management is patient self-
management. In order for patients to optimize migraine management
and prevention they need knowledge and tools. Tailoring self-man-
agement materials for migraine management and prevention would
enhance personal relevance and in theory be more efficacious than
generic materials.
Objective This randomized controlled trial evaluated the impact of
tailoring migraine self-management (miSelf-T) vs. generic miSelf
(miself-G) and compared these groups to those keeping daily diaries
(DD) or usual care (UC). The following outcomes (12 weeks post-
baseline) were considered:
(a) headache days per month;
(b) number of days modifiable migraine triggers (sleep, stress,
skipping meals) were elevated;
(c) headache-related disability; and
(d) whether cognitive factors moderated efficacy.
Methods 119 individuals with migraine (91% female; Age
M = 41.66, days with headache per month M = 9.83) were ran-
domized to one of 4 conditions (miSelf-T, miSelf-G, DD, UC). The
miSelf program consisted of 8 newsletters and provided education and
tools for ‘‘managing triggers, managing medication, and managing
life’’. Materials were tailored on demographics, risk of triggers,self-
efficacy/locus of control (LOC), and disability. Individuals kept a
daily web-based diary.
Results The miSelf-T group showed the greatest improvement,
especially among those with high efficacy/LOC at baseline. MiSelf T
or G showed significant improvement at 12 weeks relative to those in
the DD or UC group for disability (p \ .05) and headache days relative
to UC (p \ .05). Relative to UC, all other conditions showed signifi-
cant improvement in managing triggers (p \ .01).Cognitive factors
also showed improvement, especially among those in miSelf-T.
Conclusions Providing self-management materials improved
migraine management, especially among those with high efficacy/
LOC at baseline. Tailoring these materials enhanced the efficacy of
the materials and suggests that more elaborate tailoring be researched
to evaluate its added benefit.
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Background and purpose Calcitonin gene-related peptide (CGRP), a
potent vasodilator, is distributed in trigeminovascular sensory nerve
fibres and CGRP is released upon its activation.
Release of CGRP is thought to be one of the underlying mechanisms
of migraine pathogenesis. Uptake and re-release of peptide signalling
molecules is generally not believed to occur, but we have previously
found functional evidence for uptake in a guinea pig basilar artery
preparation. We investigated CGRP release as well as uptake in the
intact dura mater.
Experimental approach The hemi-sected skull model was used to
study CGRP release and uptake from rat dura mater. The released
CGRP was measured using an enzyme-linked immunoassay. We used
four successive capsaicin challenges to deplete CGRP followed by
CGRP incubation to allow uptake. Immunohistochemistry was per-
formed to visualize the depletion and uptake of CGRP from sensory
nerves.
Key results Capsaicin-induced CGRP release was attenuated by the
TRPV1 antagonist capsazepine and by calcium ion free environment.
Subsequent to depletion of CGRP skull halves were incubated with
exogenous CGRP which caused an increase in capsaicin-induced
CGRP release as compared to the challenge just prior to incubation.
The CGRP uptake was not influenced by a Ca2?-free environment.
Sumatriptan, olcegepant and CGRP8-37 did not affect the uptake of
CGRP. However, a monoclonal CGRP-binding antibody decreased
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CGRP uptake significantly. Release of CGRP after incubation was
attenuated by Ca2? free environment and by capsazepine. Immuno-
histochemistry experiments also indicate CGRP uptake in rat dura
mater.
Conclusion We provide evidence that CGRP can be taken up and
subsequently released in response to chemical stimuli in a calcium
dependent manner. This new phenomenon may have considerable
influence on CGRP signalling. Deciphering the exact mechanism and
site of uptake and how it can be used to manipulate CGRP release
may be of interest for future treatment of migraine.
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